PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Laser-controlled cells	SCIENCE			English	Article																		Halfon MS, 1997, P NATL ACAD SCI USA, V94, P6255, DOI 10.1073/pnas.94.12.6255; Harris J, 1996, DEVELOPMENT, V122, P3117; STRINGHAM EG, 1993, J EXP ZOOL, V266, P227, DOI 10.1002/jez.1402660309	3	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					975	975						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9281076				2022-12-24	WOS:A1997XQ98500047
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Selecting the needle	SCIENCE			English	Article																		KETNER G, 1994, P NATL ACAD SCI USA, V91, P6186, DOI 10.1073/pnas.91.13.6186; LARIONOV V, 1997, P NATL ACAD SCI USA, V97, P7384	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					975	975						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9281076				2022-12-24	WOS:A1997XQ98500048
J	Yew, PR; Kirschner, MW				Yew, PR; Kirschner, MW			Proteolysis and DNA replication: The CDC34 requirement in the Xenopus egg cell cycle	SCIENCE			English	Article							UBIQUITIN-CONJUGATING ENZYME; LICENSING FACTOR; YEAST; TRANSITION; INITIATION; EXTRACTS; PROTEIN; COMPONENT; CLONING; EMBRYOS	The cell division cycle gene, CDC34, is required for ubiquitin-mediated degradation of G(1) regulators and cell cycle progression through the transition from G(1) to S phase in budding yeast. A CDC34 requirement for S phase onset in higher eukaryotes has not been established, Studies of the simple embryonic cell cycle of Xenopus laevis eggs demonstrated that Cdc34p in a large molecular size complex was required in the initiation of DNA replication, Cdc34p appears to regulate the initiation function of Cdk2-cyclin E, perhaps through the degradation of the Xenopus cdk inhibitor, Xic1.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School								Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BANERJEE A, 1995, J BIOL CHEM, V270, P26209, DOI 10.1074/jbc.270.44.26209; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Harlow E, 1988, ANTIBODIES LAB MANUA; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Mathias N, 1996, MOL CELL BIOL, V16, P6634; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; SATOH N, 1977, DEV GROWTH DIFFER, V19, P111; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; YEW PR, UNPUB	29	61	63	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	1997	277	5332					1672	1676		10.1126/science.277.5332.1672	http://dx.doi.org/10.1126/science.277.5332.1672			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287222				2022-12-24	WOS:A1997XV68400053
J	Peng, CY; Graves, PR; Thoma, RS; Wu, ZQ; Shaw, AS; PiwnicaWorms, H				Peng, CY; Graves, PR; Thoma, RS; Wu, ZQ; Shaw, AS; PiwnicaWorms, H			Mitotic and G(2) checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216	SCIENCE			English	Article							DNA-DAMAGE CHECKPOINT; CELL-CYCLE CONTROL; FISSION YEAST; KINASE; IDENTIFICATION; PATHWAY; ROLES	Human Cdc25C is a dual-specificity protein phosphatase that controls entry into mitosis by dephosphorylating the protein kinase Cdc2. Throughout interphase, but not in mitosis, Cdc25C was phosphorylated on serine-216 and bound to members of the highly conserved and ubiquitously expressed family of 14-3-3 proteins. A mutation preventing phosphorylation of serine-216 abrogated 14-3-3 binding. Conditional overexpression of this mutant perturbed mitotic timing and allowed cells to escape the G(2) checkpoint arrest induced by either unreplicated DNA or radiation-induced damage. Chk1, a fission yeast kinase involved in the DNA damage checkpoint response, phosphorylated Cdc25C in vitro on serine-216. These results indicate that serine-216 phosphorylation and 14-3-3 binding negatively regulate Cdc25C and identify Cdc25C as a potential target of checkpoint control in human cells.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; HARVARD UNIV,SCH MED,COMM VIROL,BOSTON,MA 02115; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)			Piwnica-Worms, Helen/C-5214-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018428, R01GM047017] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34094] Funding Source: Medline; NIGMS NIH HHS [GM47017, GM18428] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITLEN A, 1996, TRENDS CELL BIOL, V6, P341; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAVES PR, UNPUB; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng C., UNPUB; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; THOMA R, UNPUB; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	23	1185	1246	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1501	1505		10.1126/science.277.5331.1501	http://dx.doi.org/10.1126/science.277.5331.1501			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278512				2022-12-24	WOS:A1997XV42900039
J	Smith, CAD; Harrison, DJ				Smith, CAD; Harrison, DJ			Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema	LANCET			English	Article							ALPHA-1-ANTITRYPSIN DEFICIENCY; CIGARETTE-SMOKING; LUNG-DISEASE; EXPRESSION; INHIBITOR; ELASTASE; CANCER; MODEL; LIVER	Background The first-pass metabolism of foreign compounds in the lung is an mechanism against whether polymorphisms in the gene for microsomal epoxide hydrolase (mEPHX), an enzyme involved in this protective process, had any bearing on individual susceptibility to the development of chronic obstructive pulmonary disease (COPD) and emphysema. Methods We designed PCR-based genotyping assays to detect variant forms of mEPHX that confer slow and fast activity. We used these assays to screen 203 blood-donor controls and groups of patients with asthma (n=57), lung cancer (n=50), COPD (n=68), and emphysema (n=94), who were attending specialised clinics in Edinburgh, UK. Findings The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]). The odds ratios for homozygous slow activity versus all other phenotypes were 4.1 (95% CI 1.8-9.7) for COPD and 5.0 (2.3-10.9) for emphysema. Interpretation Genetic polymorphisms in xenobiotic enzymes may have a role in individual susceptibility to oxidant-related lung disease. Epoxide derivatives of cigarette-smoke components may be the cause of some of the lung damage characteristic of these diseases.	UNIV EDINBURGH, DEPT PATHOL, EDINBURGH, MIDLOTHIAN, SCOTLAND	University of Edinburgh								AARON J, 1985, AM REV RESPIR DIS, V132, P417; BARTSCH H, 1992, ENVIRON HEALTH PERSP, V98, P119, DOI 10.2307/3431257; CANTLAY AM, 1994, THORAX, V49, P1010, DOI 10.1136/thx.49.10.1010; CANTLAY AM, 1995, J CLIN PATHOL-CL MOL, V48, pM210; CARP H, 1982, P NATL ACAD SCI-BIOL, V79, P2041, DOI 10.1073/pnas.79.6.2041; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; COX DW, 1988, AM REV RESPIR DIS, V137, P371, DOI 10.1164/ajrccm/137.2.371; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; EVANS MD, 1994, AM J PHYSIOL, V266, pL593, DOI 10.1152/ajplung.1994.266.6.L593; FARBER JL, 1994, ENVIRON HEALTH PERSP, V102, P17, DOI 10.2307/3432207; FOSTER JA, 1990, J BIOL CHEM, V265, P15544; GARVER RI, 1986, NEW ENGL J MED, V314, P762, DOI 10.1056/NEJM198603203141207; HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421; Hoffmann D., 1990, CHEM CARCINOGENESIS, P63, DOI [10.1007/978-3-642-74775-5_3, DOI 10.1007/978-3-642-74775-5_3]; KALSHEKER NA, 1987, BRIT MED J, V294, P1511, DOI 10.1136/bmj.294.6586.1511; MARTORANA PA, 1993, LAB INVEST, V68, P233; MCGLYNN KA, 1995, P NATL ACAD SCI USA, V92, P2384, DOI 10.1073/pnas.92.6.2384; MORGAN K, 1992, EUR J CLIN INVEST, V22, P134, DOI 10.1111/j.1365-2362.1992.tb01946.x; OGUSHI F, 1991, J CLIN INVEST, V87, P1060, DOI 10.1172/JCI115066; OMIECINSKI CJ, 1993, PHARMACOGENETICS, V3, P150, DOI 10.1097/00008571-199306000-00005; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; SMITH CAD, 1994, EUR J CANCER, V30A, P1921, DOI 10.1016/0959-8049(94)00382-F; TETLEY TD, 1993, THORAX, V48, P560, DOI 10.1136/thx.48.5.560; TINGLE MD, 1993, BIOCHEM PHARMACOL, V46, P1529, DOI 10.1016/0006-2952(93)90319-R	24	335	360	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	1997	350	9078					630	633		10.1016/S0140-6736(96)08061-0	http://dx.doi.org/10.1016/S0140-6736(96)08061-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288046				2022-12-24	WOS:A1997XU28300011
J	Wilcken, DEL				Wilcken, DEL			MTHFR 677C->T mutation, folate intake, neural-tube defect, and risk of cardiovascular disease	LANCET			English	Editorial Material							METHYLENETETRAHYDROFOLATE REDUCTASE; VASCULAR-DISEASE; HOMOCYSTEINE				Wilcken, DEL (corresponding author), UNIV NEW S WALES,DEPT CARDIOVASC MED,SYDNEY,NSW 2036,AUSTRALIA.							BOCKXMEER FM, 1997, CIRCULATION, V95, P21; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Fowler B, 1997, J INHERIT METAB DIS, V20, P270, DOI 10.1023/A:1005369109055; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; KANG SS, 1991, AM J HUM GENET, V48, P536; Ma J, 1996, CIRCULATION, V94, P2410, DOI 10.1161/01.CIR.94.10.2410; Molloy AM, 1997, LANCET, V349, P1591, DOI 10.1016/S0140-6736(96)12049-3; SMITHELLS RW, 1980, LANCET, V1, P339; vanderPut NMJ, 1997, QJM-MON J ASSOC PHYS, V90, P111, DOI 10.1093/qjmed/90.2.111; Wilcken DEL, 1996, ARTERIOSCL THROM VAS, V16, P878, DOI 10.1161/01.ATV.16.7.878	10	47	48	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					603	604		10.1016/S0140-6736(05)63320-X	http://dx.doi.org/10.1016/S0140-6736(05)63320-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288038				2022-12-24	WOS:A1997XU28300003
J	Ichikawa, A; Kinoshita, T; Watanabe, T; Kato, H; Nagai, H; Tsushita, K; Saito, H; Hotta, T				Ichikawa, A; Kinoshita, T; Watanabe, T; Kato, H; Nagai, H; Tsushita, K; Saito, H; Hotta, T			Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; TUMOR SUPPRESSOR GENE; POLYMERASE CHAIN-REACTION; COMBINATION CHEMOTHERAPY; DISEASE PROGRESSION; MALIGNANT-LYMPHOMA; DELETIONS; REGIMEN; MARKER; CARCINOMAS	Background Mutations of the p53 gene are associated with a poor prognosis in several types of cancer. We investigated the prognostic importance of p53 mutations in patients with aggressive B-cell lymphoma. Methods We examined the relation between the presence or absence of a detectable p53 mutation in lymphoma cells and the response to chemotherapy and overall survival in 102 previously untreated patients with aggressive B-cell lymphoma. Mutations of the p53 gene were identified by polymerase-chain-reaction-mediated analysis of single-strand conformation polymorphisms and by direct sequencing. Results Of 102 cases of aggressive B-cell lymphoma, 22 (22 percent) involved p53 mutations. The rate of complete remission was significantly lower in patients with a tumor carrying a p53 mutation (6 of 22 patients, 27 percent) than in those with the wild-type p53 gene (61 of 80 patients, 76 percent) (P<0.001). Overall survival was significantly lower among patients with p53 mutations than among those with the wild-type p53 gene; the Kaplan-Meier estimates of survival at five years were 16 percent and 64 percent, respectively (P<0.001). Multivariate analysis incorporating prognostic factors from the international prognostic index demonstrated that p53 mutations had independent effects on the rates of complete remission and survival. When we categorized patients according to the international prognostic index, we found no effect of p53 mutations in patients in the groups at high-intermediate and high risk. However, these mutations were significantly associated (P<0.001) with low rates of complete remission (33 percent vs. 91 percent) and survival (27 percent vs. 81 percent at five years) in the groups at low and low-intermediate risk. Conclusions Mutations of the p53 gene are associated with a poor prognosis in patients with aggressive B-cell lymphoma. (C) 1997, Massachusetts Medical Society.	NAGOYA UNIV, SCH MED, DEPT INTERNAL MED 1, NAGOYA, AICHI 466, JAPAN	Nagoya University	Ichikawa, A (corresponding author), GIFU PREFECTURAL TAJIMI HOSP, DEPT HEMATOL ONCOL, MAEHATA CHO, TAJIMI, JAPAN.			Watanabe, Takashi/0000-0002-9015-5246				Armitage P., 2001, STAT METHODS MED RES; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; CARBONE PP, 1971, CANCER RES, V31, P1860; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COIFFIER B, 1991, J CLIN ONCOL, V9, P211, DOI 10.1200/JCO.1991.9.2.211; COIFFIER B, 1989, BLOOD, V74, P558; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR., 1970, ANAL BINARY DATA; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FISHER RI, 1981, BLOOD, V58, P45; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P1; ICHIKAWA A, 1992, BLOOD, V79, P2701; JAGANNATH S, 1986, J CLIN ONCOL, V4, P859, DOI 10.1200/JCO.1986.4.6.859; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; LAURENCE J, 1982, ANN INTERN MED, V97, P190, DOI 10.7326/0003-4819-97-2-190; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LISTER, 1990, J CLIN ONCOL, V8, P1602; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; LONGO, 1991, J CLIN ONCOL, V9, P710, DOI 10.1200/JCO.1991.9.4.710; LONGO DL, 1991, J CLIN ONCOL, V9, P25, DOI 10.1200/JCO.1991.9.1.25; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCKELVEY EM, 1976, CANCER, V38, P1484, DOI 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PUI CH, 1987, BLOOD, V70, P624; RODRIGUEZ V, 1977, BLOOD, V49, P325; ROSENBERG SA, 1982, CANCER, V49, P2112; SARKIS AS, 1993, J NATL CANCER I, V85, P53, DOI 10.1093/jnci/85.1.53; SCHOUTEN HC, 1990, BLOOD, V75, P1841; SHIMOYAMA M, 1988, J CLIN ONCOL, V6, P128, DOI 10.1200/JCO.1988.6.1.128; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SHIPP MA, 1986, ANN INTERN MED, V104, P757, DOI 10.7326/0003-4819-104-6-757; SOUSSI T, 1990, ONCOGENE, V5, P945; SUZUKI Y, 1991, ANAL BIOCHEM, V192, P82, DOI 10.1016/0003-2697(91)90188-Y; SWAN F, 1989, J CLIN ONCOL, V7, P1518, DOI 10.1200/JCO.1989.7.10.1518; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; THORLACIUS S, 1993, CANCER RES, V53, P1637; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; VOSE JM, 1988, J CLIN ONCOL, V6, P1838, DOI 10.1200/JCO.1988.6.12.1838; Wilson WH, 1997, BLOOD, V89, P601, DOI 10.1182/blood.V89.2.601	48	231	237	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					529	534		10.1056/NEJM199708213370804	http://dx.doi.org/10.1056/NEJM199708213370804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262496				2022-12-24	WOS:A1997XR54800004
J	Rainville, P; Duncan, GH; Price, DD; Carrier, B; Bushnell, MC				Rainville, P; Duncan, GH; Price, DD; Carrier, B; Bushnell, MC			Pain affect encoded in human anterior cingulate but not somatosensory cortex	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; CORTICAL AFFERENTS; MONKEY; RESPONSES	Recent evidence demonstrating multiple regions of human cerebral cortex activated by pain has prompted speculation about their individual contributions to this complex experience. To differentiate cortical areas involved in pain affect, hypnotic suggestions were used to alter selectively the unpleasantness of noxious stimuli, without changing the perceived intensity. Positron emission tomography revealed significant changes in pain-evoked activity within anterior cingulate cortex, consistent with the encoding of perceived unpleasantness, whereas primary somatosensory cortex activation was unaltered. These findings provide direct experimental evidence in humans linking frontal-lobe limbic activity with pain affect, as originally suggested by early clinical lesion studies.	UNIV MONTREAL, CTR RECH SCI NEUROL, MONTREAL, PQ H3C 3J7, CANADA; MONTREAL NEUROL INST, MCCONNELL BRAIN IMAGING CTR, MONTREAL, PQ, CANADA; MCGILL UNIV, DEPT ANESTHESIOL, MONTREAL, PQ H3A 1A1, CANADA	Universite de Montreal; McGill University; McGill University			Price, Donald D./A-3094-2008; Rainville, Pierre/M-5480-2015	Price, Donald D./0000-0002-8971-7184; Rainville, Pierre/0000-0001-9801-757X				BANDLER R, 1994, TRENDS NEUROSCI, V17, P379, DOI 10.1016/0166-2236(94)90047-7; BUSHNELL MC, 1989, EXP BRAIN RES, V78, P415; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; COGHILL RC, 1994, J NEUROSCI, V14, P4095; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; CORBETTA M, 1991, J NEUROSCI, V11, P2383; Craig A. D., 1996, Society for Neuroscience Abstracts, V22, P111; Dostrovsky J. O., 1996, Society for Neuroscience Abstracts, V22, P111; Fields H. L., 1987, PAIN; FOLTZ EL, 1962, J NEUROSURG, V19, P89, DOI 10.3171/jns.1962.19.2.0089; FOLTZ EL, 1968, INT J NEUROL, V6, P353; FRIEDMAN DP, 1986, J COMP NEUROL, V252, P323, DOI 10.1002/cne.902520304; GINGOLD SI, 1991, J COMP NEUROL, V308, P467, DOI 10.1002/cne.903080312; Hurt R W, 1974, Clin Neurosurg, V21, P334; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; KENSHALO DR, 1988, BRAIN RES, V454, P378, DOI 10.1016/0006-8993(88)90841-4; KIERNAN BD, 1995, PAIN, V60, P39, DOI 10.1016/0304-3959(94)00134-Z; MELZACK R, 1968, P423; Morin C., 1994, Society for Neuroscience Abstracts, V20, P127; MUFSON EJ, 1982, J COMP NEUROL, V212, P23, DOI 10.1002/cne.902120103; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; PAUS T, 1993, J NEUROPHYSIOL, V70, P453, DOI 10.1152/jn.1993.70.2.453; Paus T, 1996, CEREB CORTEX, V6, P207, DOI 10.1093/cercor/6.2.207; Picard N, 1996, CEREB CORTEX, V6, P342, DOI 10.1093/cercor/6.3.342; Price DD, 1988, PSYCHOL NEURAL MECH; RAINVILLE P, 1992, SOMATOSENS MOT RES, V9, P265, DOI 10.3109/08990229209144776; Rainville P., 1996, Society for Neuroscience Abstracts, V22, P117; RAUSELL E, 1991, J NEUROSCI, V11, P226; SIKES RW, 1992, J NEUROPHYSIOL, V68, P1720, DOI 10.1152/jn.1992.68.5.1720; STEVENS RT, 1993, BRAIN RES, V631, P241, DOI 10.1016/0006-8993(93)91541-Y; Talairach J., 1988, COPLANAR STEREOTAXIC; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; VOGT BA, 1979, SCIENCE, V204, P205, DOI 10.1126/science.107587; VOGT BA, 1987, J COMP NEUROL, V262, P271, DOI 10.1002/cne.902620208; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; [No title captured]; [No title captured]; [No title captured]	38	1770	1815	0	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	1997	277	5328					968	971		10.1126/science.277.5328.968	http://dx.doi.org/10.1126/science.277.5328.968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252330				2022-12-24	WOS:A1997XQ98500045
J	Chen, HW; Lin, RJ; Schiltz, RL; Chakravarti, D; Nash, A; Nagy, L; Privalsky, ML; Nakatani, Y; Evans, RM				Chen, HW; Lin, RJ; Schiltz, RL; Chakravarti, D; Nash, A; Nagy, L; Privalsky, ML; Nakatani, Y; Evans, RM			Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300	CELL			English	Article							THYROID-HORMONE RECEPTOR; TRANSCRIPTION FACTOR TFIIB; DEPENDENT TRANSACTIVATION; CO-REPRESSOR; PROTEIN CBP; DOMAIN; SUPERFAMILY; NUCLEOSOME; MEDIATE; BINDING	We report here the identification of a novel cofactor, ACTR, that directly binds nuclear receptors and stimulates their transcriptional activities in a hormone-dependent fashion. ACTR also recruits two other nuclear factors, CBP and P/CAF, and thus plays a central role in creating a multisubunit coactivator complex. In addition, and unexpectedly, we show that purified ACTR is a potent histone acetyltransferase and appears to define a distinct evolutionary branch to this recently described family. Thus, hormonal activation by nuclear receptors involves the mutual recruitment of at least three classes of histone acetyltransferases that may act cooperatively as an enzymatic unit to reverse the effects of histone cleacetylase shown to be part of the nuclear receptor corepressor complex.	HOWARD HUGHES MED INST,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,SCH MED,GRAD PROGRAM MOL PATHOL,LA JOLLA,CA 92037; NICHHD,LAB MOL GROWTH REGULAT,NATL INST HLTH,BETHESDA,MD 20892; UNIV CALIF DAVIS,MICROBIOL SECT,DIV BIOL SCI,DAVIS,CA 95616	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California Davis			Nagy, Laszlo/A-3814-2008; Evans, Ronald/AAF-4001-2019	Nagy, Laszlo/0000-0001-6653-2155; Evans, Ronald/0000-0002-9986-5965; Lin, Richard/0000-0002-0834-7880; Chakravarti, Debabrata/0000-0001-8446-8599	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026444, R37GM026444] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27183] Funding Source: Medline; NIGMS NIH HHS [GM26444] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; ING NH, 1992, J BIOL CHEM, V267, P17617; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KANKNECHT R, 1996, CURR BIOL, V6, P951; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; SOEL W, 1995, MOL ENDOCRINOL, V9, P72; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	59	1238	1267	2	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					569	580		10.1016/S0092-8674(00)80516-4	http://dx.doi.org/10.1016/S0092-8674(00)80516-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267036	Bronze			2022-12-24	WOS:A1997XQ06300020
J	Pan, GH; Ni, J; Wei, YF; Yu, GL; Gentz, R; Dixit, VM				Pan, GH; Ni, J; Wei, YF; Yu, GL; Gentz, R; Dixit, VM			An antagonist decoy receptor and a death domain-containing receptor for TRAIL	SCIENCE			English	Article							APOPTOSIS; FAS	TRAIL, also called Apo2L, is a cytotoxic protein that induces apoptosis of many transformed cell fines but not of normal tissues, even though its death domain-containing receptor, DR4, is expressed on both cell types. An antagonist decoy receptor (designated as TRID for TRAIL receptor without an intracellular domain) that may explain the resistant phenotype of normal tissues was identified. TRID is a distinct gene product with an extracellular TRAIL-binding domain and a transmembrane domain but no intracellular signaling domain. TRID transcripts were detected in many normal human tissues but not in most cancer cell lines examined. Ectopic expression of TRID protected mammalian cells from TRAIL-induced apoptosis, which is consistent with a protective role. Another death domain-containing receptor for TRAIL (designated as death receptor-5), which preferentially engaged a FLICE (caspase-8)-related death protease, was also identified.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; HUMAN GENOME SCI,ROCKVILLE,MD 20850	University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NIEHS NIH HHS [ES08111] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Baker SJ, 1996, ONCOGENE, V12, P1; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Boise LH, 1996, SCIENCE, V274, P67, DOI 10.1126/science.274.5284.67; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BROJATSH J, 1996, CELL, V87, P1; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	27	1350	1527	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					815	818		10.1126/science.277.5327.815	http://dx.doi.org/10.1126/science.277.5327.815			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242610				2022-12-24	WOS:A1997XQ24700043
J	Tang, AH; Neufeld, TP; Kwan, E; Rubin, GM				Tang, AH; Neufeld, TP; Kwan, E; Rubin, GM			PHYL acts to down-regulate TTK88, a transcriptional repressor of neuronal cell fates, by a SINA-dependent mechanism	CELL			English	Article							DROSOPHILA EYE DEVELOPMENT; ETS DOMAIN PROTEIN; TYROSINE KINASE; EXPRESSION PATTERN; ECTOPIC EXPRESSION; SEGMENTATION GENE; FUSHI-TARAZU; TRAMTRACK; SEVENLESS; UBIQUITIN	We show that Tramtrack (TTK88) expression represses neuronal fate determination in the developing Drosophila eye. Phyllopod (PHYL) acts to antagonize this repression by a mechanism that requires Seven In Absentia (SINA) and is associated with decreased TTK88 protein levels, but not reduced ttk88 gene transcription or mRNA stability. We present evidence that SINA, PHYL, and TTK88 physically interact and that SINA interacts genetically and physically with UBCD1, a component of the ubiquitin-dependent protein degradation pathway. Our results suggest a model in which activation of the Sevenless receptor tyrosine kinase induces PHYL expression, which then acts with SINA to target the transcriptional repressor TTK88 for degradation, thereby promoting R7 cell fate specification.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley			Tang, Amy/L-3226-2016	Tang, Amy/0000-0002-5772-2878; Neufeld, Thomas/0000-0001-5659-4811; Rubin, Gerald/0000-0001-8762-8703				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; BROWN JL, 1993, DEVELOPMENT, V117, P45; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CamposOrtega JA, 1996, NEURON, V17, P1, DOI 10.1016/S0896-6273(00)80274-3; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CARTHEW RW, 1994, P NATL ACAD SCI USA, V91, P11689, DOI 10.1073/pnas.91.24.11689; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DELLA NG, 1993, DEVELOPMENT, V117, P1333; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Dickson Barry, 1993, P1327; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Finley RL, 1996, P NATL ACAD SCI USA, V93, P3011, DOI 10.1073/pnas.93.7.3011; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; GUO M, 1995, NEURON, V14, P913, DOI 10.1016/0896-6273(95)90330-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HAY BA, 1994, DEVELOPMENT, V120, P2121; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Huang YZ, 1996, DEVELOPMENT, V122, P3207; Kauffmann RC, 1996, GENE DEV, V10, P2167, DOI 10.1101/gad.10.17.2167; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; Lai ZC, 1996, P NATL ACAD SCI USA, V93, P5025, DOI 10.1073/pnas.93.10.5025; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; READ D, 1992, MECH DEVELOP, V38, P183, DOI 10.1016/0925-4773(92)90052-L; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREIER M, 1992, EMBO J, V11, P367, DOI 10.1002/j.1460-2075.1992.tb05059.x; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wolff Tanya, 1993, P1277; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; XU T, 1993, DEVELOPMENT, V117, P1223; Yamamoto D, 1996, ROUX ARCH DEV BIOL, V205, P215, DOI 10.1007/BF00365799; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	65	198	201	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					459	467		10.1016/S0092-8674(00)80506-1	http://dx.doi.org/10.1016/S0092-8674(00)80506-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267026	Bronze			2022-12-24	WOS:A1997XQ06300010
J	Shaffer, LG; Phillips, MD				Shaffer, LG; Phillips, MD			Successful treatment of acquired hemophilia with oral immunosuppressive therapy	ANNALS OF INTERNAL MEDICINE			English	Article							FACTOR-VIII; CYCLOPHOSPHAMIDE; INHIBITORS; COMBINATION; PREDNISONE	Background: Acquired autoantibodies to factor VIII in patients without hemophilia are rare, but they cause severe illness and death if not eradicated. Objective: To examine daily therapy with oral cyclophosphamide and prednisone for acquired hemophilia. Design: Case series. Setting: Academic medical center. Patients: Nine consecutive patients without hemophilia who had severe hemorrhage caused by high titers of factor VIII inhibitors. Interventions: Daily oral cyclophosphamide and prednisone. Coagulation factors were used only for bleeding. Measurements: Plasma titers of factor VIII inhibitor, factor VIII activity, and clinical evidence of bleeding. Results: All patients achieved complete remission, which was defined as loss of residual inhibitor activity and return to a normal titer of factor VIII. Therapy lasted a median of 12 weeks (range, 3 to 37 weeks), Bleeding resolved in a median of 3 weeks (range, 2 to 10 weeks). Median follow-up after discontinuation of therapy was 91 weeks (range, 61 to 164 weeks). Conclusion: Daily administration of oral cyclophosphamide and prednisone without empirical factor VIII therapy seems to be an effective and well-tolerated treatment for acquired hemophilia.	UNIV TEXAS, SCH MED, DIV HEMATOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, HOUSTON, TX 77030 USA	University of Texas System; University of Texas System; UTMD Anderson Cancer Center								GREEN D, 1993, THROMB HAEMOSTASIS, V70, P753; GREEN D, 1981, THROMB HAEMOSTASIS, V45, P200; GREEN D, 1971, BLOOD-J HEMATOL, V37, P381, DOI 10.1182/blood.V37.4.381.381; HERBST KD, 1981, ANN INTERN MED, V95, P575, DOI 10.7326/0003-4819-95-5-575; Hoyer LW, 1995, ADV EXP MED BIOL, V386, P35; HULTIN MB, 1991, AM J MED, V91, pS9, DOI 10.1016/S0002-9343(91)80141-8; LIAN ECY, 1989, ANN INTERN MED, V110, P774, DOI 10.7326/0003-4819-110-10-774; LOTTENBERG R, 1987, ARCH INTERN MED, V147, P1077, DOI 10.1001/archinte.147.6.1077; MORRISON AE, 1993, BLOOD, V81, P1513	9	73	74	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					206	209		10.7326/0003-4819-127-3-199708010-00005	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245226				2022-12-24	WOS:A1997XN12900005
J	Sugimoto, Y; Yamasaki, A; Segi, E; Tsuboi, K; Aze, Y; Nishimura, T; Oida, H; Yoshida, N; Tanaka, T; Katsuyama, M; Hasumoto, K; Murata, T; Hirata, M; Ushikubi, F; Negishi, M; Ichikawa, A; Narumiya, S				Sugimoto, Y; Yamasaki, A; Segi, E; Tsuboi, K; Aze, Y; Nishimura, T; Oida, H; Yoshida, N; Tanaka, T; Katsuyama, M; Hasumoto, K; Murata, T; Hirata, M; Ushikubi, F; Negishi, M; Ichikawa, A; Narumiya, S			Failure of parturition in mice lacking the prostaglandin F receptor	SCIENCE			English	Article							OXYTOCIN RECEPTOR; LUTEOLYTIC HORMONE; RAT MYOMETRIUM; EXPRESSION	Mice lacking the gene encoding the receptor for prostaglandin F-2 alpha (FP) developed normally but were unable to deliver normal fetuses at term. Although these FP-deficient mice showed no abnormality in the estrous cycle, ovulation, fertilization, or implantation, they did not respond to exogenous oxytocin because of the lack of induction of oxytocin receptor (a proposed triggering event in parturition), and they did not show the normal decline of serum progesterone concentrations that precedes parturition. Ovariectomy at day 19 of pregnancy restored induction of the oxytocin receptor and permitted successful delivery in the FP-deficient mice. These results indicate that parturition is initiated when prostaglandin F-2 alpha interacts with FP in ovarian luteal cells of the pregnant mice to induce luteolysis.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 606,JAPAN; ONO PHARMACEUT CO LTD,FUKUI RES INST,FUKUI 913,JAPAN; OSAKA MED CTR MATERNAL & CHILD HLTH,RES INST,DIV MOL & CELLULAR IMMUNOL,OSAKA 59002,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN	Kyoto University; Ono Pharmaceutical Co Ltd; Kyoto University			Tanaka, Takashi/O-8254-2015; Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X; Segi-Nishida, Eri/0000-0002-0803-6513; Murata, Takahiko/0000-0003-0132-5424				ALEXANDROVA M, 1980, ENDOCRINOLOGY, V106, P739, DOI 10.1210/endo-106-3-739; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; FUCHS AR, 1983, ENDOCRINOLOGY, V113, P742, DOI 10.1210/endo-113-2-742; Hasumoto K, 1997, J REPROD FERTIL, V109, P45, DOI 10.1530/jrf.0.1090045; HORTON EW, 1976, PHYSIOL REV, V56, P595, DOI 10.1152/physrev.1976.56.4.595; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; LEFEBVRE DL, 1992, SCIENCE, V256, P1553, DOI 10.1126/science.1598587; LEWIS RB, 1973, LANCET, V2, P1159; MATSUMOTO K, 1981, FOLIA PHARMACOL JPN, V78, P231, DOI 10.1254/fpj.78.231; MCCRACKEN JA, 1972, NATURE-NEW BIOL, V238, P129, DOI 10.1038/newbio238129a0; MOELJONO MP, 1976, PROSTAGLANDINS, V14, P543; MONCADA S, 1985, PHARMACOL BASIS THER, P660; MURDOCH WJ, 1993, PROSTAG OTH LIPID M, V46, P85, DOI 10.1016/0090-6980(93)90037-8; Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699; SOLOFF MS, 1979, SCIENCE, V204, P1313, DOI 10.1126/science.221972; SOLOFF MS, 1988, ONSET LABOR CELLULAR, P87; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; THORBURN GD, 1979, PHYSIOL REV, V59, P863, DOI 10.1152/physrev.1979.59.4.863; Young WS, 1996, J NEUROENDOCRINOL, V8, P847, DOI 10.1046/j.1365-2826.1996.05266.x	19	484	497	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					681	683		10.1126/science.277.5326.681	http://dx.doi.org/10.1126/science.277.5326.681			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235889				2022-12-24	WOS:A1997XN90700039
J	Ryan, TA; Reuter, H; Smith, SJ				Ryan, TA; Reuter, H; Smith, SJ			Optical detection of a quantal presynaptic membrane turnover	NATURE			English	Article							EXCITATORY SYNAPSES; NERVE-TERMINALS; RAT HIPPOCAMPUS; SINGLE; MICROSCOPY; MOLECULES; NEURONS	Exploration of the mechanisms and plasticity of synaptic transmission has been hindered by the lack of a method to measure single vesicle turnover directly in individual presynaptic boutons at isolated nerve terminals. Although postsynaptic electrical recordings have provided a wealth of invaluable basic information about quantal presynaptic processes(1), this approach has often proved difficult to apply at most central nervous system synapses(2-6). Here we describe the direct optical detection of single quantal events in individual presynaptic boutons of cultured hippocampal neurons. Using the fluorescent dye FM 1-43 as a tracer for presynaptic endocytosis(7-10), we have characterized both evoked and spontaneous components of presynaptic function at the level of individual quanta. Our results are consistent with quantal interpretations of previous electrophysiological analyses(1-6) and provide new information about the unitary membrane recycling event and its coupling to individual action potential stimuli, about spontaneous vesicle turnover at individual boutons, and about the numbers of vesicles recycling at individual boutons.	STANFORD UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,STANFORD,CA 94305; UNIV BERN,DEPT PHARMACOL,CH-3010 BERN,SWITZERLAND	Stanford University; University of Bern			Ryan, Timothy/AAO-8286-2020	Smith, Stephen/0000-0002-2290-8701; Ryan, Timothy/0000-0003-2533-9548				BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; DEHANNE D, 1996, J PHYSL, V491, P163; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1995, PHYSIOL REV, V75, P759, DOI 10.1152/physrev.1995.75.4.759; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; HARRIS KM, 1989, J NEUROSCI, V9, P2982; Katz B., 1969, RELEASE NEURAL TRANS; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KULLMANN DM, 1992, J NEUROSCI METH, V44, P47, DOI 10.1016/0165-0270(92)90113-R; LIU GS, 1995, NATURE, V375, P404, DOI 10.1038/375404a0; Malgaroli Antonio, 1994, Seminars in Cell Biology, V5, P231, DOI 10.1006/scel.1994.1029; Mertz J, 1995, OPT LETT, V20, P2532, DOI 10.1364/OL.20.002532; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; REUTER H, 1995, NEURON, V14, P773, DOI 10.1016/0896-6273(95)90221-X; Ryan TA, 1996, P NATL ACAD SCI USA, V93, P5567, DOI 10.1073/pnas.93.11.5567; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; STEVENS CF, 1993, NEURON S, V10, P55; TONG G, 1994, NEURON, V12, P51, DOI 10.1016/0896-6273(94)90151-1	25	136	137	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					478	482		10.1038/41335	http://dx.doi.org/10.1038/41335			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242407	Bronze			2022-12-24	WOS:A1997XN55300050
J	Kolykhalov, AA; Agapov, EV; Blight, KJ; Mihalik, K; Feinstone, SM; Rice, CM				Kolykhalov, AA; Agapov, EV; Blight, KJ; Mihalik, K; Feinstone, SM; Rice, CM			Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA	SCIENCE			English	Article							NON-B HEPATITIS; NON-A; VIRAL-HEPATITIS; HIGH-FIDELITY; CDNA CLONE; VIRUS; IDENTIFICATION; AMPLIFICATION; CHIMPANZEES; MARMOSETS	More than 1% of the world's population is chronically infected with hepatitis C virus (HCV). HCV infection can result in acute hepatitis, chronic hepatitis, and cirrhosis, which is strongly associated with development of hepatocellular carcinoma. Genetic studies of HCV replication have been hampered by lack of a bona fide infectious molecular clone. Full-length functional clones of HCV complementary DNA were constructed. RNA transcripts from the clones were found to be infectious and to cause disease in chimpanzees after direct intrahepatic inoculation. This work defines the structure of a functional HCV genome RNA and proves that HCV alone is sufficient to cause disease.	WASHINGTON UNIV,SCH MED,DEPT MOL MICROBIOL,ST LOUIS,MO 63110; US FDA,DIV VIROL,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892	Washington University (WUSTL); US Food & Drug Administration (FDA)					NCI NIH HHS [CA57973] Funding Source: Medline; NIAID NIH HHS [AI40034] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTER HJ, 1978, LANCET, V1, P459; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; EMERSON SU, 1992, J VIROL, V66, P6649, DOI 10.1128/JVI.66.11.6649-6654.1992; FALKOW S, 1988, REV INFECT DIS, V10, pS274; FARCI P, 1992, J INFECT DIS, V165, P1006, DOI 10.1093/infdis/165.6.1006; FEINSTONE SM, 1981, J INFECT DIS, V144, P588, DOI 10.1093/infdis/144.6.588; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HOUGHTON M, 1996, FIELDS VIROLOGY, V1, P1035; INCHAUSPE G, 1991, P NATL ACAD SCI USA, V88, P10292, DOI 10.1073/pnas.88.22.10292; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; KOLYKHALOV AA, IN PRESS HEPATITIS C; KOLYKHALOV AA, UNPUB; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; MAJOR ME, 1997, HEPATOLOGY, V25, P527; Nakajima N, 1996, J VIROL, V70, P3325, DOI 10.1128/JVI.70.5.3325-3329.1996; OGATA N, 1991, P NATL ACAD SCI USA, V88, P3392, DOI 10.1073/pnas.88.8.3392; OHLINGER VF, 1990, J VIROL, V64, P3331, DOI 10.1128/JVI.64.7.3331-3336.1990; POPPER H, 1980, VIRCHOWS ARCH A, V387, P91, DOI 10.1007/BF00428432; REED KE, 1997, HEPATITIS C VIRUS, V61; RICE CM, 1996, FIELDS VIROLOGY, V1, P931; SHIMIZU YK, 1993, P NATL ACAD SCI USA, V90, P6037, DOI 10.1073/pnas.90.13.6037; SHINDO M, 1992, J INFECT DIS, V166, P424, DOI 10.1093/infdis/166.2.424; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; Tanaka T, 1996, J VIROL, V70, P3307, DOI 10.1128/JVI.70.5.3307-3312.1996; Yamada N, 1996, VIROLOGY, V223, P255, DOI 10.1006/viro.1996.0476	26	580	647	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					570	574		10.1126/science.277.5325.570	http://dx.doi.org/10.1126/science.277.5325.570			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228008				2022-12-24	WOS:A1997XM86700053
J	Nishimura, N; Balch, WE				Nishimura, N; Balch, WE			A di-acidic signal required for selective export from the endoplasmic reticulum	SCIENCE			English	Article							VESICULAR STOMATITIS-VIRUS; G-PROTEIN; MDCK CELLS; CYTOPLASMIC TAIL; TRANSPORT; SEQUENCE; ER; GLYCOPROTEIN; DEGRADATION; ENDOCYTOSIS	Transport of membrane proteins between intracellular compartments requires specific sequences in the protein cytoplasmic domain to direct packaging into vesicle shuttles. A sequence that mediates export from the endoplasmic reticulum (ER) has proved elusive. A di-acidic signal (Asp-X-Glu, where X represents any amino acid) on the cytoplasmic tail of vesicular stomatitis virus glycoprotein (VSV-G) and other cargo molecules was required for efficient recruitment to vesicles mediating export from the ER in baby hamster kidney cells. The existence of such a signal provides evidence that export from the ER occurs through a selective mechanism.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42336] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BRUAN M, 1989, EMBO J, V8, P3633; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; KLAUSNER R D, 1989, New Biologist, V1, P3; KREIS TE, 1994, CURR OPIN CELL BIOL, V6, P533, DOI 10.1016/0955-0674(94)90073-6; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; NISHIMURA N, UNPUB; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schekman R, 1995, COLD SPRING HARB SYM, V60, P11, DOI 10.1101/SQB.1995.060.01.004; SCHMID SL, IN PRESS ANN REV BIO; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749	35	394	399	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					556	558		10.1126/science.277.5325.556	http://dx.doi.org/10.1126/science.277.5325.556			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228004				2022-12-24	WOS:A1997XM86700049
J	Engel, S; Zhang, XM; Wandell, B				Engel, S; Zhang, XM; Wandell, B			Colour tuning in human visual cortex measured with functional magnetic resonance imaging	NATURE			English	Article							STRIATE CORTEX; CHROMATIC MECHANISMS; EVOKED-POTENTIALS; RED GREEN; MACAQUE; PHOTORECEPTORS; LUMINANCE; SPACE; CONE	The primate retina contains three classes of cones, the L, M and S cones, which respond preferentially to long-, middle- and short-wavelength visible light, respectively. Colour appearance results from neural processing of these cone signals within the retina and the brain. Perceptual experiments have identified three types of neural pathways that represent colour: a red-green pathway that signals differences between L- and M-cone responses; a blue-yellow pathway that signals differences between S-cone responses and a sum of L- and M-cone responses; and a luminance pathway that signals a sum of L- and M-cone responses(1-3). It might be expected that there are neurons in the primary visual cortex with response properties that resemble these three perceptual pathways, but attempts to find them have led to inconsistent results(4-7). We have therefore used functional magnetic resonance imaging (fMRI) to examine responses in the human brain to a large number of colours. In visual cortical areas V1 and V2, the strongest response is to red-green stimuli, and much of this activity is from neurons receiving opposing inputs from L and M cones. A strong response is also seen with blue-yellow stimuli, and this response declines rapidly as the temporal frequency of the stimulus is increased. These responses resemble psychophysical measurements, suggesting that colour signals relevant for perception are encoded in a large population of neurons in areas V1 and V2.	STANFORD UNIV, DEPT PSYCHOL, STANFORD, CA 94305 USA	Stanford University								BOYNTON RM, 1964, VISION RES, V4, P87, DOI 10.1016/0042-6989(64)90035-5; Calkins DJ, 1996, NATURE, V381, P613, DOI 10.1038/381613a0; COLE GR, 1993, J OPT SOC AM A, V10, P38, DOI 10.1364/JOSAA.10.000038; Cottaris N. P., 1996, Society for Neuroscience Abstracts, V22, P951; CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411; DACEY DM, 1994, NATURE, V367, P731, DOI 10.1038/367731a0; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P241, DOI 10.1113/jphysiol.1984.sp015499; DEVALOIS RL, 1965, COLD SPRING HARB SYM, V30, P567, DOI 10.1101/SQB.1965.030.01.055; DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382; ENGEL SA, 1994, NATURE, V369, P525, DOI 10.1038/369525a0; Engel SA, 1997, CEREB CORTEX, V7, P181, DOI 10.1093/cercor/7.2.181; Gur M, 1997, VISION RES, V37, P377, DOI 10.1016/S0042-6989(96)00183-6; HURVICH LM, 1957, PSYCHOL REV, V64, P384, DOI 10.1037/h0041403; KELLY DH, 1971, J OPT SOC AM, V61, P537, DOI 10.1364/JOSA.61.000537; Kleinschmidt A, 1996, EXP BRAIN RES, V110, P279; LENNIE P, 1990, J NEUROSCI, V10, P649; LIVINGSTONE MS, 1984, J NEUROSCI, V4, P2830; MULLEN KT, 1985, J PHYSIOL-LONDON, V359, P381, DOI 10.1113/jphysiol.1985.sp015591; POIRSON AB, 1993, J OPT SOC AM A, V10, P2458, DOI 10.1364/JOSAA.10.002458; RABIN J, 1994, VISION RES, V34, P2657, DOI 10.1016/0042-6989(94)90222-4; REGAN D, 1973, VISION RES, V13, P2381, DOI 10.1016/0042-6989(73)90237-X; RODIECK RW, 1991, NATO ADV SCI I A-LIF, V203, P83; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; STOCKMAN A, 1991, VISION RES, V31, P189, DOI 10.1016/0042-6989(91)90111-H; THORELL LG, 1984, VISION RES, V24, P751, DOI 10.1016/0042-6989(84)90216-5; THORNTON JE, 1983, SCIENCE, V219, P191, DOI 10.1126/science.6849131; TSO DY, 1988, J NEUROSCI, V8, P1712; VAUTIN RG, 1985, J NEUROPHYSIOL, V54, P273, DOI 10.1152/jn.1985.54.2.273; WANDELL BA, 1985, J OPT SOC AM A, V2, P62, DOI 10.1364/JOSAA.2.000062; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115	30	249	268	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	1997	388	6637					68	71		10.1038/40398	http://dx.doi.org/10.1038/40398			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214503	Bronze			2022-12-24	WOS:A1997XJ14300051
J	Akashi, K; Kondo, M; vonFreedenJeffry, U; Murray, R; Weissman, IL				Akashi, K; Kondo, M; vonFreedenJeffry, U; Murray, R; Weissman, IL			Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice	CELL			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; GAMMA-CHAIN; IL-2 RECEPTOR; POSITIVE SELECTION; NEGATIVE SELECTION; CELL-DEATH; B-CELLS; BCL-2-DEFICIENT MICE; FUNCTIONAL COMPONENT; LYMPHOID DEVELOPMENT	Mice lacking functional IL-7 or lL-7R alpha genes are severely deficient in developing thymocytes, T cells, and B cells. IL-7 and IL-7 receptor functions are believed to result in lymphoid cell proliferation and cell maturation, implying signal transduction pathways directly involved in mitogenesis and elaboration of developmentally specific new gene programs. Here, we show that enforced expression of the bcl-2 gene in T-lymphoid cells (by crossing in the E mu-bcl-2 transgene) in IL-7R alpha-deficient mice results in a significant restoration of thymic positive selection and T cell numbers and function. We propose cell survival signals to be the principal function of IL-7R engagement in thymic and T cell development.	STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; DNAX RES INST MOL & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304	Stanford University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Akashi, K (corresponding author), STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305, USA.				NCI NIH HHS [CA42551] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADKINS B, 1987, ANNU REV IMMUNOL, V5, P325, DOI 10.1146/annurev.iy.05.040187.001545; Akashi K, 1996, IMMUNITY, V5, P147, DOI 10.1016/S1074-7613(00)80491-4; APPASAMY PM, 1993, J EXP MED, V178, P2201, DOI 10.1084/jem.178.6.2201; BHATIA SK, 1995, J EXP MED, V181, P1399, DOI 10.1084/jem.181.4.1399; BRANDLE D, 1994, EUR J IMMUNOL, V24, P145, DOI 10.1002/eji.1830240122; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FRIEND SL, 1994, EXP HEMATOL, V22, P321; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRATIOTDEANS J, 1994, P NATL ACAD SCI USA, V91, P10685, DOI 10.1073/pnas.91.22.10685; GRATIOTDEANS J, 1993, J IMMUNOL, V151, P83; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; Guidos CJ, 1996, CURR OPIN IMMUNOL, V8, P225, DOI 10.1016/S0952-7915(96)80061-6; GUTMAN GA, 1972, IMMUNOLOGY, V23, P465; He YW, 1996, J EXP MED, V184, P289, DOI 10.1084/jem.184.1.289; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KONDO M, 1994, EUR J IMMUNOL, V24, P2026, DOI 10.1002/eji.1830240914; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KONDO M, 1997, IN PRESS IMMUNITY; KRAFT DL, 1993, J EXP MED, V178, P265, DOI 10.1084/jem.178.1.265; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Lucas B, 1996, IMMUNITY, V5, P461, DOI 10.1016/S1074-7613(00)80502-6; Maki K, 1996, J EXP MED, V184, P2423, DOI 10.1084/jem.184.6.2423; Maraskovsky E, 1996, J IMMUNOL, V157, P5315; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NAKAYAMA KI, 1995, J EXP MED, V182, P1101, DOI 10.1084/jem.182.4.1101; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; RAY JR, 1996, EUR J IMMUNOL, V26, P10; RODEWALD HR, 1995, IMMUNITY, V3, P313, DOI 10.1016/1074-7613(95)90116-7; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SADLACK B, 1994, EUR J IMMUNOL, V24, P281, DOI 10.1002/eji.1830240144; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; STEPHAN YL, 1997, J CLIN INVEST, V99, P169; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; SUDA T, 1991, J IMMUNOL, V146, P3068; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAO W, 1994, J EXP MED, V179, P145, DOI 10.1084/jem.179.1.145; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VEIS DJ, 1993, J IMMUNOL, V151, P2546; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; vonBoehmer H, 1996, J EXP MED, V183, P713, DOI 10.1084/jem.183.3.713; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WEISSMAN IL, 1994, CELL, V76, P207, DOI 10.1016/0092-8674(94)90329-8; YAMASHITA I, 1993, INT IMMUNOL, V5, P1139, DOI 10.1093/intimm/5.9.1139; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YOUNG E, 1997, IMMUNITY, V6, P23	66	517	525	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1033	1041		10.1016/S0092-8674(00)80291-3	http://dx.doi.org/10.1016/S0092-8674(00)80291-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215626	Bronze			2022-12-24	WOS:A1997XG83000008
J	Naka, T; Narazaki, M; Hirata, M; Matsumoto, T; Minamoto, S; Aono, A; Nishimoto, N; Kajita, T; Taga, T; Yoshizaki, K; Akira, S; Kishimoto, T				Naka, T; Narazaki, M; Hirata, M; Matsumoto, T; Minamoto, S; Aono, A; Nishimoto, N; Kajita, T; Taga, T; Yoshizaki, K; Akira, S; Kishimoto, T			Structure and function of a new STAT-induced STAT inhibitor	NATURE			English	Article							TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; ACTIVATION; INTERLEUKIN-6; PATHWAYS; GP130; FAMILY; IL-3	The signalling pathway that comprises JAK kinases and STAT proteins (for signal transducer and activator of transcription) is important for relaying signals from various cytokines outside the cell to the inside(1-3). The feedback mechanism responsible for switching off the cytokine signal has not been elucidated. We now report the cloning and characterization of an inhibitor of STAT activation which we name SSI-1 (for STAT-induced STAT inhibitor-1). We found that SSI-1 messenger RNA was induced by the cytokines interleukins 4 and 6 (IL-4, IL-6), leukaemia-inhibitory factor (LIF), and granulocyte colony-stimulating factor (G-CSF). Stimulation by IL-6 or LIF of murine myeloid leukaemia cells (M1 cells) induced SSI-1 mRNA expression which was blocked by transfection of a dominant-negative mutant of Stat3, indicating that the SSI-1 gene is a target of Stat3 (refs 4-7). Forced overexpression of SSI-1 complementary DNA interfered with IL-6- and LIF-mediated apoptosis and macrophage differentiation of M1 cells, as well as IL-6 induced tyrosine-phosphorylation of a receptor glycoprotein component, gp130, and of Stat3. When SSI-1 is overexpressed in COS7 cells, it can associate with the kinases Jak2 and Tyk2, These findings indicate that SSI-1 is responsible for negative-feedback regulation of the JAK-STAT pathway induced by cytokine stimulation.	OSAKA UNIV,SCH MED,DEPT MED 3,SUITA,OSAKA 565,JAPAN; INT REAGENTS CORP,CTR RES & DEV,NISHI KU,KOBE 65122,JAPAN; TOKYO MED & DENT UNIV,MED RES INST,DEPT MOL CELL BIOL,CHIYODA KU,TOKYO 101,JAPAN; HYOGO MED UNIV,DEPT BIOCHEM,NISHINOMIYA,HYOGO 663,JAPAN; OSAKA UNIV,SCH HLTH & SPORTS SCI,SUITA,OSAKA 565,JAPAN	Osaka University; Tokyo Medical & Dental University (TMDU); Hyogo College of Medicine; University of Hyogo; Osaka University			Kishimoto, Tadamitsu/C-8470-2009; Akira, Shizuo/C-3134-2009	narazaki, masashi/0000-0002-5613-4409; Naka, Tetsuji/0000-0002-1269-3997				Adachi M, 1996, CELL, V85, P15; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HULI J, 1989, J IMMUNOL, V142, P800; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TIAN SS, 1994, BLOOD, V84, P1760; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	27	1097	1148	0	64	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					924	929		10.1038/43219	http://dx.doi.org/10.1038/43219			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202127	Bronze			2022-12-24	WOS:A1997XG41600057
J	Hensel, WA				Hensel, WA			Bea's legacy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1913	1914						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF087	9200617				2022-12-24	WOS:A1997XF08700001
J	Minkoff, H; Bauer, T; Joyce, T				Minkoff, H; Bauer, T; Joyce, T			Welfare reform and the obstetrical care of immigrants and their newborns	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							IMPACT		NATL BUR ECON RES,NEW YORK,NY 10017	National Bureau of Economic Research	Minkoff, H (corresponding author), SUNY HLTH SCI CTR,BOX 24,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.							*ASS AM MED COLL, 1997, AAMC FACT SHEET, V1; BATES AS, 1994, JAMA-J AM MED ASSOC, V272, P1105, DOI 10.1001/jama.272.14.1105; BUESCHER PA, 1991, AM J PUBLIC HEALTH, V81, P1625, DOI 10.2105/AJPH.81.12.1625; CHAVEZ LR, 1986, WOMEN HEALTH, V11, P3, DOI 10.1300/J013v11n02_02; *DEP HLTH SERV, 1997, MED CAL FUND DEL 199; Halfon N, 1997, JAMA-J AM MED ASSOC, V277, P636, DOI 10.1001/jama.277.8.636; *MARCH DIM BIRTH D, 1995, FACTS MED PREGN WOM; Minkoff H, 1997, NEW ENGL J MED, V336, P1392, DOI 10.1056/NEJM199705083361916; *NAT GOV ASS, 1996, STAT MED COV PREGN W; Reichman NE, 1996, J HEALTH ECON, V15, P455, DOI 10.1016/S0167-6296(96)00491-2; SINGH S, 1994, FAM PLANN PERSPECT, V26, P31, DOI 10.2307/2136094	11	12	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	1997	337	10					705	707		10.1056/NEJM199709043371011	http://dx.doi.org/10.1056/NEJM199709043371011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XU349	9278471				2022-12-24	WOS:A1997XU34900011
J	Beltramo, M; Stella, N; Calignano, A; Lin, SY; Makriyannis, A; Piomelli, D				Beltramo, M; Stella, N; Calignano, A; Lin, SY; Makriyannis, A; Piomelli, D			Functional role of high-affinity anandamide transport, as revealed by selective inhibition	SCIENCE			English	Article							CANNABINOID RECEPTOR AGONIST; PHARMACOLOGICAL ACTIVITY; BRAIN CONSTITUENT; RAT-BRAIN; INVOLVEMENT; NEURONS; IDENTIFICATION; LOCALIZATION; PROTEIN; BINDING	Anandamide, an endogenous ligand for central cannabinoid receptors, is released from neurons on depolarization and rapidly inactivated. Anandamide inactivation is not completely understood, but it may occur by transport into cells or by enzymatic hydrolysis. The compound N-(4-hydroxyphenyl)arachidonylamide (AM404) was shown to inhibit high-affinity anandamide accumulation in rat neurons and astrocytes in vitro, an indication that this accumulation resulted from carrier-mediated transport. Although AM404 did not activate cannabinoid receptors or inhibit anandamide hydrolysis, it enhanced receptor-mediated anandamide responses in vitro and in vivo, The data indicate that carrier-mediated transport may be essential for termination of,the biological effects of anandamide, and may represent a potential drug target.	INST NEUROSCI,SAN DIEGO,CA 92121; UNIV NAPLES,SCH PHARM,I-80131 NAPLES,ITALY; UNIV CONNECTICUT,SCH PHARM,STORRS,CT 06269	University of Naples Federico II; University of Connecticut				CALIGNANO, Antonio/0000-0002-1742-3179				Barker Eric L., 1995, P321; Beltramo M, 1997, FEBS LETT, V403, P263, DOI 10.1016/S0014-5793(97)00061-6; BELTRAMO M, UNPUB; BITO LZ, 1976, J PHYSIOL-LONDON, V256, P257, DOI 10.1113/jphysiol.1976.sp011324; BITO LZ, 1975, NATURE, V256, P1234; Bojesen IN, 1996, ACTA PHYSIOL SCAND, V156, P501, DOI 10.1046/j.1365-201X.1996.456173000.x; Cadas H, 1996, J NEUROSCI, V16, P3934; Cadas H, 1997, J NEUROSCI, V17, P1226; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEWEY WL, 1986, PHARMACOL REV, V38, P151; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HOWLETT AC, 1986, MOL PHARMACOL, V29, P307; Jung M, 1997, J NEUROCHEM, V68, P402; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; Khanolkar AD, 1996, J MED CHEM, V39, P4515, DOI 10.1021/jm960152y; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; KUSTER JE, 1993, J PHARMACOL EXP THER, V264, P1352; MAKI R, 1994, J NEUROSCI, V14, P6754; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; MECHOULAM R, 1994, BIOCHEM PHARMACOL, V48, P1537, DOI 10.1016/0006-2952(94)90197-X; PORRECA F, 1984, J PHARMACOL EXP THER, V230, P341; PREZEAU L, 1992, P NATL ACAD SCI USA, V89, P8040, DOI 10.1073/pnas.89.17.8040; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; STEIN WD, 1990, CHANNELS PUMPS INTRO, P53; STELLA N, 1995, J NEUROSCI, V15, P3307; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823	35	652	688	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1094	1097		10.1126/science.277.5329.1094	http://dx.doi.org/10.1126/science.277.5329.1094			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262477	Green Submitted			2022-12-24	WOS:A1997XT03300034
J	Xu, ZH; Horwich, AL; Sigler, PB				Xu, ZH; Horwich, AL; Sigler, PB			The crystal structure of the asymmetric GroEL-GroES-(ADP)(7) chaperonin complex	NATURE			English	Article							ESCHERICHIA-COLI; GROEL; PROTEIN; BINDING; RELEASE; COOPERATIVITY; POLYPEPTIDE; AGGREGATION; HYDROLYSIS; MICROSCOPY	Chaperonins assist protein folding with the consumption of ATP. They exist as multi-subunit protein assemblies comprising rings of subunits stacked back to back. in Escherichia coli, asymmetric Intermediates of GroEL are formed with the co-chaperonin GroES and nucleotides bound only to one of the seven-subunit rings (the cis ring) and not to the opposing ring (the trans ring). The structure of the GroEL-GroES-(ADP), complex reveals how large en bloc movements of the cis ring's intermediate and apical domains enable bound GroES to stabilize a foiling chamber with ADP confined to the cis ring. Elevation and twist of the apical domains double the volume of the central cavity anal bury hydrophobic peptide-binding residues in the interface with GroES, as well as between GroEL subunits, leaving a hydrophilic cavity lining that is conducive to protein folding. An inward tilt of the cis equatorial domain causes an outward tilt in the trans ring that opposes the binding of a second GroES. When combined with new functional results, this negative allosteric mechanism suggests a model for an ATP-driven folding cycle that requires a double toroid.	YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,BOYER CTR MOL MED,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University; Yale University								Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; ELLIS RJ, 1996, CHAPERONINS; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRAY TE, 1992, FEBS LETT, V310, P99; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; LAMBRIGHT DG, 1994, NATURE, V369, P921; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIN S, 1995, J BIOL CHEM, V270, P1011; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; TAGUCHI H, 1995, FEBS LETT, V359, P195, DOI 10.1016/0014-5793(95)00041-7; Thiyagarajan P, 1996, STRUCTURE, V4, P79, DOI 10.1016/S0969-2126(96)00011-1; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; TRUNGER AT, 1993, X PLOR VERSION 3 1 M; Walter S, 1996, P NATL ACAD SCI USA, V93, P9425, DOI 10.1073/pnas.93.18.9425; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Yifrach O, 1996, J MOL BIOL, V255, P356, DOI 10.1006/jmbi.1996.0028; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642; ZEILSTRARYALLS J, 1994, J BACTERIOL, V176, P6558, DOI 10.1128/JB.176.21.6558-6565.1994	59	989	1019	3	115	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					741	750		10.1038/41944	http://dx.doi.org/10.1038/41944			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285585				2022-12-24	WOS:A1997XR66700042
J	Pusey, A; Williams, J; Goodall, J				Pusey, A; Williams, J; Goodall, J			The influence of dominance rank on the reproductive success of female chimpanzees	SCIENCE			English	Article							BABOONS	Female chimpanzees often forage alone and do not display obvious linear dominance hierarchies; consequently, it has been suggested that dominance is not of great importance to them. However, with the use of data from a 35-year field study of chimpanzees, high-ranking females were shown to have significantly higher infant survival, faster maturing daughters, and more rapid production of young, Given the foraging behavior of chimpanzees, high rank probably influences reproductive success by helping females establish and maintain access to good foraging areas rather than by sparing them stress from aggression.	JANE GOODALL INST,RIDGEFIELD,CT 06877		Pusey, A (corresponding author), UNIV MINNESOTA,DEPT ECOL EVOLUT & BEHAV,JANE GOODALL INST CTR PRIMATE STUDIES,ST PAUL,MN 55108, USA.		Klein, Richard G/B-5910-2009	Pusey, Anne/0000-0002-2280-8954				[Anonymous], 1993, DESIGN ANAL ECOLOGIC; Baker Kate C., 1994, P227; Bygott JD., 1979, GREAT APES, P405; Chapais Bernard, 1992, P29; CLUTTONBROCK TH, 1979, AFR J ECOL, V17, P131, DOI 10.1111/j.1365-2028.1979.tb00250.x; COLLINS DA, 1988, J HUM EVOL, V17, P553, DOI 10.1016/0047-2484(88)90084-X; DEWAAL F, 1982, CHIMPANZEE POLITICS; DEWAAL FBM, 1984, ETHOL SOCIOBIOL, V5, P239, DOI 10.1016/0162-3095(84)90004-9; ELLIS L, 1995, ETHOL SOCIOBIOL, V16, P357; Frank Laurence, 1995, SERENGETI, P364; GOODALL J, 1977, FOLIA PRIMATOL, V28, P259, DOI 10.1159/000155817; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; HARCOURT AH, 1987, J ZOOL, V213, P471, DOI 10.1111/j.1469-7998.1987.tb03721.x; MOSES LE, 1992, AM J PRIMATOL, V28, P49, DOI 10.1002/ajp.1350280105; NISHIDA T, 1987, PRIMATE SOC, P318; NISHIDA T, 1990, UNDERSTANDING CHIMPA, P68; PACKER C, 1995, NATURE, V373, P60, DOI 10.1038/373060a0; Pusey A, 1979, GREAT APES, P465; Pusey A.E., 1987, P250; PUSEY AE, 1990, BEHAVIOUR, V115, P203, DOI 10.1163/156853990X00581; PUSEY AE, 1980, ANIM BEHAV, V28, P543, DOI 10.1016/S0003-3472(80)80063-7; PUSEY AE, 1983, ANIM BEHAV, V31, P363, DOI 10.1016/S0003-3472(83)80055-4; Silk J.B., 1987, P318; SMUTS B, 1989, AM J PRIMATOL, V19, P229, DOI 10.1002/ajp.1350190405; van Schaik CP., 1989, COMP SOCIOECOLOGY BE, P195; Wallis J, 1997, J REPROD FERTIL, V109, P297; Walters J.R., 1987, P306; Wrangham R W, 1980, J Reprod Fertil Suppl, VSuppl 28, P13; WRANGHAM RW, 1980, BEHAVIOUR, V75, P262, DOI 10.1163/156853980X00447; WRANGHAM RW, 1974, ANIM BEHAV, V22, P83, DOI 10.1016/S0003-3472(74)80056-4; WRANGHAM RW, 1992, HUMAN ORIGINS, P81	31	360	367	0	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					828	831		10.1126/science.277.5327.828	http://dx.doi.org/10.1126/science.277.5327.828			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242614				2022-12-24	WOS:A1997XQ24700047
J	Woehlke, G; Ruby, AK; Hart, CL; Ly, B; HomBooher, N; Vale, RD				Woehlke, G; Ruby, AK; Hart, CL; Ly, B; HomBooher, N; Vale, RD			Microtubule interaction site of the kinesin motor	CELL			English	Article							MONOMERIC MOTOR; ATP HYDROLYSIS; PROTEIN; MYOSIN; DOMAIN; DROSOPHILA; ACTIN; MOLECULES; TRANSPORT; MOVEMENT	Kinesin and myosin are motor proteins that share a common structural core and bind to microtubules and actin filaments, respectively. While the actomyosin interface has been well studied, the location of the microtubule-binding site on kinesin has not been identified. Using alanine-scanning mutagenesis, we have found that microtubule-interacting kinesin residues are located in three loops that cluster in a patch on the motor surface. The critical residues are primarily positively charged, which is consistent with a primarily electrostatic interaction with the negatively charged tubulin molecule. The core of the microtubule-binding interface resides in a highly conserved loop and helix (L12/alpha 5) that corresponds topologically to the major actin-binding domain of myosin. Thus, kinesin and myosin have developed distinct polymer-binding domains in a similar region with respect to their common catalytic cores.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco	Woehlke, G (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.			Woehlke, Gunther/0000-0001-8462-9962	NIAMS NIH HHS [AR42895] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DOSREMEDIOS CG, 1995, BBA-BIOENERGETICS, V1228, P99, DOI 10.1016/0005-2728(94)00169-6; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; Hackney DD, 1996, ANNU REV PHYSIOL, V58, P731; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOYT MA, 1993, GENETICS, V135, P35; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Moore JD, 1996, EMBO J, V15, P3306, DOI 10.1002/j.1460-2075.1996.tb00695.x; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; Pearce KH, 1996, BIOCHEMISTRY-US, V35, P10300, DOI 10.1021/bi960513b; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; Rosenfeld SS, 1996, J BIOL CHEM, V271, P9473, DOI 10.1074/jbc.271.16.9473; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sambrook JFE, 1989, MOL CLONING LAB MANU; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Tucker C, 1997, J BIOL CHEM, V272, P9481; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; VALE RD, 1997, IN PRESS ANN REV CEL; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	56	306	312	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					207	216		10.1016/S0092-8674(00)80329-3	http://dx.doi.org/10.1016/S0092-8674(00)80329-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244295	Green Published, Bronze			2022-12-24	WOS:A1997XN24900005
J	Lauretta, DS; Lodders, K; Fegley, B				Lauretta, DS; Lodders, K; Fegley, B			Experimental simulations of sulfide formation in the solar nebula	SCIENCE			English	Article							IRON-NICKEL ALLOY; FE-NI; CHONDRITES; METEORITES; ORIGIN; SYSTEM; SULFUR	Sulfurization of meteoritic metal in H2S-H-2 gas produced three different sulfides: monosulfide solid solution [(Fe,Ni)(1-x)S], pentlandite [(Fe,Ni)(9-x)S-8], and a phosphorus-rich sulfide. The composition of the remnant metal was unchanged. These results are contrary ta theoretical predictions that sulfide formation in the solar nebula produced troilite (FeS) and enriched the remaining metal in nickel. The experimental sulfides are chemically and morphologically similar to sulfide grains in the matrix of the Alais (class Cl) carbonaceous chondrite, suggesting that these meteoritic sulfides may be condensates from the solar nebula.			Lauretta, DS (corresponding author), WASHINGTON UNIV,PLANETARY CHEM LAB,DEPT EARTH & PLANETARY SCI,CAMPUS BOX 1169,1 BROOKINGS DR,ST LOUIS,MO 63130, USA.			Lodders, Katharina/0000-0001-7531-626X				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BASTOW BD, 1985, CORROS SCI, V25, P253, DOI 10.1016/0010-938X(85)90080-0; CLARK JB, 1963, T METALL SOC AIME, V227, P1250; CONDIT RH, 1974, OXID MET, V8, P409, DOI 10.1007/BF00603390; DEAN DC, 1986, METALL TRANS A, V17, P1131, DOI 10.1007/BF02665311; DEVOUARD B, UNPUB METEORIT PLANE; DREIBUS G, 1995, METEORITICS, V30, P439, DOI 10.1111/j.1945-5100.1995.tb01150.x; Folinsbee R.E., 1967, GEOCHIM COSMOCHIM AC, V31, P1625; HANOWSKI NP, 1996, METEORIT PLANET SC S, V31, pA57; HUSS GR, 1981, GEOCHIM COSMOCHIM AC, V45, P33, DOI 10.1016/0016-7037(81)90262-3; KERRIDGE JF, 1979, EARTH PLANET SC LETT, V43, P359, DOI 10.1016/0012-821X(79)90091-8; KERRIDGE JF, 1979, EARTH PLANET SC LETT, V43, P1, DOI 10.1016/0012-821X(79)90149-3; LARIMER JW, 1967, GEOCHIM COSMOCHIM AC, V31, P1215, DOI 10.1016/S0016-7037(67)80013-9; Lauretta D.S., 1996, P NIPR S ANT MET, V9, P97; Lauretta D.S., 1996, P NIPR S ANT MET, V9, P111; Lauretta DS, 1996, ICARUS, V122, P288, DOI 10.1006/icar.1996.0126; LAURETTA DS, 1995, LUNAR PLANET SCI, V26, P831; LAURETTA DS, UNPUB METEORIT PLANE; LEWIS JS, 1972, EARTH PLANET SC LETT, V15, P286, DOI 10.1016/0012-821X(72)90174-4; LEWIS RS, 1975, P NATL ACAD SCI USA, V72, P268, DOI 10.1073/pnas.72.1.268; MILLION B, 1981, MATER SCI ENG, V50, P43, DOI 10.1016/0025-5416(81)90084-7; NARITA T, 1975, DENKI KAGAKU, V43, P443; Nazarov M. F., 1996, LUNAR PLANET SCI, V27, P939; ORCHARD JP, 1989, OXID MET, V31, P105, DOI 10.1007/BF00665489; ORCHARD JP, 1989, J ELECTROCHEM SOC, V136, P545, DOI 10.1149/1.2096679; RAMDOHR P, 1963, J GEOPHYS RES, V68, P2011, DOI 10.1029/JZ068i007p02011; SHEWMAN RW, 1970, CAN J EARTH SCI, V7, P67, DOI 10.1139/e70-005; UREY HC, 1952, PLANETS	28	65	68	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					358	360		10.1126/science.277.5324.358	http://dx.doi.org/10.1126/science.277.5324.358			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219690				2022-12-24	WOS:A1997XL35800042
J	Deng, HK; Unutmaz, D; KewalRamani, VN; Littman, DR				Deng, HK; Unutmaz, D; KewalRamani, VN; Littman, DR			Expression cloning of new receptors used by simian and human immunodeficiency viruses	NATURE			English	Article							INFECTION; IDENTIFICATION; DETERMINANT; TYPE-1; STRAIN; HIV-1	Several members of the chemokine-receptor family serve, in conjunction with CD4, as receptors for the entry of human immunodeficiency virus type I (HIV-1) into cells(1-6). The principal receptor for entry of macrophage-tropic (M-tropic) HIV-1 strains is CCR5, whereas that for T-cell-line-tropic (T-tropic) strains is CXCR4. Unlike HlV-1, infection with either M-tropic or T-tropic strains of simian immunodeficiency virus (SIV) can be mediated by CCR5, but not CXCR4 (refs 7-10). SIV strains will also infect CD4(+) cells that lack CCR5, which suggests that these strains use as yet unidentified receptors(7,9,10). Here we use an expression-cloning strategy to identify SIV receptors and have isolated genes encoding two members of the seven-transmembrane G-protein-coupled receptor family that are used not only by SIVs, but also by strains of HIV-2 and M-tropic HIV-1. Both receptors are closely related to the chemokine-receptor family and are expressed in lymphoid tissues. One of the receptors is also expressed in colon and may therefore be important in viral transmission. Usage of these new receptors following experimental infection of non-human primates with SIV strains may provide important insight into viral transmission and the mechanisms of SIV- and HIV-induced acquired immune-deficiency syndrome.	NYU,MED CTR,HOWARD HUGHES MED INST,SKIRBALL INST BIOMOL MED,DIV MOL PATHOGENESIS,NEW YORK,NY 10016	Howard Hughes Medical Institute; New York University			KewalRamani, Vineet/V-5084-2019					Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BARNETT SW, 1993, J VIROL, V67, P1006, DOI 10.1128/JVI.67.2.1006-1014.1993; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P4005, DOI 10.1073/pnas.94.8.4005; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FUKASAWA M, 1988, NATURE, V333, P457, DOI 10.1038/333457a0; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Heiber M, 1996, GENOMICS, V32, P462, DOI 10.1006/geno.1996.0143; HILL CM, IN PRESS J VIROL; HWANG SS, 1992, SCIENCE, V257, P535, DOI 10.1126/science.1636088; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; KONG LI, 1988, SCIENCE, V240, P1525, DOI 10.1126/science.3375832; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; LIAO S, 1997, J EXP MED, V185, P2015; MARCON J, 1997, J VIROL, V71, P2522; MARTHAS ML, 1989, J MED PRIMATOL, V18, P311; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; STEFANO KA, 1993, J VIROL, V67, P6707, DOI 10.1128/JVI.67.11.6707-6715.1993; THEODOROU J, 1997, LANCET, V349, P1219; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097	31	590	615	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					296	300		10.1038/40894	http://dx.doi.org/10.1038/40894			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230441	Bronze			2022-12-24	WOS:A1997XL12100056
J	Hata, A; Lo, RS; Wotton, D; Lagna, G; Massague, J				Hata, A; Lo, RS; Wotton, D; Lagna, G; Massague, J			Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4	NATURE			English	Article							BETA	Smad2 and Smad4 are related tumour-suppressor proteins(1,2), which, when stimulated by the growth factor TGF-beta, form a complex to inhibit growth(3). The effector function of Smad2 and Smad4 is located in the conserved carboxy-terminal domain (C domain) of these proteins and is inhibited by the presence of their amino-terminal domains (N domain)(4,5). This inhibitory function of the N domain is shown here to involve an interaction with the C domain that prevents the association of Smad2 with Smad4. This inhibitory function is increased in tumour-derived forms of Smad2 and 4 that carry a missense mutation in a conserved N domain arginine residue. The mutant N domains have an increased affinity for their respective C domains, inhibit the Smad2-Smad4 interaction, and prevent TGF beta-induced Smad2-Smad4 association and signalling. Whereas mutations in the C domain disrupt the effector function of the Smad proteins, N-domain arginine mutations inhibit SMAD signalling through a g-ain of autoinhibitory function. Gain of autoinhibitory function isa new mechanism for inactivating tumour suppressors.	ROCKEFELLER UNIV,CELL BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOL EMBRYOL LAB,NEW YORK,NY 10021	Rockefeller University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Rockefeller University; Rockefeller University				Massague, Joan/0000-0001-9324-8408; Wotton, David/0000-0002-4652-5350				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Barrett MT, 1996, CANCER RES, V56, P4351; Bartel P. L., 1993, CELLULAR INTERACTION, P153; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kim SK, 1996, CANCER RES, V56, P2519; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Nagatake M, 1996, CANCER RES, V56, P2718; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Uchida K, 1996, CANCER RES, V56, P5583; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	24	295	308	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					82	87		10.1038/40424	http://dx.doi.org/10.1038/40424			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214507	Bronze			2022-12-24	WOS:A1997XJ14300055
J	Lappalainen, P; Drubin, DG				Lappalainen, P; Drubin, DG			Cofilin promotes rapid actin filament turnover in vivo	NATURE			English	Article							DEPOLYMERIZING FACTOR; SACCHAROMYCES-CEREVISIAE; INTERNALIZATION STEP; GENE ENCODES; YEAST; CYTOSKELETON; ENDOCYTOSIS; POLYMERIZATION; ORGANIZATION; INHIBITION	The ability of actin filaments to function in cell morphogenesis and motility is coupled to their capacity for rapid assembly and disassembly. Because disassembly in vitro is much slower than in vivo, cellular factors that stimulate disassembly have long been assumed to exist. Although numerous proteins can affect actin dynamics in vitro, demonstration of in vivo relevance of these effects has not been achieved. We have used genetics and an actin-inhibitor in yeast to demonstrate that rapid cycles of actin assembly and disassembly depend on the small actin-binding protein cofilin, and that cofilin stimulates filament disassembly. These results may explain why cofilin is ubiquitous in eukaryotes and is essential for viability in every organism in which its function has been tested genetically. Magnitudes of disassembly defects in cofilin mutants in vivo were found to be correlated closely with the magnitudes of disassembly defects observed in vitro, supporting our conclusions. Furthermore, these cofilin mutants provided an opportunity to distinguish in living cells those actin functions that depend specifically on filament turnover (endocytosis) from those that do not (cortical actin patch motility).	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley				Lappalainen, Pekka/0000-0001-6227-0354				Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; ADAMS AEM, 1991, NATURE, V354, P404, DOI 10.1038/354404a0; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Ausubel FA, 1990, CURRENT PROTOCOLS MO; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Doyle T, 1996, P NATL ACAD SCI USA, V93, P3886, DOI 10.1073/pnas.93.9.3886; DULIC V, 1991, METHOD ENZYMOL, V194, P697; FREEMAN NL, 1995, J BIOL CHEM, V270, P5680, DOI 10.1074/jbc.270.10.5680; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; MCKIM KS, 1994, MOL GEN GENET, V242, P346, DOI 10.1007/BF00280425; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; Waddle JA, 1996, J CELL BIOL, V132, P861, DOI 10.1083/jcb.132.5.861; WELCH MD, 1997, OPIN CELL BIOL, V9, P54; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382	30	367	370	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	1997	388	6637					78	82		10.1038/40418	http://dx.doi.org/10.1038/40418			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214506	Bronze			2022-12-24	WOS:A1997XJ14300054
J	Ginsburg, J				Ginsburg, J			Unanswered questions in carcinoma of the testis	LANCET			English	Editorial Material									UCL, SCH MED, LONDON NW3 2QG, ENGLAND	University of London; University College London; UCL Medical School	Ginsburg, J (corresponding author), ROYAL FREE HOSP, JOINT UNIV DEPT MED, POND ST, LONDON NW3 2QG, ENGLAND.							BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298	1	7	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1785	1786		10.1016/S0140-6736(05)61688-1	http://dx.doi.org/10.1016/S0140-6736(05)61688-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269209				2022-12-24	WOS:A1997XF73500005
J	Genbacev, O; Zhou, Y; Ludlow, JW; Fisher, SJ				Genbacev, O; Zhou, Y; Ludlow, JW; Fisher, SJ			Regulation of human placental development by oxygen tension	SCIENCE			English	Article							CYTOTROPHOBLASTS; EXPRESSION; TROPHOBLAST; INVASION; PROTEINS; TUMORS; CELLS	Cytotrophoblasts, specialized placental cells, proliferate early in pregnancy and then differentiate into tumor-like cells that establish blood flow to the placenta by invading the uterus and its vasculature. In this study, cytotrophoblasts cultured under hypoxic conditions (2 percent oxygen), mimicking the environment near the uterine surface before 10 weeks of gestation, continued proliferating and differentiated poorly. When cultured in 20 percent oxygen, mimicking the environment near uterine arterioles, the cells stopped proliferating and differentiated normally. Thus, oxygen tension determines whether cytotrophoblasts proliferate or invade, thereby regulating placental growth and cellular architecture.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV ROCHESTER,CTR CANC,DEPT BIOCHEM & BIOPHYS,ROCHESTER,NY 14642	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Rochester					NCI NIH HHS [CA 56904] Funding Source: Medline; NICHD NIH HHS [HD30367] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD030367] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Boyd J D, 1967, J Obstet Gynaecol Br Commonw, V74, P161; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAMSKY CH, 1994, DEVELOPMENT, V120, P3657; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; Fisher S J, 1993, Semin Cell Biol, V4, P183, DOI 10.1006/scel.1993.1022; FISHER SJ, 1989, J CELL BIOL, V109, P891, DOI 10.1083/jcb.109.2.891; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; GENBACEV O, 1992, PLACENTA, V13, P439, DOI 10.1016/0143-4004(92)90051-T; Genbacev O, 1996, J CLIN INVEST, V97, P540, DOI 10.1172/JCI118447; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hertig A.T., 1942, ANAT REC, V82, P420; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KURMAN RJ, 1984, INT J GYNECOL PATHOL, V3, P101, DOI 10.1097/00004347-198403010-00009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; MCMASTER MT, 1995, J IMMUNOL, V154, P3771; RODESCH F, 1992, OBSTET GYNECOL, V80, P283; SCHWARTING R, 1993, LAB INVEST, V68, P597; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387; ZHOU Y, 1993, J CLIN INVEST, V91, P950, DOI 10.1172/JCI116316	22	691	738	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1669	1672		10.1126/science.277.5332.1669	http://dx.doi.org/10.1126/science.277.5332.1669			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287221				2022-12-24	WOS:A1997XV68400052
J	AgerholmLarsen, B; TybjaergHansen, A; FrikkeSchmidt, R; Gronholdt, MLM; Jensen, G; Nordestgaard, BG				AgerholmLarsen, B; TybjaergHansen, A; FrikkeSchmidt, R; Gronholdt, MLM; Jensen, G; Nordestgaard, BG			ACE gene polymorphism as a risk factor for ischemic cerebrovascular disease	ANNALS OF INTERNAL MEDICINE			English	Article						polymorphism (genetics); peptidyl-dipeptidase A; cerebrovascular disorders; cerebral ischemia; cerebral ischemia, transient	ANGIOTENSIN-CONVERTING-ENZYME; INSERTION DELETION POLYMORPHISM; MYOCARDIAL-INFARCTION; STROKE; JAPANESE	Background: Researchers have suggested that the deletional allele of the ACE (angiotensin-converting enzyme) gene insertion-deletion polymorphism is a potent risk factor for myocardial infarction. This association could not be confirmed in the Copenhagen City Heart Study, in which 10 150 persons were studied. The ACE gene polymorphism has also recently been suggested as a potent risk factor for ischemic cerebrovascular disease. Objective: To investigate the association between ACE gene polymorphism and ischemic cerebrovascular disease. Design: Two case-referent studies and a cross-sectional study. Setting: University hospital in Copenhagen, Denmark. Participants: Case-referent study 1: 35 women and 38 men who developed ischemic cerebrovascular disease before 50 years of age compared with 1454 women and 1737 men from a general population sample. Case-referent study 2: 82 women and 137 men with ischemic cerebrovascular disease and carotid stenosis greater than 40% compared with 4273 women and 3091 men from the general population sample. Cross-sectional study of the general population sample: 67 women and 93 men with ischemic cerebrovascular disease compared with 4077 women and 3156 men without such disease. Measurements: Genotype; age; body mass index; smoking habits; levels of lipids, lipoproteins, apolipoproteins, and fibrinogen; and diagnosis of hypertension, diabetes mellitus, and ischemic cerebrovascular disease. Results: Odds ratios for ischemic cerebrovascular disease by ACE genotype classes were not significantly different from 1.0 in women or men in any of the three studies, separately or combined. In a logistic regression analysis that controlled for age and conventional cardiovascular risk factors, odds ratios in either sex still did not significantly differ from 1.0 in any study, separately or combined. Conclusion: In two case-referent studies, a cross-sectional study, and the three studies combined, no statistically significant difference was found in the development of ischemic cerebrovascular disease between genotype classes of the ACE gene polymorphism in women or men.	HERLEV UNIV HOSP, DEPT CLIN BIOCHEM, DK-2730 HERLEV, DENMARK; UNIV COPENHAGEN, NATL HOSP, DEPT VASC SURG, DK-2100 COPENHAGEN, DENMARK; UNIV COPENHAGEN, COPENHAGEN, DENMARK	University of Copenhagen; Herlev & Gentofte Hospital; Rigshospitalet; University of Copenhagen; University of Copenhagen			Nordestgaard, Borge Gronne/ABF-1310-2020	Frikke-Schmidt, Ruth/0000-0003-4084-5027				AgerholmLarsen B, 1997, CIRCULATION, V95, P2358, DOI 10.1161/01.CIR.95.10.2358; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; Catto A, 1996, STROKE, V27, P435, DOI 10.1161/01.STR.27.3.435; ERDOS EG, 1987, LAB INVEST, V56, P345; Hosmer D., 1989, APPL LOGISTIC REGRES, P82; Kario K, 1996, CIRCULATION, V93, P1630, DOI 10.1161/01.CIR.93.9.1630; LACHURIE ML, 1995, CIRCULATION, V91, P2933, DOI 10.1161/01.CIR.91.12.2933; LEE EJD, 1994, BRIT J CLIN PHARMACO, V37, P212, DOI 10.1111/j.1365-2125.1994.tb04264.x; LINDENSTROM E, 1992, STROKE, V23, P28, DOI 10.1161/01.STR.23.1.28; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103; Margaglione M, 1996, ARTERIOSCL THROM VAS, V16, P304, DOI 10.1161/01.ATV.16.2.304; MARKUS HS, 1995, STROKE, V26, P1329, DOI 10.1161/01.STR.26.8.1329; NAKAI K, 1994, CIRCULATION, V90, P2199, DOI 10.1161/01.CIR.90.5.2199; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; Samani NJ, 1996, CIRCULATION, V94, P708, DOI 10.1161/01.CIR.94.4.708; *SPSS WIND, 1993, ADV STAT, P1; *SPSS WIND, 1993, BAS SYST US GUID; TALMUD P, 1991, ATHEROSCLEROSIS, V89, P137, DOI 10.1016/0021-9150(91)90053-6; TIRET L, 1992, AM J HUM GENET, V51, P197; Winkelmann BR, 1996, ANN INTERN MED, V125, P19, DOI 10.7326/0003-4819-125-1-199607010-00004; 1989, SCAND J SOC MED S, V41, P1	22	53	54	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1997	127	5					346	+		10.7326/0003-4819-127-5-199709010-00002	http://dx.doi.org/10.7326/0003-4819-127-5-199709010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU100	9273825				2022-12-24	WOS:A1997XU10000002
J	BoltonMaggs, PHB; Moon, I				BoltonMaggs, PHB; Moon, I			Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines	LANCET			English	Article							LONG-TERM FOLLOW; THERAPY	Background Guidelines for management of acute immune thrombocytopenic purpura (ITP) in childhood were published in 1992. Regional audit in 1995 showed substantial variation in clinical practice not related to clinical differences in patient groups, which indicated a need for national audit. Methods Individuals aged from birth to their 16th birthday newly presenting with ITP were identified over 14 months by regular mailing of paediatricians and haematologists for case notification. Information was obtained from follow-up by a detailed questionnaire. Findings ITP was clinically mild and benign in 323 (76%) of 427 cases, including 181 (70%) of 260 cases with platelet counts below 10x10(9)/L. There were no deaths or intracranial haemorrhages. There was a substantial discrepancy between clinical practice and published guidelines: many children were admitted to hospital and received treatment unnecessarily; there was overuse of intravenous immunoglobulin (IVIg) as first-line therapy (94 children); children received steroids without marrow examination; and there was inappropriate use of platelet transfusions (41 with mild or moderate disease). Interpretation Our results indicate a need for change in practice.			BoltonMaggs, PHB (corresponding author), ALDER HEY CHILDRENS HOSP,DEPT HAEMATOL,LIVERPOOL L12 2AP,MERSEYSIDE,ENGLAND.							BLANCHERRE VS, 1985, ROYAL SOC MED INT C, V84, P71; BLANCHETTE VS, 1993, J PEDIATR-US, V123, P989, DOI 10.1016/S0022-3476(05)80400-7; BOLTONMAGGS PHB, 1995, THROMB HAEMOSTASIS, V73, P1069; BUCHANAN GR, 1987, EUR J PEDIATR, V146, P107, DOI 10.1007/BF02343213; Buchanan GR, 1997, BLOOD, V89, P1464, DOI 10.1182/blood.V89.4.1464; CHESSELLS J, 1989, ARCH DIS CHILD, V64, P1326, DOI 10.1136/adc.64.9.1326; DUHEM C, 1994, CLIN EXP IMMUNOL, V97, P79; EDEN OB, 1992, ARCH DIS CHILD, V67, P1056, DOI 10.1136/adc.67.8.1056; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; HALPERIN DS, 1988, AM J DIS CHILD, V142, P508, DOI 10.1001/archpedi.1988.02150050046027; LILLEYMAN JS, 1994, ARCH DIS CHILD, V71, P251, DOI 10.1136/adc.71.3.251; MCELFRESH AE, 1975, J PEDIATR-US, V87, P160, DOI 10.1016/S0022-3476(75)80110-7; REID MM, 1992, ACTA PAEDIATR, V81, P1052, DOI 10.1111/j.1651-2227.1992.tb12175.x; REID MM, 1995, ARCH DIS CHILD, V72, P125, DOI 10.1136/adc.72.2.125; SEKUL EA, 1994, ANN INTERN MED, V121, P259, DOI 10.7326/0003-4819-121-4-199408150-00004; TAMARY H, 1994, ACTA PAEDIATR, V83, P931, DOI 10.1111/j.1651-2227.1994.tb13175.x; WALKER RW, 1984, ARCH DIS CHILD, V59, P316, DOI 10.1136/adc.59.4.316	17	148	154	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					620	623		10.1016/S0140-6736(97)04143-3	http://dx.doi.org/10.1016/S0140-6736(97)04143-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288044				2022-12-24	WOS:A1997XU28300009
J	vantHof, AWJ; Liem, A; deBoer, MJ; Zijlstra, F				vantHof, AWJ; Liem, A; deBoer, MJ; Zijlstra, F			Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction	LANCET			English	Article							LEFT-VENTRICULAR FUNCTION; PRIMARY CORONARY ANGIOPLASTY; INTRAVENOUS STREPTOKINASE; SUCCESSFUL THROMBOLYSIS; RANDOMIZED TRIAL; ARTERY PATENCY; SIZE; PREDICTOR; ELEVATION; INTERVENTION	Background A simple clinical method to stratify risk for patients who have had successful reperfusion therapy after myocardial infarction is attractive since it facilitates the tailoring of therapy. Methods We investigated the clinical value of the 12-lead electrocardiogram (EGG), in 403 patients after successful reperfusion therapy by primary coronary angioplasty, in relation to infarct size measured by enzyme activity, left-ventricular function, and clinical outcome. ECGs were analysed to find the extent of the ST-segment-elevation resolution 1 h after reperfusion therapy. Findings A normalised ST segment was seen in 51% of patients, a partly normalised ST segment in 34%, and 15% had no ST-segment-elevation resolution. Enzymatic infarct size and ejection fraction were related to the extent of the early resolution of the ST segment. The relative risk of death among patients with no resolution compared with patients with a normalised ST segment was 8.7 (95% CI 3.7-20.1), and that among patients with partial resolution compared with patients with a normalised ST segment was 3.6 (1.6-8.3). Interpretation Our findings suggest that ECG patterns reflect the effectiveness of myocardial reperfusion. Patients for whom reperfusion therapy by primary angioplasty was successful and who had normalised ST segments had limited damage to the myocardium and an excellent outlook during follow-up. Patients with persistent ST elevation after reperfusion therapy may need additional interventions since they have more extensive myocardial damage and have a higher mortality rate.	ZIEKENHUIS WEEZENLANDEN, DEPT CARDIOL, NL-8011 JW ZWOLLE, NETHERLANDS				de Boer, M.J./H-8014-2014					BARBASH GI, 1990, BRIT HEART J, V64, P241; CALIFF RM, 1988, ANN INTERN MED, V108, P658, DOI 10.7326/0003-4819-108-5-658; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CLEMMENSEN P, 1990, AM J CARDIOL, V66, P1407, DOI 10.1016/0002-9149(90)90524-5; COX DR, 1972, J R STAT SOC B, V34, P187; DEBOER MJ, 1994, CIRCULATION, V90, P753, DOI 10.1161/01.CIR.90.2.753; DEBOER MJ, 1995, EUR HEART J, V16, P1347, DOI 10.1093/oxfordjournals.eurheartj.a060741; DEZWAAN C, 1988, BRIT HEART J, V59, P175; FERRARI R, 1995, AM J CARDIOL, V76, pB17; *FIBR THER TRIAL F, 1994, LANCET, V43, P311; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HASCHE ET, 1995, CIRCULATION, V92, P710, DOI 10.1161/01.CIR.92.4.710; Hashimoto A, 1996, AM J CARDIOL, V77, P25, DOI 10.1016/S0002-9149(97)89129-1; HERMENS WT, 1992, LANCET, V340, P1297, DOI 10.1016/0140-6736(92)93003-6; Iliceto S, 1996, AM J CARDIOL, V77, P441, DOI 10.1016/S0002-9149(97)89334-4; ITO H, 1992, CIRCULATION, V85, P1699, DOI 10.1161/01.CIR.85.5.1699; Ito H, 1996, CIRCULATION, V93, P223, DOI 10.1161/01.CIR.93.2.223; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klootwijk P, 1996, EUR HEART J, V17, P689; MAES A, 1995, CIRCULATION, V92, P2072, DOI 10.1161/01.CIR.92.8.2072; MAURI F, 1994, J AM COLL CARDIOL, V24, P600, DOI 10.1016/0735-1097(94)90003-5; OHMAN EM, 1994, CIRCULATION, V90, P792, DOI 10.1161/01.CIR.90.2.792; Raitt MH, 1996, CIRCULATION, V93, P48, DOI 10.1161/01.CIR.93.1.48; RENTROP KP, 1995, J AM COLL CARDIOL, V25, pS1; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P203; SCHRODER R, 1994, J AM COLL CARDIOL, V24, P384, DOI 10.1016/0735-1097(94)90292-5; VANDERLAARSE A, 1986, AM HEART J, V112, P672, DOI 10.1016/0002-8703(86)90460-6; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WONG PHC, 1994, CATHETER CARDIO DIAG, V33, P39, DOI 10.1002/ccd.1810330111; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	32	477	483	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	1997	350	9078					615	619		10.1016/S0140-6736(96)07120-6	http://dx.doi.org/10.1016/S0140-6736(96)07120-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288043				2022-12-24	WOS:A1997XU28300008
J	Seppala, H; Klaukka, T; VuopioVarkila, J; Muotiala, A; Helenius, H; Lager, K; Huovinen, P; Kontiainen, S; Eskola, J; Korpela, J; KostialaThompson, A; Sarkkinen, H; Schauman, K; Sivonen, A; Vaara, M; Eerola, E; Hiekkaniemi, H; Jarvinen, H; Klossner, ML; Lehtonen, OP; Meurman, O; Oinonen, S; Katila, ML; Karkkainen, P; Liimatainen, O; Vuento, R; Nissinen, A; Hirvonen, P; Kauppinen, M; Kirsi, O; Larinkari, U; Ahonen, E; Herva, E; Jagerroos, H; Koskela, M; Lantto, K; Ruuska, P				Seppala, H; Klaukka, T; VuopioVarkila, J; Muotiala, A; Helenius, H; Lager, K; Huovinen, P; Kontiainen, S; Eskola, J; Korpela, J; KostialaThompson, A; Sarkkinen, H; Schauman, K; Sivonen, A; Vaara, M; Eerola, E; Hiekkaniemi, H; Jarvinen, H; Klossner, ML; Lehtonen, OP; Meurman, O; Oinonen, S; Katila, ML; Karkkainen, P; Liimatainen, O; Vuento, R; Nissinen, A; Hirvonen, P; Kauppinen, M; Kirsi, O; Larinkari, U; Ahonen, E; Herva, E; Jagerroos, H; Koskela, M; Lantto, K; Ruuska, P			The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group a streptococci in Finland	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROUP-A STREPTOCOCCI; JAPAN; PYOGENES; DECLINE	Background In the early 1990s there was an increase in erythromycin resistance among group A streptococci in Finland. In response, policies regarding outpatient antibiotic therapy were changed, and nationwide recommendations were issued that called for reductions in the use of macrolide antibiotics for respiratory and skin infections in outpatients. We studied the effect of this policy on the pattern of erythromycin resistance throughout Finland. Methods From 1991 through 1996, a total of 39,247 group A streptococcal isolates from throat swabs (82 percent of the isolates) and pus samples (18 percent) and 290 isolates from blood cultures were studied in regional microbiology laboratories. The susceptibility of the isolates to erythromycin was tested by the disk-diffusion or the screening-prate method. Results Consumption of macrolide antibiotics decreased from 2.40 defined daily doses per 1000 inhabitants per day in 1991 to 1.38 in 1992 (P=0.007) and remained near the lower level during the study period. The change in consumption was followed by a steady decrease in the frequency of erythromycin resistance among group A streptococcal isolates from throat swabs and pus samples, from 16.5 percent in 1992 to 8.6 percent in 1996 (odds ratio for 1996 as compared with 1992, 0.5; 95 percent confidence interval, 0.4 to 0.5). Conclusions in Finland, after nationwide reductions in the use of macrolide antibiotics for outpatient therapy, there was a significant decline in the frequency of erythromycin resistance among group A streptococci isolated from throat swabs and pus samples. (C) 1997, Massachusetts Medical Society.	NATL PUBL HLTH INST,DEPT BACTERIOL,TURKU 20521,FINLAND; NATL PUBL HLTH INST,HELSINKI,FINLAND; SOCIAL INSURANCE INST,HELSINKI,FINLAND; UNIV TURKU,DEPT BIOSTAT,TURKU,FINLAND; AURORA HOSP,SF-00250 HELSINKI,FINLAND; CENT HOSP KANTA HAME,HAMEENLINNA,FINLAND; JORVI HOSP,SF-02740 ESPOO,FINLAND; CENT HOSP PAIJAT HAME,LAHTI,FINLAND; DEACONESS INST HELSINKI,HELSINKI,FINLAND; UNIV HELSINKI,HELSINKI,FINLAND; UNIV HELSINKI HOSP,HELSINKI,FINLAND; CENT HOSP VAASA,VAASA,FINLAND; CENT HOSP SATAKUNTA,PORI,FINLAND; UNIV TURKU,CENT HOSP,FIN-20520 TURKU,FINLAND; CENT HOSP ETELA POHJANMAA,SEINAJOKI,FINLAND; KUOPIO UNIV HOSP,SF-70210 KUOPIO,FINLAND; CENT HOSP MIKKELI,MIKKELI,FINLAND; TAMPERE UNIV HOSP,TAMPERE,FINLAND; CENT HOSP KESKI SUOMI,JYVASKYLA,FINLAND; CENT HOSP ETELA KARJALA,LAPPEENRANTA,FINLAND; CENT HOSP POHJOIS KARJALA,JOENSUU,FINLAND; CENT HOSP SAVONLINNA,SAVONLINNA,FINLAND; CENT HOSP KYMENLAAKSO,KOTKA,FINLAND; CENT HOSP KAINUU,KAJAANI,FINLAND; NATL PUBL HLTH INST,OULU,FINLAND; CENT HOSP LAPPI,ROVANIEMI,FINLAND; UNIV HOSP OULU,OULU,FINLAND; DEACONESS INST OULU,OULU,FINLAND; UNIV OULU,OULU,FINLAND	Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; University of Turku; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Vaasa Central Hospital; Satakunta Central Hospital; University of Turku; Kuopio University Hospital; University of Eastern Finland; Tampere University; Tampere University Hospital; Central Finland Central Hospital; Finland National Institute for Health & Welfare; University of Oulu	Seppala, H (corresponding author), NATL PUBL HLTH INST,ANTIMICROBIAL RES LAB,POB 57,TURKU 20521,FINLAND.		Vaara, Martti S/D-1698-2013; Huovinen, Pentti/C-1917-2009					Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Arason VA, 1996, BMJ-BRIT MED J, V313, P387; BAQUERO F, 1991, J ANTIMICROB CHEMOTH, V28, P31, DOI 10.1093/jac/28.suppl_C.31; BASS JW, 1994, ARCH PEDIAT ADOL MED, V148, P67, DOI 10.1001/archpedi.1994.02170010069016; Bronze MS, 1996, AM J MED SCI, V311, P41, DOI 10.1097/00000441-199601000-00008; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; FUJITA K, 1994, PEDIATR INFECT DIS J, V13, P1075, DOI 10.1097/00006454-199412000-00001; GERBER MA, 1995, PEDIATR CLIN N AM, V42, P539; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; HOUVINEN P, 1991, FINN MED J, V46, P3241; HUOVINEN P, 1992, FINN MED J, V47, P13; LEPPER MH, 1953, J LAB CLIN MED, V42, P832; MARUYAMA S, 1979, AM J DIS CHILD, V133, P1143, DOI 10.1001/archpedi.1979.02130110051007; MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033; MITSUHASHI S, 1982, MICROBIOLOGY 1982, P151; MOLSTAD S, 1988, SCAND J INFECT DIS, V20, P329, DOI 10.3109/00365548809032459; Muotiala A, 1997, J INFECT DIS, V175, P392, DOI 10.1093/infdis/175.2.392; *NAT AG MED, 1995, FINN STAT MED 1994; *NAT COMM CLIN LAB, 1995, PERF STAND ANT SUSC, V15, pM100; National Agency for Medicines and Social Insurance Institution, 1996, FINN STAT MED 1995; NISSINEN A, 1995, SCAND J INFECT DIS, V27, P52, DOI 10.3109/00365549509018972; RIDLEY M, 1970, LANCET, V1, P230; SAS Institute, 1990, SAS STAT US GUID VER; SEPPALA H, 1993, J ANTIMICROB CHEMOTH, V32, P885, DOI 10.1093/jac/32.6.885; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; Seppala H, 1995, CLIN INFECT DIS, V21, P1378, DOI 10.1093/clinids/21.6.1378; Tenover FC, 1996, AM J MED SCI, V311, P9, DOI 10.1097/00000441-199601000-00003	27	915	948	0	74	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	1997	337	7					441	446		10.1056/NEJM199708143370701	http://dx.doi.org/10.1056/NEJM199708143370701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ499	9250845				2022-12-24	WOS:A1997XQ49900001
J	Gerber, JK; Gogel, E; Berger, C; Wallisch, M; Muller, F; Grummt, I; Grummt, F				Gerber, JK; Gogel, E; Berger, C; Wallisch, M; Muller, F; Grummt, I; Grummt, F			Termination of mammalian rDNA replication: Polar arrest of replication fork movement by transcription termination factor TTF-I	CELL			English	Article							RIBOSOMAL-RNA GENES; BACILLUS-SUBTILIS CHROMOSOME; SIMIAN VIRUS-40 DNA; POLYMERASE-I; 3' END; SACCHAROMYCES-CEREVISIAE; TERMINUS REGION; BINDING DOMAIN; SEQUENCES; ORGANIZATION	A replication fork barrier (RFB) al the 3' end of eukaryotic ribosomal RNA genes blocks bidirectional fork progression and limits DNA replication to the same direction as transcription. We have reproduced the RFB in vitro in HeLa cell extracts using 3' terminal murine rDNA fused to an SV40 origin-based vector. The RFB is polar and modularly organized, requiring both the Sal box transcription terminator and specific flanking sequences. Mutations within the terminator element, depletion of the RNA polymerase I-specific transcription termination factor TTF-I, or deletion of the termination domain of TTF-I abolishes RFB activity. Thus, the same factor that blocks elongating RNA polymerase I prevents head-on collision between the DNA replication apparatus and the transcription machinery.	UNIV WURZBURG,INST BIOCHEM,D-97074 WURZBURG,GERMANY; GERMAN CANC RES CTR,DIV MOL BIOL CELL 2,D-69120 HEIDELBERG,GERMANY; INST MOL BIOTECHNOL,DIV BIOCHEM,D-07745 JENA,GERMANY	University of Wurzburg; Helmholtz Association; German Cancer Research Center (DKFZ)				Wallisch, Michael/0000-0002-7133-795X				BAKER TA, 1995, CELL, V80, P521, DOI 10.1016/0092-8674(95)90504-9; BARTSCH I, 1988, MOL CELL BIOL, V8, P3891, DOI 10.1128/MCB.8.9.3891; BARTSCH I, 1987, MOL CELL BIOL, V7, P2521, DOI 10.1128/MCB.7.7.2521; Bastia D., 1996, DNA REPLICATION EUKA, P177; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; CARRIGAN CM, 1991, J MOL BIOL, V222, P197, DOI 10.1016/0022-2836(91)90206-L; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; Ermakova OV, 1996, J BIOL CHEM, V271, P33009, DOI 10.1074/jbc.271.51.33009; EVERS R, 1995, EMBO J, V14, P1248, DOI 10.1002/j.1460-2075.1995.tb07108.x; EVERS R, 1995, P NATL ACAD SCI USA, V92, P5827, DOI 10.1073/pnas.92.13.5827; Gogel E, 1996, CHROMOSOMA, V104, P511, DOI 10.1007/BF00352115; GRUMMT I, 1985, CELL, V43, P801, DOI 10.1016/0092-8674(85)90253-3; GRUMMT I, 1986, CELL, V45, P837, DOI 10.1016/0092-8674(86)90558-1; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; HILL TM, 1992, ANNU REV MICROBIOL, V46, P603, DOI 10.1146/annurev.micro.46.1.603; HOSS A, 1990, J VIROL, V64, P4799; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KERMEKCHIEV MB, 1987, NUCLEIC ACIDS RES, V15, P4131, DOI 10.1093/nar/15.10.4131; KUEMPEL PL, 1977, P NATL ACAD SCI USA, V74, P3927, DOI 10.1073/pnas.74.9.3927; KUHN A, 1988, EMBO J, V7, P1497, DOI 10.1002/j.1460-2075.1988.tb02968.x; LABHART P, 1987, MOL CELL BIOL, V7, P1900, DOI 10.1128/MCB.7.5.1900; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; Langst G, 1997, EMBO J, V16, P760, DOI 10.1093/emboj/16.4.760; LEWIS PJ, 1990, J MOL BIOL, V214, P73, DOI 10.1016/0022-2836(90)90147-E; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; LUCCHINI R, 1994, MOL CELL BIOL, V14, P318, DOI 10.1128/MCB.14.1.318; Mohanty BK, 1996, EMBO J, V15, P2530, DOI 10.1002/j.1460-2075.1996.tb00610.x; MORROW BE, 1993, MOL CELL BIOL, V13, P1173, DOI 10.1128/MCB.13.2.1173; PFLEIDERER C, 1990, NUCLEIC ACIDS RES, V18, P4727, DOI 10.1093/nar/18.16.4727; REEDER RH, 1994, MOL MICROBIOL, V12, P11, DOI 10.1111/j.1365-2958.1994.tb00989.x; Sander EE, 1996, NUCLEIC ACIDS RES, V24, P3677, DOI 10.1093/nar/24.19.3677; SANDER EE, 1997, NUCLEIC ACIDS RES, V25, P3677; SMID A, 1992, J MOL BIOL, V227, P635, DOI 10.1016/0022-2836(92)90213-4; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710	43	100	103	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					559	567		10.1016/S0092-8674(00)80515-2	http://dx.doi.org/10.1016/S0092-8674(00)80515-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267035	Bronze			2022-12-24	WOS:A1997XQ06300019
J	Hanson, PI; Roth, R; Morisaki, H; Jahn, R; Heuser, JE				Hanson, PI; Roth, R; Morisaki, H; Jahn, R; Heuser, JE			Structure and conformational changes in NSF and its membrane receptor complexes visualized by quick-freeze/deep-etch electron microscopy	CELL			English	Article							SENSITIVE FUSION PROTEIN; VESICLE FUSION; VESICULAR TRANSPORT; ESCHERICHIA-COLI; CLPAP PROTEASE; GENE-PRODUCT; IN-VITRO; YEAST; MECHANISM; BINDING	Using quick-freeze/deep-etch electron microscopy of recombinant proteins adsorbed to mica, we show that NSF, the oligomeric ATPase involved in membrane fusion, is a hollow 10 x 16 nm cylinder whose conformation depends upon nucleotide binding. Depleted of nucleotide, NSF converts to a ''splayed'' protease-sensitive conformation that reveals its subunit composition. NSF's synaptic membrane substrate, the ternary SNARE complex containing syntaxin, SNAP-25, and synaptobrevin, is a 4 x 14 nm rod with a ''tail'' at one end, corresponding to the N-terminus of syntaxin. Using epitope tags, antibodies, and maltose-binding protein markers, we find that syntaxin and synaptobrevin are aligned in parallel in the complex, with their membrane anchors located at the same end of the rod. This SNARE rod binds with alpha-SNAP to one end of the NSF cylinder to form an asymmetric ''20S'' complex. Together, these images suggest how NSF could dissociate the SNARE complex and how association and dissociation of the complex could be related to membrane fusion.	HOWARD HUGHES MED INST, BOYER CTR MOL MED, NEW HAVEN, CT 06510 USA	Howard Hughes Medical Institute	Hanson, PI (corresponding author), YALE UNIV, DEPT PHARMACOL, ROOM 247, 295 CONGRESS AVE, NEW HAVEN, CT 06510 USA.		Hanson, Phyllis/E-9420-2012; Heuser, John/H-5940-2012	Jahn, Reinhard/0000-0003-1542-3498	NIGMS NIH HHS [GM-29647] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029647] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; RAND RP, 1986, ANNU REV PHYSIOL, V48, P201; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHELLER RH, 1995, NEURON, V14, P893; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SINGH SK, 1994, J BIOL CHEM, V269, P29537; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILLIAMS RC, 1946, J APPL PHYS, V17, P23, DOI 10.1063/1.1707630; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	49	653	669	2	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	1997	90	3					523	535		10.1016/S0092-8674(00)80512-7	http://dx.doi.org/10.1016/S0092-8674(00)80512-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267032	hybrid			2022-12-24	WOS:A1997XQ06300016
J	Dolan, RJ; Fletcher, PC				Dolan, RJ; Fletcher, PC			Dissociating prefrontal and hippocampal function in episodic memory encoding	NATURE			English	Article							AMNESIA; ACTIVATION; RETRIEVAL	Human lesion data indicate that an intact left hippocampal formation is necessary for auditory-verbal memory(1). By contrast, functional neuroimaging has highlighted the role of the left prefrontal cortex(2-4) but has generally failed to reveal the predicted left hippocampal activation. Here we describe an experiment involving learning category-exemplar word pairs (such as 'dog...boxer') in which we manipulate the novelty of either individual elements or the entire category-exemplar pairing. We demonstrate both left medial temporal (including hippocampal) and left prefrontal activation and show that these activations are dissociable with respect to encoding demands. Left prefrontal activation is maximal with a change in category-exemplar pairings, whereas medial temporal activation is sensitive to the overall degree of novelty. Thus, left prefrontal cortex is sensitive to processes required to establish meaningful connections between a category and its exemplar, a process maximized when a previously formed connection is changed. Conversely, the left medial temporal activation reflects processes that register the overall novelty of the presented material. Our results provide striking evidence of functionally dissociable roles for the prefrontal cortex and hippocampal formation during learning of auditory-verbal material.	ROYAL FREE HOSP,SCH MED,LONDON NW3,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Dolan, RJ (corresponding author), INST NEUROL,WELLCOME DEPT COGNIT NEUROL,QUEEN SQ,LONDON WC1N 3BG,ENGLAND.		Fletcher, Paul/F-5380-2011	Fletcher, Paul/0000-0001-8257-1517; Dolan, Ray/0000-0001-9356-761X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLACK FW, 1976, J CLIN PSYCHOL, V32, P366, DOI 10.1002/1097-4679(197604)32:2<366::AID-JCLP2270320234>3.0.CO;2-F; DIMSDALE H, 1964, NEUROPSYCHOLOGIA, V1, P287, DOI 10.1016/0028-3932(64)90022-3; FAHY FL, 1993, EXP BRAIN RES, V96, P457; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GERSHBERG FB, 1995, NEUROPSYCHOLOGIA, V13, P1305; GRADY CL, 1994, J NEUROSCI, V14, P1450, DOI 10.1523/JNEUROSCI.14-03-01450.1994; Grafman, 1989, HDB NEUROPSYCHOLOGY, P91; GRASBY PM, 1993, NEUROSCI LETT, V163, P185, DOI 10.1016/0304-3940(93)90378-X; Halgren Eric, 1995, P1137; JETTER W, 1986, CORTEX, V22, P229, DOI 10.1016/S0010-9452(86)80047-8; KAPUR S, 1994, P NATL ACAD SCI USA, V91, P2008, DOI 10.1073/pnas.91.6.2008; Knight RT, 1996, NATURE, V383, P256, DOI 10.1038/383256a0; LI L, 1993, J NEUROPHYSIOL, V69, P1918, DOI 10.1152/jn.1993.69.6.1918; Martin A, 1996, NATURE, V379, P649, DOI 10.1038/379649a0; MOSCOVITCH M, 1982, MULTIPLE DISSOCIATIO, P337; NYBERG J, 1996, P NATL ACAD SCI USA, V93, P11280; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; SCHACTER DL, 1987, PSYCHOBIOLOGY, V15, P21; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; SHIMAMURA AP, 1995, J COGNITIVE NEUROSCI, V7, P144, DOI 10.1162/jocn.1995.7.2.144; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660; Tulving E, 1996, CEREB CORTEX, V6, P71, DOI 10.1093/cercor/6.1.71; ZATORRE RJ, 1983, BRAIN COGNITION, V2, P331, DOI 10.1016/0278-2626(83)90017-9; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	29	328	329	2	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					582	585		10.1038/41561	http://dx.doi.org/10.1038/41561			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252188	Bronze, Green Submitted			2022-12-24	WOS:A1997XP72200049
J	Dickens, M; Rogers, JS; Cavanagh, J; Raitano, A; Xia, ZG; Halpern, JR; Greenberg, ME; Sawyers, CL; Davis, RJ				Dickens, M; Rogers, JS; Cavanagh, J; Raitano, A; Xia, ZG; Halpern, JR; Greenberg, ME; Sawyers, CL; Davis, RJ			A cytoplasmic inhibitor of the JNK signal transduction pathway	SCIENCE			English	Article							PROTEIN-KINASES; ACTIVATION DOMAIN; PHOSPHORYLATION; JUN; TRANSFORMATION; INTEGRATION; ASSOCIATION; MECHANISM; ONCOGENE; CONTAINS	The c-Jun amino-terminal kinase (JNK) is a member of the stress-activated group of mitogen-activated protein (MAP) kinases that are implicated in the control of cell growth. A murine cytoplasmic protein that binds specifically to JNK [the JNK interacting protein-1 (JIP-1)] was characterized and cloned. JIP-1 caused cytoplasmic retention of JNK and inhibition of JNK-regulated gene expression. In addition, JIP-1 suppressed the effects of the JNK signaling pathway on cellular proliferation, including transformation by the Bcr-Abl oncogene. This analysis identifies JIP-1 as a specific inhibitor of the JNK signal transduction pathway and establishes protein targeting as a mechanism that regulates signaling by stress-activated MAP kinases.	UNIV MASSACHUSETTS, SCH MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOL BIOL, PROGRAM MOL MED, WORCESTER, MA 01605 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90095 USA; CHILDRENS HOSP, DEPT NEUROL, DIV NEUROSCI, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Dickens, Martin/B-2001-2012; Sawyers, Charles/G-5327-2016		NATIONAL CANCER INSTITUTE [R01CA043855, R01CA065861] Funding Source: NIH RePORTER; NCI NIH HHS [CA65861, CA43855] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHOI KY, 1994, CELL, V78, P499; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DICKENS M, UNPUB; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; Rincon Mercedes, 1997, Genes and Function, V1, P51; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu X, 1996, ONCOGENE, V13, P135; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	37	616	647	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 1	1997	277	5326					693	696		10.1126/science.277.5326.693	http://dx.doi.org/10.1126/science.277.5326.693			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235893				2022-12-24	WOS:A1997XN90700043
J	Riechmann, L; Holliger, P				Riechmann, L; Holliger, P			The C-terminal domain of ToIA is the coreceptor for filamentous phage infection of E-coli	CELL			English	Article							GENE-III PROTEIN; ESCHERICHIA-COLI; ADSORPTION PROTEIN; FD; MEMBRANE; TOLA; BACTERIOPHAGES; TRANSLOCATION; ATTACHMENT; PRODUCTS	Filamentous bacteriophages infecting gram-negative bacteria display tropism for a variety of pilus structures. However, the obligatory coreceptor of phage infection, postulated from genetic studies, has remained elusive. Here we identify the C-terminal domain of the periplasmic protein TolA as the coreceptor for infection of Escherichia coli by phage fd and the N-terminal domain of the phage minor coat protein g3p as its cognate ligand. The neighboring g3p domain binds the primary receptor of phage infection, the F pilus, and blocks TolA binding in its absence. Contact with the pilus releases this blockage during infection. Our findings support a sequential two-way docking mechanism for phage infection, analogous to infection pathways proposed for a range of eukaryotic Viruses including herpes simplex, adenoviruses, and also lentiviruses like HIV-1.	MRC, CTR PROT ENGN, CAMBRIDGE CB2 2QH, ENGLAND	University of Cambridge	Riechmann, L (corresponding author), MRC, MOL BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							ARMSTRONG GD, 1980, J BACTERIOL, V141, P333, DOI 10.1128/JB.141.1.333-341.1980; BAYER ME, 1975, MEMBRANE BIOGENESIS, P393; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOEKE JD, 1982, MOL GEN GENET, V186, P185, DOI 10.1007/BF00331849; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CRISSMAN JW, 1984, VIROLOGY, V132, P445, DOI 10.1016/0042-6822(84)90049-7; Derouiche R, 1996, EMBO J, V15, P6408, DOI 10.1002/j.1460-2075.1996.tb01032.x; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; DUENAS M, 1994, BIO-TECHNOL, V12, P999, DOI 10.1038/nbt1094-999; ENDEMANN H, 1995, J MOL BIOL, V250, P496, DOI 10.1006/jmbi.1995.0393; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Gibson T., 1984, THESIS U CAMBRIDGE C; GLASERWUTTKE G, 1989, BIOCHIM BIOPHYS ACTA, V985, P239, DOI 10.1016/0005-2736(89)90408-2; GRAMATIKOFF K, 1994, NUCLEIC ACIDS RES, V22, P5761, DOI 10.1093/nar/22.25.5761; Groisman EA, 1996, CELL, V87, P791, DOI 10.1016/S0092-8674(00)81985-6; GUIHARD G, 1994, J BIOL CHEM, V269, P5874; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; Holliger P, 1997, STRUCTURE, V5, P265, DOI 10.1016/S0969-2126(97)00184-6; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; JACOBSON A, 1972, J VIROL, V10, P835, DOI 10.1128/JVI.10.4.835-843.1972; KAMPFENKEL K, 1993, J BACTERIOL, V175, P4485, DOI 10.1128/JB.175.14.4485-4491.1993; KREBBER K, 1995, FEBS LETT, V377, P227; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; LEVENGOOD SK, 1989, J BACTERIOL, V171, P6600, DOI 10.1128/jb.171.12.6600-6609.1989; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; Model P., 1988, BACTERIOPHAGES, P375; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, P7; RAMPF B, 1991, FEBS LETT, V280, P27, DOI 10.1016/0014-5793(91)80196-A; RIECHMANN L, 1995, J BIOMOL NMR, V6, P141, DOI 10.1007/BF00211778; RUSSEL M, 1988, J BACTERIOL, V170, P5312, DOI 10.1128/jb.170.11.5312-5316.1988; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1992, CLONING FUSE VECTORS; STENGELE I, 1990, J MOL BIOL, V212, P143, DOI 10.1016/0022-2836(90)90311-9; SUN TP, 1986, J BACTERIOL, V165, P107, DOI 10.1128/jb.165.1.107-115.1986; SUN TP, 1987, J BACTERIOL, V169, P2667, DOI 10.1128/jb.169.6.2667-2674.1987; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x; WEISS RA, 1995, CELL, V82, P531, DOI 10.1016/0092-8674(95)90024-1; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; ZACHER AN, 1980, GENE, V9, P127, DOI 10.1016/0378-1119(80)90171-7	46	151	178	5	18	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					351	360		10.1016/S0092-8674(00)80342-6	http://dx.doi.org/10.1016/S0092-8674(00)80342-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244308	Bronze			2022-12-24	WOS:A1997XN24900018
J	Zeng, ZH; Castano, AR; Segelke, BW; Stura, EA; Peterson, PA; Wilson, IA				Zeng, ZH; Castano, AR; Segelke, BW; Stura, EA; Peterson, PA; Wilson, IA			Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove	SCIENCE			English	Article							CLASS-I MOLECULES; T-CELL RECEPTOR; NEONATAL FC RECEPTOR; 3-DIMENSIONAL STRUCTURE; HISTOCOMPATIBILITY ANTIGEN; PEPTIDE ANTIGENS; VIRAL PEPTIDES; ALPHA-3 DOMAIN; COMPLEX; RECOGNITION	CD1 represents a third lineage of antigen-presenting molecules that are distantly related to major histocompatibility complex (MHC) molecules in the immune system. The crystal structure of mouse CD1d1, corresponding to human CD1d, at 2.8 Angstrom resolution shows that CD1 adopts an MHC fold that is more closely related to that of MHC class I than to that of MHC class II. The binding groove, although significantly narrower, is substantially larger because of increased depth and it has only two major pockets that are almost completely hydrophobic. The extreme hydrophobicity and shape of the binding site are consistent with observations that human CD1b and CD1c can present mycobacterial cell wall antigens, such as mycolic acid and lipoarabinomannans. However, mouse CD1d1 can present very hydrophobic peptides, but must do so in a very different way from MHC class Ia and class II molecules.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, RW JOHNSON PHARMACEUT RES INST, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute			Castaño, A. Raul/A-5905-2012; Stura, Enrico A./A-2793-2010	Castaño, A. Raul/0000-0003-2107-8862; Stura, Enrico A./0000-0001-6718-2118; Segelke, Brent/0000-0003-3358-5028	NCI NIH HHS [CA-58896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BALK SP, 1994, SCIENCE, V265, P259, DOI 10.1126/science.7517575; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; Beckman EM, 1996, J IMMUNOL, V157, P2795; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1995, SCIENCE, V269, P185, DOI 10.1126/science.7542402; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; CASTANO AM, UNPUB; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; COLLINS EJ, 1995, P NATL ACAD SCI USA, V92, P1218, DOI 10.1073/pnas.92.4.1218; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; DELLABONA P, 1994, J EXP MED, V180, P1171, DOI 10.1084/jem.180.3.1171; DELLABONA P, 1993, J EXP MED, V177, P1763, DOI 10.1084/jem.177.6.1763; ERNST W, COMMUNICATION; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; Gulden PH, 1996, IMMUNITY, V5, P73, DOI 10.1016/S1074-7613(00)80311-8; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; Lenz LL, 1996, IMMUNITY, V5, P63, DOI 10.1016/S1074-7613(00)80310-6; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARTIN LH, 1986, P NATL ACAD SCI USA, V83, P9154, DOI 10.1073/pnas.83.23.9154; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MCMICHAEL AJ, 1979, EUR J IMMUNOL, V9, P205, DOI 10.1002/eji.1830090307; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nataraj C, 1996, INT IMMUNOL, V8, P367, DOI 10.1093/intimm/8.3.367; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI SA, 1995, ADV IMMUNOL, V59, P1, DOI 10.1016/S0065-2776(08)60629-X; Prigozy TI, 1997, IMMUNITY, V6, P187, DOI 10.1016/S1074-7613(00)80425-2; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SEGELKE BW, UNPUB; SHIN DH, 1995, STRUCTURE, V3, P189, DOI 10.1016/S0969-2126(01)00149-6; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; Smith KJ, 1996, IMMUNITY, V4, P215, DOI 10.1016/S1074-7613(00)80430-6; SMITH KJ, 1996, P NATL ACAD SCI USA, V4, P203; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Sugita M, 1996, SCIENCE, V273, P349, DOI 10.1126/science.273.5273.349; Teitell M, 1997, J IMMUNOL, V158, P2143; *UCSF MGL, 1995, UCSF MID US MAN; VILLIEUX FMD, 1993, DEMON PROGRAM SUITE; VYAS NK, 1991, J BIOL CHEM, V266, P5226; VYAS NK, 1983, P NATL ACAD SCI-BIOL, V80, P1792, DOI 10.1073/pnas.80.7.1792; Wang C., COMMUNICATION; WANG CR, 1995, CELL, V82, P655, DOI 10.1016/0092-8674(95)90037-3; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	77	537	563	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					339	345		10.1126/science.277.5324.339	http://dx.doi.org/10.1126/science.277.5324.339			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219685				2022-12-24	WOS:A1997XL35800037
J	Song, HJ; Ming, GL; Poo, MM				Song, HJ; Ming, GL; Poo, MM			CAMP-induced switching in turning direction of nerve growth cones	NATURE			English	Article							ADENYLYL-CYCLASE; PROTEIN-KINASE; AXONS; GUIDANCE; RECEPTORS; NEURONS; SYSTEM; CA2+	Development of the nervous system depends on the correct pathfinding and target recognition by the growing tip of an axon, the growth cone(1-3). Diffusible or substrate-bound molecules present in the environment may serve as either attractants or repellents to influence the direction of growth-cone extension(4-11). Here we report that differences in cyclic-AMP-dependent activity in a neuron may result in opposite turning of the growth cone in response to the same guidance cue. A gradient of brain-derived neurotrophic factor normally triggers an attractive turning response of the growth cone of Xenopus spinal neurons in culture, but the same gradient induces repulsive turning of these growth cones in the presence of a competitive analogue of cAMP or of a specific inhibitor of protein kinase A. This cAMP-dependent switch of the turning response was also found for turning induced by acetylcholine, but not for the turning induced by neurotrophin-3 (NT-3). Thus, in the presence of other factors that modulate neuronal cAMP-dependent activity, the same guidance cue may trigger opposite turning behaviours of the growth cone during its pathfinding in the nervous system.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego			Ming, Guo-li/J-7880-2013	Ming, Guo-li/0000-0002-2517-6075				BIXBY JL, 1984, DEV BIOL, V106, P89, DOI 10.1016/0012-1606(84)90065-4; BONHOEFFER F, 1980, NATURE, V288, P162, DOI 10.1038/288162a0; BRAY D, 1988, ANNU REV CELL BIOL, V4, P43, DOI 10.1146/annurev.cb.04.110188.000355; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Cooper J.R., 1996, BIOCH BASIS NEUROPHA, Vseventh; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; Hempel CM, 1996, NATURE, V384, P166, DOI 10.1038/384166a0; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KATER SB, 1988, TRENDS NEUROSCI, V11, P317; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Kim YT, 1996, J NEUROSCI, V16, P5593; LAUFER R, 1987, EMBO J, V6, P901, DOI 10.1002/j.1460-2075.1987.tb04836.x; LOHOF AM, 1992, J NEUROSCI, V12, P1253; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; Stoop R, 1996, J NEUROSCI, V16, P3256; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; YOVELL Y, 1992, J NEUROCHEM, V59, P1736, DOI 10.1111/j.1471-4159.1992.tb11005.x; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	30	508	521	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					275	279		10.1038/40864	http://dx.doi.org/10.1038/40864			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230436				2022-12-24	WOS:A1997XL12100051
J	Sainz, J; VanTornout, JM; Loro, ML; Sayre, J; Roe, TF; Gilsanz, V				Sainz, J; VanTornout, JM; Loro, ML; Sayre, J; Roe, TF; Gilsanz, V			Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREMENOPAUSAL WOMEN; OSTEOPOROSIS; ALLELES; MASS; PUBERTY; VIEW	Background Bone mass is under strong genetic control, and recent studies in adults have suggested that allelic differences in the gene for the vitamin D receptor may account for inherited variability in bone mass. We studied the relations of the vitamin D-receptor genotype to skeletal development and variation in the size, volume, and density of bone in children. Methods We identified three allelic variants of the vitamin D-receptor gene using the polymerase chain reaction and three restriction enzymes (Apal, Bsml, and Taql) in 100 normal prepubertal American girls of Mexican descent. We then determined the relations of the different vitamin D-receptor genotypes (AA, Aa, aa, BE, Bb, bb, TT, Tt, and tt) to the cross-sectional area, cortical area, and cortical bone density of the femoral shaft and the cross-sectional area and density of the lumbar vertebrae. Results The vitamin D-receptor genotype was associated with femoral and vertebral bone density. Girls with aa and bb genotypes had 2 to 3 percent higher femoral bone density (P=0.008 and P=0.04, respectively) and 8 to 10 percent higher vertebral bone density (P=0.01 and P=0.03, respectively) than girls with AA and BE genotypes. There was no association between the cross-sectional area of the vertebrae or the cross-sectional or cortical area of the femur and the vitamin D-receptor genotype. The chronologic age, bone age, height, weight, body-surface area, and body-mass index did not differ significantly among girls with different vitamin D-receptor genotypes. Conclusions Vitamin D-receptor gene alleles predict the density of femoral and vertebral bone in prepubertal American girls of Mexican descent. (C) 1997, Massachusetts Medical Society.	CHILDRENS HOSP LOS ANGELES, DEPT RADIOL, LOS ANGELES, CA 90027 USA; CHILDRENS HOSP LOS ANGELES, DEPT PEDIAT, LOS ANGELES, CA 90027 USA; UNIV CALIF LOS ANGELES, DEPT BIOSTAT, SCH MED, LOS ANGELES, CA USA	Children's Hospital Los Angeles; Children's Hospital Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [1K11 CA61870 02] Funding Source: Medline; NIAMS NIH HHS [R01-AR4-1853-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA061870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041853] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARGERLUX MJ, 1995, CALCIFIED TISSUE INT, V57, P161, DOI 10.1007/BF00298438; BEHRMAN RE, 1987, NELSON TXB PEDIAT, P24; BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; CANN CE, 1991, EXPANDING ROLE MED P, P250; CARTER DR, 1992, J BONE MINER RES, V7, P137; CHRISTIAN JC, 1989, AM J HUM GENET, V44, P429; Cooper GS, 1996, J BONE MINER RES, V11, P1841; Dawson-Hughes Bess, 1995, P335; DAWSONHUGHES B, 1995, J CLIN ENDOCR METAB, V80, P3657, DOI 10.1210/jc.80.12.3657; DYSON ED, 1970, NATURE, V225, P957, DOI 10.1038/225957a0; EISMAN JA, 1995, J BONE MINER RES, V10, P1289; FLEET JC, 1995, J BONE MINER RES, V10, P985; GARNERO P, 1995, J BONE MINER RES, V10, P1283; Genant HK, 1996, J BONE MINER RES, V11, P707; GILSANZ V, 1991, NEW ENGL J MED, V325, P1597, DOI 10.1056/NEJM199112053252302; GILSANZ V, 1994, RADIOLOGY, V190, P673, DOI 10.1148/radiology.190.3.8115609; GONG JK, 1964, ANAT REC, V149, P325, DOI 10.1002/ar.1091490303; Greulich WW, 1950, RADIOGRAPHIC ATLAS S; Hangartner TN, 1996, J BONE MINER RES, V11, P1518, DOI 10.1002/jbmr.5650111019; HOWARD G, 1995, J CLIN ENDOCR METAB, V80, P2800, DOI 10.1210/jc.80.9.2800; HUSTMYER FG, 1994, J CLIN INVEST, V94, P2130, DOI 10.1172/JCI117568; KALENDER WA, 1992, OSTEOPOROSIS INT, V2, P82, DOI 10.1007/BF01623841; Matkovic V, 1996, J CLIN ENDOCR METAB, V81, P2013, DOI 10.1210/jc.81.6.2013; MELHUS H, 1994, LANCET, V344, P949, DOI 10.1016/S0140-6736(94)92297-7; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; Need AG, 1996, EUR J CLIN INVEST, V26, P793, DOI 10.1046/j.1365-2362.1996.2080554.x; PEACOCK M, 1995, J BONE MINER RES, V10, P1294; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; SAMBROOK PN, 1994, BRIT J RHEUMATOL, V33, P1007; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SHOHAT T, 1995, HUM HERED, V45, P150, DOI 10.1159/000154276; Terwilliger J., 1994, HDB HUMAN GENETIC LI; Viitanen AM, 1996, CALCIFIED TISSUE INT, V59, P231, DOI 10.1007/s002239900113; [No title captured]	35	238	251	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 10	1997	337	2					77	82		10.1056/NEJM199707103370202	http://dx.doi.org/10.1056/NEJM199707103370202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ822	9211676				2022-12-24	WOS:A1997XJ82200002
J	Manuelidis, L; Fritch, W; Xi, YG				Manuelidis, L; Fritch, W; Xi, YG			Evolution of a strain of CJD that induces BSE-like plaques	SCIENCE			English	Article								Bovine spongiform encephalopathy (BSE) has become a public health issue because a recently evolved BSE agent has infected people, yielding an unusual form of Creutzfeld-Jakob disease (CJD). A new CJD agent that provokes similar amyloid plaques and cerebellar pathology was serially propagated. First-passage rats showed obvious clinical signs and activated microglia but had negligible PrP-res (the more protease-resistant form of host PrP) or cerebellar lesions. Microglia and astrocytes may participate in strain selection because the agent evolved, stabilized, and reproducibly provoked BSE-like disease in subsequent passages. Early vacuolar change involving activated microglia and astrocytes preceded significant PrP-res accumulation by more than 50 days. These studies reveal several inflammatory host reactions to an exogenous agent.			Manuelidis, L (corresponding author), YALE UNIV,SCH MED,SECT NEUROPATHOL,310 CEDAR ST,NEW HAVEN,CT 06510, USA.				NINDS NIH HHS [NS34569, NS12674] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034569, R01NS012674] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))			0	119	121	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					94	98		10.1126/science.277.5322.94	http://dx.doi.org/10.1126/science.277.5322.94			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204907				2022-12-24	WOS:A1997XJ41800047
J	Ogas, J; Cheng, JC; Sung, ZR; Somerville, C				Ogas, J; Cheng, JC; Sung, ZR; Somerville, C			Cellular differentiation regulated by gibberellin in the Arabidopsis thaliana pickle mutant	SCIENCE			English	Article							LYCOPERSICON-ESCULENTUM MILL; GENE FAMILY; GA1 LOCUS; WILD-TYPE; PLANT; GROWTH; TRANSFORMATION; ROOTS; SITES; ACID	The plant growth regulator gibberellin (GA) has a profound effect on shoot development and promotes developmental transitions such as flowering. Little is known about any analogous effect GA might have on root development. In a screen for mutants, Arabidopsis plants carrying a mutation designated pickle (pkl) were isolated in which the primary root meristem retained characteristics of embryonic tissue. Expression of this aberrant differentiation state was suppressed by GA. Root tissue from plants carrying the pkl mutation spontaneously regenerated new embryos and plants.	UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	Ogas, J (corresponding author), CARNEGIE INST WASHINGTON,DEPT PLANT BIOL,290 PANAMA ST,STANFORD,CA 94305, USA.		Somerville, Christopher R/A-4048-2009	Somerville, Christopher R/0000-0003-4647-0094; Ogas, Joe/0000-0002-1332-7729; Sung, Zinmay/0000-0003-0478-9144				BALUSKA F, 1993, PLANTA, V191, P149, DOI 10.1007/BF00199744; BARLOW PW, 1991, J EXP BOT, V42, P339, DOI 10.1093/jxb/42.3.339; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BRUNDRETT MC, 1991, BIOTECH HISTOCHEM, V66, P111, DOI 10.3109/10520299109110562; Chien JC, 1996, PLANT PHYSIOL, V111, P1321, DOI 10.1104/pp.111.4.1321; FAY JM, 1991, ECON BOT, V45, P16, DOI 10.1007/BF02860046; FINKELSTEIN RR, 1994, ARABIDOPSIS, P523; GUERCHE P, 1990, PLANT CELL, V2, P469, DOI 10.1105/tpc.2.5.469; IZUMI K, 1985, PLANT CELL PHYSIOL, V26, P821; KOORNNEEF M, 1985, PHYSIOL PLANTARUM, V65, P33, DOI 10.1111/j.1399-3054.1985.tb02355.x; KOORNNEEF M, 1983, GENET RES, V41, P57, DOI 10.1017/S0016672300021066; KREBBERS E, 1988, PLANT PHYSIOL, V87, P859, DOI 10.1104/pp.87.4.859; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; MARTON L, 1991, PLANT CELL REP, V10, P235, DOI 10.1007/BF00232565; MCCLINTON RS, IN PRESS PLANTA; METZ AM, 1992, GENE, V120, P313, DOI 10.1016/0378-1119(92)90112-3; MORRIS PC, 1994, ARABIDOPSIS, P173; NAKIELSKI J, 1995, PLANTA, V196, P30, DOI 10.1007/BF00193214; OHLROGGE JB, 1991, BIOCHIM BIOPHYS ACTA, V1082, P1, DOI 10.1016/0005-2760(91)90294-R; Okamuro JK, 1996, P NATL ACAD SCI USA, V93, P13831, DOI 10.1073/pnas.93.24.13831; PATTON DA, 1990, AM J BOT, V77, P653, DOI 10.2307/2444811; PENG JR, 1993, PLANT CELL, V5, P351, DOI 10.1105/tpc.5.3.351; Ross JHE, 1996, PLANT J, V9, P625, DOI 10.1046/j.1365-313X.1996.9050625.x; SUN TP, 1992, PLANT CELL, V4, P119, DOI 10.1105/tpc.4.2.119; SUN TP, 1994, PLANT CELL, V6, P1509, DOI 10.1105/tpc.6.10.1509; TRAAS J, 1995, PLANT J, V7, P785, DOI 10.1046/j.1365-313X.1995.07050785.x; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VANROOIJEN GJH, 1992, PLANT MOL BIOL, V18, P1177, DOI 10.1007/BF00047721; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362	29	248	277	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					91	94		10.1126/science.277.5322.91	http://dx.doi.org/10.1126/science.277.5322.91			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204906				2022-12-24	WOS:A1997XJ41800046
J	Wald, NJ; Watt, HC				Wald, NJ; Watt, HC			Prospective study of effect of switching from cigarettes to pipes or cigars on mortality from three smoking related diseases	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TOBACCO-SMOKE; EXPOSURE	Objective: To estimate the extent to which cigarette smokers who switch to cigars or pipes alter their risk of dying of three smoking related diseases-lung cancer, ischaemic heart disease, and chronic obstructive lung disease. Design: A prospective study of 21 520 men aged 35-64 years when recruited in 1975-82 with detailed history of smoking and measurement of carboxyhaemoglobin. Main outcome measures: Notification of deaths (to 1993) classified by cause. Results: Pipe and cigar smokers who had switched from cigarettes over 20 years before entry to the study smoked less tobacco than cigarette smokers (8.1 g/day v 20 g/day), but they had the same consumption as pipe and cigar smokers who had never smoked cigarettes (8.1 g) and had higher carboxyhaemoglobin saturations (1.2% v 1.0%, P < 0.001), indicating that they inhaled tobacco smoke to a greater extent They had a 51% higher risk of dying of the three smoking related diseases than pipe or cigar smokers who had never smoked cigarettes (relative risk 1.51; 95% confidence interval 0.96 to 2.38), a 68% higher risk than lifelong non-smokers (1.68; 1.16 to 2.45), a 57% higher risk than former cigarette smokers who gave up smoking over 20 years before entry (1.57; 1.04 to 2.38), and a 46% lower risk than continuing cigarette smokers (0.54; 0.38 to 0.77). Conclusion: Cigarette smokers who have difficulty in giving up smoking altogether are better off changing to cigars or pipes than continuing to smoke cigarettes. Much of the effect is due to the reduction in the quantity of tobacco smoked, and some is due to inhaling less. Men who switch do not, however, achieve the lower risk of pipe and cigar smokers who have never smoked cigarettes. All pipe and cigar smokers have a greater risk of lung cancer than lifelong non-smokers or former smokers.	ROYAL LONDON SCH MED & DENT, LONDON EC1M 6BQ, ENGLAND	University of London; Queen Mary University London	Wald, NJ (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL, WOLFSON INST PREVENT MED, BUPA EPIDEMIOL RES GRP, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					BENSHLOMO Y, 1994, AM J PUBLIC HEALTH, V84, P1235, DOI 10.2105/AJPH.84.8.1235; CASTLEDEN CM, 1973, LANCET, V2, P21; COWIE J, 1973, LANCET, V1, P1033; GOLDMAN AL, 1977, CHEST, V72, P33, DOI 10.1378/chest.72.1.33; KAUFMAN DW, 1987, BRIT MED J, V294, P1315, DOI 10.1136/bmj.294.6583.1315; OCKENE JK, 1987, AM J PUBLIC HEALTH, V77, P1412, DOI 10.2105/AJPH.77.11.1412; PECHACEK TF, 1985, JAMA-J AM MED ASSOC, V254, P3330, DOI 10.1001/jama.254.23.3330; RODENSTEIN DO, 1985, AM REV RESPIR DIS, V132, P628; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; TURNER JAM, 1977, BMJ-BRIT MED J, V2, P1387, DOI 10.1136/bmj.2.6099.1387; WALD N, 1978, THORAX, V33, P201, DOI 10.1136/thx.33.2.201; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1	12	66	68	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 28	1997	314	7098					1860	1863		10.1136/bmj.314.7098.1860	http://dx.doi.org/10.1136/bmj.314.7098.1860			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224127	Green Published			2022-12-24	WOS:A1997XH73800020
J	Maraskovsky, E; OReilly, LA; Teepe, M; Corcoran, LM; Peschon, JJ; Strasser, A				Maraskovsky, E; OReilly, LA; Teepe, M; Corcoran, LM; Peschon, JJ; Strasser, A			Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1(-/-) mice	CELL			English	Article							NEGATIVE SELECTION; TRANSGENIC MICE; B-CELLS; THYMOCYTE DEVELOPMENT; RAG-1-DEFICIENT MICE; V(D)J REARRANGEMENT; POSITIVE SELECTION; CONTROL POINTS; GROWTH-FACTOR; GAMMA-CHAIN	Signals from cytokine and antigen receptors play crucial roles during lymphocyte development. Mice lacking interleukin-7 receptor are lymphopenic, due to a defect in cell expansion at an early stage of differentiation, and the few mature T cells that develop in IL-7R(-/-) animals are functionally impaired. Both defects were rescued completely by overexpression of the anti-apoptosis protein Bcl-2. T cell progenitors lacking antigen receptor molecules are also blocked in differentiation and die, presumably because they fail to receive a positive signal via their pre-T cell receptor. Surprisingly, Bcl-2 did not promote survival or differentiation of T cells in rag-1(-/-) mice. These results provide evidence that blocking apoptosis is the essential function of IL-7R during differentiation and activation of T lymphocytes and that pre-TCR signaling blocks a pathway to apoptosis that is insensitive to Bcl-2.	IMMUNEX RES & DEV CORP,DEPT MOL IMMUNOL,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT CELLULAR IMMUNOL,SEATTLE,WA 98101		Maraskovsky, E (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.		Corcoran, Lynn M/C-9316-2013; Strasser, Andreas/C-7581-2013	Strasser, Andreas/0000-0002-5020-4891				CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; EGERTON M, 1990, INT IMMUNOL, V2, P501, DOI 10.1093/intimm/2.6.501; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; FISHER AG, 1995, INT IMMUNOL, V7, P415, DOI 10.1093/intimm/7.3.415; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; FULCHER DA, 1994, J EXP MED, V179, P125, DOI 10.1084/jem.179.1.125; GODFREY DI, 1992, J IMMUNOL, V149, P2281; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; Maraskovsky E, 1996, J IMMUNOL, V157, P5315; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MEMON SA, 1995, J IMMUNOL, V155, P4644; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOLLINA TJ, 1992, NATURE, V357, P161; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORRISSEY PJ, 1991, J IMMUNOL, V147, P561; MORRISSEY PJ, 1989, J EXP MED, V169, P707, DOI 10.1084/jem.169.3.707; MUEGGE K, 1993, SCIENCE, V261, P93, DOI 10.1126/science.7686307; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Murray R, 1989, Int Immunol, V1, P526, DOI 10.1093/intimm/1.5.526; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PENIT C, 1995, J IMMUNOL, V154, P5103; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PETRIE HT, 1993, J EXP MED, V178, P615, DOI 10.1084/jem.178.2.615; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; Raff MC, 1996, CELL, V86, P173, DOI 10.1016/S0092-8674(00)80087-2; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; RODEWALD HR, 1995, IMMUNITY, V3, P313, DOI 10.1016/1074-7613(95)90116-7; ROLINK A, 1993, J EXP MED, V178, P1263, DOI 10.1084/jem.178.4.1263; SAMARIDIS J, 1991, EUR J IMMUNOL, V21, P453, DOI 10.1002/eji.1830210230; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; STRASSER A, 1994, P NATL ACAD SCI USA, V91, P1376, DOI 10.1073/pnas.91.4.1376; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; VEIS DJ, 1993, J IMMUNOL, V151, P2546; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Young F, 1997, IMMUNITY, V6, P23, DOI 10.1016/S1074-7613(00)80239-3	59	426	427	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1011	1019		10.1016/S0092-8674(00)80289-5	http://dx.doi.org/10.1016/S0092-8674(00)80289-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215624	Bronze			2022-12-24	WOS:A1997XG83000006
J	Hoffman, DA; Magee, JC; Colbert, CM; Johnston, D				Hoffman, DA; Magee, JC; Colbert, CM; Johnston, D			K+ channel regulation of signal propagation in dendrites of hippocampal pyramidal neurons	NATURE			English	Article							ACTION-POTENTIALS; CELL DENDRITES; IN-VITRO; CA1; CONDUCTANCE; MODULATION; AMPLIFICATION; INACTIVATION; INTEGRATION; ACTIVATION	Pyramidal neurons receive tens of thousands of synaptic inputs on their dendrites. The dendrites dynamically after the strengths of these synapses and coordinate them to produce an output in ways that are not well understood. surprisingly, there turns out to be a very high density of transient A-type potassium ion channels in dendrites of hippocampal CA1 pyramidal neurons. These channels prevent initiation of an action potential in the dendrites, limit the back-propagation of action potentials into the dendrites, and reduce excitatory synaptic events. The channels act to prevent large, rapid dendritic depolarizations, thereby regulating orthograde and retrograde propagation of dendritic potentials.	BAYLOR COLL MED,DEPT NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine			Hoffman, Dax A/E-5155-2011	Hoffman, Dax A/0000-0001-6999-2157				Alonso G, 1997, NEUROSCIENCE, V77, P617; ANDREASEN M, 1995, J PHYSIOL-LONDON, V483, P421, DOI 10.1113/jphysiol.1995.sp020595; CALLAWAY JC, 1995, J NEUROPHYSIOL, V74, P1395, DOI 10.1152/jn.1995.74.4.1395; CHEN QX, 1991, J NEUROSCI, V11, P337; Christie BR, 1996, LEARN MEMORY, V3, P160, DOI 10.1101/lm.3.2-3.160; Colbert CM, 1996, J NEUROSCI, V16, P6676; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; GAGE PW, 1992, TRENDS NEUROSCI, V15, P46, DOI 10.1016/0166-2236(92)90025-4; HALLIWELL JV, 1986, P NATL ACAD SCI USA, V83, P493, DOI 10.1073/pnas.83.2.493; Helmchen F, 1996, BIOPHYS J, V70, P1069, DOI 10.1016/S0006-3495(96)79653-4; Hines M, 1993, NEURAL SYSTEMS ANAL, P127; HOUNSGAARD J, 1988, J PHYSIOL-LONDON, V402, P731, DOI 10.1113/jphysiol.1988.sp017231; JAFFE DB, 1995, NATURE, V374, P1395; Johnston D, 1996, BIOPHYS J, V70, P1095, DOI 10.1016/S0006-3495(96)79674-1; Johnston D, 1996, ANNU REV NEUROSCI, V19, P165, DOI 10.1146/annurev.ne.19.030196.001121; KLEE R, 1995, J NEUROPHYSIOL, V74, P1982, DOI 10.1152/jn.1995.74.5.1982; Lipowsky R, 1996, J NEUROPHYSIOL, V76, P2181, DOI 10.1152/jn.1996.76.4.2181; MAGEE JC, 1995, J PHYSIOL-LONDON, V487, P67, DOI 10.1113/jphysiol.1995.sp020862; Magee JC, 1996, J NEUROPHYSIOL, V76, P3460, DOI 10.1152/jn.1996.76.5.3460; MAGEE JC, 1995, SCIENCE, V268, P301, DOI 10.1126/science.7716525; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; Mainen ZF, 1995, NEURON, V15, P1427, DOI 10.1016/0896-6273(95)90020-9; MALETICSAVATIC M, 1995, J NEUROSCI, V15, P3840; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; NICOLL A, 1993, J PHYSIOL-LONDON, V468, P693, DOI 10.1113/jphysiol.1993.sp019795; Rapp M, 1996, P NATL ACAD SCI USA, V93, P11985, DOI 10.1073/pnas.93.21.11985; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SCHWINDT PC, 1995, J NEUROPHYSIOL, V74, P2220, DOI 10.1152/jn.1995.74.5.2220; SEGAL M, 1984, J NEUROSCI, V4, P604; SEGAL M, 1984, J NEUROPHYSIOL, V51, P1409, DOI 10.1152/jn.1984.51.6.1409; SERIDIO P, 1994, J NEUROPHYSIOL, V72, P1516; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; SOLC CK, 1987, SCIENCE, V236, P1094, DOI 10.1126/science.2437657; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; STORM JF, 1988, NATURE, V336, P379, DOI 10.1038/336379a0; STUART G, 1995, NEURON, V15, P1065, DOI 10.1016/0896-6273(95)90095-0; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; TALUKDER G, 1995, J NEUROPHYSIOL, V73, P73, DOI 10.1152/jn.1995.73.1.73; Tsubokawa H, 1996, J NEUROPHYSIOL, V76, P2896, DOI 10.1152/jn.1996.76.5.2896; TURNER RW, 1991, J NEUROSCI, V11, P2270; WU RL, 1992, J NEUROSCI, V12, P2235; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4	44	1044	1089	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					869	875		10.1038/43119	http://dx.doi.org/10.1038/43119			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202119	Bronze			2022-12-24	WOS:A1997XG41600041
J	Conte, JE				Conte, JE			A novel approach to preventing insect-borne diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARTHROPOD VECTOR COMPETENCE				Conte, JE (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.							BEARD CB, 1993, PARASITOL TODAY, V9, P179, DOI 10.1016/0169-4758(93)90142-3; BEARD CB, 1992, AM J TROP MED HYG, V46, P195, DOI 10.4269/ajtmh.1992.46.195; Durvasula RV, 1997, P NATL ACAD SCI USA, V94, P3274, DOI 10.1073/pnas.94.7.3274; Richards F. F., 1993, ASM News (Washington), V59, P509; Ward E S, 1993, Adv Pharmacol, V24, P1, DOI 10.1016/S1054-3589(08)60931-X	5	11	11	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	1997	337	11					785	786		10.1056/NEJM199709113371112	http://dx.doi.org/10.1056/NEJM199709113371112			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV174	9287238				2022-12-24	WOS:A1997XV17400012
J	Blattner, FR; Plunkett, G; Bloch, CA; Perna, NT; Burland, V; Riley, M; ColladoVides, J; Glasner, JD; Rode, CK; Mayhew, GF; Gregor, J; Davis, NW; Kirkpatrick, HA; Goeden, MA; Rose, DJ; Mau, B; Shao, Y				Blattner, FR; Plunkett, G; Bloch, CA; Perna, NT; Burland, V; Riley, M; ColladoVides, J; Glasner, JD; Rode, CK; Mayhew, GF; Gregor, J; Davis, NW; Kirkpatrick, HA; Goeden, MA; Rose, DJ; Mau, B; Shao, Y			The complete genome sequence of Escherichia coli K-12	SCIENCE			English	Review							SINGLE-STRANDED-DNA; CODON USAGE; SALMONELLA-TYPHIMURIUM; MYCOPLASMA-GENITALIUM; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; BINDING-PROTEIN; FLAGELLAR HOOK; REGION; REPLICATION	The 4,639,221-base pair sequence of Escherichia coli K-12 is presented. Of 4288 protein-coding genes annotated, 38 percent have no attributed function. Comparison with five other sequenced microbes reveals ubiquitous as well as narrowly distributed gene families; many families of similar genes within E. coli are also evident. The largest family of paralogous proteins contains 80 ABC transporters. The genome as a whole is strikingly organized with respect to the local direction of replication; guanines, oigonucleotides possibly related to replication and recombination, and most genes are so oriented. The genome also contains insertion sequence (IS) elements, phage remnants, and many other patches of unusual composition indicating genome plasticity through horizontal transfer.	UNIV MICHIGAN, SCH MED, DEPT PEDIAT, ANN ARBOR, MI 48105 USA; FMC BIOPROD, ROCKLAND, ME 04841 USA; MARINE BIOL LABS, WOODS HOLE, MA 02543 USA; UNIV NACL AUTONOMA MEXICO, CTR INVEST FIJAC NITROGENO, CUERNAVACA 62100, MORELOS, MEXICO	University of Michigan System; University of Michigan; Marine Biological Laboratory - Woods Hole; Universidad Nacional Autonoma de Mexico	Blattner, FR (corresponding author), UNIV WISCONSIN, GENET LAB, 445 HENRY MALL, MADISON, WI 53706 USA.		Riley, Monica/E-1427-2011; Mayhew, George F/B-4042-2016; Plunkett, Guy/B-8058-2009; Riley, Andrew/F-3526-2013	Mayhew, George F/0000-0003-0609-6018; Plunkett, Guy/0000-0003-1422-469X; Collado-Vides, Julio/0000-0001-8780-7664; Riley, Andrew/0000-0001-9003-3540; Perna, Nicole/0000-0001-8208-0929	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010379] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG001428] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR10379] Funding Source: Medline; NHGRI NIH HHS [P01 HG01428] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ABDULLAH KM, 1991, J BACTERIOL, V173, P5597, DOI 10.1128/jb.173.18.5597-5603.1991; Aiba H, 1996, DNA Res, V3, P363, DOI 10.1093/dnares/3.6.363; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bachellier S, 1996, CELLULAR MOL BIOL, VII, P2012; BACHMANN BJ, 1996, CELLULAR MOL BIOL, V2, P2460; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P21, DOI 10.1093/nar/24.1.21; BHAGWAT AS, 1992, NUCLEIC ACIDS RES, V20, P1663, DOI 10.1093/nar/20.7.1663; BLAISDELL BE, 1993, J MOL BIOL, V229, P833, DOI 10.1006/jmbi.1993.1090; BLATTNER FR, 1983, SCIENCE, V222, P719, DOI 10.1126/science.222.4625.719; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; Bloch CA, 1996, BIOCHEM BIOPH RES CO, V223, P104, DOI 10.1006/bbrc.1996.0853; BLOCH CA, UNPUB; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; BREWER BJ, 1990, BACTERIAL CHROMOSOME, P61; BUGG TDH, 1993, BIOCHIM BIOPHYS ACTA, V1202, P258, DOI 10.1016/0167-4838(93)90013-H; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGE C, 1992, P NATL ACAD SCI USA, V89, P1358, DOI 10.1073/pnas.89.4.1358; BURLAND V, 1993, NUCLEIC ACIDS RES, V21, P3385, DOI 10.1093/nar/21.15.3385; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; BURLAND V, 1995, NUCLEIC ACIDS RES, V23, P2105, DOI 10.1093/nar/23.12.2105; Burland V, 1996, BIOTECHNIQUES, V21, P142; BURLINGAME RP, 1986, J BACTERIOL, V168, P55, DOI 10.1128/jb.168.1.55-64.1986; CAMPBELL AM, 1996, CELLULAR MOL BIOL, V2, P2041; CARDON LR, 1993, NUCLEIC ACIDS RES, V21, P3875, DOI 10.1093/nar/21.16.3875; CHUANG SE, 1993, J BACTERIOL, V175, P2026, DOI 10.1128/JB.175.7.2026-2036.1993; DANIELS DL, 1990, BACTERIAL CHROMOSOME, P43; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DANIELS DL, 1982, COLD SPRING HARB SYM, V47, P1009; DEONIER RC, 1996, CELLULAR MOL BIOL, V2, P2000; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRANCOIS V, 1989, MOL MICROBIOL, V3, P995, DOI 10.1111/j.1365-2958.1989.tb00250.x; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FUJITA N, 1994, NUCLEIC ACIDS RES, V22, P1637, DOI 10.1093/nar/22.9.1637; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; GRALLA JD, 1996, CELLULAR MOL BIOL, V1, P1232; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; HILL TM, 1996, CELLULAR MOL BIOL, V2, P1602; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HLASA H, 1989, GENE, V84, P9; HOMMA M, 1990, J MOL BIOL, V213, P819, DOI 10.1016/S0022-2836(05)80266-9; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; Itoh T, 1996, DNA Res, V3, P379, DOI 10.1093/dnares/3.6.379; JENSEN KF, 1993, J BACTERIOL, V175, P3401, DOI 10.1128/jb.175.11.3401-3407.1993; Kaneko T, 1996, DNA Res, V3, P109; KARLIN S, 1994, ANNU REV MICROBIOL, V48, P619, DOI 10.1146/annurev.mi.48.100194.003155; Karp PD, 1997, NUCLEIC ACIDS RES, V25, P43, DOI 10.1093/nar/25.1.43; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KIRBY JE, 1994, J BACTERIOL, V176, P2068, DOI 10.1128/jb.176.7.2068-2081.1994; KOFOID E, COMMUNICATION; KUTSUKAKE K, 1994, GENE, V143, P49; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LABEDAN B, 1995, MOL BIOL EVOL, V12, P980; LAWTHER RP, 1982, J BACTERIOL, V149, P294, DOI 10.1128/JB.149.1.294-298.1982; LIM DB, 1992, MOL MICROBIOL, V6, P3531, DOI 10.1111/j.1365-2958.1992.tb01788.x; LINDSEY DF, 1992, J BACTERIOL, V174, P3834, DOI 10.1128/JB.174.11.3834-3835.1992; LIU D, 1994, MICROBIOL-UK, V140, P49, DOI 10.1099/13500872-140-1-49; Lobry JR, 1996, SCIENCE, V272, P745, DOI 10.1126/science.272.5262.745; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LU Y, 1992, J BIOL CHEM, V267, P24848; MACNAB RM, 1996, CELLULAR MOL BIOL, V2, P123; MATSUTANI S, 1993, GENE, V127, P111; MCCLELLAND M, 1992, NATURE, V355, P595; MEDIGUE C, 1991, J MOL BIOL, V222, P851, DOI 10.1016/0022-2836(91)90575-Q; MEDIGUE C, 1991, MOL MICROBIOL, V5, P2629, DOI 10.1111/j.1365-2958.1991.tb01972.x; MERKL R, 1992, NUCLEIC ACIDS RES, V20, P1657, DOI 10.1093/nar/20.7.1657; MISSIAKAS D, 1993, J BACTERIOL, V175, P2613, DOI 10.1128/JB.175.9.2613-2624.1993; NAKATA A, 1989, J BACTERIOL, V171, P3553, DOI 10.1128/jb.171.6.3553-3556.1989; NEIDHARDT FC, 1996, CELLULAR MOL BIOL, V2, P1; NEIDHARDT FC, 1996, CELLULAR MOL BIOL; OHNISHI K, 1994, J BACTERIOL, V176, P2272, DOI 10.1128/JB.176.8.2272-2281.1994; Ohno S., 1970, EVOLUTION GENE DUPLI; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; Oshima T, 1996, DNA Res, V3, P137, DOI 10.1093/dnares/3.3.137; PERNA NT, 1995, J MOL EVOL, V41, P353, DOI 10.1007/BF01215182; PERRIN A, 1993, EMBO J, V12, P2939, DOI 10.1002/j.1460-2075.1993.tb05956.x; PLUNKETT G, 1993, NUCLEIC ACIDS RES, V21, P3391, DOI 10.1093/nar/21.15.3391; POSFAI G, 1994, NUCLEIC ACIDS RES, V22, P2392, DOI 10.1093/nar/22.12.2392; RETALLACK DM, 1994, J BACTERIOL, V176, P2082, DOI 10.1128/jb.176.7.2082-2089.1994; Riley M, 1997, NUCLEIC ACIDS RES, V25, P51, DOI 10.1093/nar/25.1.51; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; RILEY M, 1997, J MOL BIOL, V269, P1; RILEY M, 1996, CELLULAR MOL BIOL, V2, P2118; RODE CK, 1995, GENE, V166, P1, DOI 10.1016/0378-1119(95)00630-5; Rosenblueth DA, 1996, COMPUT APPL BIOSCI, V12, P415; SACERDOT C, 1982, EMBO J, V1, P311, DOI 10.1002/j.1460-2075.1982.tb01166.x; SALYERS AA, 1994, BACTERIOL PATHOGENES; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SCHULTZ DW, 1981, J MOL BIOL, V146, P275, DOI 10.1016/0022-2836(81)90388-0; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; Spence EL, 1996, J BACTERIOL, V178, P5249, DOI 10.1128/jb.178.17.5249-5256.1996; STAHL F, 1995, J HERED, V86, P327, DOI 10.1093/oxfordjournals.jhered.a111599; SWART JR, 1993, J BIOL CHEM, V268, P12970; TAN HM, 1993, GENE, V130, P33, DOI 10.1016/0378-1119(93)90343-2; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; VANVLIET F, 1988, ANN INST PASTEUR MIC, V139, P493, DOI 10.1016/0769-2609(88)90111-1; WANG TCV, 1994, BIOCHEM BIOPH RES CO, V198, P844, DOI 10.1006/bbrc.1994.1120; WANG TCV, 1992, BIOCHEM BIOPH RES CO, V184, P1496, DOI 10.1016/S0006-291X(05)80052-X; WU CI, 1987, NATURE, V327, P169, DOI 10.1038/327169a0; YODA K, 1991, MOL GEN GENET, V227, P1, DOI 10.1007/BF00260698; YODA KY, 1988, NUCLEIC ACIDS RES, V16, P6531, DOI 10.1093/nar/16.14.6531; YURA T, 1992, NUCLEIC ACIDS RES, V20, P3305, DOI 10.1093/nar/20.13.3305	105	5760	10587	23	781	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	1997	277	5331					1453	+		10.1126/science.277.5331.1453	http://dx.doi.org/10.1126/science.277.5331.1453			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278503				2022-12-24	WOS:A1997XV42900030
J	Furnari, B; Rhind, N; Russell, P				Furnari, B; Rhind, N; Russell, P			Cdc25 mitotic inducer targeted by Chk1 DNA damage checkpoint kinase	SCIENCE			English	Article							WEE1 PROTEIN-KINASE; FISSION YEAST; NEGATIVE REGULATION; FEEDBACK CONTROLS; MITOSIS; PHOSPHORYLATION; PATHWAY; ARREST	Arrest of the cell cycle at the G(2) checkpoint, induced by DNA damage, requires inhibitory phosphorylation of the kinase Cdc2 in both fission yeast and human cells. The kinase Wee1 and the phosphatase Cdc25, which regulate Cdc2 phosphorylation, were evaluated as targets of Chk1, a kinase essential for the checkpoint. Fission yeast cdc2-3w Delta cdc25 cells, which express activated Cdc2 and lack Cdc25, were responsive to Wee1 but insensitive to Chk1 and irradiation. Expression of large amounts of Chk1 produced the same phenotype as did loss of the cdc25 gene in cdc2-3w cells. Cdc25 associated with Chk1 in vivo and was phosphorylated when copurified in Chk1 complexes. These findings identify Cdc25, but not Wee1, as a target of the DNA damage checkpoint.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute				Rhind, Nicholas/0000-0003-1758-7736				ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BARBET NC, 1993, NATURE, V364, P824, DOI 10.1038/364824a0; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FEILOTTER H, 1991, GENETICS, V127, P309; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FUMARI B, UNPUB; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SHELDRICK KS, 1993, BIOESSAYS, V15, P775, DOI 10.1002/bies.950151202; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0	29	468	480	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	1997	277	5331					1495	1497		10.1126/science.277.5331.1495	http://dx.doi.org/10.1126/science.277.5331.1495			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278510				2022-12-24	WOS:A1997XV42900037
J	Jones, GRN				Jones, GRN			Are CS sprays safe?	LANCET			English	Editorial Material																		ABDO K, 1990, NIH PUBL; BHATTACHARYA ST, 1993, ANAESTHESIA, V48, P896, DOI 10.1111/j.1365-2044.1993.tb07424.x; GIBBONS S, 1996, POLICE REV      0216, P4; HELLREICH A, 1967, 4075 EDGW ARS; HIMSWORTH H, 1971, CMND4775; Himsworth H., 1969, CMND4173; PARNEIXSPAKE A, 1993, ARCH DERMATOL, V129, P913, DOI 10.1001/archderm.1993.01680280103029	7	6	6	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					605	606		10.1016/S0140-6736(05)63322-3	http://dx.doi.org/10.1016/S0140-6736(05)63322-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288040				2022-12-24	WOS:A1997XU28300005
J	Tomioka, N; Fujino, K				Tomioka, N; Fujino, K			Natural (Mg,Fe)SiO3-ilmenite and -perovskite in the Tenham meteorite	SCIENCE			English	Article							PHASES; MGSIO3	The minerals (Mg, Fe)SiO3-ilmenite and -perovskite were identified in the shock-induced veins in the Tenham chondritic meteorite. Both phases are inferred to have transformed from pyroxene at high pressures and temperatures by shock metamorphism. Columnar-shaped ilmenite grains, one of two types of morphologies, have a topotaxial relationship with neighboring pyroxene grains, indicating shear transformation. Granular-shaped perovskite grains showed a diffraction pattern consistent with orthorhombic perovskite, but these grains were not stable under the electron beam irradiation and became amorphous. The higher iron concentration in both phases compared with those experimentally reported may suggest their metastable transition from enstatite because of shock compression.			Tomioka, N (corresponding author), HOKKAIDO UNIV,GRAD SCH SCI,DIV EARTH & PLANETARY SCI,SAPPORO,HOKKAIDO 060,JAPAN.		Tomioka, Naotaka/AID-3472-2022; Tomioka, Naotaka/B-1888-2011	Tomioka, Naotaka/0000-0001-5725-9513				BINNS RA, 1969, NATURE, V221, P943, DOI 10.1038/221943a0; Chen M, 1996, SCIENCE, V271, P1570, DOI 10.1126/science.271.5255.1570; Coleman LC, 1977, CAN MINERAL, V15, P97; Fei YW, 1996, J GEOPHYS RES-SOL EA, V101, P11525, DOI 10.1029/96JB00408; FUJINO K, 1996, P US JAP SEM MAU HI; ITO E, 1989, J GEOPHYS RES-SOLID, V94, P10637, DOI 10.1029/JB094iB08p10637; Ito E., 1977, HIGH PRESSURE RES, P193; Ito E., 1982, HIGH PRESSURE RES GE, P405; KATO T, 1985, NATURE, V316, P803, DOI 10.1038/316803a0; LIU L, 1975, GEOPHYS RES LETT, V2, P417, DOI 10.1029/GL002i010p00417; LIU LG, 1976, EARTH PLANET SC LETT, V31, P200, DOI 10.1016/0012-821X(76)90212-0; MASON B, 1968, SCIENCE, V160, P66, DOI 10.1126/science.160.3823.66; MORI H, 1985, LUNAR PLANET SCI, V16, P579; PRICE GD, 1979, CONTRIB MINERAL PETR, V71, P211, DOI 10.1007/BF00375437; PRICE GD, 1983, CAN MINERAL, V21, P29; PUTNIS A, 1979, NATURE, V280, P217, DOI 10.1038/280217a0; Sawamoto H., 1987, HIGH PRESSURE RES MI, P209; Stu┬ffler D., 1972, FORTSCHRITTE MINERAL, V49, P50; VANSCHMUS WR, 1967, GEOCHIM COSMOCHIM AC, V31, P747, DOI 10.1016/S0016-7037(67)80030-9	19	112	117	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1084	1086		10.1126/science.277.5329.1084	http://dx.doi.org/10.1126/science.277.5329.1084			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262473				2022-12-24	WOS:A1997XT03300030
J	Fraser, FC				Fraser, FC			Trinucleotide repeats not the only cause of anticipation	LANCET			English	Editorial Material											Fraser, FC (corresponding author), MCGILL UNIV,CTR HUMAN GENET,MONTREAL,PQ H3A 1B1,CANADA.							CROW TJ, 1991, EUR ARCH PSY CLIN N, V240, P314, DOI 10.1007/BF02279759; Horwitz M, 1996, AM J HUM GENET, V59, P990; McInnis MG, 1996, AM J HUM GENET, V59, P973; Paterson AD, 1996, AM J HUM GENET, V59, P264; PENROSE LS, 1948, ANN EUGENIC, V14, P125; Petronis A., 1996, American Journal of Human Genetics, V59, pA186; Polito JMII, 1996, LANCET, V347, P798, DOI 10.1016/S0140-6736(96)90870-3; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636	8	44	45	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					459	460		10.1016/S0140-6736(05)63077-2	http://dx.doi.org/10.1016/S0140-6736(05)63077-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274580				2022-12-24	WOS:A1997XR13500006
J	Gore, SM; Bingham, S; Day, NE				Gore, SM; Bingham, S; Day, NE			Age related dietary exposure to meat products from British dietary surveys of teenagers and adults in the 1980s and 1990s	BRITISH MEDICAL JOURNAL			English	Article									MRC,DUNN CLIN NUTR CTR,CAMBRIDGE CB2 2SR,ENGLAND		Gore, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; *COUNC ROYAL SOC, 1997, UPD BSE, P1; Gregory J., 1990, DIETARY NUTR SURVEY; Ministry of Agriculture Fisheries and Food, 1991, 50 YEARS NAT FOOD SU; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					404	405		10.1136/bmj.315.7105.404	http://dx.doi.org/10.1136/bmj.315.7105.404			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277606	Green Published			2022-12-24	WOS:A1997XR54900022
J	Maggiorini, M; Bartsch, P; Oelz, O				Maggiorini, M; Bartsch, P; Oelz, O			Association between raised body temperature and acute mountain sickness: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							PULMONARY-EDEMA; HIGH-ALTITUDE		UNIV CLIN MED,HEIDELBERG,GERMANY; STADTSPITAL TRIEMLI,DEPT MED,ZURICH,SWITZERLAND	Triemli Hospital	Maggiorini, M (corresponding author), UNIV ZURICH HOSP,DEPT MED,CH-8091 ZURICH,SWITZERLAND.			Maggiorini, Marco/0000-0001-8180-2117				HOUSTON CS, 1987, GOING HIGHER STORY M; Kleger GR, 1996, J APPL PHYSIOL, V81, P1917, DOI 10.1152/jappl.1996.81.5.1917; MAGGIORINI M, 1990, BRIT MED J, V301, P853, DOI 10.1136/bmj.301.6756.853; SCHOENE RB, 1988, J APPL PHYSIOL, V64, P2605, DOI 10.1152/jappl.1988.64.6.2605; VOCK P, 1989, RADIOLOGY, V170, P661, DOI 10.1148/radiology.170.3.2916019	5	19	19	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					403	404		10.1136/bmj.315.7105.403	http://dx.doi.org/10.1136/bmj.315.7105.403			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277605	Green Published			2022-12-24	WOS:A1997XR54900021
J	Ewalt, KL; Hendrick, JP; Houry, WA; Hartl, FU				Ewalt, KL; Hendrick, JP; Houry, WA; Hartl, FU			In vivo observation of polypeptide flux through the bacterial chaperonin system	CELL			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; REACTION CYCLE; ATPASE CYCLE; IN-VIVO; GROEL; EXPRESSION; RHODANESE; BINDING	The quantitative contribution of chaperonin GroEL to protein folding in E. coli was analyzed. A diverse set of newly synthesized polypeptides, predominantly between 10-55 kDa, interacts with GroEL, accounting for 10%-15% of all cytoplasmic protein under normal growth conditions, and for 30% or more upon exposure to heat stress. Most proteins leave GroEL rapidly within 10-30 s. We distinguish three classes of substrate proteins: (I) proteins with a chaperonin-independent folding pathway; (II) proteins, more than 50% of total, with an intermediate chaperonin dependence for which normally only a small fraction transits GroEL; and (III) a set of highly chaperonin-dependent proteins, many of which dissociate slowly from GroEL and probably require sequestration of aggregation-sensitive intermediates within the GroEL cavity for successful folding.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MAX PLANCK INST BIOCHEM,DEPT CELLULAR BIOCHEM,D-82152 MARTINSRIED,GERMANY	Memorial Sloan Kettering Cancer Center; Max Planck Society	Ewalt, KL (corresponding author), MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021, USA.		Hartl, F. Ulrich/Y-8206-2019					Ausubel FM, 1992, CURRENT PROTOCOLS MO; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Clark AC, 1996, BIOCHEMISTRY-US, V35, P5893, DOI 10.1021/bi953051v; Corrales FJ, 1996, P NATL ACAD SCI USA, V93, P4509, DOI 10.1073/pnas.93.9.4509; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FLANAGAN JM, 1992, P NATL ACAD SCI USA, V89, P748, DOI 10.1073/pnas.89.2.748; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; GAITANARIS GA, 1994, MOL MICROBIOL, V14, P861, DOI 10.1111/j.1365-2958.1994.tb01322.x; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOODSELL DS, 1991, TRENDS BIOCHEM SCI, V16, P203, DOI 10.1016/0968-0004(91)90083-8; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hagenmaier S, 1997, J BACTERIOL, V179, P2073, DOI 10.1128/jb.179.6.2073-2076.1997; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HOHFELD J, 1995, CELL, V83, P589; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; KANDROR O, 1995, EMBO J, V14, P6021, DOI 10.1002/j.1460-2075.1995.tb00290.x; KIM HB, 1991, BIOCHEM INT, V25, P381; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; Kudlicki W, 1997, FOLD DES, V2, P101, DOI 10.1016/S1359-0278(97)00014-X; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MARTIN J, 1997, P NATL ACAD SCI USA, V94, P14107; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MILLER DM, 1991, J BIOL CHEM, V266, P4686; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, P13; PRATT JM, 1984, TRANSCRIPTION TRANSL, P179; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rospert S, 1996, EMBO J, V15, P764, DOI 10.1002/j.1460-2075.1996.tb00412.x; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5	49	280	286	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					491	500		10.1016/S0092-8674(00)80509-7	http://dx.doi.org/10.1016/S0092-8674(00)80509-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267029	Bronze			2022-12-24	WOS:A1997XQ06300013
J	Casson, IF; Clarke, CA; Howard, CV; McKendrick, O; Pennycook, S; Pharoah, POD; Platt, MJ; Stanisstreet, M; vanVelszen, D; Walkinshaw, S				Casson, IF; Clarke, CA; Howard, CV; McKendrick, O; Pennycook, S; Pharoah, POD; Platt, MJ; Stanisstreet, M; vanVelszen, D; Walkinshaw, S			Outcomes of pregnancy in insulin dependent diabetic women: results of a five year population cohort study	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL-ANOMALIES; SPONTANEOUS-ABORTION; MELLITUS; CARE	Objective: To monitor pregnancies in women with pre-existent insulin dependent diabetes for pregnancy loss, congenital malformations, and fetal growth in a geographically defined area of north west England. Design: Population cohort study. Setting: 10 maternity units in Cheshire, Lancashire, and Merseyside which had no regional guidelines for the management of pregnancy in diabetic women. Subjects: 462 pregnancies in 355 women with insulin dependent diabetes from the 10 centres over five years (1990-4 inclusive). Main outcome measures: Numbers and rates of miscarriages, stillbirths, and neonatal and postneonatal deaths; prevalence of congenital malformations; birth weight in relation to gestational age. Results: Among 462 pregnancies, 351 (76%) resulted in a liveborn infant, 78 (17%) aborted spontaneously, nine (2%) resulted in stillbirth, and 24 (5%) were terminated. Of the terminations, nine were for congenital malformation. The stillbirth rate was 25.0/1000 total births (95% confidence interval 8.9 to 41.1) compared with a population rate of 5.0/1000, and infant mortality was 19.9/1000 live births (5.3 to 34.6) compared with 6.8/1000. The prevalence of congenital malformations was 94.0/1000 live births (63.5 to 124.5) compared with 9.7/1000 in the general population. When corrected for gestational age, mean birth weight in the sample was 1.3 standard deviations greater than that of infants of non-diabetic mothers. Infants with congenital malformations weighed less than those without. Conclusion: In an unselected population the infants of women with pre-existent insulin dependent diabetes mellitus have a 10-fold greater risk of a congenital malformation and a fivefold greater risk of being stillborn than infants in the general population. Further improvements in the management of pregnancy in diabetic women are needed if target of die St Vincent declaration of 1989 is to be met.	BROADGREEN HOSP,LIVERPOOL L14 3LD,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,SCH BIOL SCI,LIVERPOOL L69 38X,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; LIVERPOOL WOMENS HOSP,LIVERPOOL L8 7SS,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3GB,MERSEYSIDE,ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool			Platt, MJ/K-4588-2012	Platt, MJ/0000-0002-9372-9575; Howard, Charles Vyvyan/0000-0002-6151-3446				Albert TJ, 1996, AM J OBSTET GYNECOL, V174, P1424, DOI 10.1016/S0002-9378(96)70583-5; CORDERO L, 1993, CLIN PERINATOL, V20, P635, DOI 10.1016/S0095-5108(18)30390-7; Diabet Control Complications Trial Res Grp, 1996, AM J OBSTET GYNECOL, V174, P1343; DOLK H, 1991, DESCRIPTIVE EUROCAT; DUNLOP DC, 1996, DIABETIC MED, V13, pS44; HAWTHORNE GC, 1996, DIABET MED S3, V13, pS44; KITZMILLER JL, 1991, JAMA-J AM MED ASSOC, V265, P731, DOI 10.1001/jama.265.6.731; LANDON MB, 1987, AM J OBSTET GYNECOL, V156, P1089, DOI 10.1016/0002-9378(87)90116-5; Landon MB, 1995, MED DISORDERS PREGNA, P63; LOWRY C, 1986, DIABETIC MED, V3, P458; MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204; MILLS JL, 1988, NEW ENGL J MED, V319, P1617, DOI 10.1056/NEJM198812223192501; *N W REG HLTH AUTH, 1995, HLTH N W ENGL COMM D; *NW REG HLTH AUTH, 1995, N W REG 1994 PUBL HL; OATS JN, 1995, BAILLIERE CLIN OB GY, V9, P481, DOI 10.1016/S0950-3552(05)80376-1; *OFF NAT STAT, 1996, POP TRENDS 84; *OFF POP CENS SURV, 1982, INF PER MORT SOC BIO; *OFF POP CENS SURV, 1992, INF PER MORT SOC BIO; *OFF POP CENS SURV, 1992, BRITH STAT; *OFF POP CENS SURV, 1992, CONG MALF STAT; ROSENN B, 1994, OBSTET GYNECOL, V84, P515; *SCOTT HLTH SERV C, 1991, BIRTHW HEAD CIRC LEN; STEEL JM, 1990, BRIT MED J, V301, P1070, DOI 10.1136/bmj.301.6760.1070; WEATHERALL JAC, 1978, POPUL TRENDS, V11, P27; WHO/IDF Europe, 1990, DIABETIC MED, V7, P360; ZAR JH, 1984, BIOSTAT ANAL, P386	26	368	374	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					275	278		10.1136/bmj.315.7103.275	http://dx.doi.org/10.1136/bmj.315.7103.275			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274545	Green Published			2022-12-24	WOS:A1997XP75000019
J	Swerlick, RA; Lawley, TJ				Swerlick, RA; Lawley, TJ			Hypersensitivity vasculitis - not always benign?	LANCET			English	Editorial Material											Swerlick, RA (corresponding author), EMORY UNIV,SCH MED,DEPT DERMATOL,ATLANTA,GA 30345, USA.		Swerlick, Robert/AAY-1998-2020	Swerlick, Robert/0000-0002-9802-4144				EKENSTAM AE, 1984, ARCH DERMATOL, V120, P484; MartinezTaboada VM, 1997, AM J MED, V102, P186; TancredeBohin E, 1997, ARCH DERMATOL, V133, P438, DOI 10.1001/archderm.133.4.438; WINKELMANN RK, 1964, MEDICINE, V43, P59, DOI 10.1097/00005792-196401000-00003; WISNIESKI JJ, 1995, MEDICINE, V74, P24, DOI 10.1097/00005792-199501000-00003	5	5	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					306	307		10.1016/S0140-6736(05)63383-1	http://dx.doi.org/10.1016/S0140-6736(05)63383-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251631				2022-12-24	WOS:A1997XP24200004
J	Gewirtz, JC; Davis, M				Gewirtz, JC; Davis, M			Second-order fear conditioning prevented by blocking NMDA receptors in amygdala	NATURE			English	Article							LONG-TERM POTENTIATION; LATERAL NUCLEUS; INTRAAMYGDALA INFUSION; BASOLATERAL AMYGDALA; IMPAIRS ACQUISITION; STARTLE; ANTAGONIST; EXPRESSION; MEMORY; BLOCKADE	Antagonists of NMDA (N-methyl-D-aspartate)-type glutamate receptors disrupt several forms of learning(1-8). Although this might indicate that NMDA-receptor-mediated processes are critical for synaptic plasticity, there may be other mechanisms by which NMDA-receptor antagonism could interfere with learning(1,9-12). For instance, fear conditioning would be blocked by microinfusion of the NMDA-receptor antagonist AP5 (D,L-2-amino-5-phosphonovalerate) into the basolateral amygdala(6,13,14) if AP5 inhibited routine synaptic transmission, thereby reducing the ability of stimuli to activate amygdala neurons(15,16). In second-order fear conditioning(17,18), the reinforcer is a fear-eliciting conditioned stimulus rather than an unconditioned stimulus. Expression of conditioned fear is amygdala-dependent(19,20) and so provides a behavioural assessment of the ability of the reinforcer to activate amygdala neurons in the presence of AP5. We report here that intra-amygdala AP5 actually enhances expression of conditioned fear to the conditioned stimulus that provides the reinforcement signal for second-order conditioning. Nevertheless, acquisition of second-order fear conditioning is completely blocked. Our findings strongly support the view that NMDA receptors are critically involved in synaptic plasticity.	YALE UNIV,RIBICOFF RES FACIL,CONNECTICUT MENTAL HLTH CTR,DEPT PSYCHIAT,NEW HAVEN,CT 06508	Yale University	Gewirtz, JC (corresponding author), YALE UNIV,RIBICOFF RES FACIL,CONNECTICUT MENTAL HLTH CTR,DEPT PSYCHOL,34 PK ST,NEW HAVEN,CT 06508, USA.							BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; BURNS LH, 1994, BEHAV NEURAL BIOL, V61, P242, DOI 10.1016/S0163-1047(05)80007-X; CAMPEAU S, 1995, J NEUROSCI, V15, P2312, DOI 10.1523/JNEUROSCI.15-03-02312.1995; CAMPEAU S, 1995, J NEUROSCI, V15, P2301, DOI 10.1523/JNEUROSCI.15-03-02301.1995; CAMPEAU S, 1991, BRAIN RES, V565, P349, DOI 10.1016/0006-8993(91)91669-R; CAMPEAU S, 1992, BEHAV NEUROSCI, V106, P569, DOI 10.1037/0735-7044.106.3.569; CARAMANOS Z, 1994, BEHAV NEUROSCI, V108, P30, DOI 10.1037/0735-7044.108.1.30; CASSELLA JV, 1986, PHYSIOL BEHAV, V36, P377, DOI 10.1016/0031-9384(86)90032-6; EVERITT B J, 1992, P401; FALLS WA, 1992, J NEUROSCI, V12, P854; FANSELOW MS, 1994, BEHAV NEUROSCI, V108, P210, DOI 10.1037/0735-7044.108.1.210; HATFIELD T, 1995, BEHAV NEUROSCI, V109, P663, DOI 10.1037/0735-7044.109.4.663; Hatfield T, 1996, J NEUROSCI, V16, P5256; IZQUIERDO I, 1995, NEUROBIOL LEARN MEM, V63, P19, DOI 10.1006/nlme.1995.1002; KEITH JR, 1990, PSYCHOBIOLOGY, V18, P251; KIM JJ, 1991, BEHAV NEUROSCI, V105, P125; KIM M, 1993, BEHAV NEURAL BIOL, V59, P5, DOI 10.1016/0163-1047(93)91075-X; KIM M, 1992, BRAIN RES, V585, P35, DOI 10.1016/0006-8993(92)91188-K; LI XF, 1995, EXP BRAIN RES, V105, P87; Li XF, 1996, LEARN MEMORY, V3, P229, DOI 10.1101/lm.3.2-3.229; Maren S, 1996, BEHAV NEUROSCI, V110, P1365, DOI 10.1037/0735-7044.110.6.1365; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; Pavlov I.P., 1927, CONDITIONED REFLEXES; Rescorla R. A, 1980, PAVLOVIAN 2 ORDER CO; ROMANSKI LM, 1992, J NEUROSCI, V12, P4501; ROMANSKI LM, 1993, BEHAV NEUROSCI, V107, P444, DOI 10.1037/0735-7044.107.3.444; SAUCIER D, 1995, NATURE, V378, P186, DOI 10.1038/378186a0; Servatius RJ, 1996, BEHAV NEUROSCI, V110, P1040; STAUBLI U, 1989, BEHAV NEUROSCI, V103, P54, DOI 10.1037/0735-7044.103.1.54; WILLICK ML, 1995, BEHAV NEUROSCI, V109, P929, DOI 10.1037/0735-7044.109.5.929	30	168	170	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					471	474		10.1038/41325	http://dx.doi.org/10.1038/41325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242405	Bronze			2022-12-24	WOS:A1997XN55300048
J	Ido, Y; Vindigni, A; Chang, K; Stramm, L; Chance, R; Heath, WF; DiMarchi, RD; DiCera, E; Williamson, JR				Ido, Y; Vindigni, A; Chang, K; Stramm, L; Chance, R; Heath, WF; DiMarchi, RD; DiCera, E; Williamson, JR			Prevention of vascular and neural dysfunction in diabetic rats by C-peptide	SCIENCE			English	Article							ELEVATED GLUCOSE-LEVELS; RENAL-FUNCTION; PROTEIN; POLYPEPTIDE; SORBITOL; CONFORMATION; TYPE-1	C-peptide, a cleavage product from the processing of proinsulin to insulin, has been considered to possess little if any biological activity other than its participation in insulin synthesis, Injection of human C-peptide prevented or attenuated vascular and neural (electrophysiological) dysfunction and impaired Na+- and K+-dependent adenosine triphosphate activity in tissues of diabetic rats. Nonpolar amino acids in the midportion of the peptide were required for these biological effects. Synthetic reverse sequence (retro) and all-D-amino acid (enantio) C-peptides were equipotent to native C-peptide, which indicates that the effects of C-peptide on diabetic vascular and neural dysfunction were mediated by nonchiral interactions instead of stereospecific receptors or binding sites.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOL BIOPHYS, ST LOUIS, MO 63110 USA; ELI LILLY & CO, LILLY CORP CTR, LILLY RES LABS, DIV ENDOCRINE, INDIANAPOLIS, IN 46285 USA; ELI LILLY & CO, LILLY CORP CTR, LILLY RES LABS, RES TECHNOL & PROT, INDIANAPOLIS, IN 46285 USA	Washington University (WUSTL); Washington University (WUSTL); Eli Lilly; Eli Lilly				Ido, Yasuo/0000-0002-3036-9971	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058141, R01HL039934] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06600] Funding Source: Medline; NHLBI NIH HHS [HL 39934, HL 58141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, DIABETES, V44, P968; BESSALLE R, 1990, FEBS LETT, V274, P151, DOI 10.1016/0014-5793(90)81351-N; CHANCE RE, 1971, DIABETES, P292; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CRAWFORD JL, 1973, P NATL ACAD SCI USA, V70, P538, DOI 10.1073/pnas.70.2.538; DRYBURGH JR, 1980, DIABETOLOGIA, V19, P397, DOI 10.1007/BF00280527; EADES DM, 1989, J CHROMATOGR-BIOMED, V490, P1, DOI 10.1016/S0378-4347(00)82755-3; FRANK BH, 1983, MUNCH MED WSCHR S1, V125, pS14; Frank BH, 1981, PEPTIDES SYNTHESIS S, P729; GORKA J, 1989, Peptide Research, V2, P376; IDO Y, 1994, DIABETES, V43, P1469, DOI 10.2337/diabetes.43.12.1469; IDO Y, UNPUB; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; JOHANSSON BL, 1992, DIABETOLOGIA, V35, P121, DOI 10.1007/BF00402543; JOHANSSON BL, 1993, J CLIN ENDOCR METAB, V77, P976, DOI 10.1210/jc.77.4.976; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KITABCHI AE, 1977, METABOLISM, V26, P547, DOI 10.1016/0026-0495(77)90099-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEHMANN EL, 1975, NONPARAMETRICS; LEWIS PN, 1971, P NATL ACAD SCI USA, V68, P2293, DOI 10.1073/pnas.68.9.2293; MARKUSSEN J, 1973, INT J PEPT PROT RES, V5, P69; MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; PUGLIESE G, 1990, DIABETES, V39, P323, DOI 10.2337/diabetes.39.3.323; ROGERS D, 1988, DIABETES, V37, P1689, DOI 10.2337/diabetes.37.12.1689; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Scheffe H., 1959, ANAL VARIANCE; SNELL CR, 1975, J BIOL CHEM, V250, P6291; SRINIVASAN R, 1995, PROTEINS, V22, P81, DOI 10.1002/prot.340220202; STEINER DF, 1978, DIABETES, V27, P145, DOI 10.2337/diab.27.1.S145; STEINER DF, 1995, ENDOCRINOLOGY, V2, P1296; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TILTON RG, 1995, DIABETES, V44, P234, DOI 10.2337/diabetes.44.2.234; Tilton RG, 1997, J CLIN INVEST, V99, P2192, DOI 10.1172/JCI119392; TOYOTA T, 1975, TOHOKU J EXP MED, V117, P79, DOI 10.1620/tjem.117.79; VANDENENDEN MK, 1995, INVEST OPHTH VIS SCI, V36, P1675; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; WILLIAMSON JR, 1990, J CLIN INVEST, V85, P1167, DOI 10.1172/JCI114549; WOJCIKOWSKI C, 1983, DIABETOLOGIA, V25, P288, DOI 10.1007/BF00279945; WOLF BA, 1991, J CLIN INVEST, V87, P31, DOI 10.1172/JCI114988; Zierath JR, 1996, DIABETOLOGIA, V39, P306	42	299	340	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 25	1997	277	5325					563	566		10.1126/science.277.5325.563	http://dx.doi.org/10.1126/science.277.5325.563			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228006				2022-12-24	WOS:A1997XM86700051
J	Neubuser, A; Peters, H; Balling, R; Martin, GR				Neubuser, A; Peters, H; Balling, R; Martin, GR			Antagonistic interactions between FGF and BMP signaling pathways: A mechanism for positioning the sites of tooth formation	CELL			English	Article							APICAL ECTODERMAL RIDGE; LIMB DEVELOPMENT; MOUSE; EXPRESSION; GROWTH; OUTGROWTH; INDUCTION; CHICK; GENE; DIFFERENTIATION	Vertebrate organogenesis is initiated at sites that are often morphologically indistinguishable from the surrounding region. Here we have identified Pax9 as a marker for prospective tooth mesenchyme prior to the first morphological manifestation of odontogenesis. We provide evidence that the sites of Pax9 expression in the mandibular arch are positioned by the combined activity of two signals, one (FGF8) that induces Pax9 expression and the other (BMP2 and BMP4) that prevents this induction. Thus it appears that the position of the teeth is determined by a combination of two different types of signaling molecules produced in wide but overlapping domains rather than by a single localized inducer. We suggest that a similar mechanism may be used for specifying the sites of development of other organs.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST SAUGETIERGENET,D-85764 NEUHERBERG,GERMANY	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Balling, Rudi/E-9680-2010	Balling, Rudi/0000-0003-2902-5650	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034380] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD34380] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Chen YP, 1996, DEVELOPMENT, V122, P3035; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; GAUNT WA, 1964, ACTA ANAT, V57, P115; Grobstein C, 1967, Natl Cancer Inst Monogr, V26, P279; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; JONES CM, 1991, DEVELOPMENT, V111, P531; Kaufman MH, 1994, ATLAS MOUSE DEV; KOLLAR EJ, 1970, J EMBRYOL EXP MORPH, V24, P173; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; Lee SMK, 1997, DEVELOPMENT, V124, P959; Lough J, 1996, DEV BIOL, V178, P198, DOI 10.1006/dbio.1996.0211; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; LUMSDEN AGS, 1986, ARCH ORAL BIOL, V31, P301, DOI 10.1016/0003-9969(86)90044-0; LYONS KM, 1990, DEVELOPMENT, V109, P833; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; Means AL, 1996, CELL GROWTH DIFFER, V7, P989; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MINA M, 1987, ARCH ORAL BIOL, V32, P123, DOI 10.1016/0003-9969(87)90055-0; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NISWANDER L, 1993, DEVELOPMENT, V119, P287; NORTHROP J, 1995, DEV BIOL, V172, P242, DOI 10.1006/dbio.1995.0019; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; RUCH JV, 1984, DENTIN DENTINOGENESI, P47; SCHULTEMERKER S, 1995, CURR BIOL, V5, P62, DOI 10.1016/S0960-9822(95)00017-0; Spemann H., 1938, EMBRYONIC DEV INDUCT; Thesleff I, 1996, ANAT REC, V245, P151; Thesleff I, 1996, SEMIN CELL DEV BIOL, V7, P185, DOI 10.1006/scdb.1996.0025; Thesleff I, 1996, CURR OPIN CELL BIOL, V8, P844, DOI 10.1016/S0955-0674(96)80086-X; THESLEFF I, 1977, DEV BIOL, V58, P197, DOI 10.1016/0012-1606(77)90085-9; THESLEFF I, 1995, INT J DEV BIOL, V39, P35; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; Vogel A, 1996, DEVELOPMENT, V122, P1737; WANG YQ, 1995, DEV BIOL, V168, P374, DOI 10.1006/dbio.1995.1087; Wehr R, 1996, INT J DEV BIOL, V40, P369; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	43	483	498	2	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					247	255		10.1016/S0092-8674(00)80333-5	http://dx.doi.org/10.1016/S0092-8674(00)80333-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244299	Bronze			2022-12-24	WOS:A1997XN24900009
J	Schnitzer, MJ; Block, SM				Schnitzer, MJ; Block, SM			Kinesin hydrolyses one ATP per 8-nm step	NATURE			English	Article							HEAD DOMAINS; MICROTUBULE; MOVEMENT; MOLECULES; MOTILITY; KINETICS; PROTEIN; FORCE; ASSAY; SIZE	Kinesin is a two-headed, ATP-dependent motor protein(1,2) that moves along microtubules in discrete steps(3) of 8 nm. In vitro, single molecules produce processive movement(4,5); motors typically take similar to 100 steps before releasing from a microtubule(5-7). A central question relates to mechanochemical coupling in this enzyme: how many molecules of ATP are consumed per step? For the actomyosin system, experimental approaches to this issue have generated considerable controversy(8,9). Here we take advantage of the processivity of kinesin to determine the coupling ratio without recourse to direct measurements of ATPase activity, which are subject to large experimental uncertainties(8,10-12). Beads carrying single molecules of kinesin moving on microtubules were tracked with high spatial and temporal resolution by interferometry(3,13). Statistical analysis of the intervals between steps at limiting ATP, and studies of fluctuations in motor speed as a function of ATP concentration(14,15), allow the coupling ratio to be determined. At near-zero load, kinesin molecules hydrolyse a single ATP molecule per 8-nm advance. This finding excludes various one-to-many and many-to-one coupling schemes, analogous to those advanced for myosin, and places severe constraints on models for movement.	PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544; PRINCETON UNIV,PRINCETON MAT INST,PRINCETON,NJ 08544	Princeton University; Princeton University	Schnitzer, MJ (corresponding author), PRINCETON UNIV,DEPT PHYS,PRINCETON,NJ 08544, USA.							BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Block SM, 1996, CELL, V87, P151, DOI 10.1016/S0092-8674(00)81332-X; BLOCK SM, 1995, BIOPHYS J, V68, pS230; BURTON K, 1992, J MUSCLE RES CELL M, V13, P590, DOI 10.1007/BF01738249; Coppin CM, 1996, P NATL ACAD SCI USA, V93, P1913, DOI 10.1073/pnas.93.5.1913; Derenyi I, 1996, P NATL ACAD SCI USA, V93, P6775, DOI 10.1073/pnas.93.13.6775; Duke T, 1996, BIOPHYS J, V71, P1235, DOI 10.1016/S0006-3495(96)79323-2; GELLES J, 1995, BIOPHYS J, V68, pS276; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; Kreis T., 1993, GUIDEBOOK CYTOSKELET; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LEIBLER S, 1993, J CELL BIOL, V121, P1357, DOI 10.1083/jcb.121.6.1357; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; PESKIN CS, 1995, BIOPHYS J, V68, pS202; Samuel ADT, 1996, BIOPHYS J, V71, P918, DOI 10.1016/S0006-3495(96)79295-0; Schnitzer MJ, 1995, COLD SPRING HARB SYM, V60, P793, DOI 10.1101/SQB.1995.060.01.085; SOWERBY AJ, 1993, J MOL BIOL, V234, P114, DOI 10.1006/jmbi.1993.1567; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; SVOBODA K, 1994, P NATL ACAD SCI USA, V91, P11782, DOI 10.1073/pnas.91.25.11782; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; YANAGIDA T, 1993, TRENDS BIOCHEM SCI, V18, P319, DOI 10.1016/0968-0004(93)90064-T	30	603	617	2	95	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					386	390		10.1038/41111	http://dx.doi.org/10.1038/41111			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237757				2022-12-24	WOS:A1997XM52800053
J	Anderson, DG; Kowalczykowski, SC				Anderson, DG; Kowalczykowski, SC			The translocating RecBCD enzyme stimulates recombination by directing RecA protein onto ssDNA in a chi-regulated manner	CELL			English	Article							SINGLE-STRANDED-DNA; HOT SPOT ACTIVITY; COLI SSB PROTEIN; ESCHERICHIA-COLI; PHAGE-LAMBDA; BINDING-PROTEIN; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; BACTERIOPHAGE-LAMBDA; SERRATIA-MARCESCENS	Double-stranded DNA break repair and homologous recombination in E. coli are initiated by the RecBCD enzyme, which unwinds and simultaneously degrades DNA from a double-stranded DNA end. This process is stimulated by cis-acting DNA elements, known as chi sites. Using both in vitro pairing and nuclease protection assays, we demonstrate that the translocating RecBCD enzyme, which has been activated by chi, coordinates the preferential loading of the homologous pairing protein, RecA, onto the resultant single-stranded DNA downstream of chi. This facilitated loading of RecA protein results in a substantial increase in both the efficiency and rate of in vitro recombination reactions and offers an explanation for stimulation of recombination and repair in vivo by chi.	UNIV CALIF DAVIS,GENET GRAD GRP,DAVIS,CA 95616; UNIV CALIF DAVIS,MICROBIOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,SECT MOL & CELLULAR BIOL,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41347] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Anderson DG, 1997, GENES CELLS, V2, P117, DOI 10.1046/j.1365-2443.1997.1130311.x; BIANCO PR, 1997, IN PRESS P NATL ACAD; BRAEDT G, 1989, P NATL ACAD SCI USA, V86, P871, DOI 10.1073/pnas.86.3.871; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CHABBERT M, 1987, BIOCHEMISTRY-US, V26, P2218, DOI 10.1021/bi00382a022; CHENG KC, 1989, GENETICS, V123, P5; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; DEVRIES J, 1992, J GEN MICROBIOL, V138, P31, DOI 10.1099/00221287-138-1-31; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1995, J BIOL CHEM, V270, P16360, DOI 10.1074/jbc.270.27.16360; DUNDERDALE HJ, 1994, CURR OPIN GENET DEV, V4, P221, DOI 10.1016/S0959-437X(05)80048-6; EMMERSON PT, 1968, GENETICS, V60, P19; ENNIS DG, 1987, GENETICS, V115, P11; FRIEDBERG EC, 1995, DNA REPAIR; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HOWARDFLANDERS P, 1966, GENETICS, V53, P1137; Kogoma T, 1996, CELL, V85, P625, DOI 10.1016/S0092-8674(00)81229-5; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KONFORTI BB, 1990, J BIOL CHEM, V265, P6916; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KOWALCZYKOWSKI SC, 1994, J MOL BIOL, V63, P991; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; KUZMINOV A, 1996, MOL BIOL INTELLIGENC, P135; LAM ST, 1974, GENETICS, V77, P425; LEBOWITZ J, 1985, THESIS J HOPKINS U B; MADIRAJU MVVS, 1992, BIOCHEMISTRY-US, V31, P10529, DOI 10.1021/bi00158a016; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; MOLINEUX IJ, 1975, J MOL BIOL, V98, P811, DOI 10.1016/S0022-2836(75)80012-X; MYERS RS, 1995, GENETICS, V141, P805; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; RINKEN R, 1991, BIOCHIMIE, V73, P375, DOI 10.1016/0300-9084(91)90104-9; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1990, P NATL ACAD SCI USA, V88, P3367; RUYECHAN WT, 1975, BIOCHEMISTRY-US, V14, P5529, DOI 10.1021/bi00696a023; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SARGENTINI NJ, 1986, RADIAT RES, V107, P58, DOI 10.2307/3576850; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; STAHL FW, 1975, J MOL BIOL, V94, P203, DOI 10.1016/0022-2836(75)90078-9; STAHL FW, 1980, GENETICS, V94, P235; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SUNSHINE MG, 1971, J BACTERIOL, V108, P695, DOI 10.1128/JB.108.2.695-704.1971; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; Telander-Muskavitch K.M, 1981, ENZYMES, P233; TELANDERMUSKAVI.KM, 1980, MECHANISTIC STUDIES, P901; TRACY KRB, 1996, GENE DEV, V10, P1890; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005	61	245	253	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					77	86		10.1016/S0092-8674(00)80315-3	http://dx.doi.org/10.1016/S0092-8674(00)80315-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230304	Bronze			2022-12-24	WOS:A1997XL36200010
J	Zeng, L; Fagotto, F; Zhang, T; Hsu, W; Vasicek, TJ; Perry, WL; Lee, JJ; Tilghman, SM; Gumbiner, BM; Costantini, F				Zeng, L; Fagotto, F; Zhang, T; Hsu, W; Vasicek, TJ; Perry, WL; Lee, JJ; Tilghman, SM; Gumbiner, BM; Costantini, F			The mouse fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation	CELL			English	Article							PRIMITIVE STREAK FORMATION; BETA-CATENIN; SPEMANN ORGANIZER; XENOPUS-EMBRYOS; INDUCTION; PROTEIN; GENE; DROSOPHILA; LOCALIZATION; GASTRULATION	Mutations at the mouse Fused locus have pleiotropic developmental effects, including the formation of axial duplications in homozygous embryos. The product of the Fused locus, Axin, displays similarities to RGS (Regulators of G-Protein Signaling) and Dishevelled proteins. Mutant Fused alleles that cause axial duplications disrupt the major mRNA, suggesting that Axin negatively regulates the response to an axis-inducing signal. Injection of Axin mRNA into Xenopus embryos inhibits dorsal axis formation by interfering with signaling through the Wnt pathway. Furthermore, ventral injection of an Axin mRNA lacking the RGS domain induces an ectopic axis, apparently through a dominant-negative mechanism. Thus, Axin is a novel inhibitor of Wnt signaling and regulates an early step in embryonic axis formation in mammals and amphibians.	COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; PRINCETON UNIV,HOWARD HUGHES MED INST,PRINCETON,NJ 08544; PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Columbia University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Princeton University; Princeton University			Fagotto, Francois/AAA-9983-2021; Hsu, Wei/ABG-6856-2021	Fagotto, Francois/0000-0002-1495-2112; Hsu, Wei/0000-0001-6738-6030	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037432, R37GM037432] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08784] Funding Source: Medline; NIDDK NIH HHS [DK-46934] Funding Source: Medline; NIGMS NIH HHS [GM37432] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHVAROVA RF, 1996, ADV DEV BIO, V4, P147; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Carnac G, 1996, DEVELOPMENT, V122, P3055; CHENCHIK A, 1995, CLONTECHNIQUES, V10, P5; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; Conlon Frank, 1995, Seminars in Developmental Biology, V6, P249, DOI 10.1016/S1044-5781(06)80050-2; COOKE J, 1972, J EMBRYOL EXP MORPH, V28, P27; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; FAGOTTO F, 1994, DEVELOPMENT, V120, P3667; Fagotto F, 1997, DEVELOPMENT, V124, P453; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GARDNER RL, 1992, J EXP ZOOL, V264, P437, DOI 10.1002/jez.1402640409; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; GREENSPAN RJ, 1986, P NATL ACAD SCI USA, V83, P4413, DOI 10.1073/pnas.83.12.4413; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; HUME CR, 1993, DEVELOPMENT, V119, P1147; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; JACOBSCOHEN RJ, 1984, GENET RES, V43, P43, DOI 10.1017/S0016672300025702; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KHANER O, 1989, DEV BIOL, V134, P206, DOI 10.1016/0012-1606(89)90090-0; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; LYON MF, 1996, GENETIC VARIANTS STR; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PERRY WL, 1995, GENETICS, V141, P321; PIERCE SB, 1995, DEVELOPMENT, V121, P755; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; StJacques B, 1996, CURR OPIN GENET DEV, V6, P439, DOI 10.1016/S0959-437X(96)80065-7; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TLIGHMAN SM, 1996, GENOME RES, V6, P773; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Wylie C, 1996, DEVELOPMENT, V122, P2987; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZIV T, 1992, DEVELOPMENT, V115, P689	56	750	783	1	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					181	192		10.1016/S0092-8674(00)80324-4	http://dx.doi.org/10.1016/S0092-8674(00)80324-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230313	hybrid			2022-12-24	WOS:A1997XL36200019
J	Irmler, M; Thome, M; Hahne, M; Schneider, P; Hofmann, B; Steiner, V; Bodmer, JL; Schroter, M; Burns, K; Mattmann, C; Rimoldi, D; French, LE; Tschopp, J				Irmler, M; Thome, M; Hahne, M; Schneider, P; Hofmann, B; Steiner, V; Bodmer, JL; Schroter, M; Burns, K; Mattmann, C; Rimoldi, D; French, LE; Tschopp, J			Inhibition of death receptor signals by cellular FLIP	NATURE			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROTEIN; FAS; CYTOTOXICITY; INTERACTS; DOMAIN; SITE; P35	The widely expressed protein Fas is a member of the tumour necrosis factor receptor family which fan trigger apoptosis(1). However, Fas surface expression does not necessarily render cells susceptible to Fas ligand-induced death signals(1,2), indicating that inhibitors of the apoptosis-signalling pathway must exist. Here we report the characterization of an inhibitor of apoptosis, designated FLIP (for FLICE-inhibitory protein), which is predominantly expressed in muscle and lymphoid tissues. The short form, FLIPS, contains two death effector domains and is structurally related to the viral FLIP inhibitors of apoptosis(3), whereas the long form, FLIPL, contains in addition a caspase-like domain in which the active-centre cysteine residue is substituted by a tyrosine residue. FLIPS and FLIPL interact with the adaptor protein FADD(4,5) and the protease FLICE6,7, and potently inhibit apoptosis induced by all known human death receptors(1). FLIPL is expressed during the early stage of T-cell activation, but disappears when T cells become susceptible to Fas ligand-mediated apoptosis. High levels of FLIPL protein are also detectable in melanoma cell lines and malignant melanoma tumours. Thus FLIP may be implicated in tissue homeostasis as an important regulator of apoptosis.	UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND; UNIV LAUSANNE,LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND; SWISS INST EXPT CANC RES,BIL BIOMED RES CTR,CH-1066 EPALINGES,SWITZERLAND; UNIV GENEVA,SCH MED,DEPT DERMATOL,CH-1211 GENEVA 4,SWITZERLAND	University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne; Swiss Institute Experimental Cancer Research; University of Geneva			Thome, Margot/F-8167-2011; Irmler, Martin/B-3317-2013; French, Lars/AAL-5977-2020; Hofmann, Kay/D-6714-2011	Thome, Margot/0000-0002-5656-2139; Irmler, Martin/0000-0003-3169-479X; French, Lars/0000-0002-4629-1486; Hofmann, Kay/0000-0002-2289-9083; Schneider, Pascal/0000-0003-0677-9409				Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BODNER JL, 1997, IMMUNITY, V6, P79; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FRANCIS MJ, 1991, IMMUNOLOGY, V73, P249; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YU GL, 1996, SCIENCE, V274, P990	30	2072	2172	1	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					190	195		10.1038/40657	http://dx.doi.org/10.1038/40657			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217161	Bronze, Green Submitted			2022-12-24	WOS:A1997XK10900054
J	Jordan, BD; Relkin, NR; Ravdin, LD; Jacobs, AR; Bennett, A; Gandy, S				Jordan, BD; Relkin, NR; Ravdin, LD; Jacobs, AR; Bennett, A; Gandy, S			Apolipoprotein E epsilon 4 associated with chronic traumatic brain injury in boxing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMYLOID PROTEIN DEPOSITION; SEVERE HEAD-INJURY; ALZHEIMERS-DISEASE; DEMENTIA-PUGILISTICA; PRECURSOR PROTEIN; TYPE-4 ALLELE; BETA-PROTEIN; BOXERS; AFTERMATH; DAMAGE	Context.-Given the similarities between Alzheimer disease and dementia pugilistica, we evaluated the relationship between apolipoprotein E (APOE) genotype and chronic traumatic brain injury (CTBI) in boxers to determine whether there is a genetic susceptibility to the effects of head trauma. Objective.-To assess the relationship between CTBI and APOE genotype in boxers. Design and Setting.-Clinical characterization of 24 volunteer and 6 referred boxers in an outpatient setting. Participants.-Thirty professional boxers aged 23 to 76 years underwent neurologic and behavioral assessment in conjunction with APOE genotyping. Main Outcome Measures.-Apolipoprotein E genotype was examined in relationship to measures of CTBI. A 10-point clinical rating scale (0-9), the Chronic Brain Injury (CBI) scale, was devised to assess the severity of traumatic encephalopathy associated with boxing, Boxers with abnormal CTBI scores were further classified on the basis of whether their impairments were possibly or probably related to boxing. Scores were analyzed in relation to boxing exposure (number of bouts) and APOE genotype. Results.-Among the 30 boxers, 11 were found to be normal (CBI score=0), 12 showed mild deficits (CBI score=1-2), 4 were moderately impaired (CBI score=3-4), and 3 showed signs of severe impairment (CBI score >4). High-exposure boxers tie, those with greater than or equal to 12 professional bouts) had significantly higher CBI scores (mean [SD], 2.6 [1.9]) than low-exposure boxers (mean [SD], 0.3 [0.7]) (P<.001), indicating that neurologic impairment as measured by the CBI scale seems related to boxing exposure. The APOE genotype frequencies of the study population were approximately the same as those found in the general population. Boxers with low exposure had mean CBI scores of 0.33, irrespective of APOE genotype. However, high-exposure boxers with an APOE epsilon 4 allele had significantly greater CBI scores (mean [SD], 3.9 [2.3]) than high-exposure boxers without APOE epsilon 4 (mean [SD], 1.8 [1.2]) (P=.04), All boxers with severe impairment possessed at least 1 APOE epsilon 4 allele. The tendency for greater CTBI among those with both high exposure and an epsilon 4 allele was statistically significant at the P<.001 level. ConcIusions.-These preliminary findings suggest that possession or an APOE epsilon 4 allele may be associated with increased severity of chronic neurologic deficits in high-exposure boxers.	CORNELL UNIV MED COLL,NEW YORK HOSP,DEPT NEUROL & NEUROSCI,NEW YORK,NY; CORNELL UNIV MED COLL,HOSP SPECIAL SURG,SPORTS NEUROL PROGRAM,NEW YORK,NY	Cornell University; NewYork-Presbyterian Hospital; Cornell University								BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BUTLER RJ, 1994, BRIT J SPORT MED, V28, P187, DOI 10.1136/bjsm.28.3.187; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; JORDAN BD, 1993, MED ASPECTS BOXING, P147; JORDAN BD, 1993, MED ASPECTS BOXING, P177; Katzman R, 1996, NEUROLOGY, V46, P889; LEHMANN EL, 1975, NONPARAMETRICS; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; *NAT I AG ALZH ASS, 1996, LANCET, V347, P1091; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Roberts A. H., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; UHL GR, 1982, ANN NEUROL, V12, P99; vanDuijn CM, 1996, J NEUROL NEUROSUR PS, V60, P478, DOI 10.1136/jnnp.60.5.478; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	37	493	505	0	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	1997	278	2					136	140		10.1001/jama.278.2.136	http://dx.doi.org/10.1001/jama.278.2.136			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH667	9214529				2022-12-24	WOS:A1997XH66700034
J	Maisonpierre, PC; Suri, C; Jones, PF; Bartunkova, S; Wiegand, S; Radziejewski, C; Compton, D; McClain, J; Aldrich, TH; Papadopoulos, N; Daly, TJ; Davis, S; Sato, TN; Yancopoulos, GD				Maisonpierre, PC; Suri, C; Jones, PF; Bartunkova, S; Wiegand, S; Radziejewski, C; Compton, D; McClain, J; Aldrich, TH; Papadopoulos, N; Daly, TJ; Davis, S; Sato, TN; Yancopoulos, GD			Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; ENDOTHELIAL GROWTH-FACTOR; MOLECULAR-CLONING; EXPRESSION; PROTEIN; GENES; TEK; VASCULOGENESIS; INHIBITION; PATTERNS	Angiogenesis is thought to depend on a precise balance of positive and negative regulation. Angiopoietin-1 (Ang1) is an angiogenic factor that signals through the endothelial cell-specific Tie2 receptor tyrosine kinase. Like Vascular endothelial growth factor, Ang1 is essential for normal vascular development in the mouse. An Ang1 relative, termed angiopoietin-2 (Ang2), was identified by homology screening and shown to be a naturally occurring antagonist for Ang1 and Tie2. Transgenic overexpression of Ang2 disrupts blood vessel formation in the mouse embryo. in adult mice and humans, Ang2 is expressed only at sites of vascular remodeling. Natural antagonists for vertebrate receptor tyrosine kinases are atypical; thus, the discovery of a negative regulator acting on Tie2 emphasizes the need for exquisite regulation of this angiogenic receptor system.	REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591; BETH ISRAEL DEACONESS MED CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Regeneron; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School								AREND WP, 1990, J CLIN INVEST, V85, P1694, DOI 10.1172/JCI114622; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Davis S.M, UNPUB; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FINDLAY JK, 1986, J ENDOCRINOL, V111, P357, DOI 10.1677/joe.0.1110357; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/0008-6363(96)00063-6; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; MAISONPIERRE P, UNPUB; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHALABY F, 1996, NATURE, V380, P435; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; ZIEGLER SF, 1993, ONCOGENE, V8, P663	37	2724	2984	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					55	60		10.1126/science.277.5322.55	http://dx.doi.org/10.1126/science.277.5322.55			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204896				2022-12-24	WOS:A1997XJ41800036
J	Noll, KS; Roush, TL; Cruikshank, DP; Johnson, RE; Pendleton, YJ				Noll, KS; Roush, TL; Cruikshank, DP; Johnson, RE; Pendleton, YJ			Detection of ozone on Saturn's satellites Rhea and Dione	NATURE			English	Article							CHARGED-PARTICLE IRRADIATION; EUROPA; GANYMEDE; OXYGEN; CALLISTO; SPECTRA; ALBEDO; SEARCH; ICES; LIFE	The satellites Rhea and Dione orbit within the magnetosphere of Saturn, where they are exposed to particle irradiation from trapped ions. A similar situation applies to the galilean moons Europa, Ganymede and Callisto, which reside within Jupiter's radiation belts. All of these satellites have surfaces rich in water ice(1,2). Laboratory studies of the interaction of charged-particle radiation with water ice predicted(3) the tenuous oxygen atmospheres recently found on Europa(4) and Ganymede(5). However, theoretical investigations did not anticipate the trapping of significantly larger quantities of O-2 within the surface ice(6). The accumulation of detectable abundances of O-3, produced by the action of ultraviolet or charged-particle radiation on O-2, was also not predicted before being observed on Ganymede(7). Here we report the identification of O-3 in spectra of the saturnian satellites Rhea and Dione. The presence of trapped O-3 is thus no longer unique to Ganymede, suggesting that special circumstances may not be required for its production.	NASA, AMES RES CTR, MOFFETT FIELD, CA 94035 USA; SAN FRANCISCO STATE UNIV, DEPT GEOSCI, SAN FRANCISCO, CA 94132 USA; UNIV VIRGINIA, CHARLOTTESVILLE, VA 22901 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; California State University System; San Francisco State University; University of Virginia	Noll, KS (corresponding author), SPACE TELESCOPE SCI INST, 3700 SAN MARTIN DR, BALTIMORE, MD 21218 USA.		Noll, Keith/C-8447-2012					BARTH CA, IN PRESS GEOPHYS RES; BURATTI B, 1984, ICARUS, V58, P254, DOI 10.1016/0019-1035(84)90042-3; BURATTI BJ, 1990, ICARUS, V87, P339, DOI 10.1016/0019-1035(90)90138-Y; BURATTI BJ, 1991, ICARUS, V92, P312, DOI 10.1016/0019-1035(91)90054-W; BURKE BF, 1986, NATURE, V322, P340, DOI 10.1038/322340a0; CLARK RN, 1980, ICARUS, V44, P388, DOI 10.1016/0019-1035(80)90033-0; CLARK RN, 1984, ICARUS, V58, P265, DOI 10.1016/0019-1035(84)90043-5; ELSILA J, IN PRESS ASTROPHYS J; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; Johnson R.E., 1990, ENERGETIC CHARGED PA, DOI [10.1007/978-3-642-48375-2, DOI 10.1007/978-3-642-48375-2]; Johnson RE, 1997, ASTROPHYS J, V480, pL79, DOI 10.1086/310614; KHARE BN, 1993, ICARUS, V103, P290, DOI 10.1006/icar.1993.1071; LANE AL, 1981, NATURE, V292, P38, DOI 10.1038/292038a0; LEGER A, 1994, ADV SPACE RES, V14, P117, DOI 10.1016/0273-1177(94)90016-7; MATICH AJ, 1993, J PHYS CHEM-US, V97, P10539, DOI 10.1021/j100143a007; MORRISON D, 1975, ICARUS, V24, P157, DOI 10.1016/0019-1035(75)90093-7; Noll KS, 1997, GEOPHYS RES LETT, V24, P1139, DOI 10.1029/97GL00876; Noll KS, 1996, SCIENCE, V273, P341, DOI 10.1126/science.273.5273.341; NOLL KS, 1995, J GEOPHYS RES-PLANET, V100, P19057, DOI 10.1029/94JE03294; OWEN T, 1992, NATURE, V358, P43, DOI 10.1038/358043a0; POSPIESZALSKA MK, 1989, ICARUS, V78, P1, DOI 10.1016/0019-1035(89)90065-1; ROUSH TL, 1995, VOLATILES EARTH SOLA, V341, P143; SPENCER JR, 1995, J GEOPHYS RES-PLANET, V100, P19049, DOI 10.1029/95JE01503; TAUBE H, 1957, T FARADAY SOC, V53, P656, DOI 10.1039/tf9575300656; THOMPSON WR, 1987, J GEOPHYS RES, V92, P14933, DOI 10.1029/JA092iA13p14933; TIELENS AGGM, 1982, ASTRON ASTROPHYS, V114, P245; VAIDA V, 1989, J PHYS CHEM-US, V93, P506, DOI 10.1021/j100339a003; Vilas F, 1996, ICARUS, V124, P262, DOI 10.1006/icar.1996.0202; WOODS TN, 1993, J GEOPHYS RES-ATMOS, V98, P10679, DOI 10.1029/93JD00463	29	128	128	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					45	47		10.1038/40348	http://dx.doi.org/10.1038/40348			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214500				2022-12-24	WOS:A1997XJ14300043
J	Eisenberg, DM				Eisenberg, DM			Advising patients who seek alternative medical therapies	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							EOSINOPHILIA-MYALGIA-SYNDROME; HERBAL MEDICINES; CHIROPRACTIC MANIPULATION; SPINAL MANIPULATION; ADVERSE REACTIONS; CLINICAL-TRIALS; UNITED-STATES; CHINESE HERBS; CHRONIC PAIN; HEPATITIS-B	Alternative medical therapies, such as chiropractic, acupuncture, homeopathy, and herbal remedies, are in great public demand. Some managed care organizations now offer these therapies as an ''expanded benefit.'' Because the safety and efficacy of these practices remain largely unknown, advising patients who use or seek alternative treatments presents a professional challenge. A step-by-step strategy is proposed whereby conventionally trained medical providers and their patients can preactively discuss the use or avoidance of alternative therapies. This strategy involves a formal discussion of patients' preferences and expectations, the maintenance of symptom diaries, and follow-up visits to monitor for potentially harmful situations. In the absence of professional medical and legal guidelines, the proposed management plan emphasizes patient safety, the need for documentation in the patient record, and the importance of shared decision making.			Eisenberg, DM (corresponding author), BETH ISRAEL DEACONESS MED CTR, CTR ALTERNAT MED RES, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U24 AR43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson IB, 1996, ANN INTERN MED, V124, P726, DOI 10.7326/0003-4819-124-8-199604150-00004; ANGELL M, 1985, NEW ENGL J MED, V312, P1570, DOI 10.1056/NEJM198506133122411; [Anonymous], 1988, HERBAL MED; ASSENDELFT WJJ, 1992, J MANIP PHYSIOL THER, V15, P487; BAILEY DG, 1994, CLIN PHARMACOKINET, V26, P91, DOI 10.2165/00003088-199426020-00002; BARRETT S, 1990, HLTH SCHEMES SCAMS F; BELLAVITE P, 1995, HOMEOPATHY FRONTIER; Bigos S, 1994, CLIN PRACTICE GUIDEL; BLUMENTHAL M, 1996, COMMISSION E MONOGRA; *BURT GOLDB GROUP, 1993, ALT MED DEF GUID; BUTLER K, 1992, CONSUMERS GUIDE ALTE; CARRON H, 1974, JAMA-J AM MED ASSOC, V228, P1552; Carton Barbara, 1995, WALL ST J       0116, pB1; CHAN TYK, 1993, LANCET, V342, P1532, DOI 10.1016/S0140-6736(05)80091-1; CHENG TO, 1989, AM J MED, V87, P489, DOI 10.1016/S0002-9343(89)80853-8; COLLINGE W, 1996, COMPLETE GUIDE ALTER; CONN JW, 1968, J AMER MED ASSOC, V205, P492, DOI 10.1001/jama.205.7.492; Coulter ID, 1995, APPROPRIATENESS SPIN; COWLEY G, 1996, NEWSWEEK        0603, P60; DANDEKAR UP, 1992, J ETHNOPHARMACOL, V35, P285, DOI 10.1016/0378-8741(92)90026-N; DARCY PF, 1991, ADVERSE DRUG REACT T, V10, P189; DARCY PF, 1993, ADVERSE DRUG REACT T, V12, P147; De Smet P. A. G. M., 1992, P1209; De Smet P. A. G. M., 1993, ADVERSE EFFECTS HERB; De Smet PAGM, 1992, TOXICOLOGICAL OUTLOO, P1; DESMET PAGM, 1995, DRUG SAFETY, V13, P81, DOI 10.2165/00002018-199513020-00003; DESMET PAGM, 1991, J ETHNOPHARMACOL, V32, P43, DOI 10.1016/0378-8741(91)90102-J; DUNKIN A, 1995, BUSINESS WEEK   1127, P134; Egan Timothy, 1996, NY TIMES, pA6; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; EISENBERG DM, 1996, HARVARD MED ALUMNI B, V70, P20; EPSTEIN WL, 1987, ANN EMERG MED, V16, P950, DOI 10.1016/S0196-0644(87)80739-4; FAST A, 1987, SPINE, V12, P840, DOI 10.1097/00007632-198711000-00003; FRIEDMAN RA, 1996, NY TIMES        0419, pA29; Fugh-Berman A., 1996, ALTERNATIVE MED WHAT; FUSHIMI R, 1989, LANCET, V1, P339, DOI 10.1016/S0140-6736(89)91361-5; Gevitz N., 1988, OTHER HEALERS UNORTH, P124; GLOCK M, 1995, NIH PUBLICATION; GOLDMAN JA, 1991, ARTHRITIS RHEUM, V34, P1207, DOI 10.1002/art.1780340922; GOLEMAN D, 1993, MIND BODY MED HOW US; GORDON DW, 1995, JAMA-J AM MED ASSOC, V273, P489, DOI 10.1001/jama.273.6.489; HALDEMAN S, 1992, SPINE, V17, P1469, DOI 10.1097/00007632-199212000-00005; HENDEE WR, 1987, JAMA-J AM MED ASSOC, V257, P1929; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; HEWALL CA, 1996, HERBAL MED GUIDE HLT; HILTS PJ, 1995, NY TIMES        1227, pB10; HOGAN RP, 1983, JAMA-J AM MED ASSOC, V249, P2679, DOI 10.1001/jama.249.19.2679; Hurwitz EL, 1996, SPINE, V21, P1746, DOI 10.1097/00007632-199608010-00007; HUXTABLE RJ, 1990, DRUG SAFETY, V5, P126, DOI 10.2165/00002018-199000051-00020; JACKSON C, 1996, TAMPA TRIBUNE   0108, P8; James, 1995, ACUPUNCT MED, V13, P26, DOI [10.1136/aim.13.1.26, DOI 10.1136/AIM.13.1.26]; KAMB ML, 1992, JAMA-J AM MED ASSOC, V267, P77, DOI 10.1001/jama.267.1.77; KANE JA, 1995, GUT, V36, P146, DOI 10.1136/gut.36.1.146; Kaptchuk T.J., 1983, WEB HAS NO WEAVER; KASSIRER JP, 1983, NEW ENGL J MED, V308, P898, DOI 10.1056/NEJM198304143081511; KEMPIN SJ, 1983, NEW ENGL J MED, V308, P1229; KENT GP, 1988, AM J EPIDEMIOL, V127, P591, DOI 10.1093/oxfordjournals.aje.a114834; KLEIJNEN J, 1991, THORAX, V46, P799, DOI 10.1136/thx.46.11.799; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KRAUSS C, 1996, NY TIMES        0524, pB1; LAGNADO L, 1996, WALL STREET J   1007, pB9; LARREY D, 1992, ANN INTERN MED, V117, P129, DOI 10.7326/0003-4819-117-2-129; LEE KP, 1995, NEUROLOGY, V45, P1213, DOI 10.1212/WNL.45.6.1213; LERNER M, 1994, CHOICES HEALING INTE; Marti J, 1995, ALTERNATIVE HLTH MED; MICOZZI MS, 1996, FUNDAMENTALS COMPLEN; MOORE JS, 1993, CHIROPRACTIC AM HIST; NEFF R, 1995, BUSINESS WEEK   0130, P60; *NIH OFF ALT MED, 1994, ALT MED EXP MED HOR; OConnor BB, 1995, STUDIES HLTH ILLNESS, Vxxiv; OLIVER LD, 1984, TEX MED, V80, P40; PATEL M, 1989, INT J EPIDEMIOL, V18, P900, DOI 10.1093/ije/18.4.900; PHALON R, 1993, FORBES          1220, P254; PIZZORNO JE, 1993, TXB NATURAL MED; POWELL FC, 1993, NEUROSURGERY, V33, P73; RASO J, 1993, MYSTICAL DIETS PARAN; REILLY D, 1994, LANCET, V344, P1601, DOI 10.1016/S0140-6736(94)90407-3; RIDKER PM, 1989, LANCET, V1, P657, DOI 10.1016/S0140-6736(89)92154-5; ROBERTS IF, 1979, BRIT MED J, V1, P296, DOI 10.1136/bmj.1.6159.296; RUSSELL FE, 1975, JAMA-J AM MED ASSOC, V233, P341, DOI 10.1001/jama.233.4.341; RUSSELL S, 1996, SAN FRANCISCO C 0925, pA1; SALE JD, 1994, OVERVIEW LEGISLATIVE; SCHECK A, 1995, INVESTORS BUSIN 0620; SEGELMAN AB, 1976, JAMA-J AM MED ASSOC, V236, P477, DOI 10.1001/jama.236.5.477; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; SHERLOCK P, 1967, J AMER MED ASSOC, V199, P794, DOI 10.1001/jama.199.11.794; SLATER PE, 1988, EUR J EPIDEMIOL, V4, P322, DOI 10.1007/BF00148918; SMITH GW, 1993, BRIT J RHEUMATOL, V32, P87; STALKER D, 1989, EXAMINING HOLISTIC M; STRYKER WS, 1986, J FAM PRACTICE, V22, P155; TAI YT, 1992, LANCET, V340, P1254, DOI 10.1016/0140-6736(92)92951-B; TAYLOR GD, 1985, CAN MED ASSOC J, V133, P767; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; TERRIET G, 1990, BRIT J GEN PRACT, V40, P379; TRESOLINI CP, 1994, HLTH ED RELATIONSHIP; Tyler V. E., 1994, HERBS CHOICE THERAPE; Tyler VE, 1993, HONEST HERBAL SENSIB, V3rd; *US C, 1990, OTAH405; VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; Vithoulkas G., 1980, SCI HOMEOPATHY; VITTECOQ D, 1989, NEW ENGL J MED, V320, P250; WARDWELL W, 1992, CHIROPRACTIC HIST EV; WEINER M, 1982, COMPLETE BOOK HOMEOP; Werbach MR, 1994, BOT INFLUENCES ILLNE; *WHO, 1992, HERB MED CONT GERM W; WILKINSON JA, 1995, BRIT J PHYTOTHERAPY, V4, P34; WOOLF GM, 1994, ANN INTERN MED, V121, P729, DOI 10.7326/0003-4819-121-10-199411150-00001; Zwicky JF, 1993, READERS GUIDE ALTERN; 1996, NY TIMES        1009, pA11; 1997, J MIND BODY HLTH, V13, P79; 1990, CAN MED ASSOC J, V143, P1009; 1995, MMWR-MORBID MORTAL W, V44, P41; 1997, INNOVIOSN COMMUNICAT, V3, P125; 1997, UPC C TRAIN SEM ALT, V3, P72; 1993, MMWR-MORBID MORTAL W, V42, P521	116	299	303	0	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					61	69		10.7326/0003-4819-127-1-199707010-00010	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214254				2022-12-24	WOS:A1997XG91400009
J	Chao, QM; Rothenberg, M; Solano, R; Roman, G; Terzaghi, W; Ecker, JR				Chao, QM; Rothenberg, M; Solano, R; Roman, G; Terzaghi, W; Ecker, JR			Activation of the ethylene gas response pathway in Arabidopsis by the nuclear protein ETHYLENE-INSENSITIVE3 and related proteins	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAY; DNA-BINDING PROTEINS; MAP KINASE CASCADE; 2-COMPONENT REGULATORS; MUTANT ARABIDOPSIS; WILD-TYPE; YEAST; THALIANA; GENE; PLANTS	Mutations in the Arabidopsis ETHYLENE-INSENSITIVE3 (EIN3) gene severely limit a plant's response to the gaseous hormone ethylene. ein3 mutants show a loss of ethylene-mediated effects including gene expression, the triple response, cell growth inhibition, and accelerated senescence. EIN3 acts downstream of the histidine kinase ethylene receptor, ETR1, and the Raf-like kinase, CTR1. The EIN3 gene encodes a novel nuclear-localized protein that shares sequence similarity, structural features, and genetic function with three EIN3-LIKE (EIL) proteins. In addition to EIN3, EIL1 or EIL2 were able to complement ein3, suggesting their participation in the ethylene signaling pathway. Overexpression of EIN3 or EIL2 in wild-type or ethylene-insensitive2 plants conferred constitutive ethylene phenotypes, indicating their sufficiency for activation of the pathway in the absence of ethylene.	UNIV PENN,INST PLANT SCI,DEPT BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania			Roman, Gregg/W-1586-2019; Solano, Roberto/O-5908-2017; Ecker, Joseph R/B-9144-2008	Roman, Gregg/0000-0003-1519-4699; Solano, Roberto/0000-0001-5459-2417; Ecker, Joseph R/0000-0001-5799-5895; Terzaghi, William/0000-0002-7536-6432	NIGMS NIH HHS [1F32GM18003-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018003] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEL S, 1994, PLANT J, V5, P421, DOI 10.1111/j.1365-313X.1994.00421.x; Abeles F, 1992, ETHYLENE PLANT BIOL; BAULCOMBE DC, 1986, NATURE, V321, P446, DOI 10.1038/321446a0; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; Bleecker AB, 1996, PLANT PHYSIOL, V111, P653, DOI 10.1104/pp.111.3.653; Chang C, 1996, TRENDS BIOCHEM SCI, V21, P129, DOI 10.1016/0968-0004(96)10019-0; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHEN QHG, 1995, PLANT PHYSIOL, V108, P597, DOI 10.1104/pp.108.2.597; Darwin CR., 1881, POWER MOVEMENT PLANT; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; GOESCHL JD, 1966, PLANT PHYSIOL, V41, P877, DOI 10.1104/pp.41.5.877; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HARPHAM NVJ, 1991, ANN BOT-LONDON, V68, P55, DOI 10.1093/oxfordjournals.aob.a088218; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KIEBER JJ, 1993, TRENDS GENET, V9, P356, DOI 10.1016/0168-9525(93)90041-F; KNIGHT LI, 1910, SCIENCE, V31, P635; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAWTON KA, 1994, PLANT CELL, V6, P581, DOI 10.1105/tpc.6.5.581; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)90126-7; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Matallana E., 1992, Methods in Arabidopsis research., P144; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORAN R, 1982, PLANT PHYSIOL, V69, P1376, DOI 10.1104/pp.69.6.1376; ODonnell PJ, 1996, SCIENCE, V274, P1914, DOI 10.1126/science.274.5294.1914; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.1105/tpc.7.2.173; Orzaez D, 1997, PLANT J, V11, P137, DOI 10.1046/j.1365-313X.1997.11010137.x; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; Penmetsa RV, 1997, SCIENCE, V275, P527, DOI 10.1126/science.275.5299.527; Penninckx IAMA, 1996, PLANT CELL, V8, P2309, DOI 10.1105/tpc.8.12.2309; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; ROMAN G, 1995, GENETICS, V139, P1393; Rothenberg M, 1993, SEMIN DEV BIOL, V4, P3, DOI [10.1006/sedb.1993.1002, DOI 10.1006/SEDB.1993.1002]; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; Tanimoto M, 1995, PLANT J, V8, P943, DOI 10.1046/j.1365-313X.1995.8060943.x; Terzaghi WB, 1997, PLANT J, V11, P967, DOI 10.1046/j.1365-313X.1997.11050967.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VAN DER STRAETEN D, 1993, PLANT PHYSIOL, V102, P401, DOI 10.1104/pp.102.2.401; WEIGEL D, 1995, PLANT CELL, V7, P338; ZHOU JM, 1993, PLANT MOL BIOL, V22, P517, DOI 10.1007/BF00015980	55	717	807	6	130	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1133	1144		10.1016/S0092-8674(00)80300-1	http://dx.doi.org/10.1016/S0092-8674(00)80300-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215635	hybrid			2022-12-24	WOS:A1997XG83000017
J	Starr, R; Willson, TA; Viney, EM; Murray, LJL; Rayner, JR; Jenkins, BJ; Gonda, TJ; Alexander, WS; Metcalf, D; Nicola, NA; Hilton, DJ				Starr, R; Willson, TA; Viney, EM; Murray, LJL; Rayner, JR; Jenkins, BJ; Gonda, TJ; Alexander, WS; Metcalf, D; Nicola, NA; Hilton, DJ			A family of cytokine-inducible inhibitors of signalling	NATURE			English	Article							TYROSINE PHOSPHORYLATION; ACTIVATION; RECEPTORS; CLONING; CHAIN	Cytokines are secreted proteins that regulate important cellular responses such as proliferation and differentiation(1). Key events in cytokine signal transduction are well defined: cytokines induce receptor aggregation, leading to activation of members of the JAK family of cytoplasmic tyrosine kinases. In turn, members af the STAT family of transcription factors are phosphorylated, dimerize and increase the transcription of genes with STAT recognition sites in their promoters(1-4). Less is known of how cytokine signal transduction is switched off. We have cloned a complementary DNA encoding a protein SOCS-1, containing an SH2-domain, by its ability to inhibit the macrophage differentiation of M1 cells in response to interleukin-6. Expression of SOCS-1 inhibited both interleukin-6-induced receptor phosphorylation and STAT activation. We have also cloned two-relatives of SOCS-1, named SOCS-2 and SOCS-3, which together with the previously described CIS (ref. 5) form a new family of proteins. Transcription of all four SOCS genes is increased rapidly in response to interleukin-6, in vitro and in vivo, suggesting they may act in a classic negative feedback loop to regulate cytokine signal transduction.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3052, AUSTRALIA; COOPERAT RES CTR CELLULAR GROWTH FACTORS, PARKVILLE, VIC 3052, AUSTRALIA; INST MED & VET SCI, HANSON CTR CANC RES, ADELAIDE, SA 5000, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Institute Medical & Veterinary Science Australia			Hilton, Douglas J/C-7250-2013; Nicola, Nicos/D-2989-2011; jenkins, brendan/J-7854-2012; Gonda, Thomas J/A-3620-2012; jenkins, brendan/A-2401-2009	Hilton, Douglas J/0000-0002-7698-2392; Nicola, Nicos/0000-0003-1054-7889; Jenkins, Brendan/0000-0002-7552-4656				ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FENG J, IN PRESS MOL CELL BI; Hilton DJ, 1996, J BIOL CHEM, V271, P4699; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; Howard M, 1994, GUIDEBOOK CYTOKINES; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1994, BLOOD CELLS, V20, P65; LOTEM J, 1989, LEUKEMIA, V3, P804; METCALF D, 1988, LEUKEMIA, V2, P216; METCALF D, 1995, LEUKEMIA, V9, P1556; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nicola NA, 1996, GROWTH FACTORS, V13, P141, DOI 10.3109/08977199609034574; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; QUELLE EW, 1996, MOL CELL BIOL, V16, P1622; Rasko JEJ, 1995, LEUKEMIA, V9, P2058; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; Schluter G, 1996, MOL REPROD DEV, V43, P1, DOI 10.1002/(SICI)1098-2795(199601)43:1&lt;1::AID-MRD1&gt;3.0.CO;2-W; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	27	1734	1847	0	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	1997	387	6636					917	921		10.1038/43206	http://dx.doi.org/10.1038/43206			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202125	Bronze			2022-12-24	WOS:A1997XG41600055
J	Villard, J; LisowskaGrospierre, B; vandenElsen, P; Fischer, A; Reith, W; Mach, B				Villard, J; LisowskaGrospierre, B; vandenElsen, P; Fischer, A; Reith, W; Mach, B			Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BARE LYMPHOCYTE SYNDROME; BINDING-PROTEIN; COOPERATIVE BINDING; X-BOX; COMPLEMENTATION; EXPRESSION; IMMUNODEFICIENCY; INDUCTION; PROMOTERS; REQUIRES	Background Major-histocompatibility - complex (MHC) class II deficiency is an autosomal recessive primary immunodeficiency disease in which MHC class II molecules are absent, It is a genetically heterogeneous disease of gene regulation resulting from defects in several transactivating genes that regulate the expression of MHC class II genes, The mutations responsible for MHC class II deficiency are classified according to complementation group (a group in which the phenotype remains uncorrected in pairwise fusions of cells), There are three known complementation groups (A, B, and C). Methods To elucidate the genetic defect in patients with MHC class II deficiency that was not classified genetically, we performed direct complementation assays with the three genes known to regulate the expression of MHC class II genes, CIITA, RFX5, and RFXAP, and the relevant mutations were identified in each patient. Results Mutations in the RFXAP gene were found in three patients from unrelated families, and the resulting defect was classified as belonging to a novel complementation group (D), Transfection with the wild-type RFXAP gene restored the expression of MHC class II molecules in the patients' cells. Conclusions Mutations in a novel MHC class II transactivating factor, RFXAP, can cause MHC class II deficiency. These mutations abolish the expression of MHC class II genes and lead to the same clinical picture of immunodeficiency as in patients with mutations in the other two MHC class II regulatory genes. (C) 1997, Massachusetts Medical Society.	UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,LOUIS JEANTET LAB MOL GENET,CH-1211 GENEVA 4,SWITZERLAND; HOP NECKER ENFANTS MALAD,INSERM,U429,PARIS,FRANCE; LEIDEN UNIV HOSP,DEPT IMMMUNOHEMATOL,LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,BLOOD BANK,LEIDEN,NETHERLANDS	University of Geneva; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)								AMALDI I, 1989, J IMMUNOL, V142, P999; BENICHOU B, 1991, P NATL ACAD SCI USA, V88, P4285, DOI 10.1073/pnas.88.10.4285; CHENG YSE, 1986, J INTERFERON RES, V6, P417, DOI 10.1089/jir.1986.6.417; DEPREVAL C, 1985, NATURE, V318, P291, DOI 10.1038/318291a0; DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GRISCELLI C, 1993, NEW CONCEPTS IMMUNOD, P177; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HAUBER I, 1995, J EXP MED, V181, P1411, DOI 10.1084/jem.181.4.1411; KLEIN C, 1995, BLOOD, V85, P580; KLEIN C, 1993, J PEDIATR-US, V123, P921, DOI 10.1016/S0022-3476(05)80388-9; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LISOWSKAGROSPIERRE B, 1994, HUM MOL GENET, V3, P953, DOI 10.1093/hmg/3.6.953; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; PEIJNENBURG A, 1995, IMMUNOGENETICS, V41, P287, DOI 10.1007/BF00172153; REITH W, 1994, J BIOL CHEM, V269, P20020; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707; SEIDL C, 1992, J IMMUNOL, V148, P1576; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TOURAINE JL, 1981, HUM IMMUNOL, V2, P147, DOI 10.1016/0198-8859(81)90061-6; TOURAINE JL, 1978, J PEDIATR-US, V93, P47, DOI 10.1016/S0022-3476(78)80598-8; VILLARD J, IN PRESS HUM MUTAT; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10934, DOI 10.1093/nar/16.22.10934; WOLF HM, 1995, NEW ENGL J MED, V332, P86, DOI 10.1056/NEJM199501123320204	30	57	59	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	1997	337	11					748	753		10.1056/NEJM199709113371104	http://dx.doi.org/10.1056/NEJM199709113371104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV174	9287230				2022-12-24	WOS:A1997XV17400004
J	Otis, TS; Kavanaugh, MP; Jahr, CE				Otis, TS; Kavanaugh, MP; Jahr, CE			Postsynaptic glutamate transport at the climbing fiber Purkinje cell synapse	SCIENCE			English	Article							GATED CHLORIDE CHANNEL; GLIAL-CELLS; RAT-BRAIN; CONDUCTANCE; TRANSMITTER; SALAMANDER; TRANSMISSION; RECEPTOR; RELEASE; NEURONS	The role of postsynaptic, neuronal glutamate transporters in terminating signals at central excitatory synapses is not known. Stimulation of a climbing fiber input to cerebellar Purkinje cells was shown to generate an anionic current mediated by glutamate transporters. The kinetics of transporter currents were resolved by pulses of glutamate to outside-out membrane patches from Purkinje cells. Comparison of synaptic transporter currents to transporter currents expressed in Xenopus oocytes suggests that postsynaptic uptake at the climbing fiber synapse removes at least 22 percent of released glutamate. These neuronal transporter currents arise from synchronous activation of transporters that greatly outnumber activated AMPA receptors.			Otis, TS (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,L 474,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.				NINDS NIH HHS [NS33270, NS21419] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033270, R01NS021419] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; Billups B, 1996, J NEUROSCI, V16, P6722; BRUNS D, 1993, NEURON, V10, P559, DOI 10.1016/0896-6273(93)90159-O; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; Diamond JS, 1997, J NEUROSCI, V17, P4672; Eliasof S, 1996, P NATL ACAD SCI USA, V93, P4153, DOI 10.1073/pnas.93.9.4153; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FERKANY J, 1986, J NEUROSCI RES, V16, P491, DOI 10.1002/jnr.490160305; GRANT GB, 1995, J NEUROSCI, V15, P3852; Kanai Y, 1995, NEUROREPORT, V6, P2357, DOI 10.1097/00001756-199511270-00020; Kataoka Y, 1996, J NEUROPHYSIOL, V76, P1870, DOI 10.1152/jn.1996.76.3.1870; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2262; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Muller T, 1995, INT REV NEUROBIOL, V38, P341, DOI 10.1016/S0074-7742(08)60530-9; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PERKEL DJ, 1990, P ROY SOC B-BIOL SCI, V241, P116, DOI 10.1098/rspb.1990.0074; PICAUD SA, 1995, J NEUROPHYSIOL, V74, P1760, DOI 10.1152/jn.1995.74.4.1760; RIVAROS N, 1986, BRAIN RES, V386, P405; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; Takahashi M, 1996, J PHYSIOL-LONDON, V497, P523, DOI 10.1113/jphysiol.1996.sp021785; TAKAHASHI M, 1995, J NEUROSCI, V15, P5693; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; TRAYNELIS SF, 1993, NEURON, V11, P279, DOI 10.1016/0896-6273(93)90184-S; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; WYLLIE DJA, 1993, J PHYSIOL-LONDON, V463, P193, DOI 10.1113/jphysiol.1993.sp019591; Yamada K, 1996, NEUROREPORT, V7, P2013, DOI 10.1097/00001756-199608120-00032; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	34	153	156	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1515	1518		10.1126/science.277.5331.1515	http://dx.doi.org/10.1126/science.277.5331.1515			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278516				2022-12-24	WOS:A1997XV42900043
J	Cooper, GW; Thiemens, MH; Jackson, TL; Chang, S				Cooper, GW; Thiemens, MH; Jackson, TL; Chang, S			Sulfur and hydrogen isotope anomalies in meteorite sulfonic acids	SCIENCE			English	Article							MURCHISON METEORITE; CARBONACEOUS CHONDRITES; HYDROCARBONS; MONOSULFIDE; CHEMISTRY; OZONE	Intramolecular carbon, hydrogen, and sulfur isotope ratios were measured on a homologous series of organic sulfonic acids discovered in the Murchison meteorite. Mass independent sulfur isotope fractionations were observed along with high deuterium/hydrogen ratios. The deuterium enrichments indicate formation of the hydrocarbon portion of these compounds in a low-temperature environment that is consistent with that of interstellar clouds. Sulfur-33 enrichments observed in methanesulfonic acid could have resulted from gas-phase ultraviolet irradiation of a precursor, carbon disulfide, The source of the sulfonic acid precursors may have been the reactive interstellar molecule carbon monosulfide.	NASA, AMES RES CTR, MOFFETT FIELD, CA 94035 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of California System; University of California San Diego	Cooper, GW (corresponding author), SETI INST, MS 239-4, MOFFETT FIELD, CA 94035 USA.							BOHN RB, 1992, J AM CHEM SOC, V114, P6452, DOI 10.1021/ja00042a024; BUNCH TE, 1980, GEOCHIM COSMOCHIM AC, V44, P1543, DOI 10.1016/0016-7037(80)90118-0; COLEMAN ML, 1978, ANAL CHEM, V50, P1594, DOI 10.1021/ac50033a056; Colman JJ, 1996, SCIENCE, V273, P774, DOI 10.1126/science.273.5276.774; Cooper G. W., 1995, LPS, VXXVI, P281; COOPER GW, 1995, GEOCHIM COSMOCHIM AC, V59, P1003, DOI 10.1016/0016-7037(95)00018-6; COOPER GW, 1992, GEOCHIM COSMOCHIM AC, V56, P4109, DOI 10.1016/0016-7037(92)90023-C; COOPER GW, 1995, METEORITICS, V30, P500; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; DESORGO M, 1965, CAN J CHEMISTRY, V43, P1886; EPSTEIN S, 1987, NATURE, V326, P477, DOI 10.1038/326477a0; GAO X, 1993, GEOCHIM COSMOCHIM AC, V57, P3159, DOI 10.1016/0016-7037(93)90300-L; Gao X., 1991, GEOCHIM COSMOCHIM AC, V55, P2671, DOI DOI 10.1016/0016-7037(91)90381-E; HAYES JM, 1968, GEOCHIM COSMOCHIM AC, V32, P239, DOI 10.1016/S0016-7037(68)80006-7; HEIDENREICH JE, 1986, J CHEM PHYS, V84, P2129, DOI 10.1063/1.450373; HOGG MAP, 1958, J CHEM SOC, P4196; KLABUNDE KJ, 1989, PHOSPHORUS SULFUR, V43, P47, DOI 10.1080/10426508908040278; MAUERSBERGER K, 1993, GEOPHYS RES LETT, V20, P1031, DOI 10.1029/93GL01080; MOLTZEN EK, 1988, CHEM REV, V88, P391, DOI 10.1021/cr00084a003; STEUDEL R, 1966, Z NATURFORSCH B, V218, P1106; STUDIER MH, 1972, GEOCHIM COSMOCHIM AC, V36, P189; THIEMENS MH, 1994, METEORITICS, V29, P540; THIEMENS MH, 1995, LUNAR PLANET SCI, V26, P1405; van Dishoeck E. F., 1993, PROTOSTARS PLANETS, P163; WHITE CM, 1974, THESIS U N DAKOTA GR; Xu X.Y, UNPUB; YUEN G, 1984, NATURE, V307, P252, DOI 10.1038/307252a0	27	69	70	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1072	1074		10.1126/science.277.5329.1072	http://dx.doi.org/10.1126/science.277.5329.1072			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262469	Green Submitted			2022-12-24	WOS:A1997XT03300026
J	Korolev, S; Hsieh, J; Gauss, GH; Lohman, TM; Waksman, G				Korolev, S; Hsieh, J; Gauss, GH; Lohman, TM; Waksman, G			Major domain swiveling revealed by the crystal structures of complexes of E-coli Rep helicase bound to single-stranded DNA and ADP	CELL			English	Article							ADENINE-NUCLEOTIDE BINDING; XERODERMA-PIGMENTOSUM; INDUCED DIMERIZATION; KINETIC MECHANISM; EXCISION-REPAIR; UVRD PROTEINS; SEQUENCE; MONOMER; HYDROLYSIS; PROGRAM	Crystal structures of binary and ternary complexes of the E. coli Rep helicase bound to single-stranded (ss) DNA or ssDNA and ADP were determined to a resolution of 3.0 Angstrom and 3.2 Angstrom, respectively. The asymmetric unit in the crystals contains two Rep monomers differing from each other by a large reorientation of one of the domains, corresponding to a swiveling of 130 degrees about a hinge region. Such domain movements are sufficiently large to suggest that these may be coupled to translocation of the Rep dimer along DNA. The ssDNA binding site involves the helicase motifs la, Iii, and V, whereas the ADP binding site involves helicase motifs I and IV. Residues in motifs II and VI may function to transduce the allosteric effects of nucleotides on DNA binding. These structures represent the first view of a DNA helicase bound to DNA.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOL BIOPHYS, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Korolev, Sergey/ABA-7517-2020	Korolev, Sergey/0000-0001-9313-7126	NIGMS NIH HHS [R01 GM045948, GM54033] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054033, R01GM045948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Bjornson KP, 1996, BIOCHEMISTRY-US, V35, P2268, DOI 10.1021/bi9522763; Bjornson KP, 1996, J MOL BIOL, V263, P411, DOI 10.1006/jmbi.1996.0585; Brosh RM, 1996, J BIOL CHEM, V271, P25360, DOI 10.1074/jbc.271.41.25360; Brunger A.T., 1992, X PLOR VERSION 3 1 M; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHAO KL, 1990, J BIOL CHEM, V265, P1067; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FRIEDBERG EC, 1992, CELL, V71, P887, DOI 10.1016/0092-8674(92)90384-O; GILCHRIST CA, 1987, NUCLEIC ACIDS RES, V15, P465, DOI 10.1093/nar/15.2.465; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HILL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4796, DOI 10.1073/pnas.78.8.4796; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1996, NATURE, V379, P621; LANE HED, 1974, J BACTERIOL, V120, P805, DOI 10.1128/JB.120.2.805-814.1974; LANE HED, 1975, J MOL BIOL, V97, P99; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14565, DOI 10.1021/bi00252a024; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; WONG I, 1992, J BIOL CHEM, V267, P7596; WONG I, 1993, J BIOL CHEM, V268, P20386; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Wong I, 1997, BIOCHEMISTRY-US, V36, P3115, DOI 10.1021/bi9621977; Wong I, 1996, P NATL ACAD SCI USA, V93, P10051, DOI 10.1073/pnas.93.19.10051; Wong I, 1996, BIOCHEMISTRY-US, V35, P5726, DOI 10.1021/bi952959i; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297	49	431	450	2	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					635	647		10.1016/S0092-8674(00)80525-5	http://dx.doi.org/10.1016/S0092-8674(00)80525-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288744	Bronze			2022-12-24	WOS:A1997XT06600008
J	Luo, JM; Sladek, R; Bader, JA; Matthyssen, A; Rossant, J; Giguere, V				Luo, JM; Sladek, R; Bader, JA; Matthyssen, A; Rossant, J; Giguere, V			Placental abnormalities in mouse embryos lacking the orphan nuclear receptor ERR-beta	NATURE			English	Article							STEM-CELLS; MICE; IDENTIFICATION; TROPHOBLAST; PROTEIN; GENES	Classical endocrine studies have shown that steroid hormones are required for the maintenance of pregnancy and placental viability. The oestrogen-receptor-related receptor beta (ERR-beta) is an orphan member of the superfamily of nuclear hormone receptors(1) Although ERR-beta is homologous to the oestrogen receptor and binds the oestrogen response element(2), it is not activated by oestrogens'. Expression of ERR-beta during embryogenesis defines a subset of extra-embryonic ectoderm that subsequently forms the dome of the chorion, suggesting that ERR-beta may be involved in early placental development. Homozygous mutant embryos generated by targeted disruption of the Estrrb gene have severely impaired placental formation, and die at 10.5 days post-coitum. The mutants display abnormal chorion development associated with an overabundance of trophoblast giant cells and a severe deficiency of diploid trophoblast. The phenotype can be rescued by aggregation of Estrrb mutant embryos with tetraploid wildtype cells, which contribute exclusively to extra-embryonic tissues. Our results indicate that ERR-beta has an important role in early placentation, and suggest that an inductive signal originating from or modified by the chorion is required for normal trophoblast proliferation and differentiation.	ROYAL VICTORIA HOSP,MOL ONCOL GRP,MONTREAL,PQ H3A 1A1,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5S 1A8,CANADA; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1A8,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; Royal Victoria Hospital; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; McGill University; McGill University; McGill University			Sladek, Robert/R-2391-2019	Sladek, Robert/0000-0002-2730-1204; Giguere, Vincent/0000-0001-9567-3694				COLOSI P, 1988, MOL ENDOCRINOL, V2, P579, DOI 10.1210/mend-2-6-579; FINNERTY H, 1993, ONCOGENE, V8, P2293; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; ILGREN EB, 1983, PLACENTA, V4, P307, DOI 10.1016/S0143-4004(83)80010-1; ILGREN EB, 1981, J EMBRYOL EXP MORPH, V62, P183; Kaufman M.H., 1992, ATLAS MOUSE DEV; LESCISIN KR, 1988, GENE DEV, V2, P1639, DOI 10.1101/gad.2.12a.1639; LINZER DIH, 1985, P NATL ACAD SCI USA, V82, P4356, DOI 10.1073/pnas.82.13.4356; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; NAGY A, 1990, DEVELOPMENT, V110, P815; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; PARAMITHIOTIS E, 1994, EUR J IMMUNOL, V24, P458, DOI 10.1002/eji.1830240229; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; ROSSANT J, 1981, J EMBRYOL EXP MORPH, V62, P217; ROSSANT J, 1977, J EMBRYOL EXP MORPH, V39, P183; Speroff L, 1994, CLIN GYNECOLOGIC END, V5th; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; Yen S. S. C., 1991, REPROD ENDOCRINOLOGY	23	321	333	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					778	782		10.1038/42022	http://dx.doi.org/10.1038/42022			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285590	Bronze			2022-12-24	WOS:A1997XR66700052
J	Palsboll, PJ; Allen, J; Berube, M; Clapham, PJ; Feddersen, TP; Hammond, PS; Hudson, RR; Jorgensen, H; Katona, S; Larsen, AH; Larsen, F; Lien, J; Mattila, DK; Sigurjonsson, J; Sears, R; Smith, T; Sponer, R; Stevick, P; Oien, N				Palsboll, PJ; Allen, J; Berube, M; Clapham, PJ; Feddersen, TP; Hammond, PS; Hudson, RR; Jorgensen, H; Katona, S; Larsen, AH; Larsen, F; Lien, J; Mattila, DK; Sigurjonsson, J; Sears, R; Smith, T; Sponer, R; Stevick, P; Oien, N			Genetic tagging of humpback whales	NATURE			English	Article							MEGAPTERA-NOVAEANGLIAE; SIMPLE SEQUENCES; DNA; POPULATION; MAINE; GULF	The ability to recognize individual animals has substantially increased our knowledge of the biology and behaviour of many taxa(1). However, not all species lend themselves to this approach, either because of insufficient phenotypic variation or because tag attachment is not feasible. The use of genetic markers ('tags') represents a viable alternative to traditional methods of individual recognition, as they are permanent and exist in all individuals. We tested the use of genetic markers as the primary means of identifying individuals in a study of humpback whales in the North Atlantic Ocean. Analysis of six microsatellite loci(2,3) among 3,060 skin samples collected throughout this ocean allowed the unequivocal identification of individuals. Analysis of 692 'recaptures', identified by their genotype, revealed individual local and migratory movements of up to 10,000 km, limited exchange among summer feeding grounds, and mixing in winter breeding areas, and also allowed the first estimates of animal abundance based solely on genotypic data. Our study demonstrates that genetic tagging is not only feasible, but generates data (for example, on sex) that can be valuable when interpreting-the results of tagging experiments.	COLL ATLANTIC,BAR HARBOR,ME 04609; DEPT NAT RESOURCES SCI,ST ANNE BELLEVUE,PQ H9X 3V9,CANADA; CTR COASTAL STUDIES,PROVINCETOWN,MA 02657; UNIV ST ANDREWS,SEA MAMMAL RES UNIT,ST ANDREWS KY16 9LB,FIFE,SCOTLAND; UNIV CALIF IRVINE,DEPT ECOL & EVOLUTIONARY BIOL,IRVINE,CA 92697; GREENLAND INST NAT RESOURCES,NUUK 3900,GREENLAND; MEM UNIV NEWFOUNDLAND,WHALE RES GRP,ST JOHNS,NF A1B 3X9,CANADA; MARINE RES INST,IS-121 REYKJAVIK,ICELAND; MINGAN ISL CETACEAN STUDY INC,ST LAMBERT,PQ J4P 1T3,CANADA; NATL MARINE FISHERIES SERV,NE FISHERIES SCI CTR,WOODS HOLE,MA 02543; INST MARINE RES,N-5024 BERGEN,NORWAY	University of St Andrews; University of California System; University of California Irvine; Greenland Institute of Natural Resources; Memorial University Newfoundland; Marine & Freshwater Research Institute (MFRI); National Oceanic Atmospheric Admin (NOAA) - USA; Institute of Marine Research - Norway	Palsboll, PJ (corresponding author), DEPT POPULAT BIOL,UNIV PK 15,DK-2100 COPENHAGEN,DENMARK.		Palsbøll, Per J/L-3494-2013; Palsboll, Per J/G-6988-2011	Palsbøll, Per J/0000-0002-4198-7599; Palsboll, Per J/0000-0002-4198-7599; Berube, Martine/0000-0002-1831-2657; Larsen, Finn/0000-0001-6498-9012				AMOS B, 1993, SCIENCE, V260, P670, DOI 10.1126/science.8480176; [Anonymous], 1982, ESTIMATION ANIMAL AB; Barlow J, 1997, ECOLOGY, V78, P535; Berube M, 1996, MOL ECOL, V5, P283; CLAPHAM PJ, 1993, CAN J ZOOL, V71, P1065, DOI 10.1139/z93-142; CLAPHAM PJ, 1993, MAR MAMMAL SCI, V9, P213, DOI 10.1111/j.1748-7692.1993.tb00448.x; Clapham PJ, 1997, P ROY SOC B-BIOL SCI, V264, P95, DOI 10.1098/rspb.1997.0014; CLAPHAM PJ, 1995, MAR MAMMAL SCI, V11, P227, DOI 10.1111/j.1748-7692.1995.tb00520.x; CLAPHAM PJ, 1993, CAN J ZOOL, V71, P440, DOI 10.1139/z93-063; CONSTABLE JJ, 1995, NATURE, V373, P393, DOI 10.1038/373393a0; GERLOFF U, 1995, MOL ECOL, V4, P515, DOI 10.1111/j.1365-294X.1995.tb00247.x; Hammond PS, 1990, REPORT INT WHALING C, P440; Katona S.K., 1981, Polar Record, V20, P439; KATONA S. K., 1990, REPORT INT WHALING C, P295; LAMBERTSEN RH, 1987, J MAMMAL, V68, P443, DOI 10.2307/1381495; LARSEN AH, 1996, P R SOC LOND B, V263, P611; Maniatis T., 1982, MOL CLONING; MATTILA DK, 1989, CAN J ZOOL, V67, P281, DOI 10.1139/z89-041; MORIN PA, 1992, PATERNITY IN PRIMATES : GENETIC TESTS AND THEORIES, P63; PAETKAU D, 1994, MOL ECOL, V3, P489, DOI 10.1111/j.1365-294X.1994.tb00127.x; Palsboll P.J., 1991, Reports of the International Whaling Commission Special Issue, P71; PALSBOLL PJ, 1995, MAR ECOL PROG SER, V116, P1, DOI 10.3354/meps116001; PALSBOLL PJ, IN PRESS MOL ECOL; ROY MS, 1994, MOL BIOL EVOL, V11, P553; STEVICK PT, IN PRESS MAR MAMM SC; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; WEBER JL, 1989, AM J HUM GENET, V44, P388	28	209	227	2	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					767	769		10.1038/42005	http://dx.doi.org/10.1038/42005			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285587	Green Submitted, Bronze			2022-12-24	WOS:A1997XR66700049
J	Ledent, C; Vaugeois, JM; Schiffmann, SN; Pedrazzini, T; ElYacoubi, M; Vanderhaeghen, JJ; Costentin, J; Heath, JK; Vassart, G; Parmentier, M				Ledent, C; Vaugeois, JM; Schiffmann, SN; Pedrazzini, T; ElYacoubi, M; Vanderhaeghen, JJ; Costentin, J; Heath, JK; Vassart, G; Parmentier, M			Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A(2a) receptor	NATURE			English	Article							GENE-EXPRESSION; CAFFEINE; RAT; STRIATUM; AGONISTS; CLONING; NEURONS; BRAIN	Adenosine is released from metabolically active cells by facilitated diffusion, and is generated extracellularly by degradation of released ATP. It is a potent biological mediator that modulates the activity of numerous cell types, including various neuronal populations, platelets, neutrophils and mast cells, and smooth muscle cells in bronchi and vasculatue. Most of these effects help to protect cells and tissues during stress conditions such as ischaemia. Adenosine mediates its effects through four receptor subtypes: the A(1), A(2a), A(2b) and A(3) receptors(1). The A(2a) receptor (A(2a)R)(2,3) is abundant in basal ganglia, vasculature and platelets, and stimulates adenylyl cyclase. It is a major target of caffeine, the most widely used psychoactive drug(4). Here we investigate the role of the A(2a) receptor by disrupting the gene in mice. Here found that A(2a)R-knockout (A(2a)R(-/-)) mice were viable and bred normally. Their exploratory activity was reduced, whereas caffeine, which normally stimulates exploratory behaviour, became a depressant of exploratory activity. Knockout animals scored higher in anxiety tests, and male mice were much more aggressive towards intruders. The response of A(2a)R(-/-) mice to acute pain stimuli was slower. Blood pressure and heart rate were increased, as well as platelet aggregation. The specific A(2a) agonist CGS 21680 lost its biological activity in all systems tested.	FREE UNIV BRUSSELS, IRIBHN, LAB RECH NEUROPEPTIDES, B-1070 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, SERV GENET MED, B-1070 BRUSSELS, BELGIUM; FAC MED & PHARM, IFRMP,UNITE NEUROPSYCHOPHARMACOL EXPT,CNRS, UPRESA 6036, F-76803 ST ETIENNE DU ROUVRAY, FRANCE; UNIV LAUSANNE, SCH MED, DIV HYPERTENS, CH-1011 LAUSANNE, SWITZERLAND; UNIV OXFORD, DEPT BIOCHEM, CRC GROWTH FACTORS, OXFORD OX1 3QU, ENGLAND	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); University of Lausanne; University of Oxford				Parmentier, Marc/0000-0001-8081-4685; Schiffmann, Serge/0000-0002-0118-9816; Vaugeois, Jean-Marie/0000-0001-8296-672X; EL YACOUBI, Malika/0000-0002-1010-9179				BALK JH, 1995, NATURE, V377, P424; COSTENTIN J, 1986, EUR J PHARMACOL, V123, P37, DOI 10.1016/0014-2999(86)90684-9; CRISTALLI G, 1994, N-S ARCH PHARMACOL, V349, P644, DOI 10.1007/PL00004904; DELANDER GE, 1994, J PHARMACOL EXP THER, V268, P943; DIONISOTTI S, 1992, N-S ARCH PHARMACOL, V346, P673; FILE SE, 1988, PHARMACOL BIOCHEM BE, V30, P809, DOI 10.1016/0091-3057(88)90104-9; FINK JS, 1992, MOL BRAIN RES, V14, P186, DOI 10.1016/0169-328X(92)90173-9; FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P93, DOI 10.1111/j.1600-0773.1995.tb00111.x; FURLONG TJ, 1992, MOL BRAIN RES, V15, P62, DOI 10.1016/0169-328X(92)90152-2; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; HOPKER VH, 1995, NEUROREPORT, V6, P1153; JAIN N, 1995, BRIT J PHARMACOL, V116, P2127, DOI 10.1111/j.1476-5381.1995.tb16421.x; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MCQUEEN DS, 1986, BRIT J PHARMACOL, V88, P615, DOI 10.1111/j.1476-5381.1986.tb10242.x; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NIKODIJEVIC O, 1993, PHARMACOL BIOCHEM BE, V44, P199, DOI 10.1016/0091-3057(93)90299-9; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; Ongini E, 1996, TRENDS PHARMACOL SCI, V17, P364, DOI 10.1016/S0165-6147(96)10045-6; PALMOUR RM, 1989, LIFE SCI, V44, P1293, DOI 10.1016/0024-3205(89)90367-6; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; SAWYNOK J, 1993, PHARMACOL REV, V45, P43; SCHIFFMANN SN, 1992, J COMP NEUROL, V317, P117, DOI 10.1002/cne.903170202; SCHIFFMANN SN, 1993, J NEUROSCI, V13, P1080; SWEENEY MI, 1987, EUR J PHARMACOL, V141, P169, DOI 10.1016/0014-2999(87)90428-6; Varani K, 1996, BRIT J PHARMACOL, V117, P1693, DOI 10.1111/j.1476-5381.1996.tb15341.x; WEAVER DR, 1993, MOL BRAIN RES, V20, P313, DOI 10.1016/0169-328X(93)90058-W; WORST W, 1993, GENE TARGETING PRACT, P33	28	721	748	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	1997	388	6643					674	678		10.1038/41771	http://dx.doi.org/10.1038/41771			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262401	Bronze			2022-12-24	WOS:A1997XQ86300049
J	Davies, SW; Turmaine, M; Cozens, BA; DiFiglia, M; Sharp, AH; Ross, CA; Scherzinger, E; Wanker, EE; Mangiarini, L; Bates, GP				Davies, SW; Turmaine, M; Cozens, BA; DiFiglia, M; Sharp, AH; Ross, CA; Scherzinger, E; Wanker, EE; Mangiarini, L; Bates, GP			Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation	CELL			English	Article							DISEASE GENE HOMOLOG; IT15 PROTEIN PRODUCT; HUNTINGTONS-DISEASE; EMBRYONIC LETHALITY; CAUDATE-NUCLEUS; BRAIN; EXPRESSION; LOCALIZATION; REPEAT; EXPANSION	Huntington's disease (HD) is one of an increasing number of human neurodegenerative disorders caused by a CAG/polyglutamine-repeat expansion. The mutation occurs in a gene of unknown function that is expressed in a wide range of tissues. The molecular mechanism responsible for the delayed onset, selective pattern of neuropathology, and cell death observed in HD has not been described. We have observed that mice transgenic for exon 1 of the human Ho gene carrying (GAG)(115) to (CAG)(156) repeat expansions develop pronounced neuronal intranuclear inclusions, containing the proteins huntingtin and ubiquitin, prior to developing a neurological phenotype. The appearance in transgenic mice of these inclusions, followed by characteristic morphological change within neuronal nuclei, is strikingly similar to nuclear abnormalities observed in biopsy material from HD patients.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02114; JOHNS HOPKINS UNIV,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV MED & MOL GENET,LONDON SE1 9RT,ENGLAND; MAX PLANCK INST MOL GENET,BERLIN,DAHLEM,GERMANY	Harvard University; Harvard Medical School; Massachusetts General Hospital; Johns Hopkins University; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Max Planck Society	Davies, SW (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.		Ross, Christopher A/H-8395-2013; Bates, Gillian P/E-1146-2012	Bates, Gillian P/0000-0002-4041-6305; Wanker, Erich/0000-0001-8072-1630	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALZHEIMER A, 1911, Z GES NEUROL PSYCH, V3, P566; [Anonymous], ADV NEUROL; ARONIN N, 1995, NEURON, V15, P1193, DOI 10.1016/0896-6273(95)90106-X; BATES GP, 1997, IN PRESS HUM MOL GEN; Bhide PG, 1996, J NEUROSCI, V16, P5523; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruyn GW, 1987, ACTA NEUROPATHOL, V5, P21; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; DELAMONTE SM, 1988, J NEUROPATH EXP NEUR, V47, P516, DOI 10.1097/00005072-198809000-00003; DeRooij KE, 1996, HUM MOL GENET, V5, P1093, DOI 10.1093/hmg/5.8.1093; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Ebling FJP, 1996, BRAIN RES BULL, V41, P257, DOI 10.1016/S0361-9230(96)00192-X; FORNO LS, 1979, ADV NEUROL, V23, P95; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; HADREEN JC, 1995, J NEUROPATHOL EXP NE, V54, P105; HARPER PS, 1991, MAJOR PROBLEMS NEURO, V22; Hollen KM, 1997, MOL BRAIN RES, V47, P31, DOI 10.1016/S0169-328X(97)00034-X; *HUNT DIS COLL RES, 1993, CELL, V72, P971; IDE K, 1995, BIOCHEM BIOPH RES CO, V209, P1119, DOI 10.1006/bbrc.1995.1613; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; KEMP JM, 1971, PHILOS T R SOC B, V262, P383, DOI 10.1098/rstb.1971.0102; KOSINSKI CM, 1997, IN PRESS EXP NEUROL; KOWALL NW, 1987, TRENDS NEUROSCI, V10, P24, DOI 10.1016/0166-2236(87)90120-2; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lieberman A R, 1971, Int Rev Neurobiol, V14, P49, DOI 10.1016/S0074-7742(08)60183-X; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; LOWE J, 1989, NEUROSCI LETT, V105, P7, DOI 10.1016/0304-3940(89)90003-7; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MYERS RH, 1991, J NEUROPATH EXP NEUR, V50, P729, DOI 10.1097/00005072-199111000-00005; MYERS RH, 1988, NEUROLOGY, V38, P341, DOI 10.1212/WNL.38.3.341; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Perutz MF, 1996, CURR OPIN STRUC BIOL, V6, P848, DOI 10.1016/S0959-440X(96)80016-9; Peters A, 1991, FINE STRUCTURE NERVO; ROOS RAC, 1983, J NEUROL SCI, V61, P37, DOI 10.1016/0022-510X(83)90053-9; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SCHILLING G, 1995, HUM MOL GENET, V4, P1365, DOI 10.1093/hmg/4.8.1365; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SPILLANTINI MG, 1990, P NATL ACAD SCI USA, V87, P3952, DOI 10.1073/pnas.87.10.3952; TELLEZNAGEL I, 1974, J NEUROCYTOL, V3, P308; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	55	1812	1871	2	69	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					537	548		10.1016/S0092-8674(00)80513-9	http://dx.doi.org/10.1016/S0092-8674(00)80513-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267033	hybrid			2022-12-24	WOS:A1997XQ06300017
J	Nightingale, SL				Nightingale, SL			Public health advisory on protease inhibitors for HIV treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					379	379		10.1001/jama.278.5.379	http://dx.doi.org/10.1001/jama.278.5.379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244318				2022-12-24	WOS:A1997XN51800009
J	Hawthorne, G; Robson, S; Ryall, EA; Sen, D; Roberts, SH; Platt, MPW				Hawthorne, G; Robson, S; Ryall, EA; Sen, D; Roberts, SH; Platt, MPW			Prospective population based survey of outcome of pregnancy in diabetic women: results of the northern diabetic pregnancy audit, 1994	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL-ANOMALIES; PRECONCEPTION CARE	Objective: To determine whether the St Vincent declaration (1989) target of diabetic pregnancy outcome approximating non-diabetic pregnancy outcome is near to being achieved. Design: Prospective collection of population based information on pregnancies in women with diabetes from all participating hospitals. Setting: District general and teaching hospitals of the former Northern region. Subjects: 111 diabetic women booking with pregnancy during 1 January to 31 December 1994. Main outcome measures: Diabetic control, perinatal mortality rate, fetal abnormality rate. Results: The perinatal mortality rate was 48/1000 for diabetic pregnancies compared with 8.9/1000 for the background population (odds ratio 5.38; 95% confidence interval 2.27 to 12.70) and the neonatal mortality rate was 59/1000 compared with 3.9/1000 (15.0; 6.77 to 33.10). Two late neonatal deaths were due to congenital heart defects. Six per cent of all fetal losses (6/109 cases) were due to major malformations. The congenital malformation rate was 83/1000 compared with 21.3/1000 (3.76; 2.00 to 7.06) in the background population. Conclusion: Diabetic pregnancy remains a high risk state with perinatal mortality and fetal malformation rates much higher than in the background population.	UNIV NEWCASTLE UPON TYNE, ROYAL VICTORIA INFIRM, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND; N TEES GEN HOSP, STOCKTON ON TEES TS19 8PE, ENGLAND; N TYNESIDE HOSP, DIABET RESOURCE CTR, N SHIELDS NE29 8NH, TYNE & WEAR, ENGLAND	Newcastle University - UK; University Hospital of North Tees	Hawthorne, G (corresponding author), HARTLEPOOL GEN HOSP, HARTLEPOOL TS24 9AH, CLEVELAND, ENGLAND.		Platt, Martin Ward/D-4008-2014	Platt, Martin Ward/0000-0003-0536-5749				Diabetes care and research in Europe, 1990, DIABETIC MED, V7, P360; ELIXHAUSER A, 1993, DIABETES CARE, V16, P1146, DOI 10.2337/diacare.16.8.1146; GREGORY R, 1992, J ROY COLL PHYS LOND, V26, P162; KITZMILLER JL, 1991, JAMA-J AM MED ASSOC, V265, P731, DOI 10.1001/jama.265.6.731; MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204; MORRIS JA, 1989, STAT CONFIDENCE, P50; *N REG HLTH AUTH, 1995, REG FET ABN SURV PRO; *NO REG HLTH AUTH, 1995, COLL SURV PER LAT NE; RENWICK M, 1992, ARCH DIS CHILD-FETAL, V67, P770; ROSENN B, 1991, OBSTET GYNECOL, V77, P846; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEEL JM, 1990, BRIT MED J, V301, P1070, DOI 10.1136/bmj.301.6760.1070; TIN W, IN PRESS BR J OBSTET; TRAUB AI, 1987, BRIT J OBSTET GYNAEC, V94, P957, DOI 10.1111/j.1471-0528.1987.tb02269.x	14	157	160	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					279	281		10.1136/bmj.315.7103.279	http://dx.doi.org/10.1136/bmj.315.7103.279			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274546	Green Published			2022-12-24	WOS:A1997XP75000020
J	Blaumueller, CM; Qi, HL; Zagouras, P; ArtavanisTsakonas, S				Blaumueller, CM; Qi, HL; Zagouras, P; ArtavanisTsakonas, S			Intracellular cleavage of notch leads to a heterodimeric receptor on the plasma membrane	CELL			English	Article							DROSOPHILA-NOTCH; GENE-PRODUCT; MAMMALIAN NOTCH; HUMAN HOMOLOG; CELL-FATE; PROTEIN; LOCUS; EXPRESSION; NEUROGENESIS; MELANOGASTER	Previous models for signal transduction via the Notch pathway have depicted the full-length Notch receptor expressed at the cell surface. We present evidence demonstrating that the Notch receptor on the plasma membrane is cleaved. This cleavage is an evolutionarily conserved, general property of Notch and occurs in the trans-Golgi network as the receptor traffics toward the plasma membrane. Although full-length Notch is detectable in the cell, it does not reach the surface. Cleavage results in a C-terminal fragment, N(TM), that appears to be cleaved N-terminal to the transmembrane domain, and an N-terminal fragment, N-EC, that contains most of the extracellular region. We provide evidence that these fragments are tethered together on the plasma membrane by a link that is sensitive to reducing conditions, forming a heterodimeric receptor.	YALE UNIV, HOWARD HUGHES MED INST, DEPT CELL BIOL & BIOL, BOYER CTR MOL MED, NEW HAVEN, CT 06536 USA	Howard Hughes Medical Institute; Yale University				Blaumueller, Christine/0000-0002-1236-9353	NINDS NIH HHS [NS26084] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026084, R01NS026084] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; AHMAD I, 1995, MECH DEVELOP, V53, P73, DOI 10.1016/0925-4773(95)00425-4; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Baker R, 1996, DEVELOPMENT, V122, P617; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Blaumueller CM, 1997, PERSPECT DEV NEUROBI, V4, P325; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; CRITTENDEN SL, 1994, DEVELOPMENT, V120, P2901; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FOSTER GG, 1975, GENETICS, V81, P99; GEHRING WJ, 1973, GENETIC MECHANISMS D, P103; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HOPPE PE, 1990, DEVELOPMENT, V109, P875; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MARKOPOULOU K, 1990, J EXP ZOOL, V27, P23; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, THESIS YALE U NEW HA; STERN C, 1968, P NATL ACAD SCI USA, V60, P1252, DOI 10.1073/pnas.60.4.1252; STERNBERG PW, 1993, CURR BIOL, V3, P763, DOI 10.1016/0960-9822(93)90025-J; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Sun X, 1996, DEVELOPMENT, V122, P2465; TECHNAU GM, 1987, P NATL ACAD SCI USA, V84, P4500, DOI 10.1073/pnas.84.13.4500; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	49	475	496	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					281	291		10.1016/S0092-8674(00)80336-0	http://dx.doi.org/10.1016/S0092-8674(00)80336-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244302	hybrid			2022-12-24	WOS:A1997XN24900012
J	Annas, GJ				Annas, GJ			Patients' rights in managed care - Exit, voice, and choice	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS G, 1989, RIGHTS PATIENTS; ANNAS GJ, 1974, VANDERBILT LAW REV, V27, P243; [Anonymous], 1970, EXIT VOICE LOYALTY R, DOI DOI 10.3917/RCE.002.0244; *BNA, 1996, BNAS HLTH LAW R 1107, P1631; Bodenheimer T, 1996, NEW ENGL J MED, V335, P1601, DOI 10.1056/NEJM199611213352112; CHASE M, 1997, WALL ST J       0929, pB1; GAYNOR P, 1997, PITTSBURGH POST 0202, pC21; *HCFA, 1996, BNAS MANAGED CA 1211, P1159; HILTZIK MA, 1995, LOS ANGELES TIM 0827, pA1; Kinney ED, 1996, AM J LAW MED, V22, P301; Mariner WK, 1996, NEW ENGL J MED, V335, P1986, DOI 10.1056/NEJM199612263352610; RODWIN MA, 1996, HOUSTON LAW REV, V32, P1319; 1997, CHASREG, V62, P23368	13	38	39	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	1997	337	3					210	215		10.1056/NEJM199707173370323	http://dx.doi.org/10.1056/NEJM199707173370323			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK818	9219710	Green Published			2022-12-24	WOS:A1997XK81800030
J	Raymond, GJ; Hope, J; Kocisko, DA; Priola, SA; Raymond, LD; Bossers, A; Ironside, J; Will, RG; Chen, SG; Petersen, RB; Gambetti, P; Rubenstein, R; Smits, MA; Lansbury, PT; Caughey, B				Raymond, GJ; Hope, J; Kocisko, DA; Priola, SA; Raymond, LD; Bossers, A; Ironside, J; Will, RG; Chen, SG; Petersen, RB; Gambetti, P; Rubenstein, R; Smits, MA; Lansbury, PT; Caughey, B			Molecular assessment of the potential transmissibilities of BSE and scrapie to humans	NATURE			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; PRION PROTEIN; SHEEP; GENOTYPE; FIBRILS; DISEASE; CATTLE; MICE; PRP	More than a million cattle infected with bovine spongiform encephalopathy (BSE) may have entered the human food chain(1). Fears that BSE might transmit to man were raised when atypical cases of Creutzfeldt-Jakob disease (CJD), a human transmissible spongiform encephalopathy (TSE), emerged in the UK2,3. I, BSE and other TSE diseases, the conversion of the protease-sensitive host prion protein (PrP-sen) to a protease-resistant isoform (PrP-res) is an important event in pathogenesis(4-7). Biological aspects of TSE diseases are reflected in the specificities of in vitro PrP conversion reactions(8-12). Here we show that there is a correlation between in vitro conversion efficiencies and known transmissibilities of BSE, sheep scrapie and CJD. On this basis, we used an in vitro system to gauge the potential transmissibility of scrapie and BSE to humans. We found Limited conversion of human PrP-sen to PrP-res driven by PrP-res associated with both scrapie (PrPSc) and BSE (prp(BSE)). The efficiencies of these heterologous conversion reactions were similar but much lower than those of relevant homologous conversions. Thus the inherent ability of these infectious agents of BSE and scrapie to affect humans following equivalent exposure may be finite but similarly low.	BBSRC,INST ANIM HLTH,COMPTON LAB,NEWBURY RG20 7NN,BERKS,ENGLAND; NIAID,ROCKY MT LABS,NIH,HAMILTON,MT 59840; MIT,DEPT CHEM,CAMBRIDGE,MA 02139; DLO,INST ANIM SCI & HLTH,DEPT BACTERIOL,NL-8200 AB LELYSTAD,NETHERLANDS; WESTERN GEN HOSP,CJD SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106; NEW YORK STATE INST BASIC RES DEV DISABIL,NEW YORK,NY 10314; HARVARD UNIV,SCH MED,BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Pirbright Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Massachusetts Institute of Technology (MIT); University of Edinburgh; Case Western Reserve University; Institute for Basic Research in Developmental Disabilities; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Petersen, Robert/B-5075-2011; Bossers, Alex/AAA-6025-2021; smits, mari/J-4892-2013; Chen, Shu/Z-2943-2019; Bossers, Alex/F-7757-2019; Chen, Shu G./O-4750-2014; Chen, Shu G./AAK-7301-2021; Hope, James/C-4966-2011	Petersen, Robert/0000-0002-3154-0072; Bossers, Alex/0000-0002-6586-717X; smits, mari/0000-0002-3493-291X; Bossers, Alex/0000-0002-6586-717X; Chen, Shu G./0000-0001-7180-3001; Chen, Shu G./0000-0001-7180-3001; Ironside, James/0000-0001-5869-2108				Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; Bessen RA, 1997, J BIOL CHEM, V272, P15227, DOI 10.1074/jbc.272.24.15227; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Bossers A, 1997, P NATL ACAD SCI USA, V94, P4931, DOI 10.1073/pnas.94.10.4931; Caughey B, 1997, J VIROL, V71, P4107, DOI 10.1128/JVI.71.5.4107-4110.1997; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CAUGHEY B, 1996, PRION DIS, P285; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; DAWSON M, 1990, VET REC, V126, P112; FOSTER JD, 1993, VET REC, V133, P339, DOI 10.1136/vr.133.14.339; FRASER H, 1988, VET REC, V123, P472, DOI 10.1136/vr.123.18.472; GOLDMANN W, 1994, J GEN VIROL, V75, P989, DOI 10.1099/0022-1317-75-5-989; HOPE J, 1988, NATURE, V336, P390, DOI 10.1038/336390a0; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; RICK R, 1996, NATURE, V382, P180; VANKEULEN LJM, 1995, VET PATHOL, V32, P299, DOI 10.1177/030098589503200312; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	26	221	234	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					285	288		10.1038/40876	http://dx.doi.org/10.1038/40876			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230438				2022-12-24	WOS:A1997XL12100053
J	Corazza, GR; Biagi, F; Volta, U; Andreani, ML; DeFranceschi, L; Gasbarrini, G				Corazza, GR; Biagi, F; Volta, U; Andreani, ML; DeFranceschi, L; Gasbarrini, G			Autoimmune enteropathy and villous atrophy in adults	LANCET			English	Article							EPITHELIAL-CELL AUTOANTIBODIES; SMALL-INTESTINE; CELIAC-DISEASE; PROTRACTED DIARRHEA; SPRUE; ANTIBODY; PATHOGENESIS; JEJUNUM; INFANCY	Background Autoimmune enteropathy is a condition described in children and characterised by villous atrophy, which is unresponsive to any dietary restrictions, and by the presence of enterocyte autoantibodies. We report two adult patients who fulfilled all the criteria for the diagnosis of this disorder. Methods Over the past 5 years we have seen four adult patients (all women, median age 51.5 [range 38-64] years) with subtotal villous atrophy, which was unresponsive to a gluten-free diet. The patients were HLA-DQ2 positive. IgA antigliadin and antiendomysial antibodies were not found in any of the patients. We did an indirect immunofluorescence search for enterocyte autoantibodies on monkey jejunum and for other autoantibodies for all four patients. Findings Of the four patients, two were positive for enterocyte autoantibodies and one of these two patients was positive for antiactin, antiparietal cell, and antithyroid microsomal autoantibodies. Interpretation To the best of our knowledge the two patients affected by severe enteropathy, who had never responded to any exclusion diet, and who were positive for enterocyte autoantibodies are the first cases of autoimmune enteropathy described in adults. We propose that adult patients whose disorders are unresponsive to a gluten-free diet should be tested for enterocyte autoantibodies.	UNIV BOLOGNA, DEPT INTERNAL MED, BOLOGNA, ITALY; CATHOLIC UNIV ROME, DEPT INTERNAL MED, ROME, ITALY	University of Bologna; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Corazza, GR (corresponding author), UNIV AQUILA, DEPT INTERNAL MED, VIA S SISTO 22E, I-67100 LAQUILA, ITALY.		Corazza, Gino Roberto/K-8500-2016; Biagi, Federico/G-2812-2011	Corazza, Gino Roberto/0000-0001-9532-0573; Biagi, Federico/0000-0002-2227-4622; De Franceschi, Lucia/0000-0003-1257-8101; Volta, Umberto/0000-0003-3405-3808				BOTTAZZO GF, 1986, IMMUNOL REV, V94, P137, DOI 10.1111/j.1600-065X.1986.tb01168.x; CATASSI C, 1988, J PEDIATR GASTR NUTR, V7, P608, DOI 10.1097/00005176-198807000-00022; CHORZELSKI TP, 1984, BRIT J DERMATOL, V111, P395, DOI 10.1111/j.1365-2133.1984.tb06601.x; CORAZZA GR, 1995, SCAND J GASTROENTERO, V30, P153, DOI 10.3109/00365529509093254; CORAZZA GR, 1985, J CLIN PATHOL, V38, P765, DOI 10.1136/jcp.38.7.765; CUENOD B, 1990, GASTROENTEROLOGY, V99, P1037, DOI 10.1016/0016-5085(90)90624-A; FERGUSON A, 1977, GUT, V18, P921, DOI 10.1136/gut.18.11.921; KATZ AJ, 1979, GASTROENTEROLOGY, V76, P375; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MARTINVILLA JM, 1991, GASTROENTEROLOGY, V101, P390, DOI 10.1016/0016-5085(91)90016-E; MARTINVILLA JM, 1993, LANCET, V342, P380, DOI 10.1016/0140-6736(93)91531-P; MCCARTHY DM, 1978, J IMMUNOL, V120, P932; MIRAKIAN R, 1986, BRIT MED J, V293, P1132, DOI 10.1136/bmj.293.6555.1132; MIRAKIAN R, 1988, J AUTOIMMUN, V1, P263, DOI 10.1016/0896-8411(88)90032-7; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; RUBIN CE, 1970, GASTROENTEROLOGY, V58, P409; SAVILAHTI E, 1985, ACTA PAEDIATR SCAND, V74, P472, DOI 10.1111/j.1651-2227.1985.tb11011.x; TRIER JS, 1978, GASTROENTEROLOGY, V75, P307; TRIER JS, 1991, NEW ENGL J MED, V325, P1709, DOI 10.1056/NEJM199112123252406; UNSWORTH DJ, 1985, J PEDIATR GASTR NUTR, V4, P375, DOI 10.1097/00005176-198506000-00009; VOLTA U, 1985, GUT, V26, P667, DOI 10.1136/gut.26.7.667; WALKERSMITH JA, 1982, LANCET, V1, P566; WALKERSMITH JA, 1991, DEV GASTRO, V13, P131; WALL AJ, 1970, GUT, V11, P7, DOI 10.1136/gut.11.1.7	24	105	111	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					106	109		10.1016/S0140-6736(97)01042-8	http://dx.doi.org/10.1016/S0140-6736(97)01042-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228963				2022-12-24	WOS:A1997XK11400011
J	Carstea, ED; Morris, JA; Coleman, KG; Loftus, SK; Zhang, D; Cummings, C; Gu, J; Rosenfeld, MA; Pavan, WJ; Krizman, DB; Nagle, J; Polymeropoulos, MH; Sturley, SL; Ioannou, YA; Higgins, ME; Comly, M; Cooney, A; Brown, A; Kaneski, CR; BlanchetteMackie, EJ; Dwyer, NK; Neufeld, EB; Chang, TY; Liscum, L; Strauss, JF; Ohno, K; Zeigler, M; Carmi, R; Sokol, J; Markie, D; ONeill, RR; vanDiggelen, OP; Elleder, M; Patterson, MC; Brady, RO; Vanier, MT; Pentchev, PG; Tagle, DA				Carstea, ED; Morris, JA; Coleman, KG; Loftus, SK; Zhang, D; Cummings, C; Gu, J; Rosenfeld, MA; Pavan, WJ; Krizman, DB; Nagle, J; Polymeropoulos, MH; Sturley, SL; Ioannou, YA; Higgins, ME; Comly, M; Cooney, A; Brown, A; Kaneski, CR; BlanchetteMackie, EJ; Dwyer, NK; Neufeld, EB; Chang, TY; Liscum, L; Strauss, JF; Ohno, K; Zeigler, M; Carmi, R; Sokol, J; Markie, D; ONeill, RR; vanDiggelen, OP; Elleder, M; Patterson, MC; Brady, RO; Vanier, MT; Pentchev, PG; Tagle, DA			Niemann-Pick C1 disease gene: Homology to mediators of cholesterol homeostasis	SCIENCE			English	Article							LOW-DENSITY LIPOPROTEIN; NIEMANN-PICK DISEASE; DI-LEUCINE MOTIF; CULTURED FIBROBLASTS; STORAGE; ENDOCYTOSIS; LYSOSOMES; SITES	Niemann-Pick type C (NP-C) disease, a fatal neurovisceral disorder, is characterized by lysosomal accumulation of low density lipoprotein (LDL)-derived cholesterol. BY positional cloning methods, a gene (NPC1) with insertion, deletion, and missense mutations has been identified in NP-C patients. Transfection of NP-C fibroblasts with wild-type NPC1 cDNA resulted in correction of their excessive lysosomal storage of LDL cholesterol, thereby defining the critical role of NPC1 in regulation of intracellular cholesterol trafficking. The 1278-amino acid NPC1 protein has sequence similarity to the morphogen receptor PATCHED and the putative sterol-sensing regions of SREBP cleavage-activating protein (SCAP) and 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase.	NINCDS,NIH,BETHESDA,MD 20892; NIH,NATL HUMAN GENOME RES INST,BETHESDA,MD 20892; COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032; CUNY MT SINAI SCH MED,NEW YORK,NY 10029; NIDDKD,NIH,BETHESDA,MD 20892; DARTMOUTH COLL,SCH MED,HANOVER,NH 03755; TUFTS UNIV,SCH MED,BOSTON,MA 02111; UNIV PENN,PHILADELPHIA,PA 19104; HADASSAH UNIV HOSP,IL-91120 JERUSALEM,ISRAEL; BEN GURION UNIV NEGEV,IL-84105 BEER SHEVA,ISRAEL; HILLEL YAFFE MED CTR,HADERA,ISRAEL; DUNEDIN SCH MED,DUNEDIN,NEW ZEALAND; ERASMUS UNIV ROTTERDAM,ROTTERDAM,NETHERLANDS; FAC MED,PRAGUE,CZECH REPUBLIC; UNIV HOSP,PRAGUE,CZECH REPUBLIC; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905; INSERM,U189,OULLINS,FRANCE; TOTTORI UNIV,FAC MED,YONAGO,TOTTORI 683,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Dartmouth College; Tufts University; University of Pennsylvania; Hebrew University of Jerusalem; Ben Gurion University; University of Otago; Erasmus University Rotterdam; General University Hospital Prague; Mayo Clinic; Institut National de la Sante et de la Recherche Medicale (Inserm); Tottori University			Neufeld, Edward/R-3819-2019; Patterson, Marc/AAI-5056-2020; Patterson, Marc C./H-5331-2019; Markie, David/I-7893-2019	Kaneski, Christine/0000-0003-1453-2502; Patterson, Marc/0000-0002-1116-126X; Markie, David/0000-0001-5452-9194; Pavan, William/0000-0001-8281-5120; Chang, Ta-Yuan/0000-0002-3249-0468; Loftus, Stacie/0000-0002-1958-4689				BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CARSTEA ED, 1993, P NATL ACAD SCI USA, V90, P2002, DOI 10.1073/pnas.90.5.2002; CARSTEA ED, UNPUB; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P8487; GU JZ, IN PRESS P NATL ACAD; Hofmann K., 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; Krizman D B, 1997, Methods Mol Biol, V68, P167; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LISCUM L, 1987, J BIOL CHEM, V262, P17002; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; ORTGATA S, 1994, J BIOL CHEM, V269, P5210; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Vanier MT, 1996, AM J HUM GENET, V58, P118; WANG X, 1994, CELL, V77, P52	30	1131	1174	2	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					228	231		10.1126/science.277.5323.228	http://dx.doi.org/10.1126/science.277.5323.228			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211849	Green Submitted			2022-12-24	WOS:A1997XK41800042
J	Nowak, MA; Boerlijst, MC; Cooke, J; Smith, JM				Nowak, MA; Boerlijst, MC; Cooke, J; Smith, JM			Evolution of genetic redundancy	NATURE			English	Article							PROTEIN-TYROSINE KINASES; DUPLICATE LOCI; MICE; TENASCIN; DEVELOP	Genetic redundancy means that two or more genes are performing the same function and that inactivation of one of these genes has little or no effect on the biological phenotype. Redundancy seems to be widespread in genomes of higher organisms(1-9). Examples of apparently redundant genes come from numerous studies of developmental biology(10-15), immunology(16,17), neurobiology(18,19) and the cell cycle(20,21). Yet there is a problem: genes encoding functional proteins must be under selection pressure, If a gene was truly redundant then it would not be protected against the accumulation of deleterious mutations. A widespread view is therefore that such redundancy cannot be evolutionarily stable. Here we develop a simple genetic model to analyse selection pressures acting on redundant genes. We present four cases that can explain why genetic redundancy is common, In three cases, redundancy is even evolutionarily stable. Our theory provides a framework for exploring the evolution of genetic organization.	NATL INST MED RES,RIDGEWAY,LONDON NW7 1AA,ENGLAND; UNIV SUSSEX,SCH BIOL SCI,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND	University of Sussex	Nowak, MA (corresponding author), UNIV OXFORD,DEPT ZOOL,S PARKS RD,OXFORD OX1 3PS,ENGLAND.		Nowak, Martin A/A-6977-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLENDORF FW, 1978, NATURE, V272, P76, DOI 10.1038/272076a0; BAILEY GS, 1978, P NATL ACAD SCI USA, V75, P5575, DOI 10.1073/pnas.75.11.5575; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; Brookfield JFY, 1997, ADV GENET, V36, P137, DOI 10.1016/S0065-2660(08)60308-9; Brookfield John, 1992, Current Biology, V2, P553, DOI 10.1016/0960-9822(92)90036-A; CHRISTIANSEN FB, 1977, AM J HUM GENET, V29, P195; DOVER GA, 1993, CURR OPIN GENET DEV, V3, P902, DOI 10.1016/0959-437X(93)90012-E; Fisher RA, 1935, AM NAT, V69, P446, DOI 10.1086/280618; GOLDSTEIN DB, 1992, EVOLUTION, V46, P412, DOI [10.2307/2409861, 10.1111/j.1558-5646.1992.tb02048.x]; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KIMURA M, 1979, P NATL ACAD SCI USA, V76, P2858, DOI 10.1073/pnas.76.6.2858; Krakauer DC, 1996, PHILOS T ROY SOC B, V351, P647, DOI 10.1098/rstb.1996.0062; Laney JD, 1996, DEVELOPMENT, V122, P2303; LI WH, 1980, GENETICS, V95, P237; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; OBRIEN SJ, 1973, NATURE-NEW BIOL, V242, P52, DOI 10.1038/newbio242052a0; OHTA T, 1989, GENETICS, V123, P579; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; PICKETT FB, 1995, PLANT CELL, V7, P1347, DOI 10.1105/tpc.7.9.1347; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; STEINDLER DA, 1995, J NEUROSCI, V15, P1971, DOI 10.1523/JNEUROSCI.15-03-01971.1995; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TAUTZ D, 1992, BIOESSAYS, V14, P263, DOI 10.1002/bies.950140410; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; YANG Y, 1996, NATURE, V379, P823	30	497	510	0	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					167	171		10.1038/40618	http://dx.doi.org/10.1038/40618			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217155	Bronze			2022-12-24	WOS:A1997XK10900048
J	Vignes, M; Collingridge, GL				Vignes, M; Collingridge, GL			The synaptic activation of kainate receptors	NATURE			English	Article							LONG-TERM POTENTIATION; GLUTAMATE RECEPTORS; HIPPOCAMPAL-NEURONS; NERVOUS-SYSTEM; EXPRESSION; SUBUNIT; CLONING; CELLS; AMPA; CYCLOTHIAZIDE	L-Glutamate, the principal excitatory neurotransmitter in the vertebrate central nervous system, acts on three classes of ionotropic glutamate receptors, named after the agonists AMPA, NMDA and kainate(1). AMPA receptors are known to mediate fast synaptic responses and NMDA receptors to mediate slow synaptic responses at most excitatory synapses in the brain(2). Kainate receptors are formed from a separate set of genes (GluR5-7, KA-1 and KA-2) and are widely distributed throughout the brain(3-8). They are implicated in epileptogenesis and cell death(9). However, the physiological functions of kainate receptors are not known. The development of 2,3-benzodiazepine antagonists that are selective for AMPA receptors(10) enables kainate receptors to be specifically activated by exogenous ligands, such as kainate(11-16). Here we demonstrate that high-frequency stimulation of messy fibres in rat hippocampal slices, in the presence of the highly selective AMPA receptor antagonist GYKI 53655 (refs 13-15) plus NMDA- and GABA-receptor antagonists, activates an inward current in CA3 neurons that has a pharmacology typical of kainate receptors. The finding that kainate receptors can be activated synaptically adds to the diversity of information transfer at glutamatergic synapses.	UNIV BRISTOL, SCH MED SCI, DEPT ANAT, BRISTOL BS8 1TD, AVON, ENGLAND	University of Bristol			Collingridge, Graham L/C-4605-2015; collingridge, graham/AAI-8362-2020; Vignes, Michel/AAA-7693-2019	Collingridge, Graham L/0000-0002-9572-5359; Vignes, Michel/0000-0003-0969-2966				BAHN S, 1994, J NEUROSCI, V14, P5525; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FELDMEYER D, 1994, CURR BIOL, V4, P82, DOI 10.1016/S0960-9822(00)00021-X; Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Miller LDP, 1995, J NEUROSCI, V15, P8320; MONAGHAN DT, 1985, BRAIN RES, V340, P378, DOI 10.1016/0006-8993(85)90936-9; PALMER AJ, 1993, EUR J PHARM-MOLEC PH, V244, P193, DOI 10.1016/0922-4106(93)90027-7; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; Rammes G, 1996, BRIT J PHARMACOL, V117, P1209, DOI 10.1111/j.1476-5381.1996.tb16718.x; RENARD A, 1995, NEUROPHARMACOLOGY, V34, P335, DOI 10.1016/0028-3908(94)00165-O; ROBINSON JH, 1981, BRAIN RES, V221, P117, DOI 10.1016/0006-8993(81)91067-2; ROCHE KW, 1995, NEUROSCIENCE, V69, P383, DOI 10.1016/0306-4522(95)00253-F; RUANO D, 1995, NEURON, V14, P1009, DOI 10.1016/0896-6273(95)90339-9; Salin PA, 1996, P NATL ACAD SCI USA, V93, P13304, DOI 10.1073/pnas.93.23.13304; TARNAWA I, 1990, AMINO ACIDS CHEM BIO, P538; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WESTBROOK GL, 1983, BRAIN RES, V273, P97, DOI 10.1016/0006-8993(83)91098-3; WILDING TJ, 1995, MOL PHARMACOL, V47, P582; WONG LA, 1993, MOL PHARMACOL, V44, P504; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	30	353	358	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 10	1997	388	6638					179	182		10.1038/40639	http://dx.doi.org/10.1038/40639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217158	Bronze			2022-12-24	WOS:A1997XK10900051
J	Helbing, D; Keltsch, J; Molnar, P				Helbing, D; Keltsch, J; Molnar, P			Modelling the evolution of human trail systems	NATURE			English	Article							ACTIVE WALKER MODELS; GROWTH-PATTERNS	Many human social phenomena, such as cooperation(1-3), the growth of settlements(4), traffic dynamics(5-7) and pedestrian movement(7-10), appear to be accessible to mathematical descriptions that invoke self-organization(11,12). Here we develop a model of pedestrian motion to explore the evolution of trails in urban green spaces such as parks. Our aim is to address such questions as what the topological structures of these trail systems are(13), and whether optimal path systems can be predicted for urban planning. We use an 'active walker' model(14-19) that takes into account pedestrian motion and orientation and the concomitant feedbacks with the surrounding environment. Such models have previously been applied to the study of complex structure formation in physical(14-16), chemical(17) and biological(18,19) systems. We find that our model is able to reproduce many of the observed large-scale spatial features of trail systems.	SCI COMP,D-72070 TUBINGEN,GERMANY; CLARK ATLANTA UNIV,CTR THEORET STUDIES PHYS SYST,ATLANTA,GA 30314	Clark Atlanta University	Helbing, D (corresponding author), UNIV STUTTGART,INST THEORET PHYS,PFAFFENWALDRING 57-3,D-70550 STUTTGART,GERMANY.		Helbing, Dirk/C-6114-2008					AXELROD R, 1988, SCIENCE, V242, P1385, DOI 10.1126/science.242.4884.1385; BENJACOB E, 1994, NATURE, V368, P46, DOI 10.1038/368046a0; CLEARWATER SH, 1991, SCIENCE, V254, P1181, DOI 10.1126/science.254.5035.1181; Eigen M, 1979, HYPERCYCLE; Feistel R, 1989, EVOLUTION COMPLEX SY; HAKEN H, 1987, ADV SYNERGETICS; HELBING D, 1995, PHYS REV E, V51, P4282, DOI 10.1103/PhysRevE.51.4282; Helbing D., 1995, QUANTITATIVE SOCIODY; Helbing D., 1997, VERKEHRSDYNAMIK NEUE; HENDERSON LF, 1971, NATURE, V229, P381, DOI 10.1038/229381a0; HENDERSON LF, 1972, NATURE, V240, P353, DOI 10.1038/240353a0; HERMAN R, 1979, SCIENCE, V204, P148, DOI 10.1126/science.204.4389.148; HERMAN R, 1973, SCIENCE, V179, P918, DOI 10.1126/science.179.4076.918; Hillier B., 1996, SPACE MACHINE CONFIG; KAYSER DR, 1992, PHYSICA A, V191, P17, DOI 10.1016/0378-4371(92)90499-G; LAM L, 1995, CHAOS SOLITON FRACT, V6, P267, DOI 10.1016/0960-0779(95)80033-D; MAKSE HA, 1995, NATURE, V377, P608, DOI 10.1038/377608a0; Nicolis G., 1977, SELF ORG NONEQUILIBR; SCHENK M, 1995, THESIS U STUTTGART; SCHIMANSKYGEIER L, 1995, PHYS LETT A, V207, P140, DOI 10.1016/0375-9601(95)00700-D; SCHWEITZER F, 1994, PHYSICA A, V206, P359, DOI 10.1016/0378-4371(94)90312-3; Stevens A, 1997, MATH BIOSCI INTERAC, P183; TIMMERMANS H, 1992, TRANSPORT RES B-METH, V26, P45, DOI 10.1016/0191-2615(92)90019-S	23	237	252	6	85	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					47	50		10.1038/40353	http://dx.doi.org/10.1038/40353			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214501	Green Submitted, Bronze			2022-12-24	WOS:A1997XJ14300044
J	Bangsberg, D; Tulsky, JP; Hecht, FM; Moss, AR				Bangsberg, D; Tulsky, JP; Hecht, FM; Moss, AR			Protease inhibitors in the homeless	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; TUBERCULOSIS; COMMUNITY; RISK; RESISTANT; ADULTS; HIV; PREVALENCE; MANAGEMENT		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,AIDS RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Hecht, Frederick/0000-0002-5782-1171	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55729] Funding Source: Medline; NIMH NIH HHS [MH54907, R01 MH054907] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ASHE J, 1996, SAN FRANCISCO DEATH; *BHIVA GUID COORD, 1997, LANCET, V349, P1086; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BUSH CT, 1990, HOSP COMMUNITY PSYCH, V41, P647; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P151; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONLON CP, 1994, J INFECT DIS, V169, P411, DOI 10.1093/infdis/169.2.411; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DIEHR P, 1989, MED CARE, V27, P942, DOI 10.1097/00005650-198910000-00005; ElSadr W, 1996, AM J PUBLIC HEALTH, V86, P1146, DOI 10.2105/AJPH.86.8_Pt_1.1146; Fournier AM, 1996, AM J MED, V100, P582, DOI 10.1016/S0002-9343(95)00019-4; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P329; Gerberding JL, 1996, ANN INTERN MED, V125, P497, DOI 10.7326/0003-4819-125-6-199609150-00011; HANZLICK R, 1993, PUBLIC HEALTH REP, V108, P488; Havlir DV, 1996, ANN INTERN MED, V124, P984, DOI 10.7326/0003-4819-124-11-199606010-00006; HIBBS JR, 1994, NEW ENGL J MED, V331, P304, DOI 10.1056/NEJM199408043310506; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; LELAND J, 1996, NEWSWEEK        1202, P65; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; POWE NR, 1992, JAMA-J AM MED ASSOC, V268, P1434, DOI 10.1001/jama.268.11.1434; SARAVOLATZ LD, 1982, ANN INTERN MED, V96, P11, DOI 10.7326/0003-4819-96-1-11; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; Sontag Deborah, 1997, N Y Times Web, pB6; Stansell JD, 1997, AM J RESP CRIT CARE, V155, P60, DOI 10.1164/ajrccm.155.1.9001290; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; Susser E, 1997, AM J PUBLIC HEALTH, V87, P256, DOI 10.2105/AJPH.87.2.256; THOMAS SB, 1991, AM J PUBLIC HEALTH, V81, P1498, DOI 10.2105/AJPH.81.11.1498; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; WALDMAN A, 1997, WASHINGTON POST 0427, pCO1; Wilfert CM, 1996, CLIN INFECT DIS, V23, P438, DOI 10.1093/clinids/23.3.438; ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455	37	117	122	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					63	65		10.1001/jama.278.1.63	http://dx.doi.org/10.1001/jama.278.1.63			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XG387	9207341				2022-12-24	WOS:A1997XG38700039
J	Xu, XZS; Li, HS; Guggino, WB; Montell, C				Xu, XZS; Li, HS; Guggino, WB; Montell, C			Coassembly of TRP and TRPL produces a distinct store-operated conductance	CELL			English	Article							CAPACITATIVE CALCIUM-ENTRY; LIGHT-SENSITIVE CHANNELS; DROSOPHILA TRP; PLASMA-MEMBRANE; HUMAN HOMOLOG; K+ CHANNEL; T-CELLS; GENE; PHOTOTRANSDUCTION; PHOTORECEPTORS	The Drosophila retinal-specific protein, TRP (transient receptor potential), is the founding member of a family of store-operated channels (SOCs) conserved from C. elegans to humans. In vitro studies indicate that TRP is a SOC, but that the related retinal protein, TRPL, is constitutively active. In the current work, we report that coexpression of TRP and TRPL leads to a store-operated, outwardly rectifying current distinct from that owing to either TRP or TRPL alone. TRP and TRPL interact directly, indicating that the TRP-TRPL-dependent current is mediated by heteromultimeric association between the two subunits. We propose that the light-activated current in photoreceptor cells is produced by a combination of TRP homo- and TRP-TRPL heteromultimers.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University	Xu, XZS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.		Montell, Craig/AAH-3357-2021	Montell, Craig/0000-0001-5637-1482	NEI NIH HHS [EY10852] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010852] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arnon A, 1997, SCIENCE, V275, P1119, DOI 10.1126/science.275.5303.1119; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hardie RC, 1995, J NEUROPHYSIOL, V74, P2590, DOI 10.1152/jn.1995.74.6.2590; HARDIE RC, 1994, J GEN PHYSIOL, V103, P409, DOI 10.1085/jgp.103.3.409; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; Huber A, 1996, J BIOL CHEM, V271, P11710, DOI 10.1074/jbc.271.20.11710; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Krause E, 1996, J BIOL CHEM, V271, P32523, DOI 10.1074/jbc.271.51.32523; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; Minke B, 1996, MOL NEUROBIOL, V12, P163, DOI 10.1007/BF02740652; MONTELL C, 1985, SCIENCE, V230, P1040, DOI 10.1126/science.3933112; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P695, DOI 10.1113/jphysiol.1988.sp016942; NEHER E, 1992, ION CHANNELS, P123; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Sinkins W. G., 1997, Biophysical Journal, V72, pA271; SUSSTOBY E, 1991, J GEN PHYSIOL, V98, P848; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; WONG F, 1989, NEURON, V3, P81, DOI 10.1016/0896-6273(89)90117-7; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209	50	263	280	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1155	1164		10.1016/S0092-8674(00)80302-5	http://dx.doi.org/10.1016/S0092-8674(00)80302-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215637	hybrid			2022-12-24	WOS:A1997XG83000019
J	Vitek, CR; Redd, SC; Redd, SB; Hadler, SC				Vitek, CR; Redd, SC; Redd, SB; Hadler, SC			Trends in importation of measles to the United States, 1986-1994	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPORTING EFFICIENCY	Objectives.-To describe patterns among imported measles cases to the United States. Design.-Descriptive analysis of national case-based surveillance data on measles cases. Setting.-United States in the period 1986 through 1994. Patients.-All reported confirmed cases of measles. Main Outcome Measures.-Demographic variables, immunization history, country of exposure, and reporting state. Results.-The number of reported imported cases of measles to the United States has dropped from an average of 99 cases annually in 1986 through 1988 and 190 cases in 1989 through 1991 to 61 cases in 1992 through 1994. Since 1990, the number of imported cases originating in Latin America declined by 98%, despite continued increase in the number of travelers to this region; cases from other regions remained relatively constant. This decrease paralleled the rapid decrease in measles incidence in the Western Hemisphere associated with national measles elimination programs. Most imported cases occurred among children, although 22% of cases occurred among young adults. Rates of measles cases per 1 million travelers are higher among non-US citizens than among US citizens. Conclusions.-The sharp decline in importations into the United States from Latin America since 1991 provides evidence of the success of measles control efforts undertaken there. The decrease in imported cases has been associated with a decline in total measles cases in the United States. Sustained elimination of measles in the United States will require improved measles control in other countries in addition to a high level of population immunity.			Vitek, CR (corresponding author), CTR DIS CONTROL & PREVENT,NATL IMMUNIZAT PROGRAM,EPIDEMIOL & SURVEILLANCE DIV,MAILSTOP E-61,ATLANTA,GA 30333, USA.							[Anonymous], 1990, MMWR Recomm Rep, V39, P1; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P57; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P925; *CDCP, 1978, MMWR-MORBID MORTAL W, V27, P391; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P486; CONRAD JL, 1971, AM J PUBLIC HEALTH N, V61, P2304, DOI 10.2105/AJPH.61.11.2304; DAVIS SF, 1993, AM J PUBLIC HEALTH, V83, P1011, DOI 10.2105/AJPH.83.7.1011; deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224; EWERT DP, 1994, AM J PUBLIC HEALTH, V84, P868, DOI 10.2105/AJPH.84.5.868-a; HERSH BS, 1992, JAMA-J AM MED ASSOC, V267, P1936, DOI 10.1001/jama.267.14.1936; *OFF RES US TRAV T, 1994, ABSTR INT TRAV US 19; Rota JS, 1996, J INFECT DIS, V173, P32, DOI 10.1093/infdis/173.1.32; *US IMM NAT SERV, 1996, STAT YB IMM NAT SERV; World Health Organization, 1995, WHO PUBL; 1989, MMWR MORB MORTAL S9, V38, P1; 1996, WKLY EPIDEMIOL REC, V71, P305	16	23	23	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1952	1956						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XF087	9200636				2022-12-24	WOS:A1997XF08700040
J	Iyo, M; Namba, H; Fukushi, K; Shinotoh, H; Nagatsuka, S; Suhara, T; Sudo, Y; Suzuki, K; Irie, T				Iyo, M; Namba, H; Fukushi, K; Shinotoh, H; Nagatsuka, S; Suhara, T; Sudo, Y; Suzuki, K; Irie, T			Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease	LANCET			English	Article							COMPUTED-TOMOGRAPHY; IN-VIVO; DEMENTIA; DEFICITS; RECEPTORS; SEVERITY	Background Acetylcholinesterase activity, a marker for degeneration of the central cholinergic system, has consistently been reported, in necropsy brain studies, to be reduced in the cerebral cortex of patients with Alzheimer's disease. We have shown regional acetylcholinesterase activity in vivo in rodent and primate brains with radioactive acetylcholine analogues. In the present study, we used one of the analogues to map acetylcholinesterase activity in the brains of living people. Methods Positron emission tomography (PET) and a radiolabelled acetylcholine analogue with high hydrolytic specificity to acetylcholinesterase [C-11]N-methyl-4-piperidyl acetate (MP4A), was used in eight elderly healthy controls and five patients with Alzheimer's disease who had mild dementia. All participants were given an intravenous injection of [C-11]MP4A and then sequential patterns of radioactivity in various brain regions were obtained by PET. Time courses of [C-11]MP4A concentration in arterial blood were also measured to obtain an input function. A three-compartment model was used to estimate regional acetylcholinesterase activity in the brain. Findings The estimated acetylcholinesterase distribution in the brain of the control participants agreed with the acetylcholinesterase distribution at necropsy. All patients with Alzheimer's disease had multiple cortical regions with a reduced estimated acetylcholinesterase activity in comparison with control participants. The reduction was more pronounced in the parietotemporal cortex, with an average reduction rate of 31% in temporal and 38% in parietal cortex, and less pronounced in other cortical lesions (19% in frontal, 24% in occipital, and 20% in sensorimotor cortex), Each patient was found to have at least two cortical regions with significantly reduced acetylcholinesterase activity. Interpretation The method we describe for non-invasive in-vivo detection of regional acetylcholinesterase changes in the living human brain that is feasible for biochemical assessment of Alzheimer's disease.	NATL INST RADIOL SCI,DIV CLIN RES,INAGE KU,CHIBA 263,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST MENTAL HLTH,CHIBA,JAPAN; CHIBA CANC CTR HOSP,DIV NEUROL SURG,CHIBA,JAPAN; CHIBA UNIV,SCH MED,DEPT NEUROL,CHIBA 280,JAPAN; DAIICHI PURE CHEM CO LTD,TOKAI RES LABS,IBARAKI,OSAKA,JAPAN	National Institutes for Quantum Science & Technology; National Center for Neurology & Psychiatry - Japan; Chiba Cancer Center; Chiba University; Sekisui Chemical Co Ltd								Arai H, 1984, Rinsho Shinkeigaku, V24, P1128; ATACK JR, 1986, J NEUROCHEM, V47, P263; BIERER LM, 1995, J NEUROCHEM, V64, P749; CARLSSON A, 1987, GERONTOLOGY, V33, P159, DOI 10.1159/000212870; DAVIES P, 1976, LANCET, V2, P1403; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DEWEY SL, 1990, SYNAPSE, V5, P213, DOI 10.1002/syn.890050307; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOTTFRIES CG, 1985, PSYCHOPHARMACOLOGY, V86, P245, DOI 10.1007/BF00432208; HAMBA H, 1996, ANN NUCL MED, V10, P161; HANSEN LA, 1988, NEUROLOGY, V38, P48, DOI 10.1212/WNL.38.1.48; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Irie T, 1996, J NUCL MED, V37, P649; IRIE T, 1994, NUCL MED BIOL, V21, P801, DOI 10.1016/0969-8051(94)90159-7; JAGUST WJ, 1987, ARCH NEUROL-CHICAGO, V44, P258, DOI 10.1001/archneur.1987.00520150014011; JOHNSON KA, 1987, ARCH NEUROL-CHICAGO, V44, P165, DOI 10.1001/archneur.1987.00520140035014; LASSEN NA, 1988, J CEREBR BLOOD F MET, V8, pS13, DOI 10.1038/jcbfm.1988.28; MARTIN EM, 1987, NEUROLOGY, V37, P1201, DOI 10.1212/WNL.37.7.1201; MCKHANN G, 1984, NEUROLOGY, V35, P939; NAMBA H, 1994, BRAIN RES, V667, P278, DOI 10.1016/0006-8993(94)91507-5; Pappata S, 1996, J NEUROCHEM, V67, P876; PERRY EK, 1978, BRIT MED J, V2, P1427; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; SIMS NR, 1983, J NEUROCHEM, V40, P503, DOI 10.1111/j.1471-4159.1983.tb11311.x; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; WALDEMAR G, 1994, J NEUROL NEUROSUR PS, V57, P285, DOI 10.1136/jnnp.57.3.285; WEINBERGER DR, 1991, ARCH NEUROL-CHICAGO, V48, P169, DOI 10.1001/archneur.1991.00530140061018; WILCOCK GK, 1982, J NEUROL SCI, V57, P407, DOI 10.1016/0022-510X(82)90045-4	28	201	207	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1805	1809		10.1016/S0140-6736(96)09124-6	http://dx.doi.org/10.1016/S0140-6736(96)09124-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269216				2022-12-24	WOS:A1997XF73500012
J	Farr, GW; Scharl, EC; Schumacher, RJ; Sondek, S; Horwich, AL				Farr, GW; Scharl, EC; Schumacher, RJ; Sondek, S; Horwich, AL			Chaperonin-mediated folding in the eukaryotic cytosol proceeds through rounds of release of native and nonnative forms	CELL			English	Article							CYTOPLASMIC CHAPERONIN; BETA-ACTIN; G-PROTEIN; IN-VIVO; BINDING; ALPHA; TUBULIN; COMPLEX; TCP-1; EXTRACTS	The eukaryotic cytosolic chaperonin, CCT, plays an essential role in mediating ATP-dependent folding of actin and tubulin. There is debate about whether it mediates folding through a single round of association followed by release of native forms, or through cycles of binding and full release in which only a fraction of released molecules reaches native form in any cycle. We examine the fate of newly synthesized substrate proteins bound to CCT in reticulocyte lysate or intact Xenopus oocytes. When a chaperonin ''trap,'' able to bind but not release substrate protein, is introduced, production of the native state is strongly inhibited, associated with transfer to trap. While predominantly nonnative forms of actin, tubulin, and a newly identified substrate, G(alpha)-transducin, are released from CCT, a small fraction reaches native form with each round of release, inaccessible to trap. This overall mechanism resembles that of the bacterial chaperonin, GroEL.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University								Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; Fenton WA, 1997, PROTEIN SCI, V6, P743; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAO Y, 1994, J CELL BIOL, V125, P980; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LEVILLIERS N, 1984, BIOCHIMIE, V66, P531, DOI 10.1016/0300-9084(84)90147-0; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; MARCO S, 1994, BIOPHYS J, V67, P364, DOI 10.1016/S0006-3495(94)80489-8; Martin J, 1997, P NATL ACAD SCI USA, V94, P1107, DOI 10.1073/pnas.94.4.1107; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MAZZONI MR, 1989, BIOCHEMISTRY-US, V28, P9873, DOI 10.1021/bi00451a047; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Melki R, 1996, BIOCHEMISTRY-US, V35, P10422, DOI 10.1021/bi960788r; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; ROSENBLATT J, 1995, MOL BIOL CELL, V6, P227, DOI 10.1091/mbc.6.2.227; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; STERNLICHT H, 1979, J BIOL CHEM, V254, P540; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TIAN GL, 1995, J BIOL CHEM, V270, P23910, DOI 10.1074/jbc.270.41.23910; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YAFFE MB, 1988, J BIOL CHEM, V263, P16023; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	38	147	148	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					927	937		10.1016/S0092-8674(00)80278-0	http://dx.doi.org/10.1016/S0092-8674(00)80278-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200611	hybrid			2022-12-24	WOS:A1997XE35700013
J	Woo, KS; Robinson, JTC; Chook, P; Adams, MR; Yip, G; Mai, ZJ; Lam, CWK; Sorensen, KE; Deanfield, JE; Celermajer, DS				Woo, KS; Robinson, JTC; Chook, P; Adams, MR; Yip, G; Mai, ZJ; Lam, CWK; Sorensen, KE; Deanfield, JE; Celermajer, DS			Differences in the effect of cigarette smoking on endothelial function in Chinese and white adults	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTHY-YOUNG ADULTS; PASSIVE SMOKING; ATHEROSCLEROSIS; EPIDEMIOLOGY; DYSFUNCTION; DISEASE	Background: The prevalence of coronary artery disease in southern China is approximately one fifth that in ''westernized'' countries, even though approximately 70% of Chinese men smoke cigarettes and Chinese women have substantial passive exposure to cigarette smoke. Objectives: Endothelial dysfunction is an early event in atherosclerosis and occurs in young white active and passive smokers; we compared endothelial physiology in healthy young Chinese and white smokers and nonsmokers. Patients: 144 healthy adults who were 16 to 45 years of age: 72 Chinese persons in a village in southern China and 72 white persons in Australia and England who were matched for exposure to cigarette smoke. Each ethnic group comprised 36 controls (lifelong nonsmokers with no regular exposure to cigarette smoke; 16 men and 20 women) and 36 active or passive smokers (15 men and 21 women). Measurements: Arterial endothelial function was tested with high-resolution external vascular ultrasonography, and brachial artery diameter was measured at rest, after flow increase (which causes endothelium-dependent dilatation), and after administration of sublingual nitroglycerin (an endothelium-independent dilator). Results: Endothelium-dependent dilatation was similar in Chinese (7.9%) and white (8.4%) nonsmokers (P > 0.2). Among white persons, endothelium-dependent dilatation was lower in active or passive smokers (3.9%) than in nonsmokers (8.4%) (P < 0.001). Among Chinese persons, dilatation was not significantly lower in active or passive smokers (7.3%) than in nonsmokers (7.9%) (P > 0.2). Dilatation was higher in Chinese active or passive smokers (7.3%) than in white active or passive smokers (3.9%) (P < 0.001). Dilatation responses to nitroglycerin were similar in all groups (P = 0.17). Conclusion: Young Chinese adults have less evidence of arterial endothelial dysfunction than young white adults with similar direct or indirect exposure to cigarette smoke.	ROYAL PRINCE ALFRED HOSP, DEPT CARDIOL, CAMPERDOWN, NSW 2050, AUSTRALIA; PAN YU CTY HOSP, PAN YU, PEOPLES R CHINA; GREAT ORMOND ST HOSP CHILDREN, CARDIOTHORAC UNIT, LONDON WC1N 3JH, ENGLAND; HEART RES INST, SYDNEY, NSW, AUSTRALIA; CHINESE UNIV HONG KONG, HONG KONG, HONG KONG	University of Sydney; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Sydney; Heart Research Institute; Chinese University of Hong Kong			Deanfield, John E/C-5178-2008; YIP, Gabriel/A-8837-2008	YIP, Gabriel/0000-0002-3859-7194; Deanfield, John/0000-0001-8806-6052				Adams MR, 1996, J VASC INVEST, V2, P146; CELERMAJER DS, 1993, CIRCULATION, V88, P2149, DOI 10.1161/01.CIR.88.5.2149; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; Celermajer DS, 1996, NEW ENGL J MED, V334, P150, DOI 10.1056/NEJM199601183340303; Cook NC, 1996, J NUTR BIOCHEM, V7, P66, DOI 10.1016/0955-2863(95)00168-9; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; Heitzer T, 1996, CIRCULATION, V93, P1346, DOI 10.1161/01.CIR.93.7.1346; *HLTH BEN SMOK CES, 1990, 9084161917 DHHS CDC; HOLBROOK JH, 1984, CIRCULATION, V70, P1114; HONORE EK, 1995, CIRCULATION S1, V92, P1; PITTILO RM, 1984, BRIT J HAEMATOL, V58, P627, DOI 10.1111/j.1365-2141.1984.tb06109.x; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SORENSEN KE, 1995, BRIT HEART J, V74, P247; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; WENG XZ, 1988, CHINESE MED J-PEKING, V101, P371; WENG XZ, 1987, CHINESE MED J-PEKING, V100, P886; WOO KS, 1989, INT J CARDIOL, V24, P83, DOI 10.1016/0167-5273(89)90045-4	17	42	43	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1997	127	5					372	375		10.7326/0003-4819-127-5-199709010-00006	http://dx.doi.org/10.7326/0003-4819-127-5-199709010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU100	9273828				2022-12-24	WOS:A1997XU10000005
J	Fitzpatrick, DC; Batra, R; Stanford, TR; Kuwada, S				Fitzpatrick, DC; Batra, R; Stanford, TR; Kuwada, S			A neuronal population code for sound localization	NATURE			English	Article							INFERIOR COLLICULUS; UNANESTHETIZED RABBIT; BINAURAL INTERACTION; CHANGING FREQUENCY; INTERAURAL DELAYS; INFORMATION; DIRECTION; MOVEMENT	The accuracy with which listeners can locate sounds is much greater than the spatial sensitivity of single neurons(1-3). The broad spatial tuning of auditory neurons indicates that a code based on the responses of ensembles of neurons, a population code, must be used to determine the position of a sound in space, Here we show that the tuning of neurons to the most potent localization cue, the interaural time difference in low-frequency signals (< similar to 2 kHz; refs 4, 5), becomes sharper as the information ascends through the auditory system, We also show that this sharper tuning increases the efficiency of the population code, in the sense that fewer neurons are required to achieve a given acuity.			Fitzpatrick, DC (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT ANAT, FARMINGTON, CT 06030 USA.		Fitzpatrick, Douglas/AFT-2814-2022	Fitzpatrick, Douglas/0000-0001-8099-7194; Stanford, Terrence/0000-0003-0759-5599				BATRA R, 1989, J NEUROPHYSIOL, V61, P257, DOI 10.1152/jn.1989.61.2.257; BATRA R, IN PRESS J NEUROPHYS; BLAUERT J, 1982, SPATIAL HEARING; BRUGGE JF, 1997, BINAURAL SPATIAL HEA, P447; CAPUANO U, 1981, J COMP NEUROL, V196, P13, DOI 10.1002/cne.901960103; DYE RH, 1990, J ACOUST SOC AM, V88, P2159, DOI 10.1121/1.400113; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Green D. M., 1966, SIGNAL DETECTION THE, V1; HAFTER ER, 1975, J ACOUST SOC AM, V57, P181, DOI 10.1121/1.380412; HEFFNER H, 1980, J ACOUST SOC AM, V68, P1584, DOI 10.1121/1.385213; Heller LM, 1996, J ACOUST SOC AM, V99, P3632, DOI 10.1121/1.414961; Hinton G.E., 1986, P PDP, VVolume 1, P77; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KUWADA S, 1987, J NEUROPHYSIOL, V57, P1338, DOI 10.1152/jn.1987.57.5.1338; KUWADA S, 1997, BINAURAL SPATIAL HEA, P399; LEE CK, 1988, NATURE, V332, P357, DOI 10.1038/332357a0; LI L, 1992, J NEUROSCI, V12, P4530; Mills A. W., 1958, J ACOUST SOC AM, V65, P991; PERROTT DR, 1984, J ACOUST SOC AM, V75, P1201, DOI 10.1121/1.390771; RUMMELHART DE, 1986, PARALLEL DISTRIBUTED, V2, P77; Salinas E, 1994, J Comput Neurosci, V1, P89, DOI 10.1007/BF00962720; STANFORD TR, 1992, J NEUROSCI, V12, P3200, DOI 10.1523/JNEUROSCI.12-08-03200.1992; STERN RM, 1992, ADV BIOSCI, V83, P547; STERN RM, 1978, J ACOUST SOC AM, V64, P127, DOI 10.1121/1.381978; THEUNISSEN FE, 1991, J NEUROPHYSIOL, V66, P1690, DOI 10.1152/jn.1991.66.5.1690; TRAHIOTIS C, 1990, J ACOUST SOC AM, V87, P810, DOI 10.1121/1.398892; VANGISBERGEN JAM, 1987, NEUROSCIENCE, V21, P541, DOI 10.1016/0306-4522(87)90140-0; WIGHTMAN FL, 1992, J ACOUST SOC AM, V91, P1648, DOI 10.1121/1.402445; YIN TCT, 1983, J NEUROPHYSIOL, V50, P1020, DOI 10.1152/jn.1983.50.4.1020	30	131	133	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					871	874		10.1038/42246	http://dx.doi.org/10.1038/42246			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278047	Bronze			2022-12-24	WOS:A1997XT75400048
J	Gu, W; Roeder, RG				Gu, W; Roeder, RG			Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain	CELL			English	Article							NUCLEAR-PROTEIN CBP; TRANSCRIPTIONAL ACTIVATION; SUPPRESSION; COACTIVATOR; GROWTH; LOOP; SITE; TRANSFORMATION; EXPRESSION; INHIBITOR	The tumor suppressor p53 exerts antiproliferation effects through its ability to function as a sequence-specific DNA-binding transcription factor. Here, we demonstrate that p53 can be modified by acetylation both in vivo and in vitro. Remarkably, the site of p53 that is acetylated by its coactivator, p300, resides in a C-terminal domain known to be critical for the regulation of p53 DNA binding. Furthermore, the acetylation of p53 can dramatically stimulate its sequence-specific DNA-binding activity, possibly as a result of an acetylation-induced conformational change. These observations clearly indicate a novel pathway for p53 activation and, importantly, provide an example of an acetylation-mediated change in the function of a nonhistone regulatory protein. These results have significant implications regarding the molecular mechanisms of various acetyltransferase-containing transcriptional coactivators whose primary targets have been presumed to be histones.	ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021	Rockefeller University								Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Buckley AR, 1996, CELL GROWTH DIFFER, V7, P1713; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen WY, 1997, P NATL ACAD SCI USA, V94, P5798, DOI 10.1073/pnas.94.11.5798; CHIANG CM, 1993, PEPTIDE RES, V6, P62; Chresta CM, 1996, NAT MED, V2, P745, DOI 10.1038/nm0796-745; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; FISCELLA M, 1994, ONCOGENE, V9, P3249; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MIYASHITA T, 1995, CELL, V80, P293; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shaw P, 1996, ONCOGENE, V12, P921; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SOUSSI T, 1990, ONCOGENE, V5, P945; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	83	2109	2193	1	128	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					595	606		10.1016/S0092-8674(00)80521-8	http://dx.doi.org/10.1016/S0092-8674(00)80521-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288740	Bronze			2022-12-24	WOS:A1997XT06600004
J	Averof, M; Patel, NH				Averof, M; Patel, NH			Crustacean appendage evolution associated with changes in Hox gene expression	NATURE			English	Article							BODY PLANS; ULTRABITHORAX; MORPHOLOGY; ANTIBODY; INSECT	Homeotic (Hox) genes specify the differential identity of segments along the body axis of insects. Changes in the segmental organization of arthropod bodies may therefore be driven by changes in the function of Hox genes(1-3), but so far this has been difficult to demonstrate. We shaw here that changes in the expression pattern of the Hox genes Ubx and AbdA in different crustaceans correlate well with the modification of their anterior thoracic limbs into feeding appendages (maxillipeds). Our observations provide direct evidence that major morphological changes in arthropod body plans are associated with changes in Hox gene regulation. They suggest that homeotic changes(1,4) may play a role in the normal process of adaptive evolutionary change.	UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND	Howard Hughes Medical Institute; University of Chicago				Patel, Nipam/0000-0003-4328-654X; Averof, Michalis/0000-0002-6803-7251	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAM M, 1995, PHILOS T R SOC B, V349, P313, DOI 10.1098/rstb.1995.0119; AKAM M, 1988, DEVELOPMENT, V104, P123; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; AVEROF M, 1995, NATURE, V376, P420, DOI 10.1038/376420a0; Averof M, 1996, SEMIN CELL DEV BIOL, V7, P539, DOI 10.1006/scdb.1996.0068; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BRIGGS DEG, 1978, PHILOS T ROY SOC B, V281, P439, DOI 10.1098/rstb.1978.0005; Brusca R.C., 1990, INVERTEBRATES, P1; BURKE AC, 1995, DEVELOPMENT, V121, P333; CALMAN WT, 1909, CRUSTACEA; CASTELLIGAIR J, 1995, DEVELOPMENT, V121, P2973; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; GAUNT SJ, 1994, INT J DEV BIOL, V38, P549; GIESBRECHT W, 1931, HANDWORTERBUCH NATUR, P800; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; LEWIS EB, 1978, NATURE, V276, P567; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MULLER KJ, 1988, FOSSILS STRATA, V23, P1; PANGANIBAN G, 1995, SCIENCE, V270, P1363, DOI 10.1126/science.270.5240.1363; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; PATEL NH, 1989, DEVELOPMENT, V107, P201; Raff R. A., 1991, EMBRYOS GENES EVOLUT; Salser SJ, 1996, DEVELOPMENT, V122, P1651; Schram F.R., 1986, CRUSTACEA; WAGNER GP, 1989, ANNU REV ECOL SYST, V20, P51, DOI 10.1146/annurev.es.20.110189.000411; Walossek Dieter, 1993, Fossils and Strata, V32, P1	26	269	274	1	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					682	686		10.1038/41786	http://dx.doi.org/10.1038/41786			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262403	Bronze			2022-12-24	WOS:A1997XQ86300051
J	Fass, D; Blacklow, S; Kim, PS; Berger, JM				Fass, D; Blacklow, S; Kim, PS; Berger, JM			Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module	NATURE			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; CYSTEINE-RICH REPEAT; 3-DIMENSIONAL STRUCTURE; APOLIPOPROTEIN-E; BINDING DOMAIN; PROTEIN; MODELS; ERRORS; MAPS	The low-density lipoprotein receptor (LDLR) is responsible for the uptake of cholesterol-containing lipoprotein particles into cells(1,2). The amino-terminal region of LDLR, which consists of seven tandemly repeated, similar to 40-amino-acid, cysteine-rich modules (LDL-A modules), mediates binding to lipoproteins(3,4). LDL-A modules are biologically ubiquitous domains, found in over 100 proteins in the sequence database(5). The structure of ligand-binding repeat 5 (LR5) of the LDLR, determined to 1.7 Angstrom resolution by X-ray crystallography and presented here, contains a calcium ion coordinated by acidic residues that lie at the carboxy-terminal end of the domain and are conserved among LDL-A modules. Naturally occurring point mutations found in patients with the disease familial hypercholesterolaemia(6) alter residues that directly coordinate Ca2+ or that serve as scaffolding residues of LR5.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02142; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute								ABBADI A, 1991, J AM CHEM SOC, V113, P2729, DOI 10.1021/ja00007a056; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, X PLOR VERSION 3 1 S; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; ESSER V, 1988, J BIOL CHEM, V263, P13282; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; JI ZS, 1994, J BIOL CHEM, V269, P2764; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUSSELL DW, 1989, J BIOL CHEM, V264, P21782; *SERC DAR LAB, 1979, 4 SERC DAR LAB; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	27	296	307	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					691	693		10.1038/41798	http://dx.doi.org/10.1038/41798			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262405	Bronze			2022-12-24	WOS:A1997XQ86300053
J	Leger, J; LevyMarchal, C; Bloch, J; Pinet, A; Chevenne, D; Porquet, D; Collin, D; Czernichow, P				Leger, J; LevyMarchal, C; Bloch, J; Pinet, A; Chevenne, D; Porquet, D; Collin, D; Czernichow, P			Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: regional cohort study	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; CORONARY HEART-DISEASE; LOW-BIRTH-WEIGHT; BLOOD-PRESSURE; ADULT LIFE; FETAL GROWTH; INFANT GROWTH; CARDIOVASCULAR-DISEASE; INTRAUTERINE GROWTH; CHILDREN	Objective: To investigate whether the association between low birth weight and increased risk of developing impaired glucose tolerance, insulin resistance, hypertriglyceridaemia, and hypertension in middle age is apparent by the age of 20 in people born small for gestational age, Design: Regional cohort study. Setting: Maternity registry, Haguenau, France, Subjects: 236 full term singleton babies born small for gestational age (birth weight or length, or both, below third centile) during 1971-8 and 281 with normal birth weight (between 25th and 75th centile). All subjects were contacted and evaluated at a mean (SD) age of 20.6 (2.1) years. Main outcome measures: Adult height; concentrations of glucose, insulin, and proinsulin during an oral glucose tolerance test; lipid and fibrinogen concentrations; and blood pressure, Results: After sex and target height were adjusted for, subjects who had been born small for gestational age were significantly shorter at age 20 than those with a normal birth weight (men 4.5 cm shorter (95% confidence interval 6.0 to 3.0 cm); women 3.94 cm shorter (5.2 to 2.7 cm)), After sex and body mass index were adjusted for, mean plasma glucose concentration 30 minutes after a glucose load, fasting insulin concentration (in women), and insulin and proinsulin concentrations 30 and 120 minutes after a glucose load were significantly higher in subjects who had been born small for gestational age than in those with a normal birth weight Mean lipid and fibrinogen concentrations and blood pressure were not different between the two groups. Conclusions: Intrauterine growth retardation has long term consequences such as reduced final height Raised insulin and proinsulin concentrations are present in young adults born small for gestational age and could be markers of early changes in insulin sensitivity.	HOP ROBERT DEBRE,INSERM,CJF 9313,F-75019 PARIS,FRANCE; HOP ROBERT DEBRE,DEPT BIOCHEM,F-75019 PARIS,FRANCE; CTR HOSP HAGUENAU,MATERN UNIT,HAGUENAU,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	Leger, J (corresponding author), HOP ROBERT DEBRE,ENDOCRINOL & DIABET UNIT,F-75019 PARIS,FRANCE.							BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARKER DJP, 1989, BRIT MED J, V298, P567; CHEVENNE D, 1994, CLIN CHEM, V40, P754; CHEVENNE D, 1995, ANN BIOL CLIN-PARIS, V53, P3; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; deZegher F, 1996, J CLIN ENDOCR METAB, V81, P1887, DOI 10.1210/jc.81.5.1887; FALL CHD, 1995, BRIT MED J, V310, P17, DOI 10.1136/bmj.310.6971.17; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; HAFFNER SM, 1994, J CLIN ENDOCR METAB, V79, P1806, DOI 10.1210/jc.79.6.1806; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HOKKENKOELEGA ACS, 1995, PEDIATR RES, V38, P267, DOI 10.1203/00006450-199508000-00022; Job JC, 1996, PEDIATR RES, V39, P354, DOI 10.1203/00006450-199602000-00027; KARLBERG J, 1995, PEDIATR RES, V38, P733, DOI 10.1203/00006450-199511000-00017; KRAMER MS, 1990, PEDIATRICS, V86, P707; KRAMER MS, 1987, PEDIATRICS, V80, P502; LAUNER LJ, 1993, BMJ-BRIT MED J, V307, P1451, DOI 10.1136/bmj.307.6917.1451; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; LESAGE C, 1991, J PEDIATR-US, V119, P29, DOI 10.1016/S0022-3476(05)81034-0; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; MACINTYRE S, 1991, J EPIDEMIOL COMMUN H, V45, P143, DOI 10.1136/jech.45.2.143; MATTHES JWA, 1994, BMJ-BRIT MED J, V308, P1074, DOI 10.1136/bmj.308.6936.1074; MILLER HC, 1971, PEDIATRICS, V48, P511; NILSEN ST, 1984, ACTA PAEDIATR SCAND, V73, P168, DOI 10.1111/j.1651-2227.1984.tb09923.x; PAPIERNIK E, 1985, PEDIATRICS, V76, P154; PAZ I, 1993, AM J DIS CHILD, V47, P337; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P592; PHILLIPS DIW, 1994, DIABETIC MED, V11, P286, DOI 10.1111/j.1464-5491.1994.tb00273.x; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; Sheu W, 1996, J CLIN ENDOCR METAB, V81, P1156; TANNER JM, 1970, ARCH DIS CHILD, V45, P755, DOI 10.1136/adc.45.244.755; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157; WALKER J, 1989, J CLIN ENDOCR METAB, V69, P253, DOI 10.1210/jcem-69-2-253; WESTWOOD M, 1983, PEDIATRICS, V71, P376; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L; YAJNIK CS, 1995, DIABETIC MED, V12, P330, DOI 10.1111/j.1464-5491.1995.tb00487.x	51	290	296	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					341	347						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270455				2022-12-24	WOS:A1997XQ86400020
J	VargaWeisz, PD; Wilm, M; Bonte, E; Dumas, K; Mann, M; Becker, PB				VargaWeisz, PD; Wilm, M; Bonte, E; Dumas, K; Mann, M; Becker, PB			Chromatin-remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II	NATURE			English	Article							PROMOTER IN-VITRO; CELL-FREE SYSTEM; TRANSCRIPTION FACTOR; DROSOPHILA EMBRYOS; ATP; IDENTIFICATION; INVOLVEMENT; DISRUPTION; MICROSCOPY; BINDING	Repressive chromatin structures need to be unravelled to allow DNA-binding proteins access to their target sequences. This de-repression constitutes an important point at which transcription and presumably other nuclear processes can be regulated(1,2). Energy-consuming enzyme complexes that facilitate the interaction of transcription factors with chromatin by modifying nucleosome structure are involved in this regulation(3-5). One such factor, nucleosome-remodelling factor (NURF), has been isolated from Drosophila embryo extracts(4,6,7), We have now identified a chromatin-accessibility complex (CHRAC) which uses energy to increase the general accessibility of DNA in chromatin. However, unlike other known chromatin remodelling factors, CHRAC can also function during chromatin assembly: it uses ATP to convert irregular chromatin into a regular array of nucleosomes with even spacing. CHRAC combines enzymes that modulate nucleosome structure and DNA topology. Using mass spectrometry, we identified two of the five CHRAC subunits as the ATPase ISWI, which is also part of NURF6,8, and topoisomerase II, The presence of ISWI in different contexts suggests that chromatin remodelling machines have a modular nature and that ISWI has a central role in different chromatin remodelling reactions.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Varga-Weisz, Patrick/0000-0001-7409-8686; Wilm, Matthias/0000-0002-5461-6834; Becker, Peter/0000-0001-7186-0372				ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BECKER PB, 1994, METHOD CELL BIOL, V44, P207, DOI 10.1016/S0091-679X(08)60915-2; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BUCHENAU P, 1993, J CELL SCI, V104, P1175; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CHEN GL, 1984, J BIOL CHEM, V259, P3560; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; POLJAK L, 1995, TRENDS CELL BIOL, V5, P348, DOI 10.1016/S0962-8924(00)89068-6; SANDALTZOPOULOS R, 1995, NUCLEIC ACIDS RES, V23, P2479, DOI 10.1093/nar/23.13.2479; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	29	424	429	2	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					598	602		10.1038/41587	http://dx.doi.org/10.1038/41587			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252192	Bronze			2022-12-24	WOS:A1997XP72200053
J	Jones, AL; Hayes, PC; Proudfoot, AT; Vale, JA; Prescott, LF				Jones, AL; Hayes, PC; Proudfoot, AT; Vale, JA; Prescott, LF			Controversies in management - Should methionine be added to every paracetamol tablet? No: The risks are not well enough known	BRITISH MEDICAL JOURNAL			English	Article							SERUM TOTAL HOMOCYSTEINE; ORAL METHIONINE; ACETAMINOPHEN OVERDOSE; NITROGEN; DISEASE; INJURY; MEN		ROYAL INFIRM EDINBURGH NHS,SCOTTISH LIVER TRANSPLANT UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; CITY HOSP NHS TRUST,W MIDLANDS POISON UNIT,NATL POISONS INFORMAT SERV,BIRMINGHAM CTR,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND; WESTERN GEN HOSP,PHARMACOL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,RES CTR,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	Jones, AL (corresponding author), ROYAL INFIRM EDINBURGH NHS,SCOTTISH POISONS INFORMAT BUR,EDINBURGH CTR,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.		Vale, Allister/AAA-9216-2019					ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BOND GR, 1995, PHARMACOECONOMICS, V8, P177, DOI 10.2165/00019053-199508030-00001; BREILLOT F, 1986, ANTICANCER RES, V76, P629; CHO ES, 1979, J NUTR, V109, P1086, DOI 10.1093/jn/109.6.1086; COHEN SM, 1974, BIOL PSYCHIAT, V8, P209; CONNOR H, 1978, POSTGRAD MED J, V54, P318, DOI 10.1136/pgmj.54.631.318; CROME P, 1976, LANCET, V2, P829; GATTONUMPHRESS TL, 1993, HOSP PRACT, V28, P83, DOI 10.1080/21548331.1993.11442926; GUO HY, 1993, CANCER RES, V53, P5676; HAMLYN AN, 1981, J INT MED RES, V9, P226, DOI 10.1177/030006058100900314; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; HAWTON K, 1992, BRIT MED J, V304, P1409, DOI 10.1136/bmj.304.6839.1409; LEMANN J, 1956, J CLIN INVEST, V38, P2215; LITOVITZ TL, 1995, AM J EMERG MED, V13, P551, DOI 10.1016/0735-6757(95)90171-X; MACLEAN AEM, 1975, BIOCHEM PHARMACOL, V24, P37; Matthias D, 1996, ATHEROSCLEROSIS, V122, P201, DOI 10.1016/0021-9150(95)05740-4; MCLEAN AEM, 1974, LANCET, V1, P729; MURPHYCHUTORIAN DR, 1985, J AM COLL CARDIOL, V6, P725, DOI 10.1016/S0735-1097(85)80473-3; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; PHEAR EA, 1956, CLIN SCI, V15, P93; PRESCOTT LF, 1976, LANCET, V2, P109; PRINTEN KJ, 1979, AM J CLIN NUTR, V32, P1200, DOI 10.1093/ajcn/32.6.1200; SKOGLUND LA, 1992, GEN PHARMACOL, V23, P155, DOI 10.1016/0306-3623(92)90002-2; SPOONER JB, 1993, PHARM J, V250, P706; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; TAI J, 1994, P NATL ACAD SCI USA, V91, P6369; UELAND PM, 1992, ATHEROSCLEROTIC CARD, P1832; VALE JA, 1981, ARCH INTERN MED, V141, P394, DOI 10.1001/archinte.141.3.394; VALE JA, 1954, HUM TOXICOL, V3, P135; ZEZULKA AY, 1976, J NUTR, V106, P1286, DOI 10.1093/jn/106.9.1286	31	15	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					301	303		10.1136/bmj.315.7103.301	http://dx.doi.org/10.1136/bmj.315.7103.301			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274554	Green Published			2022-12-24	WOS:A1997XP75000029
J	Plummer, MA; Phillips, FM; FabrykaMartin, J; Turin, HJ; Wigand, PE; Sharma, P				Plummer, MA; Phillips, FM; FabrykaMartin, J; Turin, HJ; Wigand, PE; Sharma, P			Chlorine-36 in fossil rat urine: An archive of cosmogenic nuclide deposition during the past 40,000 years	SCIENCE			English	Article							LAST GLACIAL MAXIMUM; ENVIRONMENTAL TRACERS; ATMOSPHERIC C-14/C-12; YOUNGER DRYAS; ICE CORE; BE-10; ISOTOPES; C-14; CLIMATE; AGES	Knowledge of the production history of cosmogenic nuclides, which is needed for geological and archaeological dating, has been uncertain. Measurements of chlorine-36/chlorine (Cl-36/Cl) ratios in fossil packrat middens from Nevada that are radiocarbon-dated between about 38 thousand years ago (ka) and the present showed that Cl-36/Cl ratios were higher by a factor of about 2 before similar to 11 ka. This raises the possibility that cosmogenic production rates just before the close of the Pleistocene were up to 50% higher than is suggested by carbon-14 calibration data. The discrepancy could be explained by addition of low-carbon-14 carbon dioxide to the atmosphere during that period, which would have depressed atmospheric radiocarbon activity. Alternatively, climatic effects on Cl-36 deposition may have enhanced the Cl-36/Cl ratios.	LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545; DESERT RES INST,RENO,NV 89512; PURDUE UNIV,DEPT PHYS,W LAFAYETTE,IN 47907	United States Department of Energy (DOE); Los Alamos National Laboratory; Nevada System of Higher Education (NSHE); Desert Research Institute NSHE; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Plummer, MA (corresponding author), NEW MEXICO INST MIN & TECHNOL,DEPT EARTH & ENVIRONM SCI,SOCORRO,NM 87801, USA.			Turin, H J/0000-0003-3861-692X				BARD E, 1993, RADIOCARBON, V35, P191, DOI 10.1017/S0033822200013886; BARNOLA JM, 1991, TELLUS B, V43, P83, DOI 10.1034/j.1600-0889.1991.t01-1-00002.x; BAUMGARTNER S, 1995, SOLID STATE RES LARG; BEER J, 1988, NATURE, V331, P675, DOI 10.1038/331675a0; BENSON L, 1995, PALAEOGEOGR PALAEOCL, V117, P1, DOI 10.1016/0031-0182(94)00103-F; Bentley H.W., 1986, HDB ENV GEOCHEMISTRY, P422; BENTLEY HW, 1986, WATER RESOUR RES, V22, P1991, DOI 10.1029/WR022i013p01991; Betancourt J.L., 1990, PACKRAT MIDDENS LAST; Bierman P, 1995, QUATERNARY RES, V44, P378, DOI 10.1006/qres.1995.1082; BROWN ET, 1995, EARTH PLANET SC LETT, V129, P193, DOI 10.1016/0012-821X(94)00249-X; CERLING TE, 1994, ANNU REV EARTH PL SC, V22, P273, DOI 10.1146/annurev.ea.22.050194.001421; EDWARDS RL, 1993, SCIENCE, V260, P962, DOI 10.1126/science.260.5110.962; FABRYKAMARTIN JT, 1993, DISTRIBUTION CHOLINE; FINKEL RC, IN PRESS J GEOPHYS R; FORESTER RM, 1997, 3GCA102M US GEOL SUR; FRIEDLINGSTEIN P, 1995, J GEOPHYS RES-ATMOS, V100, P7203, DOI 10.1029/94JD02948; GOSLAR T, 1995, NATURE, V377, P414, DOI 10.1038/377414a0; Guyodo Y, 1996, EARTH PLANET SC LETT, V143, P23, DOI 10.1016/0012-821X(96)00121-5; HAJDAS I, 1995, RADIOCARBON, V37, P75, DOI 10.1017/S0033822200014818; HOERING TC, 1961, GEOCHIM COSMOCHIM AC, V23, P186, DOI 10.1016/0016-7037(61)90043-6; HOUTERMA.J, 1966, Z PHYS, V193, P1, DOI 10.1007/BF01326455; HOUTERMANS JC, 1973, J GEOPHYS RES, V78, P1897, DOI 10.1029/JC078i012p01897; Huggle D, 1996, PLANET SPACE SCI, V44, P147, DOI 10.1016/0032-0633(95)00085-2; KAUFMANN R, 1984, NATURE, V309, P338, DOI 10.1038/309338a0; KUTZBACH JE, 1985, QUATERNARY SCI REV, V4, P147, DOI 10.1016/0277-3791(85)90024-1; KVENVOLDEN KA, 1993, REV GEOPHYS, V31, P173, DOI 10.1029/93RG00268; Laj C, 1996, GEOPHYS RES LETT, V23, P2045, DOI 10.1029/96GL02152; LAL D, 1987, GEOPHYS RES LETT, V14, P785, DOI 10.1029/GL014i008p00785; LAL D, 1988, SOLAR TERRESTRIAL RE, P216; LAL D, 1985, CARBON CYCLE ATMOSPH, P221; LAO Y, 1992, NATURE, V357, P576, DOI 10.1038/357576a0; LEHMANN BE, 1993, WATER RESOUR RES, V29, P2027, DOI 10.1029/93WR00543; Libby WF., 1952, RADIOCARBON DATING; MAZAUD A, 1991, GEOPHYS RES LETT, V18, P1885, DOI 10.1029/91GL02285; MCHARGUE LR, 1995, GEOPHYS RES LETT, V22, P659, DOI 10.1029/95GL00169; MIFFLIN MD, 1979, B NEVADA BUREAU MINE, V94; MORRIS JD, 1990, NATURE, V344, P31, DOI 10.1038/344031a0; NEWELL RE, 1971, SCI AM, V224, P32, DOI 10.1038/scientificamerican0171-32; OBRIEN K, 1979, J GEOPHYS RES-SPACE, V84, P423, DOI 10.1029/JA084iA02p00423; PAPKE KG, 1976, B NEVADA BUREAU MINE, V87; PHILLIPS FM, 1994, SOIL SCI SOC AM J, V58, P15, DOI 10.2136/sssaj1994.03615995005800010003x; PHILLIPS FM, 1995, REV GEOPHYS, V33, P1029, DOI 10.1029/95RG00247; PLUMMER MA, 1996, THESIS NEW MEXICO I; REHEIS MC, 1995, J GEOPHYS RES-ATMOS, V100, P8893, DOI 10.1029/94JD03245; Richards J. H., 1986, MINERAL EXPLORATION, P82; Robinson C, 1995, EARTH PLANET SC LETT, V136, P551, DOI 10.1016/0012-821X(95)00202-N; SARNTHEIN M, 1996, EOS S, V77, pF14; Schmidt-Nielsen K., 1964, DESERT ANIMALS PHYSL; STUIVER M, 1991, QUATERNARY RES, V35, P1, DOI 10.1016/0033-5894(91)90091-I; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; THOUVENY N, 1993, GLOBAL PLANET CHANGE, V7, P157, DOI 10.1016/0921-8181(93)90047-R; TYLER SW, 1994, SOIL SCI SOC AM J, V58, P25, DOI 10.2136/sssaj1994.03615995005800010004x; WELLS PV, 1976, QUATERNARY RES, V6, P223, DOI 10.1016/0033-5894(76)90052-1; Wood WW, 1995, WATER RESOUR RES, V31, P3121, DOI 10.1029/95WR02572; [No title captured]	55	49	51	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					538	541		10.1126/science.277.5325.538	http://dx.doi.org/10.1126/science.277.5325.538			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9227999				2022-12-24	WOS:A1997XM86700044
J	Kim, TW; Pettingell, WH; Jung, YK; Kovacs, DM; Tanzi, RE				Kim, TW; Pettingell, WH; Jung, YK; Kovacs, DM; Tanzi, RE			Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease	SCIENCE			English	Article							DISEASE; NEURODEGENERATION; DEATH	Most cases of early-onset familiar Alzheimer's disease (FAD) are caused by mutations in the genes encoding the presenilin 1 (PS1) and PS2 proteins, both of which undergo regulated endoproteolytic processing. During apoptosis, PS1 and PS2 were shown to be cleaved at sites distal to their normal cleavage sites by a caspase-3 family protease. In cells expressing PS2 containing the asparagine-141 FAD mutant, the ratio of alternative to normal PS2 cleavage fragments was increased relative to wild-type PS2-expressing cells, suggesting a potential role for apoptosis-associated cleavage of presenilins in the pathogenesis of Alzheimer's disease.	HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT NEUROL,GENET & AGING UNIT,CHARLESTOWN,MA 02129; KWANGJU INST SCI & TECHNOL,DEPT LIFE SCI,KWANGJU,SOUTH KOREA	Harvard University; Massachusetts General Hospital; Gwangju Institute of Science & Technology (GIST)			Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454; Jung, Yong-Keun/0000-0002-9686-3120				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BUSH AI, 1992, ANN NEUROL, V32, P57, DOI 10.1002/ana.410320110; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JOHNSON EM, 1994, NEUROBIOL AGING, V15, P5187; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim T. J., UNPUB; Kim TW, 1997, J BIOL CHEM, V272, P11006; KOVACS DG, UNPUB; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LEBLANC A, 1996, MOL MECH DEMENTIA, P57; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; NEAMATI N, 1994, J IMMUNOL, V154, P1693; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; Paradis E, 1996, J NEUROSCI, V16, P7533; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; TANZI RE, 1997, TRENDS NEUROSCI, V20, P154; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; XIE W, 1997, J BIOL CHEM, V272, P7977	40	325	337	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					373	376		10.1126/science.277.5324.373	http://dx.doi.org/10.1126/science.277.5324.373			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219695				2022-12-24	WOS:A1997XL35800047
J	Rowan, R; Knowlton, N; Baker, A; Jara, J				Rowan, R; Knowlton, N; Baker, A; Jara, J			Landscape ecology of algal symbionts creates variation in episodes of coral bleaching	NATURE			English	Article							ULTRAVIOLET-RADIATION; REEF CORALS; TEMPERATURE; ZOOXANTHELLAE	Reef-building corals are obligate, mutualistic symbioses of heterotrophic animals and phototrophic dinoflagellates (Symbiodinium spp.)(1). Contrary to the earlier, widely accepted belief that corals harbour only one symbiont, we found that the ecologically dominant Caribbean corals Montastraea annularis and M. faveolata can act as hosts to dynamic, multi-species communities of Symbiodinium. Composition of these communities follows gradients of environmental irradiance, implying that physiological acclimatization(2-4) is not the only mechanism by which corals cope with environmental heterogeneity. The importance of this diversity was underlined by analysis of a natural episode of coral bleaching. Patterns of bleaching could be explained by the preferential elimination of a symbiont associated with low irradiance from the brightest parts of its distribution. Comparative analyses of symbionts before and after bleaching from the same corals supported this interpretation, and suggested that some corals were protected from bleaching by hosting an additional symbiont that is more tolerant of high irradiance and temperature. This 'natural experiment' suggests that temporal and spatial variability can favour the coexistence of diverse symbionts within a host, despite the potential for destabilizing competition among them(5,6).	SMITHSONIAN TROP RES INST,BALBOA,PANAMA; UNIV MIAMI,ROSENSTIEL SCH MARINE & ATMOSPHER SCI,MIAMI,FL 33149	Smithsonian Institution; Smithsonian Tropical Research Institute; University of Miami	Rowan, R (corresponding author), UNIV GUAM,MARINE LAB,MANGILAO,GU 96923, USA.			Baker, Andrew/0000-0002-7866-2587				BROWN BE, IN PRESS CORAL REEFS; BUDDEMEIER RW, 1993, BIOSCIENCE, V43, P320, DOI 10.2307/1312064; DCROZ L, 1997, P 8 INT COR REEF S, V2, P203; DUNBAR RB, 1993, 10 CLIM GLOB CHANG P; EDMUNDS PJ, 1994, MAR BIOL, V121, P127; Falkowski P.G., 1990, P89; Fitt WK, 1995, BIOL BULL, V189, P298, DOI 10.2307/1542147; GATES RD, 1990, CORAL REEFS, V8, P193, DOI 10.1007/BF00265010; GLEASON DF, 1993, NATURE, V365, P836, DOI 10.1038/365836a0; GLYNN PW, 1993, CORAL REEFS, V12, P1, DOI 10.1007/BF00303779; GOREAU TF, 1959, ECOLOGY, V40, P67, DOI 10.2307/1929924; IGLESIASPRIETO R, 1994, MAR ECOL PROG SER, V113, P163, DOI 10.3354/meps113163; JEFFREY SW, 1968, BIOL BULL, V135, P149, DOI 10.2307/1539622; JOKIEL PL, 1990, CORAL REEFS, V8, P155, DOI 10.1007/BF00265006; LASKER HR, 1984, CORAL REEFS, V3, P183, DOI 10.1007/BF00288253; Leigh Egbert Giles Jr, 1995, Ecologie, V26, P131; LESSER MP, 1990, CORAL REEFS, V8, P225, DOI 10.1007/BF00265015; LESSIOS HA, 1997, P 8 INT COR REEF S, V1, P673; PORTER JW, 1989, P NATL ACAD SCI USA, V86, P9342, DOI 10.1073/pnas.86.23.9342; REYNOLDS RW, 1994, J CLIMATE, V7, P929, DOI 10.1175/1520-0442(1994)007<0929:IGSSTA>2.0.CO;2; ROWAN R, 1991, MAR ECOL PROG SER, V71, P65, DOI 10.3354/meps071065; ROWAN R, 1991, SCIENCE, V251, P1348, DOI 10.1126/science.251.4999.1348; ROWAN R, 1995, P NATL ACAD SCI USA, V92, P2850, DOI 10.1073/pnas.92.7.2850; SANDEMAN IM, 1988, MASS BLEACHING CORAL, P46; Smith J. M., 1995, MAJOR TRANSITIONS EV; TRENCH RK, 1993, ENDOCYTOBIOSIS CELL, V9, P135; Ware JR, 1996, ECOL MODEL, V84, P199, DOI 10.1016/0304-3800(94)00132-4; WEIL E, 1994, B MAR SCI, V55, P151; Williams EH, 1990, ATOLL RES B, P330, DOI DOI 10.5479/SI.00775630.335.1; [No title captured]	30	580	599	2	258	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					265	269		10.1038/40843	http://dx.doi.org/10.1038/40843			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230434	Bronze			2022-12-24	WOS:A1997XL12100048
J	Epstein, Y				Epstein, Y			Predominance of type II fibres in exertional heat stroke	LANCET			English	Editorial Material							ENERGY				Epstein, Y (corresponding author), CHAIM SHEBA MED CTR,HELLER INST MED RES,IL-52621 TEL HASHOMER,ISRAEL.							ARMSTRONG RB, 1986, SPORTS MED, V3, P370, DOI 10.2165/00007256-198603050-00006; BALLBURNETT M, 1991, J PHYSIOL-LONDON, V437, P257, DOI 10.1113/jphysiol.1991.sp018594; EPSTEIN Y, 1983, J APPL PHYSIOL, V54, P831, DOI 10.1152/jappl.1983.54.3.831; Frank A, 1996, ENV ERGONOMICS RECEN, P194; Hsu YD, 1997, J NEUROL NEUROSUR PS, V62, P182, DOI 10.1136/jnnp.62.2.182; HUBBARD RW, 1990, MED SCI SPORT EXER, V22, P19; Siejo B K, 1985, BRIT J ANAESTH, V57, P47	7	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					83	84		10.1016/S0140-6736(05)61811-9	http://dx.doi.org/10.1016/S0140-6736(05)61811-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228957				2022-12-24	WOS:A1997XK11400005
J	Ito, T; Bulger, M; Pazin, MJ; Kobayashi, R; Kadonaga, JT				Ito, T; Bulger, M; Pazin, MJ; Kobayashi, R; Kadonaga, JT			ACF, an ISWI-containing and ATP-utilizing chromatin assembly and remodeling factor	CELL			English	Article							DNA-REPLICATION INVITRO; POLYMERASE-II TRANSCRIPTION; CELL-FREE SYSTEM; NUCLEOSOME; HISTONES; PURIFICATION; ACTIVATOR; BINDING; PROTEIN; GAL4-VP16	We describe the purification and characterization of ACF, an ATP-utilizing chromatin assembly and remodeling factor. ACF is a multisubunit factor that contains ISWI protein and is distinct from NURF, another ISWI-containing factor. In chromatin assembly, purified ACF and a core histone chaperone (such as NAP-1 or CAF-1) are sufficient for the ATP-dependent formation of periodic nucleosome arrays. In chromatin remodeling, ACF is able to modulate the internucleosomal spacing of chromatin by an ATP-dependent mechanism. Moreover, ACF can mediate promoter-specific nucleosome reconfiguration by Gal4-VP16 in an ATP-dependent manner. These results suggest that ACF acts catalytically both in chromatin assembly and in the remodeling of nucleosomes that occurs during transcriptional activation.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	University of California System; University of California San Diego; Cold Spring Harbor Laboratory				Pazin, Michael/0000-0002-7561-3640	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BLANK TA, 1995, J MOL BIOL, V252, P305, DOI 10.1006/jmbi.1995.0498; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; GERMOND JE, 1976, NUCLEIC ACIDS RES, V3, P3173, DOI 10.1093/nar/3.11.3173; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GRUNSTEIN M, 1997, IN PRESS NATURE; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 1996, J BIOL CHEM, V271, P25041, DOI 10.1074/jbc.271.40.25041; JEONG SW, 1991, J MOL BIOL, V222, P1131, DOI 10.1016/0022-2836(91)90597-Y; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOGO JM, 1995, CHROMATIN STRUCTURE, P49; STEIN A, 1985, BIOCHEMISTRY-US, V24, P1783, DOI 10.1021/bi00328a032; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TREMETHICK DJ, 1992, J BIOL CHEM, V267, P15041; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; van Holde KE., 1989, SPRINGER SERIES MOL; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wolffe A., 1995, CHROMATIN STRUCTURE; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735	51	513	523	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					145	155		10.1016/S0092-8674(00)80321-9	http://dx.doi.org/10.1016/S0092-8674(00)80321-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230310	Bronze			2022-12-24	WOS:A1997XL36200016
J	Woo, K; Fraser, SE				Woo, K; Fraser, SE			Specification of the zebrafish nervous system by nonaxial signals	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; RETINOIC ACID CAUSES; ANTEROPOSTERIOR AXIS; XENOPUS EMBRYOS; MUTANT EMBRYOS; MOUSE EMBRYO; EXPRESSION; GENE; HINDBRAIN; INDUCTION	The organizer of the amphibian gastrula provides the neurectoderm with both neuralizing and posteriorizing (transforming) signals. In zebrafish, transplantations show that a spatially distinct transformer signal emanates from tissues other than the organizer. Cells of the germring (nonaxial mesendoderm) posteriorized forebrain progenitors when grafted nearby, resulting in an ectopic hindbrain-like structure; in contrast, cells of the organizer (axial mesendoderm) caused no posterior transformation, Local application of basic fibroblast growth factor, a candidate transformer in Xenopus, caused malformation but not hindbrain transformation in the forebrain, Thus, the zebrafish gastrula may integrate spatially distinct signals from the organizer and the germring to pattern the neural axis.	CALTECH, BECKMAN INST, DIV BIOL, PASADENA, CA 91125 USA; CALTECH, BECKMAN INST, BIOL IMAGING CTR, PASADENA, CA 91125 USA	California Institute of Technology; California Institute of Technology			Fraser, Scott/Y-3406-2019	Fraser, Scott/0000-0002-5377-0223				ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Blader P, 1996, DEV GENES EVOL, V206, P3, DOI 10.1007/s004270050025; Blumberg B, 1997, DEVELOPMENT, V124, P373; Cox WG, 1995, DEVELOPMENT, V121, P4349; DAI ZS, 1995, J NEUROSCI, V15, P5466; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; DONIACH T, 1993, J NEUROBIOL, V24, P1256, DOI 10.1002/neu.480241003; Doniach T, 1995, CELL, V83, P1067, DOI 10.1016/0092-8674(95)90133-7; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EYAL-GILADI H., 1954, ARCH BIOL [PARIS], V65, P179; GRIFFIN K, 1995, DEVELOPMENT, V121, P2983; HAMMERSCHMIDT M, 1993, DEVELOPMENT, V119, P1107; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HOLDER N, 1991, DEVELOPMENT, V113, P1159; Hyatt GA, 1996, DEVELOPMENT, V122, P195; JOLY JS, 1993, DEVELOPMENT, V119, P1261; KELLY GM, 1995, DEVELOPMENT, V121, P1787; KELLY GM, 1995, DEV GENET, V17, P129, DOI 10.1002/dvg.1020170205; KELLY GM, 1993, DEV BIOL, V158, P113, DOI 10.1006/dbio.1993.1172; KELLY OG, 1995, TRENDS GENET, V11, P273, DOI 10.1016/S0168-9525(00)89074-5; KENGAKU M, 1995, DEVELOPMENT, V121, P3121; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KRAUSS S, 1992, DEVELOPMENT, V116, P249; Kroll KL, 1996, DEVELOPMENT, V122, P3173; LAMB TM, 1995, DEVELOPMENT, V121, P3627; LI Y, 1994, WEINBERG MECH DEV, V48, P229; Mason I, 1996, CURR BIOL, V6, P672, DOI 10.1016/S0960-9822(09)00446-1; MCGREW LL, 1995, DEV BIOL, V172, P337, DOI 10.1006/dbio.1995.0027; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NIEUWKOOP PD, 1952, J EXP ZOOL, V120, P1, DOI 10.1002/jez.1401200102; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; Psychoyos D, 1996, DEVELOPMENT, V122, P3263; Sagerstrom CG, 1996, DEVELOPMENT, V122, P1873; Sala M., 1955, Proceedings Akademie van Wetenschappen Amsterdam, V58C, P635; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; SAXEN L, 1992, PRIMARY EMBRYONIC IN; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SHARPE CR, 1991, NEURON, V7, P239, DOI 10.1016/0896-6273(91)90262-X; SHIH J, 1995, DEVELOPMENT, V121, P2755; Shih J, 1996, DEVELOPMENT, V122, P1313; Sive H, 1996, DEV DYNAM, V205, P265, DOI 10.1002/(SICI)1097-0177(199603)205:3<265::AID-AJA7>3.0.CO;2-G; SLACK JMW, 1992, DEVELOPMENT, V114, P285; Spemann H., 1938, EMBRYONIC DEV INDUCT; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; THISSE C, 1993, DEVELOPMENT, V119, P1203; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WOO K, 1995, DEVELOPMENT, V121, P2595; WOO K, 1995, DEV BIOL, V170, P764; WOO K, UNPUB; Yoshikawa Y, 1997, DEV BIOL, V183, P234, DOI 10.1006/dbio.1997.8502	52	118	119	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					254	257		10.1126/science.277.5323.254	http://dx.doi.org/10.1126/science.277.5323.254			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211857				2022-12-24	WOS:A1997XK41800050
J	Bebb, G; Glickman, B; Gelmon, K; Gatti, R				Bebb, G; Glickman, B; Gelmon, K; Gatti, R			''AT risk'' for breast cancer	LANCET			English	Editorial Material							ATAXIA-TELANGIECTASIA		UNIV VICTORIA,CTR ENVIRONM HLTH,VICTORIA,BC,CANADA; UNIV CALIF LOS ANGELES,DEPT PATHOL,LOS ANGELES,CA 90024	University of Victoria; University of California System; University of California Los Angeles	Bebb, G (corresponding author), BRITISH COLUMBIA CANC AGCY,DEPT ADV THERAPEUT,VANCOUVER,BC V5Z 4E6,CANADA.							Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Bhatia S, 1996, NEW ENGL J MED, V334, P745, DOI 10.1056/NEJM199603213341201; EASTON DF, 1995, BRIT J CANCER, V72, P805; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; KASTAN MB, 1992, CELL, V74, P353; KIRSCH IR, 1994, INT J RADIAT BIOL, V66, pS97, DOI 10.1080/09553009414551921; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Telatar M, 1996, AM J HUM GENET, V59, P40; TOMLINSON IPM, 1995, J CLIN PATHOL, V48, P424, DOI 10.1136/jcp.48.5.424	10	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1784	1785		10.1016/S0140-6736(05)61687-X	http://dx.doi.org/10.1016/S0140-6736(05)61687-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269208				2022-12-24	WOS:A1997XF73500004
J	Hudson, LD; Martin, TR				Hudson, LD; Martin, TR			Predicting ARDS: Problems and prospects	LANCET			English	Editorial Material							RESPIRATORY-DISTRESS SYNDROME		UNIV WASHINGTON,SCH MED,SEATTLE,WA 98104	University of Washington; University of Washington Seattle	Hudson, LD (corresponding author), SEATTLE VA MED CTR,HARBORVIEW MED CTR,SECT PULM CRIT CARE MED,SEATTLE,WA 98104, USA.							Connelly KG, 1997, AM J RESP CRIT CARE, V155, P21, DOI 10.1164/ajrccm.155.1.9001283; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; Goodman RB, 1996, AM J RESP CRIT CARE, V154, P602, DOI 10.1164/ajrccm.154.3.8810593; HAMMERSCHMIDT DE, 1980, LANCET, V1, P947; HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182; MOSS M, 1995, AM J RESP CRIT CARE, V151, P15, DOI 10.1164/ajrccm.151.1.7812545; PITTET JF, IN PRESS AM J RESP C; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1783	1783		10.1016/S0140-6736(05)61686-8	http://dx.doi.org/10.1016/S0140-6736(05)61686-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269207				2022-12-24	WOS:A1997XF73500003
J	Shalaby, F; Ho, J; Stanford, WL; Fischer, KD; Schuh, AC; Schwartz, L; Bernstein, A; Rossant, J				Shalaby, F; Ho, J; Stanford, WL; Fischer, KD; Schuh, AC; Schwartz, L; Bernstein, A; Rossant, J			A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis	CELL			English	Article							RECEPTOR TYROSINE KINASE; ENDOTHELIAL GROWTH-FACTOR; YOLK-SAC; MOUSE EMBRYO; STEM-CELLS; PARAAORTIC SPLANCHNOPLEURA; VASCULAR ENDOTHELIUM; INVITRO DEVELOPMENT; ES CELLS; C-KIT	Mouse embryos lacking the receptor tyrosine kinase, Flk1, die without mature endothelial and hematopoietic cells. To investigate the role of Flk1 during vasculogenesis and hematopoiesis, we examined the developmental potential of Flk1(-/-) embryonic stem cells in chimeras. We show that Flk1 is required cell autonomously for endothelial development. Furthermore, Flk1(-/-) cells do not contribute to primitive hematopoiesis in chimeric yolk sacs or definitive hematopoiesis in adult chimeras and chimeric fetal livers. We also demonstrate that cells lacking Flk1 are unable to reach the correct location to form blood islands, suggesting that Flk1 is involved in the movement of cells from the posterior primitive streak to the yolk sac and, possibly, to the intraembryonic sites of early hematopoiesis.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON, CANADA; UNIV TORONTO, DEPT MED, DEPT MED BIOPHYS, TORONTO, ON, CANADA; UNIV TORONTO, DEPT OBSTET & GYNECOL, TORONTO, ON, CANADA; TORONTO HOSP, DIV HEMATOL ONCOL, TORONTO, ON M5G 2C4, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto			Ho, Jackie/AAP-1531-2021	Ho, Jackie/0000-0001-7115-1381; Stanford, William/0000-0002-5813-8016				Batard P, 1996, BLOOD, V87, P2212, DOI 10.1182/blood.V87.6.2212.bloodjournal8762212; Bautch VL, 1996, DEV DYNAM, V205, P1; BERGER CN, 1995, DEV BIOL, V170, P651, DOI 10.1006/dbio.1995.1244; BRUNKOW ME, 1995, GENOMICS, V25, P421, DOI 10.1016/0888-7543(95)80042-K; CUMANO A, 1993, P NATL ACAD SCI USA, V90, P6429, DOI 10.1073/pnas.90.14.6429; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIETERLENLIEVRE F, 1981, DEV BIOL, V88, P180, DOI 10.1016/0012-1606(81)90228-1; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GARCIAPORRERO JA, 1995, ANAT EMBRYOL, V192, P427; GODIN I, 1995, P NATL ACAD SCI USA, V92, P773, DOI 10.1073/pnas.92.3.773; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; Hashiyama M, 1996, BLOOD, V87, P93; HUANG H, 1993, P NATL ACAD SCI USA, V90, P10110, DOI 10.1073/pnas.90.21.10110; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; LIU CP, 1991, DEVELOPMENT, V113, P1315; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; Murray PDF, 1932, P R SOC LOND B-CONTA, V111, P497, DOI 10.1098/rspb.1932.0070; Nagy A., 1993, Gene targeting: a practical approach., P147; OGAWA M, 1993, DEVELOPMENT, V117, P1089; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Partanen J, 1996, DEVELOPMENT, V122, P3013; PERAH G, 1977, J CELL PHYSIOL, V91, P193, DOI 10.1002/jcp.1040910205; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; REITH AD, 1991, GENOME ANAL, V3, P105; RISAU W, 1991, PHARMACOL THERAPEUT, V51, P371, DOI 10.1016/0163-7258(91)90066-U; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sabin FR, 1920, CONTRIB EMBRYOL, V9, P215; Sanchez MJ, 1996, IMMUNITY, V5, P513, DOI 10.1016/S1074-7613(00)80267-8; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SONODA T, 1983, DEV BIOL, V97, P89, DOI 10.1016/0012-1606(83)90066-0; SPRITZ RA, 1994, GENOMICS, V22, P431, DOI 10.1006/geno.1994.1405; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; SYMANN M, 1978, EXP HEMATOL, V6, P749; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WILES MV, 1991, DEVELOPMENT, V111, P259; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; Wurst W., 1993, Gene targeting: a practical approach., P33; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	61	696	731	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					981	990		10.1016/S0092-8674(00)80283-4	http://dx.doi.org/10.1016/S0092-8674(00)80283-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200616	Bronze			2022-12-24	WOS:A1997XE35700018
J	Richards, B; Zhang, H; Phear, G; Meuth, M				Richards, B; Zhang, H; Phear, G; Meuth, M			Conditional mutator phenotypes in hMSH2-deficient tumor cell lines	SCIENCE			English	Article							MISMATCH REPAIR DEFICIENCY; MICROSATELLITE INSTABILITY; COLON-CANCER; COLORECTAL TUMORIGENESIS; GENETIC INSTABILITY; HPRT LOCUS; MUTATIONS; PROTEIN; ACCUMULATION; DEFECTS	Two human tumor cell lines that are deficient in the mismatch repair protein hMSH2 show little or no increase in mutation rate relative to that of a mismatch repair-proficient cell line when the cells are maintained in culture conditions allowing rapid growth. However, mutations accumulate at a high rate in these cells when they are maintained at high density. Thus the mutator phenotype of some mismatch repair-deficient cell lines is conditional and strongly depends on growth conditions. These observations have implications for tumor development because they suggest that mutations may accumulate in tumor cells when growth is limited.	UNIV UTAH,ECCLES INST HUMAN GENET,DEPT ONCOL SCI,SALT LAKE CITY,UT 84112; UNIV UTAH,ECCLES INST HUMAN GENET,DEPT RADIAT ONCOL,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah				Zhang, Hong/0000-0002-3930-6731; Richards, Burt/0000-0003-1789-2335	NCI NIH HHS [R01-CA-62244, T32-CA-09602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009602, R01CA062244] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; BAKER RM, 1974, CELL, V1, P9, DOI 10.1016/0092-8674(74)90149-4; BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BOYER JC, 1995, CANCER RES, V55, P6063; BRANCH P, 1995, CANCER RES, V55, P2304; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; delaChapelle A, 1995, ANNU REV GENET, V29, P329, DOI 10.1146/annurev.ge.29.120195.001553; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; EDWARDS A, 1990, GENOMICS, V6, P593, DOI 10.1016/0888-7543(90)90493-E; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FREEDMAN RS, 1978, CANCER, V42, P2352, DOI 10.1002/1097-0142(197811)42:5<2352::AID-CNCR2820420536>3.0.CO;2-#; Glaab WE, 1997, CARCINOGENESIS, V18, P1, DOI 10.1093/carcin/18.1.1; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LOEB LA, 1991, CANCER RES, V51, P3075; Luria SE, 1943, GENETICS, V28, P491; Malkhosyan S, 1996, MUTAT RES-DNAGING G, V316, P249, DOI 10.1016/S0921-8734(96)90007-7; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marra G, 1996, ONCOGENE, V13, P2189; Meyers M, 1997, CANCER RES, V57, P206; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reynolds TY, 1996, CANCER RES, V56, P5754; RICHARDS BS, UNPUB; RISINGER JI, 1995, CANCER RES, V55, P5664; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; STRAUSS BS, 1992, CANCER RES, V52, P249	38	85	91	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1523	1526		10.1126/science.277.5331.1523	http://dx.doi.org/10.1126/science.277.5331.1523			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278518				2022-12-24	WOS:A1997XV42900045
J	Egger, G; Swinburn, B				Egger, G; Swinburn, B			An ''ecological'' approach to the obesity pandemic	BRITISH MEDICAL JOURNAL			English	Article							DIETARY-FAT INTAKE; BODY-COMPOSITION; WOMEN; WEIGHT; EPIDEMIOLOGY		DEAKIN UNIV,SCH HUMAN MOVEMENT,MELBOURNE,VIC,AUSTRALIA; UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND 1,NEW ZEALAND	Deakin University; University of Auckland								BOURDIN M, 1993, EUR J APPL PHYSIOL O, V66, P439, DOI 10.1007/BF00599618; BROWNELL KD, 1992, J CONSULT CLIN PSYCH, V60, P505, DOI 10.1037/0022-006X.60.4.505; FLATT JP, 1988, DIABETES METAB REV, V4, P571, DOI 10.1002/dmr.5610040603; FRISCH RE, 1994, P NUTR SOC, V53, P113, DOI 10.1079/PNS19940015; GLASSER GA, 1995, SPORTS MED DIGES MAR, P5; HADDON W, 1980, PUBLIC HEALTH REP, V95, P411; HAWKS SR, 1994, J HLTH ED, V25, P147; HEITMANN BL, 1995, AM J CLIN NUTR, V61, P1213, DOI 10.1093/ajcn/61.6.1213; JAMES WPT, 1992, INT J OBESITY, V16, pS23; JAMES WPT, 1995, INT J OBESITY, V19, pS37; KATAHN M, 1990, ANN NY ACAD SCI, V602, P189, DOI 10.1111/j.1749-6632.1990.tb22739.x; Kickbusch I., 1989, HLTH PROMOTION, V4, P265, DOI DOI 10.1093/HEAPR0/4.4.265; LIEBEL RL, 1995, NEW ENGL J MED, V332, P621; LISSNER L, 1995, EUR J CLIN NUTR, V49, P79; LYON XH, 1995, INT J OBESITY, V19, P260; MAGNUS P, 1994, MED J AUSTRALIA, V161, P519; PRENTICE AM, 1991, P NUTR SOC, V50, P441, DOI 10.1079/PNS19910055; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; PREWITT TE, 1991, AM J CLIN NUTR, V54, P304, DOI 10.1093/ajcn/54.2.304; RAYUSSIN E, 1992, OBESITY THEORY THERA, P97; REBUFFESCRIVE M, 1985, J CLIN INVEST, V75, P1973, DOI 10.1172/JCI111914; Rose G., 1992, STRATEGY PREVENTIVE; SCHUTZ Y, 1989, AM J CLIN NUTR, V50, P307, DOI 10.1093/ajcn/50.2.307; STUBBS RJ, 1995, INT J OBESITY, V19, pS11; SWINBURN B, 1993, AM J CLIN NUTR S, V57; TUTEN C, 1995, OBES RES, V3, P313, DOI 10.1002/j.1550-8528.1995.tb00156.x; WESTSTRATE JA, 1995, INT J OBESITY, V19, pS38; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	571	573	1	44	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					477	480		10.1136/bmj.315.7106.477	http://dx.doi.org/10.1136/bmj.315.7106.477			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284671	Green Published			2022-12-24	WOS:A1997XT71400026
J	Whiteman, MC; Deary, IJ; Lee, AJ; Fowkes, FGR				Whiteman, MC; Deary, IJ; Lee, AJ; Fowkes, FGR			Submissiveness and protection from coronary heart disease in the general population: Edinburgh Artery Study	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; WESTERN-COLLABORATIVE-GROUP; A BEHAVIOR; PATTERN; PERSONALITY; HOSTILITY	Background Type A behaviour and, more specifically, hostility and anger have been associated with increased risk of coronary heart disease (CHD). But less attention has been paid to other features of personality. Our aim was to assess whether a submissiveness trait, which is independent of hostility, was related to future risk of CHD in the general population. Methods The Edinburgh Artery Study is a cohort study of a random sample of 809 men and 783 women aged 55 to 74 years, At the baseline examination in 1988, we administered the Bedford-Foulds Personality Deviance Scales. The participants were followed up for 5 years for cardiovascular events. Criteria to define events were adapted from the American Heart Association. Events were ascertained from the Information and Statistics Division of the Scottish Office Home and Health Department, general practitioners, the UK National Health Service Central Register, annual questionnaires to the participants, and the second examination at the end of follow-up. Findings During follow-up, 57 (7.0%) men and 28 (3.6%) women had non-fatal myocardial infarctions; 25 (3.1%) men and 8 (1.0%) women had fatal myocardial infarctions; and 48 (5.9%) men and 41 (5.2%) women developed angina pectoris. We found that mean submissiveness scores were significantly higher in men and women who did not have a non-fatal myocardial infarction than in those who did (18.88 [SE 0.15] vs 17.70 [0.40], p=0.023 in men; 20.76 [0.17] vs 18.18 [0.86], p=0.002 in women). In multiple logistic-regression models, submissiveness remained independently associated with risk of myocardial infarction in women only; a decreased risk of both non-fatal myocardial infarction (relative risk 0.59 [95% Cl 0.40-0.85]) and, to a lesser extent, total myocardial infarction (0.69 [0.27-0.96]), was associated with an increase of 1 SD in submissiveness. Interpretation The personality trait of submissiveness may be protective against non-fatal myocardial infarction, particularly in women. A better understanding is required of the complicated effects of personality on CHD development.	UNIV EDINBURGH,DEPT PSYCHOL,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PUBL HLTH SCI,WOLFSON UNIT PREVENT PERIPHERAL VASC DIS,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh			Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X				[Anonymous], 1990, PERSONALITY ADULTHOO; BAREFOOT JC, 1995, AM J EPIDEMIOL, V142, P477, DOI 10.1093/oxfordjournals.aje.a117663; BEDFORD A, 1978, PERSONALITY DEVIANCE; BOOTHKEWLEY S, 1987, PSYCHOL BULL, V101, P343, DOI 10.1037/0033-2909.101.3.343; Bosma H, 1997, BRIT MED J, V314, P558, DOI 10.1136/bmj.314.7080.558; Brunner E, 1997, BMJ-BRIT MED J, V314, P1472, DOI 10.1136/bmj.314.7092.1472; CASE RB, 1985, NEW ENGL J MED, V312, P737, DOI 10.1056/NEJM198503213121201; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cook WW, 1954, J APPL PSYCHOL, V38, P414, DOI 10.1037/h0060667; DEARY IJ, 1995, PERS INDIV DIFFER, V19, P275, DOI 10.1016/0191-8869(95)00061-A; DEARY IJ, 1994, PSYCHOSOM MED, V56, P197, DOI 10.1097/00006842-199405000-00004; DEMBROSKI TM, 1987, J PERS, V55, P211, DOI 10.1111/j.1467-6494.1987.tb00435.x; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FRIEDMAN M, 1996, BEHAV ITS DIAGNOSIS; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; HAYNES SG, 1980, AM J EPIDEMIOL, V111, P37, DOI 10.1093/oxfordjournals.aje.a112873; HECKER MHL, 1988, PSYCHOSOM MED, V50, P153, DOI 10.1097/00006842-198803000-00005; Houston BK, 1997, PSYCHOSOM MED, V59, P5, DOI 10.1097/00006842-199701000-00002; JOHNSTON DW, 1993, J R SOC MED, V86, P409; Kaplan JR, 1996, PSYCHOSOM MED, V58, P598, DOI 10.1097/00006842-199611000-00008; Leng GC, 1996, INT J EPIDEMIOL, V25, P1172, DOI 10.1093/ije/25.6.1172; MATTHEWS KA, 1982, PSYCHOL BULL, V91, P293; MILLER TQ, 1991, PSYCHOL BULL, V110, P469, DOI 10.1037/0033-2909.110.3.469; Miller TQ, 1996, PSYCHOL BULL, V119, P322, DOI 10.1037/0033-2909.119.2.322; Prineas R., 1982, MINNESOTA CODE MANUA; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; ROSENMAN RH, 1975, JAMA-J AM MED ASSOC, V233, P872, DOI 10.1001/jama.233.8.872; Sapolsky RM, 1995, ANN NY ACAD SCI, V771, P626, DOI 10.1111/j.1749-6632.1995.tb44715.x; SHEKELLE RB, 1985, AM J EPIDEMIOL, V122, P559, DOI 10.1093/oxfordjournals.aje.a114135; SHEKELLE RB, 1985, AM J CARDIOL, V56, P221; SHIVELY CA, 1994, ARTERIOSCLER THROMB, V14, P721, DOI 10.1161/01.ATV.14.5.721; Stone SV, 1990, PERSONALITY DIS, P178; Whitehead M, 1992, INEQUALITIES HLTH BL	33	42	43	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					541	545		10.1016/S0140-6736(96)03141-8	http://dx.doi.org/10.1016/S0140-6736(96)03141-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284775				2022-12-24	WOS:A1997XT22100008
J	Gore, SM				Gore, SM			Age related exposure of patients to the agent of BSE should not be downplayed - Commentary	BRITISH MEDICAL JOURNAL			English	Article											Gore, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							ALPEROVITCH A, 1996, B EPIDEMIOL HEBDOM, V48, P207; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; GORE SM, 1995, BRIT MED J, V311, P1416, DOI 10.1136/bmj.311.7017.1416a; GORE SM, 1996, SCI PARLIAMENT, V53, P2; Gregory J., 1990, DIETARY NUTR SURVEY; Will RG, 1997, LANCET, V349, P847, DOI 10.1016/S0140-6736(97)24012-2	6	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					395	396		10.1136/bmj.315.7105.395	http://dx.doi.org/10.1136/bmj.315.7105.395			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277602	Green Published			2022-12-24	WOS:A1997XR54900018
J	Jentsch, JD; Redmond, DE; Elsworth, JD; Taylor, JR; Youngren, KD; Roth, RH				Jentsch, JD; Redmond, DE; Elsworth, JD; Taylor, JR; Youngren, KD; Roth, RH			Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine	SCIENCE			English	Article							PREFRONTAL CORTEX; CINGULATE CORTEX; WORKING MEMORY; MOTOR DEFICITS; SCHIZOPHRENIA; CLOZAPINE; ACTIVATION; MPTP; AMPHETAMINE; DISEASE	The effects of the psychotomimetic drug phencyclidine on the neurochemistry and function of the prefrontal cortex in vervet monkeys were investigated, Monkeys treated with phencyclidine twice a day for 14 days displayed performance deficits on a task that was sensitive to prefrontal cortex function; the deficits were ameliorated by the atypical antipsychotic drug clozapine, Repeated exposure to phencyclidine caused a reduction in both basal and evoked dopamine utilization in the dorsolateral prefrontal cortex, a brain region that has long been associated with cognitive function, Behavioral deficits and decreased dopamine utilization remained after phencyclidine treatment was stopped, an indication that these effects were not simply due to direct drug effects. The data suggest that repeated administration of phencyclidine in monkeys may be useful for studying psychiatric disorders associated with cognitive dysfunction and dopamine hypofunction in the prefrontal cortex, particularly schizophrenia.	YALE UNIV, SCH MED, DEPT PSYCHIAT, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT USA; YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT USA; YALE UNIV, SCH MED, DEPT NEUROSURG, NEW HAVEN, CT USA; YALE UNIV, SCH MED, INTERDEPT NEUROSCI PROGRAM, NEW HAVEN, CT USA	Yale University; Yale University; Yale University; Yale University; Yale University					NIMH NIH HHS [RSA K05-MH00643, MH44866, MH14092] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000643, R01MH014092, R37MH014092, P50MH044866] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANGRIST B, 1982, PSYCHOPHARMACOLOGY, V78, P128, DOI 10.1007/BF00432248; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; Bunney Blynn Garland, 1995, P1205; CARLIN AS, 1979, AM J DRUG ALCOHOL AB, V6, P273, DOI 10.3109/00952997909001717; COSGROVE J, 1991, J CLIN PSYCHOL, V47, P159, DOI 10.1002/1097-4679(199101)47:1<159::AID-JCLP2270470125>3.0.CO;2-O; Daniel D G, 1989, J Neuropsychiatry Clin Neurosci, V1, P377; DANIEL DG, 1991, J NEUROSCI, V11, P1907; DAVIS KL, 1991, AM J PSYCHIAT, V148, P11; DEUTCH AY, 1992, J NEURAL TRANSM-GEN, P61; DIAMOND A, 1989, BEHAV NEUROSCI, V103, P526, DOI 10.1037/0735-7044.103.3.526; Diamond A, 1988, THOUGHT LANGUAGE, P337; DOLAN RJ, 1995, NATURE, V378, P180, DOI 10.1038/378180a0; ELSWORTH JD, 1990, NEUROSCI LETT, V114, P316, DOI 10.1016/0304-3940(90)90583-U; FEY ET, 1951, J CONSULT PSYCHOL, V15, P311; FREEDMAN M, 1986, BEHAV NEUROSCI, V100, P337, DOI 10.1037/0735-7044.100.3.337; GOLDBERG TE, 1993, BRIT J PSYCHIAT, V162, P43, DOI 10.1192/bjp.162.1.43; GOLDBERG TE, 1994, J CLIN PSYCHIAT, V55, P88; Goldberg Terry E., 1995, P1245; Goldman-Rakic P. S., 1987, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1991, AM PSYCHOP, P1; HERTZMAN M, 1990, AM J PSYCHIAT, V147, P255; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; Jentsch JD, 1997, J NEUROSCI, V17, P1769; Jentsch JD, 1997, NEUROPSYCHOPHARMACOL, V17, P92, DOI 10.1016/S0893-133X(97)00034-1; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KARLSSON P, 1995, PSYCHOPHARMACOLOGY, V121, P309, DOI 10.1007/BF02246068; KLONOFF H, 1970, J NERV MENT DIS, V150, P291, DOI 10.1097/00005053-197004000-00004; LEE MA, 1994, J CLIN PSYCHIAT, V55, P82; LEVIN S, 1984, J PSYCHIATR RES, V18, P27, DOI 10.1016/0022-3956(84)90046-3; LEWIS JE, 1986, PHENCYCLIDINE UPDATE, P66; Milner B., 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI DOI 10.1001/ARCHNEUR.1963.00460070100010; Murphy BL, 1997, NEUROPSYCHOPHARMACOL, V16, P433, DOI 10.1016/S0893-133X(97)00019-5; OWEN AM, 1993, BRAIN, V116, P1159, DOI 10.1093/brain/116.5.1159; PARK S, 1992, ARCH GEN PSYCHIAT, V49, P975; RIDLEY RM, 1993, NEUROSCIENCE, V52, P595, DOI 10.1016/0306-4522(93)90409-9; ROBBINS TW, 1990, SCHIZOPHRENIA BULL, V16, P391, DOI 10.1093/schbul/16.3.391; SALETU B, 1987, PHARMACOPSYCHIATRY, V20, P12, DOI 10.1055/s-2007-1017125; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SHALLICE T, 1991, PSYCHOL MED, V21, P661, DOI 10.1017/S0033291700022303; TAYLOR JR, 1990, BEHAV NEUROSCI, V104, P564, DOI 10.1037/0735-7044.104.4.564; TAYLOR JR, 1990, BRAIN, V113, P617, DOI 10.1093/brain/113.3.617; WEINBERGER DR, 1988, ARCH GEN PSYCHIAT, V45, P609; WU JC, 1991, PSYCHOPHARMACOLOGIA, V11, P47; Young K. A., 1995, Society for Neuroscience Abstracts, V21, P1705; YOUNGREN KD, 1994, NEUROSCI LETT, V165, P41, DOI 10.1016/0304-3940(94)90704-8	45	324	345	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					953	955		10.1126/science.277.5328.953	http://dx.doi.org/10.1126/science.277.5328.953			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XQ985	9252326				2022-12-24	WOS:A1997XQ98500041
J	Martin, TG; Somberg, KA; Meng, YG; Cohen, RL; Heid, CA; deSauvage, FJ; Shuman, MA				Martin, TG; Somberg, KA; Meng, YG; Cohen, RL; Heid, CA; deSauvage, FJ; Shuman, MA			Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation	ANNALS OF INTERNAL MEDICINE			English	Article							C-MPL LIGAND; THROMBOCYTOPENIA	Background: Thrombocytopenia is a common manifestation of cirrhosis. Objectives: To determine plasma thrombopoietin levels in cirrhotic patients with thrombocytopenia, monitor those levels before and after orthotopic liver transplantation, and compare thrombopoietin messenger RNA (mRNA) levels in liver samples from cirrhotic patients and controls. Design: A cross-sectional study of patients with cirrhosis, including a small subset of patients who had orthotopic liver transplantation. Setting: University-affiliate hospital. Patients: 44 patients with cirrhosis, including 17 patients who had orthotopic liver transplantation. Intervention: Orthotopic liver transplantation. Measurements: Plasma thrombopoietin levels in all patients, platelet counts in all patients, and thrombopoietin mRNA levels in liver samples from nine patients with cirrhosis and eight controls. Results: Thrombopoietin levels were undetectable in 39 of 44 patients with cirrhosis. In 16 of 17 patients, the levels became detectable after liver transplantation. Thrombopoietin mRNA levels were decreased in liver samples from patients with cirrhosis compared with controls (P = 0.0103). Conclusions: The low thrombopoietin levels in cirrhotic patients with thrombocytopenia and the increased levels after orthotopic liver transplantation suggest that impaired production of thrombopoietin may contribute to thrombocytopenia associated with cirrhosis.	GENENTECH INC, BIOANALYT TECHNOL DEPT, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT MOL ONCOL, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Martin, TG (corresponding author), UNIV CALIF SAN FRANCISCO, MED CTR, DIV HEMATOL, BOX 1270, PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA.		de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584	NHLBI NIH HHS [HL54476] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054476] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alvarez OA, 1996, AM J GASTROENTEROL, V91, P134; ASTER RH, 1966, J CLIN INVEST, V45, P645, DOI 10.1172/JCI105380; CRANE C, 1962, SURG GYNECOL OBSTET, V115, P12; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; Emmons RVB, 1996, BLOOD, V87, P4068, DOI 10.1182/blood.V87.10.4068.bloodjournal87104068; FERRARA J, 1979, SURGERY, V86, P570; HARKER LA, 1969, J CLIN INVEST, V48, P963, DOI 10.1172/JCI106077; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; KAUSHANSKY K, 1995, THROMB HAEMOSTASIS, V74, P521; KUTER DJ, 1995, BLOOD, V85, P2720, DOI 10.1182/blood.V85.10.2720.bloodjournal85102720; LOK S, 1994, STEM CELLS, V12, P586, DOI 10.1002/stem.5530120606; MCALLISTER E, 1995, AM SURGEON, V61, P129; Meng YG, 1996, BRIT J HAEMATOL, V95, P535, DOI 10.1046/j.1365-2141.1996.d01-1933.x; Sanyal AJ, 1996, HEPATOLOGY, V23, P32, DOI 10.1002/hep.510230105; TOGHILL PJ, 1977, J CLIN PATHOL, V30, P367, DOI 10.1136/jcp.30.4.367	15	136	137	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1997	127	4					285	288		10.7326/0003-4819-127-4-199708150-00005	http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR266	9265428				2022-12-24	WOS:A1997XR26600007
J	Frey, M; Chomet, P; Glawischnig, E; Stettner, C; Grun, S; Winklmair, A; Eisenreich, W; Bacher, A; Meeley, RB; Briggs, SP; Simcox, K; Gierl, A				Frey, M; Chomet, P; Glawischnig, E; Stettner, C; Grun, S; Winklmair, A; Eisenreich, W; Bacher, A; Meeley, RB; Briggs, SP; Simcox, K; Gierl, A			Analysis of a chemical plant defense mechanism in grasses	SCIENCE			English	Article							TRYPTOPHAN SYNTHASE-ALPHA; ESCHERICHIA-COLI; ARABIDOPSIS-THALIANA; HYDROXAMIC ACIDS; MAIZE; EXPRESSION; GENE; BIOSYNTHESIS; SUBUNIT; MONOOXYGENASE	In the Gramineae, the cyclic hydroxamic acids 2,4-dihydroxy-1,4-benzoxazin-3-one (DIBOA) and 2,4-dihydroxy-7-methoxy-1,4-benzoxazin-3-one (DIMBOA) form part of the defense against insects and microbial pathogens. Five genes, Bx1 through Bx5, are required for DIBOA biosynthesis in maize. The functions of these five genes, clustered on chromosome 4, were demonstrated in vitro. Bx1 encodes a tryptophan synthase a homolog that catalyzes the formation of indole for the production of secondary metabolites rather than tryptophan, thereby defining the branch point from primary to secondary metabolism. Bx2 through Bx5 encode cytochrome P450-dependent monooxygenases that catalyze four consecutive hydroxylations and one ring expansion to form the highly oxidized DIBOA.	TECH UNIV MUNICH, GENET INST, D-85747 GARCHING, GERMANY; DEKALB GENET CORP, MYSTIC, CT 06355 USA; TECH UNIV MUNICH, INST ORGAN CHEM & BIOCHEM, D-85747 GARCHING, GERMANY; PIONEER HI BRED INT INC, JOHNSTON, IA 50131 USA; OHIO STATE UNIV, DEPT HORT & CROP SCI, WOOSTER, OH 44691 USA	Technical University of Munich; Technical University of Munich; DuPont; Pioneer Hi-Bred International, Inc.; University System of Ohio; Ohio State University			Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279; Glawischnig, Erich/0000-0001-9280-5065				BAILEY BA, 1991, PLANT PHYSIOL, V95, P792, DOI 10.1104/pp.95.3.792; BENSEN RJ, 1995, PLANT CELL, V7, P75, DOI 10.1105/tpc.7.1.75; Chomet Paul S., 1994, P243; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; Desai SR, 1996, CHEM COMMUN, P1321, DOI 10.1039/cc9960001321; FREY M, 1995, MOL GEN GENET, V246, P100, DOI 10.1007/BF00290138; Glawischnig E, 1997, PHYTOCHEMISTRY, V45, P715, DOI 10.1016/S0031-9422(96)00832-1; HAMILTON R. H., 1964, WEEDS, V12, P27, DOI 10.2307/4040633; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KRAMER VC, 1995, PLANT MOL BIOL, V27, P1183, DOI 10.1007/BF00020891; KUMAR P, 1994, PHYTOCHEMISTRY, V36, P893, DOI 10.1016/S0031-9422(00)90458-8; KUTCHAN TM, 1995, PLANT CELL, V7, P1059, DOI 10.2307/3870057; LIM WK, 1991, J BACTERIOL, V173, P1886, DOI 10.1128/jb.173.6.1886-1893.1991; Mena M, 1996, SCIENCE, V274, P1537, DOI 10.1126/science.274.5292.1537; NIEMEYER HM, 1988, PHYTOCHEMISTRY, V27, P3349, DOI 10.1016/0031-9422(88)80731-3; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; RADWANSKI ER, 1995, MOL GEN GENET, V248, P657, DOI 10.1007/BF02191705; RADWANSKI ER, 1995, PLANT CELL, V7, P921, DOI 10.1105/tpc.7.7.921; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; TRUAN G, 1993, GENE, V125, P49, DOI 10.1016/0378-1119(93)90744-N; TSUJI J, 1993, PHYSIOL MOL PLANT P, V43, P221, DOI 10.1006/pmpp.1993.1052; URBAN P, 1994, EUR J BIOCHEM, V222, P843, DOI 10.1111/j.1432-1033.1994.tb18931.x; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; WEISCHET WO, 1976, EUR J BIOCHEM, V65, P375, DOI 10.1111/j.1432-1033.1976.tb10351.x; WOODWARD MD, 1979, PLANT PHYSIOL, V63, P9, DOI 10.1104/pp.63.1.9; WRIGHT AD, 1992, PLANT CELL, V4, P711, DOI 10.1105/tpc.4.6.711; Zhao JM, 1996, PLANT CELL, V8, P2235, DOI 10.1105/tpc.8.12.2235	28	499	548	7	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 1	1997	277	5326					696	699		10.1126/science.277.5326.696	http://dx.doi.org/10.1126/science.277.5326.696			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235894				2022-12-24	WOS:A1997XN90700044
J	Hamel, MB; Phillips, RS; Davis, RB; Desbiens, N; Connors, AF; Teno, JM; Wenger, N; Lynn, J; Wu, AW; Fulkerson, W; Tsevat, J				Hamel, MB; Phillips, RS; Davis, RB; Desbiens, N; Connors, AF; Teno, JM; Wenger, N; Lynn, J; Wu, AW; Fulkerson, W; Tsevat, J			Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	19th Annual National Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 1996	WASHINGTON, D.C.	Soc Gen Internal Med		outcome and process assessment (health care); dialysis; cost-benefit analysis; kidney failure, acute; decision making	ACUTE-RENAL-FAILURE; CONVENIENT APPROXIMATION; REQUIRING DIALYSIS; LIFE EXPECTANCY; RISK-FACTORS; APACHE-II; SURVIVAL; SYSTEM; PROGNOSIS; SUPPORT	Background: Renal failure requiring dialysis in the setting of hospitalization for serious illness is a poor prognostic sign, and dialysis and aggressive care are sometimes withheld. Objective: To evaluate the clinical outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care for seriously ill hospitalized patients. Design: Prospective cohort study and cost-effectiveness analysis. Setting: Five geographically diverse teaching hospitals. Patients: 490 patients (median age, 61 years; 58% women) enrolled in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT) in whom dialysis was initiated. Measurements: Survival, functional status, quality of life, and health care costs. Life expectancy was estimated by extrapolating survival data (up to 4.4 years of followup) using a declining exponential function. Utilities (quality-of-life weights) were estimated by using time-tradeoff questions. Costs were based on data from SUPPORT and published Medicare data. Results: Median duration of survival was 32 days, and only 27% of patients were alive after 6 months. Survivors reported a median of one dependency in activities of daily living, and 62% rated their quality of life as ''good'' or better. Overall, the estimated cost per quality-adjusted life-year saved by initiating dialysis and continuing aggressive care rather than withholding dialysis and allowing death to occur was $128 200. For the 103 patients in the worst prognostic category, the estimated cost per quality-adjusted life-year was $274 100; for the 94 patients in the best prognostic category, the cost per quality-adjusted life-year was $61 900. Conclusions: For the few patients who survived, clinical outcomes were fairly good. With the exception of patients with the best prognoses, however, the cost-effectiveness of initiating dialysis and continuing aggressive care far exceeded $50 000 per quality-adjusted life-year, a commonly cited threshold for cost-effective care.	UNIV TENNESSEE, CHATTANOOGA UNIV, CHATTANOOGA, TN 37403 USA; UNIV VIRGINIA, SCH MED, DEPT HLTH EVALUAT SCI, CHARLOTTESVILLE, VA 22908 USA; JOHNS HOPKINS UNIV, HLTH SERV RES CTR, BALTIMORE, MD 21205 USA; DUKE UNIV, SCH MED, DURHAM, NC 27710 USA; UNIV CINCINNATI, MED CTR, SECT OUTCOMES RES, CINCINNATI, OH 45267 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90095 USA; DUKE UNIV, MED CTR, SCH MED, DURHAM, NC 27710 USA	University of Tennessee System; University of Tennessee at Chattanooga; University of Virginia; Johns Hopkins University; Duke University; University System of Ohio; University of Cincinnati; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Duke University	Hamel, MB (corresponding author), BETH ISRAEL DEACONESS MED CTR, DIV GEN MED & PRIMARY CARE, 330 BROOKLINE AVE, LY-330, BOSTON, MA 02215 USA.		Wu, Albert/AAJ-4780-2021	Connors, Alfred F./0000-0001-7123-3360				BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; CHERTOW GM, 1995, ARCH INTERN MED, V155, P1505, DOI 10.1001/archinte.155.14.1505; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; EGGERS P, 1992, SEMIN NEPHROL, V12, P284; GOLDMAN L, 1992, HEART DIS TXB CARDIO; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1976, INT J HEALTH SERV, V6, P493, DOI 10.2190/UURL-2RYU-WRYD-EY3K; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kuntz KM, 1996, CIRCULATION, V94, P957, DOI 10.1161/01.CIR.94.5.957; LIEN J, 1985, ARCH INTERN MED, V145, P2067, DOI 10.1001/archinte.145.11.2067; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; LOHR JW, 1988, AM J KIDNEY DIS, V11, P254, DOI 10.1016/S0272-6386(88)80158-6; LYNN J, 1990, J CLIN EPIDEMIOL, V43, pS1, DOI 10.1016/0895-4356(90)90211-7; MAHER ER, 1989, Q J MED, V72, P857; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; McCarthy JT, 1996, MAYO CLIN PROC, V71, P117, DOI 10.4065/71.2.117; SHUSTERMAN N, 1987, AM J MED, V83, P65, DOI 10.1016/0002-9343(87)90498-0; SPURNEY RF, 1991, CRIT CARE MED, V19, P8, DOI 10.1097/00003246-199101000-00007; Torrance G W, 1972, Health Serv Res, V7, P118; TSEVAT J, 1990, J CLIN EPIDEMIOL, V43, pS73, DOI 10.1016/0895-4356(90)90224-D; TSEVAT J, 1995, ANN INTERN MED, V122, P514, DOI 10.7326/0003-4819-122-7-199504010-00007; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WHEELER DC, 1986, Q J MED, V61, P977	29	165	166	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					195	+		10.7326/0003-4819-127-3-199708010-00003	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XN129	9245224				2022-12-24	WOS:A1997XN12900003
J	Edmonson, MB; Stoddard, JJ; Owens, LM				Edmonson, MB; Stoddard, JJ; Owens, LM			Hospital readmission with feeding-related problems after early postpartum discharge of normal newborns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TERM NEWBORN	Context.-Increasingly short postpartum hospital stays in the United States precipitated a policy debate that culminated in passage of the Newborns' and Mothers' Health Protection Act of 1996. The debate occurred without population-based evidence for adverse health effects in newborns who are discharged early. Objective.-To determine whether early postpartum hospital discharge of normal newborns increases their risk for hospital readmission with feeding-related problems. Design and Setting.-Nested case-control analysis of 1991 to 1994 Wisconsin birth certificate and hospital discharge data. Subjects.-A total of 210 readmitted case patients and 630 control subjects selected from a cohort of 120 290 normal newborns who weighed at least 2500 g, were delivered vaginally of mothers with uncomplicated medical and obstetrical histories, and were discharged from the hospital either early (day of life 1 or 2) or conventionally (day 3). Outcome Measure.-Readmission at age 4 to 28 days with discharge diagnoses indicating a primary feeding problem, secondary dehydration, or inadequate weight gain. Results.-Early discharges increased 3-fold (reaching 521/1000 discharges) during the study period, but feeding-related readmissions (1.7/1000) remained stable. Most readmitted newborns (53.8%) were 4 to 7 days old, many (34.3%) had concurrent dehydration and jaundice, and 29% were admitted through emergency departments. Readmitted newborns were significantly (P<.05) more likely to have been breast-fed, firstborn, or preterm or to have mothers who were poorly educated (<12th grade), unmarried, or receiving Medicaid. Readmission was not associated with early discharge (adjusted odds ratio, 1.05; 95% confidence interval, 0.71-1.53), Conclusion.-Although several neonatal and maternal factors increase the risk that a normal newborn will be rehospitalized with a feeding-related problem, early discharge following an uncomplicated postpartum hospital stay appears to have little or no independent effect on this risk.	UNIV WISCONSIN,CTR HLTH SCI,DEPT PREVENT MED,MADISON,WI 53792; WISCONSIN DEPT HLTH & SOCIAL SERV,CTR HLTH STAT,MADISON,WI	University of Wisconsin System; University of Wisconsin Madison	Edmonson, MB (corresponding author), UNIV WISCONSIN,CTR HLTH SCI,DEPT PEDIAT,H6-440 CLIN SCI CTR,600 HIGHLAND AVE,MADISON,WI 53792, USA.							*AM AC PED COMM FE, 1995, PEDIATRICS, V96, P788; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; BRITTON JR, 1994, PEDIATRICS, V94, P291; Center for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P335; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P700; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; Iezzoni L I, 1990, Int J Technol Assess Health Care, V6, P272; Kini N, 1995, Wis Med J, V94, P143; LEE KS, 1995, J PEDIATR-US, V127, P758, DOI 10.1016/S0022-3476(95)70170-2; MAISELS MJ, 1995, PEDIATRICS, V96, P730; Margolis LH, 1995, CLIN PEDIATR, V34, P626, DOI 10.1177/000992289503401201; Naylor CD, 1996, JAMA-J AM MED ASSOC, V275, P554, DOI 10.1001/jama.275.7.554; NEWMAN TB, 1992, PEDIATRICS, V89, P809; *OFF HLTH CAR INF, 1995, HLTH CAR DAT ANN REP; PARISI V, 1996, NEW ENGL J MED, V333, P1635; POSES RM, 1995, MED CARE, V33, pAS36; Public Health Service, 1988, INT CLASS DIS; *SAS I INC, 1990, SAS TECHN REP P 200, P175; SELBY JV, 1994, EPIDEMIOL REV, V16, P90, DOI 10.1093/oxfordjournals.epirev.a036148; Soskolne EI, 1996, ARCH PEDIAT ADOL MED, V150, P373, DOI 10.1001/archpedi.1996.02170290039006; WEN SW, 1995, JAMA-J AM MED ASSOC, V274, P1687, DOI 10.1001/jama.274.21.1687; *WI ASS PER CAR, 1993, INT C REP EARL DISCH, P1	22	93	98	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					299	303		10.1001/jama.278.4.299	http://dx.doi.org/10.1001/jama.278.4.299			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL059	9228435				2022-12-24	WOS:A1997XL05900030
J	Super, M; Postlethwaite, RJ				Super, M; Postlethwaite, RJ			Genes, familial enuresis, and clinical management	LANCET			English	Editorial Material							NOCTURNAL ENURESIS; VASOPRESSIN		ROYAL MANCHESTER CHILDRENS HOSP,DEPT PAEDIAT NEPHROL,MANCHESTER M27 4HA,LANCS,ENGLAND	Royal Manchester Children's Hospital	Super, M (corresponding author), ROYAL MANCHESTER CHILDRENS HOSP,DEPT PAEDIAT GENET,MANCHESTER M27 4HA,LANCS,ENGLAND.							Arnell H, 1997, J MED GENET, V34, P360, DOI 10.1136/jmg.34.5.360; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; EIBERG H, 1995, NAT GENET, V10, P354, DOI 10.1038/ng0795-354; FERGUSSON DM, 1986, PEDIATRICS, V78, P884; HOGG RJ, 1993, J UROLOGY, V150, P444, DOI 10.1016/S0022-5347(17)35506-4; Koff SA, 1996, PEDIATR NEPHROL, V10, P667, DOI 10.1007/s004670050186; RITTIG S, 1989, AM J PHYSIOL, V256, pF664, DOI 10.1152/ajprenal.1989.256.4.F664; Steers WD, 1997, LANCET, V349, P1604, DOI 10.1016/S0140-6736(05)61633-9; WILLE S, 1904, ACTA PAEDIAT, V93, P772	9	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					159	160		10.1016/S0140-6736(05)62347-1	http://dx.doi.org/10.1016/S0140-6736(05)62347-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250180				2022-12-24	WOS:A1997XL72200006
J	Engert, F; Bonhoeffer, T				Engert, F; Bonhoeffer, T			Synapse specificity of long-term potentiation breaks down at short distances	NATURE			English	Article							SLICE CULTURES; RAT HIPPOCAMPUS; ENHANCEMENT; PLASTICITY; TRANSMISSION; PROBABILITY; RELEASE; NEURONS	Long-term potentiation (LTP), the long-lasting increase in synaptic transmission, has been proposed to be a cellular mechanism essential for learning and memory, neuronal development, and circuit reorganization. In the original theoretical(1) and experimental(2) work it was assumed that only synapses that had experienced concurrent pre- and postsynaptic activity are subject to synaptic modification. It has since been shown, however, that LTP is also expressed in synapses on neighbouring neurons that have not undergone the induction procedure(3-5). Yet, it is still believed that this spread of LTP is limited to adjacent postsynaptic cells, and does not occur for synapses on neighbouring input fibres(2,6,7). However, for technical reasons, tests for 'input specificity' were always done for synapses relatively far apart. Here we have used a new local superfusion technique, which allowed us to assess the synaptic specificity of LTP with a spatial resolution of similar to 30 mu m. Our results indicate that there is no input specificity at a distance of less than 70 mu m. Synapses in close proximity to a site of potentiation are also potentiated regardless of their own history of activation, whereas synapses far away show no potentiation.	MAX PLANCK INST PSYCHIAT, D-82152 MUNICH, GERMANY	Max Planck Society			Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634				Arancio O, 1996, CELL, V87, P1025, DOI 10.1016/S0092-8674(00)81797-3; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; Cash S, 1996, SCIENCE, V272, P998, DOI 10.1126/science.272.5264.998; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; FROTSCHER M, 1990, PROG BRAIN RES, V83, P323; GAHWILER BH, 1981, PROC R SOC SER B-BIO, V211, P287, DOI 10.1098/rspb.1981.0007; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; HEBB DO, 1949, ORG BEHAVIOR; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; Kossel A, 1990, Neuroreport, V1, P115, DOI 10.1097/00001756-199010000-00008; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIPSKI J, 1981, J NEUROSCI METH, V4, P1, DOI 10.1016/0165-0270(81)90015-7; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; Neveu D, 1996, J NEUROPHYSIOL, V75, P2157, DOI 10.1152/jn.1996.75.5.2157; OTANI S, 1995, LEARN MEMORY, V2, P101, DOI 10.1101/lm.2.2.101; Scanziani M, 1996, NATURE, V380, P446, DOI 10.1038/380446a0; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; Veselovsky NS, 1996, PFLUG ARCH EUR J PHY, V432, P351, DOI 10.1007/s004240050143; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; WOLBURG H, 1991, J NEUROCYTOL, V20, P552, DOI 10.1007/BF01215263	25	192	195	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 17	1997	388	6639					279	284		10.1038/40870	http://dx.doi.org/10.1038/40870			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230437	Bronze			2022-12-24	WOS:A1997XL12100052
J	Song, YH				Song, YH			Why tyrosinase for treatment of melanoma	LANCET			English	Editorial Material							VITILIGO				Song, YH (corresponding author), UNIV FLORIDA, DEPT PATHOL IMMUNOL & LAB MED, GAINESVILLE, FL 32610 USA.		Song, Yao-Hua/A-2516-2011					ALBADRI AMT, 1993, J PATHOL, V170, P149, DOI 10.1002/path.1711700209; Baharav E, 1996, CLIN EXP IMMUNOL, V105, P84, DOI 10.1046/j.1365-2249.1996.d01-727.x; Becker JC, 1996, J INVEST DERMATOL, V107, P627, DOI 10.1111/1523-1747.ep12584237; Berd D, 1996, CANCER IMMUNOL IMMUN, V42, P263, DOI 10.1007/s002620050280; BOLOGNIA JL, 1988, J AM ACAD DERMATOL, V19, P217, DOI 10.1016/S0190-9622(88)70168-1; DUHRA P, 1991, CLIN EXP DERMATOL, V16, P303, DOI 10.1111/j.1365-2230.1991.tb00383.x; HARA I, 1995, J EXP MED, V182, P1609, DOI 10.1084/jem.182.5.1609; SALTER J, 1995, MELANOMA RES, V5, P267, DOI 10.1097/00008390-199508000-00010; SCHALLREUTER KU, 1991, DERMATOLOGICA, V183, P239, DOI 10.1159/000247693; SONG YH, 1994, LANCET, V344, P1049, DOI 10.1016/S0140-6736(94)91709-4; VISSEREN MJW, 1995, J IMMUNOL, V154, P3991	11	20	20	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	1997	350	9071					82	83		10.1016/S0140-6736(05)61810-7	http://dx.doi.org/10.1016/S0140-6736(05)61810-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228956				2022-12-24	WOS:A1997XK11400004
J	Giannelli, G; FalkMarzillier, J; Schiraldi, O; StetlerStevenson, WG; Quaranta, V				Giannelli, G; FalkMarzillier, J; Schiraldi, O; StetlerStevenson, WG; Quaranta, V			Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; IV COLLAGENASE; KERATINOCYTES; CARCINOMAS; ACTIVATION; ADHESION; COMPLEX	Structural changes in the extracellular matrix are necessary for cell migration during tissue remodeling and tumor invasion. Specific cleavage of laminin-5 (Ln-5) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells. MMP2 cleaved the Ln-5 gamma 2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility. This altered form of Ln-5 is found in tumors and in tissues undergoing remodeling, but not in quiescent tissues. Cleavage of Ln-5 by MMP2 and the resulting activation of the Ln-5 cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling.	SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV BARI, INST MED CLIN 2, I-70124 BARI, ITALY; NCI, PATHOL LAB, BETHESDA, MD 20892 USA	Scripps Research Institute; Universita degli Studi di Bari Aldo Moro; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012; Quaranta, Vito/G-6512-2016; giannelli, gianluigi/A-8169-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808; Quaranta, Vito/0000-0001-7491-8672; 	NATIONAL CANCER INSTITUTE [R01CA047858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010063] Funding Source: NIH RePORTER; NCI NIH HHS [CA47858] Funding Source: Medline; NIDCR NIH HHS [DE10063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AUMAILLEY M, 1990, FEBS LETT, V262, P82, DOI 10.1016/0014-5793(90)80159-G; Baker SE, 1996, J CELL SCI, V109, P2509; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BURDSAL CA, 1991, DEV BIOL, V144, P327, DOI 10.1016/0012-1606(91)90425-3; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CALOF AL, 1994, NEURON, V13, P117, DOI 10.1016/0896-6273(94)90463-4; CALOF AL, 1996, NATURE, V383, P441; Chen Wen-Tien, 1992, Current Opinion in Cell Biology, V4, P802; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; Giannelli G, 1996, LAB INVEST, V74, P1091; GIANNELLI G, UNPUB; HORMIA M, 1995, J INVEST DERMATOL, V105, P557, DOI 10.1111/1523-1747.ep12323451; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; KARECLA PI, 1994, CELL ADHES COMMUN, V2, P309, DOI 10.3109/15419069409014206; KOHN EC, 1995, CANCER RES, V55, P1856; LANGHOFER M, 1993, J CELL SCI, V105, P753; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAURIE GW, 1982, J CELL BIOL, V95, P340, DOI 10.1083/jcb.95.1.340; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; MONTEAGUDO C, 1990, AM J PATHOL, V136, P585; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; Plopper G, 1996, J CELL SCI, V109, P1965; PYKE C, 1995, CANCER RES, V55, P4132; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SOULE HD, 1990, CANCER RES, V50, P6075; WANG X, 1994, CANCER RES, V54, P4726; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	32	997	1020	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					225	228		10.1126/science.277.5323.225	http://dx.doi.org/10.1126/science.277.5323.225			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211848				2022-12-24	WOS:A1997XK41800041
J	Wang, B; Kuspa, A				Wang, B; Kuspa, A			Dictyostelium development in the absence of cAMP	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; 3-DIMENSIONAL SCROLL WAVES; ADENYLATE-CYCLASE ACTIVITY; GENE-EXPRESSION; CELL-DIFFERENTIATION; PHOSPHODIESTERASE GENE; SIGNAL-TRANSDUCTION; EXTRACELLULAR CAMP; CATALYTIC SUBUNIT; DISCOIDEUM	Adenosine 3',5'-monophosphate (cAMP) and cAMP-dependent protein kinase (PKA) are regulators of development in many organisms. Dictyostelium uses cAMP as an extracellular chemoattractant and as an intracellular signal for differentiation. Cells that are mutant in adenylyl cyclase do not develop. Moderate expression of the catalytic subunit of PKA in adenylyl cyclase-null cells led to near-normal development without detectable accumulation of cAMP. These results suggest that all intracellular cAMP signaling is effected through PKA and that signals other than extracellular cAMP coordinate morphogenesis in Dictyostelium.	BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Kuspa, Adam/0000-0002-9156-149X	NIGMS NIH HHS [R01 GM052359] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052359] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; ABE K, 1983, J GEN MICROBIOL, V129, P1623; ANJARD C, 1992, DEVELOPMENT, V115, P785; BONNER JT, 1952, AM NAT, V86, P79, DOI 10.1086/281707; BONNER JT, 1959, P NATL ACAD SCI USA, V45, P379, DOI 10.1073/pnas.45.3.379; BRETSCHNEIDER T, 1995, P NATL ACAD SCI USA, V92, P4387, DOI 10.1073/pnas.92.10.4387; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; Dormann D, 1996, DEVELOPMENT, V122, P761; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; FOSNAUGH KL, 1989, NUCLEIC ACIDS RES, V17, P9489, DOI 10.1093/nar/17.22.9489; FRANKE J, 1987, DEV BIOL, V124, P504, DOI 10.1016/0012-1606(87)90503-3; GERISCH G, 1985, COLD SPRING HARB SYM, V50, P813, DOI 10.1101/SQB.1985.050.01.099; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HARWOOD AJ, 1992, DEV BIOL, V149, P90, DOI 10.1016/0012-1606(92)90266-J; HARWOOD AJ, 1992, CELL, V69, P615, DOI 10.1016/0092-8674(92)90225-2; HOPPER NA, 1993, DEVELOPMENT, V119, P147; KENCHT DA, 1986, MOL CELL BIOL, V6, P3973; KLEIN C, 1976, FEBS LETT, V68, P125, DOI 10.1016/0014-5793(76)80419-X; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; Levine H, 1996, P NATL ACAD SCI USA, V93, P6382, DOI 10.1073/pnas.93.13.6382; Loomis WF, 1996, MICROBIOL REV, V60, P135, DOI 10.1128/MMBR.60.1.135-150.1996; MANN SKO, 1993, DEVELOPMENT, V119, P135; MANN SKO, 1994, P NATL ACAD SCI USA, V91, P10561, DOI 10.1073/pnas.91.22.10561; Mann SKO, 1997, DEV BIOL, V183, P208, DOI 10.1006/dbio.1996.8499; MANN SKO, 1992, P NATL ACAD SCI USA, V89, P10701, DOI 10.1073/pnas.89.22.10701; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MCROBBIE SJ, 1988, DEVELOPMENT, V104, P275; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; PART D, 1985, CELL DIFFER DEV, V17, P221, DOI 10.1016/0045-6039(85)90496-8; PETERS DJM, 1991, P NATL ACAD SCI USA, V88, P9219, DOI 10.1073/pnas.88.20.9219; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PITT GS, 1993, GENE DEV, V7, P2172, DOI 10.1101/gad.7.11.2172; RAPER KENNETH B., 1940, JOUR ELISHA MITCHELL SCI SOC, V56, P241; Reymond CD, 1995, EXPERIENTIA, V51, P1166, DOI 10.1007/BF01944734; RICHARDSON DL, 1991, DEV BIOL, V144, P269, DOI 10.1016/0012-1606(91)90421-X; Rietdorf J, 1996, DEV BIOL, V177, P427, DOI 10.1006/dbio.1996.0175; ROOS W, 1977, NATURE, V266, P259, DOI 10.1038/266259a0; SCHAAP P, 1986, CELL, V45, P137, DOI 10.1016/0092-8674(86)90545-3; SCHULKES C, 1995, FEBS LETT, V368, P381, DOI 10.1016/0014-5793(95)00676-Z; SHAULSKY G, 1995, GENE DEV, V9, P1111, DOI 10.1101/gad.9.9.1111; SIEGERT F, 1992, P NATL ACAD SCI USA, V89, P6433, DOI 10.1073/pnas.89.14.6433; SIEGERT F, 1995, CURR BIOL, V5, P937, DOI 10.1016/S0960-9822(95)00184-9; SIMON MN, 1992, NATURE, V356, P171, DOI 10.1038/356171a0; Soede RDM, 1996, DEV BIOL, V177, P152, DOI 10.1006/dbio.1996.0152; STERNFELD J, 1981, DIFFERENTIATION, V20, P10, DOI 10.1111/j.1432-0436.1981.tb01150.x; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; STRUTT DI, 1995, NATURE, V373, P705, DOI 10.1038/373705a0; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; TOMCHIK KJ, 1981, SCIENCE, V212, P443, DOI 10.1126/science.6259734; TRAYNOR D, 1992, P NATL ACAD SCI USA, V89, P8303, DOI 10.1073/pnas.89.17.8303; VanHaastert PJM, 1995, EXPERIENTIA, V51, P1144; WALLRAFF E, 1984, J GEN MICROBIOL, V130, P2103; Wang B., UNPUB; WEIJER CJ, 1987, METHOD CELL BIOL, V28, P449; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WU L, 1995, DEV BIOL, V171, P149, DOI 10.1006/dbio.1995.1267	62	87	87	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					251	254		10.1126/science.277.5323.251	http://dx.doi.org/10.1126/science.277.5323.251			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211856				2022-12-24	WOS:A1997XK41800049
J	Chuang, HH; Jan, YN; Jan, LY				Chuang, HH; Jan, YN; Jan, LY			Regulation of IRK3 inward rectifier K+ channel by m1 acetylcholine receptor and intracellular magnesium	CELL			English	Article							BETA-GAMMA-SUBUNITS; NUCLEUS ACCUMBENS NEURONS; RAT SYMPATHETIC NEURONS; M-CURRENT INHIBITION; POTASSIUM CHANNEL; MUSCARINIC RECEPTOR; CALCIUM CURRENT; SUBSTANCE-P; CARDIAC MYOCYTES; ATRIAL MYOCYTES	Inward rectifier K+ channels control the cell's membrane potential and neuronal excitability. We report that the IRK3 but not the IRK1 inward rectifier K+ channel activity is inhibited by mi muscarinic acetylcholine receptor. This m1 modulation cannot be accounted for by protein kinase C, Ca2+, or channel phosphorylation, but can be mimicked by Mg2+. Based on quantitative analyses of IRK3 and two different IRK1 mutant channels bestowed with sensitivity to m1 modulation, we suggest that the resting Mg2+ level causes chronic inhibition of IRK3 channels, and m1 receptor stimulation may lead to an increase of cytoplasmic Mg2+ concentration and further channel inhibition, due to the ability of Mg2+ to lead these channels into a prolonged inactivated state.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				AGUS ZS, 1991, ANNU REV PHYSIOL, V53, P299, DOI 10.1146/annurev.physiol.53.1.299; BRAUN AP, 1992, PFLUG ARCH EUR J PHY, V421, P431, DOI 10.1007/BF00370253; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CAULFIELD MP, 1994, J PHYSIOL-LONDON, V477, P415, DOI 10.1113/jphysiol.1994.sp020203; CECH SY, 1980, MOL CELL BIOCHEM, V33, P67; Collins A, 1996, J NEUROSCI, V16, P1; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; CROWFROF.PJ, 1971, J PHYSIOL-LONDON, V219, P443, DOI 10.1113/jphysiol.1971.sp009671; DIFRANCESCO D, 1980, PFLUG ARCH EUR J PHY, V387, P83, DOI 10.1007/BF00584257; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; EGAN TM, 1986, NATURE, V319, P405, DOI 10.1038/319405a0; ELLIOTT DA, 1974, J BIOL CHEM, V249, P3985; ERDOS JJ, 1983, J PHYSIOL-LONDON, V337, P351, DOI 10.1113/jphysiol.1983.sp014628; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; GRUBBS RD, 1986, J BIOL CHEM, V261, P2550; GUPTA RK, 1984, ANNU REV BIOPHYS BIO, V13, P221; HARTZELL HC, 1989, J GEN PHYSIOL, V94, P745, DOI 10.1085/jgp.94.4.745; Hille B., 1992, IONIC CHANNELS EXCIT; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; INOUE M, 1988, J PHYSIOL-LONDON, V407, P177, DOI 10.1113/jphysiol.1988.sp017409; JONES S, 1995, NEURON, V14, P399, DOI 10.1016/0896-6273(95)90295-3; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; KURACHI Y, 1986, PFLUG ARCH EUR J PHY, V407, P264, DOI 10.1007/BF00585301; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Marrion NV, 1996, NEURON, V16, P163, DOI 10.1016/S0896-6273(00)80033-1; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MCLACHLAN EM, 1989, J PHYSIOL-LONDON, V415, P109, DOI 10.1113/jphysiol.1989.sp017714; MORISHIGE KI, 1994, FEBS LETT, V346, P251, DOI 10.1016/0014-5793(94)00483-8; MURPHY E, 1991, ANNU REV PHYSIOL, V53, P273, DOI 10.1146/annurev.physiol.53.1.273; NAKAJIMA Y, 1988, P NATL ACAD SCI USA, V85, P3643, DOI 10.1073/pnas.85.10.3643; NOBLE D, 1984, J PHYSIOL-LONDON, V353, P1; NORTH RA, 1989, J PHYSIOL-LONDON, V417, P1; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; OH U, 1995, J MEMBRANE BIOL, V147, P241; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; RIJKERS GT, 1993, BIOCHEM J, V289, P373, DOI 10.1042/bj2890373; ROBBINS J, 1993, J PHYSIOL-LONDON, V469, P153, DOI 10.1113/jphysiol.1993.sp019809; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SATO R, 1995, J MEMBRANE BIOL, V148, P185; Selyanko AA, 1996, NEURON, V16, P151, DOI 10.1016/S0896-6273(00)80032-X; SHEN KZ, 1992, J PHYSIOL-LONDON, V455, P471, DOI 10.1113/jphysiol.1992.sp019312; Sodickson DL, 1996, J NEUROSCI, V16, P6374; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; STANFIELD PR, 1985, NATURE, V315, P498, DOI 10.1038/315498a0; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; STOREY KB, 1992, ANAL BIOCHEM, V201, P119; TAKANO K, 1995, NEURON, V14, P999, DOI 10.1016/0896-6273(95)90338-0; UCHIMURA N, 1990, J PHYSIOL-LONDON, V422, P369, DOI 10.1113/jphysiol.1990.sp017989; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; VELIMIROVIC BM, 1995, P NATL ACAD SCI USA, V92, P1590, DOI 10.1073/pnas.92.5.1590; Wang HS, 1996, J PHYSIOL-LONDON, V492, P467, DOI 10.1113/jphysiol.1996.sp021322; WHITE RE, 1988, SCIENCE, V239, P778, DOI 10.1126/science.2448878; WHITE RE, 1989, BIOCHEM PHARMACOL, V38, P859, DOI 10.1016/0006-2952(89)90272-4; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YAMADA M, 1994, BIOCHEM BIOPH RES CO, V200, P1484, DOI 10.1006/bbrc.1994.1618; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7	67	51	55	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1121	1132		10.1016/S0092-8674(00)80299-8	http://dx.doi.org/10.1016/S0092-8674(00)80299-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215634	Bronze			2022-12-24	WOS:A1997XG83000016
J	Lisman, J; Malenka, RC; Nicoll, RA; Malinow, R				Lisman, J; Malenka, RC; Nicoll, RA; Malinow, R			Neuroscience - Learning mechanisms: The case for CaM-KII	SCIENCE			English	Editorial Material							LONG-TERM POTENTIATION; PROTEIN-KINASE; CALMODULIN; INDUCTION; LTP; AUTOPHOSPHORYLATION; TRANSMISSION; STORAGE; PKC		BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Brandeis University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cold Spring Harbor Laboratory	Lisman, J (corresponding author), BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254, USA.							Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; BARRIA A, 1997, SCIENCE, V276, P2022; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HVALBY O, 1994, P NATL ACAD SCI USA, V91, P4761, DOI 10.1073/pnas.91.11.4761; Lem J, 1996, CURR OPIN NEUROBIOL, V6, P453, DOI 10.1016/S0959-4388(96)80049-3; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; OTMAKHOV N, IN PRESS J NEUROSCI; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; WANG JH, 1995, NEURON, V15, P443, DOI 10.1016/0896-6273(95)90048-9	19	108	111	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2001	2002		10.1126/science.276.5321.2001	http://dx.doi.org/10.1126/science.276.5321.2001			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9221509				2022-12-24	WOS:A1997XG74800050
J	Kledal, TN; Rosenkilde, MM; Coulin, F; Simmons, G; Johnsen, AH; Alouani, S; Power, CA; Luttichau, HR; Gerstoft, J; Clapham, PR; ClarkLewis, I; Wells, TNC; Schwartz, TW				Kledal, TN; Rosenkilde, MM; Coulin, F; Simmons, G; Johnsen, AH; Alouani, S; Power, CA; Luttichau, HR; Gerstoft, J; Clapham, PR; ClarkLewis, I; Wells, TNC; Schwartz, TW			A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus	SCIENCE			English	Article							PROTEIN-COUPLED RECEPTOR; DNA-SEQUENCES; MOLECULAR MIMICRY; INTERLEUKIN-8; RANTES; GENES; CHEMOATTRACTANT; EXPRESSION; PATHWAYS; CLONING	Kaposi's sarcoma-associated herpesvirus encodes a chemokine called vMIP-II, This protein displayed a broader spectrum of receptor activities than any mammalian chemokine as it bound with high affinity to a number of both CC and CXC chemokine receptors, Binding of vMIP-II, however, was not associated with the normal, rapid mobilization of calcium from intracellular stores; instead, it blocked calcium mobilization induced by endogenous chemokines, In freshly isolated human monocytes the virally encoded vMIP-II acted as a potent and efficient antagonist of chemotaxis induced by chemokines. Because vMIP-II could inhibit cell entry of human immunodeficiency virus (HIV) mediated through CCR3 and CCR5 as well as CXCR4, this protein may serve as a lead for development of broad-spectrum anti-HIV agents.	GLAXO WELLCOME RES & DEV LTD,GENEVA BIOMED RES INST,CH-1228 PLAN LES OUATES,GENEVA,SWITZERLAND; UNIV COPENHAGEN,PANUM INST,MOL PHARMACOL LAB,INST PHARMACOL,DK-2200 COPENHAGEN,DENMARK; RIGSHOSP,DEPT INFECT DIS,DK-2100 COPENHAGEN,DENMARK; INST CANC RES,CHESTER BEATTY LABS,SECT VIROL,LONDON SW3 6JB,ENGLAND; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA	GlaxoSmithKline; University of Copenhagen; Rigshospitalet; University of Copenhagen; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of British Columbia			Simmons, Graham/G-3523-2012	Simmons, Graham/0000-0002-9615-7023; Wells, Timothy/0000-0001-9796-847X; Luttichau, Hans Rudolf/0000-0002-5428-4075; Schwartz, Thue W./0000-0002-0261-6904; Rosenkilde, Mette Marie/0000-0001-9600-3254				AHUJA SK, 1994, IMMUNOL TODAY, V15, P281, DOI 10.1016/0167-5699(94)90008-6; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; AKRANITAKIS L, 1997, NATURE, V385, P347; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; BOSHOFF C, 1995, LANCET, V345, P1043; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLORE GM, 1989, J BIOL CHEM, V264, P18907; Damaj BB, 1996, J BIOL CHEM, V271, P20540, DOI 10.1074/jbc.271.34.20540; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; DRAJIC T, 1996, NATURE, V381, P667; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FINCHAM NJ, 1988, J IMMUNOL, V140, P4294; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; JUNG YK, 1992, MOL ENDOCRINOL, V6, P2027, DOI 10.1210/me.6.12.2027; LUSTINARASIMHAN M, 1995, J BIOL CHEM, V270, P2716, DOI 10.1074/jbc.270.6.2716; LustiNarasimhan M, 1996, J BIOL CHEM, V271, P3148, DOI 10.1074/jbc.271.6.3148; MacDonald MR, 1997, J VIROL, V71, P1671, DOI 10.1128/JVI.71.2.1671-1678.1997; MCKEATING JA, 1991, J VIROL, V65, P852, DOI 10.1128/JVI.65.2.852-860.1991; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Power CA, 1996, TRENDS PHARMACOL SCI, V17, P209, DOI 10.1016/0165-6147(96)10019-5; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; Weiss RA, 1996, NAT MED, V2, P277, DOI 10.1038/nm0396-277; WULFF BS, 1993, MOL CELL ENDOCRINOL, V91, P135, DOI 10.1016/0303-7207(93)90265-L; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641	37	402	444	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1656	1659		10.1126/science.277.5332.1656	http://dx.doi.org/10.1126/science.277.5332.1656			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287217				2022-12-24	WOS:A1997XV68400048
J	Jeong, B; Bae, YH; Lee, DS; Kim, SW				Jeong, B; Bae, YH; Lee, DS; Kim, SW			Biodegradable block copolymers as injectable drug-delivery systems	NATURE			English	Article							CONTROLLED RELEASE; MEMBRANE; PH	Polymers that display a physicochemical response to stimuli are widely explored as potential drug-delivery systems(1-4), Stimuli studied to date include chemical substances and changes in temperature, pH and electric field, Homopolymers or copolymers of N-isopropylacrylamide(5,6) and poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (known as poloxamers)(7) are typical examples of thermosensitive polymers, but their use in drug delivery is problematic because they are toxic and nonbiodegradable, Biodegradable polymers used for drug delivery to date have mostly been in the form of injectable microspheres or implant systems, which require complicated fabrication processes using organic solvents(8). Such systems have the disadvantage that the use of organic solvents can cause denaturation when protein drugs are to be encapsulated. Furthermore, the solid form requires surgical insertion, which often results in tissue irritation and damage, Here we report the synthesis of a thermosensitive, biodegradable hydrogel consisting of blocks of poly(ethylene oxide) and poly(L-lactic acid), Aqueous solutions of these copolymers exhibit temperature-dependent reversible gel-sol transitions, The hydrogel can be loaded with bioactive molecules in an aqueous phase at an elevated temperature (around 45 degrees C), where they form a sol. In this form, the polymer is injectable. On subcutaneous injection and subsequent rapid cooling to body temperature, the loaded copolymer forms a gel that can act as a sustained-release matrix for drugs.	UNIV UTAH, CCCD PHARMACEUT, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah			LEE, DOO SUNG/D-3363-2011; Kang, Bo Kyung/F-6726-2015; Jeong, Byeongmoon/AAB-1570-2021	Jeong, Byeongmoon/0000-0001-9582-1343				ALEXANDRIDIS P, 1994, MACROMOLECULES, V27, P2414, DOI 10.1021/ma00087a009; BAE YH, 1987, MAKROMOL CHEM-RAPID, V8, P481; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; ISHIHARA K, 1984, J APPL POLYM SCI, V29, P211, DOI 10.1002/app.1984.070290119; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; MALSTOM M, 1992, MACROMOLECULES, V25, P5440; MORITZ AR, 1947, AM J PATHOL, V23, P695; Ronneberger B, 1996, J BIOMED MATER RES, V30, P31; THOMAS JL, 1995, J AM CHEM SOC, V117, P2949, DOI 10.1021/ja00115a039; Wout Z G, 1992, J Parenter Sci Technol, V46, P192; YOUXIN L, 1993, J CONTROL RELEASE, V27, P247; ZHU KJ, 1990, J APPL POLYM SCI, V39, P1, DOI 10.1002/app.1990.070390101	13	1742	1895	30	1251	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	1997	388	6645					860	862		10.1038/42218	http://dx.doi.org/10.1038/42218			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278046				2022-12-24	WOS:A1997XT75400044
J	Weinstein, MR; Litt, M; Kertesz, DA; Wyper, P; Rose, D; Coulter, M; McGeer, A; Facklam, R; Ostach, C; Willey, BM; Borczyk, A; Low, DE				Weinstein, MR; Litt, M; Kertesz, DA; Wyper, P; Rose, D; Coulter, M; McGeer, A; Facklam, R; Ostach, C; Willey, BM; Borczyk, A; Low, DE			Invasive infections due to a fish pathogen, Streptococcus iniae	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)	SEP 15-18, 1996	NEW ORLEANS, LA				ENTEROCOCCUS-SERIOLICIDA; SP-NOV; MENINGITIS; SUIS; MENINGOENCEPHALITIS; DIAGNOSIS; MASTITIS; CRITERIA; SYNONYM; STRAINS	Background Streptococcus iniae is a pathogen in fish, capable of causing invasive disease and outbreaks in aquaculture farms. During the winter of 1995-1996 in the greater Toronto area there was a cluster of four cases of invasive S. iniae infection in people who had recently handled fresh, whole fish from such farms. Methods We conducted a prospective and retrospective community-based surveillance for cases of S. iniae infection in humans. To obtain a large sample of isolates, we studied cultures obtained from the surface of fish from aquaculture farms. Additional isolates were obtained from the brains of infected tilapia (oreochromis species). All the isolates were characterized by pulsed-field gel electrophoresis (PFGE). Results During one year, our surveillance identified a total of nine patients with invasive S. iniae infection (cellulitis of the hand in eight and endocarditis in one). All the patients had handled live or freshly killed fish, and eight had percutaneous injuries. Six of the nine fish were tilapia, which are commonly used in Asian cooking. Thirteen additional S. iniae isolates (2 from humans and 11 from infected tilapia) were obtained from normally sterile sites. The isolates from the nine patients were indistinguishable by PFGE and were highly related to the other clinical isolates. There was substantial genetic diversity among the 42 surveillance isolates from the surface of fish, but in 10 isolates the PFGE patterns were identical to those from the patients with S. iniae infection. Conclusions S. iniae can produce invasive infection after skin injuries during the handling of fresh fish grown by aquaculture. We identified a clone of S. iniae that causes invasive disease in both humans and fish. (C) 1997, Massachusetts Medical Society.	MT SINAI HOSP,DEPT MICROBIOL,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; LAB CTR DIS CONTROL,OTTAWA,ON K1A 0L2,CANADA; SCARBOROUGH GRACE HOSP,SCARBOROUGH,ON,CANADA; PRINCESS MARGARET HOSPS,TORONTO,ON,CANADA; CITY SCARBOROUGH PUBL HLTH DEPT,SCARBOROUGH,ON,CANADA; PUBL HLTH LAB,TORONTO,ON,CANADA; CTR DIS CONTROL & PREVENT,ATLANTA,GA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Scarborough Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Centers for Disease Control & Prevention - USA			mcgeer, allison/H-7747-2014; Low, Donald/B-1726-2012; McGeer, Allison/AAB-6885-2020	mcgeer, allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137				ARENDS JP, 1988, REV INFECT DIS, V10, P131; BAIRDPARKER AC, 1994, MICROBIOL-UK, V140, P687, DOI 10.1099/00221287-140-4-687; BARNHAM M, 1987, EPIDEMIOL INFECT, V99, P257, DOI 10.1017/S0950268800067728; CHAU PY, 1983, MED J AUSTRALIA, V1, P414, DOI 10.5694/j.1326-5377.1983.tb136138.x; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; ELDAR A, 1995, INT J SYST BACTERIOL, V45, P840, DOI 10.1099/00207713-45-4-840; ELDAR A, 1994, CURR MICROBIOL, V28, P139, DOI 10.1007/BF01571054; ELDAR A, 1995, VET MICROBIOL, V43, P33, DOI 10.1016/0378-1135(94)00052-X; HOOK EW, 1986, ARCH INTERN MED, V146, P295; KAIGE N, 1984, Fish Pathology, V19, P173; KITAO T, 1981, Fish Pathology, V15, P301; KUSUDA R, 1991, INT J SYST BACTERIOL, V41, P406, DOI 10.1099/00207713-41-3-406; Kusuda Riichi, 1992, Israeli Journal of Aquaculture Bamidgeh, V44, P140; LEE PC, 1985, J CLIN MICROBIOL, V22, P80, DOI 10.1128/JCM.22.1.80-83.1985; *METR TOR PLANN DE, 1995, MUN METR TOR KEY FAC; Michaud S, 1996, Can J Infect Dis, V7, P329; MOGOLLON JD, 1990, J CLIN MICROBIOL, V28, P2462, DOI 10.1128/JCM.28.11.2462-2466.1990; MURRAY BE, 1991, J INFECT DIS, V163, P780, DOI 10.1093/infdis/163.4.780; Musser JM, 1996, EMERG INFECT DIS, V2, P1, DOI 10.3201/eid0201.960101; *NAT COMM CLIN LAB, 1994, M7A3 NAT COMM CLIN L; Perera Ramesh P., 1994, Journal of Aquatic Animal Health, V6, P335, DOI 10.1577/1548-8667(1994)006&lt;0335:SIAWMO&gt;2.3.CO;2; PIER GB, 1976, INT J SYST BACTERIOL, V26, P545, DOI 10.1099/00207713-26-4-545; PIER GB, 1978, INT J SYST BACTERIOL, V28, P311, DOI 10.1099/00207713-28-2-311; ROBINSON JA, 1966, J BACTERIOL, V92, P512, DOI 10.1128/JB.92.2.512-512.1966; Ruoff Kathryn L., 1995, P299; SHARP MW, 1995, VET REC, V137, P128, DOI 10.1136/vr.137.5.128-b; Teixeira LM, 1996, INT J SYST BACTERIOL, V46, P664, DOI 10.1099/00207713-46-3-664; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Vandamme P, 1997, INT J SYST BACTERIOL, V47, P81, DOI 10.1099/00207713-47-1-81; Vidaver AK, 1996, ASM NEWS, V62, P583; Walsh B., 1992, Reviews in Medical Microbiology, V3, P65; WEINBERG AN, 1995, MANDELL DOUGLAS BENN, V2, P2790; Weinstein M, 1996, Can Commun Dis Rep, V22, P129; WINDSOR RS, 1975, J HYG-CAMBRIDGE, V75, P69, DOI 10.1017/S0022172400047070; 1996, MMWR-MORBID MORTAL W, V45, P650; 1975, LANCET, V1, P1286; 1994, C D R WKLY REP, V4, P241	37	217	239	2	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	1997	337	9					589	594		10.1056/NEJM199708283370902	http://dx.doi.org/10.1056/NEJM199708283370902			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT394	9271480	Green Published			2022-12-24	WOS:A1997XT39400002
J	PowellTuck, J				PowellTuck, J			Glutamine supplementation in artificial nutritional support	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; TOTAL PARENTERAL-NUTRITION; DOUBLE-BLIND				PowellTuck, J (corresponding author), ROYAL LONDON HOSP,ST BARTHOLOMEWS & ROYAL LONDON HOSP SCH MED,RANK DEPT HUMAN NUTR,LONDON E1 1BB,ENGLAND.							Bozzetti F, 1997, NUTRITION, V13, P748, DOI 10.1016/S0899-9007(97)83038-9; GRIFFITHS RD, 1997, NUTRITION, V13, P302; JEBB SA, 1995, CLIN NUTR, V14, P143; Jensen GL, 1996, AM J CLIN NUTR, V64, P615, DOI 10.1093/ajcn/64.4.615; MORLION BJ, 1996, CLIN NUTR S1, V15, P48; ORIORDAIN MG, 1994, ANN SURG, V220, P212, DOI 10.1097/00000658-199408000-00014; POWELLTUCK J, 1997, NUTRITION, V13, P725; SCHLOERB PR, 1993, JPEN-PARENTER ENTER, V17, P407, DOI 10.1177/0148607193017005407; VANDERHULST RRWJ, 1993, LANCET, V341, P1363, DOI 10.1016/0140-6736(93)90939-E; ZIEGLER TR, 1992, ANN INTERN MED, V116, P821, DOI 10.7326/0003-4819-116-10-821	10	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					534	534		10.1016/S0140-6736(05)63136-4	http://dx.doi.org/10.1016/S0140-6736(05)63136-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284773				2022-12-24	WOS:A1997XT22100006
J	Anzick, SL; Kononen, J; Walker, RL; Azorsa, DO; Tanner, MM; Guan, XY; Sauter, G; Kallioniemi, OP; Trent, JM; Meltzer, PS				Anzick, SL; Kononen, J; Walker, RL; Azorsa, DO; Tanner, MM; Guan, XY; Sauter, G; Kallioniemi, OP; Trent, JM; Meltzer, PS			AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer	SCIENCE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; AMPLIFICATION; SEQUENCE	Members of the recently recognized SRC-1 family of transcriptional coactivators interact with steroid hormone receptors to enhance ligand-dependent transcription. AIB1, a member of the SRC-1 family, was cloned during a search on the long arm of chromosome 20 for genes whose expression and copy number were elevated in human breast cancers. AIB1 amplification and overexpression were observed in four of five estrogen receptor-positive breast and ovarian cancer cell lines. Subsequent evaluation of 105 unselected specimens of primary breast cancer found AIB1 amplification in approximately 10 percent and high expression in 64 percent of the primary tumors analyzed. AIB1 protein interacted with estrogen receptors in a ligand-dependent fashion, and transfection of AIB1 resulted in enhancement of estrogen-dependent transcription, These observations identify AIB1 as a nuclear receptor coactivator whose altered expression may contribute to development of steroid-dependent cancers.	NATL HUMAN GENOME RES INST,CANC GENET LAB,NIH,BETHESDA,MD 20892; UNIV TAMPERE,INST MED TECHNOL,CANC GENET LAB,FIN-33101 TAMPERE,FINLAND; TAMPERE UNIV HOSP,FIN-33101 TAMPERE,FINLAND; UNIV BASEL,INST PATHOL,CH-4003 BASEL,SWITZERLAND	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Tampere University; Tampere University; Tampere University Hospital; University of Basel			Kallioniemi, Olli P/H-5111-2011; /A-3639-2009; Guan, Xin-Yuan/A-3639-2009	Kallioniemi, Olli P/0000-0002-3231-0332; /0000-0003-1874-9805; Guan, Xin-Yuan/0000-0002-4485-6017; Kononen, Juha/0000-0002-0157-2137; Walker, Robert/0000-0001-8235-4686				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; DEVILEE P, 1994, CRIT REV ONCOGENESIS, V5, P247, DOI 10.1615/CritRevOncog.v5.i2-3.70; Guan XY, 1996, CANCER RES, V56, P3446; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; ISOLA JJ, 1995, AM J PATHOL, V147, P905; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; ONATE SA, 1995, SCIENCE, V270, P1354; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Sallinen P, 1997, AM J PATHOL, V150, P1159; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1996, CANCER RES, V56, P3441; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	21	1357	1401	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					965	968		10.1126/science.277.5328.965	http://dx.doi.org/10.1126/science.277.5328.965			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252329	Green Submitted			2022-12-24	WOS:A1997XQ98500044
J	Murata, T; Ushikubi, F; Matsuoka, T; Hirata, M; Yamasaki, A; Sugimoto, Y; Ichikawa, A; Aze, Y; Tanaka, T; Yoshida, N; Ueno, A; Ohishi, S; Narumiya, S				Murata, T; Ushikubi, F; Matsuoka, T; Hirata, M; Yamasaki, A; Sugimoto, Y; Ichikawa, A; Aze, Y; Tanaka, T; Yoshida, N; Ueno, A; Ohishi, S; Narumiya, S			Altered pain perception and inflammatory response in mice lacking prostacyclin receptor	NATURE			English	Article							MOUSE; HYPERALGESIA; RATS; EXPRESSION; INJECTION; MORPHINE; GENE	Prostanoids are a group of bioactive lipids working as local mediators' and include D, E, F and I types of prostaglandins (PGs) and thromboxanes. Prostacyclin (PGI(2)) acts on platelets and blood vessels to inhibit platelet aggregation and to cause vasodilatation, and is thought to be important for vascular homeostasis(2). Aspirin-like drugs, including indomethacin, which inhibit prostanoid biosynthesis, Suppress fever, inflammatory swelling and pain, and interfere with female reproduction, suggesting that prostanoids are involved in these processes(1,3), although it is not clear which prostanoid is the endogenous mediator of a particular process, Prostanoids act on seven-transmembrane-domain receptors which are selective for each type(4). Here we disrupt the gene for the prostacyclin receptor(5) in mice by using homologous recombination. The receptor-deficient mice are viable, reproductive and normotensive. However, their susceptibility to thrombosis is increased, and their inflammatory and pain responses are reduced to the levels observed in indomethacin-treated wild-type mice, Our results establish that prostacyclin is an antithrombotic agent in vivo and provide evidence for its role as a mediator of inflammation and pain.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 60601,JAPAN; KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,SAKYO KU,KYOTO 60601,JAPAN; ONO PHARMACEUT CO,FUKUI INST SAFETY RES,MIKUNI,FUKUI 913,JAPAN; RES INST OSAKA MED CTR MATERNAL & CHILD HLTH,DIV MOL & CELLULAR IMMUNOL,IZUMI,OSAKA 59002,JAPAN; KITASATO UNIV,SCH PHARMACEUT SCI,DEPT PHARMACOL,SHIROGANEDAI,TOKYO 108,JAPAN	Kyoto University; Kyoto University; Ono Pharmaceutical Co Ltd; Kitasato University			Tanaka, Takashi/O-8254-2015; Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X; Murata, Takahiko/0000-0003-0132-5424				ARMSTRONG RA, 1989, BRIT J PHARMACOL, V97, P657, DOI 10.1111/j.1476-5381.1989.tb12001.x; BUNTING S, 1983, BR MED B, V39, P371; CAMPBELL WB, 1996, PHARMACOL BASIS THER, P601; DAVIES P, 1984, ANNU REV IMMUNOL, V2, P335, DOI 10.1146/annurev.immunol.2.1.335; DEJANA E, 1979, THROMB RES, V15, P191, DOI 10.1016/0049-3848(79)90064-1; DOHERTY NS, 1987, BRIT J PHARMACOL, V91, P39, DOI 10.1111/j.1476-5381.1987.tb08981.x; FERREIRA SH, 1981, TRENDS PHARMACOL SCI, V2, P183, DOI 10.1016/0165-6147(81)90306-0; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KOSTER R, 1959, FED PROC, V18, P412; KURZ KD, 1990, THROMB RES, V60, P269, DOI 10.1016/0049-3848(90)90106-M; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; MILLAN MJ, 1991, J PHARMACOL EXP THER, V256, P983; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MURATA T, 1989, ARZNEIMITTEL-FORSCH, V39-2, P867; NAMBA T, 1994, J BIOL CHEM, V269, P9986; OIDA H, 1995, BRIT J PHARMACOL, V116, P2828, DOI 10.1111/j.1476-5381.1995.tb15933.x; OKA T, 1993, BRAIN RES, V624, P61, DOI 10.1016/0006-8993(93)90060-Z; PIERCEY MF, 1981, EUR J PHARMACOL, V74, P135, DOI 10.1016/0014-2999(81)90523-9; RITTER JM, 1987, BRIT J PHARMACOL, V92, P857, DOI 10.1111/j.1476-5381.1987.tb11391.x; UENO A, 1995, EUR J PHARMACOL, V284, P211, DOI 10.1016/0014-2999(95)00439-R; USHIKUBI F, 1995, J LIPID MEDIAT CELL, V12, P343, DOI 10.1016/0929-7855(95)00022-I; UTSUNOMIYA I, 1994, EUR J PHARMACOL, V252, P213, DOI 10.1016/0014-2999(94)90599-1; VADAS P, 1981, NATURE, V293, P583, DOI 10.1038/293583a0; VANE JR, 1990, NEW ENGL J MED, V323, P27; WINTER CA, 1965, J PHARMACOL EXP THER, V150, P165	26	611	660	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					678	682		10.1038/41780	http://dx.doi.org/10.1038/41780			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262402	Bronze			2022-12-24	WOS:A1997XQ86300050
J	Scherzinger, E; Lurz, R; Turmaine, M; Mangiarini, L; Hollenbach, B; Hasenbank, R; Bates, GP; Davies, SW; Lehrach, H; Wanker, EE				Scherzinger, E; Lurz, R; Turmaine, M; Mangiarini, L; Hollenbach, B; Hasenbank, R; Bates, GP; Davies, SW; Lehrach, H; Wanker, EE			Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo	CELL			English	Article							GLUTATHIONE-S-TRANSFERASE; NEURODEGENERATIVE DISEASES; GLUTAMINE REPEATS; LOCALIZATION; BRAIN; PRODUCT; SCRAPIE; EPITOPE	The mechanism by which an elongated polyglutamine sequence causes neurodegeneration in Huntington's disease (HD) is unknown. In this study, we show that the proteolytic cleavage of a GST-huntingtin fusion protein leads to the formation of insoluble high molecular weight protein aggregates only when the polyglutamine expansion is in the pathogenic range. Electron micrographs of these aggregates revealed a fibrillar or ribbon-like morphology, reminiscent of scrapie prions and beta-amyloid fibrils in Alzheimer's disease. Subcellular fractionation and ultrastructural techniques showed the in vivo presence of these structures in the brains of mice transgenic for the HD mutation. Our in vitro model will aid in an eventual understanding of the molecular pathology of HD and the development of preventative strategies.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,GUYS HOSP,DIV MED & MOL GENET,LONDON SE1 7EH,ENGLAND; MAX PLANCK INST MOL GENET,D-14195 BERLIN,DAHLEM,GERMANY; UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Max Planck Society; University of London; University College London			Bates, Gillian P/E-1146-2012	Bates, Gillian P/0000-0002-4041-6305; Wanker, Erich/0000-0001-8072-1630				[Anonymous], ADV NEUROL; BATES GP, 1997, IN PRESS HUM MOL GEN; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; CAPUTO CB, 1992, ARCH BIOCHEM BIOPHYS, V292, P199, DOI 10.1016/0003-9861(92)90068-8; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DeRooij KE, 1996, HUM MOL GENET, V5, P1093, DOI 10.1093/hmg/5.8.1093; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; Harper PS, 1991, HUNTINGTONS DIS; HOOGEVEEN AT, 1993, HUM MOL GENET, V2, P2069, DOI 10.1093/hmg/2.12.2069; *HUNT DIS COLL RES, 1993, CELL, V72, P971; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; KALCHMAN MA, 1997, NAT GENET, V16, P4; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LIM K, 1994, PROTEIN SCI, V3, P2233, DOI 10.1002/pro.5560031209; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Onodera O, 1996, FEBS LETT, V399, P135, DOI 10.1016/S0014-5793(96)01301-4; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Perutz MF, 1996, CURR OPIN STRUC BIOL, V6, P848, DOI 10.1016/S0959-440X(96)80016-9; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; ROOS RAC, 1983, J NEUROL SCI, V61, P37, DOI 10.1016/0022-510X(83)90053-9; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Rubinsztein DC, 1996, AM J HUM GENET, V59, P16; Sathasivam K, 1997, HUM GENET, V99, P692, DOI 10.1007/s004390050432; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; TELLEZNAGEL I, 1974, J NEUROCYTOL, V3, P308; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487	41	1038	1076	1	80	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					549	558		10.1016/S0092-8674(00)80514-0	http://dx.doi.org/10.1016/S0092-8674(00)80514-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267034	Bronze			2022-12-24	WOS:A1997XQ06300018
J	Nightingale, SL				Nightingale, SL			National conference on implementation of the waiver of informed consent in emergency situations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1996, JAMA-J AM MED ASSOC, V276, P1632	1	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					379	379		10.1001/jama.278.5.379	http://dx.doi.org/10.1001/jama.278.5.379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244318				2022-12-24	WOS:A1997XN51800010
J	vanderHeide, A; van der Maas, PJ; vanderWal, G; deGraaff, CLM; Kester, JGC; Kollee, LAA; deLeeuw, R; Holl, RA				vanderHeide, A; van der Maas, PJ; vanderWal, G; deGraaff, CLM; Kester, JGC; Kollee, LAA; deLeeuw, R; Holl, RA			Medical end-of-life decisions made for neonates and infants in the Netherlands	LANCET			English	Article							INTENSIVE-CARE; EUTHANASIA	Background Advances in neonatal intensive care have lowered the neonatal death rate. There are still some severely ill neonates and infants, however, for whom the application of all possible life-prolonging treatment modalities may be questioned. Methods We did two studies in the Netherlands. In the first we sent questionnaires to physicians who had attended 338 consecutive deaths (August-November, 1995) within the first year of life (death-certificate study), and in the second we interviewed 31 neonatologists or paediatric intensive-care specialists and 35 general paediatricians. The response rates were 88% and 99%, respectively. Findings in the death-certificate study, 57% of all deaths had been preceded by a decision to forgo life-sustaining treatment; this decision was accompanied by the administration of potentially life-shortening drugs to alleviate pain or other symptoms in 23%, and by the administration of drugs with the explicit aim of hastening death in 8%. A drug was given explicitly to hasten death to neonates not dependent on life-sustaining treatment in 1% of all death cases. No chance of survival was the main motive in 76% of all end-of-life decisions, and a poor prognosis was the main motive in 18%. The interview study showed that parents had been involved in making 79% of decisions, The physicians consulted colleagues about 88% of decisions, Most paediatricians favoured formal review of medical decisions by colleagues together with ethical or legal experts. Interpretation Death among neonates and infants is commonly preceded by medical end-of-life decisions. Most Dutch paediatricians seem to find prospects for survival and prognostic factors relevant in such decisions. Public control by a committee of physicians, paediatricians, ethicists, and legal experts is widely endorsed by paediatricians.	VRIJE UNIV AMSTERDAM, INST RES EXTRAMURAL MED, AMSTERDAM, NETHERLANDS; STAT NETHERLANDS, VOORBURG, NETHERLANDS	Vrije Universiteit Amsterdam	vanderHeide, A (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.							ANGELL M, 1986, NEW ENGL J MED, V314, P642, DOI 10.1056/NEJM198603063141010; BROUWERS HAA, 1995, OP GRENS LEVEN DOOD; CAMPBELL AGM, 1982, ARCH DIS CHILD, V57, P569, DOI 10.1136/adc.57.8.569; Cook L A, 1996, J Perinatol, V16, P133; de Kleine M J, 1993, Ned Tijdschr Geneeskd, V137, P496; deLeeuw R, 1996, J PEDIATR-US, V129, P661, DOI 10.1016/S0022-3476(96)70146-4; DUFF RS, 1973, NEW ENGL J MED, V289, P890, DOI 10.1056/NEJM197310252891705; EGANDERSEN G, 1989, ACTA PAEDIATR SCAND, P56; Frader JE, 1996, PEDIATRICS, V98, P149; KOPELMAN LM, 1988, NEW ENGL J MED, V318, P677, DOI 10.1056/NEJM198803173181105; LEENEN HJJ, 1994, HDB GEZONDHEIDSREC 1; LUCE JM, 1995, CRIT CARE MED, V23, P760, DOI 10.1097/00003246-199504000-00027; Nederlandse Vereniging voor Kindergeneeskunde, 1992, DOEN LAT GRENZ MED H; Rivers RPA, 1996, BRIT MED BULL, V52, P238; RYAN CA, 1993, J PEDIATR-US, V123, P534, DOI 10.1016/S0022-3476(05)80946-1; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; WHITELAW A, 1986, LANCET, V2, P328	20	87	88	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 26	1997	350	9073					251	255		10.1016/S0140-6736(97)02315-5	http://dx.doi.org/10.1016/S0140-6736(97)02315-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242802	Green Submitted			2022-12-24	WOS:A1997XM86600012
J	Kim, J; Johnson, K; Chen, HJ; Carroll, S; Laughon, A				Kim, J; Johnson, K; Chen, HJ; Carroll, S; Laughon, A			Drosophila MAD binds to DNA and directly mediates activation of vestigial by decapentaplegic	NATURE			English	Article							HEDGEHOG; EXPRESSION; MELANOGASTER; ELEMENTS; PATTERN; PROTEIN; GENE; DPP	The TGF-beta (transforming growth factor-beta)-related signalling proteins, including Decapentaplegic (Dpp) in Drosophila and bone morphogenic proteins and activin in vertebrates, affect the growth and patterning of a great variety of structures. However, the mechanisms by which these ligands regulate gene expression are not understood. Activation of complexes of type I with type II receptors results in the phosphorylation and nuclear localization of members of the SMAD protein family(1-9), which are thought to act as co-activators of transcription, perhaps in conjunction with sequence-specific cofactors(10). Here we show that the aminoterminal domain of the Drosophila Mothers against dpp protein (Mad), a mediator of Dpp signalling(11-14), possesses a sequence-specific DNA-binding activity that becomes apparent when carboxy-terminal residues are removed. Mad binds to and is required for the activation of an enhancer within the vestigial wing-patterning gene in cells across the entire developing wing blade. Mad also binds to Dpp-response elements in other genes. These results suggest that Dpp signalling regulates gene expression by activating Mad binding to target gene enhancers.	UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706; UNIV WISCONSIN,DEPT MED GENET,MADISON,WI 53706; UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI 53706; UNIV WISCONSIN,MOL BIOL LAB,MADISON,WI 53706; UNIV WISCONSIN,MCARDLE LAB CANC RES,DEPT ONCOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								AUSUBEL EM, 1994, CURRENT PROTOCOLS S, V28, P1661; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR S, 1995, BIOESSAYS, V17, P229; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LIU F, 1996, NATURE, V381, P622; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; RAFTERY LA, 1995, GENETICS, V139, P241; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; THURINGER F, 1993, EMBO J, V12, P2419, DOI 10.1002/j.1460-2075.1993.tb05896.x; TREMML G, 1992, DEVELOPMENT, V116, P447; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; ZECCA M, 1995, DEVELOPMENT, V121, P2265; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	31	450	464	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					304	308		10.1038/40906	http://dx.doi.org/10.1038/40906			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230443	Bronze			2022-12-24	WOS:A1997XL12100058
J	Kopp, JB; Miller, KD; Mican, JAM; Feuerstein, IM; Vaughan, E; Baker, C; Pannell, LK; Falloon, J				Kopp, JB; Miller, KD; Mican, JAM; Feuerstein, IM; Vaughan, E; Baker, C; Pannell, LK; Falloon, J			Crystalluria and urinary tract abnormalities associated with indinavir	ANNALS OF INTERNAL MEDICINE			English	Article						crystalluria; urinary tract; indinavir; human immunodeficiency virus infections; kidney calculi	PROTEASE INHIBITOR; PATHOGENESIS; L-735,524	Background: Indinavir, a protease inhibitor widely used to treat patients with HIV infection, has been associated with nephrolithiasis. Distinctive urinary crystals and a spectrum of urologic disorders were noted in patients receiving indinavir. Objective: To determine the composition of urinary crystals and the frequency of asymptomatic crystalluria and urinary tract symptoms in patients receiving indinavir. Patients: Patients with HIV infection who were enrolled in studies conducted at the National Institutes of Health. Measurements: Microscopic urinalysis, high-performance liquid chromatography (HPLC) and mass spectrometry of urinary crystals and stones, and clinical evaluation of patients with urologic symptoms. Results: Of 240 patients receiving indinavir, 142 provided urine specimens for analysis. Twenty-nine (20%) had crystals consisting of plate-like rectangles and fan-shaped or starburst forms. Mass spectrometry and HPLC confirmed that these crystals were composed of indinavir. OF 40 patients who were not receiving indinavir, none had similar crystals (P < 0.001). Nineteen of the 240 patients receiving indinavir (8%) developed urologic symptoms. Of these, 7 (3%) had nephrolithiasis and the other 12 (5%) had previously undescribed syndromes: crystalluria associated with dysuria and crystalluria associated with back or flank pain. Four of the patients with the latter syndrome had radiographic evidence of intrarenal sludging. Conclusions: Indinavir forms characteristic crystals in the urine. This crystalluria may be associated with dysuria and urinary frequency, with flank or back pain associated with intrarenal sludging, and with the classic syndrome of renal colic.	NIAID, NIH, BETHESDA, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kopp, JB (corresponding author), NIDDK, WARREN GRANT MAGNUSON CLIN CTR, NIH, BLDG 10, ROOM 3N116, BETHESDA, MD 20892 USA.		Kopp, Jeffrey B/O-2681-2015	Kopp, Jeffrey B/0000-0001-9052-186X				BALANI SK, 1995, DRUG METAB DISPOS, V23, P266; Bartlett JG, 1996, ANN INTERN MED, V124, P1086, DOI 10.7326/0003-4819-124-12-199606150-00011; BIRCH DF, 1994, COLOR ATLAS URINE MI; COE FL, 1992, NEW ENGL J MED, V327, P1141, DOI 10.1056/NEJM199210153271607; Corey L, 1996, NEW ENGL J MED, V335, P1142, DOI 10.1056/NEJM199610103351509; Daudon M, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62506-8; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001; Farina Luis A., 1995, Archivos Espanoles de Urologia, V48, P418; GULICK R, 1996, 3 C RETR OPP INF WAS, pLB7; Haber MB, 1981, URINARY SEDIMENT TXB; LIN JH, 1995, DRUG METAB DISPOS, V23, P730; MCEVOY GK, 1996, DRUG INFORMATION; *MERCK CO, 1996, CRIX IND SULF US PAC; PATZELT WJ, 1974, POLARIZED LIGHT MICR; Piscitelli SC, 1996, CLIN INFECT DIS, V23, P685, DOI 10.1093/clinids/23.4.685; PREMINGER GM, 1992, SEMIN NEPHROL, V12, P200; Rapado A, 1987, Contrib Nephrol, V58, P25; SAWYER MH, 1988, AM J MED, V84, P1067, DOI 10.1016/0002-9343(88)90313-0; TANOUYE E, 1996, WALL STREET J   1105, pA6; Tanouye E, 1996, WALL STREET J   1106, pA1; Tashima KT, 1997, NEW ENGL J MED, V336, P138, DOI 10.1056/NEJM199701093360215	22	247	251	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					119	+		10.7326/0003-4819-127-2-199707150-00004	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9230000				2022-12-24	WOS:A1997XK15800006
J	Slemenda, C; Brandt, KD; Heilman, DK; Mazzuca, S; Braunstein, EM; Katz, BP; Wolinsky, FD				Slemenda, C; Brandt, KD; Heilman, DK; Mazzuca, S; Braunstein, EM; Katz, BP; Wolinsky, FD			Quadriceps weakness and osteoarthritis of the knee	ANNALS OF INTERNAL MEDICINE			English	Article						muscle weakness; osteoarthritis; knee joint; quadriceps; disabled	X-RAY ABSORPTIOMETRY; OSTEO-ARTHRITIS; MUSCLE; ASSOCIATION; OUTCOMES; PROGRAM; THERAPY; HEALTH	Background: The quadriceps weakness commonly associated with osteoarthritis of the knee is widely believed to result from disuse atrophy secondary to pain in the in volved joint. However, quadriceps weakness may be an etiologic factor in the development of osteoarthritis. Objective: To explore the relation between lower-extremity weakness and osteoarthritis of the knee. Design: Cross-sectional prevalence study. Setting: Population-based, with recruitment by random-digit dialing. Participants: 462 volunteers 65 years of age or older. Measurements: Radiographs of the knee were graded for the presence of osteoarthritis. Knee pain and function were assessed with the Western Ontario and McMaster Universities Arthritis Index, the strength of leg flexors and extensors was assessed with isokinetic dynamometry, and lower-extremity lean tissue mass was assessed with dual-energy x-ray absorptiometry. Results: Among participants with osteoarthritis, quadriceps weakness, but not hamstring weakness, was common. The ratio of extensor strength to body weight was approximately 20% lower in those with than in those without radiographic osteoarthritis. Notably, among women with tibiofemoral osteoarthritis, extensor weakness was present in the absence of knee pain and was seen in participants with normal lower-extremity lean mass (extensor strength, 30.1 Ib-ft for those with osteoarthritis and 34.8 Ib-ft for those without osteoarthritis; P < 0.001). After adjustment for body weight, age, and sex, lesser quadriceps strength remained predictive of both radiographic and symptomatic osteoarthritis of the knee (odds ratio for prevalence of osteoarthritis per 10 Ib-ft loss of strength, 0.8 [95% CI, 0.71 to 0.90] for radiographic osteoarthritis and 0.71 [CI, 0.51 to 0.87] for symptomatic osteoarthritis). Conclusion: Quadriceps weakness may be present in patients who have osteoarthritis but do not have knee pain or muscle atrophy; this suggests that the weakness may be due to muscle dysfunction. The data are consistent with the possibility that quadriceps weakness is a primary risk factor for knee pain, disability, and progression of joint damage in persons with osteoarthritis of the knee.	INDIANA UNIV, SCH MED, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, MED CTR, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis			Wolinsky, Fredric D/F-9231-2011	Wolinsky, Fredric/0000-0002-0916-4955	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020582] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00750] Funding Source: Medline; NIAMS NIH HHS [2P60AR20582-20] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Chamberlain M A, 1982, Int Rehabil Med, V4, P101; DAVIS MA, 1989, AM J EPIDEMIOL, V130, P278, DOI 10.1093/oxfordjournals.aje.a115334; FEINBERG J, 1992, ARTHRITIS RHEUM S5, V35, pR28; FELSON DT, 1988, ANN INTERN MED, V109, P18, DOI 10.7326/0003-4819-109-1-18; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FIATARONE MA, 1993, J AM GERIATR SOC, V41, P333, DOI 10.1111/j.1532-5415.1993.tb06714.x; FISHER NM, 1993, ARCH PHYS MED REHAB, V74, P840, DOI 10.1016/0003-9993(93)90011-X; FISHER NM, 1994, AM J PHYS MED REHAB, V73, P413, DOI 10.1097/00002060-199411000-00006; FISHER NM, 1993, ARCH PHYS MED REHAB, V74, P1319, DOI 10.1016/0003-9993(93)90087-Q; FISHER NM, 1991, ARCH PHYS MED REHAB, V72, P365; FULLER NJ, 1992, CLIN PHYSIOL, V12, P253, DOI 10.1111/j.1475-097X.1992.tb00831.x; GUCCIONE AA, 1994, AM J PUBLIC HEALTH, V84, P351, DOI 10.2105/AJPH.84.3.351; HAARBO J, 1990, J BONE MINER RES S2, V5, pS180; HADLER NM, 1992, ANN INTERN MED, V116, P598, DOI 10.7326/0003-4819-116-7-598; HURLEY MV, 1993, BRIT J RHEUMATOL, V32, P127; JEFFERSON RJ, 1990, ENG MED, V204, P21; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; LAWRENCE JS, 1966, ANN RHEUM DIS, V25, P1; Mazzuca S. A., 1995, Arthritis and Rheumatism, V38, pS227; MCALINDON TE, 1992, ANN RHEUM DIS, V51, P844, DOI 10.1136/ard.51.7.844; RUTHERFORD OM, 1986, J NEUROL NEUROSUR PS, V49, P1288, DOI 10.1136/jnnp.49.11.1288; Sharma L, 1996, J INVEST MED, V44, pA359; TATARANNI PA, 1995, AM J CLIN NUTR, V62, P730, DOI 10.1093/ajcn/62.4.730; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	27	640	674	2	51	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					97	+		10.7326/0003-4819-127-2-199707150-00001	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9230035				2022-12-24	WOS:A1997XK15800003
J	Nicoll, M; Akerib, CC; Meyer, BJ				Nicoll, M; Akerib, CC; Meyer, BJ			X-chromosome-counting mechanisms that determine nematode sex	NATURE			English	Article							CAENORHABDITIS-ELEGANS; DOSAGE COMPENSATION; C-ELEGANS; GENE; IDENTIFICATION; XOL-1	Sex is determined in Caenorhabditis elegans by an X-chromosome-counting mechanism that reliably distinguishes the twofold difference in X-chromosome dose between males (1X) and hermaphrodites (2X)(1,2). This small quantitative difference is translated into the 'on/off' response of the target gene, xol-1, a switch that specifies the male fate when active and the hermaphrodite fate when inactive(3), Specific regions of X contain counted signal elements whose combined dose sets the activity of xol-1 (ref. 4). Here we ascribe the dose effects of one region to a discrete, protein-encoding gene, fox-1. We demonstrate that the dose-sensitive signal elements on chromosome X control xol-1 through two different molecular mechanisms. One involves the transcriptional repression of xol-1 in XX animals. The other uses the putative RNA-binding protein encoded by fox-1 to reduce the level of xol-1 protein, These two mechanisms of repression act together to ensure the fidelity of the X-chromosome counting process.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley				Meyer, Barbara/0000-0002-6530-4588	NIGMS NIH HHS [R01 GM030702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERIB CC, 1994, GENETICS, V138, P1105; BARSTEAD RJ, 1991, CELL MOTIL CYTOSKEL, V20, P69, DOI 10.1002/cm.970200108; BIRD CG, 1994, SCIENCE, V265, P615; Bridges CB, 1916, GENETICS, V1, P1; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; HODGKIN J, 1994, DEVELOPMENT, V120, P3681; HODGKIN J, 1979, GENETICS, V91, P67; MADL JE, 1979, GENETICS, V93, P393; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; Nigon V., 1951, B BIOL FR BELG, V85, P187; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; Willard HF, 1996, CELL, V86, P5, DOI 10.1016/S0092-8674(00)80071-9	15	68	72	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					200	204		10.1038/40669	http://dx.doi.org/10.1038/40669			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217163	Bronze			2022-12-24	WOS:A1997XK10900056
J	Wah, DA; Hirsch, JA; Dorner, LF; Schildkraut, I; Aggarwal, AK				Wah, DA; Hirsch, JA; Dorner, LF; Schildkraut, I; Aggarwal, AK			Structure of the multimodular endonuclease FokI bound to DNA	NATURE			English	Article							CRYSTAL-STRUCTURE; RESTRICTION-ENDONUCLEASE; ZINC FINGERS; RNA GENE; BINDING; RECOGNITION; COMPLEX; MUTANTS; DOMAINS; SITES	FokI is a member of an unusual class of bipartite restriction enzymes that recognize a specific DNA sequence and cleave DNA nonspecifically a short distance away from that sequence(1-3) Because of its unusual bipartite nature, FokI has been used to create artificial enzymes with new specificities(4-7). We have determined the crystal structure at 2.8 Angstrom resolution of the complete FokI enzyme bound to DNA. As anticipated, the enzyme contains amino- and carboxy-terminal domains corresponding to the DNA-recognition and cleavage functions, respectively. The recognition domain is made of three smaller subdomains (D1, D2 and D3) which are evolutionarily related to the helix-turn-helix-containing DNA-binding domain of the catabolite gene activator protein CAP(8). The CAP core has been extensively embellished in the first two subdomains, whereas in the third subdomain it has been co-opted for protein-protein interactions. Surprisingly, the cleavage domain contains only a single catalytic centre, raising the question of how monomeric FokI manages to cleave both DNA strands. Unexpectedly, the cleavage domain is sequestered in a 'piggyback' fashion by the recognition domain. The structure suggests a new mechanism for nuclease activation and provides a framework for the design of chimaeric enzymes with altered specificities.	COLUMBIA UNIV,DEPT BIOCHEM & MOL BIOPHYS,NEW YORK,NY 10032; NEW ENGLAND BIOLABS INC,BEVERLY,MA 01915	Columbia University			Wilson, Matthew H/K-3193-2013; Hirsch, Joel/AAC-8000-2021	Hirsch, Joel/0000-0001-7544-8668				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; FUREY W, 1993, PHASES PROGRAM PACKA; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HEITMAN J, 1990, EMBO J, V9, P3369, DOI 10.1002/j.1460-2075.1990.tb07538.x; Hirsch JA, 1997, FEBS LETT, V403, P136, DOI 10.1016/S0014-5793(97)00039-2; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang BH, 1996, J PROTEIN CHEM, V15, P481, DOI 10.1007/BF01886856; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156; KIM YG, 1994, P NATL ACAD SCI USA, V91, P883, DOI 10.1073/pnas.91.3.883; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LI L, 1993, GENE, V133, P79, DOI 10.1016/0378-1119(93)90227-T; LI L, 1992, P NATL ACAD SCI USA, V89, P4275, DOI 10.1073/pnas.89.10.4275; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PODHAJSKA AJ, 1985, GENE, V40, P175, DOI 10.1016/0378-1119(85)90040-X; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SKOWRON P, 1993, GENE, V125, P1, DOI 10.1016/0378-1119(93)90738-O; SUGISAKI H, 1981, GENE, V16, P73; WAUGH DS, 1993, P NATL ACAD SCI USA, V90, P9596, DOI 10.1073/pnas.90.20.9596; WAUGH DS, 1994, J BIOL CHEM, V269, P12298; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; YONEZAWA A, 1994, BBA-GENE STRUCT EXPR, V1219, P369, DOI 10.1016/0167-4781(94)90061-2	29	212	277	3	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					97	100		10.1038/40446	http://dx.doi.org/10.1038/40446			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214510				2022-12-24	WOS:A1997XJ14300058
J	Benbow, SJ; Walsh, A; Gill, GV				Benbow, SJ; Walsh, A; Gill, GV			Diabetes in institutionalised elderly people: A forgotten population?	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIVERPOOL,CLIN DEPT AINTREE,FAZAKERLEY HOSP,DIABET & ENDOCRINOL CLIN RES GRP,LIVERPOOL L9 7AL,MERSEYSIDE,ENGLAND	University of Liverpool	Benbow, SJ (corresponding author), WALTON HOSP,CTR DIABET,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND.							SINCLAIR AJ, 1993, BRIT MED J, V306, P1142, DOI 10.1136/bmj.306.6886.1142; Sinclair AJ, 1996, POSTGRAD MED J, V72, P334, DOI 10.1136/pgmj.72.848.334; TATTERSALL RB, 1984, DIABETOLOGIA, V27, P167	3	59	59	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1868	1869		10.1136/bmj.314.7098.1868	http://dx.doi.org/10.1136/bmj.314.7098.1868			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224129	Green Published			2022-12-24	WOS:A1997XH73800023
J	Hayashi, H; Abdollah, S; Qiu, YB; Cai, JX; Xu, YY; Grinnell, BW; Richardson, MA; Topper, JN; Gimbrone, MA; Wrana, JL; Falb, D				Hayashi, H; Abdollah, S; Qiu, YB; Cai, JX; Xu, YY; Grinnell, BW; Richardson, MA; Topper, JN; Gimbrone, MA; Wrana, JL; Falb, D			The MAD-related protein Smad7 associates with the TGF beta receptor and functions as an antagonist of TGF beta signaling	CELL			English	Article							COMPLEX	TGF beta signaling is initiated when the type I receptor phosphorylates the MAD-related protein, Smad2, on C-terminal serine residues. This leads to Smad2 association with Smad4, translocation to the nucleus, and regulation of transcriptional responses. Here we demonstrate that Smad7 is an inhibitor of TGF beta signaling. Smad7 prevents TGF beta-dependent formation of Smad2/Smad4 complexes and inhibits the nuclear accumulation of Smad2. Smad7 interacts stably with the activated TGF beta type I receptor, thereby blocking the association, phosphorylation, and activation of Smad2. Furthermore, mutations in Smad7 that interfere with receptor binding disrupt its inhibitory activity. These studies thus define a novel function for MAD-related proteins as intracellular antagonists of the type I kinase domain of TGF beta family receptors.	HOSP SICK CHILDREN,DIV GASTROENTEROL,TORONTO,ON M5G 1X8,CANADA; MILLENNIUM PHARMACEUT INC,CAMBRIDGE,MA 02139; LILLY RES LABS,DIV RES TECHNOL & PROT,INDIANAPOLIS,IN 46285; BRIGHAM & WOMENS HOSP,DEPT MED,DIV VASC RES,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Eli Lilly; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hayashi, H (corresponding author), HOSP SICK CHILDREN,PROGRAM DEV BIOL,555 UNIV AVE,TORONTO,ON M5G 1X8,CANADA.		Wrana, Jeffrey/F-8857-2013					Attisano L, 1996, MOL CELL BIOL, V16, P1066; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HOODLESS P, 1997, IN PRESS CURRENT TOP; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; TOPPER JN, 1997, IN PRESS P NATL ACAD; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	31	1117	1185	1	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1165	1173		10.1016/S0092-8674(00)80303-7	http://dx.doi.org/10.1016/S0092-8674(00)80303-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215638	Bronze			2022-12-24	WOS:A1997XG83000020
J	Kendrick, KM; GuevaraGuzman, R; Zorrilla, J; Hinton, MR; Broad, KD; Mimmack, M; Ohkura, S				Kendrick, KM; GuevaraGuzman, R; Zorrilla, J; Hinton, MR; Broad, KD; Mimmack, M; Ohkura, S			Formation of olfactory memories mediated by nitric oxide	NATURE			English	Article							LONG-TERM POTENTIATION; ASPARTATE RECEPTOR ANTAGONIST; SOLUBLE GUANYLYL CYCLASE; SYNTHASE MESSENGER-RNA; SELECTIVE IMPAIRMENT; CARBON-MONOXIDE; RAT-BRAIN; HIPPOCAMPUS; INHIBITION; SYSTEM	Sheep learn to recognize the odours of their lambs within two hours of giving birth, and this learning involves synaptic changes within the olfactory bulb(1,2). Specifically, mitral cells become increasingly responsive to the learned odour, which stimulates release of both glutamate and GABA (gamma-aminobutyric acid) neurotransmitters from the reciprocal synapses between the excitatory mitral cells and inhibitory granule cells(1). Nitric oxide (NO) has been implicated in synaptic plasticity in other regions of the brain as a result of its modulation of cyclic GMP levels(3-7). Here we investigate the possible role of NO in olfactory learning. We find that the neuronal enzyme nitric oxide synthase (nNOS) is expressed in both mitral and granule cells, whereas the guanylyl cyclase subunits that are required for NO stimulation of cGMP formation(8) are expressed only in mitral cells. Immediately after birth, glutamate levels rise, inducing formation of NO and cGMP, which potentiate glutamate release at the mitral-to-granule cell synapses. Inhibition of nNOS or guanylyl cyclase activity prevents both the potentiation of glutamate release and formation of the olfactory memory. The effects of nNOS inhibition can be reversed by infusion of NO into the olfactory bulb, Once memory has formed, however, inhibition of nNOS or guanylyl cyclase activity cannot impair either its recall or the neurochemical release evoked by the learned lamb odour. Nitric oxide therefore seems to act as a retrograde and/or intracellular messenger, being released from both mitral and granule cells to potentiate glutamate release from mitral cells by modulating cGMP concentrations. We propose that the resulting changes in the functional circuitry of the olfactory bulb underlie the formation of olfactory memories.			Kendrick, KM (corresponding author), BABRAHAM INST,DEPT NEUROBIOL,CAMBRIDGE CB2 4AT,ENGLAND.		Guevara-Guzman, Rosalinda/GXV-2779-2022	Kendrick, Keith/0000-0002-0371-5904				Arancio O, 1996, CELL, V87, P1025, DOI 10.1016/S0092-8674(00)81797-3; BANNERMAN DM, 1994, J NEUROSCI, V14, P7404; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOULTON CL, 1995, NEUROSCIENCE, V69, P699, DOI 10.1016/0306-4522(95)00349-N; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRENNAN PA, 1989, NEUROSCIENCE, V33, P463, DOI 10.1016/0306-4522(89)90398-9; BRUNE B, 1991, BIOCHEM BIOPH RES CO, V181, P921, DOI 10.1016/0006-291X(91)91279-L; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DOZE VA, 1991, NEURON, V6, P889, DOI 10.1016/0896-6273(91)90229-S; FUJISAWA H, 1994, J NEUROCHEM, V63, P140; FURUYAMA T, 1993, MOL BRAIN RES, V20, P335, DOI 10.1016/0169-328X(93)90060-3; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; KENDRICK KM, 1992, SCIENCE, V256, P833, DOI 10.1126/science.1589766; Kendrick KM, 1996, EUR J NEUROSCI, V8, P2619, DOI 10.1111/j.1460-9568.1996.tb01557.x; KENDRICK KM, 1994, BEHAV PROCESS, V33, P89, DOI 10.1016/0376-6357(94)90061-2; KISHIMOTO J, 1993, EUR J NEUROSCI, V5, P1684, DOI 10.1111/j.1460-9568.1993.tb00236.x; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; LEVY F, 1990, BEHAV NEUROSCI, V104, P464, DOI 10.1037/0735-7044.104.3.464; LEVY F, 1995, PHYSIOL BEHAV, V57, P97, DOI 10.1016/0031-9384(94)00200-O; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MURPHY KPSJ, 1994, NEUROPHARMACOLOGY, V33, P1375, DOI 10.1016/0028-3908(94)90039-6; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; SALTER M, 1995, NEUROPHARMACOLOGY, V34, P327, DOI 10.1016/0028-3908(94)00162-L; VANDENPOL AN, 1995, J COMP NEUROL, V359, P253, DOI 10.1002/cne.903590206; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	28	221	225	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					670	674		10.1038/41765	http://dx.doi.org/10.1038/41765			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262400				2022-12-24	WOS:A1997XQ86300048
J	Ohno, T; Stribley, JA; Wu, G; Hinirichs, SH; Weisenburger, DD; Chan, WC				Ohno, T; Stribley, JA; Wu, G; Hinirichs, SH; Weisenburger, DD; Chan, WC			Clonality in nodular lymphocyte-predominant Hodgkin's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	38th Annual Meeting of the American-Society-of-Hematology	DEC 06-10, 1996	ORLANDO, FL	Amer Soc Hematol, US Dept Vet Affairs Merit Res Funds, NIH			REED-STERNBERG CELLS; POLYMERASE CHAIN-REACTION; V-H GENES; B-CELL; HISTOLOGICAL SECTIONS; GERMINAL CENTER; IMMUNOGLOBULIN; LINEAGE; REARRANGEMENTS; VARIANTS	Background There is general agreement that lymphocytic and histiocytic (L&H) cells, the variants of Reed-Sternberg cells in nodular lymphocyte-predominant Hodgkin's disease, belong to the B-cell lineage. However, the clonality of L&H cells remains controversial. Methods We used complementarity-determining region 3 (CDR3) of the immunoglobulin heavy-chain gene as a clonal marker to study individual L&H cells isolated by micromanipulation from tissue sections of five patients with nodular lymphocyte-predominant Hodgkin's disease. The heavy-chain CDR3 of each cell was amplified by the polymerase chain reaction, The products were analyzed by gel electrophoresis, and representative amplification products from each patient were sequenced. Results L&H cells whose heavy-chain CDR3 was related, indicating the presence of a clonal population, were detected in all five patients and were the dominant population in three. In four of the five patients, members of the clone were found in different nodules in the tissue section, different tissue blocks from the same tumor, or different lymph nodes from the same patient. The CDR3 sequences in each clone frequently contained nucleotide substitutions indicative of intraclonal mutation. Conclusions Clonal populations of L&H cells occur in nodular lymphocyte-predominant Hodgkin's disease. Intraclonal variation in nucleotide sequences suggests that hypermutation of the heavy-chain CDR3 continues to occur among the clonal progeny. (C) 1997, Massachusetts Medical Society.	UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center					NCI NIH HHS [R01 CA61453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALAVAIKKO MJ, 1991, AM J CLIN PATHOL, V95, P194, DOI 10.1093/ajcp/95.2.194; ANGEL CA, 1987, J PATHOL, V153, P21, DOI 10.1002/path.1711530104; ANGEL CA, 1993, J CLIN PATHOL, V46, P337, DOI 10.1136/jcp.46.4.337; ANGEL CA, 1993, J CLIN PATHOL, V46, P940, DOI 10.1136/jcp.46.10.940; BEREK C, 1992, IMMUNOL REV, V126, P5, DOI 10.1111/j.1600-065X.1992.tb00628.x; BORGGRECH A, 1989, J CLIN ONCOL, V71, P303; CHANG B, 1994, IMMUNOL TODAY, V15, P367, DOI 10.1016/0167-5699(94)90175-9; dAmore F, 1997, LAB INVEST, V76, P219; DELABIE J, 1994, BLOOD, V84, P3291; Greiner TC, 1996, BLOOD, V88, P657, DOI 10.1182/blood.V88.2.657.bloodjournal882657; HELL K, 1993, J PATHOL, V171, P137, DOI 10.1002/path.1711710211; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KNOWLES DM, 1986, P NATL ACAD SCI USA, V83, P7942, DOI 10.1073/pnas.83.20.7942; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; KUZU I, 1993, HISTOPATHOLOGY, V22, P141, DOI 10.1111/j.1365-2559.1993.tb00092.x; LINDEN MD, 1988, HUM PATHOL, V19, P591, DOI 10.1016/S0046-8177(88)80210-7; LUKES RJ, 1966, CANCER RES, V26, P1063; MANZANAL A, 1995, HISTOPATHOLOGY, V27, P21, DOI 10.1111/j.1365-2559.1995.tb00286.x; Pan LX, 1996, BLOOD, V87, P2428, DOI 10.1182/blood.V87.6.2428.bloodjournal8762428; PINKUS GS, 1988, AM J PATHOL, V133, P211; POPPEMA S, 1989, AM J PATHOL, V135, P351; POPPEMA S, 1980, J HISTOCHEM CYTOCHEM, V28, P788, DOI 10.1177/28.8.6777426; REGULA DP, 1988, NEW ENGL J MED, V318, P214, DOI 10.1056/NEJM198801283180404; SAID JW, 1991, AM J PATHOL, V138, P261; STEIN H, 1986, AM J CLIN PATHOL, V86, P292, DOI 10.1093/ajcp/86.3.292; STOLER MH, 1995, AM J PATHOL, V146, P812; TAMARU J, 1994, BLOOD, V84, P708; TIMENS W, 1986, LAB INVEST, V54, P457; WICKERT RS, 1995, BLOOD, V86, P2312, DOI 10.1182/blood.V86.6.2312.bloodjournal8662312; WU G, IN PRESS DIAGN MOL P; YAMADA M, 1989, P NATL ACAD SCI USA, V86, P5123, DOI 10.1073/pnas.86.13.5123	33	119	121	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	1997	337	7					459	465		10.1056/NEJM199708143370704	http://dx.doi.org/10.1056/NEJM199708143370704			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ499	9250848				2022-12-24	WOS:A1997XQ49900004
J	Orci, L; Stamnes, M; Ravazzola, M; Amherdt, M; Perrelet, A; Sollner, TH; Rothman, JE				Orci, L; Stamnes, M; Ravazzola, M; Amherdt, M; Perrelet, A; Sollner, TH; Rothman, JE			Bidirectional transport by distinct populations of COPI-coated vesicles	CELL			English	Article							ADP-RIBOSYLATION FACTOR; ENDOPLASMIC-RETICULUM; GOLGI-COMPLEX; BREFELDIN-A; BETA-COP; PROTEIN-TRANSPORT; MONOCLONAL-ANTIBODIES; VESICULAR TRANSPORT; GUANINE-NUCLEOTIDE; MEDIATED RETRIEVAL	Electron microscope immunocytochemistry reveals that both anterograde-directed (proinsulin and VSV G protein) and retrograde-directed (the KDEL receptor) cargo are present in coPI-coated vesicles budding from every level of the Golgi stack in whole cells; however, they comprise two distinct populations that together can account for at least 80% of the vesicles budding from Golgi cisternae. Segregation of antero-grade- from retrograde-directed cargo into distinct sets of COPI-coated vesicles is faithfully reproduced in the cell-free Golgi transport system, in which VSV G protein and KDEL receptor are packaged into separable vesicles, even when budding is driven by highly purified coatomer and a recombinant ARF protein.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Orci, L (corresponding author), UNIV GENEVA,CTR MED,FAC MED,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND.			Stamnes, Mark/0000-0002-5869-7985				ALLEN VJ, 1986, J CELL BIOL, V103, P2229; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, J BIOL CHEM, V269, P24486; DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GERICH B, 1995, P NATL ACAD SCI USA, V92, P8532; GRIFFITHS G, 1995, J CELL SCI, V108, P2839; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; KUGE O, 1993, J CELL BIOL, V123, P1727, DOI 10.1083/jcb.123.6.1727; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MADSEN OD, 1983, ENDOCRINOLOGY, V113, P2135, DOI 10.1210/endo-113-6-2135; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELKONIAN M, 1991, J ELECTRON MICR TECH, V17, P165, DOI 10.1002/jemt.1060170205; MORRE DJ, 1977, INT REV CYTOL      S, V5, P61; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1973, J ULTRA MOL STRUCT R, V43, P270, DOI 10.1016/S0022-5320(73)80039-5; ORCI L, 1994, P NATL ACAD SCI USA, V91, P11924, DOI 10.1073/pnas.91.25.11924; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; ORCI L, 1986, Diabetes Metabolism Reviews, V2, P71; ORCI L, 1974, DIABETOLOGIA, V10, P163, DOI 10.1007/BF00423031; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTHMAN JE, 1981, SCIENCE, V213, P1212, DOI 10.1126/science.7268428; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Sonnichsen B, 1996, J CELL BIOL, V134, P1411, DOI 10.1083/jcb.134.6.1411; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; STORCH MJ, 1985, DIABETES, V34, P808, DOI 10.2337/diabetes.34.8.808; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066	73	342	351	0	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					335	349		10.1016/S0092-8674(00)80341-4	http://dx.doi.org/10.1016/S0092-8674(00)80341-4			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244307	Bronze			2022-12-24	WOS:A1997XN24900017
J	Lusser, A; Brosch, G; Loidl, A; Haas, H; Loidl, P				Lusser, A; Brosch, G; Loidl, A; Haas, H; Loidl, P			Identification of maize histone deacetylase HD2 as an acidic nucleolar phosphoprotein	SCIENCE			English	Article							ACETYLATION	The steady state of histone acetylation is established and maintained by multiple histone acetyltransferases and deacetylases, and this steady state affects chromatin structure and function. The identification of a maize complementary DNA encoding the chromatin-bound deacetylase HD2 is reported. This protein was not homologous to the yeast RPD3 transcriptional regulator. It was expressed throughout embryo germination in correlation with the proliferative activity of cells. Antibodies against recombinant HD2-p39 immunoprecipitated the native enzyme complex, which was composed of phosphorylated p39 subunits. Immunofluorescence microscopy and sequence homologies suggested nucleolar localization. HD2 is an acidic nucleolar phosphoprotein that might regulate ribosomal chromatin structure and function.	UNIV INNSBRUCK, SCH MED, DEPT MICROBIOL, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck				Lusser, Alexandra/0000-0002-2226-9081				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BROSCH G, 1992, J BIOL CHEM, V267, P20561; BROSCH G, 1995, PLANT CELL, V7, P1941, DOI 10.1105/tpc.7.11.1941; Brosch G, 1996, BIOCHEMISTRY-US, V35, P15907, DOI 10.1021/bi961294x; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; DarkinRattray SJ, 1996, P NATL ACAD SCI USA, V93, P13143, DOI 10.1073/pnas.93.23.13143; DeRubertis F, 1996, NATURE, V384, P589; GEORGIEVA EI, 1994, PLANTA, V192, P118, DOI 10.1007/BF00198701; GRABHER A, 1994, BIOCHEMISTRY-US, V33, P14887, DOI 10.1021/bi00253a028; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Lechner T, 1996, BBA-PROTEIN STRUCT M, V1296, P181, DOI 10.1016/0167-4838(96)00069-6; LECHNER T, UNPUB; LOIDL P, 1994, CHROMOSOMA, V103, P441; LUSSER A, UNPUB; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Trendelenburg MF, 1996, HISTOCHEM CELL BIOL, V106, P167; TURNER BM, 1991, J CELL SCI, V99, P13; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845	23	193	216	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					88	91		10.1126/science.277.5322.88	http://dx.doi.org/10.1126/science.277.5322.88			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204905				2022-12-24	WOS:A1997XJ41800045
J	Blomley, M; Cosgrove, D				Blomley, M; Cosgrove, D			Microbubble echo-enhancers: A new direction for ultrasound?	LANCET			English	Editorial Material											Blomley, M (corresponding author), HAMMERSMITH HOSP,DEPT IMAGING,LONDON W12 0HS,ENGLAND.							FLEISCHER AC, 1997, ULTRASOUND CONTRAST, P137; KEDAR PP, 1996, RADIOLOGY, V198, P679; Killam A, 1997, ULTRASOUND CONTRAST, P43; Nihoyannopoulos P, 1996, CLIN RADIOL, V51, P28; Schlief R., 1997, ULTRASOUND CONTRAST, P75	5	42	43	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1855	1856		10.1016/S0140-6736(05)63872-X	http://dx.doi.org/10.1016/S0140-6736(05)63872-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217754				2022-12-24	WOS:A1997XG41700005
J	Muhe, L; Lulseged, S; Mason, KE; Simoes, EAF				Muhe, L; Lulseged, S; Mason, KE; Simoes, EAF			Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children	LANCET			English	Article							COMMUNITY	Background Pneumonia is the most important cause of morbidity and mortality in children aged under 5 years worldwide. Studies in developing countries have suggested an association between nutritional rickets and pneumonia. Since both nutritional rickets and pneumonia are common in Ethiopia, we did a case-control study to determine the role of nutritional rickets in the development of pneumonia. Methods Cases were children younger than 5 years admitted to the Ethio-Swedish Children's Hospital during a 5-year period with a diagnosis of pnuemonia (n=521), but data were incomplete for 21 of these and they were not included. Controls (n=500) were matched for admission within 3 months of cases and age within 3 months and had no evidence of pneumonia. Nutritional, demographic, and clinical and radiographic data for rickets and pneumonia were collected. Matched odd ratios and logistic regression were used to test the significance of the association of richets and pneumonia. Findings Rickets was present in 210 of 500 cases compared with 20 of 500 controls (odds ratio 22.11). There were significant differences between cases and controls for family size, birth order, crowding, and months of exclusive breastfeeding (p<0.05). After correction for these confounding factors by logistic regression, there was still a 13-fold higher incidence of rickets among children with pneumonia than among controls (13.37 [95% CI 8.08-24.22], p<0.001). Interpretation Vitamin D or calcium deficiency may be important predisposing factors for pneumonia in children aged under 5 years in developing countries. Efforts to prevent vitamin D deficiency or calcium supplementation may result in significant reductions in morbidity and mortality from pneumonia in these children.	CHILDRENS HOSP,DIV INFECT DIS,DENVER,CO 80218; UNIV ADDIS ABABA,FAC MED,DEPT PEDIAT & CHILD HLTH,ADDIS ABABA,ETHIOPIA; WHO,DIV CHILD HLTH & DEV,CH-1211 GENEVA,SWITZERLAND; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DIV INFECT DIS,DENVER,CO 80262	Children's Hospital Colorado; Addis Ababa University; World Health Organization; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								AUST-KETTIS A., 1965, Ethiopian Medical Journal, V3, P109; DRIDZ TA, 1979, AM J CLIN NUTR, V32, P607; *ETH SWED CHILDR H, 1994, ANN REP ETH SWED CHI; Gupta S K, 1971, J Indian Med Assoc, V57, P141; HORTAL M, 1990, REV INFECT DIS, V12, pS966; Kirkwood BR, 1995, B WORLD HEALTH ORGAN, V73, P793; LAWSON DEM, 1987, HUM NUTR-CLIN NUTR, V41C, P199; LEMIRE JM, 1985, J IMMUNOL, V134, P3032; LUBANI MM, 1989, ANN TROP PAEDIATR, V3, P134; LULSEGED S, 1990, ETHIOPIAN MED J, V28, P175; MA XC, 1986, J PRAC PEDIAT, V1, P323; MUHE L, 1995, PUBLIC HEALTH, V109, P99, DOI 10.1016/S0033-3506(05)80003-4; Oginni LM, 1996, J PEDIATR-US, V128, P692, DOI 10.1016/S0022-3476(96)80137-5; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; ROOK GAW, 1986, IMMUNOLOGY, V57, P159; SALIMPOUR R, 1975, ARCH DIS CHILD, V50, P63, DOI 10.1136/adc.50.1.63; STRODER J, 1970, ACTA PAEDIATR SCAND, V59, P288, DOI 10.1111/j.1651-2227.1970.tb09005.x; VAHLQUIST B, 1975, ACTA PAEDIATR SCAND, V64, P161; Wellcome Trust Working Party, 1970, LANCET, V2, P302; *WHO, 1994, WHOARL9433; WOLDEMARIAM T, 1973, J PAEDIAT, V82, P876; *WORLD BANK, 1993, WORLD DEV REP	22	238	247	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1801	1804		10.1016/S0140-6736(96)12098-5	http://dx.doi.org/10.1016/S0140-6736(96)12098-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269215				2022-12-24	WOS:A1997XF73500011
J	Michalet, X; Ekong, R; Fougerousse, F; Rousseaux, S; Schurra, C; Hornigold, N; vanSlegtenhorst, M; Wolfe, J; Povey, S; Beckmann, JS; Bensimon, A				Michalet, X; Ekong, R; Fougerousse, F; Rousseaux, S; Schurra, C; Hornigold, N; vanSlegtenhorst, M; Wolfe, J; Povey, S; Beckmann, JS; Bensimon, A			Dynamic molecular combing: Stretching the whole human genome for high-resolution studies	SCIENCE			English	Article							IN-SITU HYBRIDIZATION; TUBEROUS-SCLEROSIS; PRENATAL-DIAGNOSIS; HUMAN-CHROMOSOMES; CANDIDATE REGION; COSMID CONTIGS; DNA; CHROMATIN; 9Q34; CELLS	DNA in amounts representative of hundreds of eukaryotic genomes was extended on silanized surfaces by dynamic molecular combing. The precise measurement of hybridized DNA probes was achieved directly without requiring normalization. This approach was validated with the high-resolution mapping of cosmid contigs on a yeast artificial chromosome (YAC) within yeast genomic DNA. It was extended to human genomic DNA for precise measurements ranging from T to 150 kilobases, of gaps within a contig, and of microdeletions in the tuberous sclerosis 2 gene on patients' DNA. The simplicity, reproducibility, and precision of this approach makes it a powerful tool for a variety of genomic studies.	INST PASTEUR, DEPT BIOTECHNOL, LAB BIOPHYS ADN, F-75724 PARIS 15, FRANCE; UCL, MRC, HUMAN BIOCHEM GENET UNIT, LONDON NW1 2HE, ENGLAND; GENETHON, URA 1922, F-91002 EVRY, FRANCE; UCL, DEPT BIOL, GALTON LAB, LONDON NW1 2HE, ENGLAND; ERASMUS UNIV ROTTERDAM, DEPT CLIN GENET, NL-3015 GE ROTTERDAM, NETHERLANDS	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of London; University College London; University of London; University College London; Erasmus University Rotterdam			Beckmann, Jacques S/A-9772-2008; Rousseaux, Sophie/G-1697-2013; Michalet, Xavier/A-9704-2009	Beckmann, Jacques S/0000-0002-9741-1900; Rousseaux, Sophie/0000-0001-5246-5350; Michalet, Xavier/0000-0001-6602-7693; Ekong, Rosemary/0000-0002-5984-7893	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEMAND JF, IN PRESS BIOPHYS J; BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; BENSIMON A, 1995, PHYS REV LETT, V76, P4754; BLANCATO JK, 1995, J REPROD MED, V40, P537; Boysen C, 1997, GENOME RES, V7, P330, DOI 10.1101/gr.7.4.330; BROOKCARTER PT, 1994, NAT GENET, V8, P328, DOI 10.1038/ng1294-328; Cheung MC, 1996, NAT GENET, V14, P264, DOI 10.1038/ng1196-264; CHUMAKOV IM, 1995, NATURE S, V373, P175; DAVIES KE, 1988, GENOME ANAL PRACTICA; EKONG R, UNPUB; EVANS IH, 1996, METHOD MOL BIOL, V53, P71; FIDLEROVA H, 1994, CYTOGENET CELL GENET, V65, P203, DOI 10.1159/000133632; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FLORIJN RJ, 1995, HUM MOL GENET, V4, P831, DOI 10.1093/hmg/4.5.831; FOUGEROUSSE F, 1994, HUM MOL GENET, V3, P285, DOI 10.1093/hmg/3.2.285; GIBBS RA, 1995, NAT GENET, V11, P121, DOI 10.1038/ng1095-121; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Green P, 1997, GENOME RES, V7, P410, DOI 10.1101/gr.7.5.410; GROFFEAU A, 1996, SCIENCE, V274, P546; HAAF T, 1994, HUM MOL GENET, V3, P697, DOI 10.1093/hmg/3.5.697; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; HEISKANEN M, 1995, GENOMICS, V30, P31, DOI 10.1006/geno.1995.0005; Hornigold N, 1997, GENOMICS, V41, P385, DOI 10.1006/geno.1997.4681; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Lastowska M, 1997, GENE CHROMOSOME CANC, V18, P162; MENG X, 1995, NAT GENET, V9, P432, DOI 10.1038/ng0495-432; MICHALET X, UNPUB; NAHMIAS J, 1995, EUR J HUM GENET, V3, P65; NELLIST M, 1993, CELL, V75, P1305; Niederacher D, 1997, GENE CHROMOSOME CANC, V18, P181, DOI 10.1002/(SICI)1098-2264(199703)18:3<181::AID-GCC5>3.0.CO;2-Y; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; PERTL B, 1994, LANCET, V343, P1197, DOI 10.1016/S0140-6736(94)92404-X; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; RICHARD I, 1995, MAMM GENOME, V6, P754, DOI 10.1007/BF00354303; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; SAMPSON J, COMMUNICATION; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; SCHWARTZ DC, 1993, SCIENCE, V262, P110, DOI 10.1126/science.8211116; SENGER G, 1994, HUM MOL GENET, V3, P1275, DOI 10.1093/hmg/3.8.1275; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Tomizuka K, 1997, NAT GENET, V16, P133, DOI 10.1038/ng0697-133; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; VANSLEGTENHORST M, 1995, EUR J HUM GENET, V3, P78; Veldman T, 1997, NAT GENET, V15, P406, DOI 10.1038/ng0497-406; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401; WEIER HUG, 1995, HUM MOL GENET, V4, P1903; WIEGANT J, 1992, HUM MOL GENET, V1, P587, DOI 10.1093/hmg/1.8.587; Yokota H, 1997, NUCLEIC ACIDS RES, V25, P1064, DOI 10.1093/nar/25.5.1064	48	482	528	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1518	1523		10.1126/science.277.5331.1518	http://dx.doi.org/10.1126/science.277.5331.1518			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278517				2022-12-24	WOS:A1997XV42900044
J	Forti, L; Bossi, M; Bergamaschi, A; Villa, A; Malgaroli, A				Forti, L; Bossi, M; Bergamaschi, A; Villa, A; Malgaroli, A			Loose-patch recordings of single quanta at individual hippocampal synapses	NATURE			English	Article							LONG-TERM POTENTIATION; SYNAPTIC CURRENTS; RAT HIPPOCAMPUS; NEURONS; SLICES; VARIABILITY; MINIATURE; CHANNELS; CLAMP; CA3	Synapses in the central nervous system are typically studied by recording electrical responses from the cell body of the postsynaptic cell. Because neurons are normally connected by multiple synaptic contacts, these postsynaptic responses reflect the combined activity of many thousands synapses, and it remains unclear to what extent the properties of individual synapses can be deduced from the population response(1-5). We have therefore developed a method for recording the activity of individual hippocampal synapses. By capturing an isolated presynaptic bouton inside a loose-patch pipette and recording from the associated patch of postsynaptic membrane, we were able to detect miniature excitatory postsynaptic currents ('minis') arising from spontaneous vesicle exocytosis at a single synaptic site, and to compare these with minis recorded simultaneously from the cell body. The average peak conductance at a single synapse was about 900 pS, corresponding roughly to the opening of 90 AMPA-type glutamate-receptor channels, The variability in this conductance was about 30%, matching the value reported for the neuromuscular junction(6). Given that our synapses displayed single postsynaptic densities (PSDs), this variability is larger than would be predicted from the random opening of receptor channels, suggesting that they are not saturated by the content of a single vesicle. Therefore the response to a quantum of neurotransmitter at these synapses is not limited by the number of available postsynaptic receptors.	SAN RAFFAELE SCI INST,DIBIT,DEPT BIOL & TECHNOL RES,I-20123 MILAN,ITALY; UNIV MILAN,CELLULAR & MOL PHARMACOL CTR,CNR,DEPT PHARMACOL,I-20123 MILAN,ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); University of Milan			Forti, Lia/AAU-8156-2020; Forti, Lia/E-9957-2018; Malgaroli, Antonio/I-5090-2013; Villa, Antonello/B-4781-2012	Forti, Lia/0000-0003-3979-0284; Forti, Lia/0000-0003-3979-0284; Malgaroli, Antonio/0000-0003-3758-7477; Villa, Antonello/0000-0002-3820-8072	Telethon [D.044] Funding Source: Medline	Telethon(Fondazione Telethon)		Bauerfeind Rudol, 1994, Trends in Cell Biology, V4, P155, DOI 10.1016/0962-8924(94)90191-0; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; EDWARDS FA, 1995, PHYSIOL REV, V75, P759, DOI 10.1152/physrev.1995.75.4.759; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FABER DS, 1992, SCIENCE, V258, P1494, DOI 10.1126/science.1279813; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; FERKING M, 1996, CURR OPIN NEUROBIOL, V6, P395; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JACK JJB, 1994, ADV SEC MESS PHOSPH, V29, P275; JACK JJB, 1983, ELECTRIC CURRENT FLO; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; KORN H, 1994, ADV SEC MESS PHOSPH, V29, P301; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; Lewis CA, 1996, J NEUROPHYSIOL, V76, P461, DOI 10.1152/jn.1996.76.1.461; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LIU GS, 1995, NATURE, V375, P404, DOI 10.1038/375404a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; Silver RA, 1996, J PHYSIOL-LONDON, V494, P231, DOI 10.1113/jphysiol.1996.sp021487; SPRUSTON N, 1993, J NEUROPHYSIOL, V70, P781, DOI 10.1152/jn.1993.70.2.781; SPRUSTON N, 1995, J PHYSIOL-LONDON, V482, P325, DOI 10.1113/jphysiol.1995.sp020521; Stricker C, 1996, J PHYSIOL-LONDON, V490, P419, DOI 10.1113/jphysiol.1996.sp021155; STUEHMER W, 1983, SINGLE CHANNEL RECOR, P123	30	145	148	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					874	878		10.1038/42251	http://dx.doi.org/10.1038/42251			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278048	Bronze			2022-12-24	WOS:A1997XT75400049
J	Schorey, JS; Carroll, MC; Brown, EJ				Schorey, JS; Carroll, MC; Brown, EJ			A macrophage invasion mechanism of pathogenic mycobacteria	SCIENCE			English	Article							COMPLEMENT RECEPTORS; IMMUNE-COMPLEXES; HUMAN-MONOCYTES; TUBERCULOSIS; PHAGOCYTOSIS; ACTIVATION; ANTIBODIES; INFECTION; DEFICIENT; SECRETION	Tuberculosis is the leading cause of death due to an infectious organism, killing an estimated 3 million people annually, Mycobacterium tuberculosis, the causative agent of tuberculosis, and other pathogenic mycobacteria require entry into host macrophages to initiate infection, An invasion mechanism was defined that was shared among pathogenic mycobacteria including M. tuberculosis, M. leprae, and M. avium but not by nonpathogenic mycobacteria or nonmycobacterial intramacrophage pathogens. This pathway required the association of the complement cleavage product C2a with mycobacteria resulting in the formation of a C3 convertase. The mycobacteria-associated C2a cleaved C3, resulting in C3b opsonization of the mycobacteria and recognition by macrophages.	WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, DIV INFECT DIS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOL MICROBIOL, ST LOUIS, MO 63110 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Washington University (WUSTL); Washington University (WUSTL); Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033348] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33348] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABA KSSS, 1990, TUBERCLE, V71, P103, DOI 10.1016/0041-3879(90)90004-R; BROSTOFF J, 1981, TUBERCLE, V62, P169, DOI 10.1016/0041-3879(81)90002-7; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CARR RI, 1980, CLIN EXP IMMUNOL, V39, P562; COLE FS, 1980, J IMMUNOL, V125, P1120; ELLNER JJ, 1991, J INFECT DIS, V163, P1326, DOI 10.1093/infdis/163.6.1326; Fenton MJ, 1996, INFECT IMMUN, V64, P683, DOI 10.1128/IAI.64.3.683-690.1996; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; LAUNOIS P, 1992, INT J LEPROSY, V60, P225; LEPOW IH, 1963, J EXP MED, V117, P983, DOI 10.1084/jem.117.6.983; MULLEREBERHARD HJ, 1967, J EXP MED, V125, P359, DOI 10.1084/jem.125.2.359; POLLEY MJ, 1968, J EXP MED, V128, P533, DOI 10.1084/jem.128.3.533; ROACH TIA, 1993, J IMMUNOL, V150, P1886; SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920; SCHLESINGER LS, 1991, J IMMUNOL, V147, P1983; SCHLESINGER LS, 1990, J IMMUNOL, V144, P2771; SCHORLEMMER HU, 1977, IMMUNOLOGY, V32, P929; SCHORLEMMER HU, 1976, IMMUNOLOGY, V31, P781; SITOMER G, 1966, IMMUNOCHEMISTRY, V3, P57, DOI 10.1016/0019-2791(66)90282-5; STOKES RW, 1993, J IMMUNOL, V151, P7067; STROUD RM, 1966, IMMUNOCHEMISTRY, V3, P163, DOI 10.1016/0019-2791(66)90182-0; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; WEISSLER JC, 1993, AM J MED SCI, V305, P52, DOI 10.1097/00000441-199301000-00009; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; ZHELEZNYAK A, 1992, J BIOL CHEM, V267, P12042	28	135	143	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	1997	277	5329					1091	1093		10.1126/science.277.5329.1091	http://dx.doi.org/10.1126/science.277.5329.1091			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262476				2022-12-24	WOS:A1997XT03300033
J	Shen, WC; Green, MR				Shen, WC; Green, MR			Yeast TAF(II)145 functions as a core promoter selectivity factor, not a general coactivator	CELL			English	Article							TATA-BINDING PROTEIN; RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; BOX-BINDING; DNA; ELEMENTS; COMPLEX; DOWNSTREAM; SEQUENCES	In yeast, TATA box binding protein associated factors (TAF(II)s) are dispensable for transcription of most genes. Here we use differential display to identify a small subset of yeast genes whose transcription in vivo requires yTAF(II)145. Promoter-mapping studies reveal, unexpectedly, that the region of a gene that renders it yTAF(II)145-dependent is not the upstream activating sequence, which contains the activator-binding sites, but rather the core promoter. In fact, a core promoter requiring yTAF(II)145 retained that requirement when its transcription was directed by several unrelated upstream activating sequences and even in the absence of an activator. Taken together, our results indicate that yTAF(II)145 functions in recognition and selection of core promoters by a mechanism not involving upstream activators.			Shen, WC (corresponding author), UNIV MASSACHUSETTS, MED CTR, HOWARD HUGHES MED INST, PROGRAM MOL MED, WORCESTER, MA 01605 USA.							Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Baker RT, 1996, J BIOL CHEM, V271, P13549, DOI 10.1074/jbc.271.23.13549; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CROSS FR, 1994, MOL CELL BIOL, V14, P4779, DOI 10.1128/MCB.14.7.4779; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; GE H, 1994, J BIOL CHEM, V269, P17136; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; Guthrie C, 1991, GUIDE YEAST GENETICS; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; IGNATOVICH O, 1995, NUCLEIC ACIDS RES, V23, P4616, DOI 10.1093/nar/23.22.4616; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; INOSTROZA JA, 1992, CELL, V70, P477; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOLAKOWSKI LF, 1988, NUCLEIC ACIDS RES, V16, P10441, DOI 10.1093/nar/16.22.10441; LEER RJ, 1982, NUCLEIC ACIDS RES, V10, P5869, DOI 10.1093/nar/10.19.5869; Lenfant F, 1996, EMBO J, V15, P3974, DOI 10.1002/j.1460-2075.1996.tb00771.x; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Planta RJ, 1995, BIOCHEM CELL BIOL, V73, P825, DOI 10.1139/o95-090; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; SELLECK SB, 1987, MOL CELL BIOL, V7, P3260, DOI 10.1128/MCB.7.9.3260; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; STUART D, 1994, MOL CELL BIOL, V14, P4788, DOI 10.1128/MCB.14.7.4788; SYPES MA, 1994, NUCLEIC ACIDS RES, V22, P807, DOI 10.1093/nar/22.5.807; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TORNOW J, 1990, GENE, V90, P79, DOI 10.1016/0378-1119(90)90441-S; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; WOOLFORD JL, 1991, MOL CELLULAR BIOL YE, V1, P587; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	69	165	166	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					615	624		10.1016/S0092-8674(00)80523-1	http://dx.doi.org/10.1016/S0092-8674(00)80523-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288742	Bronze			2022-12-24	WOS:A1997XT06600006
J	Sutani, T; Yanagida, M				Sutani, T; Yanagida, M			DNA renaturation activity of the SMC complex implicated in chromosome condensation	NATURE			English	Article							UBIQUITOUS PROTEIN FAMILY; DOSAGE COMPENSATION; FISSION YEAST; RECA PROTEIN; GENE; SEGREGATION; SCAFFOLD; DEFINES; STRANDS	Chromosome condensation occurs in mitosis before the separation of sister chromatids, and requires DNA topoisomerase II (refs 1, 2) and a group of proteins called SMCs3-5. The resulting condensed chromosomes in metaphase have a complex hierarchical structure(6,7). SMCs, the components of condensed chromosomes, are also required for the separation of sister chromatids and gene dosage compensation, and are found in a range of organisms from yeasts to mammals(8-13). However, the mechanisms by which the SMCs contribute to chromosome condensation are unknown. We have studied chromosomes in fission-yeast SMC mutants cut3-477 and cut14-208 (ref. 9), which remain largely non-condensed during mitosis at the restrictive temperature (36 degrees C)(9). To test their role in DNA condensation, we isolated the proteins Cut3 and Cut14 as an oligomeric complex, and tested their interactions with isolated DNA. The complex efficiently promoted the DNA renaturation reactions (the winding up of single-strand DNAs into double helical DNA) as much as similar to 70-fold more efficiently than RecA(14), which is a bacterial protein with similar activity. The activity of the mutant complex was heat sensitive. As DNA winding by renaturation is a potential cause of supercoiling, the SMC complex may be implicated in promoting the higher-order DNA coiling found in condensed chromosomes.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University				Sutani, Takashi/0000-0002-9959-9513				BELMONT AS, 1987, J CELL BIOL, V105, P77, DOI 10.1083/jcb.105.1.77; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; BRYANT FR, 1989, BIOCHEMISTRY-US, V28, P1062, DOI 10.1021/bi00429a021; BRYANT FR, 1985, P NATL ACAD SCI USA, V82, P297, DOI 10.1073/pnas.82.2.297; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; FUNABIKI H, 1996, NATURE, V381, P468; GASSER SM, 1995, CURR BIOL, V5, P357, DOI 10.1016/S0960-9822(95)00071-6; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Swedlow JR, 1993, CURR OPIN CELL BIOL, V5, P412, DOI 10.1016/0955-0674(93)90005-B	23	112	113	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					798	801		10.1038/42062	http://dx.doi.org/10.1038/42062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285594				2022-12-24	WOS:A1997XR66700056
J	Zuo, J; DeJager, PL; Takahashi, KA; Jiang, WN; Linden, DJ; Heintz, N				Zuo, J; DeJager, PL; Takahashi, KA; Jiang, WN; Linden, DJ; Heintz, N			Neurodegeneration in Lurcher mice caused by mutation in delta 2 glutamate receptor gene	NATURE			English	Article							CEREBELLAR PURKINJE-CELLS; POLYMERASE CHAIN-REACTION; HUMPBACK-WHALES; SIMPLE SEQUENCES; DNA; MOUSE; POPULATION; EXPRESSION; SUBUNIT; MAINE	Lurcher (Lc) is a spontaneous, semidominant mouse neurological mutation(1). Heterozygous Lurcher mite (Lc/+) display ataxia as a result of a selective, coil-autonomous and apoptotic death of cerebellar Purkinje cells during postnatal develoment(2-4). Homozygous Lurcher mice (Lc/Lc) die shortly after birth because of a massive loss of mid-and hindbrain neurons during late embryogenesis(5). We have used positional cloning to identify the mutations responsible for neurodegeneration in two independent Lc alleles as G-to-A transitions that change a highly conserved alanine to a threonine residue in transmembrane domain III of the mouse delta 2 glutamate receptor gene (GluR delta 2). Lc/+ Purkinje cells have a very high membrane conductance and a depolarized resting potential, indicating the presence of a large, constitutive inward current. Expression of the mutant GluR delta 2(Lc) protein in Xenopus oocytes confirmed these results, demonstrating that Lc is inherited as a neurodegenerative disorder resulting from a gain-of-function mutation in a glutamate receptor gene. Thus the activation of apoptotic neuronal death in Lurcher mice may provide a physiologically relevant model for excitotoxic cell death.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOL BIOL LAB,NEW YORK,NY 10021; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Rockefeller University; Johns Hopkins University					NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051106, R37MH051106, R29MH051106] Funding Source: NIH RePORTER; NIMH NIH HHS [MH51106] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMOS B, 1993, SCIENCE, V260, P670, DOI 10.1126/science.8480176; [Anonymous], 1982, ESTIMATION ANIMAL AB; ARAKI K, 1993, BIOCHEM BIOPH RES CO, V197, P1267, DOI 10.1006/bbrc.1993.2614; Barlow J, 1997, ECOLOGY, V78, P535; Berube M, 1996, MOL ECOL, V5, P283; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; BURGESS DL, 1995, NAT GENET, V10, P461, DOI 10.1038/ng0895-461; CADDY KWT, 1979, PHILOS T ROY SOC B, V287, P167, DOI 10.1098/rstb.1979.0055; Cheng SSW, 1997, J NEUROSCI, V17, P2400, DOI 10.1523/jneurosci.17-07-02400.1997; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; CLAPHAM PJ, 1993, CAN J ZOOL, V71, P1065, DOI 10.1139/z93-142; CLAPHAM PJ, 1993, MAR MAMMAL SCI, V9, P213, DOI 10.1111/j.1748-7692.1993.tb00448.x; Clapham PJ, 1997, P ROY SOC B-BIOL SCI, V264, P95, DOI 10.1098/rspb.1997.0014; CLAPHAM PJ, 1995, MAR MAMMAL SCI, V11, P227, DOI 10.1111/j.1748-7692.1995.tb00520.x; CLAPHAM PJ, 1993, CAN J ZOOL, V71, P440, DOI 10.1139/z93-063; CONSTABLE JJ, 1995, NATURE, V373, P393, DOI 10.1038/373393a0; DeJager PL, 1997, GENOME RES, V7, P736, DOI 10.1101/gr.7.7.736; DEJAGER PL, IN PRESS MAMM GENOME; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; GERLOFF U, 1995, MOL ECOL, V4, P515, DOI 10.1111/j.1365-294X.1995.tb00247.x; Hammond PS, 1990, REPORT INT WHALING C, P440; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; Katona S.K., 1981, Polar Record, V20, P439; KATONA S. K., 1990, REPORT INT WHALING C, P295; LAMBERTSEN RH, 1987, J MAMMAL, V68, P443, DOI 10.2307/1381495; Landsend AS, 1997, J NEUROSCI, V17, P834, DOI 10.1523/jneurosci.17-02-00834.1997; Larsen AH, 1996, P ROY SOC B-BIOL SCI, V263, P1611, DOI 10.1098/rspb.1996.0236; LOMELI H, 1993, FEBS LETT, V315, P318, DOI 10.1016/0014-5793(93)81186-4; Maniatis T., 1982, MOL CLONING; MATTILA DK, 1989, CAN J ZOOL, V67, P251; MAYAT E, 1995, J NEUROSCI, V15, P2533, DOI 10.1523/JNEUROSCI.15-03-02533.1995; MORIN PA, 1992, PATERNITY IN PRIMATES : GENETIC TESTS AND THEORIES, P63; NORMAN DJ, 1995, DEVELOPMENT, V121, P1183; PAETKAU D, 1994, MOL ECOL, V3, P489, DOI 10.1111/j.1365-294X.1994.tb00127.x; PALSBALL PJ, IN PRESS MOL ECOL; Palsboll P.J., 1991, Reports of the International Whaling Commission Special Issue, P71; PALSBOLL PJ, 1995, MAR ECOL PROG SER, V116, P1, DOI 10.3354/meps116001; PATEL N, 1995, NAT GENET, V11, P126; PHILLIPS RITA J. S., 1960, JOUR GENET, V57, P35, DOI 10.1007/BF02985337; QUICK MW, 1994, METH NEUROSCI, V19, P261; ROY MS, 1994, MOL BIOL EVOL, V11, P553; STEVICK PT, IN PRESS MAR MAMM SC; Takayama C, 1996, DEV BRAIN RES, V92, P147, DOI 10.1016/0165-3806(95)00212-X; TAKAYAMA C, 1995, NEUROSCI LETT, V188, P89, DOI 10.1016/0304-3940(95)11403-J; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; WEBER JL, 1989, AM J HUM GENET, V44, P388; WETTS R, 1982, J EMBRYOL EXP MORPH, V68, P87; ZUO J, 1995, GENOME RES, V5, P381, DOI 10.1101/gr.5.4.381	51	429	435	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					769	773		10.1038/42009	http://dx.doi.org/10.1038/42009			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285588	Bronze			2022-12-24	WOS:A1997XR66700050
J	Rivara, FP; Mueller, BA; Somes, G; Mendoza, CT; Rushforth, NB; Kellermann, AL				Rivara, FP; Mueller, BA; Somes, G; Mendoza, CT; Rushforth, NB; Kellermann, AL			Alcohol and illicit drug abuse and the risk of violent death in the home	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUN OWNERSHIP; SUICIDE; CONSUMPTION; SMOKING; DRINKING; BEHAVIOR; YOUTH	Context.-While acute alcohol and illicit drug use are common in homicide and suicide victims, the role of chronic substance use in violent death is unclear. Objective.-To measure the magnitude of risk of violent death in the home associated with alcohol use or chronic abuse and use of illicit drugs. Data Sources.-Data obtained from a case-control study of risk factors for homicide and suicide in 3 large metropolitan areas of the United States. Design.-Matched case-control study including 388 homicide cases, 438 suicide cases, and equal numbers of controls matched for age, sex, race, neighborhood, and county. Data were analyzed by means of conditional logistic regressions in which other potential risk factors for violent death were also considered. Outcome and Exposure Measures.-Homicide and suicide victims were identified from medical examiner reports in Shelby County, Tennessee; King County, Washington; and Cuyahoga County, Ohio. Structured interviews were conducted with proxy respondents close to the decedents to obtain information about alcohol or illicit drug use, and history of alcohol-related hospitalization or trouble at work because of drinking by the subject. Data about alcohol use by others living in the same house as the subject were also obtained. Results.-The risks of homicide and suicide associated with alcohol or illicit drug use were elevated, as were the risks of violent death associated with several indicators of chronic alcohol abuse. In addition, nondrinkers living in a home with alcohol users were at increased risk of homicide (odds ratio, 1.7; 95% confidence interval, 0.98-3.0), and non-drug-using individuals residing in homes with illicit drug users were at greatly increased risk of homicide (odds ratio, 11.3, 95% confidence interval, 4.4-28.8). Conclusions.-Alcohol and illicit drug use appear to be associated with an increased risk of violent death. The risk of homicide was increased for non-substance-abusing individuals living in households in which other members abused alcohol or drugs. The concept of the individual at risk of homicide should be broadened to include not only the abuser but also those who may be at risk because of their exposure to others.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV TENNESSEE,DEPT PREVENT MED,MEMPHIS,TN; CASE WESTERN RESERVE UNIV,DEPT BIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT EPIDEMIOL & BIOSTAT,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,CTR ADOLESCENT HLTH,CLEVELAND,OH 44106; EMORY UNIV,EMORY CTR INJURY CONTROL,ATLANTA,GA 30322	University of Washington; University of Washington Seattle; University of Tennessee System; University of Tennessee Health Science Center; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Emory University	Rivara, FP (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,HARBORVIEW INJURY PREVENT & RES CTR,325 9TH AVE,POB 359960,SEATTLE,WA 98104, USA.				PHS HHS [R49/CCR002570, CCR402424] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bailey JE, 1997, ARCH INTERN MED, V157, P777, DOI 10.1001/archinte.157.7.777; Biro M, 1991, Crisis, V12, P64; Blumstein A, 1995, J CRIM LAW CRIM, V86, P10, DOI 10.2307/1143998; BRENT DA, 1987, JAMA-J AM MED ASSOC, V257, P3369, DOI 10.1001/jama.257.24.3369; Breslow N, 1980, STATISTICAL METHODS, V32; CHEREK DR, 1985, J STUD ALCOHOL, V46, P321, DOI 10.15288/jsa.1985.46.321; COLLINS JJ, 1988, J STUD ALCOHOL, V49, P516, DOI 10.15288/jsa.1988.49.516; Collins JJ, 1993, ALCOHOL HEALTH RES W, V17, P93; CORNELIUS JR, 1995, AM J PSYCHIAT, V152, P358; Farrington D. P., 1990, CRIMINALITY PERSONAL, P115, DOI DOI 10.1007/978-3-642-75418-0_9; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; GENTILELLO LM, 1995, JAMA-J AM MED ASSOC, V274, P1043, DOI 10.1001/jama.274.13.1043; GOODMAN RA, 1991, J STUD ALCOHOL, V52, P156, DOI 10.15288/jsa.1991.52.156; GREENBERG SW, 1981, DRINKING CRIME PERSP, P253; HOLDER HD, 1993, J STUD ALCOHOL, V54, P23, DOI 10.15288/jsa.1993.54.23; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; LI GH, 1994, AM J PUBLIC HEALTH, V84, P1402, DOI 10.2105/AJPH.84.9.1402; Lindqvist P, 1986, Int J Law Psychiatry, V8, P19, DOI 10.1016/0160-2527(86)90081-6; MACK TM, 1986, JNCI-J NATL CANCER I, V76, P49; MERRILL J, 1992, BRIT J ADDICT, V87, P83; MICZEK KA, 1994, UNDERSTANDING PREVEN, V3, P377; Miller B A, 1990, NIDA Res Monogr, V103, P177; MURDOCH D, 1990, INT J ADDICT, V25, P1065, DOI 10.3109/10826089009058873; Pernanen K., 1991, ALCOHOL HUMAN VIOLEN; PETRONIS KR, 1990, SOC PSYCH PSYCH EPID, V25, P193; PULKKINEN L, 1983, J YOUTH ADOLESCENCE, V12, P253, DOI 10.1007/BF02088726; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; RICHARDSON J, 1994, HEALTH ECON, V3, P73, DOI 10.1002/hec.4730030204; RIVARA FP, 1995, ANN EMERG MED, V26, P609, DOI 10.1016/S0196-0644(95)70013-7; ROSSOW I, 1995, ADDICTION, V90, P685, DOI 10.1111/j.1360-0443.1995.tb02206.x; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; STEPHENSCHERPIT.CJ, 1988, ALCOHOLISM CLIN EXP, V12, P105; Tinklenberg J. R., 1981, BIOBEHAVIORAL ASPECT, P121; Wagenaar A C, 1994, J Public Health Policy, V15, P37, DOI 10.2307/3342606; Wolfgang M. E., 1958, PATTERNS CRIMINAL HO; YU MC, 1983, CANCER RES, V43, P6077	37	84	85	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					569	575		10.1001/jama.278.7.569	http://dx.doi.org/10.1001/jama.278.7.569			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XQ986	9268278				2022-12-24	WOS:A1997XQ98600031
J	Neal, DE				Neal, DE			Watchful waiting or drug therapy for benign prostatic hyperplasia?	LANCET			English	Editorial Material							PROSTATECTOMY; SYMPTOMS				Neal, DE (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT SURG,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Neal, David/0000-0002-6033-5086				Andersen JT, 1997, UROLOGY, V49, P839, DOI 10.1016/S0090-4295(97)00185-4; Barry MJ, 1997, J UROLOGY, V157, P10, DOI 10.1016/S0022-5347(01)65267-4; EMBERTON M, 1995, BRIT J UROL, V75, P301, DOI 10.1111/j.1464-410X.1995.tb07341.x; JACOBSEN SJ, 1997, J UROL S, V17, P191; Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801; NEAL DE, 1987, BRIT J UROL, V60, P554, DOI 10.1111/j.1464-410X.1987.tb05041.x; WASSON JH, 1995, NEW ENGL J MED, V332, P75, DOI 10.1056/NEJM199501123320202	7	17	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					305	306		10.1016/S0140-6736(05)63382-X	http://dx.doi.org/10.1016/S0140-6736(05)63382-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251630				2022-12-24	WOS:A1997XP24200003
J	Fitzsimonds, RM; Song, HJ; Poo, MM				Fitzsimonds, RM; Song, HJ; Poo, MM			Propagation of activity-dependent synaptic depression in simple neural networks	NATURE			English	Article							LONG-TERM DEPRESSION; NEUROMUSCULAR SYNAPSES; HIPPOCAMPAL-NEURONS; AREA CA1; POTENTIATION; INDUCTION; TRANSMISSION; STIMULATION; MECHANISMS; PLASTICITY	Triple whole-cell recordings from simple networks of cultured hippocampal neurons show that induction of long-term depression at glutamatergic synapses is accompanied by a back propagation of depression to input synapses on the dendrite of the presynaptic neuron. The depression also propagates laterally to divergent outputs of the presynaptic neuron and to convergent inputs on the postsynaptic neuron. There is no forward propagation of depression to the output of the postsynaptic neuron and no presynaptic propagation accompanying long-term depression at GABAergic synapses. Activity-induced synaptic modification is therefore not restricted to the activated synapse, but selectively propagates throughout the neural network.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego				Fitzsimonds, Reiko/0000-0002-0576-9885				ABRAHAM WC, 1983, NATURE, V305, P717, DOI 10.1038/305717a0; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BROCHER S, 1992, P NATL ACAD SCI USA, V89, P123, DOI 10.1073/pnas.89.1.123; Cash S, 1996, SCIENCE, V272, P998, DOI 10.1126/science.272.5264.998; Cash S, 1996, NEURON, V16, P745, DOI 10.1016/S0896-6273(00)80095-1; CHRISTIE BR, 1992, SYNAPSE, V10, P1, DOI 10.1002/syn.890100102; CHURCHLAND PS, 1972, COMPUTATIONAL BRAIN; Clarke P.G.H., 1991, Concepts in Neuroscience, V2, P201; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; Dan Yang, 1994, Current Opinion in Neurobiology, V4, P95, DOI 10.1016/0959-4388(94)90037-X; DAVIS GW, 1994, J NEUROBIOL, V25, P740, DOI 10.1002/neu.480250612; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; Engert F, 1997, NATURE, V388, P279, DOI 10.1038/40870; FITZSIMONDS RM, IN PRESS PHYSL REV; Goda Y, 1996, NEURON, V16, P103, DOI 10.1016/S0896-6273(00)80027-6; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Ito M, 1991, Curr Opin Neurobiol, V1, P616, DOI 10.1016/S0959-4388(05)80038-8; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kossel A, 1990, Neuroreport, V1, P115, DOI 10.1097/00001756-199010000-00008; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MATHEWS MR, 1975, J PHYSIOL-LONDON, V245, P91; MCMAHON LL, 1977, NEURON, V18, P737; MCMAHON LL, 1977, NEURON, V18, P266; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; OTANI S, 1995, LEARN MEMORY, V2, P101, DOI 10.1101/lm.2.2.101; PILAR G, 1972, SCIENCE, V177, P1116, DOI 10.1126/science.177.4054.1116; PURVES D, 1975, J PHYSIOL-LONDON, V252, P429, DOI 10.1113/jphysiol.1975.sp011151; PURVES D, 1985, PRINCIPLES NEURAL DE; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; RUMELHART DE, 1986, PARALLEL DISTRIBUTED, V1, P316; Scanziani M, 1996, NATURE, V380, P446, DOI 10.1038/380446a0; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; Tong G, 1996, NEURON, V16, P1147, DOI 10.1016/S0896-6273(00)80141-5; VINCENT P, 1993, NEURON, V11, P885, DOI 10.1016/0896-6273(93)90118-B; WILCOX KS, 1994, SYNAPSE, V18, P128, DOI 10.1002/syn.890180206; WOOD MR, 1986, J COMP NEUROL, V244, P43; XIAO MY, 1994, EUR J NEUROSCI, V6, P1055, DOI 10.1111/j.1460-9568.1994.tb00600.x; Zipser D., 1990, COMPUTATIONAL NEUROS, P192	51	141	143	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					439	448		10.1038/41267	http://dx.doi.org/10.1038/41267			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242402	Bronze			2022-12-24	WOS:A1997XN55300039
J	Ramsden, DA; Paull, TT; Gellert, M				Ramsden, DA; Paull, TT; Gellert, M			Cell-free V(D)J recombination	NATURE			English	Article							DNA-LIGASE-I; MOUSE THYMOCYTES; MAMMALIAN-CELLS; REARRANGEMENT; REPAIR	V(D)J recombination generates diversity in the immune system through the lymphoid-specific assembly of multiple gene segments into functional immunoglobulin and T-cell receptor genes (for reviews, see refs 1, 2). The first step in V(D)J recombination is cleavage of DNA at recombination signal sequences. Cleavage produces a blunt DNA end on each signal sequence and a hairpin end on adjacent coding gene segments(3,4), and can be reproduced in vitro by using purified RAG1 and RAG2 proteins(5,6). The later steps involve processing and joining of the cleaved DNA ends, and until now have been studied only in cells, Here we reconstitute the complete V(D)J recombination reaction in a cell-free system, We find that the RAG proteins are not only involved in cleavage, but are also needed in the later steps for efficient joining of coding ends. Joining is largely directed by short pieces of identical sequence in the coding flanks, but addition of human DNA ligase I results in greater diversity. Coding junctions contain short deletions as well as additions complementary to a coding flank (P nucleotides). Addition of non-templated nucleotides into coding junctions is mediated by terminal deoxyribonucleotidyl transferase. The cell-free reaction can therefore reproduce the complete set of processing events that occur in cells.	NIDDKD,MOL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Paull, Tanya/0000-0002-2991-651X; Ramsden, Dale/0000-0003-1575-4748				Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; ARRAND JE, 1986, J BIOL CHEM, V261, P9079; Cortes P, 1996, P NATL ACAD SCI USA, V93, P14008, DOI 10.1073/pnas.93.24.14008; ELDER RH, 1992, EUR J BIOCHEM, V203, P53, DOI 10.1111/j.1432-1033.1992.tb19826.x; GELLERT M, 1992, ANNU REV GENET, V22, P425; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PETRINI JHJ, 1995, MOL CELL BIOL, V15, P4303; PETRINI JHJ, 1994, J IMMUNOL, V152, P176; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; ROBBINS DJ, 1988, NUCLEIC ACIDS RES, V16, P2943, DOI 10.1093/nar/16.7.2943; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WEI YF, 1995, MOL CELL BIOL, V15, P3206	22	111	112	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					488	491		10.1038/41351	http://dx.doi.org/10.1038/41351			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242409	Bronze			2022-12-24	WOS:A1997XN55300052
J	Zeyl, C; Bell, G				Zeyl, C; Bell, G			The advantage of sex in evolving yeast populations	NATURE			English	Article							DELETERIOUS MUTATIONS; EVOLUTION; TY3	Sex is a general feature of the life cycle of eukaryotes. It is not universal, however, as many organisms seem to lack sex entirely(1). The widespread occurrence of sex is puzzling, both because meiotic recombination can disrupt co-adapted combinations of genes, and because it halves the potential rate of reproduction in organisms with strongly differentiated male and female gametes(2). Most attempts to explain the maintenance of sexuality invoke differences between parents and sexual offspring. These differences may be advantageous in novel or changing environments if new gene combinations are favoured from time to time(1). Sex would then serve to concentrate beneficial mutations that have arisen independently into the same line of descent. But in a stable environment sex might serve to concentrate deleterious mutations, so that they will be more effectively purged from the population by selection(3). We have studied the effect of sex on mean fitness in experimental populations of the budding yeast Saccharomyces cervisiae. Our results show that sex increases mean fitness in an environment to which the populations were well adapted, but not in an environment to which new adaptation occurred, supporting the hypothesis that the advantage of sexuality lay in the removal of deleterious mutations.	MICHIGAN STATE UNIV, CTR MICROBIAL ECOL, E LANSING, MI 48824 USA; MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 1B1, CANADA; MCGILL UNIV, REDPATH MUSEUM, MONTREAL, PQ H3A 1B1, CANADA	Michigan State University; McGill University; McGill University								Bell G., 1982, MASTERPIECE NATURE; BILANCHONE VW, 1993, GENETICS, V134, P685; Birdsell J, 1996, P NATL ACAD SCI USA, V93, P908, DOI 10.1073/pnas.93.2.908; CHARLESWORTH D, 1993, GENET RES, V61, P39, DOI 10.1017/S0016672300031086; Crow J. F., 1988, EVOLUTION SEX EXAMIN, P56; deVisser JAGM, 1996, P ROY SOC B-BIOL SCI, V263, P193, DOI 10.1098/rspb.1996.0031; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KUNZ BA, 1981, MOL BIOL YEAST SACCH, V1, P371; MALMBERG RL, 1977, GENETICS, V86, P607; Maynard Smith J., 1978, EVOLUTION SEX; MCPHEE CP, 1970, GENET RES, V16, P1, DOI 10.1017/S0016672300002238; MENEES TM, 1994, MOL CELL BIOL, V14, P8229, DOI 10.1128/MCB.14.12.8229; MORTIMER RK, 1981, MOL BIOL YEAST SACCH, V3, P341; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; PECK JR, 1994, GENETICS, V137, P597	17	112	118	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 31	1997	388	6641					465	468		10.1038/41312	http://dx.doi.org/10.1038/41312			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242403	Bronze			2022-12-24	WOS:A1997XN55300046
J	Bowie, WR; King, AS; Werker, DH; IsaacRenton, JL; Bell, A; Eng, SB; Marion, SA				Bowie, WR; King, AS; Werker, DH; IsaacRenton, JL; Bell, A; Eng, SB; Marion, SA			Outbreak of toxoplasmosis associated with municipal drinking water	LANCET			English	Article							OOCYSTS; GONDII; OZONE; CATS	Background Outbreaks of toxoplasmosis are recognised infrequently. In March, 1995, a sudden increase of serologically diagnosed cases of acute toxoplasmosis was noted in the Greater Victoria area of British Columbia, Canada. Concurrently, but independently, seven cases of acute toxoplasma retinitis were diagnosed against a background of no cases in the previous 5 years. Methods Cases were defined by serological testing, clinical presentation, and residence in Greater Victoria. A screening programme for women who were or had been pregnant was started. Geographical mapping of cases, and case-control studies of symptomatic cases and of women enrolled in the screening programme were done. Findings 100 individuals aged 6 to 83 years met the definition for an acute, outbreak-related case. 94 resided in Greater Victoria and six had visited it; 19 had retinitis, 51 had lymphadenopathy, four others had symptoms consistent with toxoplasmosis, seven had other symptoms, 18 were symptom-free, and one would not provide information. 36 (0.9%) of 3812 screened pregnant and postnatal women were cases. Excess cases were not detected outside Greater Victoria and no conventional source of toxoplasmosis was implicated. Mapping studies of cases and of the screened women, and both case-control studies showed significant associations between acute infection and residence in the distribution system of one reservoir supplying water to Greater Victoria (ORs or RRs: 3.53, 3.05, 8.27, acid 5.42, respectively). The epidemic curve appeared bimodal, with peaks in December, 1994, and March, 1995, that were preceded by increased rainfall and turbidity in the implicated reservoir. Interpretation A municipal water system that uses unfiltered, chloraminated surface water was the likely source of this large community-wide outbreak of toxoplasmosis.	UNIV BRITISH COLUMBIA, DIV INFECT DIS, VANCOUVER, BC V5Z 1M9, CANADA; UNIV BRITISH COLUMBIA, DEPT PATHOL & LAB MED, VANCOUVER, BC V5Z 1M9, CANADA; UNIV BRITISH COLUMBIA, DEPT HLTH CARE & EPIDEMIOL, VANCOUVER, BC V6T 1W5, CANADA; BC CTR DIS CONTROL, EPIDEMIOL SERV, VANCOUVER, BC, CANADA; BC CTR DIS CONTROL, PROV LAB, VANCOUVER, BC, CANADA; HLTH CANADA, LAB CTR DIS CONTROL, FIELD EPIDEMIOL TRAINING PROGRAM, OTTAWA, ON K1A 0L2, CANADA; CAPITAL REG DIST HLTH, VICTORIA, BC, CANADA	University of British Columbia; University of British Columbia; University of British Columbia; Health Canada								BEAMAN MH, 1995, PRINCIPLES PRACTICE, P2455; BENENSON MW, 1982, NEW ENGL J MED, V307, P666, DOI 10.1056/NEJM198209093071107; DANNEMANN BR, 1990, J CLIN MICROBIOL, V28, P1928, DOI 10.1128/JCM.28.9.1928-1933.1990; Dubey J.P., 1988, TOXOPLASMOSIS ANIMAL; Dubey JP, 1996, J PARASITOL, V82, P438, DOI 10.2307/3284082; DUBEY JP, 1970, J EXP MED, V132, P636, DOI 10.1084/jem.132.4.636; FINCH GR, 1993, APPL ENVIRON MICROB, V59, P3674, DOI 10.1128/AEM.59.11.3674-3680.1993; FRENKEL JK, 1975, AM J TROP MED HYG, V24, P439, DOI 10.4269/ajtmh.1975.24.439; FRENKEL JK, 1972, J INFECT DIS, V126, P664, DOI 10.1093/infdis/126.6.664; KEAN BH, 1969, J AMER MED ASSOC, V208, P1002; KORICH DG, 1990, APPL ENVIRON MICROB, V56, P1423, DOI 10.1128/AEM.56.5.1423-1428.1990; Magaldi C., 1969, Revista Latinoamericana de Microbiologia y Parasitologia, V11, P5; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; *MAP CORP, 1992, MAP WIND 3 0 US GUID; MILLER NL, 1972, J PARASITOL, V58, P928, DOI 10.2307/3286588; MONTOYA JG, 1995, CLIN INFECT DIS, V20, P781, DOI 10.1093/clinids/20.4.781; Remington JS., 1995, INFECT DIS FETUS NEW, V4, P140; SNOW J, 1965, SNOW CHOLERA; Stephen C, 1996, CAN VET J, V37, P241; TEUTSCH SM, 1979, NEW ENGL J MED, V300, P695, DOI 10.1056/NEJM197903293001302; WONG SY, 1994, CLIN INFECT DIS, V18, P853, DOI 10.1093/clinids/18.6.853; YILMAZ SM, 1972, J PARASITOL, V58, P938, DOI 10.2307/3286589	22	424	461	2	63	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 19	1997	350	9072					173	177		10.1016/S0140-6736(96)11105-3	http://dx.doi.org/10.1016/S0140-6736(96)11105-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250185				2022-12-24	WOS:A1997XL72200012
J	Gardon, J; GardonWendel, N; DemangaNgangue, D; Kamgno, J; Chippaux, JP; Boussinesq, M				Gardon, J; GardonWendel, N; DemangaNgangue, D; Kamgno, J; Chippaux, JP; Boussinesq, M			Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection	LANCET			English	Article							LOIASIS; DISEASE	Background In 1995, the World Bank launched an African Programme for Onchocerciasis Control to eliminate Onchocerca volvulus disease from 19 African countries by means of community-based ivermectin treatment (CBIT). Several cases of encephalopathy have been reported after ivermectin in people heavily infected with microfilariae of Loa loa (loiasis). We assessed the incidence of serious events in an area where onchocerciasis and loiasis are both endemic. Methods Ivermectin (at 150 mu g/kg) was given to 17 877 people living in the Lekie area of Cameroon. 50 mu L samples of capillary blood were taken during the daytime before treatment from all adults (aged greater than or equal to 15 years), and the numbers of L loa and Mansonella perstans microfilariae in them were counted. Patients were monitored for 7 days after treatment. Adverse reactions were classified as mild, marked, or serious. Serious reactions were defined as those associated with a functional impairment that required at least a week of full-time assistance to undertake normal activities. We calculated the relative risk of developing marked or serious reactions for increasing L loa microfilarial loads, Risk factors for serious reactions were identified and assessed with a logistic regression model. Findings 20 patients (0.11%) developed serious reactions without neurological signs but associated with a functional impairment lasting more than a week. Two other patients were in coma for 2-3 days, associated with L loa microfilariae in cerebrospinal fluid. Occurrence of serious reactions was related to the intensity of pretreatment L loa microfilaraemia. The relative risk of developing marked or serious reactions was significantly higher when the L loa load exceeded 8000 microfilariae/mL; for serious reactions, the risk is very high (odds ratio >1000) for loads above 50 000 microfilariae/mL. Interpretation Epidemiological surveys aimed at assessing the intensity of infection with L loa microfilariae should be done before ivermectin is distributed for onchocerciasis control in areas where loiasis is endemic, In communities at risk, monitoring procedures should be established and adhered to during CBIT so that people developing serious reactions may receive appropriate treatment.	SECT DEPT SANTE PUBL MBAM,BAFIA,CAMEROON		Gardon, J (corresponding author), CTR PASTEUR,ANTENNE ORSTOM,BP 1274,YAOUNDE,CAMEROON.		Boussinesq, Michel/J-7256-2016; Gardon, Jacques/AAQ-8410-2020; Gardon, Jacques/J-8022-2016	Boussinesq, Michel/0000-0001-6312-0681; Gardon, Jacques/0000-0002-0570-634X; Gardon, Jacques/0000-0002-0570-634X; Chippaux, Jean-Philippe/0000-0002-1976-8568				ABIOSE A, 1993, LANCET, V341, P130, DOI 10.1016/0140-6736(93)90002-X; *ASS RECH METH PHA, 1992, AN INC PHARM; AZIZ MA, 1982, LANCET, V2, P171; BERTRANDFONTAIN, 1948, B MEM SOC MED HOP P, V64, P1092; BONNET R., 1943, Medecine Tropicale, V3, P273; BOUSSINESQ M, 1995, AM J TROP MED HYG, V53, P63; BRUNETIERE M, 1913, GAZ HEBDOM SCI MED B, V30, P351; CARME B, 1991, AM J TROP MED HYG, V44, P684, DOI 10.4269/ajtmh.1991.44.684; CARME B, 1991, ANN SOC BELG MED TR, V71, P47; Chippaux JP, 1996, PARASITOL TODAY, V12, P448, DOI 10.1016/0169-4758(96)40006-0; Ducorps M, 1995, B SOC PATHOL EXOT, V88, P105; FAIN A, 1978, B WORLD HEALTH ORGAN, V56, P155; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; KULZ H, 1908, ARCH SCHIFFS TROP, V12, P547; MARTINPREVEL Y, 1993, AM J TROP MED HYG, V48, P186, DOI 10.4269/ajtmh.1993.48.186; PACQUE M, 1991, AM J MED, V90, P590, DOI 10.1016/S0002-9343(05)80010-5; REMME JHF, 1995, PARASITOL TODAY, V11, P403, DOI 10.1016/0169-4758(95)80017-4; RICHARDLENOBLE D, 1988, AM J TROP MED HYG, V39, P480, DOI 10.4269/ajtmh.1988.39.480; TAYLOR HR, 1989, AM J TROP MED HYG, V41, P460, DOI 10.4269/ajtmh.1989.41.460; *WHO EXP COMM ONCH, 1995, TECHN REP SER WHO, V852, P27; 1991, WHO DRUG INFORMATION, V5, P127	21	388	392	0	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					18	22		10.1016/S0140-6736(96)11094-1	http://dx.doi.org/10.1016/S0140-6736(96)11094-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217715				2022-12-24	WOS:A1997XH86900011
J	Collins, JJ; Brennan, FT				Collins, JJ; Brennan, FT			Euthanasia and the potential adverse effects for Northern Territory Aborigines	LANCET			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; PAIN		AUSTRALIAN NATL UNIV,RES SCH SOCIAL SCI,CANBERRA,ACT 2600,AUSTRALIA	Australian National University	Collins, JJ (corresponding author), MEM SLOAN KETTERING CANC CTR,PAIN & PALLIAT CARE SERV,1275 YORK AVE,NEW YORK,NY 10021, USA.							ALCORN G, 1996, SYDNEY MORNING  0823; AUSTIN N, 1996, LETS MEET HALF WAY P; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; *CANC PAIN REL PAL, 1990, WHO TECHN REP SER, V804; Carapetis JR, 1996, MED J AUSTRALIA, V164, P146, DOI 10.5694/j.1326-5377.1996.tb122012.x; CHASSIN MR, 1994, WHEN DEATH IS SOUGHT; CORDNER S, 1995, LANCET, V346, P692, DOI 10.1016/S0140-6736(95)92295-4; Cunningham J, 1996, MED J AUSTRALIA, V165, P309, DOI 10.5694/j.1326-5377.1996.tb124987.x; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; FOLEY KM, 1995, PAIN FORUM, V4, P163; HARRISON B, 1994, DEMOGRAPHY NO TERRIT; Hoy WE, 1996, MED J AUSTRALIA, V165, P126, DOI 10.5694/j.1326-5377.1996.tb124882.x; Maguire GP, 1996, MED J AUSTRALIA, V164, P721, DOI 10.5694/j.1326-5377.1996.tb122270.x; MCLENNON W, 1994, DEATHS AUSTR; MOBBS R, 1994, HLTH ABORIGINAL AUST, P292; PORTENOY RK, IN PRESS PSYCHOSOMAT; REID J, 1994, HLTH ABORIGINAL AUST, pR11; Ryan CJ, 1996, NEW ENGL J MED, V334, P326, DOI 10.1056/NEJM199602013340512; 1997, SYDNEY MORNING  0116	19	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1907	1908		10.1016/S0140-6736(96)12388-6	http://dx.doi.org/10.1016/S0140-6736(96)12388-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217772				2022-12-24	WOS:A1997XG41700043
J	Hurley, SF; Jolley, DJ; Kaldor, JM				Hurley, SF; Jolley, DJ; Kaldor, JM			Effectiveness of needle-exchange programmes for prevention of HIV infection	LANCET			English	Article							INJECTING DRUG-USERS	Background Needle-exchange programmes (NEPs) are potentially a key strategy for containing the spread of HIV infection among injecting drug users, but their implementation has been limited by uncertainty about their effectiveness. We used an ecological study design to compare changes over time in HIV seroprevalence in injecting drug users worldwide, for cities with and without NEPs. Methods Published reports of HIV seroprevalence in injecting drug users were identified, and unpublished information on HIV seroprevalence for injecting drug users entering drug treatment in the USA between 1988 and 1993 was obtained from the Centers for Disease Control and Prevention. Details of the implementation of NEPs were obtained from published reports and experts. For each of the 81 cities with HIV seroprevalence data from more than 1 year and NEP implementation details, the rate of change of seroprevalence was estimated by regression analysis. The average difference in this rate for cities with and without NEPs was calculated. Findings On average, seroprevalence increased by 5.9% per year in the 52 cities without NEPs, and decreased by 5.8% per year in the 29 cities with NEPs. The average annual change in seroprevalence was 11% lower in cities with NEPs (95% CI - 17.6 to -3.9, p = 0.004). Interpretation A plausible explanation for this difference is that NEPs led to a reduction in HIV incidence among injecting drug users. Despite the possibility of confounding, our results, together with the clear theoretical mechanisms by which NEPs could reduce HIV incidence, strongly support the view that NEPs are effective.	UNIV MELBOURNE, DEPT PUBL HLTH & COMMUNITY MED, PARKVILLE, VIC 3052, AUSTRALIA; UNIV NEW S WALES, NATL CTR HIV EPIDEMIOL & CLIN RES, SYDNEY, NSW, AUSTRALIA	University of Melbourne; University of New South Wales Sydney; Kirby Institute			Kaldor, John M/D-4545-2011					Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P392; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DESJARLAIS DC, 1995, JAMA-J AM MED ASSOC, V274, P1226, DOI 10.1001/jama.274.15.1226; HAGAN H, 1995, AM J PUBLIC HEALTH, V85, P1531, DOI 10.2105/AJPH.85.11.1531; Hills, 1993, STAT MODELS EPIDEMIO; *I HLTH POL STUD, 1993, PUBL HLTH IMP NEEDL; Jarlais DCD, 1996, LANCET, V348, P987, DOI 10.1016/S0140-6736(96)02536-6; KAPLAN EH, 1994, AIDS, V8, P567, DOI 10.1097/00002030-199405000-00001; KAPLAN EH, 1994, STAT MED, V13, P2179, DOI 10.1002/sim.4780131923; NICOLOSI A, 1992, AM J EPIDEMIOL, V135, P225, DOI 10.1093/oxfordjournals.aje.a116275; *PAN NEEDL EXCH BL, 1995, PREV HIV TRANSM ROL; Prevots DR, 1996, AM J EPIDEMIOL, V143, P733, DOI 10.1093/oxfordjournals.aje.a008807; STIMSON GV, 1989, AIDS, V3, P253, DOI 10.1097/00002030-198905000-00001; *US GEN ACC OFF, 1993, NEEDL EXCH PROGR RES	14	254	256	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 21	1997	349	9068					1797	1800		10.1016/S0140-6736(96)11380-5	http://dx.doi.org/10.1016/S0140-6736(96)11380-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269214				2022-12-24	WOS:A1997XF73500010
J	Liu, D; Diorio, J; Tannenbaum, B; Caldji, C; Francis, D; Freedman, A; Sharma, S; Pearson, D; Plotsky, PM; Meaney, MJ				Liu, D; Diorio, J; Tannenbaum, B; Caldji, C; Francis, D; Freedman, A; Sharma, S; Pearson, D; Plotsky, PM; Meaney, MJ			Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress	SCIENCE			English	Article							CORTICOTROPIN-RELEASING FACTOR; MEDIAN-EMINENCE; MESSENGER-RNA; ADULT-RATS; SECRETION; BEHAVIOR; ALTERS; FEEDBACK; NEUROENDOCRINE; CORTICOSTERONE	Variations in maternal care affect the development of individual differences in neuroen-docrine responses to stress in rats. As adults, the offspring of mothers that exhibited more licking and grooming of pups during the first 10 days of life showed reduced plasma adrenocorticotropic hormone and corticosterone responses to acute stress, increased hippocampal glucocorticoid receptor messenger RNA expression, enhanced glucocorticoid feedback sensitivity, and decreased levels of hypothalamic corticotropin-releasing hormone messenger RNA. Each measure was significantly correlated with the frequency of maternal licking and grooming (all r's > -0.6). These findings suggest that maternal behavior serves to ''program'' hypothalamic-pituitary-adrenal responses to stress in the offspring.	MCGILL UNIV, FAC MED,DEPT PSYCHIAT,DEV NEUROENDOCRINOL LAB, DOUGLAS HOSP,RES CTR, MONTREAL, PQ H4H 1R3, CANADA; MCGILL UNIV, FAC MED,DEPT NEUROL & NEUROSURG, DEV NEUROENDOCRINOL LAB,DOUGLAS HOSP, RES CTR, MONTREAL, PQ H4H 1R3, CANADA; EMORY UNIV, DEPT PSYCHIAT & BEHAV SCI, ATLANTA, GA 30322 USA	McGill University; McGill University; Emory University			Meaney, Michael/N-5931-2019					ALBERTS JR, 1989, HDB BEHAV NEUROBIOLO, V9, P1; BARNETT SA, 1967, NATURE, V213, P150, DOI 10.1038/213150a0; BELL R W, 1971, Developmental Psychobiology, V4, P181, DOI 10.1002/dev.420040209; BELL RW, 1980, MATERNAL INFLUENCES, P201; BHATNAGAR S, 1995, J NEUROENDOCRINOL, V7, P97, DOI 10.1111/j.1365-2826.1995.tb00672.x; BUTLER SR, 1978, SCIENCE, V199, P445; DALY M, 1973, BRIT J PSYCHOL, V64, P435, DOI 10.1111/j.2044-8295.1973.tb01370.x; DEKLOET ER, 1991, FRONT NEUROENDOCRIN, V12, P95; FLEMING AS, 1974, J COMP PHYSIOL PSYCH, V86, P221, DOI 10.1037/h0035937; Francis D, 1996, ANN NY ACAD SCI, V794, P136, DOI 10.1111/j.1749-6632.1996.tb32517.x; HALTMEYE.GC, 1967, PHYSIOL BEHAV, V2, P61, DOI 10.1016/0031-9384(67)90012-1; HESS JL, 1969, PHYSIOL BEHAV, V4, P109, DOI 10.1016/0031-9384(69)90023-7; Hofer M. A., 1983, SYMBIOSIS PARENT OFF, P61; IMAKI T, 1991, J NEUROSCI, V11, P585; JACOBSON L, 1991, ENDOCR REV, V12, P118, DOI 10.1210/edrv-12-2-118; JANS JE, 1990, DEV PSYCHOBIOL, V23, P519, DOI 10.1002/dev.420230607; KELLERWOOD ME, 1984, ENDOCR REV, V5, P1, DOI 10.1210/edrv-5-1-1; KREY LC, 1975, ENDOCRINOLOGY, V96, P1088, DOI 10.1210/endo-96-5-1088; KUHN CM, 1978, SCIENCE, V201, P1034, DOI 10.1126/science.684424; LEE MHS, 1974, ANIM BEHAV, V22, P679, DOI 10.1016/S0003-3472(74)80016-3; LEON M, 1978, PHYSIOL BEHAV, V21, P793, DOI 10.1016/0031-9384(78)90021-5; LEVINE S, 1959, SCIENCE, V129, P42, DOI 10.1126/science.129.3340.42; LEVINE S, 1957, SCIENCE, V126, P405, DOI 10.1126/science.126.3270.405; LEVINE S, 1962, SCIENCE, V135, P795, DOI 10.1126/science.135.3506.795-a; Levine S., 1975, SOC STRESS DIS, P43; Levine S, 1994, ANN NY ACAD SCI, V746, P260; LIU D, UNPUB; MEANEY MJ, 1991, NEUROBIOL AGING, V12, P31, DOI 10.1016/0197-4580(91)90036-J; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MEANEY MJ, 1985, DEV BRAIN RES, V22, P301, DOI 10.1016/0165-3806(85)90183-X; MEANEY MJ, 1989, NEUROENDOCRINOLOGY, V50, P597, DOI 10.1159/000125287; MEANEY MJ, 1985, BEHAV NEUROSCI, V99, P765, DOI 10.1037/0735-7044.99.4.765; MOORE CL, 1984, DEV PSYCHOBIOL, V17, P347, DOI 10.1002/dev.420170403; MYERS MM, 1992, EXPERIENTIA, V48, P322, DOI 10.1007/BF01923426; MYERS MM, 1989, DEV PSYCHOBIOL, V22, P55, DOI 10.1002/dev.420220105; ODONNELL D, 1994, MOL BRAIN RES, V26, P242, DOI 10.1016/0169-328X(94)90096-5; PLOTSKY PM, 1986, ENDOCRINOLOGY, V119, P1126, DOI 10.1210/endo-119-3-1126; PLOTSKY PM, 1987, ENDOCRINOLOGY, V120, P1361, DOI 10.1210/endo-120-4-1361; PLOTSKY PM, 1991, J NEUROENDOCRINOL, V3, P1, DOI 10.1111/j.1365-2826.1991.tb00231.x; PLOTSKY PM, 1993, MOL BRAIN RES, V18, P195, DOI 10.1016/0169-328X(93)90189-V; SAPOLSKY RM, 1984, P NATL ACAD SCI-BIOL, V81, P6174, DOI 10.1073/pnas.81.19.6174; SAPOLSKY RM, 1995, NEUROSCIENCE, V66, P571; SARRIEAU A, 1988, DEV BRAIN RES, V43, P158, DOI 10.1016/0165-3806(88)90162-9; SAWCHENKO PE, 1987, J NEUROSCI, V7, P1093; SCHANBERG SM, 1987, CHILD DEV, V58, P1431, DOI 10.1111/j.1467-8624.1987.tb03856.x; SECKL JR, 1990, J NEUROENDOCRINOL, V2, P911, DOI 10.1111/j.1365-2826.1990.tb00659.x; SHANKS N, 1995, J NEUROSCI, V15, P376, DOI 10.1523/jneurosci.15-01-00376.1995; Vallee M, 1997, J NEUROSCI, V17, P2626; VIAU V, 1991, ENDOCRINOLOGY, V129, P2503, DOI 10.1210/endo-129-5-2503; VIAU V, 1993, J NEUROSCI, V13, P1097; WALKER CD, 1990, ENDOCRINOLOGY, V127, P832, DOI 10.1210/endo-127-2-832; WHITNALL MH, 1993, PROG NEUROBIOL, V40, P573, DOI 10.1016/0301-0082(93)90035-Q; WOODSIDE BC, UNPUB; ZARROW MX, 1972, P SOC EXP BIOL MED, V356, P141	54	2287	2335	7	254	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	1997	277	5332					1659	1662		10.1126/science.277.5332.1659	http://dx.doi.org/10.1126/science.277.5332.1659			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287218				2022-12-24	WOS:A1997XV68400049
J	Michelotti, EF; Sanford, S; Levens, D				Michelotti, EF; Sanford, S; Levens, D			Marking of active genes on mitotic chromosomes	NATURE			English	Article							PROMOTER; DISPLACEMENT; PROPAGATION; REPLICATION; CHROMATIN; INVIVO	During development and differentiation, cellular phenotypes are stably propagated through numerous cell divisions(1). This epigenetic 'cell memory' helps to maintain stable patterns of gene expression(2). DNA methylation(3) and the propagation of specific chromatin structures may both contribute to cell memory(4). There are two impediments during the cell cycle that can hinder the inheritance of specific chromatin configurations: first, the pertinent structures must endure the passage of DNA-replication forks in S phase(5); second, the chromatin state must survive mitosis, when chromatin condenses, transcription is turned off, and almost all double-stranded DNA-binding proteins are displaced(6,7). After mitosis, the previous pattern of expressed and silent genes must be restored. This restoration might be governed by mass action, determined by the binding affinities and concentrations of individual components, Alternatively, a subset of factors might remain bound to mitotic chromosomes, providing a molecular bookmark to direct proper chromatin reassembly, Here we analyse DNA at transcription start sites during mitosis in vivo and find that it is conformationally distorted in genes scheduled for reactivation but is undistorted in repressed genes. These protein-dependent conformational perturbations could help to re-establish transcription after mitosis by 'marking' genes for re-expression.	NCI,PATHOL LAB,GENE REGULAT SECT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Levens, David/C-9216-2009	Levens, David/0000-0002-7616-922X				ALBERTS B, 1994, MOL BIOLCELL; BHAUMIK D, 1994, J BIOL CHEM, V269, P15861; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; CASTANO IB, 1996, GENE DEV, V10, P2546; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GROUDINE M, 1982, CELL, V30, P131, DOI 10.1016/0092-8674(82)90019-8; Juan G, 1996, EXP CELL RES, V227, P197, DOI 10.1006/excr.1996.0267; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KOIWAI O, 1988, BIOCHEM BIOPH RES CO, V154, P91, DOI 10.1016/0006-291X(88)90654-7; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; MARTIENSSEN RA, 1995, CURR OPIN GENET DEV, V5, P234, DOI 10.1016/0959-437X(95)80014-X; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MAVROTHALASSITIS GJ, 1990, ONCOGENE, V5, P1337; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; SCHWEIZER D, 1994, CHROMOSOME ANAL PROT; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3	21	136	139	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					895	899		10.1038/42282	http://dx.doi.org/10.1038/42282			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278053	Bronze			2022-12-24	WOS:A1997XT75400054
J	Sontheimer, EJ; Sun, SG; Piccirilli, JA				Sontheimer, EJ; Sun, SG; Piccirilli, JA			Metal ion catalysis during splicing of premessenger RNA	NATURE			English	Article							PRE-MESSENGER-RNA; SITE; SPLICEOSOME; DNA; 3'-THIOTHYMIDINE; STEREOCHEMISTRY; HEXOKINASE; PRECURSORS; COMPLEXES; SUBSTRATE	The removal of intervening sequences from premessenger RNA is essential for the expression of most eukaryotic genes. The spliceosome ribonucleoprotein complex catalyses intron removal by two sequential phosphotransesterification reactions', but the catalytic mechanisms are unknown. It has been proposed that two divalent metal ions may mediate catalysis of both reaction steps, activating the 2'-or 3'-hydroxyl groups for nucleophilic attack and stabilizing the 3'-oxyanion leaving groups by direct coordination(2). Here we show that in splicing reactions with a precursor RNA containing a 3'-sulphur substitution at the 5' splice site, interaction between metal ion and leaving group is essential for catalysis of the first reaction step. This establishes that the spliceosome is a metalloenzyme and demonstrates a direct parallel with the catalytic strategy used by the self-splicing group I intron from Tetrahymena(3). In contrast, 3'-sulphur substitution at the 3' splice site provides no evidence for a metal ion-leaving group interaction in the second reaction step, suggesting that the two steps of splicing proceed by different catalytic mechanisms and therefore in distinct active sites.	UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CHEM,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago; University of Chicago				Sontheimer, Erik/0000-0002-0881-0310				ABMAYR SM, 1988, P NATL ACAD SCI USA, V85, P7216, DOI 10.1073/pnas.85.19.7216; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; Anderegg G., 1987, COMPLEXONES, V2, P777; BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; COSSTICK R, 1990, NUCLEIC ACIDS RES, V18, P829, DOI 10.1093/nar/18.4.829; Dantzman CL, 1996, J AM CHEM SOC, V118, P11715, DOI 10.1021/ja962265c; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; JAFFE EK, 1979, J BIOL CHEM, V254, P839; JAFFE EK, 1978, J BIOL CHEM, V253, P4823; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; Kramer A., 1995, PREMRNA PROCESSING, P35; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NARLIKAR GJ, 1995, P NATL ACAD SCI USA, V92, P3668, DOI 10.1073/pnas.92.9.3668; PEARSON RG, 1966, SCIENCE, V151, P172, DOI 10.1126/science.151.3707.172; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; QUERY CC, 1994, GENE DEV, V8, P587, DOI 10.1101/gad.8.5.587; Reyes J, 1996, RNA, V2, P213; SEIWERT SD, 1993, MOL CELL BIOL, V13, P3135, DOI 10.1128/MCB.13.6.3135; Sigel RKO, 1997, J AM CHEM SOC, V119, P744, DOI 10.1021/ja962970l; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TARN WY, IN PRESS BIOCHIMIE; VYLE JS, 1992, BIOCHEMISTRY-US, V31, P3012, DOI 10.1021/bi00126a024; Weinstein LB, 1996, J AM CHEM SOC, V118, P10341, DOI 10.1021/ja9616903	28	145	151	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					801	805		10.1038/42068	http://dx.doi.org/10.1038/42068			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285595	Bronze			2022-12-24	WOS:A1997XR66700057
J	Maisel, WH; Kuntz, KM; Reimold, SC; Lee, TH; Antman, EM; Friedman, PL; Stevenson, WG				Maisel, WH; Kuntz, KM; Reimold, SC; Lee, TH; Antman, EM; Friedman, PL; Stevenson, WG			Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital	ANNALS OF INTERNAL MEDICINE			English	Article							ARRHYTHMIA SUPPRESSION TRIAL; CARDIOVERSION; QUINIDINE; EFFICACY; MORTALITY; AGE	Background: The risks of antiarrhythmic therapy are increasingly recognized, but the risks associated with the initiation of antiarrhythmic therapy in patients hospitalized for atrial fibrillation are poorly defined. Objective: To determine the incidence, time course, and predictors of adverse cardiac events that require intervention during initiation of antiarrhythmic drug therapy for atrial fibrillation. Design: Retrospective chart review. Setting: University hospital. Participants: 417 consecutive patients who underwent a total of 597 drug trials during a total of 550 hospitalizations for atrial fibrillation. Intervention: Initiation of therapy with antiarrhythmic drugs: procainamide (189 trials), quinidine (179 trials), disopyramide (20 trials), propafenone (110 trials), flecainide (2 trials), sotalol (72 trials), and amiodarone (25 trials). Electrical conversion was performed during 247 trials. Measurements: Incidence of adverse events and daily hazard rate were measured. Logistic regression was done to identify risk factors. Results: During the 597 drug trials, 80 (13.4%) cardiac adverse events occurred in 73 patients. The risk was greatest during the first 24 hours of therapy. Bradyarrhythmias were the most common adverse event, occurring in 47 trials (7.9%); prolongation of the QT interval warranting discontinuation of drug therapy (9 trials; 1.5%) and ventricular arrhythmias (8 trials; 1.3%) were less frequent. In multivariate analysis, previous myocardial infarction was associated with increased risk (odds ratio, 1.90 [95% CI, 1.05 to 3.43]) and the association between older age and increased risk (odds ratio, 1.29 per decade [CI, 0.97 to 1.72]) was of borderline statistical significance. Conclusions: A significant risk for cardiac adverse events exists during initiation of antiarrhythmic therapy in patients hospitalized for atrial fibrillation. Observation with electrocardiographic monitoring seems advisable for 24 to 48 hours during initiation of antiarrhythmic therapy, particularly for elderly patients and patients who have previously had myocardial infarction.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital								AKIYAMA T, 1992, J AM GERIATR SOC, V40, P666, DOI 10.1111/j.1532-5415.1992.tb01957.x; COLLETT D, 1994, MODELLING SURVIVAL D, P27; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; FALK RH, 1992, ANN INTERN MED, V117, P141, DOI 10.7326/0003-4819-117-2-141; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; HILL JD, 1987, J ROY COLL GEN PRACT, V37, P172; HOHNLOSER SH, 1995, J AM COLL CARDIOL, V26, P852, DOI 10.1016/0735-1097(95)00286-5; MANCINI GBJ, 1982, AM HEART J, V104, P617; OSTRANDER LD, 1965, CIRCULATION, V31, P888, DOI 10.1161/01.CIR.31.6.888; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; RODEN DM, 1994, NEW ENGL J MED, V331, P785; RUSKIN JN, 1989, NEW ENGL J MED, V321, P386, DOI 10.1056/NEJM198908103210608; STRATMANN HG, 1987, AM HEART J, V113, P1470, DOI 10.1016/0002-8703(87)90664-8; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	16	75	78	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1997	127	4					281	+		10.7326/0003-4819-127-4-199708150-00004	http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR266	9265427				2022-12-24	WOS:A1997XR26600006
J	Robbins, DJ; Nybakken, KE; Kobayashi, R; Sisson, JC; Bishop, JM; Therond, PP				Robbins, DJ; Nybakken, KE; Kobayashi, R; Sisson, JC; Bishop, JM; Therond, PP			Hedgehog elicits signal transduction by means of a large complex containing the kinesin-related protein costal2	CELL			English	Article							POLARITY GENE; DROSOPHILA-MELANOGASTER; SEGMENTAL POLARITY; SONIC-HEDGEHOG; FUSED GENE; PATTERN; FAMILY; TRANSCRIPTION; EXPRESSION; SUPPRESSOR	The hedgehog gene of Drosophila melanogaster encodes a secreted protein (HH) that plays a vital role in cell fate and patterning. Here we describe a protein complex that mediates signal transduction from HH. The complex includes the products of at least three genes:fused (a protein-serine/threonine kinase), cubitus interruptus (a transcription factor), and costal2 (a kinesin-like protein). The complex binds with great affinity to microtubules in the absence of HH, but binding is reversed by HH. Mutations in the extracatalytic domain of FU abolish both the biological function of the protein and its association with COS2. We conclude that the complex may facilitate signaling from HH by governing access of the cubitus interruptus protein to the nucleus.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University	Robbins, DJ (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.		Therond, pascal/AAE-4811-2019		NCI NIH HHS [CA44338, CA45508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044338, P30CA045508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BUSSON D, 1988, ROUX ARCH DEV BIOL, V197, P221, DOI 10.1007/BF02439429; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CHANG DT, 1994, DEVELOPMENT, V120, P3339; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COLE DG, 1994, J BIOL CHEM, V269, P22913; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FORBES AJ, 1993, DEVELOPMENT S, V119, P115; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harlow E, 1988, ANTIBODIES LAB MANUA; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HIDALGO A, 1991, MECH DEVELOP, V35, P77, DOI 10.1016/0925-4773(91)90059-F; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; MOHLER J, 1988, GENETICS, V120, P1061; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PHAM A, 1995, GENETICS, V140, P587; PREAT T, 1993, GENETICS, V135, P1047; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; Therond P, 1996, GENETICS, V142, P1181; THEROND P, 1993, MECH DEVELOP, V44, P65, DOI 10.1016/0925-4773(93)90017-R; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; ZECCA M, 1995, DEVELOPMENT, V121, P2265	56	307	316	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					225	234		10.1016/S0092-8674(00)80331-1	http://dx.doi.org/10.1016/S0092-8674(00)80331-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244297	Bronze			2022-12-24	WOS:A1997XN24900007
J	Dickson, RM; Cubitt, AB; Tsien, RY; Moerner, WE				Dickson, RM; Cubitt, AB; Tsien, RY; Moerner, WE			On/off blinking and switching behaviour of single molecules of green fluorescent protein	NATURE			English	Article							OPTICAL MICROSCOPY	Optical studies of individual molecules at low and room temperature can provide information about the dynamics of local environments in solids, liquids and biological systems unobscured by ensemble averaging(1-14). Here we present a study of the photophysical behaviour of single molecules of the green fluorescent protein (GFP) derived from the jellfish Aequorea victoria. Wild-type GFP and its mutant have attracted interest as fluorescent biological labels because the fluorophore may be formed in vivo(15,16). GFP mutants immobilized in aereated aqueous polymer gels and excited by 488-nm light undergo repeated cycles of fluorescent emission ('blinking') on a timescale of several seconds-behaviour that would be unobservable in bulk studies. Eventually the individual GFP molecules reach a long-lasting dark state, from which they can be switched back to the original emissive state by irradiation at 405 nm. This suggests the possibility of using these GFPs as fluorescent markers for time-dependent cell processes, and as molecular photonic switches or optical storage elements, addressable on the single-molecule level.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM 0340, LA JOLLA, CA 92093 USA; AURORA BIOSCI, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST 0647, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Wood, David W/B-2992-2012; Moerner, William E/C-3260-2008	Moerner, William E/0000-0002-2830-209X				AMBROSE WP, 1994, SCIENCE, V265, P364, DOI 10.1126/science.265.5170.364; BARBARA PF, 1996, ACC CHEM RES, V29; Basche T., 1997, SINGLE MOL OPTICAL D; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; Brejc K, 1997, P NATL ACAD SCI USA, V94, P2306, DOI 10.1073/pnas.94.6.2306; Chattoraj M, 1996, P NATL ACAD SCI USA, V93, P8362, DOI 10.1073/pnas.93.16.8362; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Dickson RM, 1996, SCIENCE, V274, P966, DOI 10.1126/science.274.5289.966; Fawcett J. S., 1966, SEP SCI, V1, P9; FOX GEP, 1970, TIME SERIES ANAL FOR; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; IRIE M, 1994, PHOTOREACTIVE MAT UL, P1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lu HP, 1997, NATURE, V385, P143, DOI 10.1038/385143a0; MOERNER WE, 1989, PHYS REV LETT, V62, P2535, DOI 10.1103/PhysRevLett.62.2535; MOERNER WE, 1994, SCIENCE, V265, P46, DOI 10.1126/science.265.5168.46; MOERNER WE, 1994, J PHYS CHEM-US, V98, P7382, DOI 10.1021/j100081a025; NIE SM, 1994, SCIENCE, V266, P1018, DOI 10.1126/science.7973650; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; ORRIT M, 1990, PHYS REV LETT, V65, P2716, DOI 10.1103/PhysRevLett.65.2716; PARTHENOPOULOS DA, 1989, SCIENCE, V245, P843, DOI 10.1126/science.245.4920.843; REILLY PD, 1993, PHYS REV LETT, V71, P4257, DOI 10.1103/PhysRevLett.71.4257; Sakmann B., 1995, SINGLE CHANNEL RECOR; Schmidt T, 1996, P NATL ACAD SCI USA, V93, P2926, DOI 10.1073/pnas.93.7.2926; STUART JA, 1996, 6 BIENN IEEE INT NON, P35; Trautman JK, 1996, CHEM PHYS, V205, P221, DOI 10.1016/0301-0104(95)00391-6; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252	30	1073	1113	16	432	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 24	1997	388	6640					355	358		10.1038/41048	http://dx.doi.org/10.1038/41048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237752	Bronze			2022-12-24	WOS:A1997XM52800043
J	Kaplan, SL				Kaplan, SL			Prevention of hearing loss from meningitis	LANCET			English	Editorial Material									TEXAS CHILDRENS HOSP,HOUSTON,TX 77030	Baylor College of Medicine	Kaplan, SL (corresponding author), BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030, USA.							Dodds A, 1997, ARCH DIS CHILD, V76, P139, DOI 10.1136/adc.76.2.139; FORTNUM HM, 1992, ARCH DIS CHILD, V67, P1128, DOI 10.1136/adc.67.9.1128; Kaplan S L, 1995, Adv Pediatr Infect Dis, V10, P167; Merchant SN, 1996, AM J OTOL, V17, P375; Richardson MP, 1997, ARCH DIS CHILD, V76, P134, DOI 10.1136/adc.76.2.134; Winter A, 1996, ACTA OTO-LARYNGOL, V116, P401, DOI 10.3109/00016489609137864; WOLFF AB, 1987, AM ANN DEAF, V131, P26	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					158	159		10.1016/S0140-6736(05)62346-X	http://dx.doi.org/10.1016/S0140-6736(05)62346-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250179				2022-12-24	WOS:A1997XL72200005
J	Sharpe, M; Hawton, K; Clements, A; Cowen, PJ				Sharpe, M; Hawton, K; Clements, A; Cowen, PJ			Increased brain serotonin function in men with chronic fatigue syndrome	BRITISH MEDICAL JOURNAL			English	Article									UNIV OXFORD,LITTLEMORE HOSP,DEPT PSYCHIAT,OXFORD OX4 4XN,ENGLAND; UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX4 4XN,ENGLAND	University of Oxford; University of Oxford				sharpe, michael/0000-0002-6474-9980; Cowen, Philip/0000-0001-5518-6138				BAKHEIT AMO, 1992, BRIT MED J, V304, P1010, DOI 10.1136/bmj.304.6833.1010; BEARN J, 1995, BIOL PSYCHIAT, V37, P245, DOI 10.1016/0006-3223(94)00121-I; CLEARE AJ, 1995, J AFFECT DISORDERS, V35, P283; Sharpe M, 1996, PSYCHIAT CLIN N AM, V19, P549, DOI 10.1016/S0193-953X(05)70305-1; YATHAM LN, 1995, CAN J PSYCHIAT, V40, P3	5	50	50	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 19	1997	315	7101					164	165		10.1136/bmj.315.7101.164	http://dx.doi.org/10.1136/bmj.315.7101.164			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XM321	9251547	Green Published			2022-12-24	WOS:A1997XM32100021
J	Rand, JH; Wu, XX; Andree, HAM; Lockwood, CJ; Guller, S; Scher, J; Harpel, PC				Rand, JH; Wu, XX; Andree, HAM; Lockwood, CJ; Guller, S; Scher, J; Harpel, PC			Pregnancy loss in the antiphospholipid-antibody syndrome - A possible thrombogenic mechanism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACENTAL ANTICOAGULANT PROTEIN; PHOSPHOLIPID-BINDING; ANNEXIN-V; LIPOCORTIN FAMILY; FETAL LOSS; LINES; CELLS; MICE	Background The mechanisms of vascular thrombosis and pregnancy loss in the antiphospholipid-antibody syndrome are unknown. Levels of annexin V, a phospholipid-binding protein with potent anticoagulant activity, are markedly reduced on placental villi from women with this syndrome. Hypercoagulability in such women may therefore be due to the reduction of surface-bound annexin V by antiphospholipid antibodies. To test this idea, we studied how antiphospholipid antibodies affect levels of annexin V on cultured trophoblasts and human umbilical vein endothelial cells and how they affect the procoagulant activity of these cells. Methods We isolated IgG fractions from three patients with the antiphospholipid-antibody syndrome and from normal controls. These antibodies were incubated with cultured BeWo cells (a placental-trophoblast cell line), primary cultured trophoblasts, and human umbilical-vein endothelial cells. Annexin V on the cell surfaces was measured by an enzyme-linked immunosorbent assay. The coagulation times of plasma overlaid on the cells were also determined. Results Trophoblasts and endothelial cells exposed to antiphospholipid-antibody IgG as compared with control IgG had reduced levels of annexin V (trophoblasts, 0.37+/-0.02 vs. 0.85+/-0.12 ng per well, P=0.02; endothelial cells, 1.6+/-0.04 vs. 2.1+/-0.05 ng per well, P=0.001). Also, trophoblasts and endothelial cells exposed to antiphospholipid-antibody IgG had faster mean (+/-SE) plasma coagulation times than cells exposed to control IgG (trophoblasts, 8.7+/-2.0 vs. 21.3+/-2.9 minutes, P=0.02; endothelial cells, 9.8+/-0.8 vs. 14.2+/-1.2 minutes, P=0.04). Conclusions Antiphospholipid antibodies reduce the levels of annexin V and accelerate the coagulation of plasma on cultured trophoblasts and endothelial cells. The reduction of annexin V levels on vascular cells may be an important mechanism of thrombosis and pregnancy loss in the antiphospholipid-antibody syndrome. (C)1997, Massachusetts Medical Society.	MT SINAI SCH MED,DEPT MED,DIV THROMBOSIS,NEW YORK,NY; MT SINAI SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,NEW YORK,NY; NYU,SCH MED,DEPT OBSTET & GYNECOL,NEW YORK,NY	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; New York University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029019, R01HL032200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024671] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-32200, HL-29019] Funding Source: Medline; NIAID NIH HHS [AI-24671] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREE HAM, 1992, J BIOL CHEM, V267, P17907; ANDREE HAM, 1992, PHOSPHOLIPID BINDING, P73; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; BLANK M, 1994, J AUTOIMMUN, V7, P441, DOI 10.1006/jaut.1994.1032; BRANCH DW, 1990, AM J OBSTET GYNECOL, V163, P210, DOI 10.1016/S0002-9378(11)90700-5; DOUGLAS GC, 1989, J IMMUNOL METHODS, V119, P259, DOI 10.1016/0022-1759(89)90405-5; FLAHERTY MJ, 1990, J LAB CLIN MED, V115, P174; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; HASEGAWA I, 1994, THROMB RES, V74, P77, DOI 10.1016/0049-3848(94)90037-X; HINEGARDNER RT, 1971, ANAL BIOCHEM, V39, P197, DOI 10.1016/0003-2697(71)90476-3; HUBER R, 1994, ANNEXINS, P105; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KRAUSE I, 1993, AM J REPROD IMMUNOL, V29, P155, DOI 10.1111/j.1600-0897.1993.tb00581.x; KRIKUN G, 1994, PLACENTA, V15, P601, DOI 10.1016/S0143-4004(05)80407-2; LOCKSHIN M D, 1991, Current Opinion in Rheumatology, V3, P797, DOI 10.1097/00002281-199110000-00008; Lockwood C J, 1994, Obstet Gynecol Surv, V49, P432, DOI 10.1097/00006254-199406000-00026; MESSMORE H, 1994, SEMIN THROMB HEMOST, V20, P79, DOI 10.1055/s-2007-1001892; ORNSTEIN MH, 1994, J RHEUMATOL, V21, P1360; Pierangeli SS, 1996, LUPUS, V5, P451, DOI 10.1177/096120339600500524; RAND JH, 1994, AM J OBSTET GYNECOL, V171, P1566, DOI 10.1016/0002-9378(94)90403-0; ROUBEY RAS, 1994, BLOOD, V84, P2854; SAMMARITANO LR, 1990, SEMIN ARTHRITIS RHEU, V20, P81, DOI 10.1016/0049-0172(90)90021-7; SAMMARITANO LR, 1992, J CLIN IMMUNOL, V12, P27, DOI 10.1007/BF00918270; Shapiro SS, 1996, ANNU REV MED, V47, P533; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; TRIPLETT DA, 1995, THROMB HAEMOSTASIS, V74, P329	29	376	390	1	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	1997	337	3					154	160		10.1056/NEJM199707173370303	http://dx.doi.org/10.1056/NEJM199707173370303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK818	9219701				2022-12-24	WOS:A1997XK81800003
J	Rowe, JA; Moulds, JM; Newbold, CI; Miller, LH				Rowe, JA; Moulds, JM; Newbold, CI; Miller, LH			P-falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1	NATURE			English	Article							PLASMODIUM-FALCIPARUM; INFECTED ERYTHROCYTES; SWAIN-LANGLEY; MALARIA; EXPRESSION; PHENOTYPES; CYTOADHERENCE; ANTIGENS; SURFACE; DOMAINS	The factors determining disease severity in malaria are complex and include host polymorphisms, acquired immunity and parasite virulence(1). Studies in Africa have shown that severe malaria is associated with the ability of erythrocytes infected with the parasite Plasmodium falciparum to bind uninfected erythrocytes and form rosettes(2-5). The molecular basis of resetting is not well understood, although a group of low-molecular-mass proteins called rosettins have been described as potential parasite ligands(6). Infected erythrocytes also bind to endothelial cells, and this interaction is mediated by the parasite-derived variant erythrocyte membrane protein PfEMP1 (refs 7, 8), which is encoded by the var gene family(9-11). Here we report that the parasite ligand for resetting in a P. falciparum done is PfEMP1, encoded by a specific var gene, We also report that Complement-receptor 1 (CR1) on erythrocytes plays a role in the formation of rosettes and that erythrocytes with a common African CR1 polymorphism (Sl(a(-)))(12) have reduced adhesion to the domain of PfEMP1 that binds normal erythrocytes. Thus we describe a new adhesive function for PfEMP1 and raise the possibility that CR1 polymorphisms in Africans that influence the interaction between erythrocytes and PfEMP1 may protect against severe malaria.	JOHN RADCLIFFE HOSP,INST MOL MED,MOL PARASITOL GRP,OXFORD OX3 9DU,ENGLAND; UNIV TEXAS,HOUSTON MED SCH,DIV RHEUMATOL & CLIN IMMUNOGENET,HOUSTON,TX 77030	University of Oxford; University of Texas System; University of Texas Health Science Center Houston	Rowe, JA (corresponding author), NIAID,PARASIT DIS LAB,NIH,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.			Newbold, Chris/0000-0002-9274-3789; Rowe, Alexandra/0000-0002-7702-1892	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arnold C, 1991, PCR Methods Appl, V1, P39; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; CARLSON J, 1992, J EXP MED, V176, P1311, DOI 10.1084/jem.176.5.1311; CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N; CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497; COHEN GH, 1988, J VIROL, V62, P1932, DOI 10.1128/JVI.62.6.1932-1940.1988; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7; HANDUNNETTI SM, 1992, AM J TROP MED HYG, V46, P371, DOI 10.4269/ajtmh.1992.46.371; HANDUNNETTI SM, 1992, BLOOD, V80, P2097; HELMBY H, 1993, INFECT IMMUN, V61, P284, DOI 10.1128/IAI.61.1.284-288.1993; HILL AVS, 1992, T ROY SOC TROP MED H, V86, P225, DOI 10.1016/0035-9203(92)90282-H; MILLER LH, 1994, P NATL ACAD SCI USA, V91, P2415, DOI 10.1073/pnas.91.7.2415; MOULDS JM, 1992, VOX SANG, V62, P230, DOI 10.1111/j.1423-0410.1992.tb01204.x; MOULDS JM, 1991, J EXP MED, V173, P1159, DOI 10.1084/jem.173.5.1159; MOULDS MK, 1981, AM J MED TECHNOL, V47, P789; PETERSON DS, 1995, P NATL ACAD SCI USA, V92, P7100, DOI 10.1073/pnas.92.15.7100; RINGWALD P, 1993, INFECT IMMUN, V61, P5198, DOI 10.1128/IAI.61.12.5198-5204.1993; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; ROWE A, 1994, EXP PARASITOL, V79, P506, DOI 10.1006/expr.1994.1111; ROWE A, 1995, INFECT IMMUN, V63, P2323, DOI 10.1128/IAI.63.6.2323-2326.1995; Scholander C, 1996, NAT MED, V2, P204, DOI 10.1038/nm0296-204; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; TREUTIGER CJ, 1992, AM J TROP MED HYG, V46, P503, DOI 10.4269/ajtmh.1992.46.503; VENGELENTYLER V, 1996, AABB TECHNICAL MANUA; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; Yadava A, 1996, P NATL ACAD SCI USA, V93, P4595, DOI 10.1073/pnas.93.10.4595	29	451	460	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					292	295		10.1038/40888	http://dx.doi.org/10.1038/40888			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230440	Bronze			2022-12-24	WOS:A1997XL12100055
J	Krongrad, A; Lai, H; Lai, SH				Krongrad, A; Lai, H; Lai, SH			Survival after radical prostatectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; MORTALITY; OUTCOMES	Context.-The generalizability of currently available estimates of survival after radical prostatectomy is theoretically limited. Objective.-To obtain generalizable estimates of survival after radical prostatectomy. Design.-A population-based retrospective cohort study. Setting.-Nine regions of the United States. Patients.-Patients who were diagnosed with prostate cancer between 1983 and 1987 and underwent radical prostatectomy and lymph node dissection. Main Outcome Measures-Proportional hazards models incorporating geographical region, age, race, pathological stage, lymph node involvement, and tumor grade to identify independent correlates of disease-specific and overall survival and life table analyses to estimate 10-year survival distributions. Results.-A total of 3626 patients with a mean age of 65 years were included in the study; 92.6% were white, 54.2% had moderate-grade cancer, 60.4% had no extension beyond the prostate, and 91.2% had no lymph node involvement. Using San Francisco-Oakland, Calif, as a reference region, no other region was significantly associated with a risk of disease-specific or overall mortality. Older age and black race were independently associated with worse overall but not disease-specific survival. Higher grade, extension beyond the prostate, and lymph node involvement were independently associated with worse disease-specific and overall survival. Estimates of 10-year disease-specific survival ranged from 75% to 97% for patients with well-differentiated and moderately differentiated cancers and from 60% to 86% for patients with poorly differentiated cancers. Conclusions.-Neither disease-specific nor overall survival varied by region, suggesting geographically uniform assessments of risk in patient selection for radical prostatectomy. Across regions, overall survival varied by patient and prostate cancer characteristic while disease-specific survival varied substantially by prostate cancer but not patient characteristics. The present analyses provide the most generalizable current estimates of survival after radical prostatectomy.	UNIV MIAMI,SCH MED,DEPT UROL,MIAMI,FL; UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL; UNIV MIAMI,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,MIAMI,FL; UNIV MIAMI,SYLVESTER COMPREHENS CANC CTR,MIAMI,FL 33152	University of Miami; University of Miami; University of Miami; University of Miami	Krongrad, A (corresponding author), VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN,1201 NW 16TH ST,MIAMI,FL 33125, USA.							BENNETT CL, 1991, CANCER, V67, P2633, DOI 10.1002/1097-0142(19910515)67:10<2633::AID-CNCR2820671039>3.0.CO;2-9; COX DR, 1972, J R STAT SOC B, V34, P187; Fryback DG, 1996, JAMA-J AM MED ASSOC, V276, P1723; Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615; Gilliland FD, 1996, UROLOGY, V48, P67, DOI 10.1016/S0090-4295(96)00083-0; Helgesen F, 1996, JNCI-J NATL CANCER I, V88, P1216, DOI 10.1093/jnci/88.17.1216; HSING AW, 1994, CANCER EPIDEM BIOMAR, V3, P527; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; Krongrad A, 1996, J UROLOGY, V156, P1084, DOI 10.1016/S0022-5347(01)65710-0; Krongrad A, 1996, Urol Oncol, V2, P35, DOI 10.1016/1078-1439(96)00038-5; KRONGRAD A, IN PRESS J UROL; KRONGRAD A, IN PRESS MANAGE CLIN; LERNER SE, 1995, J UROLOGY, V154, P1447, DOI 10.1016/S0022-5347(01)66888-5; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; Riley G, 1985, Health Care Financ Rev, V7, P37; Schellhammer P, 1997, UROLOGY, V49, P27, DOI 10.1016/S0090-4295(99)80321-5; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933	18	38	38	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					44	46						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207337				2022-12-24	WOS:A1997XG38700035
J	Freeman, G; Hjortdahl, P				Freeman, G; Hjortdahl, P			What future for continuity of care in general practice?	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE; PRACTITIONERS KNOWLEDGE; PATIENT SATISFACTION; PERSONAL CONTINUITY; DOCTOR; CONSULTATIONS; QUALITY; VIEWS; KEY		UNIV OSLO,DEPT GEN PRACTICE & COMMUNITY MED,N-0317 OSLO,NORWAY	University of Oslo	Freeman, G (corresponding author), UNIV LONDON,CHARING CROSS & WESTMINSTER MED SCH,DEPT PUBL HLTH & PRIMARY CARE,LONDON SW10 9NH,ENGLAND.							BAKER R, 1995, BRIT J GEN PRACT, V45, P654; Baker R, 1996, BRIT J GEN PRACT, V46, P601; BANAHAN BF, 1981, J FAM PRACTICE, V12, P767; BECKER MH, 1974, AM J PUBLIC HEALTH, V64, P1062, DOI 10.2105/AJPH.64.11.1062; BRESLAU N, 1982, MED CARE, V20, P347, DOI 10.1097/00005650-198204000-00001; CHACKO MR, 1987, J ADOLESCENT HEALTH, V8, P261, DOI 10.1016/0197-0070(87)90429-3; DIETRICH AJ, 1982, J FAM PRACTICE, V15, P929; ETTLINGER PRA, 1981, BRIT MED J, V282, P1192, DOI 10.1136/bmj.282.6271.1192; FLYNN SP, 1985, J FAM PRACTICE, V21, P375; FREEDMAN R, 1987, ALCOHOL, V4, P249, DOI 10.1016/0741-8329(87)90019-X; FREEMAN G, 1984, FAM PRACT, V1, P245, DOI 10.1093/fampra/1.4.245; Freeman G., 1985, J ROYAL COLL GEN PRA, V5, P423; FREEMAN GK, 1994, BRIT J GEN PRACT, V44, P395; FREEMAN GK, 1989, J ROY COLL GEN PRACT, V39, P145; FREEMAN GK, 1993, BRIT J GEN PRACT, V43, P493; Freidson E., 1970, PROFESSION MED STUDY; *GEN MED SERV COMM, 1995, COR GEN MED SERV CLA; GORLIN R, 1983, NEW ENGL J MED, V308, P1059, DOI 10.1056/NEJM198305053081804; GROL R, 1985, FAM PRACT, V2, P128, DOI 10.1093/fampra/2.3.128; Haig-Smith C, 1989, BRIT MED J, V299, P494; Harris MF, 1996, MED J AUSTRALIA, V164, P456, DOI 10.5694/j.1326-5377.1996.tb122119.x; Heath I., 1995, MYSTERY GEN PRACTICE; Hennen B K, 1975, J Fam Pract, V2, P371; HJORTDAHL P, 1991, BRIT MED J, V303, P1181, DOI 10.1136/bmj.303.6811.1181; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; Hjortdahl P, 1990, Fam Med, V22, P361; HJORTDAHL P, 1992, FAM PRACT, V9, P3, DOI 10.1093/fampra/9.1.3; LEWIS JR, 1994, SOC SCI MED, V39, P655, DOI 10.1016/0277-9536(94)90022-1; MCWHINNEY IR, 1989, TXB FAMILY MED, P12; MILLER MH, 1973, J HEALTH SOC BEHAV, V14, P176, DOI 10.2307/2137067; MOREHEAD MA, 1974, MED CARE, V12, P301, DOI 10.1097/00005650-197404000-00002; PENDLETON DA, 1996, OXFORD GEN PRACTICE, V37; PHILLIPS DM, 1984, J FAM PRACTICE, V19, P793; PRATT J, 1995, PRACTITIONERS PRACTI, P60; ROOS LL, 1980, MED CARE, V18, P174, DOI 10.1097/00005650-198002000-00004; *ROYAL COLL GEN PR, 1985, EV ROYAL COMM NAT HL, P1; Schon Donald A., 1988, ED REFLECTIVE PRACTI; SMITH WG, 1985, EVAL HEALTH PROF, V8, P339, DOI 10.1177/016327878500800305; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; STARFIELD B, 1980, AM J PUBLIC HEALTH, V70, P117, DOI 10.2105/AJPH.70.2.117; VANDULMEN AM, 1995, PSYCHOL MED, V25, P1011, DOI 10.1017/S0033291700037508; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; WILLIAMS SJ, 1991, FAM PRACT, V8, P237, DOI 10.1093/fampra/8.3.237; WILSON M, 1996, MED WORKFORCE	44	105	107	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1870	1873		10.1136/bmj.314.7098.1870	http://dx.doi.org/10.1136/bmj.314.7098.1870			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XH738	9224130	Green Published			2022-12-24	WOS:A1997XH73800025
J	Barkai, N; Leibler, S				Barkai, N; Leibler, S			Robustness in simple biochemical networks	NATURE			English	Article							BACTERIAL CHEMOTAXIS; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; METHYLATION; ADAPTATION; MODEL; MECHANISM; PROTEINS	Cells use complex networks of interacting molecular components to transfer and process information, These ''computational devices of living cells''(1) are responsible for many important cellular processes, including cell-cycle regulation and signal transduction. Here we address the issue of the sensitivity of the networks to variations in their biochemical parameters, We propose a mechanism for robust adaptation in simple signal transduction networks. We show that this mechanism applies in particular to bacterial chemotaxis(2-7). This is demonstrated within a quantitative model which explains, in a unified way, many aspects of chemotaxis, including proper responses to chemical gradients(8-12). The adaptation property(10,13-16) is a consequence of the network's connectivity and does not require the 'fine-tuning' of parameters. We argue that the key properties of biochemical networks should be robust in order to ensure their proper functioning.	PRINCETON UNIV,DEPT PHYS,PRINCETON,NJ 08544; PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Princeton University; Princeton University								ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; ADLER J, 1975, ANNU REV BIOCHEM, V44, P341, DOI 10.1146/annurev.bi.44.070175.002013; ASAKURA S, 1984, J MOL BIOL, V176, P349, DOI 10.1016/0022-2836(84)90494-7; BERG HC, 1975, P NATL ACAD SCI USA, V72, P3235, DOI 10.1073/pnas.72.8.3235; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; BLOCK SM, 1982, CELL, V31, P215, DOI 10.1016/0092-8674(82)90421-4; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; HAURI DC, 1995, BIOPHYS J, V68, P708, DOI 10.1016/S0006-3495(95)80232-8; HAZELBAUER GL, 1993, CELL, V73, P15, DOI 10.1016/0092-8674(93)90156-K; KHAN S, 1995, P NATL ACAD SCI USA, V92, P9757, DOI 10.1073/pnas.92.21.9757; KLEENE SJ, 1979, P NATL ACAD SCI USA, V76, P6309, DOI 10.1073/pnas.76.12.6309; KOSHLAND DE, 1977, SCIENCE, V196, P1055, DOI 10.1126/science.870969; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; SEGEL LA, 1986, J THEOR BIOL, V120, P151, DOI 10.1016/S0022-5193(86)80171-0; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103	21	1070	1095	1	120	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					913	917		10.1038/43199	http://dx.doi.org/10.1038/43199			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202124				2022-12-24	WOS:A1997XG41600054
J	Matlack, KES; Plath, K; Misselwitz, B; Rapoport, TA				Matlack, KES; Plath, K; Misselwitz, B; Rapoport, TA			Protein transport by purified yeast sec complex and Kar2p without membranes	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL SEQUENCE; ER MEMBRANE; TRANSLOCATION; BIP; ENVIRONMENT; BINDING; DNAJ	Posttranslational protein translocation across the endoplasmic reticulum membrane of yeast requires a seven-component transmembrane complex (the Sec complex) in collaboration with the lumenal Kar2 protein (Kar2p). A translocation substrate was initially bound to the cytosolic face of the purified Sec complex in a signal-sequence-dependent but Kar2p- and nucleotide-independent manner. In a subsequent reaction, in which Kar2p interacted with the lumenal face of the Sec complex and hydrolyzed adenosine triphosphate, the substrate moved through a channel formed by the Sec complex and was released at the lumenal end. Movement through the channel occurred in detergent solution in the absence of a lipid bilayer.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Misselwitz, Benjamin/L-7193-2016	Misselwitz, Benjamin/0000-0002-8719-5175; Plath, Kathrin/0000-0001-7796-3372	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054238] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54238-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1988, MOL CELL BIOL, V8, P1915, DOI 10.1128/MCB.8.5.1915; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; LYMAN SK, 1995, J CELL BIOL, V131, P1163, DOI 10.1083/jcb.131.5.1163; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; MATLACK KES, UNPUB; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NELSON MK, 1993, GENETICS, V134, P159; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANZ P, 1989, J CELL BIOL, V108, P2101, DOI 10.1083/jcb.108.6.2101; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677	20	63	63	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					938	941		10.1126/science.277.5328.938	http://dx.doi.org/10.1126/science.277.5328.938			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252322				2022-12-24	WOS:A1997XQ98500037
J	Kuhl, PK; Andruski, JE; Chistovich, IA; Chistovich, LA; Kozhevnikova, EV; Ryskina, VL; Stolyarova, EI; Sundberg, U; Lacerda, F				Kuhl, PK; Andruski, JE; Chistovich, IA; Chistovich, LA; Kozhevnikova, EV; Ryskina, VL; Stolyarova, EI; Sundberg, U; Lacerda, F			Cross-language analysis of phonetic units in language addressed to infants	SCIENCE			English	Article							SPEECH; MOTHERESE; PATTERNS; PREFERENCE; PROTOTYPES; CATEGORIES; FEATURES; SUPPORT; WORDS	In the early months of life, infants acquire information about the phonetic properties of their native language simply by listening to adults speak. The acoustic properties of phonetic units in language input to young infants in the United States, Russia, and Sweden, were examined. In all three countries, mothers addressing their infants produced acoustically more extreme vowels than they did when addressing adults, resulting in a ''stretching'' of vowel space. The findings show that language input to infants provides exceptionally well-specified information about the linguistic units that form the building blocks for words.	EARLY INTERVENT INST, ST PETERSBURG 191194, RUSSIA; UNIV STOCKHOLM, INST LINGUIST, S-10691 STOCKHOLM, SWEDEN	Stockholm University	Kuhl, PK (corresponding author), UNIV WASHINGTON, DEPT SPEECH & HEARING SCI, BOX 357920, SEATTLE, WA 98195 USA.		Kozhevnikova, Elena/ABB-3431-2020	de Lacerda, Francisco/0000-0002-7980-3601	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P01DC000520] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC 00520] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Chomsky Noam, 1980, RULES REPRESENTATION; Fant G., 1973, SPEECH SOUNDS FEATUR; FERNALD A, 1987, INFANT BEHAV DEV, V10, P279, DOI 10.1016/0163-6383(87)90017-8; FERNALD A, 1985, INFANT BEHAV DEV, V8, P181, DOI 10.1016/S0163-6383(85)80005-9; FERNALD A, 1984, DEV PSYCHOL, V20, P104, DOI 10.1037/0012-1649.20.1.104; FROMKIN V, 1974, BRAIN LANG, V1, P81, DOI 10.1016/0093-934X(74)90027-3; GRIESER D, 1989, DEV PSYCHOL, V25, P577, DOI 10.1037/0012-1649.25.4.577; GRIESER DL, 1988, DEV PSYCHOL, V24, P14, DOI 10.1037/0012-1649.24.1.14; HILLENBRAND J, 1995, J ACOUST SOC AM, V97, P3099, DOI 10.1121/1.411872; IVERSON P, 1995, J ACOUST SOC AM, V97, P553, DOI 10.1121/1.412280; Jakobson R., 1969, PRELIMINARIES SPEECH; JOHNSON K, 1993, LANGUAGE, V69, P505, DOI 10.2307/416697; JUSCZYK PW, 1993, CHILD DEV, V64, P675, DOI 10.2307/1131210; JUSCZYK PW, 1993, J MEM LANG, V32, P402, DOI 10.1006/jmla.1993.1022; KENT RD, 1982, J ACOUST SOC AM, V72, P353, DOI 10.1121/1.388089; KUHL PK, 1994, CURR OPIN NEUROBIOL, V4, P812, DOI 10.1016/0959-4388(94)90128-7; Kuhl PK, 1996, J ACOUST SOC AM, V100, P2425, DOI 10.1121/1.417951; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; KUHL PK, 1991, PERCEPT PSYCHOPHYS, V50, P93, DOI 10.3758/BF03212211; Lane H., 1976, WILD BOY AVEYRON; LILJENCRANTS J, 1972, LANGUAGE, V48, P839, DOI 10.2307/411991; LINDBLOM B, 1963, J ACOUST SOC AM, V35, P1773, DOI 10.1121/1.1918816; LINDBLOM B, 1990, NATO ADV SCI I D-BEH, V55, P403; LIVELY SE, 1993, J ACOUST SOC AM, V94, P1242, DOI 10.1121/1.408177; Merzenich MM, 1996, SCIENCE, V271, P77, DOI 10.1126/science.271.5245.77; Perkell J.S., 1986, INVARIANCE VARIABILI; PETERSON GE, 1952, J ACOUST SOC AM, V24, P175, DOI 10.1121/1.1906875; PETITTO LA, 1993, NATO ADV SCI INST SE, V69, P365; RATNER NB, 1984, J CHILD LANG, V11, P557, DOI 10.1017/S030500090000595X; Saffran JR, 1996, SCIENCE, V274, P1926, DOI 10.1126/science.274.5294.1926; Snow C.E., 1977, TALKING CHILDREN, P31; Stevens KN, 1994, INTRO COMMUNICATION, P399; Stevens SS, 1937, J ACOUST SOC AM, V8, P185, DOI 10.1121/1.1915893; StuddertKennedy M, 1995, PSYCHON B REV, V2, P508, DOI 10.3758/BF03210986; SWOBODA PJ, 1978, CHILD DEV, V49, P332, DOI 10.1111/j.1467-8624.1978.tb02320.x; Tallal P, 1996, SCIENCE, V271, P81, DOI 10.1126/science.271.5245.81	36	532	538	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 1	1997	277	5326					684	686		10.1126/science.277.5326.684	http://dx.doi.org/10.1126/science.277.5326.684			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XN907	9235890				2022-12-24	WOS:A1997XN90700040
J	Grawunder, U; Wilm, M; Wu, XT; Kulesza, P; Wilson, TE; Mann, M; Lieber, MR				Grawunder, U; Wilm, M; Wu, XT; Kulesza, P; Wilson, TE; Mann, M; Lieber, MR			Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells	NATURE			English	Article							STRAND BREAK REPAIR; V(D)J RECOMBINATION; MOLECULAR-CLONING; ATAXIA-TELANGIECTASIA; CATALYTIC SUBUNIT; EXPRESSION; HAMSTER; GENE; DEFICIENCY; MUTATION	Mutation of the XRCC4 gene in mammalian cells(1,2) prevents the formation of the signal and coding joints in the V(D)J recombination reaction(3), which is necessary for production of a functional immunoglobulin gene, and renders the cells highly sensitive to ionizing radiation(4). However, XRCC4 shares no sequence homology with other proteins, nor does it have a biochemical activity to indicate what its function might be(2). Here we show that DNA ligase IV (ref. 5) co-immunoprecipitates with XRCC4 and that these two proteins specifically interact with one another in a yeast two-hybrid system. Ligation of DNA double-strand breaks in a cell-free system by DNA ligase IV is increased fivefold by purified XRCC4 and seven- to eightfold when XRCC4 is co-expressed with DNA ligase IV. We conclude that the biological consequences of mutating XRCC4 are primarily due to the loss of its stimulatory effect on DNA ligase IV: the function of the XRCC4-DNA ligase IV complex may be to carry out the final steps of V(D)J recombination and joining of DNA ends.	EUROPEAN MOL BIOL LAB,PROT & PEPTIDE GRP,D-69012 HEIDELBERG,GERMANY; WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV MOL ONCOL,ST LOUIS,MO 63110	European Molecular Biology Laboratory (EMBL); Washington University (WUSTL)			Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Lieber, Michael/0000-0003-3700-6345; Wilm, Matthias/0000-0002-5461-6834; Lieber, Michael/0000-0001-8809-0909				BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CHEN JW, 1995, MOL CELL BIOL, V15, P5412; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GERSTEIN RM, 1993, NATURE, V363, P625, DOI 10.1038/363625a0; GIACCIA AJ, 1989, SOMAT CELL MOLEC GEN, V15, P71, DOI 10.1007/BF01534671; Grawunder U, 1996, J EXP MED, V183, P1731, DOI 10.1084/jem.183.4.1731; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MILLER RD, 1995, P NATL ACAD SCI USA, V92, P10792, DOI 10.1073/pnas.92.23.10792; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; PETRINI JHJ, 1994, J IMMUNOL, V152, P176; REEVES WH, 1989, J BIOL CHEM, V264, P5047; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; STAMATO TD, 1983, SOMAT CELL GENET, V9, P165, DOI 10.1007/BF01543175; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; WEI YF, 1995, MOL CELL BIOL, V15, P3206; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Wu XT, 1996, MOL CELL BIOL, V16, P5186; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	30	518	530	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					492	495		10.1038/41358	http://dx.doi.org/10.1038/41358			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242410	Bronze			2022-12-24	WOS:A1997XN55300053
J	Goldstein, FW; Garau, J				Goldstein, FW; Garau, J			30 years of penicillin-resistant S pneumoniae: Myth or reality?	LANCET			English	Editorial Material							PNEUMOCOCCI; MENINGITIS		UNIV BARCELONA,HOSP MUTUA TERRASSA,DEPT MED,BARCELONA,SPAIN	Hospital Universitario Mutua Terrassa; University of Barcelona	Goldstein, FW (corresponding author), FDN HOP ST JOSEPH,LAB MICROBIOL MED,F-75674 PARIS 14,FRANCE.							Baquero F, 1995, MICROB DRUG RESIST, V1, P115, DOI 10.1089/mdr.1995.1.115; Bradley JS, 1997, CLIN INFECT DIS, V24, pS213, DOI 10.1093/clinids/24.Supplement_2.S213; Goldstein FW, 1996, J ANTIMICROB CHEMOTH, V38, P71, DOI 10.1093/jac/38.suppl_A.71; HANSMAN D, 1974, MED J AUSTRALIA, V2, P353, DOI 10.5694/j.1326-5377.1974.tb70836.x; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; Jacobs RF, 1996, ANTIMICROB AGENTS CH, V40, P895, DOI 10.1128/AAC.40.4.895; Keefer CS, 1943, JAMA-J AM MED ASSOC, V122, P1217; NARAQI S, 1974, J PEDIATR-US, V85, P671, DOI 10.1016/S0022-3476(74)80513-5; PARIS MM, 1995, ANTIMICROB AGENTS CH, V39, P2171, DOI 10.1128/AAC.39.10.2171	9	28	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					233	234		10.1016/S0140-6736(05)62222-2	http://dx.doi.org/10.1016/S0140-6736(05)62222-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242797				2022-12-24	WOS:A1997XM86600006
J	Sisson, JC; Ho, KS; Suyama, K; Scott, MP				Sisson, JC; Ho, KS; Suyama, K; Scott, MP			Costal2, a novel kinesin-related protein in the Hedgehog signaling pathway	CELL			English	Article							POLARITY GENE COSTAL-2; DROSOPHILA-MELANOGASTER; KINASE-A; ENGRAILED LOCUS; HOMEOTIC GENES; IMAGINAL DISKS; SEGMENT; PATTERN; TRANSDUCTION; EXPRESSION	The Hedgehog (HH) signaling proteins control cell fates and patterning during animal development. In Drosophila, HH protein induces the transcription of target genes encoding secondary signals such as DPP and WG proteins by opposing a repressor system. The repressors include Costal2, protein kinase A, and the HH receptor Patched. Like HH, the kinase Fused and the transcription factor Cubitus interruptus (CI) act positively upon targets. Here we show that costal2 encodes a kinesin-related protein that accumulates preferentially in cells capable of responding to HH. COS2 is cytoplasmic and binds microtubules. We find that CI associates with COS2 in a large protein complex, suggesting that COS2 directly controls the activity of CI.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University								Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Ashburner M., 1989, DROSOPHILA LAB HDB; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COLE DG, 1994, J BIOL CHEM, V269, P22913; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; Foe Victoria E., 1993, P149; FORBES AJ, 1993, DEVELOPMENT S, V119, P115; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GRAU Y, 1987, DEV BIOL, V122, P186, DOI 10.1016/0012-1606(87)90344-7; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Harlow E, 1988, ANTIBODIES LAB MANUA; HEITZLER P, 1993, GENETICS, V135, P105; Hepker J, 1997, DEVELOPMENT, V124, P549; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LASEK RJ, 1985, NATURE, V316, P645, DOI 10.1038/316645a0; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; LILLIE SH, 1992, NATURE, V356, P358, DOI 10.1038/356358a0; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; MATHIES LD, 1994, DEVELOPMENT, V120, P2799; MILLER KG, 1989, J CELL BIOL, V109, P2963, DOI 10.1083/jcb.109.6.2963; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PARDUE ML, 1994, METHOD CELL BIOL, V44, P333, DOI 10.1016/S0091-679X(08)60922-X; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PREAT T, 1993, GENETICS, V135, P1047; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SanchezHerrero E, 1996, MECH DEVELOP, V55, P159, DOI 10.1016/0925-4773(96)00498-4; SAXTON WM, 1994, METHOD CELL BIOL, V44, P279, DOI 10.1016/S0091-679X(08)60919-X; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIMPSON P, 1987, DEV BIOL, V122, P201, DOI 10.1016/0012-1606(87)90345-9; SLUSARSKI DC, 1995, GENETICS, V139, P229; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THEROND P, 1993, MECH DEVELOP, V44, P65, DOI 10.1016/0925-4773(93)90017-R; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; THEURKAUF WE, 1992, DEV BIOL, V154, P205, DOI 10.1016/0012-1606(92)90060-T; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; WHITTLE JRS, 1976, DEV BIOL, V51, P257, DOI 10.1016/0012-1606(76)90142-1; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818; XU T, 1994, PRACTICAL USES CELL, V44, P655; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	68	287	302	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					235	245		10.1016/S0092-8674(00)80332-3	http://dx.doi.org/10.1016/S0092-8674(00)80332-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244298	Bronze			2022-12-24	WOS:A1997XN24900008
J	Straight, AF; Marshall, WF; Sedat, JW; Murray, AW				Straight, AF; Marshall, WF; Sedat, JW; Murray, AW			Mitosis in living budding yeast: Anaphase a but no metaphase plate	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; MITOTIC SPINDLE; SEGREGATION; KINETOCHORES; CHECKPOINT; DYNAMICS; FORCES; CELLS	Chromosome movements and spindle dynamics were visualized in living cells of the budding yeast Saccharomyces cerevisiae. Individual chromosomal loci were detected by expression of a protein fusion between green fluorescent protein (GFP) and the Lac repressor, which bound to an array of Lac operator binding sites integrated into the chromosome. Spindle microtubules were detected by expression of a protein fusion between GFP and Tub1, the major alpha tubulin. Spindle elongation and chromosome separation exhibited biphasic kinetics, and centromeres separated before telomeres. Budding yeast did not exhibit a conventional metaphase chromosome alignment but did show anaphase A, movement of the chromosomes to the poles.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	Straight, AF (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHYSIOL, BOX 0444, SAN FRANCISCO, CA 94143 USA.			Straight, Aaron/0000-0001-5885-7881				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; BAJER AS, 1986, J CELL BIOL, V102, P263, DOI 10.1083/jcb.102.1.263; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Guacci V, 1997, MOL BIOL CELL, V8, P957, DOI 10.1091/mbc.8.6.957; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; MITCHISON TJ, 1988, ANNU REV CELL BIOL, V4, P527, DOI 10.1146/annurev.cb.04.110188.002523; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; NICKLAS RB, 1992, J CELL SCI, V102, P681; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; PAGE BD, 1993, ANNU REV MICROBIOL, V47, P231, DOI 10.1146/annurev.mi.47.100193.001311; PETERSON JB, 1976, J CELL SCI, V22, P219; PRASHER DC, 1995, TRENDS GENET, V11, P320, DOI 10.1016/S0168-9525(00)89090-3; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; WINEY M, 1995, J CELL BIOL, V129, P1601, DOI 10.1083/jcb.129.6.1601; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687	23	313	318	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 25	1997	277	5325					574	578		10.1126/science.277.5325.574	http://dx.doi.org/10.1126/science.277.5325.574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228009				2022-12-24	WOS:A1997XM86700054
J	Ktistaki, E; Talianidis, I				Ktistaki, E; Talianidis, I			Modulation of hepatic gene expression by hepatocyte nuclear factor 1	SCIENCE			English	Article							ENRICHED TRANSCRIPTION FACTOR; HORMONE RECEPTOR SUPERFAMILY; DNA-BINDING; FACTOR-IV; LIVER; HNF-4; APOCIII; DOMAIN; LF-B1	Hepatocyte nuclear factors 1 and 4 (HNF-1 and HNF-4) are river-enriched transcription factors that function in the regulation of several liver-specific genes. HNF-1 activates genes containing promoters with HNF-1 binding sites. However, this factor negatively regulates its own expression and that of other HNF-4-dependent genes that lack HNF-1 binding sites in their promoter region. This repression is exerted by a direct interaction of HNF-1 with AF2, the main activation domain of HNF-4. The dual functions of gene activation and repression suggest that HNF-1 is a global regulator of the transcriptional network involved in the maintenance of hepatocyte-specific phenotype.	FDN RES & TECHNOL HELLAS,INST MOL BIOL & BIOTECHNOL,IRAKLION 71110,GREECE	Foundation for Research & Technology - Hellas (FORTH)			Talianidis, Iannis/F-7556-2016	Talianidis, Iannis/0000-0002-1209-3609				BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; KRITIS AA, 1993, NUCLEIC ACIDS RES, V21, P5882, DOI 10.1093/nar/21.25.5882; Kritis AA, 1996, GENE, V173, P275, DOI 10.1016/0378-1119(96)00183-7; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; KTISTAKI E, UNPUB; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; PIAGGIO G, 1994, NUCLEIC ACIDS RES, V22, P4284, DOI 10.1093/nar/22.20.4284; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, LIVER GENE EXPRESSIO, pCH11; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TRONCHE F, 1994, LIVER GENE EXPRESSIO, pCH9; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276	25	114	115	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					109	112		10.1126/science.277.5322.109	http://dx.doi.org/10.1126/science.277.5322.109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204893				2022-12-24	WOS:A1997XJ41800051
J	Ichas, F; Jouaville, LS; Mazat, JP				Ichas, F; Jouaville, LS; Mazat, JP			Mitochondria are excitable organelles capable of generating and conveying electrical and calcium signals	CELL			English	Article							RAT-LIVER MITOCHONDRIA; ASCITES TUMOR-CELLS; PERMEABILITY TRANSITION; INOSITOL TRISPHOSPHATE; INTRACELLULAR CALCIUM; EXTRACELLULAR ATP; CA2+ TRANSIENTS; INNER MEMBRANE; TRANSPORT; RELEASE	We report Ca2+-induced release of Ca2+ from mitochondria (mCICR) dependent on transitory opening of the permeability transition pore (PTP) operating in a low conductance mode. The Ca2+ fluxes taking place during mCICR are a direct consequence of the mitochondrial depolarization spike (mDPS) caused by PTP opening. Both mDPS and mCICR can propagate from one mitochondrion to another in vitro, generating traveling depolarization and Ca2+ waves. Mitochondria thus appear to be excitable organelles capable of generating and conveying electrical and Ca2+ signals. In living cells, mDPS/mCICR is triggered during IP3-induced Ca2+ mobilization and results in the amplification of the Ca2+ signals primarily emitted from the endoplasmic reticulum.			Ichas, F (corresponding author), UNIV BORDEAUX 2,DEPT MED BIOCHEM & MOL BIOL,INTEGRATED BIOL SYST STUDY GRP,F-33076 BORDEAUX,FRANCE.		Ichas, François/ABD-8277-2020	Ichas, François/0000-0001-8184-5248				ALTSCHULD RA, 1992, AM J PHYSIOL, V262, pH1699, DOI 10.1152/ajpheart.1992.262.6.H1699; ARTALEJO AR, 1988, BIOCHIM BIOPHYS ACTA, V941, P48, DOI 10.1016/0005-2736(88)90212-X; BABCOCK DF, 1979, J BIOL CHEM, V254, P8117; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BERNARDI P, 1984, BIOCHEMISTRY-US, V23, P1645, DOI 10.1021/bi00303a010; BERNARDI P, 1996, J BIOENERG BIOMEMBR, V28, P129; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIDEN TJ, 1984, J BIOL CHEM, V261, P7223; BRARN RJ, 1994, NATURE, V371, P355; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; CASWELL AH, 1972, J MEMBRANE BIOL, V7, P345, DOI 10.1007/BF01867925; CASWELL AH, 1971, BIOCHEM BIOPH RES CO, V43, P625, DOI 10.1016/0006-291X(71)90660-7; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLL KE, 1982, J BIOL CHEM, V257, P8696; Connern CP, 1996, BIOCHEMISTRY-US, V35, P8172, DOI 10.1021/bi9525177; CROMPTON M, 1990, BIOCHEM J, V266, P33, DOI 10.1042/bj2660033; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; DIVIRGILIO F, 1990, CELL CALCIUM, V11, P57, DOI 10.1016/0143-4160(90)90059-4; DUBUY HG, 1961, SCIENCE, V133, P196, DOI 10.1126/science.133.3447.196; DUBYAK GR, 1986, ARCH BIOCHEM BIOPHYS, V245, P84, DOI 10.1016/0003-9861(86)90192-X; DUCHEN MR, 1992, BIOCHEM J, V283, P41, DOI 10.1042/bj2830041; EVTODIENKO YV, 1994, CELL CALCIUM, V15, P143, DOI 10.1016/0143-4160(94)90053-1; Evtodienko YV, 1996, FEBS LETT, V393, P86, DOI 10.1016/0014-5793(96)00875-7; FABIATO A, 1979, NATURE, V281, P146, DOI 10.1038/281146a0; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; GUNTER KK, 1994, J BIOENERG BIOMEMBR, V26, P471, DOI 10.1007/BF00762732; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; HOEK JB, 1995, BBA-MOL BASIS DIS, V1271, P93, DOI 10.1016/0925-4439(95)00015-V; HOLMUHAMEDOV EL, 1986, EUR J BIOCHEM, V158, P543, DOI 10.1111/j.1432-1033.1986.tb09788.x; HOLMUHAMEDOV EL, 1995, BIOCHEM MOL BIOL INT, V36, P39; ICHAS F, 1994, FEBS LETT, V348, P211, DOI 10.1016/0014-5793(94)00615-6; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; IGBAVBOA U, 1991, BIOCHIM BIOPHYS ACTA, V1059, P339, DOI 10.1016/S0005-2728(05)80219-1; IKEDA K, 1993, HEARING RES, V66, P169, DOI 10.1016/0378-5955(93)90138-Q; JOUAVILLE LS, 1995, NATURE, V377, P348; KIM JV, 1984, CELL CALCIUM, V5, P29, DOI 10.1016/0143-4160(84)90152-0; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; LUTHRA R, 1976, BIOCHIM BIOPHYS ACTA, V440, P744, DOI 10.1016/0005-2728(76)90056-6; LUVISETTO S, 1991, EUR J BIOCHEM, V202, P121, DOI 10.1111/j.1432-1033.1991.tb16352.x; MASSARI S, 1972, J MEMBRANE BIOL, V9, P57, DOI 10.1007/BF01868043; Massari S, 1996, J BIOL CHEM, V271, P31942; MIYAZAKI S, 1995, CURR OPIN CELL BIOL, V7, P190, DOI 10.1016/0955-0674(95)80027-1; MOLLER IM, 1986, BIOCHEM J, V237, P765, DOI 10.1042/bj2370765; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; Nicholls D.G., 1982, BIOENERGETICS INTRO; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; PUSKIN JS, 1973, BIOCHEM BIOPH RES CO, V51, P797, DOI 10.1016/0006-291X(73)91385-5; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RUSTENBECK I, 1993, BIOCHEM BIOPH RES CO, V194, P1261, DOI 10.1006/bbrc.1993.1959; SCHONFELD P, 1992, FEBS LETT, V304, P273, DOI 10.1016/0014-5793(92)80636-U; SCHUSTER SM, 1974, J BIOL CHEM, V249, P7151; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; TEDESCHI H, 1955, ARCH BIOCHEM BIOPHYS, V58, P52, DOI 10.1016/0003-9861(55)90092-8; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; WINGROVE DE, 1984, J BIOL CHEM, V259, P9390; WISE D, 1984, CHROMOSOMA, V90, P156, DOI 10.1007/BF00292453; ZAMZAMI N, 1996, J EXP MED, V183, P1633; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	68	622	643	4	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1145	1153		10.1016/S0092-8674(00)80301-3	http://dx.doi.org/10.1016/S0092-8674(00)80301-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215636	Bronze			2022-12-24	WOS:A1997XG83000018
J	Krasnopolsky, VA; Mumma, MJ; Abbott, M; Flynn, BC; Meech, KJ; Yeomans, BK; Feldman, PD; Cosmovici, CB				Krasnopolsky, VA; Mumma, MJ; Abbott, M; Flynn, BC; Meech, KJ; Yeomans, BK; Feldman, PD; Cosmovici, CB			Detection of soft x-rays and a sensitive search for noble gases in comet Hale-Bopp (C/1995 O1)	SCIENCE			English	Article							ONE-ELECTRON CAPTURE; CROSS-SECTIONS; B2 HYAKUTAKE; P/HALLEY; COLLISIONS; IONS; EVOLUTION; HELIUM; SOLAR; EUVE	An image of comet Hale-Bopp (C/1995 O1) in soft x-rays reveals a central emission offset from the nucleus, as well as an extended emission feature that does not correlate with the dust jets seen at optical wavelengths, Neon was found to be depleted in the cometary ice by more than a factor of 25 relative to solar abundance, which suggests that ices in Hale-Bopp formed at (or later experienced) temperatures higher than 25 kelvin, A helium line emission at a wavelength of 584 angstroms was detected and may be attributable to charge transfer of solar wind alpha particles in the cometary coma, Ionized oxygen and another helium line contribute to an emission observed at 538 angstroms.	NASA, GODDARD SPACE FLIGHT CTR, GREENBELT, MD 20771 USA; UNIV CALIF BERKELEY, CTR EXTREME ULTRAVIOLET ASTROPHYS, BERKELEY, CA 94720 USA; UNIV HAWAII, INST ASTRON, HONOLULU, HI 96822 USA; CALTECH, JET PROP LAB, PASADENA, CA 91109 USA; JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA; CNR, IST FIS SPAZIO INTERPLANETARIO, I-00044 FRASCATI, ITALY	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of California System; University of California Berkeley; University of Hawaii System; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Johns Hopkins University; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale Astrofisica (INAF)	Krasnopolsky, VA (corresponding author), CATHOLIC UNIV AMER, WASHINGTON, DC 20064 USA.		Krasnopolsky, Vladimir/L-5085-2013; Meech, Karen/CAH-1412-2022; mumma, michael j/I-2764-2013; Flynn, Brigid/ABC-2003-2021	mumma, michael j/0000-0003-4627-750X; Flynn, Brigid/0000-0002-9329-724X				Abbott MJ, 1996, ASTROPHYS J SUPPL S, V107, P451, DOI 10.1086/192371; AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; AHEARN MF, 1984, ASTRON J, V89, P579, DOI 10.1086/113552; ALTWEGG K, 1993, ASTRON ASTROPHYS, V279, P260; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BARNUN A, 1988, ASTROPHYS J, V324, pL31, DOI 10.1086/185084; Bingham R, 1997, SCIENCE, V275, P49, DOI 10.1126/science.275.5296.49; Biver N, 1997, SCIENCE, V275, P1915, DOI 10.1126/science.275.5308.1915; Bowyer S., 1991, EXTREME ULTRAVIOLET, P397; BREKKE P, 1993, ASTROPHYS J, V408, P735, DOI 10.1086/172633; CHAKRABARTI S, 1983, J GEOPHYS RES-SPACE, V88, P4898, DOI 10.1029/JA088iA06p04898; Cravens TE, 1997, GEOPHYS RES LETT, V24, P105, DOI 10.1029/96GL03780; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; DIJKKAMP D, 1985, J PHYS B-AT MOL OPT, V18, P737, DOI 10.1088/0022-3700/18/4/018; FELDMAN PD, 1991, ASTROPHYS J, V379, pL37, DOI 10.1086/186148; FELDMAN PD, 1987, ASTRON ASTROPHYS, V187, P325; GLADSTONE GR, 1994, GEOPHYS RES LETT, V21, P461, DOI 10.1029/93GL03290; GLADSTONE GR, 1995, SCIENCE, V268, P1595, DOI 10.1126/science.268.5217.1595; GOLDSTEIN BE, 1987, ASTRON ASTROPHYS, V187, P174; GRINGAUZ KI, 1990, COMET HALLEY INVESTI, P147; Haberli RM, 1997, SCIENCE, V276, P939, DOI 10.1126/science.276.5314.939; HODGKINSON JM, 1995, J PHYS B-AT MOL OPT, V28, pL393, DOI 10.1088/0953-4075/28/12/001; JANEV RK, 1988, ATOM DATA NUCL DATA, V40, P249, DOI 10.1016/0092-640X(88)90008-3; JESSBERGER EK, 1991, ASTROPHYS SPACE SC L, V167, P1075, DOI 10.1017/S0252921100012823; KELLY RL, 1987, J PHYS CHEM REF DATA, V16, P1; Krasnopolsky V, 1997, ICARUS, V128, P368, DOI 10.1006/icar.1997.5722; Krasnopolsky V, 1997, PHYS WORLD, V10, P21; KRASNOPOLSKY VA, 1991, ASTRON ASTROPHYS, V245, P662; KRASNOPOLSKY VA, 1994, ICARUS, V109, P337, DOI 10.1006/icar.1994.1098; Krasnopolsky VA, 1996, J GEOPHYS RES-SPACE, V101, P15765, DOI 10.1029/96JA01080; KRASNOPOLSKY VA, 1996, B AM ASTRON SOC, V28, P1095; LIDE DR, 1995, CRC HDB CHEM PHYSICS; Lisse CM, 1996, SCIENCE, V274, P205, DOI 10.1126/science.274.5285.205; MCCULLOUGH RW, 1992, J PHYS B-AT MOL OPT, V25, pL193, DOI 10.1088/0953-4075/25/7/007; MCDONALD K, 1994, ASTRON J, V108, P1843, DOI 10.1086/117197; MEIER RR, 1991, SPACE SCI REV, V58, P1, DOI 10.1007/BF01206000; Millis R.L., 1996, B AM ASTRON SOC, V28, P1095; Mumma MJ, 1996, SCIENCE, V272, P1310, DOI 10.1126/science.272.5266.1310; MUMMA MJ, 1993, PROTOSTARS PLANETS, V3, P1172; MUMMA MJ, 1997, 6696 IAU; Northrop TG, 1997, ICARUS, V127, P246, DOI 10.1006/icar.1997.5694; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; Rauer H, 1997, SCIENCE, V275, P1909, DOI 10.1126/science.275.5308.1909; RICHARDS PG, 1994, J GEOPHYS RES-SPACE, V99, P8981, DOI 10.1029/94JA00518; RYUFUKU H, 1980, PHYS REV A, V21, P745, DOI 10.1103/PhysRevA.21.745; Safronov V S., 1969, EVOLUTION PROTOPLANE; Safronov V.S., 1972, EVOLUTION PROTOPLANE; Schleicher DG, 1997, SCIENCE, V275, P1913, DOI 10.1126/science.275.5308.1913; SHAH MB, 1974, J PHYS B-AT MOL OPT, V7, P256, DOI 10.1088/0022-3700/7/2/011; STERN SA, 1992, ICARUS, V95, P157, DOI 10.1016/0019-1035(92)90198-G; STEWART AIF, 1987, ASTRON ASTROPHYS, V187, P369; VEMAZZA JE, 1978, ASTROPHYS J SUPPL SE, V37, P485; Weaver HA, 1997, SCIENCE, V275, P1900, DOI 10.1126/science.275.5308.1900; WEAVER HA, 1987, ASTRON ASTROPHYS, V187, P411; Wickramasinghe NC, 1996, ASTROPHYS SPACE SCI, V239, P121, DOI 10.1007/BF00653772	55	93	93	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1488	1491		10.1126/science.277.5331.1488	http://dx.doi.org/10.1126/science.277.5331.1488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278508	Green Submitted			2022-12-24	WOS:A1997XV42900035
J	Cornwall, J				Cornwall, J			Tuberculosis: a clinical problem of international importance	LANCET			English	Article																			0	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					660	661		10.1016/S0140-6736(96)12039-0	http://dx.doi.org/10.1016/S0140-6736(96)12039-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288062				2022-12-24	WOS:A1997XU28300044
J	Raviglione, MC; Dye, C; Schmidt, S; Kochi, A				Raviglione, MC; Dye, C; Schmidt, S; Kochi, A			Assessment of worldwide tuberculosis control	LANCET			English	Article							UNITED-STATES; EPIDEMIOLOGY; TRENDS; EUROPE	Background Because worldwide tuberculosis (TB) control had never been assessed, WHO set up a surveillance and monitoring project in 1995. The objectives were to assess the performance of national TB programmes; to assess the extent of implementation of the WHO strategy of TB control; and to attempt a comparison between regions that had adopted the WHO strategy and those that had not. Methods In June, 1996, we sent data-collection forms requesting information on national TB programmes' control policies, 1995 case treatment results to 216 territories. We assessed the performance of national TB programmes by comparing case notifications with estimated incidence and by outcome of treatment in cohorts of patients. We also investigated worldwide treatment success and case detection among sputum-smear-positive patients. Findings 180 (83%) of the 216 countries, areas, and replied to WHO (98% of the In 1995, the WHO control strategy had been implemented in 75 countries, and in 39 of these implementation was countrywide. Up to 23% of the worldwide population lived in regions where the strategy was available. In 1995, 3 297 688 cases of TB (all types) were reported, of which 1 161 411 (35%) were sputum-smear positive. 54% of all reported cases in countries that used the WHO strategy were sputum-smear positive, compared with 30% in other countries. The worldwide case-detection rate of new sputum-smear-positive cases was 35%. 92% of cases registered for treatment in 1994 in regions that used WHO strategy were assessed for outcome and 76% were treated successfully, compared with 54% and 42%, respectively, in regions that had not implemented the WHO strategy. Among cases reported worldwide in 1994, the documented treatment-success rate was 43%. Interpretation National TB programmes that have control adopted the WHO TB strategy achieve higher cure rates, but their impact on TB is modest on a worldwide scale. Wider continuous coverage with the WHO strategy is needed for effective worldwide TB control.			Raviglione, MC (corresponding author), WHO, GLOBAL TB PROGRAMME, 20 AVE APPIA, CH-1211 GENEVA 27, SWITZERLAND.		Dye, Christopher/AIC-4659-2022	Dye, Christopher/0000-0002-2957-1793; RAVIGLIONE, Mario/0000-0002-9331-2067				CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; Enarson D A, 1991, Bull Int Union Tuberc Lung Dis, V66, P195; Harries AD, 1996, LANCET, V347, P807, DOI 10.1016/S0140-6736(96)90874-0; Jain NK, 1992, IND J TUBERC, V92, P145; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; *NAT TUB I, 1974, B WORLD HEALTH ORGAN, V51, P473; RAVIGLIONE MC, 1994, TUBERCLE LUNG DIS, V75, P400, DOI 10.1016/0962-8479(94)90113-9; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; SPRINGETT V H, 1971, Tubercle, V52, P73, DOI 10.1016/0041-3879(71)90015-8; SRYBLO K, 1989, REV INFECT DIS S2, V11, pS339; Styblo K., 1985, B INT UNION TUBERC, V60, P117; UPLEKAR MW, 1993, TUBERCLE LUNG DIS, V74, P332, DOI 10.1016/0962-8479(93)90108-A; *WHO, 1997, WHOTB97225; *WHO, 1991, 44WORLD HLTH ASS GEN; World Bank, 2013, WOR DEV REP, P1, DOI 10.1596/978-0-8213-9575-2; World Health Organization, 1994, WHOTB94179; Yanai H, 1996, AIDS, V10, P527, DOI 10.1097/00002030-199605000-00012; Zhao FZ, 1996, LANCET, V347, P358, DOI 10.1016/S0140-6736(96)90537-1	22	153	158	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	1997	350	9078					624	629		10.1016/S0140-6736(97)04146-9	http://dx.doi.org/10.1016/S0140-6736(97)04146-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288045				2022-12-24	WOS:A1997XU28300010
J	Lodmell, JS; Dahlberg, AE				Lodmell, JS; Dahlberg, AE			A conformational switch in Escherichia coli 16S ribosomal RNA during decoding of messenger RNA	SCIENCE			English	Article							DIRECTED CROSS-LINKING; AFFECT TRANSLATIONAL FIDELITY; HIGHER-ORDER STRUCTURE; SECONDARY STRUCTURE; 30S SUBUNIT; A-SITE; P-SITE; REGION; BINDING; INITIATION	Direct evidence is presented for a conformational switch in 16S ribosomal RNA (rRNA) that affects tRNA binding to the ribosome and decoding of messenger RNA (mRNA). These data support the hypothesis that dynamic changes in rRNA structure occur during translation. The switch involves two alternating base-paired arrangements apparently facilitated by ribosomal proteins S5 and S12, and produces significant changes in the rRNA structure, Chemical probing shows reciprocal enhancements or protections at sites in 16S rRNA that are at or very near sites that were previously crosslinked to mRNA. These data indicate that the switch affects codon-anticodon arrangement acid proper selection of tRNA at the ribosomal A site, and that the switch is a fundamental mechanism in all ribosomes.	BROWN UNIV, DEPT MOL & CELL BIOL & BIOCHEM, PROVIDENCE, RI 02912 USA	Brown University					NIGMS NIH HHS [GM19756, GM07601] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABAD JP, 1994, J MOL BIOL, V235, P1251, DOI 10.1006/jmbi.1994.1078; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; ALLEN PN, 1989, J MOL BIOL, V208, P457, DOI 10.1016/0022-2836(89)90509-3; ANDERSSON DI, 1982, MOL GEN GENET, V187, P467, DOI 10.1007/BF00332630; ANDERSSON DI, 1986, BIOCHIMIE, V68, P705, DOI 10.1016/S0300-9084(86)80164-X; BILGIN N, 1990, EMBO J, V9, P735, DOI 10.1002/j.1460-2075.1990.tb08167.x; BOHMAN K, 1984, MOL GEN GENET, V198, P90, DOI 10.1007/BF00328706; BRAKIERGINGRAS L, COMMUNICATION; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BRINK MF, 1993, EMBO J, V12, P3987, DOI 10.1002/j.1460-2075.1993.tb06076.x; CALOGERO RA, 1988, P NATL ACAD SCI USA, V85, P6427, DOI 10.1073/pnas.85.17.6427; CHERNOFF YO, 1994, EMBO J, V13, P906, DOI 10.1002/j.1460-2075.1994.tb06334.x; CURRAN JF, 1989, J MOL BIOL, V209, P65, DOI 10.1016/0022-2836(89)90170-8; DAMMEL CS, 1993, GENE DEV, V7, P660, DOI 10.1101/gad.7.4.660; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; Ehrenberg M, 1995, BIOCHEM CELL BIOL, V73, P1049, DOI 10.1139/o95-112; EHRESMANN C, 1986, NUCLEIC ACIDS RES, V14, P4803, DOI 10.1093/nar/14.12.4803; ERICSON G, 1995, J MOL BIOL, V250, P407, DOI 10.1006/jmbi.1995.0386; GESTELAND RF, 1993, RNA WORLD; GLOTZ C, 1980, NUCLEIC ACIDS RES, V8, P2377, DOI 10.1093/nar/8.11.2377; Gorini L., 1974, RIBOSOMES; GRAVEL M, 1987, BIOCHEMISTRY-US, V26, P6227, DOI 10.1021/bi00393a041; GUTELL RR, 1994, MICROBIOL REV, V58, P10, DOI 10.1128/MMBR.58.1.10-26.1994; Heilek GM, 1996, SCIENCE, V272, P1659, DOI 10.1126/science.272.5268.1659; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HUI A, 1987, P NATL ACAD SCI USA, V84, P4762, DOI 10.1073/pnas.84.14.4762; JACOB WF, 1987, P NATL ACAD SCI USA, V84, P4757, DOI 10.1073/pnas.84.14.4757; Karimi R, 1996, EMBO J, V15, P1149, DOI 10.1002/j.1460-2075.1996.tb00453.x; KURLAND CG, 1990, RIBOSOME, P513; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; LATEANA A, 1995, RNA, V1, P772; LAUGHREA M, 1992, BIOCHEMISTRY-US, V31, P12035, DOI 10.1021/bi00163a011; Liebman Stuart., COMMUNICATION; LODMELL JS, 1995, P NATL ACAD SCI USA, V92, P10555, DOI 10.1073/pnas.92.23.10555; LODMELL JS, 1993, BIOCHEMISTRY-US, V32, P4067, DOI 10.1021/bi00066a030; LODMELL JS, UNPUB; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1986, J MOL BIOL, V191, P483, DOI 10.1016/0022-2836(86)90143-9; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1996, RIBOSOMAL RNA STRUCT, P239; OCONNOR M, 1992, NUCLEIC ACIDS RES, V20, P4221, DOI 10.1093/nar/20.16.4221; OCONNOR M, 1993, P NATL ACAD SCI USA, V90, P9214, DOI 10.1073/pnas.90.19.9214; POWERS T, 1991, EMBO J, V10, P2203, DOI 10.1002/j.1460-2075.1991.tb07756.x; POWERS T, 1995, RNA, V1, P194; PUROHIT P, 1994, NATURE, V370, P659, DOI 10.1038/370659a0; RHEINBERGER HJ, 1983, EUR J BIOCHEM, V134, P421, DOI 10.1111/j.1432-1033.1983.tb07584.x; RINKEAPPEL J, 1994, NUCLEIC ACIDS RES, V22, P3018, DOI 10.1093/nar/22.15.3018; RINKEAPPEL J, 1993, NUCLEIC ACIDS RES, V21, P2853, DOI 10.1093/nar/21.12.2853; Rodnina MV, 1995, BIOCHEM CELL BIOL, V73, P1221, DOI 10.1139/o95-132; Sergiev PV, 1997, RNA, V3, P464; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SIPLEY J, 1993, P NATL ACAD SCI USA, V90, P2315, DOI 10.1073/pnas.90.6.2315; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; TRIMAN K, 1989, J MOL BIOL, V209, P645, DOI 10.1016/0022-2836(89)92000-7; VandePeer Y, 1996, NUCLEIC ACIDS RES, V24, P86, DOI 10.1093/nar/24.1.86; VANRYK DI, 1995, NUCLEIC ACIDS RES, V23, P3563, DOI 10.1093/nar/23.17.3563; VILA A, 1994, P NATL ACAD SCI USA, V91, P11148, DOI 10.1073/pnas.91.23.11148; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WATANABE S, 1972, J MOL BIOL, V67, P443, DOI 10.1016/0022-2836(72)90462-7; WELLER JW, 1992, BIOCHEMISTRY-US, V31, P2748, DOI 10.1021/bi00125a015; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; ZAMIR A, 1971, J MOL BIOL, V60, P347, DOI 10.1016/0022-2836(71)90299-3; ZIMMERMANN RA, 1996, RIBOSOMAL RNA STRUCT, P277	67	183	192	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	1997	277	5330					1262	1267		10.1126/science.277.5330.1262	http://dx.doi.org/10.1126/science.277.5330.1262			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT827	9271564				2022-12-24	WOS:A1997XT82700043
J	Cabral, JHM; Jackson, AP; Smith, CV; Shikotra, N; Maxwell, A; Liddington, RC				Cabral, JHM; Jackson, AP; Smith, CV; Shikotra, N; Maxwell, A; Liddington, RC			Crystal structure of the breakage-reunion domain of DNA gyrase	NATURE			English	Article							A PROTEIN; COMPLEX; TOPOISOMERASE; TRANSPORT; GRAPHICS; PROGRAM	DNA gyrase is a type II DNA topoisomerase from bacteria that introduces supercoils into DNA(1,2). It catalyses the breakage of a DNA duplex (the G segment), the passage of another segment (the T segment) through the break, and then the reunification of the break. This activity involves the opening and dosing of a series of molecular 'gates' which is coupled to ATP hydrolysis. Here we present the crystal structure of the 'breakage-reunion' domain of the gyrase at 2.8 Angstrom resolution. Comparison of the structure of this 59K (relative molecular mass, 59,000) domain with that of a 92K fragment of yeast topoisomerase II (ref. 3) reveals a very different quaternary organization, and we propose that the two structures represent two principal conformations that participate in the enzymatic pathway. The gyrase structure reveals a new dimer contact with a grooved concave surface for binding the G segment and a duster of conserved charged residues surrounding the active-site tyrosines. It also shows how breakage of the G segment can occur and, together with the topoisomerase II structure, suggests a pathway by which the T segment can be released through the second gate of the enzyme. Mutations that confer resistance to the quinolone antibacterial agents cluster at the new dimer interface, indicating how these drugs might interact with the gyrase-DNA complex.	UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, LEICS, ENGLAND	University of Leicester			Morais-Cabral, Joao H/J-4914-2013	Morais-Cabral, Joao H/0000-0002-4461-9716; Maxwell, Anthony/0000-0002-5756-6430				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Caron P R, 1994, Adv Pharmacol, V29B, P271; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUEGER S, 1990, J MOL BIOL, V211, P211, DOI 10.1016/0022-2836(90)90021-D; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nicholls A., 1992, GRASP GRAPHICAL REPR; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; REECE RJ, 1991, J BIOL CHEM, V266, P3540; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; Wigley D.B., 1995, NUCL ACIDS MOL BIOL, P165; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126	22	382	388	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	1997	388	6645					903	906		10.1038/42294	http://dx.doi.org/10.1038/42294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278055	Bronze			2022-12-24	WOS:A1997XT75400056
J	Severin, FF; Sorger, PK; Hyman, AA				Severin, FF; Sorger, PK; Hyman, AA			Kinetochores distinguish GTP from GDP forms of the microtubule lattice	NATURE			English	Article							SLOWLY HYDROLYZABLE ANALOG; NEWT LUNG-CELLS; DYNAMIC INSTABILITY; BUDDING YEAST; MITOTIC SPINDLE; PROTEIN COMPLEX; LIVING CELLS; IN-VITRO; CENTROMERE; HYDROLYSIS	During prometaphase in mitotic cell division, chromosomes attach to the walls of microtubules and subsequently move to microtubule ends, where they stay throughout mitosis(1,2). This end-attachment seems to be essential for correct chromosome segregating. However, the mechanism by which kinetochores, the multiprotein complexes that link chromosomes to the microtubules of the mitotic spindle(3,4), recognize and stay attached to microtubule ends is not understood. One due comes from the hydrolysis of GTP that occurs during microtubule polymerization. Although tubulin dimers must contain GTP to polymerize, this GTP is rapidly hydrolysed following the addition of dimers to a growing polymer. This creates a microtubule consisting largely of GDP-tubulin, with a small cap of GTP-tubulin at the ends. It is possible that kinetochores distinguish the different structural states of a GTP-versus a GDP-microtubule lattice, We have examined this question in vitro using reconstituted kinetochores from the yeast Saccharomyces cerevisiae. We found that kinetochores in vitro bind preferentially to GTP-rather than GDP-microtubules, and to the plus-end preferentially over the lattice. Our results could explain how kinetochores stay at microtubule ends and thus segregate chromosomes correctly during mitosis in vivo. This result demonstrates that proteins exist that can distinguish the GTP conformation of the microtubule lattice.	EUROPEAN MOL BIOL LAB, D-69012 HEIDELBERG, GERMANY; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	European Molecular Biology Laboratory (EMBL); Massachusetts Institute of Technology (MIT)			Severin, Fedor/AAD-5444-2019; Hyman, Anthony A/B-3917-2017; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; Sorger, Peter/0000-0002-3364-1838; Severin, Fedor/0000-0001-6703-1256				ARNAL I, 1995, CURR BIOL, V5, P900, DOI 10.1016/S0960-9822(95)00180-1; BAILEY NTJ, 1995, STATISTICAL METHODS; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BLOOM K, 1993, CELL, V73, P621, DOI 10.1016/0092-8674(93)90242-I; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; EARNSHAW W C, 1992, Current Opinion in Cell Biology, V4, P86, DOI 10.1016/0955-0674(92)90063-I; HUITOREL P, 1988, J CELL BIOL, V106, P151, DOI 10.1083/jcb.106.1.151; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; JIANG WD, 1993, J CELL BIOL, V121, P513, DOI 10.1083/jcb.121.3.513; KINGSBURY J, 1991, CELL, V66, P483, DOI 10.1016/0092-8674(81)90012-X; KINGSBURY J, 1993, MOL BIOL CELL, V4, P859, DOI 10.1091/mbc.4.8.859; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; MCINTOSH JR, 1984, J CELL BIOL, V98, P525, DOI 10.1083/jcb.98.2.525; MILLER JM, 1990, J CELL BIOL, V110, P703, DOI 10.1083/jcb.110.3.703; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; OBRIEN ET, 1987, BIOCHEMISTRY-US, V26, P4148, DOI 10.1021/bi00387a061; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SCHILSTRA MJ, 1987, BIOCHEM BIOPH RES CO, V147, P588, DOI 10.1016/0006-291X(87)90971-5; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; SORGER PK, 1994, J CELL BIOL, V127, P995, DOI 10.1083/jcb.127.4.995; STEWART RJ, 1990, BIOCHEMISTRY-US, V29, P6489, DOI 10.1021/bi00479a022; STRUNNIKOV AV, 1995, J CELL BIOL, V128, P749, DOI 10.1083/jcb.128.5.749; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WANG W, 1993, J BIOL CHEM, V268, P24796	31	41	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	1997	388	6645					888	891		10.1038/42270	http://dx.doi.org/10.1038/42270			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278051	Bronze			2022-12-24	WOS:A1997XT75400052
J	Kerneis, S; Bogdanova, A; Kraehenbuhl, JP; Pringault, E				Kerneis, S; Bogdanova, A; Kraehenbuhl, JP; Pringault, E			Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria	SCIENCE			English	Article							VIBRIO-CHOLERAE; EXPRESSION; BINDING; CACO-2; VILLIN; MODEL; LINE	The epithelium that lines the gut is impermeable to macromolecules and microorganisms, except in Peyer's patches (PPs), where the lymphoid follicle-associated epithelium (FAE) contains M cells that transport antigens and microorganisms. A cultured system that reproduces the main characteristics of FAE and M cells was established by cultivation of PP lymphocytes with the differentiated human intestinal cell line Caco-2. Lymphocytes settled into the epithelial monolayer, inducing reorganization of the brush border and a temperature-dependent transport of particles and Vibrio cholerae. This model system could prove useful for intestinal physiology, vaccine research, and drug delivery studies.	UNIV LAUSANNE, INST BIOCHEM, CH-1066 EPALINGES, SWITZERLAND; UNIV LAUSANNE, SWISS INST EXPT CANC RES, CH-1066 EPALINGES, SWITZERLAND	University of Lausanne; Swiss Institute Experimental Cancer Research; University of Lausanne								Bens M, 1996, AM J PHYSIOL-CELL PH, V270, pC1666, DOI 10.1152/ajpcell.1996.270.6.C1666; Bienenstock J., 1994, HDB MUCOSAL IMMUNOLO, P403; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DANIELSEN EM, 1994, BIOCHEMISTRY-US, V33, P1599, DOI 10.1021/bi00172a041; DEBEAUREGARD MAC, 1995, EMBO J, V14, P409, DOI 10.1002/j.1460-2075.1995.tb07017.x; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; FREEMAN TC, 1995, PFLUG ARCH EUR J PHY, V430, P394, DOI 10.1007/BF00373915; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; KAOUTZANI P, 1994, J CLIN INVEST, V94, P788, DOI 10.1172/JCI117398; KEMEIS S, UNPUB; Kerneis S, 1996, GASTROENTEROLOGY, V110, P515, DOI 10.1053/gast.1996.v110.pm8566599; KRAEHENBUHL JP, UNPUB; MACDONALD TT, 1982, IMMUNOLOGY, V45, P769; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; OWEN RL, 1983, AM J ANAT, V168, P199, DOI 10.1002/aja.1001680207; OWEN RL, 1986, J INFECT DIS, V153, P1108, DOI 10.1093/infdis/153.6.1108; PANIGRAHI P, 1990, INFECT IMMUN, V58, P3415, DOI 10.1128/IAI.58.10.3415-3424.1990; PAPPO J, 1989, CLIN EXP IMMUNOL, V76, P144; PINTO M, 1983, BIOL CELL, V47, P323; SAVIDGE TC, 1994, PFLUG ARCH EUR J PHY, V428, P391, DOI 10.1007/BF00724523; SAVIDGE TC, 1995, ADV EXP MED BIOL, V371, P239; Siebers A, 1996, TRENDS MICROBIOL, V4, P22, DOI 10.1016/0966-842X(96)81501-0; SMITH MW, 1985, J CELL PHYSIOL, V124, P219, DOI 10.1002/jcp.1041240208	24	490	509	5	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					949	952		10.1126/science.277.5328.949	http://dx.doi.org/10.1126/science.277.5328.949			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252325				2022-12-24	WOS:A1997XQ98500040
J	CourtoisCoutry, N; Roush, D; Rajendran, V; McCarthy, JB; Geibel, J; Kashgarian, M; Caplan, MJ				CourtoisCoutry, N; Roush, D; Rajendran, V; McCarthy, JB; Geibel, J; Kashgarian, M; Caplan, MJ			A tyrosine-based signal targets H/K-ATPase to a regulated compartment and is required for the cessation of gastric acid secretion	CELL			English	Article							HELICOBACTER-PYLORI; MENETRIERS DISEASE; HYPERTROPHIC GASTROPATHY; PARIETAL-CELLS; TRANSFERRIN RECEPTOR; NATURAL-HISTORY; TRANSGENIC MICE; ENDOCYTOSIS; INTERNALIZATION; IDENTIFICATION	Gastric acid secretion is mediated by the H/K-ATPase of parietal cells. Activation of acid secretion involves insertion of H/K-ATPase into the parietal cell plasmalemma, while its cessation is associated with reinternalization of the H/K-ATPase into an intracellular storage compartment The cytoplasmic tail of the H/K-ATPase beta subunit includes a four residue sequence homologous to tyrosine-based endocytosis signals. We generated transgenic mice expressing H/K-ATPase beta subunit in which this motif's tyrosine residue is mutated to alanine. Gastric glands from animals expressing mutant beta subunit constitutively secrete acid and continuously express H/K-ATPase at their cell surfaces. Thus, the beta subunit's tyrosine-based signal is required for the internalization of H/K-ATPase and for the termination of acid secretion. As a consequence of chronic hyperacidity, the mice develop gastric ulcers and a hypertrophic gastropathy resembling Menetrier's disease.	YALE UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT SURG,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University			COUTRY, Nathalie/O-9352-2017	COUTRY, Nathalie/0000-0001-5830-4013; Caplan, Michael/0000-0001-5768-4405				[Anonymous], 1993, Gut, V34, P1672; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAYERDORFFER E, 1993, NEW ENGL J MED, V329, P60, DOI 10.1056/NEJM199307013290116; BAYERDORFFER E, 1994, GUT, V35, P701, DOI 10.1136/gut.35.5.701; BERGLINDH T, 1980, AM J PHYSIOL, V238, pG165, DOI 10.1152/ajpgi.1980.238.3.G165; BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J; BLASER MJ, 1994, J CLIN INVEST, V94, P4, DOI 10.1172/JCI117336; BLASER MJ, 1987, GASTROENTEROLOGY, V93, P371, DOI 10.1016/0016-5085(87)91028-6; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CHEW CS, 1986, AM J PHYSIOL, V250, pG814, DOI 10.1152/ajpgi.1986.250.6.G814; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS JM, 1977, ANN SURG, V185, P456, DOI 10.1097/00000658-197704000-00015; FORTE TM, 1977, GASTROENTEROLOGY, V73, P941; Fox JG, 1996, GASTROENTEROLOGY, V110, P155, DOI 10.1053/gast.1996.v110.pm8536852; FRANK BW, 1967, GASTROENTEROLOGY, V53, P953; GEIBEL J, 1995, GASTROENTEROLOGY, V109, P1060, DOI 10.1016/0016-5085(95)90563-4; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HERSEY SJ, 1995, PHYSIOL REV, V75, P155, DOI 10.1152/physrev.1995.75.1.155; Hogan B., 1986, MANIPULATING MOUSE E; KIRKPATRICK PM, 1980, GASTROENTEROLOGY, V79, P4; KLAASSEN CHW, 1994, CELL PHYSIOL BIOCHEM, V4, P115, DOI 10.1159/000154716; KOTHARY R, 1991, MECH DEVELOP, V35, P25, DOI 10.1016/0925-4773(91)90038-8; LENCER WI, 1990, J CELL BIOL, V111, P379, DOI 10.1083/jcb.111.2.379; Menetrier P, 1888, ARCH PHYSL NORM PATH, V1, P32; Menetrier P, 1888, ARCH PHYSL NORM PATH, V1, P236; MERCIER F, 1989, J CELL BIOL, V108, P441, DOI 10.1083/jcb.108.2.441; Murer H, 1996, ANNU REV PHYSIOL, V58, P607, DOI 10.1146/annurev.physiol.58.1.607; PETTITT JM, 1995, J CELL SCI, V108, P1127; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SCHARSCHMIDT BF, 1977, AM J MED, V63, P644, DOI 10.1016/0002-9343(77)90210-8; SCHMIDT EV, 1990, MOL CELL BIOL, V10, P4406, DOI 10.1128/MCB.10.8.4406; SCHOFIELD GC, 1979, J ANAT, V128, P669; SCHWARTZ GJ, 1986, ANNU REV PHYSIOL, V48, P153; STOLTE M, 1993, Z GASTROENTEROL, V31, P289; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; Wang L, 1996, AM J PHYSIOL-GASTR L, V271, pG613, DOI 10.1152/ajpgi.1996.271.4.G613; WOLFSEN HC, 1993, GASTROENTEROLOGY, V104, P1310, DOI 10.1016/0016-5085(93)90339-E; ZOLLINGER RM, 1955, ANN SURG, V142, P709, DOI 10.1097/00000658-195510000-00015	44	94	98	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					501	510		10.1016/S0092-8674(00)80510-3	http://dx.doi.org/10.1016/S0092-8674(00)80510-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267030	hybrid			2022-12-24	WOS:A1997XQ06300014
J	Domian, IJ; Quon, KC; Shapiro, L				Domian, IJ; Quon, KC; Shapiro, L			Cell type-specific phosphorylation and proteolysis of a transcriptional regulator controls the G1-to-S transition in a bacterial cell cycle	CELL			English	Article							HISTIDINE PROTEIN-KINASE; CAULOBACTER-CRESCENTUS; ESCHERICHIA-COLI; CHROMOSOMAL ORIGIN; DNA-REPLICATION; GENE-EXPRESSION; ACTIVATOR; DIVISION; SITE; DIFFERENTIATION	The global transcriptional regulator CtrA controls multiple events in the Caulobacter cell cycle, including the initiation of DNA replication, DNA methylation, cell division, and flagellar biogenesis. CtrA is a member of the response regulator family of two component signal transduction systems and is activated by phosphorylation. We report here that this phosphorylation signal enters the cell cycle at mid S phase. In addition, CtrA function is modulated by temporally and spatially controlled proteolysis. When an active CtrA protein is present at the wrong time in the cell cycle, owing to expression of a mutant CtrA derivative that is active in the absence of phosphorylation and is not turned over during the cell cycle, the G1-to-S transition is blocked and the cell cycle aborts. Thus, both phosphorylation and proteolysis are critical determinants of bacterial cell cycle control in a manner that is analogous to the control of the eukaryotic cell cycle.			Domian, IJ (corresponding author), STANFORD UNIV, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032506, R37GM032506] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51426, GM32506/5120MZ] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alex LA, 1996, P NATL ACAD SCI USA, V93, P3416, DOI 10.1073/pnas.93.8.3416; ALLEY MRK, 1993, SCIENCE, V259, P1754, DOI 10.1126/science.8456303; BENSON AK, 1994, P NATL ACAD SCI USA, V91, P4989, DOI 10.1073/pnas.91.11.4989; BROWN JL, 1994, EMBO J, V13, P5186, DOI 10.1002/j.1460-2075.1994.tb06849.x; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Creighton T. E., 1993, PROTEINS STRUCTURES; DEGNEN ST, 1972, J BACTERIOL, V110, P852, DOI 10.1128/JB.110.3.852-856.1972; DELGADO J, 1993, MOL MICROBIOL, V10, P1037, DOI 10.1111/j.1365-2958.1993.tb00974.x; DINGWALL A, 1992, J BACTERIOL, V174, P1760, DOI 10.1128/jb.174.6.1760-1768.1992; ELY B, 1991, METHOD ENZYMOL, V204, P372; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; GALLAGHER SR, 1995, CURRENT PROTOCOLS PR; HECHT GB, 1995, EMBO J, V14, P3915, DOI 10.1002/j.1460-2075.1995.tb00063.x; Hendrix R. W, 1983, LAMBDA, VII; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KLOSE KE, 1993, J MOL BIOL, V232, P67, DOI 10.1006/jmbi.1993.1370; MADDOCK JR, 1993, SCIENCE, V259, P1717; MARCZYNSKI GT, 1992, J MOL BIOL, V226, P959, DOI 10.1016/0022-2836(92)91045-Q; MARCZYNSKI GT, 1995, GENE DEV, V9, P1543, DOI 10.1101/gad.9.12.1543; Meisenzahl AC, 1997, J BACTERIOL, V179, P592, DOI 10.1128/jb.179.3.592-600.1997; Muffler A, 1996, EMBO J, V15, P1333, DOI 10.1002/j.1460-2075.1996.tb00475.x; NAYSMITH K, 1993, CURR OPIN CELL BIOL, V5, P166; OHTA N, 1992, P NATL ACAD SCI USA, V89, P10297, DOI 10.1073/pnas.89.21.10297; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Pogliano K, 1997, J BACTERIOL, V179, P3331, DOI 10.1128/jb.179.10.3331-3341.1997; Quardokus E, 1996, P NATL ACAD SCI USA, V93, P6314, DOI 10.1073/pnas.93.13.6314; Quon KC, 1996, CELL, V84, P83, DOI 10.1016/S0092-8674(00)80995-2; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Shapiro L, 1997, SCIENCE, V276, P712, DOI 10.1126/science.276.5313.712; Stephens C, 1996, P NATL ACAD SCI USA, V93, P1210, DOI 10.1073/pnas.93.3.1210; STEPHENS CM, 1993, MOL MICROBIOL, V9, P1169, DOI 10.1111/j.1365-2958.1993.tb01246.x; WANG SP, 1993, P NATL ACAD SCI USA, V90, P630, DOI 10.1073/pnas.90.2.630; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; WINGROVE JA, 1994, GENE DEV, V8, P1839, DOI 10.1101/gad.8.15.1839; WINGROVE JA, 1993, GENE DEV, V7, P1979, DOI 10.1101/gad.7.10.1979; Wingrove JA, 1996, SCIENCE, V274, P597, DOI 10.1126/science.274.5287.597; WINZELER E, 1995, J MOL BIOL, V251, P346, DOI 10.1006/jmbi.1995.0439; Wright R, 1996, GENE DEV, V10, P1532, DOI 10.1101/gad.10.12.1532; YU J, 1992, J BACTERIOL, V174, P3327, DOI 10.1128/jb.174.10.3327-3338.1992; ZWEIGER G, 1994, J MOL BIOL, V235, P472, DOI 10.1006/jmbi.1994.1007	43	329	330	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	1997	90	3					415	424		10.1016/S0092-8674(00)80502-4	http://dx.doi.org/10.1016/S0092-8674(00)80502-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267022	Bronze			2022-12-24	WOS:A1997XQ06300006
J	PalBhadra, M; Bhadra, U; Birchler, JA				PalBhadra, M; Bhadra, U; Birchler, JA			Cosuppression in Drosophila: Gene silencing of Alcohol dehydrogenase by white-Adh transgenes is Polycomb dependent	CELL			English	Article							MELANOGASTER; EXPRESSION; COMPLEX; ZESTE; CHROMATIN; POSITION; ELEMENT; STATE; LOCUS	When two to six copies of a white promoter-Alcohol dehydrogenase (Adh) reporter fusion gene are introduced into the genome, the expression is progressively reduced both in larvae and adults rather than the expected gene dosage effect. In addition, multiple transgenes reduce endogenous Adh transcripts, a result that is strongly analogous to ''cosuppression'' phenomena described in many plant species but which has not been previously observed in animals. Silencing of the Adh gene is not influenced by zeste-dependent transvection but strongly affected by the Polycomb and Polycomblike mutations. Polycomb and polyhomeotic proteins are bound to the chromatin at the sites of the repressed w-Adh transgenes.	UNIV MISSOURI, DIV BIOL SCI, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BABU P, 1980, DEV NEUROBIOLOGY DRO, P35; Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; BENYAJATI C, 1982, NUCLEIC ACIDS RES, V10, P7261, DOI 10.1093/nar/10.22.7261; BIALOJAN S, 1984, EMBO J, V3, P2543, DOI 10.1002/j.1460-2075.1984.tb02170.x; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; CORBIN V, 1989, NATURE, V337, P279, DOI 10.1038/337279a0; Depicker A., 1996, MECH APPL GENE SILEN, P71; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; FJOSE A, 1984, EMBO J, V3, P2087, DOI 10.1002/j.1460-2075.1984.tb02095.x; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GELBART WM, 1985, COLD SPRING HARB SYM, V50, P119, DOI 10.1101/SQB.1985.050.01.017; GREEN MM, 1959, HEREDITY, V13, P302; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; JACK JW, 1979, P NATL ACAD SCI USA, V76, P1368, DOI 10.1073/pnas.76.3.1368; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; KAUFMAN TC, 1973, GENETICS, V75, P299; LAURIE CC, 1994, GENETICS, V138, P379; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; RABINOW L, 1991, GENETICS, V129, P463; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; ROBERTSON HM, 1988, GENETICS, V118, P461; SCHMIDT ER, 1988, CHROMOSOMA, V96, P353, DOI 10.1007/BF00330701; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; Ursprnng H, 1970, Wilhelm Roux Arch. EntwMech. Org., V164, P201, DOI 10.1007/BF00582032; VANBLOKLAND R, 1994, PLANT J, V6, P861, DOI 10.1046/j.1365-313X.1994.6060861.x	31	190	202	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	1997	90	3					479	490		10.1016/S0092-8674(00)80508-5	http://dx.doi.org/10.1016/S0092-8674(00)80508-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267028	Bronze			2022-12-24	WOS:A1997XQ06300012
J	vanSlegtenhorst, M; deHoogt, R; Hermans, C; Nellist, M; Janssen, B; Verhoef, S; Lindhout, D; vandenOuweland, A; Halley, D; Young, J; Burley, M; Jeremiah, S; Woodward, K; Nahmias, J; Fox, M; Ekong, R; Osborne, J; Wolfe, J; Povey, S; Snell, RG; Cheadle, JP; Jones, AC; Tachataki, M; Ravine, D; Sampson, JR; Reeve, MP; Richardson, P; Wilmer, F; Munro, C; Hawkins, TL; Sepp, T; Ali, JBM; Ward, S; Green, AJ; Yates, JRW; Kwiatkowska, J; Henske, EP; Short, MP; Haines, JH; Jozwiak, S; Kwiatkowski, DJ				vanSlegtenhorst, M; deHoogt, R; Hermans, C; Nellist, M; Janssen, B; Verhoef, S; Lindhout, D; vandenOuweland, A; Halley, D; Young, J; Burley, M; Jeremiah, S; Woodward, K; Nahmias, J; Fox, M; Ekong, R; Osborne, J; Wolfe, J; Povey, S; Snell, RG; Cheadle, JP; Jones, AC; Tachataki, M; Ravine, D; Sampson, JR; Reeve, MP; Richardson, P; Wilmer, F; Munro, C; Hawkins, TL; Sepp, T; Ali, JBM; Ward, S; Green, AJ; Yates, JRW; Kwiatkowska, J; Henske, EP; Short, MP; Haines, JH; Jozwiak, S; Kwiatkowski, DJ			Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34	SCIENCE			English	Article							POLYCYSTIC KIDNEY-DISEASE; ABO BLOOD-GROUP; DIAGNOSTIC-CRITERIA; HETEROGENEITY; LINKAGE; LOCUS; LOCALIZATION; MUTATION; AUTISM; 16P13	Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by the widespread development of distinctive tumors termed hamartomas. TSC-determining loci have been mapped to chromosomes 9q34 (TSC1) and 16p13 (TSC2). The TSC1 gene was identified from a 900-kilobase region containing at least 30 genes. The 8.6-kilobase TSC1 transcript is widely expressed and encodes a protein of 130 kilodaltons (hamartin) that has homology to a putative yeast protein of unknown function. Thirty-two distinct mutations were identified in TSC1, 30 of which were truncating, and a single mutation (2105delAAAG) was seen in six apparently unrelated patients. In one of these six, a somatic mutation in the wild-type allele was found in a TSC-assaciated renal carcinoma, which suggests that hamartin acts as a tumor suppressor.	BRIGHAM & WOMENS HOSP, DIV EXPT MED & MED ONCOL, BOSTON, MA 02115 USA; ERASMUS UNIV ROTTERDAM, DEPT CLIN GENET, NL-3000 DR ROTTERDAM, NETHERLANDS; UNIV ROTTERDAM HOSP, ROTTERDAM, NETHERLANDS; UNIV LONDON UNIV COLL, MRC, HUMAN BIOCHEM GENET UNIT, LONDON NW1 2HE, ENGLAND; UNIV LONDON UNIV COLL, GALTON LAB, LONDON NW1 2HE, ENGLAND; UNIV BATH, BATH BA2 7AY, AVON, ENGLAND; UNIV WALES COLL MED, INST MED GENET, CARDIFF CF4 4XN, S GLAM, WALES; MIT, WHITEHEAD INST BIOMED RES, CTR GENOME RES, CAMBRIDGE, MA 02139 USA; UNIV CAMBRIDGE, ADDENBROOKES NHS TRUST, DEPT PATHOL, CAMBRIDGE CB2 2QQ, ENGLAND; UNIV CAMBRIDGE, ADDENBROOKES NHS TRUST, DEPT MED GENET, CAMBRIDGE CB2 2QQ, ENGLAND; UNIV CHICAGO, SCH MED, DEPT CHILD NEUROL, CHICAGO, IL 60637 USA; MASSACHUSETTS GEN HOSP, MOL NEUROGENET UNIT, BOSTON, MA 02129 USA; CHILDRENS HLTH CTR, DIV CHILD NEUROL, PL-04736 WARSAW, POLAND	Harvard University; Brigham & Women's Hospital; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; University of London; University College London; University of London; University College London; University of Bath; Cardiff University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Chicago; Harvard University; Massachusetts General Hospital; Children's Memorial Health Institute			Ravine, David/A-6797-2008; Hermans, Cedric/AAK-9433-2020; Lindhout, Dick/AAH-5765-2019; Jura, Jolanta/F-8889-2015; Green, Andrew/AAJ-7592-2020; Ali, Johari Mohd/B-5259-2010; Haines, Jonathan/C-3374-2012	Jura, Jolanta/0000-0002-0816-3475; Ali, Johari Mohd/0000-0002-6884-4280; Haines, Jonathan/0000-0002-4351-4728; Jozwiak, Sergiusz/0000-0003-3350-6326; Lindhout, Dick/0000-0001-9580-624X; Snell, Russell/0000-0002-8166-4014; Ekong, Rosemary/0000-0002-5984-7893; Green, Andrew/0000-0002-1077-7417				Au KS, 1996, J MED GENET, V33, P559, DOI 10.1136/jmg.33.7.559; Bjornsson J, 1996, AM J PATHOL, V149, P1201; BROOKCARTER PT, 1994, NAT GENET, V8, P328, DOI 10.1038/ng1294-328; BROOKES AJ, 1984, HUM MOL GENET, V3, P2011; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; Carbonara C, 1996, GENE CHROMOSOME CANC, V15, P18, DOI 10.1002/(SICI)1098-2264(199601)15:1<18::AID-GCC3>3.0.CO;2-7; Cook JA, 1996, J MED GENET, V33, P480, DOI 10.1136/jmg.33.6.480; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; FRYER AE, 1987, LANCET, V1, P659; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; Gomez MR, 1988, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; HAINES JL, 1991, AM J HUM GENET, V49, P764; Hawkins TL, 1997, SCIENCE, V276, P1887, DOI 10.1126/science.276.5320.1887; HAWKINS TL, 1994, NUCLEIC ACIDS RES, V22, P4543, DOI 10.1093/nar/22.21.4543; Henske EP, 1996, AM J HUM GENET, V59, P400; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; Hornigold N, 1997, GENOMICS, V41, P385, DOI 10.1006/geno.1997.4681; HUNT A, 1993, J AUTISM DEV DISORD, V23, P323, DOI 10.1007/BF01046223; JANSSEN B, 1994, HUM GENET, V94, P437, DOI 10.1007/BF00201608; JANSSEN LAJ, 1990, GENOMICS, V8, P237, DOI 10.1016/0888-7543(90)90277-2; JONES C, 1980, CYTOGENET CELL GENET, V28, P181, DOI 10.1159/000131529; KANDT RS, 1989, EXP NEUROL, V104, P223, DOI 10.1016/0014-4886(89)90033-2; KANDT RS, 1992, NAT GENET, V2, P37, DOI 10.1038/ng0992-37; KUMAR A, 1995, HUM MOL GENET, V4, P2295, DOI 10.1093/hmg/4.12.2295; KUMAR A, 1995, HUM MOL GENET, V4, P1471, DOI 10.1093/hmg/4.8.1471; KUMAR A, 1997, IN PRESS HUM MUTAT, V9, P64; Kwiatkowski David J., 1993, Cytogenetics and Cell Genetics, V64, P93, DOI 10.1159/000133566; KWIATKOWSKI DJ, 1994, ARCH DERMATOL, V130, P348, DOI 10.1001/archderm.130.3.348; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; NELLIST M, 1993, J MED GENET, V30, P224, DOI 10.1136/jmg.30.3.224; NELLIST M, 1993, CELL, V75, P1305; NORTHRUP H, 1987, LANCET, V2, P804; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; POVEY S, 1994, ANN HUM GENET, V58, P177, DOI 10.1111/j.1469-1809.1994.tb01887.x; ROACH ES, 1992, J CHILD NEUROL, V7, P221, DOI 10.1177/088307389200700219; SAMPSON JR, 1989, J MED GENET, V26, P28, DOI 10.1136/jmg.26.1.28; SAMPSON JR, 1989, J MED GENET, V26, P511, DOI 10.1136/jmg.26.8.511; Sepp T, 1996, J MED GENET, V33, P962, DOI 10.1136/jmg.33.11.962; SMALLEY SL, 1992, J AUTISM DEV DISORD, V22, P339, DOI 10.1007/BF01048239; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; Vrtel R, 1996, J MED GENET, V33, P47, DOI 10.1136/jmg.33.1.47; WANG Q, IN PRESS HUM MUTAT; WEBB DW, 1991, J MED GENET, V28, P417, DOI 10.1136/jmg.28.6.417; Wienecke R, 1996, ONCOGENE, V13, P913; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wilson PJ, 1996, HUM MOL GENET, V5, P249, DOI 10.1093/hmg/5.2.249; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Xu Y, 1994, Genet Eng (N Y), V16, P241; [No title captured]	54	1197	1215	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 8	1997	277	5327					805	808		10.1126/science.277.5327.805	http://dx.doi.org/10.1126/science.277.5327.805			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242607				2022-12-24	WOS:A1997XQ24700040
J	Schreiner, CE; Langner, G				Schreiner, CE; Langner, G			Laminar fine structure of frequency organization in auditory midbrain	NATURE			English	Article							INFERIOR COLLICULUS; CENTRAL NUCLEUS; SPECTRAL INTEGRATION; COCHLEAR NUCLEUS; SINGLE UNITS; CAT; INHIBITION; NERVE; REPRESENTATION; RESOLUTION	The perception of sound is based on signal processing by a bank of frequency-selective auditory filters, the so-called critical bands(1-3). Here we investigate how the internal frequency organization of the main auditory midbrain station, the central nucleus of the inferior colliculus (ICC), might contribute to the generation of the critical-band behaviour of its neurons. We find a unique spatial arrangement of the frequency distribution in the ICC that correlates with psychophysical critical-band characteristics. Systematic frequency discontinuities along the main tonotopic axis, in combination with a smooth frequency gradient orthogonal to the main tonotopic organization of cat ICC, reflect a layering of the frequency organization paralleling its anatomical laminae. This layered frequency organization is characterized by constant frequency ratios of corresponding locations on neighboring laminae and may provide a spatial framework for the generation of critical bands and for signal processing within(4) and across' frequency bands for the analysis of sound.	TECH UNIV DARMSTADT,INST ZOOL,D-64287 DARMSTADT,GERMANY	Technical University of Darmstadt	Schreiner, CE (corresponding author), UNIV CALIF SAN FRANCISCO,SLOAN CTR THEORET NEUROSCI,WM KECK CTR INTEGRAT NEUROSCI,COLEMAN LAB,SAN FRANCISCO,CA 94143, USA.			Schreiner, Christoph/0000-0002-4571-4328	NIDCD NIH HHS [R01 DC002260] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002260] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		CHAN JL, 1982, SOC NEUR ABSTR, V8, P348; EHRET G, 1991, BRAIN RES, V567, P350, DOI 10.1016/0006-8993(91)90819-H; EHRET G, 1984, HEARING RES, V14, P45, DOI 10.1016/0378-5955(84)90068-6; EHRET G, 1976, BIOL CYBERN, V24, P35, DOI 10.1007/BF00365592; EHRET G, 1985, SCIENCE, V227, P1245, DOI 10.1126/science.3975613; EHRET G, 1988, BRAIN RES REV, V13, P139, DOI 10.1016/0165-0173(88)90018-5; Evans E. F., 1989, BRIT J AUDIOL, V23, P151; Fletcher H, 1940, REV MOD PHYS, V12, P0047, DOI 10.1103/RevModPhys.12.47; GREENWOOD D, 1961, J ACOUST SOC AM, V33, P1344, DOI 10.1121/1.1908437; MALMIERCA MS, 1993, J COMP NEUROL, V333, P1, DOI 10.1002/cne.903330102; MERZENICH MM, 1974, BRAIN RES, V77, P397, DOI 10.1016/0006-8993(74)90630-1; NIENHUYS TGW, 1979, ACTA OTO-LARYNGOL, V88, P350, DOI 10.3109/00016487909137179; OLIVER DL, 1984, J COMP NEUROL, V224, P155, DOI 10.1002/cne.902240202; OLIVER DL, 1984, J COMP NEUROL, V222, P237, DOI 10.1002/cne.902220207; Palombi PS, 1996, J NEUROPHYSIOL, V75, P2211, DOI 10.1152/jn.1996.75.6.2211; PICKLES JO, 1976, J ACOUST SOC AM, V60, P1151, DOI 10.1121/1.381217; PICKLES JO, 1975, ACTA OTO-LARYNGOL, V80, P245, DOI 10.3109/00016487509121325; PICKLES JO, 1979, J ACOUST SOC AM, V66, P1725, DOI 10.1121/1.383645; POLLAK GD, 1993, HEARING RES, V65, P99, DOI 10.1016/0378-5955(93)90205-F; ROCKEL AJ, 1973, J COMP NEUROL, V147, P11, DOI 10.1002/cne.901470103; ROTH GL, 1978, J COMP NEUROL, V182, P661, DOI 10.1002/cne.901820407; SCHREINER CE, 1988, J NEUROPHYSIOL, V60, P1823, DOI 10.1152/jn.1988.60.6.1823; SEMPLE MN, 1979, J NEUROPHYSIOL, V42, P1626, DOI 10.1152/jn.1979.42.6.1626; SERVIERE J, 1981, NEUROSCI LETT, V27, P113, DOI 10.1016/0304-3940(81)90253-6; SHNEIDERMAN A, 1987, J COMP NEUROL, V266, P519, DOI 10.1002/cne.902660406; SUGA N, 1985, J NEUROPHYSIOL, V53, P1109, DOI 10.1152/jn.1985.53.4.1109; SUGA N, 1995, NEUROSCI RES, V21, P287, DOI 10.1016/0168-0102(94)00868-G; WATSON CS, 1963, J ACOUST SOC AM, V62, P167; YOST WA, 1989, J ACOUST SOC AM, V85, P848, DOI 10.1121/1.397556; ZWICKER E, 1957, J ACOUST SOC AM, V29, P548, DOI 10.1121/1.1908963	30	161	166	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					383	386		10.1038/41106	http://dx.doi.org/10.1038/41106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237756				2022-12-24	WOS:A1997XM52800052
J	Zuber, PLF; McKenna, MT; Binkin, NJ; Onorato, IM; Castro, KG				Zuber, PLF; McKenna, MT; Binkin, NJ; Onorato, IM; Castro, KG			Long-term risk of tuberculosis among foreign-born persons in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVENTIVE THERAPY; EPIDEMIOLOGY; INFECTION; TRANSMISSION; IMMIGRANTS; CANADA; ADULTS	Context.-Cases of tuberculosis (TB) in the United States have declined for 4 consecutive years, but cases among foreign-born persons account for an increasing percentage. Objective.-To describe the risk of tuberculosis among foreign-born persons with respect to their length of residence in the United States. Design.-Cross-sectional analysis of national surveillance data. Setting.-The United States. Patients.-All verified TB cases reported to the Centers for Disease Control and Prevention between 1986 and 1994. Main Outcome Measure.-Stratum-specific incidence rates of TB by age, place of birth, length of residence, age at arrival in the United States, or combinations of these variables. Results.-Several groups of persons from countries with a high prevalence of TB had incidence rates higher than 20 per 100 000 person-years more than 20 years after arrival. Among long-term residents, those who arrived in the United Stales after their fifth birthday had incidence rates of TB 2 to 6 times higher than those of similar age who arrived before their fifth birthday. A total of 45% of the TB cases were among persons younger than 35 years and an additional 18% were among persons who arrived in the United States before their 35th birthday. Conclusions.-Imported Mycobacterium tuberculosis infection (active or latent) is responsible for most TB cases among foreign-born persons in the United States. Detection of active cases among recent arrivals is the main priority in these populations, but many cases were in persons who arrived in the United States before the age of 35 years that could potentially have been avoided with preventive therapy. Elimination of TB in the United States may not be feasible using available diagnostic and treatment modalities without increased efforts to address the global burden of this disease.			Zuber, PLF (corresponding author), CTR DIS CONTROL & PREVENT, DIV TB ELIMINAT, 1600 CLIFTON RD, MAILSTOP E-10, ATLANTA, GA 30333 USA.		Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				*1990 CENS POP HOU, 1992, PUBL US MICR SAMPL T; AICKIN M, 1991, AM J PUBLIC HEALTH, V81, P918, DOI 10.2105/AJPH.81.7.918; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; ASCH S, 1994, WESTERN J MED, V161, P373; BALLEW KA, 1995, SOUTHERN MED J, V88, P1025, DOI 10.1097/00007611-199510000-00005; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Binkin NJ, 1996, CLIN INFECT DIS, V23, P1226, DOI 10.1093/clinids/23.6.1226; BISGARD K, 1994, AM J RESP CRIT CARE, V149, pA703; *BUR CENS, 1993, 1990 CENS POP FOR BO; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P40; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P703; *CDCP, 1996, MMWR; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P8; Centers for Disease control and prevention: Update: Trends in total alcohol syndrome-United States, 1995, MMWR-MORBID MORTAL W, V44, p[1979, 13]; DERIEMER K, 1995, 123 M AM PUBL HLTH A; ENARSON D, 1979, AM REV RESPIR DIS, V119, P11; ENARSON DA, 1994, MAYO CLIN PROC, V69, P85, DOI 10.1016/S0025-6196(12)61618-8; ENARSON DA, 1980, EUR J RESPIR DIS, V61, P139; FEIN DJ, 1990, DEMOGRAPHY, V27, P285, DOI 10.2307/2061454; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; FRIEDMAN CR, 1995, AM J RESP CRIT CARE, V152, P355, DOI 10.1164/ajrccm.152.1.7599845; GUERIN N, 1995, PEDIATR PULM, P18; HOPEWELL P, 1995, TUBER LUNG DIS S2, V76, P47; *IMM NAT SERV, 1996, STAT YB IMM NAT SERV; ISEMAN MD, 1995, NEW ENGL J MED, V332, P1094, DOI 10.1056/NEJM199504203321611; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MOHLEBOETANI JC, 1995, JAMA-J AM MED ASSOC, V274, P613, DOI 10.1001/jama.274.8.613; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; POWELL KE, 1983, JAMA-J AM MED ASSOC, V249, P1455, DOI 10.1001/jama.249.11.1455; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RIDZON R, IN PRESS J PEDIAT; ROSE DN, 1988, AM J PREV MED, V4, P102, DOI 10.1016/S0749-3797(18)31204-2; Rothman K, 1986, MODERN EPIDEMIOLOGY; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SNIDER DE, 1986, JAMA-J AM MED ASSOC, V255, P1579, DOI 10.1001/jama.255.12.1579; SPRINGETT V H, 1958, Br J Prev Soc Med, V12, P135; SPRINGETT VH, 1964, LANCET, V1, P1091; STARKE JR, 1995, JAMA-J AM MED ASSOC, V274, P652, DOI 10.1001/jama.274.8.652; STERLING TR, 1995, ARCH INTERN MED, V155, P1622, DOI 10.1001/archinte.155.15.1622; STEVENSON DK, 1962, BMJ-BRIT MED J, P1382, DOI 10.1136/bmj.1.5289.1382; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; WELLS CD, 1996, 45 ANN EP INT SERV C; WILLERT PD, 1996, MID YEAR M N AM REG; *WORLD BANK, 1993, WORLD DEV REP; Zuber PLF, 1996, TUBERCLE LUNG DIS, V77, P524, DOI 10.1016/S0962-8479(96)90050-7; Zuber PLF, 1996, AM J RESP CRIT CARE, V154, P151, DOI 10.1164/ajrccm.154.1.8680671	46	175	176	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					304	307		10.1001/jama.278.4.304	http://dx.doi.org/10.1001/jama.278.4.304			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL059	9228436				2022-12-24	WOS:A1997XL05900031
J	Grether, JK; Nelson, KB				Grether, JK; Nelson, KB			Maternal infection and cerebral palsy in infants of normal birth weight	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MECONIUM ASPIRATION SYNDROME; PRETERM PREMATURE RUPTURE; PERINATAL RISK-FACTORS; INTRAAMNIOTIC INFECTION; COMPLICATIONS; PREDICTORS; ASPHYXIA; SEPSIS; POPULATION; PREVALENCE	Context.-Exposure to maternal or placental infection is related to risk of preterm birth and, in premature infants, of brain lesions predictive of cerebral palsy (CP). Few studies have investigated whether maternal infection is associated with risk of CP in children of normal birth weight. Objective.-To investigate maternal infection during the admission for delivery as a possible risk factor for CP in infants born weighing 2500 g or more. Design.-Population-based case-control study. Setting.-All hospitals in 4 northern California counties, 1983 through 1985. Participants.-A total of 46 children with disabling spastic CP who had no recognized prenatal brain lesions and 378 randomly selected control children weighing 2500 g or more at birth and surviving to age 3 years. Main Outcome Measures.-Disabling spastic CP and signs of neonatal morbidity. Results.-Maternal fever exceeding 38 degrees C in labor was associated with increased risk of unexplained CP (odds ratio [OR], 9.3; 95% confidence interval [CI], 2.7-31.0), as was a clinical diagnosis of chorioamnionitis. One or more indicators of maternal infection were present in 2.9% of control children, 22% of children with CP (OR, 9.3; 95% CI, 3.7-23.0), and 35% of those with the spastic quadriplegic subtype of CP (OR, 19.0; 95% CI, 6.5-56.0). Newborns exposed to maternal infection, both cases and controls, had 5-minute Apgar scores below 6 more often than those unexposed. Among children with CP, those born to infected women were more often hypotensive, needed intubation, had neonatal seizures, and received a clinical diagnosis of hypoxic-ischemic encephalopathy. Conclusion.-Intrauterine exposure to maternal infection was associated with a marked increase in risk of CP in infants of normal birth weight. Maternal infection was also linked with low Apgar scores, other evidence of hypertension and need for resuscitation, and neonatal seizures-signs commonly attributed to birth asphyxia.	NINCDS,NEUROEPIDEMIOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Grether, JK (corresponding author), CALIF DEPT HLTH SERV,CALIF BIRTH DEFECTS MONITORING PROGRAM,1900 POWELL ST,SUITE 1050,EMERYVILLE,CA 94608, USA.				PHS HHS [263-95-C0255] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMSON SJ, 1995, BRIT MED J, V311, P598, DOI 10.1136/bmj.311.7005.598; ADINOLFI M, 1993, DEV MED CHILD NEUROL, V35, P549; Beebe LA, 1996, OBSTET GYNECOL, V87, P771, DOI 10.1016/0029-7844(95)00483-1; BEJAR R, 1988, AM J OBSTET GYNECOL, V159, P357, DOI 10.1016/S0002-9378(88)80084-X; BOLTON CF, 1993, ANN NEUROL, V33, P94, DOI 10.1002/ana.410330115; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; BRENNEMAN DE, 1995, INT J DEV NEUROSCI, V13, P187, DOI 10.1016/0736-5748(95)00014-8; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; COOKE RWI, 1990, ARCH DIS CHILD, V65, P201, DOI 10.1136/adc.65.2.201; COUGHREY H, 1991, AUST N Z J OBSTET GY, V31, P92; CUMMINS SK, 1993, J PEDIATR-US, V123, P230, DOI 10.1016/S0022-3476(05)81693-2; EASTMAN NJ, 1955, AM J OBSTET GYNECOL, V69, P950, DOI 10.1016/0002-9378(55)90094-6; FAIX RG, 1985, PEDIATRICS, V76, P415; GERDES JS, 1991, CLIN PERINATOL, V18, P361, DOI 10.1016/S0095-5108(18)30528-1; GOLDSTEIN I, 1988, AM J OBSTET GYNECOL, V159, P363, DOI 10.1016/S0002-9378(88)80085-1; GRAU AJ, 1995, STROKE, V26, P373, DOI 10.1161/01.STR.26.3.373; Grether J K, 1992, Paediatr Perinat Epidemiol, V6, P339, DOI 10.1111/j.1365-3016.1992.tb00774.x; HAGEMAN JR, 1995, CLIN PERINATOL, V22, P251; HANKINS GDV, 1991, AM J OBSTET GYNECOL, V164, P1261, DOI 10.1016/0002-9378(91)90696-O; HERNANDEZ C, 1993, AM J OBSTET GYNECOL, V169, P61, DOI 10.1016/0002-9378(93)90132-3; KNUDSEN FU, 1976, ACTA PAEDIATR SCAND, V65, P725, DOI 10.1111/j.1651-2227.1976.tb04961.x; KUBAN KCK, 1994, NEW ENGL J MED, V330, P188, DOI 10.1056/NEJM199401203300308; MABERRY MC, 1990, OBSTET GYNECOL, V76, P351; Magee JF, 1996, LAB INVEST, V74, P17; MANTEL N, 1959, J NATL CANCER I, V22, P719; Maseri A, 1996, BRIT MED J, V312, P1049; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MURPHY DJ, 1995, LANCET, V346, P1449, DOI 10.1016/S0140-6736(95)92471-X; NAEYE RL, 1979, BIOL NEONATE, V35, P150; NAULTY CM, 1994, AM J PERINAT, V11, P377, DOI 10.1055/s-2007-994601; NELSON KB, 1984, JAMA-J AM MED ASSOC, V251, P1843, DOI 10.1001/jama.251.14.1843; NELSON KB, 1985, JAMA-J AM MED ASSOC, V254, P1473, DOI 10.1001/jama.254.11.1473; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; PEEVY KJ, 1983, AM J OBSTET GYNECOL, V146, P989, DOI 10.1016/0002-9378(83)90985-7; Perlman JM, 1996, PEDIATRICS, V97, P822; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; ROBERTS AB, 1991, ULTRASOUND OBST GYN, V1, P36, DOI 10.1046/j.1469-0705.1991.01010036.x; ROMERO R, 1993, J REPROD MED, V38, P543; *SAS I INC, 1989, SAS STAT US GUID VER, P2; Schlesselman J, 1982, CASE CONTROL STUDIES, P220; STANLEY FJ, 1993, DEV MED CHILD NEUROL, V35, P191; USTA IM, 1995, OBSTET GYNECOL, V86, P230, DOI 10.1016/0029-7844(95)00124-A; WAITZMAN NJ, 1995, MMWR-MORBID MORTAL W, V44, P695; WEGMAN ME, 1984, PEDIATRICS, V74, P981; Wong ML, 1996, NAT MED, V2, P581, DOI 10.1038/nm0596-581; YOUNG GB, 1995, NEUROL CLIN, V13, P645, DOI 10.1016/S0733-8619(18)30037-9; Zupan V, 1996, DEV MED CHILD NEUROL, V38, P1061	48	586	602	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	1997	278	3					207	211		10.1001/jama.278.3.207	http://dx.doi.org/10.1001/jama.278.3.207			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK108	9218666				2022-12-24	WOS:A1997XK10800025
J	Dietmeier, K; Honlinger, A; Bomer, U; Dekker, PJT; Eckerskorn, C; Loffspeich, F; Kubrich, M; Pfanner, N				Dietmeier, K; Honlinger, A; Bomer, U; Dekker, PJT; Eckerskorn, C; Loffspeich, F; Kubrich, M; Pfanner, N			Tom5 functionally links mitochondrial preprotein receptors to the general import pore	NATURE			English	Article							PROTEIN IMPORT; OUTER-MEMBRANE; INSERTION PORE; COMPLEX; TRANSLOCATION; SUBUNIT; MOM22; COMPONENT; ATP	Most mitochondrial proteins are synthesized as preproteins on cytosolic polysomes and are subsequently imported into the organelle(1-3). The mitochondrial outer membrane contains a multisubunit preprotein translocase (Tom) which has receptors on the cytosolic side and a general import pore (GIP) in the membrane. Tom20-Tom22 and Tom70-Tom37 function as import receptors(4-7) with a preference for preproteins that have amino-terminal presequences or internal targeting information, respectively. Tom40 is an essential constituent of the GIP(8,9), whereas Tom6 and Tom7 modulate the assembly and dissociation of the Tom machinery(10,11). Here we report the identification of Tom5, a small subunit that has a crucial role importing preproteins destined for all four mitochondrial subcompartments. Tom5 has a single membrane anchor and a cytosolic segment with a negative net charge, and accepts preproteins from the receptors and mediates their insertion into the GIP. We conclude that Tom5 represents a functional link between surface receptors and GIP, and is part of an 'acid chain'(5) that guides the stepwise transport of positively charged mitochondrial targeting sequences.	UNIV FREIBURG,INST BIOCHEM & MOL BIOL,D-79104 FREIBURG,GERMANY; MAX PLANCK INST BIOCHEM,D-92152 MARTINSRIED,GERMANY	University of Freiburg; Max Planck Society			Pfanner, Nikolaus/AAV-7878-2021	Dekker, Peter/0000-0002-8197-8822				ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Alconada A, 1995, METHOD ENZYMOL, V260, P263, DOI 10.1016/0076-6879(95)60144-9; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; Dekker PJT, 1996, BIOL CHEM, V377, P535; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; GARTNER F, 1995, J BIOL CHEM, V270, P3788; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; HUFFAKER TC, 1987, ANNU REV GENET, V21, P259; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; PFALLER R, 1989, J BIOL CHEM, V264, P34; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; Tokatlidis K, 1996, NATURE, V384, P585, DOI 10.1038/384585a0; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0	30	223	227	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					195	200		10.1038/40663	http://dx.doi.org/10.1038/40663			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217162	Bronze			2022-12-24	WOS:A1997XK10900055
J	Salvarani, C; Cantini, F; Olivieri, I; Barozzi, L; Macchioni, L; Niccoli, L; Padula, A; DeMatteis, M; Pavlica, P				Salvarani, C; Cantini, F; Olivieri, I; Barozzi, L; Macchioni, L; Niccoli, L; Padula, A; DeMatteis, M; Pavlica, P			Proximal bursitis in active polymyalgia rheumatica	ANNALS OF INTERNAL MEDICINE			English	Article							GIANT-CELL ARTERITIS; FOLLOW-UP; SYNOVITIS; JOINT; ARTHRITIS; SHOULDER; CRITERIA	Background: The cause of musculoskeletal symptoms in the proximal extremities of patients who have polymyalgia rheumatica is not completely understood. The diffuse and severe discomfort can only be partially explained by the mild joint synovitis that is observed in these patients. Objective: To determine the involvement of the synovial structures of the shoulder girdle of patients who have active symptoms of polymyalgia rheumatica. Design: Case-control study. Setting: 2 secondary referral centers of rheumatology. Patients: 13 case-patients who had active symptoms of polymyalgia rheumatica seen during a 6-month period, 9 control-patients who had early symptoms of elderly-onset rheumatoid arthritis, and 10 age-matched healthy controls. Measurements: Magnetic resonance imaging of the shoulder was done on the 13 case-patients, 9 control-patients, and 10 healthy controls. Results: The frequency of subacromial and subdeltoid bursitis was significantly higher in the case-patients (who had polymyalgia rheumatica) than in the control-patients (who had elderly-onset rheumatoid arthritis). The frequencies of synovitis of the joints and tenosynovitis of the biceps did not significantly differ between the 13 case-patients and the 9 control-patients. None of the healthy controls showed evidence of fluid accumulation in the joints, bursae, or sheaths of the long head of the biceps. Conclusions: Inflammation of subacromial and subdeltoid bursae in association with synovitis of the glenohumeral joints and tenosynovitis of the biceps may contribute to the diffuse discomfort in the shoulder girdle observed in patients with polymyalgia rheumatica.	AZIENDA OSPED ARCISPEDALE S MARIA NUOVA, DIV MED INTERNA 2, UNITA REUMATOL, I-42100 REGGIO EMILIA, ITALY; OSPED PRATO, DIV MED INTERNA 2, UNITA REUMATOL, PRATO, ITALY; AZIENDA OSPED S ORSOLA MALPIGHI, SERV REUMATOL, BOLOGNA, ITALY; AZIENDA OSPED S ORSOLA MALPIGHI, SERV RADIOL, BOLOGNA, ITALY	IRCCS Arcispedale S. Maria Nuova; Prato Hospital; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna	Salvarani, C (corresponding author), AZIENDA OSPED ARCISPEDALE S MARIA NUOVA, DIV MED INTERNA, UNITA REUMATOL 2, V UMBERTO 1 N50, I-42100 REGGIO EMILIA, ITALY.		Salvarani, Carlo/K-2431-2018	Salvarani, Carlo/0000-0001-5426-5133				ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Boiardi L, 1996, BRIT J RHEUMATOL, V35, P642; CHOU CT, 1984, ARTHRITIS RHEUM-US, V27, P1107, DOI 10.1002/art.1780271005; CHUANG TY, 1982, ANN INTERN MED, V97, P672, DOI 10.7326/0003-4819-97-5-672; DOUGLAS WAC, 1983, ANN RHEUM DIS, V42, P311, DOI 10.1136/ard.42.3.311; HEALEY LA, 1984, SEMIN ARTHRITIS RHEU, V13, P322, DOI 10.1016/0049-0172(84)90012-X; KIEFT GJ, 1990, ANN RHEUM DIS, V49, P7, DOI 10.1136/ard.49.1.7; KOSKI JM, 1992, BRIT J RHEUMATOL, V31, P201; MCCARTY DJ, 1985, JAMA-J AM MED ASSOC, V254, P2763, DOI 10.1001/jama.254.19.2763; Meliconi R, 1996, ARTHRITIS RHEUM-US, V39, P1199, DOI 10.1002/art.1780390719; ODUFFY JD, 1976, MAYO CLIN PROC, V51, P519; OLIVIERI I, IN PRESS J CLIN EXP; ROCHE NE, 1993, ARTHRITIS RHEUM, V36, P1286, DOI 10.1002/art.1780360913; SALVARANI C, 1992, J RHEUMATOL, V19, P1100; SALVARANI C, 1995, ARTHRITIS RHEUM, V38, P369, DOI 10.1002/art.1780380311; Salvarani C, 1996, ARTHRITIS RHEUM, V39, P73, DOI 10.1002/art.1780390110; SALVARANI C, 1991, ARTHRITIS RHEUM, V34, P351, DOI 10.1002/art.1780340313; SALVARANI C, 1987, J RHEUMATOL, V14, P1209; SCHWEITZER ME, 1995, RADIOLOGY, V194, P821, DOI 10.1148/radiology.194.3.7862986	19	118	122	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					27	31		10.7326/0003-4819-127-1-199707010-00005	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214249				2022-12-24	WOS:A1997XG91400004
J	Mott, A; Rolfe, K; James, R; Evans, R; Kemp, A; Dunstan, F; Kemp, K; Sibert, J				Mott, A; Rolfe, K; James, R; Evans, R; Kemp, A; Dunstan, F; Kemp, K; Sibert, J			Safety of surfaces and equipment for children in playgrounds	LANCET			English	Article								Background The safety of playgrounds is important to protect children from injury, hut studies are mostly done mainly under laboratory conditions without epidemiological data. We investigated the safety of different playground surfaces, and types and heights of equipment in public playgrounds in the City of Cardiff, UK. Methods We did a correlational study of 330 children aged between 0 and 14 years. All children were hurt when playing in playgrounds in Cardiff and presented to the Accident and Emergency Department in Cardiff Royal Infirmary during summer (April to September) 1992 and 1993, and the whole of 1994. We studied the children's hospital records to establish the type of injury and interviewed their parents to find out the playground and type of equipment involved. The main outcome measures were the number of children injured whilst playing, and injury rates per observed number of children on different surfaces, types, and heights of equipment. Findings Children sustained significantly more injuries in playgrounds with concrete surfaces than in those with bark or rubberised surfaces (p<0.001). Playgrounds with rubber surfaces had the lowest rare of injury, with a risk half that of bark and a fifth of that of concrete. Bark surfaces were not significantly more protective against arm fractures than concrete. Most injuries were equipment related. Injury risk due to falls from monkey bars (suspended parallel bars or rings between which children swing) was twice that far climbing-frames and seven times that for swings or slides. The height of the equipment correlated significantly with the number of fractures (p=0.005) from falls. Interpretation Rubber or bath surfacing is associated with a low rate of injuries and we support their use in all public playgrounds. Bark alone is insufficient, however, to prevent all injuries, particularly arm fractures. Rubberised impact-absorbing surfaces are safer than bark. We believe that playing on monkey bars increases the risk of injury in playgrounds and that they should generally not he installed. Safety standards should be based on physical and epidemiological data. Our data suggest that the proposed raising of the maximum fall height from 2.5 m to 3.0 m in Europe is worrying.	UNIV WALES,COLL MED,ACAD CTR,LLANDOUGH HOSP,DEPT CHILD HLTH,PENARTH CF64 2XX,S GLAM,WALES; CARDIFF CTY COUNCIL,SPORTS & LEISURE DEPT,CARDIFF,S GLAM,WALES; CARDIFF ROYAL INFIRM,DEPT ACCID & EMERGENCY,CARDIFF,S GLAM,WALES	Cardiff Royal Infirmary								Altman D.G., 1991, PRACTICAL STATISTIC; ATKEN M, 1989, STAT MODELLING GLIM; BALL DJ, 1991, J ROY SOC HEALTH, V111, P134, DOI 10.1177/146642409111100405; Chalmers D J, 1996, Inj Prev, V2, P98, DOI 10.1136/ip.2.2.98; *CIT CARD LEIS AM, 1993, PLAYGR STRAT; HESELTINE P, 1989, PLAYGROUND MANAGEMEN; HESLETINE P, 1987, PLAYGROUNDS PLANNING, P20; HESLETINE P, 1989, PLAYGROUND MANAGEMEN; *HLTH PROM WAL, 1996, SAF AR YOUR PLAYGR P; LEWIS LM, 1993, J TRAUMA, V35, P932, DOI 10.1097/00005373-199312000-00020; MOTT A, 1974, ARCH DIS CHILD, V71, P328; SACKS JJ, 1990, AM J PUBLIC HEALTH, V80, P986, DOI 10.2105/AJPH.80.8.986	12	79	80	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1874	1876		10.1016/S0140-6736(96)10343-3	http://dx.doi.org/10.1016/S0140-6736(96)10343-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217759				2022-12-24	WOS:A1997XG41700010
J	Marcotrigiano, J; Gingras, AC; Sonenberg, N; Burley, SK				Marcotrigiano, J; Gingras, AC; Sonenberg, N; Burley, SK			Cocrystal structure of the messenger RNA 5' cap-binding protein (eIF4E) bound to 7-methyl-GDP	CELL			English	Article							TRANSLATION INITIATION-FACTOR; IMPORTANT AROMATIC-COMPOUNDS; SITE-DIRECTED MUTAGENESIS; FACTOR EIF-4E; INDOLE-DERIVATIVES; EUKARYOTIC TRANSLATION; STACKING INTERACTION; CRYSTAL-STRUCTURE; SEQUENCE; RECOGNITION	The X-ray structure of the eukaryotic translation initiation factor 4E (elF4E), bound to 7-methyl-GDP, has been determined at 2.2 Angstrom resolution. elF4E recognizes 5' 7-methyl-G(5')ppp(5')N mRNA caps during the rate-limiting initiation step of translation. The protein resembles a cupped hand and consists of a curved, 8-stranded antiparallel beta sheet, backed by three long alpha helices. 7-methyl-GDP binds in a narrow cap-binding slot on the molecule's concave surface, where 7-methyl-guanine recognition is mediated by base sandwiching between two conserved tryptophans, plus formation of three hydrogen bonds and a van der Waals contact between its N7-methyl group and a third conserved tryptophan. The convex dorsal surface of the molecule displays a phylogenetically conserved hydrophobic/acidic portion, which may interact with other translation initiation factors and regulatory proteins.	ROCKEFELLER UNIV,MOL BIOPHYS LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; McGill University; McGill University			Marcotrigiano, Joseph/K-6697-2016; Gingras, Anne-Claude/E-9982-2010; Gingras, Anne-Claude/ABA-8341-2020	Marcotrigiano, Joseph/0000-0003-0346-3353; Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437; Burley, Stephen K./0000-0002-2487-9713	NIGMS NIH HHS [GM07982] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS BL, 1978, J BIOL CHEM, V253, P2589; ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; ALTMANN M, 1988, J BIOL CHEM, V263, P17229; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, X PLOR V 3 1 MANUAL; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; Cohen SL, 1996, STRUCTURE, V4, P1013, DOI 10.1016/S0969-2126(96)00108-6; DARZYNKIEWICZ E, 1988, NUCLEIC ACIDS RES, V16, P8953, DOI 10.1093/nar/16.18.8953; DARZYNKIEWICZ E, 1985, BIOCHEMISTRY-US, V24, P1701, DOI 10.1021/bi00328a020; DARZYNKIEWICZ E, 1989, BIOCHEMISTRY-US, V28, P4771, DOI 10.1021/bi00437a038; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; FRIEDLAND DE, 1996, PROTEIN SCI, V6, P125; FURUICHI Y, 1979, J BIOL CHEM, V254, P6732; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HERNANDEZ G, 1995, BBA-GENE STRUCT EXPR, V1261, P427, DOI 10.1016/0167-4781(95)00039-J; Hodel AE, 1996, CELL, V85, P247, DOI 10.1016/S0092-8674(00)81101-0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ISHIDA T, 1991, J CHEM SOC PERK T 1, P1847, DOI 10.1039/p19910001847; ISHIDA T, 1983, BIOCHEMISTRY-US, V22, P3571, DOI 10.1021/bi00284a006; ISHIDA T, 1988, J AM CHEM SOC, V110, P2286, DOI 10.1021/ja00215a046; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; Jones RM, 1996, MOL CELL BIOL, V16, P4754; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; MANTEUFFEL SR, 1996, P NATL ACAD SCI USA, V93, P4076; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; Merrick WC., 1996, TRANSLATION CONTROL, P31; METZ AM, 1992, NUCLEIC ACIDS RES, V20, P4096, DOI 10.1093/nar/20.15.4096; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Miyagi Y, 1995, LAB INVEST, V73, P890; Morino S, 1996, EUR J BIOCHEM, V239, P597, DOI 10.1111/j.1432-1033.1996.0597u.x; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PATIKOGLOU G, 1997, ANNU REV BIOPH BIOM, V26, P287; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Ptushkina M, 1996, J BIOL CHEM, V271, P32818, DOI 10.1074/jbc.271.51.32818; RHOADS RE, 1983, BIOCHEMISTRY-US, V22, P6084, DOI 10.1021/bi00295a007; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; RYCHLIK W, 1992, NUCLEIC ACIDS RES, V20, P6415, DOI 10.1093/nar/20.23.6415; SACHS A, 1993, J BIOL CHEM, V268, P22955; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; SONENBERG N, 1979, P NATL ACAD SCI USA, V76, P4345, DOI 10.1073/pnas.76.9.4345; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Svitkin YV, 1996, EMBO J, V15, P7147, DOI 10.1002/j.1460-2075.1996.tb01106.x; UEDA H, 1991, FEBS LETT, V280, P207, DOI 10.1016/0014-5793(91)80294-D; UEDA H, 1991, J BIOCHEM-TOKYO, V109, P882, DOI 10.1093/oxfordjournals.jbchem.a123475; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; Vasilescu S, 1996, J BIOL CHEM, V271, P7030, DOI 10.1074/jbc.271.12.7030; WAKIYAMA M, 1995, FEBS LETT, V360, P191, DOI 10.1016/0014-5793(95)00081-J; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831	64	553	561	1	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					951	961		10.1016/S0092-8674(00)80280-9	http://dx.doi.org/10.1016/S0092-8674(00)80280-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200613	Bronze			2022-12-24	WOS:A1997XE35700015
J	Sinclair, DA; Mills, K; Guarente, L				Sinclair, DA; Mills, K; Guarente, L			Accelerated aging and nucleolar fragmentation yeast sgs1 mutants	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CLONING; GENE; DNA; HELICASE; HOMOLOG; RECQ; TRANSCRIPTION; INTERACTS; TELOMERES	The SGS1 gene of yeast encodes a DNA helicase with homology to the human WRN gene. Mutations in WRN result in Werner's syndrome, a disease with symptoms resembling premature aging. Mutation of SGS1 is shown to cause premature aging in yeast mother cells on the basis of a shortened life-span and the aging-induced phenotypes of sterility and redistribution of the Sir3 silencing protein from telomeres to the nucleolus. Further, in old sgs1 cells the nucleolus is enlarged and fragmented-changes that also occur in old wild-type cells. These findings suggest a conserved mechanism of cellular aging that may be related to nucleolar structure.			Sinclair, DA (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Sinclair, David/0000-0002-9936-436X	NATIONAL INSTITUTE ON AGING [R37AG011119, R01AG011119] Funding Source: NIH RePORTER; NIA NIH HHS [AG11119] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMSTONE FB, 1979, J MORPHOL, V154, P459; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FOREMAN PK, 1994, GENE, V144, P63, DOI 10.1016/0378-1119(94)90204-6; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HALLE J, IN PRESS EUR J CELL; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; Horiuchi J, 1997, MOL CELL BIOL, V17, P3220, DOI 10.1128/MCB.17.6.3220; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Kim S, 1996, BIOCHEM BIOPH RES CO, V219, P370, DOI 10.1006/bbrc.1996.0240; KLAR AJS, 1981, NATURE, V289, P239, DOI 10.1038/289239a0; MARTIN GM, 1985, ADV EXP MED BIOL, V190, P161; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1985, A VAN LEEUW J MICROB, V51, P1, DOI 10.1007/BF00444223; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; PUVIONDUTILLEUL F, 1983, EXP CELL RES, V138, P423; RINE J, 1987, GENETICS, V116, P9; SALK D, 1981, CYTOGENET CELL GENET, V30, P108, DOI 10.1159/000131597; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; STREHLER BL, 1986, EXP GERONTOL, V21, P283, DOI 10.1016/0531-5565(86)90038-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WEINSTEIN ME, 1988, MECH AGEING DEV, V42, P215, DOI 10.1016/0047-6374(88)90048-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	36	310	317	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 29	1997	277	5330					1313	1316		10.1126/science.277.5330.1313	http://dx.doi.org/10.1126/science.277.5330.1313			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT827	9271578				2022-12-24	WOS:A1997XT82700057
J	Kimura, K; Hirano, T				Kimura, K; Hirano, T			ATP-dependent positive supercoiling of DNA by 13S condensin: A biochemical implication for chromosome condensation	CELL			English	Article							UBIQUITOUS PROTEIN FAMILY; ESCHERICHIA-COLI; DOSAGE COMPENSATION; CRUCIFORM DNA; SMC FAMILY; GENE; TOPOISOMERASE; TEMPLATE; DOMAINS; DEFINES	13S condensin is a five-subunit protein complex that plays a central role in mitotic chromosome condensation in Xenopus egg extracts. Two core subunits of this complex, XCAP-C and XCAP-E, belong to an emerging family of putative ATPases, the SMC family. We report here that 13S condensin has a DNA-stimulated ATPase activity and exhibits a high affinity for structured DNAs such as cruciform DNA. 13S condensin is able to introduce positive supercoils into a closed circular DNA in the presence of bacterial or eukaryotic topoisomerase I. The supercoiling reaction is ATP-dependent. We propose that 13S condensin wraps DNA in a right-handed direction by utilizing the energy of ATP hydrolysis. This reaction may represent a key mechanism underlying the compaction of chromatin fibers during mitosis.			Kimura, K (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.		Hirano, Tatsuya/F-6008-2011	Hirano, Tatsuya/0000-0002-4219-6473	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053926] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53926] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELMONT AS, 1987, J CELL BIOL, V105, P77, DOI 10.1083/jcb.105.1.77; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Chuang PT, 1996, SCIENCE, V274, P1736, DOI 10.1126/science.274.5293.1736; DROGE P, 1994, BIOESSAYS, V16, P91, DOI 10.1002/bies.950160205; Earnshaw WC, 1991, CURR OPIN STRUC BIOL, V1, P237, DOI 10.1016/0959-440X(91)90068-5; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Harlow E, 1988, ANTIBODIES LAB MANUA; HIRANO T, 1995, TRENDS BIOCHEM SCI, V20, P357, DOI 10.1016/S0968-0004(00)89076-3; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; KANAAR R, 1992, CURR OPIN STRUC BIOL, V2, P369, DOI DOI 10.1016/0959-440X(92)90227-X; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; LAEMMLI UK, 1977, COLD SPRING HARB SYM, V42, P351; LEHMANN AR, 1995, MOL CELL BIOL, V15, P7067; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; MULLINGER AM, 1980, J CELL SCI, V46, P61; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; NAKASU S, 1985, EMBO J, V4, P2705, DOI 10.1002/j.1460-2075.1985.tb03990.x; Oguro A, 1995, DNA Res, V2, P95, DOI 10.1093/dnares/2.2.95; OHTANI T, 1982, NATURE, V299, P86, DOI 10.1038/299086a0; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; PETERSON RC, 1980, CELL, V20, P131, DOI 10.1016/0092-8674(80)90241-X; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; SAITOH N, 1995, BIOESSAYS, V17, P759, DOI 10.1002/bies.950170905; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SEDAT J, 1977, COLD SPRING HARB SYM, V42, P331, DOI 10.1101/SQB.1978.042.01.035; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; TANABE K, 1991, CANCER RES, V51, P4903; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YANG L, 1989, P NATL ACAD SCI USA, V86, P6121, DOI 10.1073/pnas.86.16.6121; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	48	310	318	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					625	634		10.1016/S0092-8674(00)80524-3	http://dx.doi.org/10.1016/S0092-8674(00)80524-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288743	Bronze			2022-12-24	WOS:A1997XT06600007
J	Pierre, P; Turley, SJ; Gatti, E; Hull, M; Meltzer, J; Mirza, A; Inaba, K; Steinman, RM; Mellman, I				Pierre, P; Turley, SJ; Gatti, E; Hull, M; Meltzer, J; Mirza, A; Inaba, K; Steinman, RM; Mellman, I			Developmental regulation of MHC class II transport in mouse dendritic cells	NATURE			English	Article							LANGERHANS CELLS; COMPARTMENTS; MOLECULES; COMPLEX; EXPRESSION; ENDOSOMES; LYSOSOMES; MEMBRANE; PEPTIDE	Dendritic cells (DCs) have the unique capacity to initiate primary and secondary immune responses(1-3). They acquire antigens in peripheral tissues and migrate to lymphoid organs where they present processed peptides to T cells. DCs must therefore exist in distinct functional states, an idea that is supported by observations that they downregulate endocytosis and upregulate surface molecules of the class II major histocompatibility complex (MHC) upon maturation(4-7). Here we investigate the features of DC maturation by reconstituting the terminal differentiation of mouse DCs in vitro and in situ. We find that early DCs, corresponding to those found in peripheral tissues, exhibit a phenotype in which most class II molecules are intracellular and localized to lysosomes. Upon maturation, these cells give rise to a new intermediate phenotype in which intracellular class II molecules are found in peripheral non-lysosomal vesicles, similar to the specialized CIIV population seen in B cells. The intermediate cells then differentiate into late DCs which express almost all of their class II molecules on the plasma membrane. These variations in class II compartmentalization are accompanied by dramatic alterations in the intracellular transport of the ne iv class II molecules and in antigen presentation. We found that although early DCs could not present antigen immediately after uptake, efficient presentation of the previously internalized antigen occurred after maturation, 24-48 hours later. By regulating class II transport and compartmentalization, DCs are able to delay antigen display, a property crucial to their role in immune surveillance.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520; ROCKEFELLER UNIV,NEW YORK,NY 10021	Yale University; Rockefeller University			Steinman, Ralph/F-7729-2012; Mellman, Ira/ABG-5896-2020; Gatti, Evelina/B-7941-2012	Gatti, Evelina/0000-0002-0667-0799; pierre, philippe/0000-0003-0863-8255				AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; Austyn JM, 1996, J EXP MED, V183, P1287, DOI 10.1084/jem.183.4.1287; BUUS S, 1986, P NATL ACAD SCI USA, V83, P3968, DOI 10.1073/pnas.83.11.3968; CAUX C, 1996, BLOOD CELL BIOCH, P263; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KLEIJMEER MJ, 1995, J IMMUNOL, V154, P5715; LARSEN CP, 1994, J IMMUNOL, V152, P5208; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; NIJMAN HW, 1995, J EXP MED, V182, P163, DOI 10.1084/jem.182.1.163; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; Pierre P, 1996, IMMUNITY, V4, P229, DOI 10.1016/S1074-7613(00)80431-8; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; STEINMAN RM, 1995, J EXP MED, V182, P283, DOI 10.1084/jem.182.2.283; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; THOMAS R, 1997, IMMUNOL TODAY, V17, P559; WILLIAMS LA, 1994, INT REV CYTOL, V153, P41, DOI 10.1016/S0074-7696(08)62188-9	26	632	641	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					787	792		10.1038/42039	http://dx.doi.org/10.1038/42039			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285592	Bronze			2022-12-24	WOS:A1997XR66700054
J	Cousens, SN; Zeidler, M; Esmonde, TF; DeSilva, R; Wilesmith, JW; Smith, PG; Will, RG				Cousens, SN; Zeidler, M; Esmonde, TF; DeSilva, R; Wilesmith, JW; Smith, PG; Will, RG			Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96	BRITISH MEDICAL JOURNAL			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; ENGLAND; BSE	Objective: To identify changes in the occurrence of Creutzfeldt-Jakob disease that might be related to the epidemic of bovine spongiform encephalopathy. Design: Epidemiological surveillance of the United Kingdom population for Creutzfeldt-Jakob disease based on (a) referral of suspected cases by neurologists, neuropathologists, and neurophysiologists and (b) death certificates. Setting: England and Wales during 1970-84, and whole of the United Kingdom during 1985-96. Subjects: AU 662 patients identified as sporadic cases of Creutzfeldt-Jakob disease. Main outcome measures: Age distribution of patients, age specific time trends of disease, occupational exposure to cattle, potential exposure to causative agent of bovine spongiform encephalopathy. Results: During 1970-96 there was an increase in the number of sporadic cases of Creutzfeldt-Jakob disease recorded yearly in England and Wales. The greatest increase was among people aged over 70. There was a statistically significant excess of cases among dairy farm workers and their spouses and among people at increased risk of contact with live cattle infected with bovine spongiform encephalopathy. During 1994-6 there were six deaths from sporadic Creutzfeldt-Jakob disease in the United Kingdom in patients aged under 30. Conclusions: The increase in the incidence of sporadic Creutzfeldt-Jakob disease and the high incidence in dairy farmers in the United Kingdom may be unrelated to bovine spongiform encephalopathy. The most striking change in the pattern of Creutzfeldt-Jakob disease in the United Kingdom after the epidemic of bovine spongiform encephalopathy is provided by the incidence in a group of exceptionally young patients with a consistent and unusual neuropathological profile. The outcome of mouse transmission studies and the future incidence of the disease in the United Kingdom and elsewhere, will be important in judging whether the agent causing bovine spongiform encephalopathy has infected humans.	WESTERN GEN HOSP,NATL CREUTZFELDT JAKOB DIS SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; CENT VET LAB,ADDLESTONE KT15 3NB,SURREY,ENGLAND	University of Edinburgh	Cousens, SN (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT INFECT & TROP DIS,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		smith, peter/ABH-9627-2020	smith, peter/0000-0003-0080-7560				AYLIN P, 1996, POPUL TRENDS, V85, P34; BELL JE, 1993, BRIT MED BULL, V49, P738, DOI 10.1093/oxfordjournals.bmb.a072645; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; Bruton CJ, 1995, NEURODEGENERATION, V4, P357, DOI 10.1006/neur.1995.0043; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COUSENS SN, 1990, J NEUROL NEUROSUR PS, V53, P459, DOI 10.1136/jnnp.53.6.459; DAVIES PTG, 1993, LANCET, V342, P680, DOI 10.1016/0140-6736(93)91787-M; HARRIESJONES R, 1988, J NEUROL NEUROSUR PS, V51, P113; Hill AF, 1997, LANCET, V350, P188, DOI 10.1016/S0140-6736(05)62356-2; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; MEYER LA, 1996, THESIS; *NAT CJD SURV UN, 1995, 4 ANN REP DEP HLTH; SAWCER SJ, 1993, LANCET, V341, P642, DOI 10.1016/0140-6736(93)90414-C; SMITH PEM, 1995, LANCET, V346, P898, DOI 10.1016/S0140-6736(95)92734-4; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; Wickham A, 1996, BRIT MED J, V312, P1038; WILESMITH JW, 1988, VET REC, V123, P638; WILESMITH JW, 1994, SEMIN VIROL, V5, P179, DOI 10.1006/smvy.1994.1018; WILL RG, 1986, J NEUROL NEUROSUR PS, V49, P749, DOI 10.1136/jnnp.49.7.749; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134; Will Robert G., 1996, P119; Young GR, 1996, LANCET, V348, P610, DOI 10.1016/S0140-6736(05)64822-2	24	90	91	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					389	395		10.1136/bmj.315.7105.389	http://dx.doi.org/10.1136/bmj.315.7105.389			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277601	Green Published			2022-12-24	WOS:A1997XR54900017
J	Sultan, AA; Thathy, V; Frevert, U; Robson, KJH; Crisanti, A; Nussenzweig, V; Nussenzweig, RS; Menard, R				Sultan, AA; Thathy, V; Frevert, U; Robson, KJH; Crisanti, A; Nussenzweig, V; Nussenzweig, RS; Menard, R			TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites	CELL			English	Article							MALARIA CIRCUMSPOROZOITE PROTEIN; HOST-CELL INVASION; FALCIPARUM SPOROZOITES; PROTECTIVE ANTIGEN; ANONYMOUS PROTEIN; SURFACE PROTEIN-2; EIMERIA-TENELLA; SALIVARY-GLAND; BLOOD STAGES; REGION-II	Many protozoans of the phylum Apicomplexa are invasive parasites that exhibit a substrate-dependent gliding motility. Plasmodium (malaria) sporozoites, the stage of the parasite that invades the salivary glands of the mosquito vector and the liver of the vertebrate host, express a surface protein called thrombospondin-related anonymous protein (TRAP) that has homologs in other Apicomplexa. By gene targeting in a rodent Plasmodium, we demonstrate that TRAP is critical for sporozoite infection of the mosquito salivary glands and the rat liver, and is essential for sporozoite gliding motility in vitro. This suggests that in Plasmodium sporozoites, and likely in other Apicomplexa, gliding locomotion and cell invasion have a common molecular basis.	NYU, MED CTR,MICHAEL HEIDELBERGER DIV IMMUNOL, DEPT PATHOL,KAPLAN CANC CTR, NEW YORK, NY 10016 USA; NYU, MED CTR, DEPT MED & MOL PARASITOL, NEW YORK, NY 10016 USA; JOHN RADCLIFFE HOSP, INST MOL MED, MRC, MOL HAEMATOL UNIT, OXFORD OX3 9DU, ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL, LONDON SW7 2BB, ENGLAND	New York University; New York University; University of Oxford; Imperial College London				Frevert, Ute/0000-0001-9556-7330; Thathy, Vandana/0000-0001-7797-8638				AIKAWA M, 1978, J CELL BIOL, V77, P72, DOI 10.1083/jcb.77.1.72; ARROWOOD MJ, 1991, J PARASITOL, V77, P315, DOI 10.2307/3283104; BALL GH, 1961, J PARASITOL, V47, P787, DOI 10.2307/3275472; BELER JC, 1993, PARASITOL TODAY, V9, P210; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CERAMI C, 1992, MOL BIOCHEM PARASIT, V54, P1, DOI 10.1016/0166-6851(92)90089-3; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; COWAN G, 1992, LANCET, V339, P1412, DOI 10.1016/0140-6736(92)91229-2; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5; DUBREMETZ JF, 1978, J ULTRA MOL STRUCT R, V62, P94, DOI 10.1016/S0022-5320(78)90012-6; DUBREMETZ JF, 1985, EXP PARASITOL, V59, P24, DOI 10.1016/0014-4894(85)90053-0; ENTZEROTH R, 1989, PARASITOL RES, V76, P174, DOI 10.1007/BF00930842; FINE E, 1984, AM J TROP MED HYG, V33, P220, DOI 10.4269/ajtmh.1984.33.220; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; HOLLINGDALE MR, 1982, J IMMUNOL, V128, P1929; JENSEN JB, 1978, J PROTOZOOL, V25, P169, DOI 10.1111/j.1550-7408.1978.tb04391.x; KING CA, 1988, PARASITOL TODAY, V4, P315, DOI 10.1016/0169-4758(88)90113-5; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; McCutchan TF, 1996, P NATL ACAD SCI USA, V93, P11889, DOI 10.1073/pnas.93.21.11889; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; MULLER HM, 1993, EMBO J, V12, P2881, DOI 10.1002/j.1460-2075.1993.tb05950.x; NAGASAWA H, 1988, EXP PARASITOL, V66, P27, DOI 10.1016/0014-4894(88)90047-1; Nussenzweig RS, 1997, NEW ENGL J MED, V336, P128, DOI 10.1056/NEJM199701093360210; NUSSENZWEIG V, 1985, CELL, V42, P401, DOI 10.1016/0092-8674(85)90093-5; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; PIMENTA PF, 1994, J EUKARYOT MICROBIOL, V41, P608, DOI 10.1111/j.1550-7408.1994.tb01523.x; Robson KJH, 1997, MOL BIOCHEM PARASIT, V84, P1, DOI 10.1016/S0166-6851(96)02774-0; ROBSON KJH, 1995, EMBO J, V14, P3883, DOI 10.1002/j.1460-2075.1995.tb00060.x; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROGERS WO, 1992, MOL BIOCHEM PARASIT, V53, P45, DOI 10.1016/0166-6851(92)90005-5; ROGERS WO, 1992, P NATL ACAD SCI USA, V89, P9176, DOI 10.1073/pnas.89.19.9176; RUSSELL DG, 1983, PARASITOLOGY, V87, P199, DOI 10.1017/S0031182000052562; RUSSELL DG, 1981, J CELL SCI, V50, P345; RYNING FW, 1978, INFECT IMMUN, V20, P739, DOI 10.1128/IAI.20.3.739-743.1978; Shakibaei M, 1996, J EXP MED, V184, P1699, DOI 10.1084/jem.184.5.1699; Sinnis P, 1996, J EXP MED, V184, P945, DOI 10.1084/jem.184.3.945; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; Sinnis P, 1996, INFECT AGENT DIS, V5, P182; Sinnis Photini, 1996, P15; SPEER CA, 1985, J PARASITOL, V71, P33, DOI 10.2307/3281974; STEWART MJ, 1986, INFECT IMMUN, V51, P859, DOI 10.1128/IAI.51.3.859-864.1986; STEWART MJ, 1988, J PROTOZOOL, V35, P389, DOI 10.1111/j.1550-7408.1988.tb04115.x; STEWART MJ, 1991, J PROTOZOOL, V38, P411, DOI 10.1111/j.1550-7408.1991.tb01379.x; STEWART MJ, 1992, J PROTOZOOL, V39, P663, DOI 10.1111/j.1550-7408.1992.tb04446.x; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Templeton TJ, 1997, MOL BIOCHEM PARASIT, V84, P13, DOI 10.1016/S0166-6851(96)02775-2; TOMLEY FM, 1991, MOL BIOCHEM PARASIT, V49, P277, DOI 10.1016/0166-6851(91)90071-D; VANDERBERG J, 1967, J PROTOZOOL, V14, P82, DOI 10.1111/j.1550-7408.1967.tb01452.x; VANDERBERG JP, 1975, J PARASITOL, V61, P43, DOI 10.2307/3279102; VANDERBERG JP, 1974, J PROTOZOOL, V21, P527, DOI 10.1111/j.1550-7408.1974.tb03693.x; VANDERBERG JP, 1990, J PROTOZOOL, V37, P528, DOI 10.1111/j.1550-7408.1990.tb01260.x; VANDIJK MR, 1995, SCIENCE, V268, P1358, DOI 10.1126/science.7761856; vanDijk MR, 1996, SCIENCE, V271, P662, DOI 10.1126/science.271.5249.662; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X; WARBURG A, 1992, EXP PARASITOL, V75, P303, DOI 10.1016/0014-4894(92)90215-V; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; YOSHIDA N, 1981, J EXP MED, V154, P1225, DOI 10.1084/jem.154.4.1225; YOSHIDA N, 1980, SCIENCE, V207, P71, DOI 10.1126/science.6985745	60	470	492	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	1997	90	3					511	522		10.1016/S0092-8674(00)80511-5	http://dx.doi.org/10.1016/S0092-8674(00)80511-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267031	hybrid			2022-12-24	WOS:A1997XQ06300015
J	Maldonado, R; Saiardi, A; Valverde, O; Samad, TA; Roques, BP; Borrelli, E				Maldonado, R; Saiardi, A; Valverde, O; Samad, TA; Roques, BP; Borrelli, E			Absence of opiate rewarding effects in mice lacking dopamine D2 receptors	NATURE			English	Article							VENTRAL TEGMENTAL AREA; MORPHINE-WITHDRAWAL SYNDROME; NUCLEUS-ACCUMBENS; MESOLIMBIC SYSTEM; RATS; HEROIN; INVOLVEMENT; STIMULATION; INCREASE; COCAINE	Dopamine receptors have been implicated in the behavioural response to drugs of abuse. These responses are mediated particularly by the mesolimbic dopaminergic pathway arising in the ventral tegmental area and projecting to the limbic system, The rewarding properties of opiates(1) and the somatic expression of morphine abstinence(2) have been related to changes in mesolimbic dopaminergic activity that could constitute the neural substrate for opioid addiction(3), These adaptive responses to repeated morphine administration have been investigated in mice with a genetic disruption of the dopaminergic D2 receptors(4). Although the behavioural expression of morphine withdrawal was unchanged in these mice, a total suppression of morphine rewarding properties was observed in a place-preference test. This effect is specific to the drug, as mice lacking D2 receptors behaved the same as wild-type mice when food is used as reward, We conclude that the D2 receptor plays a crucial role in the motivational component of drug addiction.	UNIV STRASBOURG 1, INST GENET & BIOL MOL & CELLULAIRE, CNRS, INSERM, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; UNIV PARIS 05, DEPT PHARMACOCHIM MOL & STRUCT,CNRS,URA D1500, INSERM,U266, F-75270 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Valverde, Olga/D-8654-2012; Borrelli, Emiliana/M-8994-2018; Maldonado, Rafael/F-5657-2014	Valverde, Olga/0000-0003-2264-7852; Maldonado, Rafael/0000-0002-4359-8773				BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; BORG PJ, 1994, PHARMACOL BIOCHEM BE, V47, P633, DOI 10.1016/0091-3057(94)90169-4; BOZARTH MA, 1981, LIFE SCI, V28, P551, DOI 10.1016/0024-3205(81)90148-X; BOZARTH MA, 1994, NEUROSCI BIOBEHAV R, V18, P373, DOI 10.1016/0149-7634(94)90050-7; BROEKKAMP CL, 1979, PHARMACOL BIOCHEM BE, V11, P289, DOI 10.1016/0091-3057(79)90137-0; DAUGE V, 1989, PSYCHOPHARMACOLOGY, V99, P168, DOI 10.1007/BF00442803; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; ELMER GI, 1995, PSYCHOPHARMACOLOGY, V117, P23, DOI 10.1007/BF02245094; ETTENBERG A, 1982, PSYCHOPHARMACOLOGY, V78, P204, DOI 10.1007/BF00428151; FOURNIEZALUSKI MC, 1992, J MED CHEM, V35, P2473, DOI 10.1021/jm00091a016; HARRIS GC, 1994, NATURE, V371, P155, DOI 10.1038/371155a0; JOYCE EM, 1979, NEUROSCI LETT, V14, P207, DOI 10.1016/0304-3940(79)96149-4; KALIVAS PW, 1986, AM J PHYSIOL, V251, pR243, DOI 10.1152/ajpregu.1986.251.2.R243; KALIVAS PW, 1983, J PHARMACOL EXP THER, V227, P229; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LONGONI R, 1987, PSYCHOPHARMACOLOGY, V93, P401, DOI 10.1007/BF00187265; MACKEY WB, 1985, PHARMACOL BIOCHEM BE, V22, P101, DOI 10.1016/0091-3057(85)90492-7; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; MALDONADO R, 1992, J PHARMACOL EXP THER, V261, P669; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; PETTIT HO, 1984, PSYCHOPHARMACOLOGY, V84, P167, DOI 10.1007/BF00427441; PHILLIPS AG, 1980, PHARMACOL BIOCHEM BE, V12, P965, DOI 10.1016/0091-3057(80)90460-8; Salamone JD, 1996, J NEUROSCI METH, V64, P137, DOI 10.1016/0165-0270(95)00125-5; SALAMONE JD, 1994, BEHAV BRAIN RES, V61, P117, DOI 10.1016/0166-4328(94)90153-8; SMITH JE, 1985, PHARMACOL BIOCHEM BE, V23, P843, DOI 10.1016/0091-3057(85)90080-2; SPYRAKI C, 1983, PSYCHOPHARMACOLOGY, V79, P278, DOI 10.1007/BF00427827; STINUS L, 1989, BIOL PSYCHIAT, V26, P363, DOI 10.1016/0006-3223(89)90052-8; Valverde O, 1996, PSYCHOPHARMACOLOGY, V123, P119, DOI 10.1007/BF02246168; Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469	30	358	391	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 7	1997	388	6642					586	589		10.1038/41567	http://dx.doi.org/10.1038/41567			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252189	Bronze			2022-12-24	WOS:A1997XP72200050
J	Adams, JS; Lee, G				Adams, JS; Lee, G			Gains in bone mineral density with resolution of vitamin D intoxication	ANNALS OF INTERNAL MEDICINE			English	Article							WOMEN; OSTEOPOROSIS; PREVENTION; MILK	Background: Vitamin D intoxication is associated with the mobilization of skeletal calcium. Objective: To ascertain how the resolution of vitamin D intoxication affects bone density. Design: Case series. Setting: Referral service for metabolic bone disease in a tertiary care teaching hospital. Patients: Four patients with osteoporosis who were each using several nonprescription dietary supplements and were found to have fasting hypercalciuria. Intervention: Discontinuation of use of dietary supplements. Measurements: Serial measurement of serum levels of 25-hydroxyvitamin D, ratio of fasting urinary calcium to creatinine, and bone mineral density for 3 years. Results: Discontinuation of use of dietary supplements resulted in the normalization of serum levels of 25-hydroxyvitamin D, the normalization of the ratio of urinary calcium to creatinine, and a mean annual increase in bone mineral density (+/-SD) of 1.9% +/- 0.6%. Conclusions: Occult vitamin D intoxication was detected in patients who were using dietary supplements that contained an unadvertised high level of vitamin D. Resolution of vitamin D intoxication was associated with a rebound in bone mineral density.	UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Adams, JS (corresponding author), CEDARS SINAI MED CTR, B131, 8700 BEVERLY BLVD, LOS ANGELES, CA 94309 USA.		Adams, John S/I-3365-2013	Adams, John S/0000-0001-9607-5020	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00425-28] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		[Anonymous], 1956, BRIT MED J, V2, P149; BERTHJONES J, 1993, BRIT J DERMATOL, V129, P411, DOI 10.1111/j.1365-2133.1993.tb03168.x; CLEMENS TL, 1990, PRINCIPLES PRACTICE, P417; DIAMOND T, 1994, ANN INTERN MED, V120, P8, DOI 10.7326/0003-4819-120-1-199401010-00002; FRASER DR, 1995, LANCET, V345, P104, DOI 10.1016/S0140-6736(95)90067-5; HENNEY JE, 1993, NEW YORK STATE J MED, V93, P86; HOLICK MF, 1992, NEW ENGL J MED, V326, P1178, DOI 10.1056/NEJM199204303261802; JACOBUS CH, 1992, NEW ENGL J MED, V326, P1173, DOI 10.1056/NEJM199204303261801; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; OOMS ME, 1995, J CLIN ENDOCR METAB, V80, P1052, DOI 10.1210/jc.80.4.1052; Parfitt AM, 1996, ANN INTERN MED, V125, P413, DOI 10.7326/0003-4819-125-5-199609010-00009; POUILLES JM, 1992, CLIN RHEUMATOL, V11, P492, DOI 10.1007/BF02283104; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P729, DOI 10.1210/jc.80.3.729; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; VANDERSCHUEREN D, 1991, CALCIFIED TISSUE INT, V49, P84, DOI 10.1007/BF02565126; ZERWEKH JE, 1992, OSTEOPOROSIS INT, V2, P128, DOI 10.1007/BF01623819	16	77	81	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					203	206		10.7326/0003-4819-127-3-199708010-00004	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245225				2022-12-24	WOS:A1997XN12900004
J	Meier, DE; Morrison, RS; Cassel, CK				Meier, DE; Morrison, RS; Cassel, CK			Improving palliative care	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CANCER PAIN MANAGEMENT; TERMINALLY ILL PATIENTS; PHYSICIAN ATTITUDES; MEDICAL-EDUCATION; ADVANCE DIRECTIVES; DYING PATIENT; UNITED-STATES; DEATH; HOSPICE; LIFE	Although most deaths in the United States occur in hospitals, data suggest that hospitals and physicians are not equipped to handle the medical and psychosocial problems of dying patients. In this article, we review the barriers to achieving a peaceful death, including inadequate medical professional education on palliative care, and public and professional uncertainty about the difference between forgoing life-sustaining treatment and active euthanasia, and health professionals' difficulty recognizing when patients are dying and the associated sense that death is a professional failure. Other barriers include fiscal constraints on the length of stay, the number of nurses available to care for dying patients, legal and regulatory constraints on obtaining opioid prescriptions, and a segregated system of hospice care that requires patients to be separated from familiar health care providers and settings in order to receive palliative care at the end of life. Identifying the opportunities that can improve the delivery of palliative care at the end of life is the first step toward developing corrective approaches. Strategies that enhance these opportunities are proposed.			Meier, DE (corresponding author), MT SINAI MED CTR, BOX 1070, NEW YORK, NY 10029 USA.							Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; *AM MED ASS, 1993, ANN MED SCH QUEST 2; *AM SOC CLIN ONC A, 1992, J CLIN ONCOL, V10, P1976; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; ANGAROLO R, 1994, APS B, V4, P9; [Anonymous], 1994, AHCPR PUBL, V94-0592; ASCH DA, 1995, AM J RESP CRIT CARE, V151, P288, DOI 10.1164/ajrccm.151.2.7842181; Asch DA, 1996, NEW ENGL J MED, V334, P1374, DOI 10.1056/NEJM199605233342106; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BERRY ZS, 1993, JAMA-J AM MED ASSOC, V270, P221, DOI 10.1001/jama.270.2.221; BLANK LL, 1995, WESTERN J MED, V163, P297; Byock I R, 1993, J Palliat Care, V9, P25; Byock I R, 1994, J Palliat Care, V10, P8; Callahan Daniel, 1993, TROUBLED DREAM LIFE; CASSEL C, 1996, ACP OBSERVER     JUL, P2; CASSEL C, 1994, I MED WORKSH EX FEAS; Cassel CK, 1996, NEW ENGL J MED, V335, P1232, DOI 10.1056/NEJM199610173351612; CHERNY NI, 1995, CANCER-AM CANCER SOC, V76, P2181, DOI 10.1002/1097-0142(19951201)76:11<2181::AID-CNCR2820761102>3.0.CO;2-F; CHERNY NI, 1994, P AMSLC CLIN ONCOL, V12, pA434; CHRISTAKIS NA, 1994, J GEN INTERN MED, V9, P314, DOI 10.1007/BF02599178; Christakis NA, 1996, J GEN INTERN MED, V11, P422, DOI 10.1007/BF02600190; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; DICKINSON GE, 1985, J MED EDUC, V60, P942; DIDICH J, 1989, CLEV CLIN J MED, V56, P762, DOI 10.3949/ccjm.56.8.762; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; EMANUEL L, 1995, JAMA-J AM MED ASSOC, V274, P501, DOI 10.1001/jama.274.6.501; FORD G, 1993, OXFORD TXB PALLIATIV, P43; GIANELLI D, 1996, AM MED NEWS     0916, P5; Gilligan T, 1996, ANN INTERN MED, V125, P137, DOI 10.7326/0003-4819-125-2-199607150-00010; GRAY D, 1987, J CHRON DIS, V40, P801, DOI 10.1016/0021-9681(87)90132-9; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; HAFFERTY FW, 1994, ACAD MED, V69, P861, DOI 10.1097/00001888-199411000-00001; *HAST CTR, 1987, GUID TERM LIF SUST T; HERMAN TA, 1980, NEW YORK STATE J MED, V80, P200; HILL CS, 1995, JAMA-J AM MED ASSOC, V274, P1881, DOI 10.1001/jama.274.23.1881; HILL TP, 1995, ARCH INTERN MED, V155, P1265, DOI 10.1001/archinte.155.12.1265; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; JORANSON DE, 1994, J PAIN SYMPTOM MANAG, V9, P244, DOI 10.1016/0885-3924(94)90101-5; JORANSON DE, 1995, AM PAIN SOC B, V5, P1; KANE AC, 1986, OMEGA, V16, P11; Kane RS, 1996, J AM GERIATR SOC, V44, P321, DOI 10.1111/j.1532-5415.1996.tb00923.x; KIDDER D, 1992, HEALTH SERV RES, V27, P195; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lewin Tamar, 1996, N Y Times Web, pD20; LO B, 1995, JAMA-J AM MED ASSOC, V274, P1634, DOI 10.1001/jama.274.20.1634; LYNN J, 1995, WESTERN J MED, V163, P250; MacDonald N, 1993, J Cancer Educ, V8, P197; MACDONALD N, 1991, CANCER DETECT PREV, V15, P253; MARTINI CJM, 1993, JAMA-J AM MED ASSOC, V270, P1053, DOI 10.1001/jama.270.9.1053; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; MCCUE JD, 1995, JAMA-J AM MED ASSOC, V273, P1039, DOI 10.1001/jama.273.13.1039; Meier DE, 1996, ARCH INTERN MED, V156, P1227, DOI 10.1001/archinte.156.11.1227; MEIER DE, 1993, PHYSICIAN ASSISTED D; MERMANN AC, 1991, ACAD MED, V66, P35, DOI 10.1097/00001888-199101000-00010; Miller FG, 1996, NEW ENGL J MED, V334, P1740, DOI 10.1056/NEJM199606273342612; Morrison R S, 1995, Trends Health Care Law Ethics, V10, P91; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; MORRISON RS, 1994, GENERATIONS, V18, P48; NARKIEWICZ R, 1986, AM J HOSP CARE, P12; *NAT CTR HLTH STAT, 1993, VIT STAT US, V2; *NAT HOSP ORG, 1995, NAT HOSP ORG FACT SH; *NEW YORK STAT TAS, 1994, DEATH IS SOUGHT; OJIMCNAIR K, 1984, HLTH MARKETING Q, V2, P119; PERRONE C, 1995, 712901 NAT HOSP ORG; Plumb J D, 1992, Am J Hosp Palliat Care, V9, P32, DOI 10.1177/104990919200900311; Portenoy R K, 1990, J Pain Symptom Manage, V5, pS46; PORTENOY RK, 1992, CANCER-AM CANCER SOC, V70, P1616, DOI 10.1002/1097-0142(19920915)70:6<1616::AID-CNCR2820700630>3.0.CO;2-7; RAPPAPORT W, 1993, SURGERY, V113, P163; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; SCOTT J, 1993, OXFORD TXB PALLIATIV; SCOTT RA, 1995, MILBANK Q, V73, P77, DOI 10.2307/3350314; SERAVALLI EP, 1988, NEW ENGL J MED, V319, P1728, DOI 10.1056/NEJM198812293192609; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; The Joint Commission on Accreditation of Healthcare Organizations, 1996, COMPR ACCR MAN HOSP; TOLLE SW, 1984, ARCH INTERN MED, V144, P2389, DOI 10.1001/archinte.144.12.2389; TULSKY JA, 1996, J GEN INTERN MED, V156, P1285; VLADECK BC, 1995, JAMA-J AM MED ASSOC, V274, P449, DOI 10.1001/jama.274.6.449; vonGunten CF, 1996, NEW ENGL J MED, V335, P1766; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WALSH D, 1994, J PAIN SYMPTOM MANAG, V9, P109, DOI 10.1016/0885-3924(94)90163-5; WEISSMAN DE, 1993, J PAIN SYMPTOM MANAG, V8, P29, DOI 10.1016/0885-3924(93)90117-E; *WHO EXP COMM, 1990, TECHN REP SER WHO, V804; 1995, MED ETHICS ADVIS NOV, P143; 1996, UPDATE UPDATE CHOICE, P1	85	113	117	2	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					225	230		10.7326/0003-4819-127-3-199708010-00008	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245229				2022-12-24	WOS:A1997XN12900008
J	Wilson, TE; Grawunder, U; Lieber, MR				Wilson, TE; Grawunder, U; Lieber, MR			Yeast DNA ligase IV mediates non-homologous DNA end joining	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; GENE; REPAIR; CDC9	The discovery of homologues from the yeast Saccharomyces cerevisiae of the human Ku DNA-end-binding proteins (HDF1 and KU80) has established that this organism is capable of non-homologous double-strand end joining (NHET)(1-5), a form of DNA double-strand break repair (DSBR) active in mammalian V(D)J recombination(6-8). Identification of the DNA ligase that mediates NHEJ in yeast will help elucidate the function of the four mammalian DNA ligases in DSBR, V(D)J recombination and other reactions(9,10). Here we show that S. cerevisiae has two typical DNA ligases, the known DNA ligase I homologue CDC9 (refs 11-14) and the previously unknown DNA ligase IV homologue DNL4. dnl4 mutants are deficient in precise and end-processed NHEJ. DNL4 and HDF1 are epistatic in this regard, with the mutation of each having equivalent effects. dn14 mutants are complemented by overexpression of Dn14 but not of Cdc9, and deficiency of Dn14 alone does not impair either cell growth or the Cdc9-mediated responses to ionizing and ultraviolet radiation. Thus, S. cerevisiae has two distinct and separate Ligation pathways.	WASHINGTON UNIV, SCH MED, DIV LAB MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, DIV MOL ONCOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)				Lieber, Michael/0000-0003-3700-6345; Lieber, Michael/0000-0001-8809-0909				BARKER DG, 1985, NUCLEIC ACIDS RES, V13, P8323, DOI 10.1093/nar/13.23.8323; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Lieber M, 1996, CURR BIOL, V6, P134, DOI 10.1016/S0960-9822(02)00443-8; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; Lindahl T, 1995, J CELL SCI, P73; Milne GT, 1996, MOL CELL BIOL, V16, P4189; MOORE CW, 1982, J BACTERIOL, V150, P1227, DOI 10.1128/JB.150.3.1227-1233.1982; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; PETRINI JHJ, 1994, J IMMUNOL, V152, P176; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Siede W, 1996, GENETICS, V142, P91; TOMKINSON AE, 1992, BIOCHEMISTRY-US, V31, P11762, DOI 10.1021/bi00162a013; Weaver D, 1995, ANN NY ACAD SCI, V764, P99; WEI YF, 1995, MOL CELL BIOL, V15, P3206; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981	24	335	335	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 31	1997	388	6641					495	498		10.1038/41365	http://dx.doi.org/10.1038/41365			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242411	Bronze			2022-12-24	WOS:A1997XN55300054
J	Edwardson, JM; An, S; Jahn, R				Edwardson, JM; An, S; Jahn, R			The secretory granule protein syncollin binds to syntaxin in a Ca2+-sensitive manner	CELL			English	Article							PANCREATIC ZYMOGEN GRANULES; NEUROTRANSMITTER RELEASE; MEMBRANE-FUSION; PLASMA-MEMBRANES; VESICLE FUSION; REGULATED EXOCYTOSIS; VESICULAR TRANSPORT; CALCIUM-DEPENDENCE; EXOCRINE PANCREAS; AMYLASE RELEASE	The membrane proteins synaptobrevin, syntaxin, and SNAP-25 form the core of a ubiquitous fusion machine that interacts with the soluble proteins NSF and alpha-SNAP. During regulated exocytosis, membrane fusion is usually strictly controlled by Ca2+ ions. However, the mechanism by which Ca2+ regulates exocytosis is still unclear. Here we show that the membranes of exocrine secretory granules contain an 18-kDa protein, syncollin, that binds to syntaxin at tow Ca2+ concentrations and dissociates at concentrations known to stimulate exocytosis. Syncollin has a single hydrophobic domain at its N-terminus and shows no significant homology with any known protein. Recombinant syncollin inhibits fusion in vitro between zymogen granules and pancreatic plasma membranes, and its potency falls as Ca2+ concentration rises. We suggest that syncollin acts as a Ca2+-sensitive regulator of exocytosis in exocrine tissues.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University	Edwardson, JM (corresponding author), UNIV CAMBRIDGE,DEPT PHARMACOL,TENNIS COURT RD,CAMBRIDGE CB2 1QJ,ENGLAND.			Jahn, Reinhard/0000-0003-1542-3498				ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROADIE K, 1994, P NATL ACAD SCI USA, V91, P10727, DOI 10.1073/pnas.91.22.10727; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DAVIETOV BA, 1993, J BIOL CHEM, V268, P26386; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; EDWARDSON JM, 1993, FEBS LETT, V320, P52, DOI 10.1016/0014-5793(93)81656-K; EDWARDSON JM, 1990, BIOCHIM BIOPHYS ACTA, V1053, P32, DOI 10.1016/0167-4889(90)90022-6; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FOHR KJ, 1993, METHOD ENZYMOL, V221, P149, DOI 10.1016/0076-6879(93)21014-Y; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; IWATSUKI N, 1980, NATURE, V283, P492, DOI 10.1038/283492a0; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KITAGAWA M, 1990, AM J PHYSIOL, V259, pG157, DOI 10.1152/ajpgi.1990.259.2.G157; KNIGHT DE, 1989, TRENDS NEUROSCI, V12, P451, DOI 10.1016/0166-2236(89)90095-7; LEE EG, 1994, BIOCHEM J, V298, P599, DOI 10.1042/bj2980599; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MACLEAN CM, 1992, BIOCHEM J, V286, P747, DOI 10.1042/bj2860747; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; NADIN CY, 1989, J CELL BIOL, V109, P2801, DOI 10.1083/jcb.109.6.2801; PADFIELD PJ, 1991, BIOCHEM BIOPH RES CO, V174, P536, DOI 10.1016/0006-291X(91)91450-Q; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PANDOL SJ, 1985, J BIOL CHEM, V260, P81; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; THOM P, 1993, CELL, V74, P661; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0	57	70	74	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					325	333		10.1016/S0092-8674(00)80340-2	http://dx.doi.org/10.1016/S0092-8674(00)80340-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244306	Bronze			2022-12-24	WOS:A1997XN24900016
J	Stamos, JK; Shulman, S				Stamos, JK; Shulman, S			Abandoning empirical antibiotics for febrile children	LANCET			English	Editorial Material							OCCULT BACTEREMIA				Stamos, JK (corresponding author), NORTHWESTERN UNIV,SCH MED,CHILDRENS MEM HOSP,DEPT PEDIAT,CHICAGO,IL 60614, USA.							BARAFF LJ, 1993, PEDIATRICS, V82, P1; BASS JW, 1993, PEDIATR INFECT DIS J, V12, P466, DOI 10.1097/00006454-199306000-00003; Browne GJ, 1997, ARCH DIS CHILD, V76, P129, DOI 10.1136/adc.76.2.129; JAFFE DM, 1987, NEW ENGL J MED, V317, P1175, DOI 10.1056/NEJM198711053171902; LONG SS, 1994, J PEDIATR-US, V124, P585, DOI 10.1016/S0022-3476(05)83137-3; MCGOWAN JE, 1973, NEW ENGL J MED, V288, P1309, DOI 10.1056/NEJM197306212882501	6	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					84	84		10.1016/S0140-6736(05)61812-0	http://dx.doi.org/10.1016/S0140-6736(05)61812-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228958				2022-12-24	WOS:A1997XK11400006
J	Saitoh, S; Takahashi, K; Yanagida, M				Saitoh, S; Takahashi, K; Yanagida, M			Mis6, a fission yeast inner centromere protein, acts during G1/S and forms specialized chromatin required for equal segregation	CELL			English	Article							SPINDLE POLE BODY; DNA TOPOISOMERASE-II; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; S-POMBE; FUNCTIONAL-ANALYSIS; GENE DISRUPTION; CHROMOSOME; MITOSIS	Disorder in sister chromatid separation can lead to genome instability and cancer. A temperature-sensitive S. pombe mis6-302 frequently loses a minichromosome at 26 degrees C and abolishes equal segregation of regular chromosomes at 36 degrees C. The mis6(+) gene is essential for viability, and its deletion results in missegregation identical to mis6-302. Miss acts before or at the onset of S phase, and mitotic missegregation defects are produced only after the passage of G1/S at 36 degrees C. Mise locates at the centromeres throughout the cell cycle. In the mutant, positioning of the centromeres becomes abnormal, and specialized chromatin in the inner centromeres, which give the smear micrococcal nuclease pattern in wild type, is disrupted. The ability to establish correct biorientation of sister centromeres in metaphase cells requires the Mis6-containing chromatin and originates during the passage of G1/S.			Saitoh, S (corresponding author), KYOTO UNIV,GRAD SCH SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN.			Saitoh, Shigeaki/0000-0001-5408-296X				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CLARKE L, 1986, P NATL ACAD SCI USA, V83, P8253, DOI 10.1073/pnas.83.21.8253; CLARKE L, 1990, MOL CELL BIOL, V10, P1863, DOI 10.1128/MCB.10.5.1863; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; FANKHAUSER C, 1993, EMBO J, V12, P2697, DOI 10.1002/j.1460-2075.1993.tb05931.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FISHEL B, 1988, MOL CELL BIOL, V8, P754, DOI 10.1128/MCB.8.2.754; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Gutz H., 1974, HDB GENETICS, V1, P395; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; HAGAN IM, 1988, J CELL SCI, V89, P343; HAHNENBERGER KM, 1991, MOL CELL BIOL, V11, P2206, DOI 10.1128/MCB.11.4.2206; HAHNENBERGER KM, 1989, P NATL ACAD SCI USA, V86, P577, DOI 10.1073/pnas.86.2.577; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KINOSHITA N, 1991, MOL CELL BIOL, V11, P5839, DOI 10.1128/MCB.11.12.5839; KOSHLAND D, 1994, CELL, V77, P951, DOI 10.1016/0092-8674(94)90432-4; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; MATSUMOTO T, 1990, CURR GENET, V18, P323, DOI 10.1007/BF00318213; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; MITCHISON TJ, 1992, J CELL BIOL, V119, P569, DOI 10.1083/jcb.119.3.569; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURAKAMI S, 1995, MOL GEN GENET, V246, P671, DOI 10.1007/BF00290712; MURAKAMI S, 1991, CHROMOSOMA, V101, P214, DOI 10.1007/BF00365153; NABESHIMA K, 1995, GENE DEV, V9, P1572, DOI 10.1101/gad.9.13.1572; NAKASEKO Y, 1986, EMBO J, V5, P1011, DOI 10.1002/j.1460-2075.1986.tb04316.x; NIWA O, 1989, EMBO J, V8, P3045, DOI 10.1002/j.1460-2075.1989.tb08455.x; NIWA O, 1986, MOL GEN GENET, V203, P397, DOI 10.1007/BF00422063; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; POLIZZI C, 1991, J CELL BIOL, V112, P191, DOI 10.1083/jcb.112.2.191; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAMEJIMA I, 1994, J CELL BIOL, V127, P1665; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SPENCER F, 1990, GENETICS, V124, P237; STEINER NC, 1994, CELL, V79, P865, DOI 10.1016/0092-8674(94)90075-2; STEINER NC, 1993, MOL CELL BIOL, V13, P457; TAKAHASHI K, 1994, MOL BIOL CELL, V5, P1145, DOI 10.1091/mbc.5.10.1145; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; TODA T, 1984, CURR GENET, V8, P93, DOI 10.1007/BF00420224; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UZAWA S, 1992, J CELL SCI, V101, P267; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; WOODS A, 1989, J CELL SCI, V93, P491	62	195	198	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					131	143		10.1016/S0092-8674(00)80320-7	http://dx.doi.org/10.1016/S0092-8674(00)80320-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230309	Bronze			2022-12-24	WOS:A1997XL36200015
J	Springer, MS; Cleven, GC; Madsen, O; deJong, WW; Waddell, VG; Amrine, HM; Stanhope, MJ				Springer, MS; Cleven, GC; Madsen, O; deJong, WW; Waddell, VG; Amrine, HM; Stanhope, MJ			Endemic African mammals shake the phylogenetic tree	NATURE			English	Article							SUBSTITUTIONS; EVOLUTION; DNA; RNA	The order Insectivora, including living taxa (lipotyphlans) and archaic fossil forms, is central to the question of higher-level relationships among placental mammals(1). Beginning with Huxley(2), it has been argued that insectivores retain many primitive features and are closer to the ancestral stock of mammals than are other living groups(3). Nevertheless, cladistic analysis suggests that living insectivores, at least, are united by derived anatomical features(4). Here we analyse DNA sequences from three mitochondrial genes and two nuclear genes to examine relationships of insectivores to other mammals. The representative insectivores are not monophyletic in any of our analyses. Rather, golden moles are included in a clade that contains hyraxes, manatees, elephants, elephant shrews and aardvarks. Members of this group are of presumed African origin(5,6). This implies that there was an extensive African radiation from a single common ancestor that gave rise to ecologically divergent adaptive types. 12S ribosomal RNA transversions suggest that the base of this radiation occurred during Africa's window of isolation in the Cretaceous period before land connections were developed with Europe in the early Cenozoic era.	UNIV NIJMEGEN,DEPT BIOCHEM,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV AMSTERDAM,INST SYSTEMAT & POPULAT BIOL,NL-1090 GT AMSTERDAM,NETHERLANDS; QUEENS UNIV,BELFAST BT9 07BL,ANTRIM,NORTH IRELAND	Radboud University Nijmegen; University of Amsterdam; Queens University Belfast	Springer, MS (corresponding author), UNIV CALIF RIVERSIDE,DEPT BIOL,RIVERSIDE,CA 92521, USA.		Madsen, Ole/E-3730-2012; Klein, Richard G/B-5910-2009	Madsen, Ole/0000-0001-8082-7881; 				Arnason U, 1996, J MOL EVOL, V43, P650, DOI 10.1007/BF02202113; Carroll RL, 1988, VERTEBRATE PALEONTOL; Cope E.D., 1884, AM NAT, V18, P790; COPE E. D., 1884, AM NAT, P892; DEJONG WW, 1981, NATURE, V292, P538, DOI 10.1038/292538a0; DERIJK P, 1994, NUCLEIC ACIDS RES, V22, P3495; FAITH DP, 1991, SYST ZOOL, V40, P366, DOI 10.2307/2992329; Fischer MS, 1993, MAMMAL PHYLOGENY, P217; Gheerbrant E, 1996, NATURE, V383, P68, DOI 10.1038/383068a0; GLOVER TD, 1973, J REPROD FERTIL, V35, P45, DOI 10.1530/jrf.0.0350045; HARTENBERGER JL, 1986, CR ACAD SCI II, V302, P247; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; Huxley TH., 1880, P R SOC LOND, V43, P649, DOI DOI 10.1111/J.1469-7998.1869.TB07343.X; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; Lavergne A, 1996, MOL PHYLOGENET EVOL, V6, P245, DOI 10.1006/mpev.1996.0074; Leunissen J. A. M., 1993, MAMMAL PHYLOGENY PLA, V2, P5; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; Madsen O, 1997, MOL BIOL EVOL, V14, P363, DOI 10.1093/oxfordjournals.molbev.a025772; Matthew W. D, 1909, MEM AM MUS NAT HIST, V9, P291; Novacek M.J., 1982, P3; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Porter CA, 1996, MOL PHYLOGENET EVOL, V5, P89, DOI 10.1006/mpev.1996.0008; SIBLEY CG, 1988, SCI AM, V254, P82; Springer MS, 1996, J MOL EVOL, V43, P357; SPRINGER MS, 1995, MOL BIOL EVOL, V12, P1138; Stanhope MJ, 1996, J MOL EVOL, V43, P83, DOI 10.1007/BF02337352; Swofford David L., 1996, P407; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; [No title captured]	31	266	282	1	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					61	64		10.1038/40386	http://dx.doi.org/10.1038/40386			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214502	Bronze, Green Submitted			2022-12-24	WOS:A1997XJ14300049
J	Gage, DA; Rhodes, D; Nolte, KD; Hicks, WA; Leustek, T; Cooper, AJL; Hanson, AD				Gage, DA; Rhodes, D; Nolte, KD; Hicks, WA; Leustek, T; Cooper, AJL; Hanson, AD			A new route for synthesis of dimethylsulphoniopropionate in marine algae	NATURE			English	Article							AMINO-ACID-METABOLISM; L-METHIONINE; BIOSYNTHESIS; DIMETHYLSULFONIOPROPIONATE; INTERMEDIATE; PHYTOPLANKTON; ESTERS; DMSP	The 3-dimethylsulphoniopropionate (DMSP) produced by marine algae is the main biogenic precursor of atmospheric dimethylsulphide (DMS)(1-3). This biogenic DMS, formed by bacterial and algal degradation of DMSP4,5, contributes about 1.5 x 10(13) g of sulphur to the atmosphere annually(3), and plays a major part in the global sulphur cycle, in cloud formation and potentially in climate regulation(1,3). Although DMSP biosynthesis has been partially elucidated in a higher plant(6,7), nothing is known about how alg-ae make DMSP except that the whole molecule is derived from methionine(8-12). Here we use in vivo isotope labelling to demonstrate that DMSP synthesis in the green macroalga Enteromorpha intestinalis proceeds by a route entirely distinct from that in higher plants. From methionine, the steps are transamination, reduction and S-methylation to give the novel sulphonium compound 4-dimethylsulphonio-2-hydroxybutyrate (DMSHB), which is oxidatively decarboxylated to DMSP. The key intermediate DMSHB was also identified in three diverse phytoplankton species, indicating that the same pathway operates in other algal classes that are important sources of DMS. The fact that a transamination initiates this pathway could help explain how algal DMSP (and thereby DMS) production is enhanced by nitrogen deficiency(12).	UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; PURDUE UNIV,DEPT HORT,W LAFAYETTE,IN 47907; RUTGERS STATE UNIV,CTR AGR MOL BIOL,NEW BRUNSWICK,NJ 08903; CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021	State University System of Florida; University of Florida; Michigan State University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Rutgers State University New Brunswick; Cornell University			Cooper, Arthur J.L./H-5171-2016; Rhodes, David/L-4602-2019					Blunden G., 1986, Progress phycol. Res., V4, P39; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; CHILLEMI R, 1990, J NAT PROD, V53, P87, DOI 10.1021/np50067a011; Christen P, 1985, TRANSAMINASES; DIBNER JJ, 1984, J NUTR, V114, P1716, DOI 10.1093/jn/114.9.1716; Gage DA, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P29; GOODAY GW, 1970, J MAR BIOL ASSOC UK, V50, P199, DOI 10.1017/S0025315400000710; GREENE RC, 1962, J BIOL CHEM, V237, P2251; GROENE T, 1995, J MARINE SYST, V6, P191, DOI 10.1016/0924-7963(94)00023-5; GUILLARD RR, 1962, CAN J MICROBIOL, V8, P229, DOI 10.1139/m62-029; HANSON AD, 1994, PLANT PHYSIOL, V105, P103, DOI 10.1104/pp.105.1.103; HUANG ZH, 1993, J CHROMATOGR, V635, P271, DOI 10.1016/0021-9673(93)80370-N; JAMES F, 1995, PLANT PHYSIOL, V108, P1439, DOI 10.1104/pp.108.4.1439; JAMES F, 1995, J BIOL CHEM, V270, P22344, DOI 10.1074/jbc.270.38.22344; Keller MD, 1989, ACS SYM SER, P167, DOI 10.1021/bk-1989-0393.ch011; Kirst GO, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P121; LAVINE TF, 1954, J BIOL CHEM, V207, P107; LEDYARD KM, 1994, MAR ECOL PROG SER, V110, P95, DOI 10.3354/meps110095; LIVESEY G, 1984, TRENDS BIOCHEM SCI, V9, P27, DOI 10.1016/0968-0004(84)90044-6; Malin G, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P177; MAYER RR, 1990, PLANT PHYSIOL, V94, P796, DOI 10.1104/pp.94.2.796; MIFLIN BJ, 1977, ANNU REV PLANT PHYS, V28, P299, DOI 10.1146/annurev.pp.28.060177.001503; MIZAYAKI HH, 1987, PLANT PHYSIOL, V84, P277; POKORNY M, 1970, PHYTOCHEMISTRY, V9, P2175, DOI 10.1016/S0031-9422(00)85382-0; SCISLOWSKI PWD, 1987, BIOCHEM J, V247, P35, DOI 10.1042/bj2470035; STEFELS J, 1993, MAR ECOL PROG SER, V97, P11, DOI 10.3354/meps097011; Uchida A, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P97; WALSH CT, 1979, ENZYMATIC REACTION M; WALTERS DS, 1990, PLANT PHYSIOL, V93, P1544, DOI 10.1104/pp.93.4.1544; ZAPPIA V, 1969, J BIOL CHEM, V244, P4499	30	139	153	4	62	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					891	894		10.1038/43160	http://dx.doi.org/10.1038/43160			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202120	Bronze			2022-12-24	WOS:A1997XG41600048
J	Cohen, S; Doyle, WJ; Skoner, DP; Rabin, BS; Gwaltney, JM				Cohen, S; Doyle, WJ; Skoner, DP; Rabin, BS; Gwaltney, JM			Social ties and susceptibility to the common cold	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE; HYPOTHESIS; MORTALITY; INFECTION; NETWORKS; SUPPORT; HEALTH; STRESS	Objective.-To examine the hypothesis that diverse ties to friends, family, work, and community are associated with increased host resistance to infection. Design.-After reporting the extent of participation in 12 types of social ties (eg, spouse, parent, friend, workmate, member of social group), subjects were given nasal drops containing 1 of 2 rhinoviruses and monitored for the development of a common cold. Setting.-Quarantine. Participants.-A total of 276 healthy volunteers, aged 18 to 55 years, neither seropositive for human immunodeficiency virus nor pregnant. Outcome Measures.-Colds (illness in the presence of a verified infection), mucus production, mucociliary clearance function, and amount of viral replication. Results.-In response to both viruses, those with more types of social ties were less susceptible to common colds, produced less mucus, were more effective in ciliary clearance of their nasal passages, and shed less virus. These relationships were unaltered by statistical controls for prechallenge virus-specific antibody, virus type, age, sex, season, body mass index, education, and race. Susceptibility to colds decreased in a dose-response manner with increased diversity of the social network. There was an adjusted relative risk of 4.2 comparing persons with fewest (1 to 3) to those with most (6 or more) types of social ties. Although smoking, poor sleep quality, alcohol abstinence, low dietary intake of vitamin C, elevated catecholamine levels, and being introverted were all associated with greater susceptibility to colds, they could only partially account for the relation between social network diversity and incidence of colds. Conclusions.-More diverse social networks were associated with greater resistance to upper respiratory illness.	CHILDRENS HOSP PITTSBURGH,DEPT OTOLARYNGOL,PITTSBURGH,PA 15213; CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA; UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Virginia	Cohen, S (corresponding author), CARNEGIE MELLON UNIV,DEPT PSYCHOL,PITTSBURGH,PA 15213, USA.			Cohen, Sheldon/0000-0003-2248-4600	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050429] Funding Source: NIH RePORTER; NCRR NIH HHS [NCRR/GCRC 5M01 RR00056] Funding Source: Medline; NIMH NIH HHS [MH50429, MH00721] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ader R, 1991, PSYCHONEUROIMMUNOLOG; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; [Anonymous], 1975, APPL MULTIPLE REGRES, DOI 10.4324/9780203774441.; [Anonymous], 1994, HDB HUMAN STRESS IMM; Baum A.A.G.N., 1995, MEASURING STRESS GUI, P175; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; Berkman LF, 1983, HLTH WAYS LIVING ALA; BLOCK G, 1992, J AM DIET ASSOC, V92, P686; Block G, 1990, Epidemiology, V1, P58, DOI 10.1097/00001648-199001000-00013; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; COHEN S, 1993, AM J PUBLIC HEALTH, V83, P1277, DOI 10.2105/AJPH.83.9.1277; COHEN S, 1988, HEALTH PSYCHOL, V7, P269, DOI 10.1037/0278-6133.7.3.269; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; COHEN S, 1991, LIFE SPAN DEV PSYCHO; Doyle W. J., 1988, AM J RHINOL, V2, P149, DOI DOI 10.2500/105065888781692961; FARR BM, 1990, J INFECT DIS, V162, P1173, DOI 10.1093/infdis/162.5.1173; FLETCHER MA, 1987, DIAGN CLIN IMMUNOL, V5, P68; Goldberg L.R., 1992, PSYCHOL ASSESSMENT, V4, P26, DOI [10.1037/1040-3590.4.1.26, DOI 10.1037/1040-3590.4.1.26]; Gwaltney J.M., 1989, DIAGNOSTIC PROCEDURE, P579; GWALTNEY JM, 1984, VIRAL INFECT HUMANS; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; KIECOLTGLASER JK, 1994, HDB HUMAN STRESS IMM, P321; PAFFENBARGER RS, 1993, MED SCI SPORT EXER, V25, P60, DOI 10.1249/00005768-199301000-00010; Stone A. A., 1993, BEHAV MED, V8, P115; THOITS PA, 1983, AM SOCIOL REV, V48, P174, DOI 10.2307/2095103; Uchino BN, 1996, PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488; VOGT TM, 1992, J CLIN EPIDEMIOL, V45, P659, DOI 10.1016/0895-4356(92)90138-D; WHITESIDE TL, 1990, J CLIN LAB ANAL, V4, P102, DOI 10.1002/jcla.1860040207	30	903	907	1	99	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1940	1944						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XF087	9200634	Green Submitted			2022-12-24	WOS:A1997XF08700038
J	PebayPeyroula, E; Rummel, G; Rosenbusch, JP; Landau, EM				PebayPeyroula, E; Rummel, G; Rosenbusch, JP; Landau, EM			X-ray structure of bacteriorhodopsin at 2.5 angstroms from microcrystals grown in lipidic cubic phases	SCIENCE			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; DRIVEN PROTON PUMP; HALOBACTERIUM-HALOBIUM; PURPLE MEMBRANE; 3-DIMENSIONAL CRYSTALS; ELECTRON-MICROSCOPY; NEUTRON-DIFFRACTION; MOLECULAR-DYNAMICS; TRANSLOCATION; LIGHT	Lipidic cubic phases provide a continuous three-dimensional bilayer matrix that facilitates nucleation and growth of bacteriorhodopsin microcrystals. The crystals diffract x-rays isotropically to 2.0 angstroms. The structure of this light-driven proton pump was solved at a resolution of 2.5 angstroms by molecular replacement, using previous results from electron crystallographic studies as a model, The earlier structure was generally confirmed, but several differences were found, including loop conformations and side chain residues, Eight water molecules are now identified experimentally in the proton pathway. These findings reveal the constituents of the proton translocation pathway in the ground state.	UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel	PebayPeyroula, E (corresponding author), UNIV GRENOBLE 1,CNRS,INST BIOL STRUCT,CEA,41 AVE MARTYRS,F-38027 GRENOBLE 1,FRANCE.							[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BLAUROCK AE, 1975, J MOL BIOL, V93, P139, DOI 10.1016/0022-2836(75)90124-2; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BROWN LS, 1995, J BIOL CHEM, V270, P27122, DOI 10.1074/jbc.270.45.27122; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; DENCHER NA, 1989, P NATL ACAD SCI USA, V86, P7876, DOI 10.1073/pnas.86.20.7876; ENGELMAN DM, 1980, P NATL ACAD SCI-BIOL, V77, P2023, DOI 10.1073/pnas.77.4.2023; FERRAND M, 1993, FEBS LETT, V327, P256, DOI 10.1016/0014-5793(93)80999-B; GERWERT K, 1990, P NATL ACAD SCI USA, V87, P9774, DOI 10.1073/pnas.87.24.9774; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HEBERLE J, UNPUB; HENDERSON R, 1975, J MOL BIOL, V93, P123, DOI 10.1016/0022-2836(75)90123-0; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENDERSON R, 1980, J MOL BIOL, V139, P99, DOI 10.1016/0022-2836(80)90298-3; HUMPHREY W, 1994, BIOCHEMISTRY-US, V33, P3668, DOI 10.1021/bi00178a025; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KHORANA HG, 1979, P NATL ACAD SCI USA, V76, P5046, DOI 10.1073/pnas.76.10.5046; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KREBS MP, 1991, P NATL ACAD SCI USA, V88, P859, DOI 10.1073/pnas.88.3.859; Landau EM, 1997, J PHYS CHEM B, V101, P1935, DOI 10.1021/jp963347q; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; leCoutre J, 1996, FEBS LETT, V398, P333, DOI 10.1016/S0014-5793(96)01254-9; LINDBLOM G, 1989, BIOCHIM BIOPHYS ACTA, V988, P221, DOI 10.1016/0304-4157(89)90020-8; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MICHEL H, 1980, P NATL ACAD SCI-BIOL, V77, P1283, DOI 10.1073/pnas.77.3.1283; MICHEL H, 1982, EMBO J, V1, P1267, DOI 10.1002/j.1460-2075.1982.tb00023.x; NI B, 1990, GENE, V90, P169, DOI 10.1016/0378-1119(90)90456-2; OESTERHELT D, 1992, J BIOENERG BIOMEMBR, V24, P181, DOI 10.1007/BF00762676; OESTERHELT D, 1973, P NATL ACAD SCI USA, V70, P2853, DOI 10.1073/pnas.70.10.2853; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P66; OVCHINNIKOV YA, 1979, FEBS LETT, V100, P219, DOI 10.1016/0014-5793(79)80338-5; PAPADOPOULOS G, 1990, J MOL BIOL, V214, P15, DOI 10.1016/0022-2836(90)90140-H; Riesle J, 1996, BIOCHEMISTRY-US, V35, P6635, DOI 10.1021/bi9600456; Russell VA, 1997, SCIENCE, V276, P575, DOI 10.1126/science.276.5312.575; SASAKI J, 1992, J BIOL CHEM, V267, P20782; SCHARNAGL C, 1995, J PHYS CHEM-US, V99, P7787, DOI 10.1021/j100019a068; SCHERTLER GFX, 1993, J MOL BIOL, V234, P156, DOI 10.1006/jmbi.1993.1570; SCHULTEN K, 1978, NATURE, V272, P85, DOI 10.1038/272085a0; SZARAZ S, 1994, BIOPHYS J, V67, P1706, DOI 10.1016/S0006-3495(94)80644-7; TAKEI H, 1994, J BIOL CHEM, V269, P7387; TITTOR J, 1994, BIOPHYS J, V67, P1682, DOI 10.1016/S0006-3495(94)80642-3; ULRICH AS, 1994, BIOCHEMISTRY-US, V33, P5370, DOI 10.1021/bi00184a003; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; WEISSBUCH I, 1995, ACTA CRYSTALLOGR B, V51, P115, DOI 10.1107/S0108768194012061; WILKINS MHF, 1971, NATURE-NEW BIOL, V230, P72, DOI 10.1038/newbio230072a0; Xu D, 1995, BIOPHYS J, V69, P2745, DOI 10.1016/S0006-3495(95)80146-3	48	800	815	0	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1676	1681		10.1126/science.277.5332.1676	http://dx.doi.org/10.1126/science.277.5332.1676			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287223				2022-12-24	WOS:A1997XV68400054
J	Sewankambo, N; Gray, RH; Wawer, MJ; Paxton, L; McNairn, D; WabwireMangen, F; Serwadda, D; Li, CJ; Kiwanuka, N; Hillier, SL; Rabe, L; Gaydos, CA; Quinn, TC; KondeLule, J				Sewankambo, N; Gray, RH; Wawer, MJ; Paxton, L; McNairn, D; WabwireMangen, F; Serwadda, D; Li, CJ; Kiwanuka, N; Hillier, SL; Rabe, L; Gaydos, CA; Quinn, TC; KondeLule, J			HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; SEXUALLY-TRANSMITTED DISEASES; PELVIC INFLAMMATORY DISEASE; PREGNANT-WOMEN; GRAM STAIN; SEROPREVALENCE; TYPE-1; SYSTEM; HEALTH; COHORT	Background In-vitro research has suggested that bacterial vaginosis may increase the survival of HIV-1 in the genital tract. Therefore, we investigated the association of HIV-1 infection with vaginal flora abnormalities, including bacterial vaginosis and depletion of lactobacilli, after adjustment for sexual activity and the presence of other sexually transmitted diseases(STDs). Methods During the initial survey round of our community-based trial of STD control for HIV-1 prevention in rural Rakai District, southwestern Uganda, we selected 4718 women aged 15-59 years. They provided interview information, blood for HIV-1 and syphilis serology, urine for detection of Chlamydia trachomatis and Neisseria gonorrhoeae, and two self-administered vaginal swabs for culture of Trichomonas vaginalis and gram-stain detection of vaginal flora, classified by standardised, quantitative, morphological scoring. Scores 0-3 were normal vaginal flora (predominant lactobacilli). Higher scores suggested replacement of lactobacilli by gram-negative, anaerobic microorganisms (4-6 intermediate; 7-8 and 9-10 moderate and severe bacterial vaginosis). Findings HIV-1 frequency was 14.2% among women with normal vaginal flora and 26.7% among those with severe bacterial vaginosis (p<0.001). We found an association between bacterial vaginosis and increased HIV-1 infection among younger women, but not among women older than 40 years; the association could not be explained by differences in sexual activity or concurrent infection with other STDs. The frequency of bacterial vaginosis was similar among HIV-l-infected women with symptoms (55.0%) and without symptoms (55.7%). The adjusted odds ratio of HIV-1 infection associated with any vaginal flora abnormality (scores 4-10) was 1.52 (95% CI 1.22-1.90), for moderate bacterial vagniosis (scores 7-8) it was 1.50 (1.18-1.89), and for severe bacterial vaginosis (scores 9-10) it was 2.08 (1.48-2.94). Interpretation This cross-sectional study cannot show whether disturbed vaginal flora increases susceptibility to HIV-1 infection. Nevertheless, the increased frequency of HIV-1 associated with abnormal flora among younger women, for whom HIV-1 acquisition is likely to be recent, but not among older women, in whom HIV-1 is likely to have been acquired earlier, suggests that loss of lactobacilli or presence of bacterial vaginosis may increase susceptibility to HIV-1 acquisition. If this inference is correct, control of bacterial vaginosis could reduce HIV-1 transmission.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21205 USA; MAKERERE UNIV, KAMPALA, UGANDA; COLUMBIA UNIV, NEW YORK, NY USA; UGANDA VIRUS RES INST, RAKAI PROJECT, ENTEBBE, UGANDA; UNIV PITTSBURGH, PITTSBURGH, PA 15260 USA	Johns Hopkins University; Makerere University; Columbia University; Uganda Virus Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Quinn, Thomas/A-2494-2010; Gaydos, Charlotte A./E-9937-2010	Sewankambo, Nelson/0000-0001-9362-053X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD006268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034826] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34826-03] Funding Source: Medline; NICHD NIH HHS [5P30HD06268] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		COHEN CR, 1995, AIDS, V9, P1093, DOI 10.1097/00002030-199509000-00017; DRAPER D, 1993, J CLIN MICROBIOL, V31, P1016, DOI 10.1128/JCM.31.4.1016-1018.1993; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; HILL JA, 1992, AM J OBSTET GYNECOL, V166, P720, DOI 10.1016/0002-9378(92)91703-D; HILLIER SL, 1992, AM J OBSTET GYNECOL, V166, P938, DOI 10.1016/0002-9378(92)91368-K; HILLIER SL, 1993, AM J OBSTET GYNECOL, V169, P455, DOI 10.1016/0002-9378(93)90340-O; Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; KAMENGA MC, 1995, AM J OBSTET GYNECOL, V172, P919, DOI 10.1016/0002-9378(95)90022-5; KLEBANOFF SJ, 1991, J EXP MED, V174, P289, DOI 10.1084/jem.174.1.289; KORN AP, 1995, OBSTET GYNECOL, V85, P387, DOI 10.1016/0029-7844(94)00400-8; KORN AP, 1995, J ACQ IMMUN DEF SYND, V9, P361; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; MARTIN HL, 1996, 11 INT C AIDS JUL, P7; MONTANER JSG, 1992, AIDS, V6, P719, DOI 10.1097/00002030-199207000-00016; MULDER D, 1995, BRIT MED J, V311, P833, DOI 10.1136/bmj.311.7009.833; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; PAAVONEN J, 1987, BRIT J OBSTET GYNAEC, V94, P454, DOI 10.1111/j.1471-0528.1987.tb03125.x; SMITH KR, 1995, J CLIN MICROBIOL, V33, P455, DOI 10.1128/JCM.33.2.455-457.1995; SWEET RL, 1993, AM J OBSTET GYNECOL, V169, P479, DOI 10.1016/0002-9378(93)90346-K; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; WAWER MJ, 1991, BRIT MED J, V303, P1303, DOI 10.1136/bmj.303.6813.1303	23	444	461	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	1997	350	9077					546	550		10.1016/S0140-6736(97)01063-5	http://dx.doi.org/10.1016/S0140-6736(97)01063-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284776	hybrid			2022-12-24	WOS:A1997XT22100009
J	Lakshmi, BB; Martin, CR				Lakshmi, BB; Martin, CR			Enantioseparation using apoenzymes immobilized in a porous polymeric membrane	NATURE			English	Article							ENZYME-FACILITATED TRANSPORT; ALPHA-AMINO-ACID; OPTICAL RESOLUTION; ORGANIC-ACIDS; SEPARATION; SURFACE	Chemical separations represent a large portion of the cost of bringing any new pharmaceutical product to the market. Membrane-based separation technologies(1,2), in which the target molecule is selectively extracted and transported across a membrane, are potentially more economical and easier to implement than competing separations methods; but membranes with higher transport selectivities are required, Here we describe an approach for preparing highly selective membranes which involves immobilizing apoenzymes within a microporous composite. The apoenzyme selectively recognizes its substrate molecule and transports it across the composite membrane, without effecting the unwanted chemical conversion of the substrate molecule to product, We demonstrate this approach using three different apoenzymes, Most importantly, it can be used to make enantioselective membranes for chiral separations, one of the most challenging and important problems in bioseparations technology, We are able to achieve a fivefold difference between the transport rates of D-and L-amino acids.	COLORADO STATE UNIV,DEPT CHEM,FT COLLINS,CO 80523	Colorado State University			Martin, Charles/AAA-1040-2019					[Anonymous], 1991, MEMBRANE SEPARATION; BORMAN S, 1990, CHEM ENG NEWS, V68, P9, DOI 10.1021/cen-v068n028.p009; BOYER PD, 1975, ENZYMES; Chen XS, 1996, B CHEM SOC JPN, V69, P255, DOI 10.1246/bcsj.69.255; Collins A.N., 1992, CHIRALITY IND; DIXON M, 1965, BIOCHIM BIOPHYS ACTA, V96, P368, DOI 10.1016/0005-2787(65)90557-5; DORDICK JS, 1989, BIOCATALYSTS IND, P311; HIGUCHI A, 1993, DESALINATION, V90, P127, DOI 10.1016/0011-9164(93)80170-R; HIGUCHI A, 1994, J MEMBRANE SCI, V93, P157, DOI 10.1016/0376-7388(94)80004-9; JENSEN RD, 1994, SCIENCE, V263, P1425; KAKUCHI T, 1990, POLYM J, V22, P199, DOI 10.1295/polymj.22.199; LAKSHMI B, UNPUB; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; Martin CR, 1996, CHEM MATER, V8, P1739, DOI 10.1021/cm960166s; MARUYAMA A, 1990, MACROMOLECULES, V23, P2748, DOI 10.1021/ma00212a027; MATSON SL, 1989, FRONTIERS BIOPROCESS; NISHIZAWA M, 1995, SCIENCE, V268, P700, DOI 10.1126/science.268.5211.700; NOBLE RD, 1989, CHEM ENG PROG, V85, P58; NOBLE RD, 1992, J MEMBRANE SCI, V75, P121, DOI 10.1016/0376-7388(92)80011-8; PARTHASARATHY A, 1994, J MEMBRANE SCI, V94, P249, DOI 10.1016/0376-7388(93)E0206-Y; PARTHASARATHY RV, 1994, NATURE, V369, P298, DOI 10.1038/369298a0; PENNER RM, 1988, J PHYS CHEM-US, V92, P5274, DOI 10.1021/j100329a042; RETHWISCH DG, 1994, J MEMBRANE SCI, V95, P83, DOI 10.1016/0376-7388(94)85031-3; RETHWISCH DG, 1990, J AM CHEM SOC, V112, P1649, DOI 10.1021/ja00160a065; SCHOLANDER PF, 1960, SCIENCE, V131, P585, DOI 10.1126/science.131.3400.585; STANLEY TJ, 1987, CHEM ENG SCI, V42, P2313, DOI 10.1016/0009-2509(87)80104-5; STEIN WD, 1967, MOVEMENT MOL ACROSS; STINSON SC, 1995, CHEM ENG NEWS, V73, P44, DOI 10.1021/cen-v073n041.p044; Winston W.S., 1992, MEMBRANE HDB; Worthington CC, 1988, WORTHINGTON MANUAL; YOSHIKAWA M, 1995, J MEMBRANE SCI, V108, P171, DOI 10.1016/0376-7388(95)00160-8	31	145	152	5	75	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					758	760		10.1038/41978	http://dx.doi.org/10.1038/41978			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285586				2022-12-24	WOS:A1997XR66700046
J	Speller, DCE; Johnson, AP; James, D; Marples, RR; Charlett, A; George, RC				Speller, DCE; Johnson, AP; James, D; Marples, RR; Charlett, A; George, RC			Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-95	LANCET			English	Article							VIRULENCE	Background Methicillin-resistant Staphylococcus aureus (MRSA) strains are colonising hospital patients in most areas of England and Wales, UK. The extent to which they cause invasive infection can be gauged from their presence in isolates from blood or cerebrospinal fluid. Methods About 200 clinical laboratories reported the results of susceptibility testing of between 4501 and 6370 isolates of S aureus from blood or cerebrospinal fluid in each of the years 1989-95. We assessed the rate of resistance to methicillin and other antibiotics for each of these years. Findings Resistance to methicillin was stable at about 1.5% of isolates during 1989-91, but increased thereafter to 13.2% in 1995 (p<0.001). At the same time there was a significant increase in the percentage of isolates resistant to erythromycin, clindamycin, ciprofloxacin, gentamicin, trimethoprim, and rifampicin (p<0.001 for each)-resistance characteristics often seen in MRSA. Resistance to benzylpenicillin increased slightly but significantly (p>0.001); resistance to fusidic acid was stable (p>0.05); resistance to tetracycline decreased significantly (P<0.001). Interpretation Among cases of S aureus bacteraemia, the proportion due to MRSA has increased significantly. Bacteraemia due to MRSA has a poor prognosis, especially if not treated with suitable antibiotics. Therefore, these findings are important, especially for management of patients and the development of antibiotic policies.	CENT PUBL HLTH LAB,LAB HOSP INFECT,LONDON NW9 5HT,ENGLAND; CENT PUBL HLTH LAB,RESP & SYST INFECT LAB,LONDON NW9 5HT,ENGLAND; CENT PUBL HLTH LAB,STAT UNIT,LONDON NW9 5HT,ENGLAND	Public Health England; Public Health England; Public Health England			Johnson, Alan P/F-4420-2014					CASEWELL MW, 1995, J HOSP INFECT, V30, P465, DOI 10.1016/0195-6701(95)90050-0; FRENCH GL, 1990, J HOSP INFECT, V15, P117, DOI 10.1016/0195-6701(90)90120-D; HERSHOW RC, 1992, INFECT CONT HOSP EP, V13, P587, DOI 10.2307/30148461; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; LACEY RW, 1987, J HOSP INFECT, V9, P103, DOI 10.1016/0195-6701(87)90046-6; MACKINTOSH CA, 1991, J HOSP INFECT, V18, P279, DOI 10.1016/0195-6701(91)90185-B; Marples R R, 1992, Commun Dis Rep CDR Rev, V2, pR25; SNELL JJS, 1994, J ANTIMICROB CHEMOTH, V33, P1, DOI 10.1093/jac/33.1.1; WENZEL RP, 1991, AM J MED, V91, pS221, DOI 10.1016/0002-9343(91)90372-5; 1995, J HOSP INFECT, V31, P1; 1997, COMMUN DIS REP CDR W, V6, P191	11	133	138	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					323	325		10.1016/S0140-6736(97)12148-1	http://dx.doi.org/10.1016/S0140-6736(97)12148-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251636				2022-12-24	WOS:A1997XP24200009
J	Gunshin, H; Mackenzie, B; Berger, UV; Gunshin, Y; Romero, MF; Boron, WF; Nussberger, S; Gollan, JL; Hediger, MA				Gunshin, H; Mackenzie, B; Berger, UV; Gunshin, Y; Romero, MF; Boron, WF; Nussberger, S; Gollan, JL; Hediger, MA			Cloning and characterization of a mammalian proton-coupled metal-ion transporter	NATURE			English	Article							RAT SMALL-INTESTINE; INTRACELLULAR PARASITES; NATURAL-RESISTANCE; XENOPUS-OOCYTES; MESSENGER-RNA; IRON; CELLS; COTRANSPORTER; INFECTION; REDUCTION	Metal ions are essential cofactors for a wealth of biological processes, including oxidative phosphorylation, gene regulation and free-radical homeostasis. Failure to maintain appropriate levels of metal ions in humans is a feature of hereditary haemoduomatosis(1), disorders of metal-ion deficiency, and certain neurodegenerative diseases(2). Despite their pivotal physiological roles, however, there is no molecular information on how metal ions are actively absorbed by mammalian cells. We have now identified a new metal-ion transporter in the rat, DCT1, which has an unusually broad substrate range that includes Fe2+ Zn2+, Mn2+, Co2+, Cd2+, Cu2+, Ni2+, and Pb2+. DCT1 mediates active transport that is proton-coupled and depends on the cell membrane potential, It is a 561-amino-acid protein with 12 putative membrane-spanning domains and is ubiquitously expressed, most notably in the proximal duodenum. DCT1 is upregulated by dietary iron deficiency, and may represent a key mediator of intestinal iron absorption. DCT1 is a member of the 'natural-resistance-associated macrophage protein' (Nramp) family(3-5) and thus its properties provide insight into how these proteins confer resistance to pathogens.	YALE UNIV,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06510; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GASTROENTEROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115	Yale University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Gunshin, H (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,77 AVE LOUIS PASTEUR,BOSTON,MA 02115, USA.		Boron, Walter/ABI-1564-2020	Mackenzie, Bryan/0000-0002-9661-8838; Romero, Michael F/0000-0002-1555-7835; Hediger, Matthias/0000-0003-1946-027X; Boron, Walter/0000-0003-4741-7287; Nussberger, Stephan/0000-0003-3619-4452	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009342] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK009342-03, F32 DK009342-02, F32 DK009342, F32 DK009342-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOORER KJ, 1994, J BIOL CHEM, V269, P20417; Boorer KJ, 1996, J BIOL CHEM, V271, P2213, DOI 10.1074/jbc.271.4.2213; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; Conrad ME, 1996, J CLIN INVEST, V98, P1449, DOI 10.1172/JCI118933; DOREY C, 1993, BRIT J NUTR, V70, P157, DOI 10.1079/BJN19930113; EIDE DJ, IN PRESS CURR OPIN C; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GRUENHEID S, 1995, GENOMICS, V25, P514, DOI 10.1016/0888-7543(95)80053-O; GUNSHIN H, 1991, AGR BIOL CHEM TOKYO, V55, P2813, DOI 10.1080/00021369.1991.10857152; HAN O, 1995, J NUTR, V125, P1291; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; HIRSCH EC, 1997, MOL NEUROL, V94, P135; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; JORDAN I, 1994, BIOCHEM J, V302, P875, DOI 10.1042/bj3020875; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; MACKENZIE B, UNPUB COUPLING STOIC; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MCEWAN GTA, 1988, PROC R SOC SER B-BIO, V234, P219, DOI 10.1098/rspb.1988.0045; NICHOLS GM, 1989, AM J GASTROENTEROL, V84, P851; Nussberger S, 1997, J BIOL CHEM, V272, P7777, DOI 10.1074/jbc.272.12.7777; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; RAJA KB, 1992, BIOCHIM BIOPHYS ACTA, V1135, P141, DOI 10.1016/0167-4889(92)90129-Y; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; VIDAL S, 1995, J LEUKOCYTE BIOL, V58, P382, DOI 10.1002/jlb.58.4.382; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D	30	2509	2611	10	185	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					482	488		10.1038/41343	http://dx.doi.org/10.1038/41343			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242408				2022-12-24	WOS:A1997XN55300051
J	Killcross, S; Robbins, TW; Everitt, BJ				Killcross, S; Robbins, TW; Everitt, BJ			Different types of fear-conditioned behaviour mediated by separate nuclei within amygdala	NATURE			English	Article							POTENTIATED STARTLE; MEMORY; ORGANIZATION; HIPPOCAMPUS; ANXIETY; EMOTION; LESIONS; SYSTEM; BRAIN	The amygdala has long been thought to be involved in emotional behaviour(1,2), and its role in anxiety and conditioned fear has been highlighted(3,4). Individual amygdaloid nuclei have been shown to project to various cortical and subcortical regions implicated in affective processing(5-7). Here we show that some of these nuclei have separate roles in distinct mechanisms underlying conditioned fear responses. Rats with lesions of the central nucleus exhibited reduction in the suppression of behaviour elicited by a conditioned fear stimulus, but were simultaneously able to direct their actions to avoid further presentations of this aversive stimulus. In contrast, animals with lesions of the basolateral amygdala were unable to avoid the conditioned aversive stimulus by their choice behaviour, but exhibited normal conditioned suppression to this stimulus. This double dissociation demonstrates that distinct neural systems involving separate amygdaloid nuclei mediate different types of conditioned fear behaviour. We suggest that theories of amygdala function should take into account the roles of discrete amygdala subsystems in controlling different components of integrated emotional responses.			Killcross, S (corresponding author), UNIV CAMBRIDGE, DEPT EXPT PSYCHOL, DOWNING ST, CAMBRIDGE CB2 3EB, ENGLAND.		Killcross, Simon/N-1426-2019; anand, amit/A-7222-2009; Robbins, Trevor W/A-7551-2008; Killcross, Simon/A-4113-2009	Killcross, Simon/0000-0002-5571-548X; Robbins, Trevor/0000-0003-0642-5977; Everitt, Barry/0000-0003-4431-6536				ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; AMARAL D G, 1992, P1; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; BECHARA A, 1995, SCIENCE, V269, P1115, DOI 10.1126/science.7652558; BOUTON ME, 1980, ANIM LEARN BEHAV, V8, P429, DOI 10.3758/BF03199629; Cahill L, 1996, P NATL ACAD SCI USA, V93, P8016, DOI 10.1073/pnas.93.15.8016; CAHILL L, 1995, NATURE, V377, P295, DOI 10.1038/377295a0; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; DAMASIO AR, 1994, DESCARTES ERROR; DAVIS M, 1987, PSYCHOL LEARN MOTIV, V21, P263; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; EVERITT B J, 1992, P401; EVERITT BJ, 1991, NEUROSCIENCE, V42, P1, DOI 10.1016/0306-4522(91)90145-E; Gallagher M, 1996, CURR OPIN NEUROBIOL, V6, P221, DOI 10.1016/S0959-4388(96)80076-6; GROENEWEGEN HJ, 1990, PROG BRAIN RES, V85, P95; Kapp BS, 1984, NEUROPSYCHOLOGY MEMO, P473; Kluver H, 1939, ARCH NEURO PSYCHIATR, V42, P979; LeDoux J. E., 1996, EMOTIONAL BRAIN; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; Maren S, 1996, BEHAV NEUROSCI, V110, P718, DOI 10.1037/0735-7044.110.4.718; Mowrer OH, 1947, HARVARD EDUC REV, V17, P102; MOWRER OH, 1954, AM J PSYCHOL, V67, P15, DOI 10.2307/1418068; PARENT MB, 1992, BEHAV NEUROSCI, V106, P789, DOI 10.1037/0735-7044.106.5.789; SANANES CB, 1992, BEHAV NEUROSCI, V106, P72, DOI 10.1037/0735-7044.106.1.72; Scott SK, 1997, NATURE, V385, P254, DOI 10.1038/385254a0; SELDEN NRW, 1991, NEUROSCIENCE, V42, P335, DOI 10.1016/0306-4522(91)90379-3; Swanson L. W., 1992, BRAIN MAPS STRUCTURE; THOMPSON RF, 1994, ANNU REV NEUROSCI, V17, P519, DOI 10.1146/annurev.neuro.17.1.519; Wan FJ, 1997, NEUROSCIENCE, V76, P715, DOI 10.1016/S0306-4522(96)00218-7; WEISKRANTZ L, 1956, J COMP PHYSIOL PSYCH, V49, P381, DOI 10.1037/h0088009	30	518	524	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 24	1997	388	6640					377	380		10.1038/41097	http://dx.doi.org/10.1038/41097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237754				2022-12-24	WOS:A1997XM52800050
J	Nightingale, SL				Nightingale, SL			Drug safety information available on the Internet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					15	15		10.1001/jama.278.1.15	http://dx.doi.org/10.1001/jama.278.1.15			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207323				2022-12-24	WOS:A1997XG38700010
J	MaierDobersberger, T; Ferenci, P; Polli, C; Balac, P; Dienes, HP; Kaserer, K; Datz, C; Vogel, W; Gangl, A				MaierDobersberger, T; Ferenci, P; Polli, C; Balac, P; Dienes, HP; Kaserer, K; Datz, C; Vogel, W; Gangl, A			Detection of the His1069Gln mutation in Wilson disease by rapid polymerase chain reaction	ANNALS OF INTERNAL MEDICINE			English	Article						hepatolenticular degeneration; polymerase chain reaction; mutation; linkage (genetics); copper	HEPATIC-FAILURE; DIAGNOSIS; GENE	Background: Most known mutations in the gene associated with Wilson disease are rare. Only the His1069Gln mutation is found often in patients of Northern or Eastern European origin. Objective: To examine the frequency of the His1069Gln mutation in Austrian patients with Wilson disease and their families by using a new, rapid polymerase chain reaction (PCR) test. Design: Cross-sectional study. Setting: University medical center. Patients: 83 patients from 72 families and 98 relatives of 11 homozygous index patients. Measurements: Results of a semi-nested PCR-based assay to detect the His1069Gln mutation in Wilson disease, clinical symptoms, and liver histologic findings. Results: 20 patients, including 5 siblings, were homozygous for the His1069Gln mutation. Thirty-three patients, including 4 siblings, were compound heterozygotes. The mutation was not detected in 30 patients, including 2 siblings. Homozygotes were older at onset of symptoms (mean age, 24 +/- 6 years) than compound heterozygotes (17 +/- 6 years [95% CI, 3.3 to 10.7 years]; P = 0.0135) and patients with other mutations (18 +/- 8 years [CI, 1.8 to 10.2 years]; P = 0.117). Homozygotes were more often female (73.3%) than were compound heterozygotes (48% [CI, 0.94% to 2.46%]) and patients with other mutations (50% [CI, 0.91% to 2.37%]) (P = 0.05). Four of 98 asymptomatic relatives of 11 homozygous index patients were also homozygotes. Heterozygosity was confirmed in 46 relatives (19 parents, 11 children, and 16 distant relatives). Conclusion: The His1069Gln mutation was detected in 61% of Austrian patients with Wilson disease. Polymerase chain reaction may be useful for diagnosis and screening of family members of homozygous index patients, even if first-degree relatives are not available for examination.	UNIV VIENNA, DEPT CLIN PATHOL, A-1090 VIENNA, AUSTRIA; UNIV SHEFFIELD, DEPT PAEDIAT, SHEFFIELD S10 2TH, S YORKSHIRE, ENGLAND; UNIV COLOGNE, DEPT PATHOL, D-50931 COLOGNE, GERMANY; LKH SALZBURG, DEPT MED 1, A-5020 SALZBURG, AUSTRIA; UNIV INNSBRUCK, DEPT INTERNAL MED, A-6020 INNSBRUCK, AUSTRIA	University of Vienna; University of Sheffield; University of Cologne; University of Innsbruck	MaierDobersberger, T (corresponding author), UNIV VIENNA, DEPT INTERNAL MED 4, WAEHRINGER GUERTEL 18, A-1090 VIENNA, AUSTRIA.							BERMAN DH, 1991, GASTROENTEROLOGY, V100, P1129, DOI 10.1016/0016-5085(91)90294-U; CZLONKOWSKA A, 1995, Z GASTROENTEROL, V33, P475; DANKS DM, 1990, BRIT MED J, V301, P331, DOI 10.1136/bmj.301.6747.331; FARRER LA, 1991, NEUROLOGY, V41, P992, DOI 10.1212/WNL.41.7.992; FASSMANN H, 1986, MIGRATIONSSTROME INN, P22; FIGUS A, 1995, AM J HUM GENET, V57, P1318; GOODMAN SN, 1994, ANN INTERN MED, V121, P200, DOI 10.7326/0003-4819-121-3-199408010-00008; HOUWEN RHJ, 1995, J MED GENET, V32, P480, DOI 10.1136/jmg.32.6.480; Hubbard R, 1996, NEW ENGL J MED, V334, P1192, DOI 10.1056/NEJM199605023341812; KASAI N, 1992, LAB ANIM SCI, V42, P363; KINGSTON HM, 1986, ANAL CHEM, V58, P2534, DOI 10.1021/ac00125a038; MAIERDOBERSBERGER T, 1995, GASTROENTEROLOGY, V109, P2015, DOI 10.1016/0016-5085(95)90771-8; MCCULLOUGH AJ, 1983, GASTROENTEROLOGY, V84, P161; PETRUKHIN K, 1993, NAT GENET, V5, P338, DOI 10.1038/ng1293-338; PROPST A, 1995, GASTROENTEROLOGY, V108, P885, DOI 10.1016/0016-5085(95)90465-4; ROSS ME, 1985, ANN NEUROL, V17, P411, DOI 10.1002/ana.410170421; Scheinberg IH, 1984, MAJOR PROBLEMS INTER, VXXIII; SCHEUER PJ, 1991, J HEPATOL, V13, P372, DOI 10.1016/0168-8278(91)90084-O; SCHILSKY ML, 1994, HEPATOLOGY, V19, P583, DOI 10.1002/hep.1840190307; STERNLIEB I, 1990, HEPATOLOGY, V12, P1234, DOI 10.1002/hep.1840120526; STRICKLAND GT, 1972, CLIN SCI, V43, P617, DOI 10.1042/cs0430617; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; THOMAS GR, 1995, AM J HUM GENET, V56, P1315; 1995, Z GASTROENTEROL, V33, P472	24	87	94	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					21	+		10.7326/0003-4819-127-1-199707010-00004	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214248				2022-12-24	WOS:A1997XG91400003
J	Cohen, MS; Hoffman, IF; Royce, RA; Kazembe, P; Dyer, JR; Daly, CC; Zimba, D; Vernazza, PL; Maida, M; Fiscus, SA; Eron, JJ; Nkata, E; Kachenje, E; Banda, T; Mughogho, G; Koller, C; Schock, J; Chakraborty, H; Dallabetta, G; Gilliam, B				Cohen, MS; Hoffman, IF; Royce, RA; Kazembe, P; Dyer, JR; Daly, CC; Zimba, D; Vernazza, PL; Maida, M; Fiscus, SA; Eron, JJ; Nkata, E; Kachenje, E; Banda, T; Mughogho, G; Koller, C; Schock, J; Chakraborty, H; Dallabetta, G; Gilliam, B			Reduction of concentration of HIV-1, in semen after treatment of urethritis: Implications for prevention of sexual transmission of HIV-1	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMITTED DISEASES; CHLAMYDIA-TRACHOMATIS; NEISSERIA-GONORRHOEAE; INFECTION; MEN; ASSOCIATION; THERAPY; SPREAD; MALAWI	Background transmission of HIV-1 is predominantly by heterosexual contact in sub-Saharan Africa, where sexually transmitted diseases (STDs) are also common. Epidemiological studies suggest that STDs facilitate transmission of HIV-1, but the biological mechanism remains unclear, We investigated the hypothesis that STDs increase the likelihood of transmission of HIV-1 through increased concentration of the virus in semen. Methods HIV-1 RNA concentrations were measured in seminal and blood plasma from 135 HIV-1-seropositive men in Malawi; 86 had urethritis and 49 controls did not have urethritis. Men with urethritis received antibiotic treatment according to the guidelines of the Malawian STD Advisory Committee. Samples were analysed at baseline and at week 1 and week 2 after antibiotic therapy in urethritis patients, and at baseline and week 2 in the control group. Findings HIV-1-seropositive men with urethritis had HIV-1 RNA concentrations in seminal plasma eight times higher than those in seropositive men without urethritis (12.4 vs 1.51x10(4) copies/mL, p=0.035), despite similar CD4 counts and concentrations of blood plasma viral RNA. Gonorrhoea was associated with the greatest concentration of HIV-1 in semen (15.8x10(4) copies/mL). After the urethritis patients received antimicrobial therapy directed against STDs, the concentration of HIV-1 RNA in semen decreased significantly (from 12.4x10(4) copies/mL to 8.91x10(4) copies/mL at 1 week [p=0.03] and 4.12x10(4) copies/mL at 2 weeks [p=0.0001]). Blood plasma viral RNA concentrations did not change. There was no significant change in seminal plasma HIV-1 RNA concentrations during the 2-week period in the control group (p=0.421). These results suggest that urethritis increases the infectiousness of men with HIV-1 infection. HIV-1-control programmes, which include detection and treatment of STDs in patients already infected with HIV-1, may help to curb the epidemic. Targeting of gonococcal urethritis may be a particularly effective strategy.	UNIV N CAROLINA,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,AIDSCAP,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT EPIDEMIOL,CHAPEL HILL,NC 27599; LILONGWE CENT HOSP,LILONGWE,MALAWI; JOHN SNOW INC,MALAWI SUPPORT AIDS & FAMILY HLTH PROJECT,BOSTON,MA; KANTONSSPITAL,DEPT MED,ST GALLEN,SWITZERLAND	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen	Cohen, MS (corresponding author), UNIV N CAROLINA,DEPT MED,CB 7030,547 BURNETT WOMACK BLDG,CHAPEL HILL,NC 27599, USA.		Royce, Rachel A/A-7964-2012		PHS HHS [UO31496, R0149381] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Atkins MC, 1996, BRIT MED J, V313, P341, DOI 10.1136/bmj.313.7053.341; BEHETS FMT, 1995, J INFECT DIS, V171, P451, DOI 10.1093/infdis/171.2.451; Busch MP, 1996, J INFECT DIS, V174, P26, DOI 10.1093/infdis/174.1.26; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; Dickerson MC, 1996, SEX TRANSM DIS, V23, P429, DOI 10.1097/00007435-199609000-00015; Dyer JR, 1996, J VIROL METHODS, V60, P161, DOI 10.1016/0166-0934(96)02063-0; Eron JJ, 1996, JAMA-J AM MED ASSOC, V275, P36, DOI 10.1001/jama.275.1.36; ERON JJ, 1997, 4 C RETR OPP INF WAS; Fang GW, 1995, P NATL ACAD SCI USA, V92, P12100, DOI 10.1073/pnas.92.26.12100; Fowke KR, 1996, LANCET, V348, P1347, DOI 10.1016/S0140-6736(95)12269-2; GARNETT GP, 1995, J ACQ IMMUN DEF SYND, V9, P500; GILLIAM BL, IN PRESS J ACQUIR IM; GOBBERS E, 1996, 11 INT C AIDS VANC J; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HAIZLIP J, 1995, SEX TRANSM DIS, V22, P145, DOI 10.1097/00007435-199505000-00002; HO JL, 1995, J EXP MED, V181, P1493, DOI 10.1084/jem.181.4.1493; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kissinger P, 1996, J GEN INTERN MED, V11, P750, DOI 10.1007/BF02598989; KIVIAT NB, 1990, HUM PATHOL, V21, P831, DOI 10.1016/0046-8177(90)90052-7; KREISS J, 1994, J INFECT DIS, V170, P1597, DOI 10.1093/infdis/170.6.1597; KRIEGER JN, 1995, J UROLOGY, V154, P1035, DOI 10.1016/S0022-5347(01)66969-6; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; Lee TH, 1996, J ACQ IMMUN DEF SYND, V12, P427, DOI 10.1097/00042560-199608010-00015; LULE G, 1994, GENITOURIN MED, V70, P384; MERSON MH, 1993, SCIENCE, V260, P1266, DOI 10.1126/science.8493570; MOSS GB, 1995, J INFECT DIS, V172, P1469, DOI 10.1093/infdis/172.6.1469; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; RAMSEY KH, 1995, J INFECT DIS, V172, P186, DOI 10.1093/infdis/172.1.186; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; SPECK CE, 1996, 11 INT C AIDS VANC; VERNAZZA P, IN PRESS AIDS; VERNAZZA PL, 1994, AIDS, V8, P1325, DOI 10.1097/00002030-199409000-00017; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996	34	687	703	0	23	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1868	1873		10.1016/S0140-6736(97)02190-9	http://dx.doi.org/10.1016/S0140-6736(97)02190-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217758				2022-12-24	WOS:A1997XG41700009
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Xenotransplanters turn xenovirologists	SCIENCE			English	Article																		BENEVISTE RE, 1974, NATURE, V248, P17; COFFIN JM, 1985, RNA TUMOR VIRUSES; MCALLISTER RM, 1972, NATURE-NEW BIOL, V235, P3, DOI 10.1038/newbio235003a0; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282	4	4	6	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1893	1893						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9206845				2022-12-24	WOS:A1997XF10300059
J	Pfrieger, FW; Barres, BA				Pfrieger, FW; Barres, BA			Synaptic efficacy enhanced by glial cells in vitro	SCIENCE			English	Article							RETINAL GANGLION-CELLS; NEURONS; TRANSMISSION; POTENTIALS; SURVIVAL; CULTURE; GROWTH; SWITCH	In the developing nervous system, glial cells guide axons to their target areas, but it is unknown whether they help neurons to establish functional synaptic connections, The role of glial cells in synapse formation and function was studied in cultures of purified neurons from the rat central nervous system, In glia-free cultures, retinal ganglion cells formed synapses with normal ultrastructure but displayed little spontaneous synaptic activity and high failure rates in evoked synaptic transmission, In cocultures with neuroglia, the frequency and amplitude of spontaneous postsynaptic currents were potentiated by 70-fold and 5-fold, respectively, and fewer transmission failures occurred, Glial cells increased the action potential-independent guantal release by 12-fold without affecting neuronal survival, Thus, developing neurons in culture form inefficient synapses that require glial signals to become fully functional.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University			Pfrieger, Frank/AAX-3208-2020	Pfrieger, Frank/0000-0001-7085-1431				ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; Kaplan MR, 1997, NATURE, V386, P724, DOI 10.1038/386724a0; KUWADA JY, 1986, SCIENCE, V233, P740, DOI 10.1126/science.3738507; MacKenzie PJ, 1996, NEURON, V16, P783, DOI 10.1016/S0896-6273(00)80098-7; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McLachlan E M, 1978, Int Rev Physiol, V17, P49; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Peters A, 1991, FINE STRUCTURE NERVO; PFRIEGER FW, 1994, NEURON, V12, P97, DOI 10.1016/0896-6273(94)90155-4; PFRIEGER FW, 1995, CELL, V83, P671, DOI 10.1016/0092-8674(95)90178-7; Pfrieger FW, 1996, CURR OPIN NEUROBIOL, V6, P615, DOI 10.1016/S0959-4388(96)80093-6; PFRIEGER FW, UNPUB; POMEROY SL, 1988, J CELL BIOL, V107, P1167, DOI 10.1083/jcb.107.3.1167; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; Ramon y Cajal S., 1897, HISTOLOGY NERVOUS SY, V1; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SILVER J, 1982, J COMP NEUROL, V210, P10, DOI 10.1002/cne.902100103; Tsacopoulos M, 1996, J NEUROSCI, V16, P877	23	568	611	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1684	1687		10.1126/science.277.5332.1684	http://dx.doi.org/10.1126/science.277.5332.1684			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287225	Green Submitted			2022-12-24	WOS:A1997XV68400056
J	Connor, WE; Connor, SL				Connor, WE; Connor, SL			Should a low-fat, high-carbohydrate diet be recommended for everyone?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CHOLESTEROL				Connor, WE (corresponding author), OREGON HLTH SCI UNIV,DEPT MED,L465,PORTLAND,OR 97201, USA.							*AM CANC SOC 1996, 1996, CA CANC J CLIN, V43, P325; Anitschkow N.N., 1933, ARTERIOSCLEROSIS, P271; [Anonymous], 1988, CIRCULATION, V77, p721A; ARMSTRONG ML, 1970, CIRC RES, V27, P59, DOI 10.1161/01.RES.27.1.59; Bang HO, 1980, ADV NUTR RES, P1, DOI [DOI 10.1007/978-1-4757-4448-4_1, 10.1007/978-1-4757-4448-4_1]; CONNOR WE, 1961, GERIATRICS, V16, P407; DE LANGEN C. D., 1922, Geneeskundig Tijdschrift voor Nederlandsche-Indie, V62, P1; *DEP AGR, 1995, IN PRESS STAT B; *DEP AGR AGR RES S, 1995, DAT TABL RES USDAS 1; *EXP PAN DET EV TR, 1993, JAMA-J AM MED ASSOC, V269, P3015; Kennedy E, 1996, J AM DIET ASSOC, V96, P234, DOI 10.1016/S0002-8223(96)00072-7; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; SCHAEFER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1450, DOI 10.1001/jama.274.18.1450; SPADY DK, 1988, J CLIN INVEST, V81, P300, DOI 10.1172/JCI113321; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	15	122	125	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					562	563						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262503				2022-12-24	WOS:A1997XR54800011
J	Rittinger, K; Walker, PA; Eccleston, JF; Nurmahomed, K; Owen, D; Laue, E; Gamblin, SJ; Smerdon, SJ				Rittinger, K; Walker, PA; Eccleston, JF; Nurmahomed, K; Owen, D; Laue, E; Gamblin, SJ; Smerdon, SJ			Crystal structure of a small G protein in complex with the GTPase-activating protein rhoGAP	NATURE			English	Article							H-RAS P21; BINDING PROTEINS; MECHANISM; HYDROLYSIS	Small G proteins transduce signals from plasma-membrane receptors to control a wide range of cellular functions(1,2). These proteins are clustered into distinct families but all act as molecular switches, active in their GTP-bound form but inactive when GDP-bound. The Rho family of G proteins, which includes Cdc42Hs, activate effecters involved in the regulation of cytoskeleton formation, cell proliferation and the JNK signalling pathway(3-9). G proteins generally have a low intrinsic GTPase hydrolytic activity but there are family-specific groups of GTPase-activating proteins (GAPs) that enhance the rate of GTP hydrolysis by up to 10(5) times(10,11). We report here the crystal structure of Cdc42Hs, with the non-hydrolysable GTP analogue GMPPNP, in complex with the GAP domain of p50rhoGAP at 2.7 Angstrom resolution. In the complex Cdc42Hs interacts, mainly through its switch I and II regions, with a shallow pocket on rhoGAP which is lined with conserved residues. Arg 85 of rhoGAP interacts with the P-loop of Cdc42Hs, but from biochemical data and by analogy with the G-protein subunit G(i alpha 1) (ref. 12), we propose that it adopts a different conformation during the catalytic cycle which enables it to stabilize the transition state of the GTP-hydrolysis reaction.	NATL INST MED RES,RIDGEWAY,LONDON NW7 1AA,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	University of Cambridge			Rittinger, Katrin/N-3344-2019; Rittinger, Katrin/D-2586-2014	Rittinger, Katrin/0000-0002-7698-4435; Rittinger, Katrin/0000-0002-7698-4435; Smerdon, Stephen/0000-0001-5688-8465; Laue, Ernest/0000-0002-7476-4148	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; GOODY RS, 1992, PHILOS T ROY SOC B, V336, P3, DOI 10.1098/rstb.1992.0037; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4	29	223	235	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					693	697		10.1038/41805	http://dx.doi.org/10.1038/41805			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262406	Bronze			2022-12-24	WOS:A1997XQ86300054
J	Dove, AW; Racaniello, VR				Dove, AW; Racaniello, VR			The polio eradication effort: Should vaccine eradication be next?	SCIENCE			English	Article									COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032	Columbia University								BEALE AJ, 1991, PEDIATR INFECT DIS J, V10, P970, DOI 10.1097/00006454-199112000-00029; ConynvanSpaendonck MAE, 1996, AM J EPIDEMIOL, V143, P929, DOI 10.1093/oxfordjournals.aje.a008836; HURST CJ, 1989, CAN J MICROBIOL, V35, P474, DOI 10.1139/m89-073; KEW O, 1996, LECT AM SOC VIR ANN; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; Knolle H, 1995, Gesundheitswesen, V57, P351; MELNICK PD, 1996, BIOLOGICALS, V6, P1; MINOR PD, 1993, BIOLOGICALS, V21, P357, DOI 10.1006/biol.1993.1096; NAKAJIMA K, 1978, NATURE, V274, P334, DOI 10.1038/274334a0; RACANIELLO VR, 1981, P NATL ACAD SCI-BIOL, V78, P4887, DOI 10.1073/pnas.78.8.4887; RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391; ROBERTSON SE, 1994, B WORLD HEALTH ORGAN, V72, P907; SWARTZ TA, 1994, PUBLIC HLTH REV, V21, P157; Van Wijngaarden JK, 1993, PUBLIC HLTH REV, V21, P107; WHO, 1996, GLOB POL ER YEAR 200; YATES MV, 1985, APPL ENVIRON MICROB, V49, P778, DOI 10.1128/AEM.49.4.778-781.1985; [No title captured]	17	38	38	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					779	780		10.1126/science.277.5327.779	http://dx.doi.org/10.1126/science.277.5327.779			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9273700				2022-12-24	WOS:A1997XQ24700031
J	Kostic, V; JacksonLewis, V; deBilbao, F; DuboisDauphin, M; Przedborski, S				Kostic, V; JacksonLewis, V; deBilbao, F; DuboisDauphin, M; Przedborski, S			Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis	SCIENCE			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; CELL-DEATH; NEURAL CELLS; MUTATIONS; GENE; DEGENERATION; DISEASE; MICE; SUPEROXIDE-DISMUTASE-1; OVEREXPRESSION	Mutations in the gene encoding copper/zinc superoxide dismutase enzyme produce an animal model of familial amyotrophic lateral sclerosis (FALS), a fatal disorder characterized by paralysis. Overexpression of the proto-oncogene bcl-2 delayed onset of motor neuron disease and prolonged survival in transgenic mice expressing the FALS-linked mutation in which glycine is substituted by alanine at position 93. it did not, however, alter the duration of the disease. Overexpression of bcl-2 also attenuated the magnitude of spinal cord motor neuron degeneration in the FALS-transgenic mice.	COLUMBIA UNIV,DEPT NEUROL,NEW YORK,NY 10032; HOP CANTONAL UNIV GENEVA,DIV NEUROPSYCHIAT,CH-1225 GENEVA,SWITZERLAND	Columbia University; University of Geneva					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001724] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01724] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BORCHELT DR, 1995, J BIOL CHEM, V270, P3234, DOI 10.1074/jbc.270.7.3234; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Brown RH, 1995, CURR OPIN NEUROBIOL, V5, P841, DOI 10.1016/0959-4388(95)80114-6; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHIU AY, 1995, MOL CELL NEUROSCI, V6, P349, DOI 10.1006/mcne.1995.1027; COSLULICH SC, 1996, CURR BIOL, V6, P997; deBilbao F, 1996, NEUROREPORT, V7, P3051, DOI 10.1097/00001756-199611250-00051; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P2459; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; GURNEY ME, UNPUB; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kostic V, 1997, ANN NEUROL, V41, P497, DOI 10.1002/ana.410410413; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mena MA, 1997, J NEUROCHEM, V69, P21; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Miller Robert G., 1997, Neurology, V48, pS28; Mu XJ, 1996, ANN NEUROL, V40, P379, DOI 10.1002/ana.410400307; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Przedborski S, 1996, ANN NEUROL, V39, P158, DOI 10.1002/ana.410390204; Przedborski S, 1996, NEURODEGENERATION, V5, P57; Przedborski S, 1996, J NEUROCHEM, V67, P1383; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTHSTEIN JD, 1995, ADV NEUROL, V68, P7; Rowland L. P., 1995, MERRITTS TXB NEUROLO, P742; SAGOT Y, 1995, J NEUROSCI, V15, P7727; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHIMIZU S, 1996, J NEUROSCI, V16, P5654; Troost D, 1995, NEUROPATH APPL NEURO, V21, P498, DOI 10.1111/j.1365-2990.1995.tb01096.x; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155; VIRGO L, 1995, BRAIN RES, V676, P196, DOI 10.1016/0006-8993(95)00052-R; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; YOSHIYAMA Y, 1994, ACTA NEUROPATHOL, V88, P207; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	46	390	397	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					559	562		10.1126/science.277.5325.559	http://dx.doi.org/10.1126/science.277.5325.559			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228005				2022-12-24	WOS:A1997XM86700050
J	Pan, DJ; Rubin, GM				Pan, DJ; Rubin, GM			Kuzbanian controls proteolytic processing of Notch and mediates lateral inhibition during Drosophila and vertebrate neurogenesis	CELL			English	Article							XENOPUS-EMBRYOS; GENE-EXPRESSION; CELL FATE; PROTEIN; MELANOGASTER; SPECIFICITY; DISINTEGRIN; PHENOTYPES; HOMOLOG; FUSION	Notch and the disintegrin metalloprotease encoded by the kuzbanian (kuz) gene are both required for a lateral inhibition process during Drosophila neurogenesis. We show that a mutant KUZ protein lacking protease activity acts as a dominant-negative form in Drosophila. Expression of such a dominant-negative KUZ protein can perturb lateral inhibition in Xenopus, leading to the overproduction of primary neurons. This suggests an evolutionarily conserved role for KUZ. The Notch family of receptors are known to be processed into smaller forms under normal physiological conditions. We provide genetic and biochemical evidence that Notch is an in vivo substrate for the KUZ protease, and that this cleavage may be part of the normal biosynthesis of functional Notch proteins.			Pan, DJ (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Campos-Ortega Jose A., 1993, P1091; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; CRITTENDEN SL, 1994, DEVELOPMENT, V120, P2901; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HAY BA, 1994, DEVELOPMENT, V120, P2121; HEBERLEIN U, 1994, MECH DEVELOP, V48, P35, DOI 10.1016/0925-4773(94)90004-3; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; HUANG F, 1991, DEVELOPMENT, V111, P1087; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; Karim FD, 1996, GENETICS, V143, P315; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SIMPSON P, 1990, DEVELOPMENT, V109, P509; STAEHLINGHAMPTON K, 1994, CELL GROWTH DIFFER, V5, P585; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wolff Tanya, 1993, P1277; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	36	434	452	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					271	280		10.1016/S0092-8674(00)80335-9	http://dx.doi.org/10.1016/S0092-8674(00)80335-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244301	Bronze			2022-12-24	WOS:A1997XN24900011
J	Netzer, WJ; Hartl, FU				Netzer, WJ; Hartl, FU			Recombination of protein domains facilitated by co-translational folding in eukaryotes	NATURE			English	Article							ESCHERICHIA-COLI; EXON THEORY; IN-VIVO; EXPRESSION; BINDING; CHAPERONIN; COMPLEX; CHAINS; GENES; GROEL	The evolution of complex genomes requires that new combinations of pre-existing protein domains successfully fold into modular polypeptides. During eukaryotic translation model two-domain polypeptides fold efficiently by sequential and co-translational folding of their domains. In contrast, folding of the same proteins in Escherichia coli is post-translational, and leads to intramolecular misfolding of concurrently folding domains. Sequential domain folding in eukaryotes may have been critical in the evolution of modular polypeptides, by increasing the probability that random gene-fusion events resulted in immediately foldable protein structures.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Max Planck Society			Hartl, F. Ulrich/Y-8206-2019					Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; Bremer H, 1996, ESCHERICHIA COLI SAL; CAMEAU DE, 1985, J BACTERIOL, V164, P578; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; DOOLITTLE RF, 1993, SCI AM, V269, P50, DOI 10.1038/scientificamerican1093-50; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAITANARIS GA, 1994, MOL MICROBIOL, V14, P861, DOI 10.1111/j.1365-2958.1994.tb01322.x; GESTELAND RF, 1966, J MOL BIOL, V18, P356, DOI 10.1016/S0022-2836(66)80253-X; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAWKINS AR, 1995, EUR J BIOCHEM, V232, P7, DOI 10.1111/j.1432-1033.1995.tb20775.x; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KENNEY LJ, 1995, P NATL ACAD SCI USA, V92, P8866, DOI 10.1073/pnas.92.19.8866; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; LAVALLIE ER, 1995, CURR OPIN BIOTECH, V6, P501, DOI 10.1016/0958-1669(95)80083-2; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MartinezHackert E, 1997, STRUCTURE, V5, P109, DOI 10.1016/S0969-2126(97)00170-6; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; PRATT JM, 1984, TRANSCRIPTION TRANSL, P179; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P341; SHARROCKS AD, 1994, GENE, V138, P105, DOI 10.1016/0378-1119(94)90789-7; STEWART ML, 1971, P NATL ACAD SCI USA, V68, P97, DOI 10.1073/pnas.68.1.97; STOLTZFUS A, 1994, SCIENCE, V265, P202, DOI 10.1126/science.8023140; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U	39	329	339	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					343	349		10.1038/41024	http://dx.doi.org/10.1038/41024			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237751	Bronze			2022-12-24	WOS:A1997XM52800040
J	Loftus, SK; Morris, JA; Carstea, ED; Gu, JZ; Cummings, C; Brown, A; Ellison, J; Ohno, K; Rosenfeld, MA; Tagle, DA; Pentchev, PG; Pavan, WJ				Loftus, SK; Morris, JA; Carstea, ED; Gu, JZ; Cummings, C; Brown, A; Ellison, J; Ohno, K; Rosenfeld, MA; Tagle, DA; Pentchev, PG; Pavan, WJ			Murine model of Niemann-Pick C disease: Mutation in a cholesterol homeostasis gene	SCIENCE			English	Article							MOUSE; ACCUMULATION; LOCALIZATION; DEGRADATION; REDUCTASE; DOMAIN; MOTIF	An integrated human-mouse positional candidate approach was used to identify the gene responsible for the phenotypes observed in a mouse model of Niemann-Pick type C (NP-C) disease. The predicted murine NPC1 protein has sequence homology to the putative transmembrane domains of the Hedgehog signaling molecule Patched, to the cholesterol-sensing regions of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and SREBP cleavage-activating protein (SCAP), and to the NPC1 orthologs identified in human, the nematode Caenorhabditis elegans, and the yeast Saccharomyces cerevisiae. The mouse model may provide an important resource for studying the role of NPC1 in cholesterol homeostasis and neurodegeneration and for assessing the efficacy of new drugs for NP-C disease.	NIH, NATL HUMAN GENOME RES INST, LAB GENET DIS RES, BETHESDA, MD 20892 USA; NINCDS, NATL HUMAN GENOME RES INST, NIH, BETHESDA, MD 20892 USA; NINCDS, DEV & METAB NEUROL BRANCH, NIH, BETHESDA, MD 20892 USA; TOTTORI UNIV, FAC MED, SCH LIFE SCI, YONAGO, TOTTORI 683, JAPAN	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Tottori University				Pavan, William/0000-0001-8281-5120; Loftus, Stacie/0000-0002-1958-4689				Akaboshi S, 1997, HUM GENET, V99, P350, DOI 10.1007/s004390050370; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CORDONNIER A, 1995, J VIROL, V69, P5890, DOI 10.1128/JVI.69.9.5890-5897.1995; COXEY RA, 1993, J LIPID RES, V34, P1165; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; Erickson RP, 1997, MAMM GENOME, V8, P355, DOI 10.1007/s003359900440; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Gu JZ, 1997, P NATL ACAD SCI USA, V94, P7378, DOI 10.1073/pnas.94.14.7378; HEILEIN UAO, 1986, NUCLEIC ACIDS RES, V14, P6403; Herz J, 1997, NAT GENET, V15, P123, DOI 10.1038/ng0297-123; HIGASHI Y, 1991, INT CONGR SER, V962, P85; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; HOMANICS GE, 1993, P NATL ACAD SCI USA, V90, P2389, DOI 10.1073/pnas.90.6.2389; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; KELLY RG, 1994, GENOMICS, V24, P509, DOI 10.1006/geno.1994.1660; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; MIYAWAKI S, 1982, J HERED, V73, P257, DOI 10.1093/oxfordjournals.jhered.a109635; MORRIS C, 1982, AM J PATHOL, V140, P140; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; OGATA S, 1994, J BIOL CHEM, V269, P5210; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; Pentchev Peter G., 1994, Trends in Cell Biology, V4, P365, DOI 10.1016/0962-8924(94)90086-8; PENTCHEV PG, 1977, BIOCHIM BIOPHYS ACTA, V488, P312, DOI 10.1016/0005-2760(77)90189-8; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; SAKAI Y, 1991, BIOCHEM GENET, V29, P103, DOI 10.1007/BF00578243; Salen G, 1996, J LIPID RES, V37, P1169; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SMIT AFA, 1993, NUCLEIC ACIDS RES, V21, P1863, DOI 10.1093/nar/21.8.1863; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Yamamoto Toshiharu, 1994, No To Hattatsu, V26, P318	41	672	706	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					232	235		10.1126/science.277.5323.232	http://dx.doi.org/10.1126/science.277.5323.232			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211850				2022-12-24	WOS:A1997XK41800043
J	Everett, C				Everett, C			Incidence and outcome of bleeding before the 20th week of pregnancy: Prospective study from general practice	BRITISH MEDICAL JOURNAL			English	Article							SPONTANEOUS-ABORTION	Objective: To estimate the miscarriage rate in a cohort of pregnant women and the final outcome of pregnancy. Design: Two year prospective community study. Setting: Women registered with four semirural practices at one health centre. Subjects: 626 pregnant women from a population 21 448. 5140 of whom were women aged 15-44 years. Main outcome measures: Vaginal bleeding and outcome of pregnancy. Results: 76 of the 89 women with an unwanted pregnancy requested a termination. In the 550 ongoing pregnancies bleeding occurred before the 20th week in 117 (21%), and 67 (12%) ended in miscarriage. The risk of miscarriage was not significantly increased after a miscarriage in the previous pregnancy (11 (15%) women had miscarriage v 55 (12%) women who had not had miscarriage who had previously had a live birth). Of the 117 women with bleeding, 64 were not admitted to hospital by the general practitioner; 42 of these women had an ultrasound examination at the heatlh centre and 19 subsequently miscarried at home. In hospital 41 of 46 women who miscarried had evacuation of the uterus. Conclusions: Bleeding occurred in one fifth of recognised pregnancies before the 20th week and over half of these miscarried. Treatment of women with miscarriage at home means current statistics on miscarriage in Britain are missing many cases.	CHURCH COTTAGE,ALTON GU34 4HD,HANTS,ENGLAND		Everett, C (corresponding author), ALTON HLTH CTR,ALTON GU34 2QX,HANTS,ENGLAND.							COHENOVERBEEK TE, 1990, LANCET, V336, P27, DOI 10.1016/0140-6736(90)91528-I; *DEP HLTH, 1993, STAT PUBL HLTH; Everett CB, 1996, BRIT J GEN PRACT, V46, P7; EVERETT CB, 1988, BRIT MED J, V295, P583; FRENCH FE, 1962, PUBLIC HEALTH REP, V77, P835, DOI 10.2307/4591645; *HOSP EP STAT HES, 1994, HOSP EP STAT HES FIN; Huisjes H. J., 1984, SPONTANEOUS ABORTION, P6; James WH, 1996, HUM REPROD, V11, P2333; KNUDSEN UB, 1991, EUR J OBSTET GYN R B, V39, P31, DOI 10.1016/0028-2243(91)90138-B; NAYLOR AF, 1979, FERTIL STERIL, V31, P282; Oakley Ann, 1984, MISCARRIAGE; *OFF POP CENS SURV, 1995, POP TRENDS, P79; RAI R, 1994, DIPLOMATE, V1, P269; REGAN L, 1989, BRIT MED J, V299, P541, DOI 10.1136/bmj.299.6698.541; REGAN L, 1991, BMJ-BRIT MED J, V302, P543, DOI 10.1136/bmj.302.6776.543; Stabile I., 1992, SPONTANEOUS ABORTION; WEINBERG CR, 1994, ANN NY ACAD SCI, V709, P280, DOI 10.1111/j.1749-6632.1994.tb30416.x; WHITTAKER PG, 1983, LANCET, V1, P1126; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401	19	217	226	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					32	34		10.1136/bmj.315.7099.32	http://dx.doi.org/10.1136/bmj.315.7099.32			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ947	9233324	Green Published			2022-12-24	WOS:A1997XJ94700027
J	Gilbert, C; Rahi, J; Eckstein, M; OSullivan, J; Foster, A				Gilbert, C; Rahi, J; Eckstein, M; OSullivan, J; Foster, A			Retinopathy of prematurity in middle-income countries	LANCET			English	Article							CHILDHOOD BLINDNESS; VISUAL IMPAIRMENT; CHILDREN; SCHOOL; EPIDEMIOLOGY; INDIA; BIRTH	Background In the 1940s and 1950s retinopathy of prematurity (ROP) was the single commonest cause of blindness in children in many industrialised countries; it now accounts for only 6-18% of blindness registrations. It is not known what proportion of blindness is due to ROP in countries that do not have blindness registers. Information on blindness in children in these countries can be obtained by examining children in schools for the blind. Methods Between 1991 and 1996, 4121 children in 23 countries with a visual acuity in the better eye of less than 6/60 were examined with a standard method. Findings The proportion of severe visual impairment or blindness due to ROP ranged from 0% in most African countries to 38.6% in Cuba. Interpretation These data suggest that ROP is becoming a major cause of potentially preventable blindness among children in middle-income countries that have introduced neonatal intensive-care services for preterm and low-birthweight babies.	INST CHILD HLTH,DEPT EPIDEMIOL,LONDON,ENGLAND; MOORFIELDS EYE HOSP,LONDON,ENGLAND	University of London; University College London; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust	Gilbert, C (corresponding author), INST OPHTHALMOL,DEPT PREVENT OPHTHALMOL,LONDON EC1V 9EL,ENGLAND.			Foster, Allen/0000-0003-2368-4436; Rahi, Jugnoo/0000-0002-5718-9209				Adekeye M., 1996, THESIS I OPHTHALMOLO; BLACKMAN JA, 1991, PEDIATR CLIN N AM, V38, P1497; *CRYOTH RET PREM C, 1996, ARCH OPHTHALMOL-CHIC, V114, P417; CUNNINGHAM S, 1995, LANCET, V346, P1464, DOI 10.1016/S0140-6736(95)92475-2; Czeizel A, 1991, Acta Paediatr Hung, V31, P365; DARLOW BA, 1988, ARCH DIS CHILD, V63, P1083, DOI 10.1136/adc.63.9.1083; DOYLE LW, 1995, MED J AUSTRALIA, V163, P11, DOI 10.5694/j.1326-5377.1995.tb126079.x; ECKSTEIN MB, 1995, BRIT J OPHTHALMOL, V79, P633, DOI 10.1136/bjo.79.7.633; FAUNDES A, 1993, HEALTH POLICY PLANN, V8, P33, DOI 10.1093/heapol/8.1.33; Fielder AR, 1997, CLIN RISK, V3, P47; FLYNN JT, 1995, PEDIATRICS, V95, P755; GILBERT C, 1993, INT OPHTHALMOL, V17, P229, DOI 10.1007/BF01007745; GILBERT C, 1993, B WORLD HEALTH ORGAN, V71, P485; GILBERT C, IN PRESS OPHTHAL EPI; Gilbert C E, 1995, Ophthalmic Epidemiol, V2, P77, DOI 10.3109/09286589509057086; GILBERT CE, 1993, EYE, V7, P184, DOI 10.1038/eye.1993.39; GILBERT CE, 1994, DEV MED CHILD NEUROL, V36, P334; GOGGIN M, 1991, BRIT J OPHTHALMOL, V75, P425, DOI 10.1136/bjo.75.7.425; HANSEN E, 1992, ACTA OPHTHALMOL, V70, P597; LUMLEY J, 1993, BAILLIERE CLIN OB GY, V7, P477, DOI 10.1016/S0950-3552(05)80445-6; MASOOD SS, 1995, THESIS I OPHTHALMOLO; NG YK, 1988, LANCET, V2, P1235; OSULLIVAN J, IN PRESS S AFR MED J; RAHI JS, 1995, EYE, V9, P545, DOI 10.1038/eye.1995.137; SAUNDERS RA, 1995, J PEDIATR OPHTHALMOL, V32, P302; Sorsby A., 1966, REPORTS PUBLIC HLTH, V114; TSUKAHARA S, 1985, JPN J OPHTHALMOL, V29, P315; *UK DEP HLTH, 1991, STAT B UK DEP HLTH, V3; VANDERPOL BAE, 1986, DOC OPHTHALMOL, V61, P223, DOI 10.1007/BF00142346	29	294	330	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					12	14		10.1016/S0140-6736(97)01107-0	http://dx.doi.org/10.1016/S0140-6736(97)01107-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217713				2022-12-24	WOS:A1997XH86900009
J	Shiff, SJ; Rigas, B				Shiff, SJ; Rigas, B			Colon adenomatous polyps - Do they grow inward?	LANCET			English	Editorial Material							CELL				Shiff, SJ (corresponding author), ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021 USA.							GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALL PA, 1994, J CELL SCI, V107, P3569; Itzkowitz SH, 1993, GASTROINTESTINAL DIS, P1402; LIGHTDALE C, 1982, CANCER RES, V42, P4280; LIPKIN M, 1992, J CELL BIOCHEM, P1; Moss SF, 1996, GASTROENTEROLOGY, V111, P1425, DOI 10.1016/S0016-5085(96)70003-3; Sinicrope FA, 1996, CLIN CANCER RES, V2, P1999	7	15	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 28	1997	349	9069					1853	1854		10.1016/S0140-6736(05)63870-6	http://dx.doi.org/10.1016/S0140-6736(05)63870-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217752				2022-12-24	WOS:A1997XG41700003
J	Fass, D; Davey, RA; Hamson, CA; Kim, PS; Cunningham, JM; Berger, JM				Fass, D; Davey, RA; Hamson, CA; Kim, PS; Cunningham, JM; Berger, JM			Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 angstrom resolution	SCIENCE			English	Article							ECOTROPIC RETROVIRUS RECEPTOR; ENVELOPE GLYCOPROTEINS; PROTEIN; GENE; CLASSIFICATION; DETERMINANTS; ALIGNMENT; SEQUENCE; VECTORS; DOMAIN	An essential step in retrovirus infection is the binding of the virus to its receptor on a target cell. The structure of the receptor-binding domain of the envelope glycoprotein from Friend murine leukemia virus was determined to 2.0 angstrom resolution by x-ray crystallography. The core of the domain is an antiparallel beta sandwich, with two interstrand loops forming a helical subdomain atop the sandwich, The residues in the helical region, but not in the beta sandwich, are highly variable among mammalian C-type retroviruses with distinct tropisms, indicating that the helical subdomain determines the receptor specificity of the virus.	MIT, WHITEHEAD INST BIOMED RES, HOWARD HUGHES MED INST, DEPT BIOL, CAMBRIDGE, MA 02142 USA; HARVARD UNIV, SCH MED,BRIGHAM & WOMENS HOSP, HOWARD HUGHES MED INST,DIV HEMATOL, DEPT MED, BOSTON, MA 02115 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute				Davey, Robert/0000-0001-9168-2892				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BATTINI JL, 1995, J VIROL, V69, P713, DOI 10.1128/JVI.69.2.713-719.1995; BATTINI JL, 1992, J VIROL, V66, P1468, DOI 10.1128/JVI.66.3.1468-1475.1992; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DAVEY RA, IN PRESS J VIROL; FASS D, 1997, THESIS MIT CAMBRIDGE; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; HEARD JM, 1991, J VIROL, V65, P4026, DOI 10.1128/JVI.65.8.4026-4032.1991; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Holm L, 1996, NUCLEIC ACIDS RES, V24, P206, DOI 10.1093/nar/24.1.206; HUNTER E, 1990, CURR TOP MICROBIOL, V157, P187; JONES TA, 1992, O MANUAL; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOCH W, 1983, J VIROL, V45, P1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LINDER M, 1992, EUR J BIOCHEM, V203, P65, DOI 10.1111/j.1432-1033.1992.tb19828.x; MacKrell AJ, 1996, J VIROL, V70, P1768, DOI 10.1128/JVI.70.3.1768-1774.1996; MORGAN RA, 1993, J VIROL, V67, P4712, DOI 10.1128/JVI.67.8.4712-4721.1993; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTT D, 1992, J VIROL, V66, P4632, DOI 10.1128/JVI.66.8.4632-4638.1992; OTWINOWSKI Z, 1993, CCP4 STUDY WEEKEND D, P56; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Peredo C, 1996, J VIROL, V70, P3142, DOI 10.1128/JVI.70.5.3142-3152.1996; PINTER A, 1982, VIROLOGY, V116, P499, DOI 10.1016/0042-6822(82)90143-X; SMITH AE, 1995, ANNU REV MICROBIOL, V49, P807; ValsesiaWittmann S, 1996, J VIROL, V70, P2059, DOI 10.1128/JVI.70.3.2059-2064.1996; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; ZHANG KYJ, 1994, PROTEIN SCI, V3, P687; 1992, NATURE, V355, P472	37	173	178	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	1997	277	5332					1662	1666		10.1126/science.277.5332.1662	http://dx.doi.org/10.1126/science.277.5332.1662			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287219				2022-12-24	WOS:A1997XV68400050
J	Anto, JM				Anto, JM			Health effects due to inhalation of oilseed rape emissions	LANCET			English	Editorial Material							POTENT ANTIGEN				Anto, JM (corresponding author), INST MUNICIPAL INVEST MED,RESP & ENVIRONM HLTH RES UNIT,E-08003 BARCELONA,SPAIN.		Anto, J M/H-2676-2014	Anto, J M/0000-0002-4736-8529				BUTCHER RD, 1995, CLIN EXP ALLERGY, V25, P985, DOI 10.1111/j.1365-2222.1995.tb00401.x; COLBORN T, 1995, ENVIRON HEALTH PERSP, V103, P81, DOI 10.2307/3432353; FELL PJ, 1992, CLIN EXP ALLERGY, V22, P501, DOI 10.1111/j.1365-2222.1992.tb00154.x; Hemmer W, 1997, CLIN EXP ALLERGY, V27, P156; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; *MED RES COUNC I E, 1997, IEH ASS OILS RAP ALL; NINAN TK, 1990, LANCET, V336, P808, DOI 10.1016/0140-6736(90)93266-R; PARRATT D, 1990, LANCET, V335, P121, DOI 10.1016/0140-6736(90)90599-Z; SOUTAR A, 1994, THORAX, V49, P352, DOI 10.1136/thx.49.4.352; SOUTAR A, 1995, OCCUP ENVIRON MED, V52, P575, DOI 10.1136/oem.52.9.575	10	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					458	459		10.1016/S0140-6736(05)63076-0	http://dx.doi.org/10.1016/S0140-6736(05)63076-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274579				2022-12-24	WOS:A1997XR13500005
J	Tokunaga, M; Larrow, JF; Kakiuchi, F; Jacobsen, EN				Tokunaga, M; Larrow, JF; Kakiuchi, F; Jacobsen, EN			Asymmetric catalysis with water: Efficient kinetic resolution of terminal epoxides by means of catalytic hydrolysis	SCIENCE			English	Article								Epoxides are versatile building blocks for organic synthesis. However, terminal epoxides are arguably the most important subclass of these compounds, and no general and practical method exists for their production in enantiomerically pure form. Terminal epoxides are available very inexpensively as racemic mixtures, and kinetic resolution is an attractive strategy for the production of optically active epoxides, given an economical and operationally simple method. Readily accessible synthetic catalysts (chiral cobalt-based salen complexes) have been used for the efficient asymmetric hydrolysis of terminal epoxides. This process uses water as the only reagent, no added solvent, and low loadings of a recyclable catalyst (<0.5 mole percent), and it affords highly valuable terminal epoxides and 1,2-diols in high yield with high enantiomeric enrichment.			Tokunaga, M (corresponding author), HARVARD UNIV,DEPT CHEM & CHEM BIOL,CAMBRIDGE,MA 02138, USA.				NIGMS NIH HHS [GM-43214] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043214, R01GM043214] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal VK, 1996, J AM CHEM SOC, V118, P7004, DOI 10.1021/ja961144+; CUMMINS J, COMMUNICATION; ELIEL EL, 1994, STEREOCHEMISTRY ORGA, P95; FABER K, 1992, BIOTRANSFORMATIONS O; Hansen KB, 1996, J AM CHEM SOC, V118, P10924, DOI 10.1021/ja962600x; Jacobsen EN, 1997, TETRAHEDRON LETT, V38, P773, DOI 10.1016/S0040-4039(96)02414-8; JACOBSEN EN, 1995, COMPRENHENSIVE ORGAN, V12; KAGAN HB, 1987, TOP STEREOCHEM, V14, P249; KOLB HC, 1994, CHEM REV, V94, P2483, DOI 10.1021/cr00032a009; Larrow JF, 1996, J AM CHEM SOC, V118, P7420, DOI 10.1021/ja961708+; Sato K, 1996, J ORG CHEM, V61, P8310, DOI 10.1021/jo961287e; SINIGALIA R, 1987, ORGANOMETALLICS, V6, P728, DOI 10.1021/om00147a009; Vanhessche KPM, 1997, CHEM-EUR J, V3, P517, DOI 10.1002/chem.19970030406; Weijers CAGM, 1997, TETRAHEDRON-ASYMMETR, V8, P639, DOI 10.1016/S0957-4166(97)00012-8	14	1238	1289	10	290	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					936	938		10.1126/science.277.5328.936	http://dx.doi.org/10.1126/science.277.5328.936			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252321				2022-12-24	WOS:A1997XQ98500036
J	Hull, HF; Aylward, RB				Hull, HF; Aylward, RB			Ending polio immunization	SCIENCE			English	Article											Hull, HF (corresponding author), WHO, EXPANDED PROGRAMME IMMUNIZAT, CH-1211 GENEVA 27, SWITZERLAND.							Banerjee K, 1997, LANCET, V349, P1630, DOI 10.1016/S0140-6736(05)61675-3; COCKBURN TA, 1961, SCIENCE, V133, P1050, DOI 10.1126/science.133.3458.1050; DOMOK I, 1982, BRIT MED J, V1, P743; Dove AW, 1997, SCIENCE, V277, P779, DOI 10.1126/science.277.5327.779; Dowdle WR, 1997, J INFECT DIS, V175, pS286, DOI 10.1093/infdis/175.Supplement_1.S286; EVANS AS, 1984, REV INFECT DIS, V6, pS571; FOX JP, 1961, 5 INT POL C, P368; Hull HF, 1997, SCIENCE, V275, P40, DOI 10.1126/science.275.5296.40; HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4; Kew OM, 1995, SEMIN VIROL, V6, P401, DOI 10.1016/S1044-5773(05)80017-4; LEE JW, 1997, NEW GENERATION VACCI, P79; MULDERS MN, 1997, IN PRESS J INFECT DI, V175; OCHOA E G, 1987, Journal of Hygiene Epidemiology Microbiology and Immunology (Prague), V31, P381; ROBINSON D, 1984, REV INFECT DIS, V6, pS586; 1997, WEEKLY EPIDEMIOL REC, V72, P189; 1997, MMWR-MORBID MORTAL W, V46, P641	16	17	17	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 8	1997	277	5327					780	780		10.1126/science.277.5327.780	http://dx.doi.org/10.1126/science.277.5327.780			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9273701				2022-12-24	WOS:A1997XQ24700032
J	Calder, JAM				Calder, JAM			Listeria meningitis in adults	LANCET			English	Editorial Material							BACTERIAL-MENINGITIS; UNITED-STATES				Calder, JAM (corresponding author), NEW YORK CITY DEPT HLTH,NEW YORK,NY 10013, USA.		Calder, Jennifer/F-4508-2015	Calder, Jennifer/0000-0003-4758-611X				BUCHNER LH, 1968, AM J MED, V45, P904, DOI 10.1016/0002-9343(68)90189-7; CHERUBIN CE, 1981, AM J MED, V71, P199, DOI 10.1016/0002-9343(81)90106-6; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; JENSEN A, 1994, SCAND J INFECT DIS, V26, P171, DOI 10.3109/00365549409011781; LAVETTER A, 1971, NEW ENGL J MED, V285, P598, DOI 10.1056/NEJM197109092851103; MICHES LI, 1994, CRIT CARE NURSE  AUG, P22; Sigurdardottir B, 1997, ARCH INTERN MED, V157, P425, DOI 10.1001/archinte.157.4.425; TAPPERO JW, 1995, JAMA-J AM MED ASSOC, V273, P1118, DOI 10.1001/jama.273.14.1118; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; *WHO, 1993, B WORLD HEALTH ORGAN, V71, P259	10	16	17	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					307	308		10.1016/S0140-6736(05)63384-3	http://dx.doi.org/10.1016/S0140-6736(05)63384-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251632				2022-12-24	WOS:A1997XP24200005
J	Freemont, AJ; Peacock, TE; Goupille, P; Hoyland, JA; OBrien, J; Jayson, MIV				Freemont, AJ; Peacock, TE; Goupille, P; Hoyland, JA; OBrien, J; Jayson, MIV			Nerve ingrowth into diseased intervertebral disc in chronic back pain	LANCET			English	Article							SUBSTANCE-P; INNERVATION; FIBERS; RAT	Background In the healthy back only the outer third of the annulus fibrosus of the intervertebral disc is innervated. Nerve ingrowth deeper into diseased intervertebral disc has been reported, but how common this feature is and whether it is associated with chronic pain are unknown. We examined nerve growth into the intervertebral disc in the pathogenesis of chronic low back pain. Methods We collected 46 samples of intervertebral discs from 38 patients during spinal fusion for chronic back pain. 30 samples were from pain levels clinically established by discography and 16 samples were from adjacent vertebral levels with no pain. We obtained 34 control samples of intervertebral disc from previously healthy individuals with normal histology within 8 h of recorded death. We used standard immunohistochemical techniques to test for a general nerve marker, a nociceptive neurotransmitter (substance P), and a protein expressed during axonogenesis (growth-associated protein 43 [GAP43]). Findings We identified nerve fibres in the outer third of the annulus fibrosus in 48 (60%) of the 80 samples of intervertebral discs. Nerves were restricted to the outer or middle third of the annulus fibrosus in the 34 control samples. Among the patients with chronic low back pain, nerves extended into the inner third of the annulus fibrosus and into the nucleus pulposus in 21 (46%) and ten (22%) samples, respectively. Nerves usually accompanied blood vessels, but in 14 of the samples from back-pain patients, isolated nerve fibres were seen in the discal matrix. Both types of nerve fibres expressed substance P, but only non-vessel-associated fibres expressed GAP43, Deep nerve ingrowth into the inner third of the annulus fibrosus, the nucleus pulposus, or both was seen in four (25%) of 16 biopsy samples from non-pain levels and in 17 (57%) samples from pain levels. Of the 16 paired samples from both pain and non-pain levels, five pain-level samples and one non-pain-level sample showed deep nerve ingrowth. Interpretation Our finding of isolated nerve fibres that express substance P deep within diseased intervertebral discs and their association with pain suggests an important role for nerve growth into the intervertebral disc in the pathogenesis of chronic low back pain.	UNIV MANCHESTER, DEPT PATHOL SCI, MANCHESTER M13 9PT, LANCS, ENGLAND; CTR HOSP UNIV, TOURS, FRANCE; LONDON CLIN, LONDON, ENGLAND	University of Manchester; CHU Tours; University of London; University College London	Freemont, AJ (corresponding author), UNIV MANCHESTER, DEPT RHEUMATOL, MANCHESTER M13 9PT, LANCS, ENGLAND.		Freemont, Tony J/A-9000-2015; Hoyland, Judith A/P-5168-2014	Freemont, Tony J/0000-0002-9780-208X; Hoyland, Judith A/0000-0003-4876-5208				AHMED M, 1993, SPINE, V18, P268, DOI 10.1097/00007632-199302000-00016; AHMED M, 1991, NEURO ORTHOP, V12, P19; ASHTON IK, 1994, ACTA ORTHOP SCAND, V65, P635, DOI 10.3109/17453679408994620; ASHTON IK, 1994, J ORTHOP RES, V12, P186, DOI 10.1002/jor.1100120206; BOGDUK N, 1981, J ANAT, V132, P39; COLLINS DH, 1949, PATHOLOGY ARTICULAR, P256; COPPES MH, 1990, LANCET, V336, P189, DOI 10.1016/0140-6736(90)91723-N; DAVIS DV, 1967, GRAYS ANATOMY DESCRI, P498; FAIRBANK JCT, 1996, INT SOC BACK PAIN RE, P86; GARDNER DL, 1992, PATHOLOGICAL BASIS C, P126; GRONBLAD M, 1991, ACTA ORTHOP SCAND, V62, P614; GRONBLAD M, 1991, CLIN ORTHOP RELAT R, P291; GRONBLAD M, 1990, ACTA ORTHOP SCA S235, V61, P40; HENRY JL, 1982, CIBA F SYMP, V91, P206; HIRSCH C., 1953, ACTA ORTHOPAED SCAND, V22, P184; JACKSON HC, 1966, J BONE JOINT SURG AM, VA 48, P1272, DOI 10.2106/00004623-196648070-00002; JESSELL TM, 1982, LANCET, V2, P1084; KANG JD, 1995, SPINE, V20, P2373, DOI 10.1097/00007632-199511001-00001; KAUPPILA LI, 1995, J BONE JOINT SURG AM, V77A, P26, DOI 10.2106/00004623-199501000-00004; KONTTINEN YT, 1990, SPINE, V15, P383, DOI 10.1097/00007632-199005000-00008; MALINSKY JII, 1959, ACTA ANAT, V38, P96; MCCARTHY PW, 1991, SPINE, V16, P653, DOI 10.1097/00007632-199106000-00010; Olmarker K, 1997, SPINE, V22, P471, DOI 10.1097/00007632-199703010-00001; Palmgren T, 1996, SPINE, V21, P1301, DOI 10.1097/00007632-199606010-00004; ROBERTS S, 1995, LUMBAR SPINE DISORDE, P73; TOLONEN J, 1995, SPINE, V20, P271, DOI 10.1097/00007632-199502000-00003; VERNONROBERTS B, 1992, LUMBAR SPINE BACK PA, P24; Virri J, 1994, Eur Spine J, V3, P336, DOI 10.1007/BF02200147; WEINSTEIN J, 1988, SPINE, V13, P1344, DOI 10.1097/00007632-198812000-00002	29	612	678	0	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 19	1997	350	9072					178	181		10.1016/S0140-6736(97)02135-1	http://dx.doi.org/10.1016/S0140-6736(97)02135-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250186				2022-12-24	WOS:A1997XL72200013
J	Deveraux, QL; Takahashi, R; Salvesen, GS; Reed, JC				Deveraux, QL; Takahashi, R; Salvesen, GS; Reed, JC			X-linked IAP is a direct inhibitor of cell-death proteases	NATURE			English	Article							APOPTOSIS	The inhibitor-of-apoptosis (IAP) family of genes has an evolutionarily conserved role in regulating programmed cell death in animals ranging from insects to humans(1-6). Ectopic expression of human IAP proteins can suppress cell death induced by a variety of stimuli, but the mechanism of this inhibition was previously unknown. Here we show that human X-chromosome-linked IAP directly inhibits at least two members of the caspase family of cell-death proteases, caspase-3 and caspase-7. As the caspases are highly conserved throughout the animal kingdom and are the principal effectors of apoptosis(7), our findings suggest how IAPs might inhibit cell death, providing evidence for a mechanism of action for these mammalian cell-death suppressors.	BURNHAM INST,PROGRAM APOPTOSIS & CELL DEATH RES,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, IN PRESS BLOOD; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YAMAKAWA T, 1995, J BIOL CHEM, V270, P25328; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	27	1637	1733	1	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					300	304		10.1038/40901	http://dx.doi.org/10.1038/40901			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230442	Green Submitted, Bronze			2022-12-24	WOS:A1997XL12100057
J	Shi, YG; Hata, A; Lo, RS; Massague, J; Pavletich, NP				Shi, YG; Hata, A; Lo, RS; Massague, J; Pavletich, NP			A structural basis for mutational inactivation of the tumour suppressor Smad4	NATURE			English	Article							PROTEIN	The Smad4/DPC4 tumour suppressor(1) is inactivated in nearly half of pancreatic carcinomas(2) and to a lesser extent in a variety of other cancers(2-4). Smad4/DPC4, and the related tumour suppressor Smad2, belong to the SMAD family of proteins that mediate signalling by the TGF-beta/activin/BMP-2/4 cytokine superfamily from receptor Ser/Thr protein kinases at the cell surface to the nucleus(5-7). SMAD proteins, which are phosphorylated by the activated receptor, propagate the signal, in part, through homo- and hetero-oligomeric interactions(8-13). Smad4/DPC4 plays a central role as it is the shared hetero-oligomerization partner of the other SMADs. The conserved carboxy-terminal domains of SMADs are sufficient for inducing most of the ligand-specific effects, and are the primary targets of tumorigenic inactivation. We now describe the crystal structure of the C-terminal domain (CTD) of the Smad4/DPC4 tumour suppressor, determined at 2.5 Angstrom resolution. The structure reveals that the Smad4/DPC4 CTD forms a crystallographic trimer through a conserved protein-protein interface, to which the majority of the tumour-derived missense mutations map. These mutations disrupt homooligomerization in vitro and in vivo indicating that the trimeric assembly of the Smad4/DPC4 CTD is critical for signalling and is disrupted by tumorigenic mutations.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL PROGRAM, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center				Shi, Yigong/0000-0003-2030-168X; Massague, Joan/0000-0001-9324-8408				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BRUNGER AT, 1991, X PLOR SYSTEM CRYSTA; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; IECHLEIDER RJ, 1996, J BIOL CHEM, V271, P17617; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim SK, 1996, CANCER RES, V56, P2519; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nagatake M, 1996, CANCER RES, V56, P2718; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SHELDRICK G, 1991, PATTERSON INTERPRETA; STURA EA, 1992, CRYSTALLIZATION NUCL, P99; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Uchida K, 1996, CANCER RES, V56, P5583; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	30	369	393	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	1997	388	6637					87	93		10.1038/40431	http://dx.doi.org/10.1038/40431			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214508	Bronze			2022-12-24	WOS:A1997XJ14300056
J	Shorr, RI; Ray, WA; Daugherty, JR; Griffin, MR				Shorr, RI; Ray, WA; Daugherty, JR; Griffin, MR			Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANGIOTENSIN-CONVERTING ENZYME; ACUTE MYOCARDIAL-INFARCTION; DIABETIC-PATIENTS; AUTONOMIC NEUROPATHY; BETA-BLOCKERS; PROPRANOLOL; UNAWARENESS; INHIBITORS; METOPROLOL; ATENOLOL	Context.-beta-Blockers and angiotensin-converting enzyme (ACE) inhibitors are effective antihypertensive agents for patients with diabetes mellitus, However, beta-blockers attenuate some components of the autonomic response to hypoglycemia and could increase the risk of hypoglycemia. ACE inhibitors may increase insulin sensitivity and predispose users to hypoglycemia. Objective.-To determine whether use of cardioselective beta-blockers, nonselective beta-blockers, ACE inhibitors, thiazide diuretics, calcium channel blockers, or other antihypertensive drugs alters the risk of developing serious hypoglycemia among older persons prescribed insulin or sulfonylureas, Design.-Retrospective cohort study, Setting.-Tennessee Medicaid Program, Patients.-A total of 13 559 elderly (mean age, 78+/-7 years) Medicaid enrollees, who were prescribed insulin (n=5171, 38%) or sulfonylureas (n=8368, 62%) from 1985 through 1989, These enrollees contributed a total of 33 107 person-years of insulin or sulfonylurea use for follow-up. Measurements.-Hospitalization, emergency department admission, or death associated with hypoglycemic symptoms and a concomitant blood glucose determination of less than 2.8 mmol/L (50 mg/dL), Results.-We identified 598 persons with an episode of serious hypoglycemia during the study period, The rate of serious hypoglycemia was 2.01 per 100 person-years among those who were not prescribed antihypertensives. Crude rates of serious hypoglycemia were highest among users of ACE inhibitors (2.47 per 100 person-years) and lowest among users of cardioselective beta-blockers (1.23 per 100 person-years), However, when we controlled for demographic characteristics and markers of comorbidity, there was no statistically significant increase or decrease in risk of serious hypoglycemia among users of any class of antihypertensive agents compared with nonusers of antihyperiensive drugs. Using nonselective beta-blockers as the reference group, each of these agents was associated with a lower, but not statistically significant, risk of hypoglycemia. Conclusions.-In this population, specific antihypertensive drug therapy had little impact an the risk of hypoglycemia in older diabetic patients. Therapy should be chosen based on other considerations of safety and effectiveness.	UNIV TENNESSEE,MEMPHIS COLL MED,DEPT PREVENT MED,MEMPHIS,TN; VANDERBILT UNIV,SCH MED,DEPT PREVENT MED,DIV PHARMACOEPIDEMIOL,NASHVILLE,TN 37212	University of Tennessee System; University of Tennessee Health Science Center; Vanderbilt University	Shorr, RI (corresponding author), METHODIST HOSP MEMPHIS,DEPT MED EDUC,1265 UNION AVE,MEMPHIS,TN 38104, USA.				NATIONAL INSTITUTE ON AGING [K08AG000559] Funding Source: NIH RePORTER; NIA NIH HHS [K08-AG00559] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*1ST INT STUD INF, 1986, LANCET, V2, P57; ARAUZPACHECO C, 1990, AM J MED, V89, P811, DOI 10.1016/0002-9343(90)90227-5; *AUSTR SWED PIND S, 1983, EUR HEART J, V4, P367; BARNETT AH, 1980, BRIT MED J, V280, P976, DOI 10.1136/bmj.280.6219.976; *BET BLOCK HEART A, 1982, JAMA-J AM MED ASSOC, V247, P1707; DEACON SP, 1977, BRIT MED J, V2, P1255, DOI 10.1136/bmj.2.6097.1255; Fatourechi V, 1996, MAYO CLIN PROC, V71, P53, DOI 10.4065/71.1.53; Harris M I, 1990, Clin Geriatr Med, V6, P703; HEPBURN DA, 1990, DIABETIC MED, V7, P711, DOI 10.1111/j.1464-5491.1990.tb01475.x; HERINGS RMC, 1995, LANCET, V345, P1195, DOI 10.1016/S0140-6736(95)91988-0; HJALMARSON A, 1981, LANCET, V2, P823; *JOINT NAT COMM DE, 1993, ARCH INTERN MED, V153, P154; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; KERR D, 1990, BRIT J CLIN PHARMACO, V29, P685, DOI 10.1111/j.1365-2125.1990.tb03689.x; KJEKSHUS J, 1990, EUR HEART J, V11, P43, DOI 10.1093/oxfordjournals.eurheartj.a059591; *MIAMI TRIAL RES G, 1985, EUR HEART J, V6, P199; *NORW MULT STUD GR, 1981, NEW ENGL J MED, V304, P801; PAYNE CD, 1987, GEN LINEAR INTERACTI; RETT K, 1988, NEW ENGL J MED, V319, P1609; RYDER REJ, 1990, BMJ-BRIT MED J, V301, P783, DOI 10.1136/bmj.301.6755.783; TSE WY, 1994, DIABETIC MED, V11, P137, DOI 10.1111/j.1464-5491.1994.tb02009.x; US Dept of Health and Human Services . International Classification of Diseases, 1988, INT CLASS DIS; WALLIN JD, 1987, ARCH INTERN MED, V147, P654, DOI 10.1001/archinte.147.4.654; *WORK GROUP HYP DI, 1987, ARCH INTERN MED, V147, P830; 1993, DIABETES CARE, V16, P1394	25	79	82	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					40	43		10.1001/jama.278.1.40	http://dx.doi.org/10.1001/jama.278.1.40			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207336				2022-12-24	WOS:A1997XG38700034
J	Williams, LA; Evans, SF; Newnham, JP				Williams, LA; Evans, SF; Newnham, JP			Prospective cohort study of factors influencing the relative weights of the placenta and the newborn infant	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC HEART-DISEASE; ADULT LIFE; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; FETAL WEIGHT; MORTALITY; DEATH; CHILDHOOD; PREGNANCY; ENGLAND	Objectives: To determine the demographic, environmental, and medical factors that influence the relative weights of the newborn infant and the placenta and compare this ratio with other factors known to predispose to adult ill health. Design: Prospective cohort study. Setting: The tertiary referral centre for perinatal care in Perth, Western Australia. Subjects: 2507 pregnant women who delivered a single live infant at term. Main outcome measures: Placental weight, birth weight, and the ratio of placental weight to birth weight. Results: By multiple regression analysis the placental weight to birthweight ratio was significantly and positively associated with gestational age, female sex, Asian parentage, increasing maternal body mass index, increased maternal weight at booking, lower socioeconomic status, maternal anaemia, and increasing number of cigarettes smoked daily. There were no consistent relations between the placental weight to birthweight ratio and measures of newborn size. Conclusions: The ratio of placental weight to birth weight is not an accurate marker of fetal growth. In its role as a predictor of adult disease the ratio may be acting as a surrogate for other factors which are already known to influence health and may act before or after birth. Determining the role that relative growth rates of the fetus and placenta have in predisposing to adult disease requires prospective study to account for the many confounding variables which complicate this hypothesis.	UNIV WESTERN AUSTRALIA,KING EDWARD MEM HOSP,WOMEN & INFANTS RES FDN,SUBIACO,WA 6008,AUSTRALIA	King Edward Memorial Hospital; University of Western Australia			Study, Raine/K-4517-2013	Newnham, John/0000-0001-9983-7457				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1987, BMJ-BRIT MED J, V295, P83, DOI 10.1136/bmj.295.6590.83; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1986, LANCET, V1, P1077; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BEISCHER N A, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P398; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Evans S, 1996, EARLY HUM DEV, V45, P203, DOI 10.1016/0378-3782(96)01728-8; Garn S.M., 1971, HUMAN RACES; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; MCCRABB GJ, 1992, J AGR SCI, V118, P127, DOI 10.1017/S002185960006809X; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PERRY IJ, 1995, BMJ-BRIT MED J, V310, P436, DOI 10.1136/bmj.310.6977.436	16	149	149	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1864	1868		10.1136/bmj.314.7098.1864	http://dx.doi.org/10.1136/bmj.314.7098.1864			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224128	Green Published			2022-12-24	WOS:A1997XH73800022
J	Coleman, JL; Gebbia, JA; Piesman, J; Degen, JL; Bugge, TH; Benach, JL				Coleman, JL; Gebbia, JA; Piesman, J; Degen, JL; Bugge, TH; Benach, JL			Plasminogen is required for efficient dissemination of B-burgdorferi in ticks and for enhancement of spirochetemia in mice	CELL			English	Article							LYME-DISEASE SPIROCHETE; OUTER SURFACE-PROTEIN; BORRELIA-BURGDORFERI; IXODES-DAMMINI; HUMAN-PLASMA; ACTIVATOR; UROKINASE; BLOOD; TRANSMISSION; SYSTEM	The role of the host plasminogen activation system in transmission of and invasion by Borrelia burgdorferi, the tick-borne spirochetal agent of Lyme disease, was investigated using plasminogen (Plg)-knockout mice. PLG was not detected in spirochetes from unfed ticks, but binding occurred as ticks fed on the host's blood. Plasminogen activators were derived from the host blood meal. PLG was required for efficient dissemination of B. burgdorferi within the tick and for enhancement of spirochetemia in mice but was not critical for transmission and infection. These results provide evidence for a bacterium using a vertebrate protease to disseminate in an invertebrate vector and underscores the interplay among vector, pathogen, and host in promoting the life cycle and disease.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PATHOL,STONY BROOK,NY 11794; CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229; CTR DIS CONTROL & PREVENT,FT COLLINS,CO 80522	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Centers for Disease Control & Prevention - USA	Coleman, JL (corresponding author), SUNY STONY BROOK,HLTH SCI CTR,NEW YORK STATE DEPT HLTH,STONY BROOK,NY 11794, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027044, R01AI027044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040445] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47826] Funding Source: Medline; NIAID NIH HHS [AI 27044] Funding Source: Medline; NIAMS NIH HHS [AR 40445] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARTHOLD SW, 1990, J INFECT DIS, V162, P133, DOI 10.1093/infdis/162.1.133; BENACH JL, 1988, J IMMUNOL, V140, P265; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; BENACH JL, 1987, J INFECT DIS, V155, P1300, DOI 10.1093/infdis/155.6.1300; Boyle MDP, 1997, THROMB HAEMOSTASIS, V77, P1; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; BURKOT TR, 1994, J INFECT DIS, V170, P883, DOI 10.1093/infdis/170.4.883; CASTELLINO FJ, 1973, BIOCHEM BIOPH RES CO, V53, P845, DOI 10.1016/0006-291X(73)90170-8; COLEMAN JL, 1995, INFECT IMMUN, V63, P2478, DOI 10.1128/IAI.63.7.2478-2484.1995; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN SJF, 1990, GENOMICS, V8, P49, DOI 10.1016/0888-7543(90)90225-J; DESILVA AM, 1995, AM J TROP MED HYG, V53, P397, DOI 10.4269/ajtmh.1995.53.397; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; FINGERLE V, 1995, J CLIN MICROBIOL, V33, P1867, DOI 10.1128/JCM.33.7.1867-1869.1995; FUCHS H, 1994, P NATL ACAD SCI USA, V91, P12594, DOI 10.1073/pnas.91.26.12594; Fuchs H, 1996, INFECT IMMUN, V64, P4307, DOI 10.1128/IAI.64.10.4307-4312.1996; GARCIAMONCO JC, 1990, J INFECT DIS, V161, P1187, DOI 10.1093/infdis/161.6.1187; GARCIAMONCO JC, 1995, ANN NEUROL, V37, P691, DOI 10.1002/ana.410370602; Gebbia JA, 1995, EXP APPL ACAROL, V19, P593, DOI 10.1007/BF00048814; Gebbia JA, 1997, GENE, V188, P221, DOI 10.1016/S0378-1119(96)00811-6; GOODMAN JL, 1995, AM J MED, V99, P6, DOI 10.1016/S0002-9343(99)80097-7; HU LT, 1995, INFECT IMMUN, V63, P3491, DOI 10.1128/IAI.63.9.3491-3496.1995; JUHANVAGUE I, 1984, THROMB RES, V33, P523, DOI 10.1016/0049-3848(84)90018-5; KIELBERG V, 1985, FEBS LETT, V182, P441, DOI 10.1016/0014-5793(85)80350-1; KLEMPNER MS, 1995, J INFECT DIS, V171, P1258, DOI 10.1093/infdis/171.5.1258; KRUITHOF EKO, 1984, BLOOD, V64, P907; LARSSON LI, 1984, J CELL BIOL, V98, P894, DOI 10.1083/jcb.98.3.894; LOTTENBERG R, 1985, AM J HEMATOL, V19, P181, DOI 10.1002/ajh.2830190211; MCDONOUGH KA, 1993, J MED ENTOMOL, V30, P772, DOI 10.1093/jmedent/30.4.772; Montgomery RR, 1996, J EXP MED, V183, P261, DOI 10.1084/jem.183.1.261; MUNDERLOH UG, 1995, ANNU REV ENTOMOL, V40, P221, DOI 10.1146/annurev.en.40.010195.001253; NADELMAN RB, 1990, AM J MED, V88, P21, DOI 10.1016/0002-9343(90)90122-T; Perides G, 1996, BIOCHEM BIOPH RES CO, V219, P690, DOI 10.1006/bbrc.1996.0296; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; PIESMAN J, 1995, J MED ENTOMOL, V32, P519, DOI 10.1093/jmedent/32.4.519; PIESMAN J, 1993, J INFECT DIS, V167, P1082, DOI 10.1093/infdis/167.5.1082; PIESMAN J, 1993, J MED ENTOMOL, V30, P199, DOI 10.1093/jmedent/30.1.199; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; SHIH CM, 1992, J INFECT DIS, V166, P827, DOI 10.1093/infdis/166.4.827; SINSKY RJ, 1989, J CLIN MICROBIOL, V27, P1723, DOI 10.1128/JCM.27.8.1723-1727.1989; Sonenshine D.E., 1993, BIOL TICKS; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; WHEELER CM, 1989, J INFECT DIS, V59, P265; YANG LM, 1994, INFECT IMMUN, V62, P492, DOI 10.1128/IAI.62.2.492-500.1994; ZUNG JL, 1989, CAN J ZOOL, V67, P1737, DOI 10.1139/z89-249	52	272	281	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1111	1119		10.1016/S0092-8674(00)80298-6	http://dx.doi.org/10.1016/S0092-8674(00)80298-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215633	Bronze			2022-12-24	WOS:A1997XG83000015
J	Lagasse, E; Weissman, IL				Lagasse, E; Weissman, IL			Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice	CELL			English	Article							COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; MONONUCLEAR PHAGOCYTE SYSTEM; OP OP MOUSE; GROWTH-FACTOR; FACTOR CSF-1; APOPTOSIS; LINEAGE; MURINE; DEATH	Osteopetrotic (op/op) mice lack functional M-CSF and have depressed levels of macrophages and osteoclasts. We prepared transgenic mice (hMRP8bcl-2) that express human Bcl-2 in monocytes. in vitro hMRP8bcl-2 monocytes do not undergo apoptosis in the absence of serum and M-CSF, while op/op and wild-type monocytes die. These Bcl-2-expressing monocytes spontaneously undergo macrophage differentiation. In vivo, the op/op hMRP8bcl-2 mice show significant replenishment of tissue macrophages. Their long bone osteopetrosis is largely reversed, and extensive medullary hematopoiesis appears in the bone marrow. We propose that M-CSF augments monocyte survival, permitting them to respond to internal and external cues for their differentiation.			Lagasse, E (corresponding author), STANFORD UNIV, SCH MED, DEPT PATHOL & DEV BIOL, STANFORD, CA 94305 USA.							BALNER H, 1963, TRANSPLANTATION, V1, P217, DOI 10.1097/00007890-196301020-00009; BUTCHER EC, 1980, J IMMUNOL METHODS, V37, P109, DOI 10.1016/0022-1759(80)90196-9; BYRNE PV, 1981, J CELL BIOL, V91, P848, DOI 10.1083/jcb.91.3.848; CARAYON P, 1992, J IMMUNOL METHODS, V147, P225, DOI 10.1016/S0022-1759(12)80012-3; CECCHINI MG, 1994, DEVELOPMENT, V120, P1357; CHAMBERS TJ, 1993, P NATL ACAD SCI USA, V90, P5578, DOI 10.1073/pnas.90.12.5578; COLIGAN JE, 1991, CURRENT PROTOCOLS IM, P3; CURRY JL, 1967, SCIENCE, V236, P1229; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GUILBERT LJ, 1980, J CELL BIOL, V85, P153, DOI 10.1083/jcb.85.1.153; GUTMAN GA, 1973, TRANSPLANTATION, V16, P621, DOI 10.1097/00007890-197312000-00014; HAGENAARS CE, 1989, BONE MINER, V6, P179, DOI 10.1016/0169-6009(89)90049-4; HATTERSLEY G, 1989, J CELL PHYSIOL, V140, P478, DOI 10.1002/jcp.1041400311; HUME DA, 1988, J IMMUNOL, V141, P3405; HUME DA, 1983, J EXP MED, V158, P1522, DOI 10.1084/jem.158.5.1522; IWAI K, 1994, BLOOD, V84, P1201; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; KOIKE K, 1986, BLOOD, V67, P859; KORN A P, 1973, Experimental Hematology (Charlottesville), V1, P362; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; LAGASSE E, 1992, BLOOD, V79, P1907; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; LEE MY, 1992, BLOOD, V80, P1710; LIESCHKE GJ, 1994, BLOOD, V84, P27; MANGAN DF, 1991, J IMMUNOL, V147, P3408; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; MARKS SC, 1984, CLIN ORTHOP RELAT R, P239; MCARTHUR GA, 1994, BLOOD, V83, P972; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; METCALF D, 1970, J CELL PHYSIOL, V76, P89, DOI 10.1002/jcp.1040760113; MUNN DH, 1995, J EXP MED, V181, P127, DOI 10.1084/jem.181.1.127; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; Olweus J, 1996, BLOOD, V88, P3741, DOI 10.1182/blood.V88.10.3741.bloodjournal88103741; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; SIMINOVITCH L, 1963, J CELL COMPAR PHYSL, V62, P327, DOI 10.1002/jcp.1030620313; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STANLEY ER, 1976, J EXP MED, V143, P631, DOI 10.1084/jem.143.3.631; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STANLEY ER, 1981, LYMPHOKINES, P102; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VANFURTH R, 1968, J EXP MED, V128, P415, DOI 10.1084/jem.128.3.415; VANFURTH R, 1988, J IMMUNOL METHODS, V108, P45, DOI 10.1016/0022-1759(88)90401-2; VANFURTH R, 1985, MONONUCLEAR PHAGOCYT, P201; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, J IMMUNOL, V151, P2546; VOLKMAN A, 1965, BRIT J EXP PATHOL, V46, P62; WANG HG, 1994, ONCOGENE, V9, P2751; WIKTORJEDRZEJCZAK W, 1991, EXP HEMATOL, V19, P1049; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WIKTORJEDRZEJCZAK W, 1982, J EXP MED, V156, P1516, DOI 10.1084/jem.156.5.1516; WIKTORJEDRZEJCZAK W, 1994, ENDOCRINOLOGY, V134, P1932, DOI 10.1210/en.134.4.1932; WU AM, 1967, J CELL PHYSIOL, V69, P177, DOI 10.1002/jcp.1040690208; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	64	250	256	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	1997	89	7					1021	1031		10.1016/S0092-8674(00)80290-1	http://dx.doi.org/10.1016/S0092-8674(00)80290-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215625	Bronze			2022-12-24	WOS:A1997XG83000007
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			A cell growth switch	SCIENCE			English	Article																		Blau CA, 1997, P NATL ACAD SCI USA, V94, P3076, DOI 10.1073/pnas.94.7.3076	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1891	1891		10.1126/science.276.5320.1891	http://dx.doi.org/10.1126/science.276.5320.1891			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9206844				2022-12-24	WOS:A1997XF10300058
J	Plemper, RK; Bohmler, S; Bordallo, J; Sommer, T; Wolf, DH				Plemper, RK; Bohmler, S; Bordallo, J; Sommer, T; Wolf, DH			Mutant analysis links the translocon and BiP to retrograde protein transport for ER degradation	NATURE			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; UBIQUITIN-PROTEASOME PATHWAY; SEC61P COMPLEX; YEAST; HOMOLOGS; ROUTE; KAR2; GENE	Proteins enter the secretory pathway through the endoplasmic reticulum(1), which delivers properly folded proteins to their site of action(2) and contains a quality-control system to monitor and prevent abnormal proteins from being delivered(3), Many of these proteins are degraded by the cytoplasmic proteasome(4-8), which requires their retrograde transport to the cytoplasm(5,6). Based on a co-immunoprecipitation of major histocompatibility complex (MHC) class I heavy-chain breakdown intermediates with the translocon subunit Sec61p (refs 9, 10), it was speculated that Sec61p maybe involved in retrograde transport(11), Here we present functional evidence from genetic studies that Sec61p mediates retrograde transport of a mutated lumenal yeast carboxypeptidase ycsY (CPY*) in vivo. The endoplasmic reticulum lumenal chaperone BiP (Kar2p) and Sec63p, which are also subunits of the import machinery(10,12), are involved in export of CPY* to the cytosol, Thus our results demonstrate that retrograde transport of proteins is mediated by a functional translocon. We consider the export of endoplasmic reticulum-localized proteins to the cytosol by the translocon for proteasome degradation to be a general process in eukaryotic cell biology.	UNIV STUTTGART,INST BIOCHEM,D-70569 STUTTGART,GERMANY; MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY	University of Stuttgart; Helmholtz Association; Max Delbruck Center for Molecular Medicine			bordallo, javier/X-5360-2019	bordallo, javier/0000-0002-5786-3929				Ausubel FM, 1992, CURRENT PROTOCOLS MO; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Corsi AK, 1997, J CELL BIOL, V137, P1483, DOI 10.1083/jcb.137.7.1483; CYYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	29	451	454	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					891	895		10.1038/42276	http://dx.doi.org/10.1038/42276			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278052	Bronze			2022-12-24	WOS:A1997XT75400053
J	Branche, CM; Conn, JM; Annest, JL				Branche, CM; Conn, JM; Annest, JL			Personal watercraft-related injuries - A growing public health concern	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							JET-SKI ACCIDENT	Context.-An increase in the recreational use of personal watercraft (PWC) raises concern about an increase in associated injuries on a national level. Objective.-To estimate the relative frequency, types of injury, and demographic features of persons injured while using PWC in the United States. Design.-Case series. Setting.-Emergency department (ED) visits to hospitals participating a national probability sample. Participants.-All persons treated for PWC-related injury from January 1, 1990, through December 31, 1995. Results.-An estimated 32 954 persons (95% confidence interval [CI], 22919-42 989) with PWC-related injuries were treated in US hospital EDs, of which 3.5% were hospitalized. Personal watercraft-related injuries have increased significantly from an estimated 2860 in 1990 to more than 12 000 in 1995. During this period, the number of PWC in operation increased 3-fold from approximately 241 500 in 1990 to an estimated 760 000 in 1995. The most prevalent diagnoses were lacerations, contusions, and fractures. Main Outcome Measures.-The estimated number and percentage of patients treated in EDs for PWC-related injuries, by year, age, sex, and the number and rate per 1000 of PWC in operation by year. Conclusions.-Since 1990, there has been at least a 4-fold increase in injuries associated with an increase in the recreational use of PWC. The rate of ED-treated injuries related to PWC was about 8.5 times higher (95% CI, 8.2-8.8; 1992 data) than the rate of those from motorboats. Specific training and adult supervision is recommended for miners using PWC. Furthermore, medical practitioners should encourage personal flotation device use and other protection for their patients who are known water enthusiasts.			Branche, CM (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,PUBL HLTH SERV,US DEPT HHS,ATLANTA,GA 30341, USA.							Annest J, 1996, INVENTORY FEDERAL DA; ARMITAGE P, 1994, STAT METHODS MED RES, P408; BEVER DL, 1996, SAFETY PERSONAL FOCU, P391; BRANCHEDORSEY CM, 1993, STUDY BOAT BOAT PROP; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P331; Francis R A, 1994, Mo Med, V91, P241; HAEFNER HK, 1991, OBSTET GYNECOL, V78, P986; HAMMAN BL, 1993, J PEDIATR SURG, V28, P920, DOI 10.1016/0022-3468(93)90697-J; Jeffery R S, 1991, Br J Sports Med, V25, P232; MARKER D, 1988, NEISS SAMPLE UPDATE; Muller R J, 1993, J La State Med Soc, V145, P27; SCHIEBER RA, 1994, JAMA-J AM MED ASSOC, V271, P1856, DOI 10.1001/jama.271.23.1856; *US COAST GUARD, 1995, BOAT STAT 1994; *US CONS PROD SAF, 1994, NAT EL INJ SURV SYST; WEIN P, 1990, AUST NZ J OBSTET GYN, V30, P384, DOI 10.1111/j.1479-828X.1990.tb02038.x	15	40	40	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	1997	278	8					663	665		10.1001/jama.278.8.663	http://dx.doi.org/10.1001/jama.278.8.663			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR547	9272899				2022-12-24	WOS:A1997XR54700040
J	Steinhubl, SR; Topol, EJ				Steinhubl, SR; Topol, EJ			Stenting for acute myocardial infarction	LANCET			English	Editorial Material							CORONARY		CLEVELAND CLIN FDN,JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL,CLEVELAND,OH 44195; OHIO STATE UNIV,DEPT MED,CLEVELAND,OH 44195	Cleveland Clinic Foundation; University System of Ohio; Ohio State University	Steinhubl, SR (corresponding author), CLEVELAND CLIN FDN,DEPT CARDIOL,CLEVELAND,OH 44195, USA.			Topol, Eric/0000-0002-1478-4729				Antoniucci D., 1997, Journal of the American College of Cardiology, V29, p456A; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; Grines C. L., 1997, Journal of the American College of Cardiology, V29, p389A; *GUSTO 2B ANG SUBS, 1997, NEW ENGL J MED, V336, P1621; HOORNTJE JC, 1996, CIRCULATION S1, V94, P570; Horstkotte D., 1996, European Heart Journal, V17, P297; Monassier Jean Pierre, 1996, Journal of the American College of Cardiology, V27, p68A; Nakagawa Y, 1996, AM J CARDIOL, V78, P980, DOI 10.1016/S0002-9149(96)00520-6; NATH FC, 1993, J AM COLL CARDIOL, V21, P622, DOI 10.1016/0735-1097(93)90093-G; Rodriguez A., 1997, Journal of the American College of Cardiology, V29, p221A; Saito S., 1997, Journal of the American College of Cardiology, V29, p390A; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201	13	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					532	533		10.1016/S0140-6736(05)63135-2	http://dx.doi.org/10.1016/S0140-6736(05)63135-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284772				2022-12-24	WOS:A1997XT22100005
J	Shimamura, M; Yasue, H; Ohshima, K; Abe, H; Kato, H; Kishiro, T; Goto, M; Munechika, I; Okada, N				Shimamura, M; Yasue, H; Ohshima, K; Abe, H; Kato, H; Kishiro, T; Goto, M; Munechika, I; Okada, N			Molecular evidence from retroposons that whales form a clade within even-toed ungulates	NATURE			English	Article							SEQUENCES; ELEMENTS; PHYLOGENY; SINES	The origin of whales and their transition from terrestrial life to a fully aquatic existence has been studied in depth. Palaeontological(1,2), morphological(3) and molecular studies(4-7) suggest that the order Cetacea (whales, dolphins and porpoises) is more closely related to the order Artiodactyla (even-toed ungulates, including cows, camels and pigs) than to other ungulate orders. The traditional view that the order Artiodactyla is monophyletic has been challenged by molecular analyses of variations in mitochondrial and nuclear DNA(5-7). We have characterized two families of short interspersed elements (SINEs) that were present exclusively in the genomes of whales, ruminants and hippopotamuses, but not in those of camels and pigs. We made an extensive survey of retropositional events that might have occurred during the divergence of whales and even-toed ungulates. We have characterized nine retropositional events of a SINE unit, each of which provides phylogenetic resolution of the relationships among whales, ruminants, hippopotamuses and pigs. Our data provide evidence that whales, ruminants and hippopotamuses form a monophyletic group.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,YOKOHAMA,KANAGAWA 226,JAPAN; NATL INST ANIM IND,ANIM GENOME RES GRP,KUKIZAKI,IBARAKI 305,JAPAN; NATL INST FAR SEAS FISHERIES,LARGE CETACEAN SECT,SHIMIZU,SHIZUOKA 424,JAPAN; INST CETACEAN RES,GENET ECOL SECT,CHUO KU,TOKYO 104,JAPAN; CHIBA ZOOL PK,WAKABA KU,CHIBA 264,JAPAN	Tokyo Institute of Technology; National Agriculture & Food Research Organization - Japan			Ohshima, Kazuhiko/AAJ-1347-2021	Ohshima, Kazuhiko/0000-0001-8437-4744; Okada, Norihiro/0000-0002-3655-8060; Abe, Hideaki/0000-0002-8965-8970				Adachi J, 1996, MOL PHYLOGENET EVOL, V6, P72, DOI 10.1006/mpev.1996.0059; FORDYCE RE, 1994, ANNU REV EARTH PL SC, V22, P419, DOI 10.1146/annurev.ea.22.050194.002223; Gatesy J, 1996, MOL BIOL EVOL, V13, P954, DOI 10.1093/oxfordjournals.molbev.a025663; Gentry AW, 1988, PHYLOGENY CLASSIFICA, V35B, P235; GINGERICH PD, 1990, SCIENCE, V249, P154, DOI 10.1126/science.249.4965.154; GOLZ DJ, 1976, NATURAL HIST MUSEUM, V26, P1; GRAUR D, 1994, MOL BIOL EVOL, V11, P357; Hasegawa M, 1996, MOL BIOL EVOL, V13, P710, DOI 10.1093/oxfordjournals.molbev.a025632; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; Irwin David M., 1994, Journal of Mammalian Evolution, V2, P37, DOI 10.1007/BF01464349; LENSTRA JA, 1993, ANIM GENET, V24, P33, DOI 10.1111/j.1365-2052.1993.tb00916.x; MILINKOVITCH MC, 1993, NATURE, V361, P346, DOI 10.1038/361346a0; MURATA S, 1993, P NATL ACAD SCI USA, V90, P6995, DOI 10.1073/pnas.90.15.6995; Murata S, 1996, GENETICS, V142, P915; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; OKADA N, 1991, TRENDS ECOL EVOL, V6, P358, DOI 10.1016/0169-5347(91)90226-N; Okada N., 1995, IMPACT SHORT INTERSP, P61; Philippe Herve, 1994, Journal of Mammalian Evolution, V2, P133, DOI 10.1007/BF01464365; Prothero D., 1988, PHYLOGENY CLASSIFICA, P201; ROSE KD, 1982, SCIENCE, V216, P621, DOI 10.1126/science.216.4546.621; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; TAKAHASHI H, 1992, ANIM GENET, V23, P443, DOI 10.1111/j.1365-2052.1992.tb02164.x; Thewissen J. G. M., 1994, Journal of Mammalian Evolution, V2, P157, DOI 10.1007/BF01473527; THEWISSEN JGM, 1993, NATURE, V361, P444, DOI 10.1038/361444a0; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215	25	313	324	1	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					666	670		10.1038/41759	http://dx.doi.org/10.1038/41759			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262399	Bronze			2022-12-24	WOS:A1997XQ86300047
J	Alm, JS; Lilja, G; Pershagen, G; Scheynius, A				Alm, JS; Lilja, G; Pershagen, G; Scheynius, A			Early BCG vaccination and development of atopy	LANCET			English	Article							CYTOKINE PRODUCTION; CHILDREN; TUBERCULOSIS; PREVALENCE; PREVENTION; INDUCTION	Background The increase in atopic diseases may be partly explicable by a decline of certain infectious diseases, dr changes in childhood Vaccination programmes, or both. We investigated whether BCG vaccination against tuberculosis influences the development of atopy. Methods We did a retrospective cohort study of 216 children with atopic heredity, born in Stockholm between 1989 and 1992, who received BCG vaccination when they were younger than 6 months, and 358 age-matched controls who had not been vaccinated. Both groups attended Sachs' Children's Hospital, Stockholm, Sweden, during 1995-96 for assessment of atopic history and clinical signs of atopic disease. All children also underwent skin-prick testing (SPT) and serum was analysed for allergen-specific IgE antibodies. Serum from parents was also analysed for IgE antibodies. Findings 77 (36%) children in the BCG group and 145 (41%) in the control group had a positive history or clinical signs of atopic disease, in the vaccinated group, 26 (12%) children had one or more positive SPT, and 61 (31%) had circulating allergen-specific IgE antibodies, whereas in the control group, the numbers were 35 (10%) and 84 (27%) respectively. Atopy was confirmed by serology in parents of almost two-thirds of the children in each group. Other risk factors for atopic disease were evenly distributed between the two groups. Interpretation early BCG vaccination in children with atopic heredity does not seem to affect the development of atopic disease before school age.	KAROLINSKA HOSP & INST, INST ENVIRONM MED, DIV ENVIRONM EPIDEMIOL, S-17176 STOCKHOLM, SWEDEN; KAROLINSKA HOSP & INST, DEPT LAB MED, DIV CLIN IMMUNOL, S-17176 STOCKHOLM, SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Alm, JS (corresponding author), KAROLINSKA INST, SACHS CHILDRENS HOSP, S-17176 STOCKHOLM, SWEDEN.			Pershagen, Goran/0000-0002-9701-1130; Alm, Johan/0000-0002-9062-4479				ALKASSIMI FA, 1995, AM J RESP CRIT CARE, V152, P1575, DOI 10.1164/ajrccm.152.5.7582297; AURELIUS G, 1995, CHILD HLTH CARE STOC, P20; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; COLDITZ GA, 1995, PEDIATRICS, V96, P29; DELPRETE G, 1992, ALLERGY, V47, P450; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HARADA M, 1990, DIABETES RES CLIN PR, V8, P85, DOI 10.1016/0168-8227(90)90017-N; Kajosaari M, 1994, Pediatr Allergy Immunol, V5, P26, DOI 10.1111/j.1399-3038.1994.tb00344.x; KJELLMAN NIM, 1977, ACTA PAEDIATR SCAND, V66, P465, DOI 10.1111/j.1651-2227.1977.tb07928.x; LARSSON LO, 1991, SENSITIVITY SENSITIN, P6; Lilja G, 1996, CLIN EXP ALLERGY, V26, P1073; MEHRA VL, 1990, NEW GENERATION VACCI, P611; Pepys J., 1975, , Clinical aspects of immunology., P877; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; ROMANUS V, 1992, TUBERCLE LUNG DIS, V73, P150, DOI 10.1016/0962-8479(92)90149-E; ROMANUS V, 1996, SWEDISH TUBERCULOSIS; RYLANDER E, 1993, EUR J EPIDEMIOL, V9, P517, DOI 10.1007/BF00209530; Sander B, 1995, IMMUNOLOGY, V86, P512; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; SHEHADEH N, 1994, LANCET, V343, P706, DOI 10.1016/S0140-6736(94)91583-0; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIGURS N, 1992, PEDIATRICS, V89, P735; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; WARD BJ, 1991, CLIN IMMUNOL IMMUNOP, V61, P236, DOI 10.1016/S0090-1229(05)80027-3; WARD BJ, 1993, CLIN IMMUNOL IMMUNOP, V67, P171, DOI 10.1006/clin.1993.1061; Wichmann HE, 1996, CLIN EXP ALLERGY, V26, P621, DOI 10.1111/j.1365-2222.1996.tb00587.x	28	213	218	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	1997	350	9075					400	403		10.1016/S0140-6736(97)02207-1	http://dx.doi.org/10.1016/S0140-6736(97)02207-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259654				2022-12-24	WOS:A1997XQ24800010
J	Cambridge, SB; Davis, RL; Minden, JS				Cambridge, SB; Davis, RL; Minden, JS			Drosophila mitotic domain boundaries as cell fate boundaries	SCIENCE			English	Article							EMBRYOS; EXPRESSION; GAL4; GENE; MELANOGASTER; PRODUCTS; YEAST	Fate determination in Drosophila embryos is evidenced by the appearance of mitotic domains. To identify fate or fates of cells, individual cells in mitotic domains 2, 8, and 15 were marked and monitored through development. Comparison of the different fates indicated that domain boundaries are cell fate boundaries. Cells were marked by expression of GAL4-dependent transgenes after photoactivation of a caged GAL4VP16 analog that had its DNA binding activity inhibited with a photolabile blocking reagent. Caged GAL4VP16 was also used to induce gene expression in Xenopus embryos. Thus, photoactivated gene expression is a versatile tool for spatiotemporal control of gene expression.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213; CARNEGIE MELLON UNIV,CTR LIGHT MICROSCOPE IMAGING & BIOTECHNOL,PITTSBURGH,PA 15213; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Carnegie Mellon University; Carnegie Mellon University; Harvard University; Harvard Medical School			Cambridge, Sidney/GYQ-5764-2022					ABRAMS JM, 1993, DEVELOPMENT, V117, P29; ADAMS SR, 1989, J AM CHEM SOC, V111, P7957, DOI 10.1021/ja00202a042; AFANASEVA GB, 1974, CHEM HETEROCYCLIC CO, V10, P302; BOMZE HM, 1994, GENETICS, V136, P965; BOSSING T, 1994, DEVELOPMENT, V120, P1895; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; DAVIS I, 1995, DEV BIOL, V170, P726, DOI 10.1006/dbio.1995.1251; FOE VE, 1989, DEVELOPMENT, V107, P1; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; Halfon MS, 1997, P NATL ACAD SCI USA, V94, P6255, DOI 10.1073/pnas.94.12.6255; Harris J, 1996, DEVELOPMENT, V122, P3117; HATCHARD CG, 1956, PROC R SOC LON SER-A, V235, P518, DOI 10.1098/rspa.1956.0102; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; Marriott G, 1996, BIOCHEMISTRY-US, V35, P3170, DOI 10.1021/bi952207o; MINDEN JS, 1989, J CELL BIOL, V109, P505, DOI 10.1083/jcb.109.2.505; Minden JS, 1996, BIOTECHNIQUES, V20, P122; Namba R, 1997, DEVELOPMENT, V124, P1393; STRINGHAM EG, 1993, J EXP ZOOL, V266, P227, DOI 10.1002/jez.1402660309; TECHNAU G M, 1985, Wilhelm Roux's Archives of Developmental Biology, V194, P196, DOI 10.1007/BF00848247; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B	24	53	53	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					825	828		10.1126/science.277.5327.825	http://dx.doi.org/10.1126/science.277.5327.825			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242613				2022-12-24	WOS:A1997XQ24700046
J	Roberts, I; Barker, M; Li, L				Roberts, I; Barker, M; Li, L			Analysis of trends in deaths from accidental drug poisoning in teenagers, 1985-95	BRITISH MEDICAL JOURNAL			English	Article											Roberts, I (corresponding author), INST CHILD HLTH,DEPT EPIDEMIOL,CHILD HLTH MONITORING UNIT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.							FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; HENRY JA, 1992, BRIT MED J, V305, P5, DOI 10.1136/bmj.305.6844.5; WRIGHT JD, 1995, BRIT MED J, V310, P20, DOI 10.1136/bmj.310.6971.20	3	20	20	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					289	289		10.1136/bmj.315.7103.289	http://dx.doi.org/10.1136/bmj.315.7103.289			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274550	Green Published			2022-12-24	WOS:A1997XP75000024
J	Benefit, BR; McCrossin, ML				Benefit, BR; McCrossin, ML			Earliest known Old World monkey skull	NATURE			English	Article							MABOKO ISLAND; FACIAL MORPHOLOGY; KENYA; VICTORIAPITHECUS; MIOCENE; AEGYPTOPITHECUS; PRIMATES; AGE	Similarities of the skull are commonly used to support hypotheses of ancestor-descendant relationships between fossil and living ape genera, especially between the late Miocene apes Sivapithecus and Dryopithecus from Eurasia and the living orang-utan (Pongo) from Borneo and Sumatra(1-4). Yet determining whether cranio-facial traits shared by extant and Miocene apes are primitive or derived is severely hampered by the rarity of well-preserved fossil crania, particularly of early members of their closest outgroup, the Old World monkeys (Cercopithecoidea). The discovery of a complete and undistorted skull of Victorispithecus at middle Miocene deposits from Maboko Island, Kenya, provides evidence of intact cranial-vault and basicranial morphology, brain size and craniofacial hafting for a primate from between 32 and 7 million years ago. Victoriapithecus represents a branch of Old World monkey that is intermediate between extant cercopithecids (Colobinae and Cercopithecinae) and the common ancestor they shared with apes (Hominoidea)(5-8). The skull preserves traits widely thought to be derived for extant and fossil members of a proposed Sivapithecus/Pongo clade, but which now appear to be primitive features of ancestral Old World higher primates in general.			Benefit, BR (corresponding author), SO ILLINOIS UNIV,DEPT ANTHROPOL,CARBONDALE,IL 62901, USA.		Klein, Richard G/B-5910-2009					ANDREWS P, 1981, J HUM EVOL, V10, P35, DOI 10.1016/S0047-2484(81)80024-3; BENEFIT BR, 1994, AM J PHYS ANTHROPOL, V95, P277, DOI 10.1002/ajpa.1330950304; BENEFIT BR, 1993, AM J PHYS ANTHROPOL, V92, P329, DOI 10.1002/ajpa.1330920307; BENEFIT BR, 1991, P NATL ACAD SCI USA, V88, P5267, DOI 10.1073/pnas.88.12.5267; BENEFIT BR, 1993, J HUM EVOL, V25, P83, DOI 10.1006/jhev.1993.1041; Brown B., 1988, P247; Delson E., 1975, P405; FEIBEL CS, 1991, J HUM EVOL, V21, P221, DOI 10.1016/0047-2484(91)90063-2; HARRISON T, 1989, J HUM EVOL, V18, P3, DOI 10.1016/0047-2484(89)90022-5; HARRISON T, 1987, J HUM EVOL, V16, P41, DOI 10.1016/0047-2484(87)90060-1; LEAKEY E, 1986, NATURE, V342, P143; LEAKEY MG, 1991, FOLIA PRIMATOL, V56, P65, DOI 10.1159/000156531; Martin R.D., 1990, PRIMATE ORIGINS EVOL; Moya Sola Salvadoor, 1995, Journal of Human Evolution, V29, P101; MOYASOLA S, 1993, NATURE, V365, P543, DOI DOI 10.1038/365543A0; PILBEAM D, 1982, NATURE, V295, P232, DOI 10.1038/295232a0; RADINSKY L, 1974, AM J PHYS ANTHROPOL, V41, P15, DOI 10.1002/ajpa.1330410104; SIMONS EL, 1987, J HUM EVOL, V16, P273, DOI 10.1016/0047-2484(87)90003-0; SIMONS EL, 1967, SCI AM, V218, P28; STRASSER E, 1987, J HUM EVOL, V16, P81, DOI 10.1016/0047-2484(87)90061-3; STROMER E, 1913, Z DTSCH GEOL GES, V65, P349; VOGEL C, 1966, BIBLIOTHECA PRIMATOL, V4, P1; Von Koenigswald G. H. R., 1969, FOSSIL VERTEBRATES A, P39	23	43	43	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					368	371		10.1038/41078	http://dx.doi.org/10.1038/41078			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XM528	9237753				2022-12-24	WOS:A1997XM52800047
J	Jacobsen, JR; Hutchinson, CR; Cane, DE; Khosla, C				Jacobsen, JR; Hutchinson, CR; Cane, DE; Khosla, C			Precursor-directed biosynthesis of erythromycin analogs by an engineered polyketide synthase	SCIENCE			English	Article							CHAIN-ELONGATION INTERMEDIATE; MACROLIDE BIOSYNTHESIS; INTACT INCORPORATION; GENE-CLUSTER; ANTIBIOTICS; NARGENICIN; ORGANIZATION; DIKETIDE; HOST; RING	A genetic block was introduced in the first condensation step of the polyketide biosynthetic pathway that leads to the formation of 6-deoxyerythronolide B (6-dEB), the macrocyclic precursor of erythromycin. Exogenous addition of designed synthetic molecules to small-scale cultures of this null mutant resulted in highly selective multimilligram production of unnatural polyketides, including aromatic and ring-expanded variants of 6-dEB. Unexpected incorporation patterns were observed, illustrating the catalytic versatility of modular polyketide synthases. Further processing of some of these scaffolds by postpolyketide enzymes of the erythromycin pathway resulted in the generation of novel antibacterials with in vitro potency comparable to that of their natural counterparts.	STANFORD UNIV,DEPT CHEM ENGN,STANFORD,CA 94305; STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305; UNIV WISCONSIN,SCH PHARM,MADISON,WI 53706; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; BROWN UNIV,DEPT CHEM,PROVIDENCE,RI 02912	Stanford University; Stanford University; Stanford University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Brown University				Khosla, Chaitan/0000-0001-6529-495X	NATIONAL CANCER INSTITUTE [R01CA066736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031925, R01GM022172] Funding Source: NIH RePORTER; NCI NIH HHS [CA66736] Funding Source: Medline; NIGMS NIH HHS [GM31925, GM22172] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abiko A, 1997, J AM CHEM SOC, V119, P2586, DOI 10.1021/ja963754f; ADACHI T, 1988, J ANTIBIOT, V41, P966, DOI 10.7164/antibiotics.41.966; BAKER WR, 1988, J ORG CHEM, V53, P2340, DOI 10.1021/jo00245a038; Bedford D, 1996, CHEM BIOL, V3, P827, DOI 10.1016/S1074-5521(96)90068-X; CANE DE, 1993, J AM CHEM SOC, V115, P527, DOI 10.1021/ja00055a024; CANE DE, 1995, J ANTIBIOT, V48, P647, DOI 10.7164/antibiotics.48.647; CANE DE, 1987, J AM CHEM SOC, V109, P1255, DOI 10.1021/ja00238a051; CANE DE, 1988, J AM CHEM SOC, V110, P4840, DOI 10.1021/ja00222a059; CANE DE, 1993, J AM CHEM SOC, V115, P522, DOI 10.1021/ja00055a023; CANE DE, 1995, J AM CHEM SOC, V117, P6633, DOI 10.1021/ja00129a044; CORNISH VW, 1994, CURR OPIN STRUC BIOL, V4, P601, DOI 10.1016/S0959-440X(94)90224-0; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DAUM SJ, 1979, ANNU REV MICROBIOL, V533, P241; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DUTTON CJ, 1991, J ANTIBIOT, V44, P357, DOI 10.7164/antibiotics.44.357; DUTTON CJ, 1994, TETRAHEDRON LETT, V35, P327, DOI 10.1016/S0040-4039(00)76544-0; EVANS DA, 1981, J AM CHEM SOC, V103, P2127, DOI 10.1021/ja00398a058; Griesgraber G, 1996, J ANTIBIOT, V49, P465, DOI 10.7164/antibiotics.49.465; HAILES HC, 1994, TETRAHEDRON LETT, V35, P307, DOI 10.1016/S0040-4039(00)76539-7; HU ZH, 1994, MOL MICROBIOL, V14, P163, DOI 10.1111/j.1365-2958.1994.tb01276.x; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; Kao CM, 1996, BIOCHEMISTRY-US, V35, P12363, DOI 10.1021/bi9616312; KAO CM, 1995, J AM CHEM SOC, V117, P9105, DOI 10.1021/ja00140a043; KAO CM, 1994, J AM CHEM SOC, V116, P11612, DOI 10.1021/ja00104a069; Kao CM, 1996, J AM CHEM SOC, V118, P9184, DOI 10.1021/ja9617552; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Khosla C, 1996, TRENDS BIOTECHNOL, V14, P335, DOI 10.1016/0167-7799(96)10046-9; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; McDaniel R, 1997, J AM CHEM SOC, V119, P4309, DOI 10.1021/ja9702531; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MORIMOTO S, 1990, J ANTIBIOT, V43, P286, DOI 10.7164/antibiotics.43.286; OHagan D., 1991, POLYKETIDE METABOLIT; OLIYNYK M, 1996, GENE, V183, P231; PATERSON I, 1985, TETRAHEDRON, V41, P3569, DOI 10.1016/S0040-4020(01)91380-8; PATZELT H, 1993, J CHEM SOC CHEM COMM, P1258, DOI 10.1039/c39930001258; PIEPER R, 1995, NATURE, V378, P263, DOI 10.1038/378263a0; Pieper R, 1996, BIOCHEMISTRY-US, V35, P2054, DOI 10.1021/bi952860b; Pieper R, 1997, BIOCHEMISTRY-US, V36, P1846, DOI 10.1021/bi962324z; PIEPER R, 1995, J AM CHEM SOC, V117, P11373, DOI 10.1021/ja00150a049; SCHUPP T, 1995, J BACTERIOL, V177, P3673, DOI 10.1128/jb.177.13.3673-3679.1995; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; Seebach D., 1990, ORG SYNTH, VVII, P153; SWAN DG, 1994, MOL GEN GENET, V242, P358, DOI 10.1007/BF00280426; Vincent JG, 1944, P SOC EXP BIOL MED, V55, P162, DOI 10.3181/00379727-55-14502; WALKER MA, 1991, J ORG CHEM, V56, P5747, DOI 10.1021/jo00020a006; WEBER JM, 1985, J BACTERIOL, V164, P425, DOI 10.1128/JB.164.1.425-433.1985; WIESMANN KEH, 1995, CHEM BIOL, V2, P583, DOI 10.1016/1074-5521(95)90122-1; YUE S, 1987, J AM CHEM SOC, V109, P1253, DOI 10.1021/ja00238a050	49	252	270	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					367	369		10.1126/science.277.5324.367	http://dx.doi.org/10.1126/science.277.5324.367			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219693				2022-12-24	WOS:A1997XL35800045
J	vanThiel, GJMW; vanDelden, JJM; deHaan, K; Huibers, AK				vanThiel, GJMW; vanDelden, JJM; deHaan, K; Huibers, AK			Retrospective study of doctors' ''end of life decisions'' in caring for mentally handicapped people in institutions in the Netherlands	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To gain insight into the reasons behind and the prevalence of doctors' decisions at the end of life that might hasten a patient's death (''end of life decisions'') in institutions caring for mentally handicapped people in the Netherlands, and to describe important aspects of the decisions making process. Design: Survey of random sample of doctors caring for mentally handicapped people by means of self completed questionnaires and structured interviews. Subjects: 89 of the 101 selected doctors completed the questionnaire. 67 doctors had taken an end of life decision and were interviewed about their most recent case. Main outcome measures: Prevalence of end of life decisions; types of decisions; characteristics of patients; reasons why the decision was taken; and the decision making process. Results: The 89 doctors reported 222 deaths for 1995, An end of life decision was taken in 97 cases (44%); in 75 the decision was to withdraw or withhold treatment, and in 22 it was to relieve pain or symptoms with opiates in dosages that may have shortened life. In the 67 most recent cases with an end of life decision the patients were mostly incompetent (63) and under 65 years old (51). Only two patients explicitly asked to die, but in 23 cases there had been some communication with the patient In 60 cases the doctors discussed the decision with nursing staff and in 46 with a colleague. Conclusions: End of life decisions are an important aspect of the institutionalised care of mentally handicapped people. The proportion of such decisions in the total number of deaths is similar to that in other specialties. However, the discussion of such decisions is less open in the care of mental handicap than in other specialties. Because of distinctive features of care in this specialty an open debate about end of life decisions should not be postponed.	HEEREN LOO LOZENOORD,ERMELO,NETHERLANDS		vanThiel, GJMW (corresponding author), UNIV UTRECHT,CTR BIOETH & HLTH LAW,POB 80105,NL-3508 TC UTRECHT,NETHERLANDS.		Van Thiel, Ghislaine/R-8977-2019	van Thiel, Ghislaine/0000-0003-1799-1894				DRANE JF, 1985, HASTINGS CENT REP, V15, P17, DOI 10.2307/3560639; Jonsen A. R., 1992, CLIN ETHICS; *MIN VOLSG WELZ SP, 1995, PERK BUIT MEERJ INT; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; VANDERMAAS PJ, 1992, EUTHANASIA MED DECIS; *VER GEH NED, 1996, JB VERST GEH DIC LRZ; *VER GEH NED, 1996, LAND REG ZORG DIENST	8	25	25	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					88	91		10.1136/bmj.315.7100.88	http://dx.doi.org/10.1136/bmj.315.7100.88			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240047	Green Published			2022-12-24	WOS:A1997XL25200020
J	Ericson, J; Rashbass, P; Schedl, A; BrennerMorton, S; Kawakami, A; vanHeyningen, V; Jessell, TM; Briscoe, J				Ericson, J; Rashbass, P; Schedl, A; BrennerMorton, S; Kawakami, A; vanHeyningen, V; Jessell, TM; Briscoe, J			Pax6 controls progenitor cell identity and neuronal fate in response to graded shh signaling	CELL			English	Article							SONIC HEDGEHOG; FLOOR PLATE; MOTOR-NEURONS; EXPRESSION PATTERN; NERVOUS-SYSTEM; CHICK-EMBRYO; NEURAL-TUBE; GENE; DIFFERENTIATION; INDUCTION	Distinct classes of motor neurons and ventral interneurons are generated by the graded signaling activity of Sonic hedgehog (Shh). Shh controls neuronal fate by establishing different progenitor cell populations in the ventral neural tube that are defined by the expression of Pax6 and Nkx2.2. Pax6 establishes distinct ventral progenitor cell populations and controls the identity of motor neurons and ventral interneurons, mediating graded Shh signaling in the ventral spinal cord and hindbrain.	COLUMBIA UNIV,DEPT BIOCHEM & MOL BIOPHYS,HOWARD HUGHES MED INST,NEW YORK,NY 10032; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; NAGOYA UNIV,DIV BIOL SCI,NAGOYA,AICHI 46401,JAPAN	Columbia University; Howard Hughes Medical Institute; University of Edinburgh; Nagoya University			van Heyningen, Veronica/B-8039-2008; VAN HEYNINGEN, Veronica/GYE-0531-2022; Schedl, Andreas/GOP-3427-2022; Schedl, Andreas/F-8823-2015; Kawakami, Atsushi/D-3785-2019	van Heyningen, Veronica/0000-0003-0359-0141; Schedl, Andreas/0000-0001-9380-7396; Kawakami, Atsushi/0000-0001-9461-6372; Ericson, Johan/0000-0002-8019-7127; Briscoe, James/0000-0002-1020-5240	MRC [MC_U127527199] Funding Source: UKRI; Medical Research Council [MC_U127527199] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BARTH KA, 1995, DEVELOPMENT, V121, P1755; CALLISTER RJ, 1987, J COMP NEUROL, V255, P369, DOI 10.1002/cne.902550305; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; ERICSON J, 1992, SCIENCE, V256, P1550; Fan CM, 1996, MOL CELL NEUROSCI, V7, P1, DOI 10.1006/mcne.1996.0001; GOSHGARIAN HG, 1981, J COMP NEUROL, V201, P441, DOI 10.1002/cne.902010309; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; KRAMMER EB, 1987, ADV ANAT EMBRYOL CEL, V103, P1; KURATANI S, 1990, ANAT EMBRYOL, V182, P435; KURATANI S, 1988, AM J ANAT, V182, P155, DOI 10.1002/aja.1001820206; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Liinamaa TL, 1997, J COMP NEUROL, V377, P298, DOI 10.1002/(SICI)1096-9861(19970113)377:2<298::AID-CNE10>3.0.CO;2-N; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; LU SW, 1994, MECH DEVELOP, V47, P187, DOI 10.1016/0925-4773(94)90089-2; MACDONALD R, 1995, DEVELOPMENT, V121, P3267; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; OSUMI N, 1997, IN PRESS DEVELOPMENT; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; Quinn JC, 1996, GENE DEV, V10, P435, DOI 10.1101/gad.10.4.435; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; RYAN G, 1995, DEVELOPMENT, V121, P867; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; Shimamura K, 1995, DEVELOPMENT, V121, P3923; Shoji H, 1996, MECH DEVELOP, V56, P25, DOI 10.1016/0925-4773(96)00509-6; SIMON H, 1994, J NEUROBIOL, V25, P1129, DOI 10.1002/neu.480250908; Stoykova A, 1996, DEVELOPMENT, V122, P3453; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Tremblay P, 1996, DEVELOPMENT, V122, P2555; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VarelaEchavarria A, 1996, MOL CELL NEUROSCI, V8, P242, DOI 10.1006/mcne.1996.0061; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Warren N, 1997, DEVELOPMENT, V124, P1573; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	51	807	822	5	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					169	180		10.1016/S0092-8674(00)80323-2	http://dx.doi.org/10.1016/S0092-8674(00)80323-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230312	hybrid			2022-12-24	WOS:A1997XL36200018
J	Zou, H; Rothstein, R				Zou, H; Rothstein, R			Holliday junctions accumulate in replication mutants via a RecA homolog-independent mechanism	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; DNA-POLYMERASE-EPSILON; ESCHERICHIA-COLI; MEIOTIC RECOMBINATION; MISMATCH REPAIR; PRIMASE COMPLEX; RIBOSOMAL DNA; GENE-PRODUCT; PROTEIN; ALPHA	The Holliday junction recombination intermediate, an X-shaped DNA molecule (xDNA), was analyzed at rDNA in mitotically growing yeast. In wild-type cells, xDNA is only detected at S phase, suggesting that recombination is stimulated to repair replication-related lesions. A search for mutations that increase the level of xDNA uncovered a gene encoding a subunit of DNA polymerase alpha. Systematic examination of replication mutants revealed that defects in polymerase alpha and delta but not the epsilon complex stimulate the level of xDNA. These xDNAs are Holliday junctions and not replication intermediates. The level of Holliday junctions is greatly reduced in rad52 mutants, but surprisingly, not in mutants defective in the three known mitotically expressed yeast RecA homologs.	COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032	Columbia University				Rothstein, Rodney/0000-0002-4107-9654	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM050237, R01GM050237] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50237] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; ASAI T, 1994, CELL, V78, P1051, DOI 10.1016/0092-8674(94)90279-8; Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BORTS RH, 1990, GENETICS, V124, P573; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; CAMPBELL JL, 1993, J BIOL CHEM, V268, P25261; CAO Y, 1995, GENETICS, V139, P1483; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; FASULLO MT, 1987, P NATL ACAD SCI USA, V84, P6215, DOI 10.1073/pnas.84.17.6215; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; FRIEDBERG EC, 1995, DNA REPAIR; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GERRING S L, 1991, P57; GNAGLOFF S, 1996, EMBO J, V15, P1715; GORDENIN DA, 1992, P NATL ACAD SCI USA, V89, P3785, DOI 10.1073/pnas.89.9.3785; HALL SD, 1994, P NATL ACAD SCI USA, V91, P3205, DOI 10.1073/pnas.91.8.3205; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; KADYK LC, 1992, GENETICS, V132, P387; KANS JA, 1991, GENE, V105, P139, DOI 10.1016/0378-1119(91)90527-I; KAWASAKI I, 1994, MOL CELL BIOL, V14, P4173, DOI 10.1128/MCB.14.6.4173; KLEIN HL, 1995, BIOESSAYS, V17, P147, DOI 10.1002/bies.950170210; Kogoma T, 1997, P NATL ACAD SCI USA, V94, P3483, DOI 10.1073/pnas.94.8.3483; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; KUNZ BA, 1989, GENETICS, V122, P535; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LIANG C, 1994, MOL CELL BIOL, V14, P1520, DOI 10.1128/MCB.14.2.1520; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; MCDONALD JP, 1994, GENETICS, V137, P393; MONTELONE BA, 1981, J BACTERIOL, V147, P517, DOI 10.1128/JB.147.2.517-525.1981; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; MORTIMER RK, 1981, P NATL ACAD SCI-BIOL, V78, P5778, DOI 10.1073/pnas.78.9.5778; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PETES TD, 1991, MOL CELLULAR BIOL YE; PLEVANI P, 1984, J BIOL CHEM, V259, P7532; RATTRAY AJ, 1995, GENETICS, V139, P45; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Rothstein R, 1995, GENOME RES, V5, P421, DOI 10.1101/gr.5.5.421; RUPP WD, 1971, J MOL BIOL, V61, P25, DOI 10.1016/0022-2836(71)90204-X; SAFFER LD, 1986, MOL CELL BIOL, V6, P1148, DOI 10.1128/MCB.6.4.1148; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; Sherman F., 1986, METHODS YEAST GENETI; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Skalka A., 1974, MECH RECOMBINATION, P421, DOI [10.1007/978-1-4684-2133-0_37, DOI 10.1007/978-1-4684-2133-0_37]; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SUGAWARA N, 1995, NATURE, V373, P84, DOI 10.1038/373084a0; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SZOSTAK JW, 1980, NATURE, V284, P426, DOI 10.1038/284426a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; WALMSLEY RM, 1984, MOL GEN GENET, V195, P260, DOI 10.1007/BF00332757; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; YOUNG CSH, 1984, J VIROL, V51, P571, DOI 10.1128/JVI.51.3.571-577.1984; ZGAGA Z, 1991, CURR GENET, V19, P329, DOI 10.1007/BF00355064	68	227	230	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					87	96		10.1016/S0092-8674(00)80316-5	http://dx.doi.org/10.1016/S0092-8674(00)80316-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230305	hybrid			2022-12-24	WOS:A1997XL36200011
J	Katritch, V; Olson, WK; Pieranski, P; Dubochet, J; Stasiak, A				Katritch, V; Olson, WK; Pieranski, P; Dubochet, J; Stasiak, A			Properties of ideal composite knots	NATURE			English	Article							NUMBER	The shortest tube of constant diameter that can form a given knot represents the 'ideal' form of the knot(1,2). Ideal knots provide an irreducible representation of the knot, and they have some intriguing mathematical and physical features, including a direct correspondence with the time-averaged shapes of knotted DNA molecules in solution(1,2). Here we describe the properties of ideal forms of composite knots-knots obtained by the sequential tying of two or more independent knots (called factor knots) on the same string. We find that the writhe (related to the handedness of crossing points) of composite knots is the sum of that of the ideal forms of the factor knots. By comparing ideal composite knots with simulated configurations of knotted, thermally fluctuating DNA, we conclude that the additivity of writhe applies also to randomly distorted configurations of composite knots and their corresponding factor knots. We show that composite knots with several factor knots may possess distinct structural isomers that can be interconverted only by loosening the knot.	UNIV LAUSANNE,LAB ANAL ULTRASTRUCT,CH-1015 LAUSANNE,SWITZERLAND; INST MOL PHYS,PL-60159 POZNAN,POLAND; POZNAN TECH UNIV,INST PHYS,PL-60965 POZNAN,POLAND; RUTGERS STATE UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08903	University of Lausanne; Poznan University of Technology; Rutgers State University New Brunswick			Katritch, Vsevolod/Q-8357-2016; Stasiak, Andrzej/E-5551-2010; Pieranski, Piotr/H-7805-2014; Katritch, Vsevolod/Y-2721-2019	Katritch, Vsevolod/0000-0003-3883-4505; Stasiak, Andrzej/0000-0002-0398-1989; 				Calugareanu G., 1959, INTEGRALE GAUSS 1 AN, P5; FULLER FB, 1978, P NATL ACAD SCI USA, V75, P3557, DOI 10.1073/pnas.75.8.3557; FULLER FB, 1971, P NATL ACAD SCI USA, V68, P815, DOI 10.1073/pnas.68.4.815; Katritch V, 1996, NATURE, V384, P142, DOI 10.1038/384142a0; Pieranski P, 1996, PRODIALOG, V5, P111; Rolfsen D., 1976, KNOTS LINKS; Stasiak A, 1996, NATURE, V384, P122, DOI 10.1038/384122a0; VanRensburg EJJ, 1997, J KNOT THEOR RAMIF, V6, P31; VOLOGODSKII AV, 1992, J MOL BIOL, V227, P1224, DOI 10.1016/0022-2836(92)90533-P	9	82	80	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					148	151		10.1038/40582	http://dx.doi.org/10.1038/40582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217153	Bronze			2022-12-24	WOS:A1997XK10900042
J	Hemmelgarn, B; Suissa, S; Huang, A; Boivin, JF; Pinard, G				Hemmelgarn, B; Suissa, S; Huang, A; Boivin, JF; Pinard, G			Benzodiazepine use and the risk of motor vehicle crash in the elderly	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRIVING PERFORMANCE; HIP FRACTURE; OLDER ADULTS; PSYCHOMOTOR; DIAZEPAM; COHORT; DRUGS; ACCIDENTS; INJURIES; DRIVERS	Context.-Benzodiazepines, used by a sizable number of the elderly population, may affect the ability to drive and thus increase the risk of a motor vehicle crash. Epidemiologic studies of this question have produced inconsistent results that may be due to the different effects of long- and short-half-life benzodiazepines and variations in their duration of use. Objective.-To determine whether the use of benzodiazepines of either long- or short-elimination half-life is associated with the risk of injurious motor vehicle crash in the elderly. Design and Setting.-Nested case-control design within a cohort of 224 734 drivers from the Canadian province of Quebec, aged 67 to 84 years, followed up from 1990 to 1993. Computerized data for the study were obtained from provincial driver's license files, police reports of injurious crashes, and health insurance records. Patients.-We identified all 5579 drivers involved in an injurious crash (cases) and a random sample of 10 controls per case selected from a subcohort of 13 256 subjects. Main Outcome.-Involvement of a cohort member as a driver in a motor vehicle crash in which at least 1 person (not necessarily the driver) sustained bodily injury. Results.-The adjusted rate ratio of crash involvement within the first week of long-half-life benzodiazepine use was 1.45 (95% confidence interval [CI], 1.04-2.03). The rate ratio for continuous use of longer duration up to 1 year was slightly lower but remained significant (rate ratio, 1.26; 95% CI, 1.09-1.45). In contrast, there was no increased risk after the initiation of treatment with short-half-life benzodiazepines (rate ratio, 1.04; 95% CI, 0.81-1.34) or with their continued use (rate ratio, 0.91; 95% CI, 0.82-1.01). Conclusions.-Brief or extended periods of exposure to long-half-life benzodiazepines are associated with an increased risk of motor vehicle crash involvement in the elderly population. There is no such elevated risk for short-half-life benzodiazepines.	ROYAL VICTORIA HOSP, DIV CLIN EPIDEMIOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MCGILL PHARMACOEPIDEMIOL RES UNIT, MONTREAL, PQ, CANADA; MCGILL UNIV, DEPT MED, MONTREAL, PQ, CANADA; MCGILL UNIV, DEPT PSYCHIAT, MONTREAL, PQ, CANADA	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University			Hemmelgarn, Brenda R./I-6894-2012					ADAMS WL, 1990, J AM GERIATR SOC, V38, P211, DOI 10.1111/j.1532-5415.1990.tb03493.x; ARANKO K, 1983, BRIT J CLIN PHARMACO, V15, P545, DOI 10.1111/j.1365-2125.1983.tb02088.x; BARR RA, 1991, HUM FACTORS, V33, P597, DOI 10.1177/001872089103300510; BROOKHUIS KA, 1990, EUR J CLIN PHARMACOL, V39, P83, DOI 10.1007/BF02657065; *CAN PHARM ASS, 1992, COMP PHARM SPEC, P27; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; EMOND A, 1988, SANTE CA VA RAPPORT; GILLEY DW, 1991, ARCH INTERN MED, V151, P941, DOI 10.1001/archinte.151.5.941; GREENBLATT DJ, 1991, NEW ENGL J MED, V324, P1691, DOI 10.1056/NEJM199106133242403; GREENBLATT DJ, 1989, J CLIN PHARMACOL, V29, P866, DOI 10.1002/j.1552-4604.1989.tb03246.x; HONKANEN R, 1980, BRIT MED J, V281, P1309, DOI 10.1136/bmj.281.6251.1309; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; JICK H, 1981, AM J PUBLIC HEALTH, V71, P1399, DOI 10.2105/AJPH.71.12.1399; JOHNSON RE, 1994, J CLIN EPIDEMIOL, V47, P1191, DOI 10.1016/0895-4356(94)90106-6; Kleinbaum D.G, 1982, EPIDEMIOLOGIC RES PR, P220; LABERGENADEAU C, 1984, U MONTREAL PUBLICATI, V340; LAGIER G, 1993, DRUG ALCOHOL DEPEN, V33, P19; LEVEILLE SG, 1994, EPIDEMIOLOGY, V5, P591, DOI 10.1097/00001648-199411000-00006; LIDDELL FDK, 1977, J R STAT SOC A STAT, V140, P469, DOI 10.2307/2345280; LINNOILA M, 1983, J CLIN PSYCHOPHARM, V3, P88; LUBIN JH, 1984, BIOMETRICS, V40, P63, DOI 10.2307/2530744; LUCKI I, 1986, PSYCHOPHARMACOLOGY, V88, P426; Neutel C. Ineke, 1995, Annals of Epidemiology, V5, P239; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; RAY WA, 1992, J CLIN PSYCHOPHARM, V12, P386; RAY WA, 1992, AM J EPIDEMIOL, V136, P873, DOI 10.1093/aje/136.7.873; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; REGESTEIN QR, 1992, CLIN GERIATRIC PSYCH, P235; SALZMAN C, 1992, CLIN GERIATRIC PSYCH, P189; SKEGG DCG, 1979, BRIT MED J, V1, P917, DOI 10.1136/bmj.1.6168.917; SUISSA S, 1994, PHARMACOEPIDEM DR S, P629; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; TAMBLYN RM, 1994, CAN MED ASSOC J, V150, P1801; VANLAAR MW, 1992, J CLIN PSYCHOPHARM, V12, P86; Volkerts ER, 1986, DRUGS DRIVING, P123; VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G; WILLIAMS AF, 1989, AM J PUBLIC HEALTH, V79, P326, DOI 10.2105/AJPH.79.3.326; WOLF ME, 1992, ANNU REV PUBL HEALTH, V13, P509, DOI 10.1146/annurev.pu.13.050192.002453; WOODS JH, 1992, PHARMACOL REV, V44, P151	39	265	274	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					27	31		10.1001/jama.278.1.27	http://dx.doi.org/10.1001/jama.278.1.27			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207334				2022-12-24	WOS:A1997XG38700032
J	Zhang, YF; Suga, N; Yan, J				Zhang, YF; Suga, N; Yan, J			Corticofugal modulation of frequency processing in bat auditory system	NATURE			English	Article							RECEPTIVE-FIELD PLASTICITY; MEDIAL GENICULATE-BODY; INFERIOR COLLICULUS; MUSTACHED BAT; CORTEX; NEURONS; CAT; REPRESENTATION; PROJECTIONS; STIMULATION	Auditory signals are transmitted from the inner ear through the brainstem to the higher auditory regions of the brain. Neurons throughout the auditory system are tuned to stimulus frequency, and in many auditory regions are arranged in topographical maps with respect to their preferred frequency, These properties are assumed to arise from the interactions of convergent and divergent projections ascending from lower to higher auditory areas(1); such a view, however, ignores the possible role of descending projections from cortical to subcortical regions(2-10). In the bat auditory system, such corticofugal connections modulate neuronal activity to improve the processing of echo-delay information(11,12), a specialized feature. Here we show that corticofugal projections are also involved in the most common type of auditory processing, frequency tuning. When cortical neurons tuned to a specific frequency are inactivated, the auditory responses of subcortical neurons tuned to the same frequency are reduced. Moreover, the responses of other subcortical neurons tuned to different frequencies are increased, and their preferred frequencies are shifted towards that of the inactivated cortical neurons. Thus the corticofugal system mediates a positive feedback which, in combination with widespread lateral inhibition, sharpens and adjusts the tuning of neurons at earlier stages in the auditory processing pathway.	WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA	Washington University (WUSTL)								ANDERSEN P, 1973, BRAIN BEHAV EVOLUT, V6, P170, DOI 10.1159/000123705; ANDERSEN RA, 1980, J COMP NEUROL, V191, P479, DOI 10.1002/cne.901910310; EDELINE JM, 1991, BEHAV NEUROSCI, V105, P154, DOI 10.1037/0735-7044.105.1.154; EDELINE JM, 1992, BEHAV NEUROSCI, V106, P81, DOI 10.1037/0735-7044.106.1.81; EDELINE JM, 1993, BEHAV NEUROSCI, V107, P539, DOI 10.1037/0735-7044.107.4.539; GOLDMAN LJ, 1977, BEHAV ECOL SOCIOBIOL, V2, P411, DOI 10.1007/BF00299509; HERBERT H, 1991, J COMP NEUROL, V304, P103, DOI 10.1002/cne.903040108; HUFFMAN RF, 1990, BRAIN RES REV, V15, P295, DOI 10.1016/0165-0173(90)90005-9; JOHNSON RA, 1974, J ACOUST SOC AM, V55, pS53, DOI 10.1121/1.1919792; MASSOPUST LC, 1962, EXP NEUROL, V6, P465, DOI 10.1016/0014-4886(62)90072-9; MITANI A, 1983, NEUROSCI LETT, V42, P185, DOI 10.1016/0304-3940(83)90404-4; OLSEN JF, 1986, THESIS WASHINGTON U; RYUGO DK, 1976, EXP NEUROL, V51, P377, DOI 10.1016/0014-4886(76)90262-4; SUGA N, 1987, J NEUROPHYSIOL, V58, P643, DOI 10.1152/jn.1987.58.4.643; Suga N, 1997, J NEUROPHYSIOL, V77, P2098, DOI 10.1152/jn.1997.77.4.2098; SUGA N, 1990, NEURAL NETWORKS, V3, P3, DOI 10.1016/0893-6080(90)90043-K; SUGA N, 1982, J NEUROPHYSIOL, V47, P225, DOI 10.1152/jn.1982.47.2.225; SUGA N, 1985, J NEUROPHYSIOL, V53, P1109, DOI 10.1152/jn.1985.53.4.1109; SUGA N, 1983, J NEUROPHYSIOL, V49, P1573, DOI 10.1152/jn.1983.49.6.1573; SUGA N, 1976, SCIENCE, V194, P542, DOI 10.1126/science.973140; SUGA N, 1995, NEUROSCI RES, V21, P287, DOI 10.1016/0168-0102(94)00868-G; SUGA N, 1975, J EXP BIOL, V63, P161; SUGA N, 1995, ACTIVE HEARING, P13; SUN X, 1989, BRAIN RES, V495, P1, DOI 10.1016/0006-8993(89)91212-2; VILLA AEP, 1991, EXP BRAIN RES, V86, P506, DOI 10.1007/BF00230524; Winer J.A., 1992, Springer Handbook of Auditory Research, V1, P222; Yan J, 1996, SCIENCE, V273, P1100, DOI 10.1126/science.273.5278.1100; YANG LC, 1992, J NEUROPHYSIOL, V68, P1760, DOI 10.1152/jn.1992.68.5.1760	28	181	184	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	1997	387	6636					900	903		10.1038/43180	http://dx.doi.org/10.1038/43180			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202121	Bronze			2022-12-24	WOS:A1997XG41600051
J	Masai, H; Arai, K				Masai, H; Arai, K			Frpo: A novel single-stranded DNA promoter for transcription and for primer RNA synthesis of DNA replication	CELL			English	Article							F-SEX FACTOR; COLE1 DNA; NUCLEOTIDE-SEQUENCE; SELECTIVE CLONING; BINDING-PROTEIN; LEADING REGION; ABC-PRIMOSOME; PLASMID DNA; ORIGIN; INITIATION	We describe a novel promoter for E. coli RNA polymerase that functions efficiently only in the form of single-stranded DNA. Derived from the leading region of F plasmid, single-stranded Frpo sequence directs RNA polymerase to initiate transcription at a specific site within Frpo, and this specific transcription is highly stimulated by SSB. Prior denaturation activates transcription from otherwise inactive duplex DNA containing Frpo. Since RNAs synthesized on SSB-coated single-stranded Frpo are efficiently elongated into DNA chains by DNA polymerase III holoenzyme, transcription at Frpo serves also for priming DNA replication. A mode of recognition by RNA polymerase of a unique secondary structure within Frpo is proposed, and possible roles of this novel single-stranded promoter in expression and replication during conjugal transfer of F plasmid are discussed.			Masai, H (corresponding author), UNIV TOKYO, INST MED SCI, DEPT MOL & DEV BIOL, MINATO KU, 4-6-1 SHIROKANEDAI, TOKYO 108, JAPAN.							BAGDASARIAN M, 1992, MOL MICROBIOL, V6, P885, DOI 10.1111/j.1365-2958.1992.tb01539.x; BOUCHE JP, 1978, J BIOL CHEM, V253, P765; CHASE JW, 1983, P NATL ACAD SCI-BIOL, V80, P5480, DOI 10.1073/pnas.80.18.5480; CRAM D, 1984, PLASMID, V11, P221, DOI 10.1016/0147-619X(84)90028-3; DUTTA A, 1993, CURR BIOL, V3, P709, DOI 10.1016/0960-9822(93)90076-Z; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GEIDER K, 1978, P NATL ACAD SCI USA, V75, P645, DOI 10.1073/pnas.75.2.645; GEIDER K, 1974, J BIOL CHEM, V249, P3999; GLUCKSMANN MA, 1992, CELL, V70, P491, DOI 10.1016/0092-8674(92)90173-A; HIGASHITANI N, 1993, J VIROL, V67, P2175, DOI 10.1128/JVI.67.4.2175-2181.1993; Higashitani N, 1996, GENES CELLS, V1, P829, DOI 10.1046/j.1365-2443.1996.d01-279.x; HONDA Y, 1989, GENE, V80, P155; HORIUCHI K, 1976, P NATL ACAD SCI USA, V73, P2341, DOI 10.1073/pnas.73.7.2341; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; ITOH T, 1979, COLD SPRING HARB SYM, V43, P409, DOI 10.1101/SQB.1979.043.01.047; JONES AL, 1992, MOL MICROBIOL, V6, P605, DOI 10.1111/j.1365-2958.1992.tb01507.x; KAGUNI JM, 1982, J BIOL CHEM, V257, P5437; LOH S, 1989, MOL GEN GENET, V219, P177, DOI 10.1007/BF00261174; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MARKIEWICZ P, 1992, GENE DEV, V6, P2010, DOI 10.1101/gad.6.10.2010; MASAI H, 1995, EUR J BIOCHEM, V230, P384; MASAI H, 1989, J BIOL CHEM, V264, P8082; MASAI H, 1990, J BIOL CHEM, V265, P15124; MASAI H, 1990, J BIOL CHEM, V265, P15134; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; MASAI H, 1996, FRONT BIOSCI, V1, P49; MELENDY T, 1993, J BIOL CHEM, V268, P3389; NOMURA N, 1982, GENE, V18, P239, DOI 10.1016/0378-1119(82)90161-5; NOMURA N, 1982, P NATL ACAD SCI-BIOL, V79, P3153, DOI 10.1073/pnas.79.10.3153; NOMURA N, 1991, GENE, V108, P15; ONEILL MC, 1989, J BIOL CHEM, V264, P5522; RAY DS, 1982, GENE, V18, P231, DOI 10.1016/0378-1119(82)90160-3; Roberts CW, 1996, CELL, V86, P495; Sambrook JFE, 1989, MOL CLONING LAB MANU; TANAKA K, 1991, PLASMID, V25, P125, DOI 10.1016/0147-619X(91)90024-Q; THOMPSON R, 1984, EMBO J, V3, P1175, DOI 10.1002/j.1460-2075.1984.tb01947.x; VANWEZENBEEK PMGF, 1980, GENE, V11, P129, DOI 10.1016/0378-1119(80)90093-1; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984	39	52	52	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					897	907		10.1016/S0092-8674(00)80275-5	http://dx.doi.org/10.1016/S0092-8674(00)80275-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200608	Bronze			2022-12-24	WOS:A1997XE35700010
J	DeMaria, R; Lenti, L; Malisan, F; dAgostino, F; Tomassini, B; Zeuner, A; Rippo, MR; Testi, R				DeMaria, R; Lenti, L; Malisan, F; dAgostino, F; Tomassini, B; Zeuner, A; Rippo, MR; Testi, R			Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis	SCIENCE			English	Article							FAS-MEDIATED APOPTOSIS; ACIDIC SPHINGOMYELINASE; EXPRESSION CLONING; G(D3) SYNTHASE; CELL-DEATH; PROTEASE; INVOLVEMENT; RECEPTOR; SIGNAL; MEMBRANE	Gangliosides participate in development and tissue differentiation, Cross-linking of the apoptosis-inducing CD95 protein (also called Fas or APO-1) in lymphoid and myeloid tumor cells triggered GD3 ganglioside synthesis and transient accumulation. CD95-induced GD3 accumulation depended on integral receptor ''death domains'' and on activation of a family of cysteine proteases called caspases. Cell-permeating ceramides, which are potent inducers of apoptosis, also triggered GD3 synthesis, GD3 disrupted mitochondrial transmembrane potential (Delta psi(m),), and induced apoptosis, in a caspase-independent fashion. Transient overexpression of the GD3 synthase gene directly triggered apoptosis, Pharmacological inhibition of GD3 synthesis and exposure to GD3 synthase antisense oligodeoxynucleotides prevented CD95-induced apoptosis. Thus, GD3 ganglioside mediates the propagation of CD95-generated apoptotic signals in hematopoietic cells.	UNIV ROMA TOR VERGATA,DEPT EXPT MED & BIOCHEM SCI,I-00133 ROME,ITALY; UNIV ROMA LA SAPIENZA,DEPT EXPT MED & PATHOL,I-00161 ROME,ITALY	University of Rome Tor Vergata; Sapienza University Rome			Zeuner, Ann/K-8607-2016; De Maria, Ruggero/S-6385-2019; Zeuner, Ann/A-8529-2010	De Maria, Ruggero/0000-0003-2255-0583; Zeuner, Ann/0000-0002-8295-3715; RIPPO, Maria Rita/0000-0003-3024-3495; MALISAN, FLORENCE/0000-0002-0213-9407				ALLAN D, 1993, PROG LIPID RES, V32, P195, DOI 10.1016/0163-7827(93)90015-O; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cascino I, 1996, J IMMUNOL, V156, P13; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; DEMARIA R, UNPUB; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MATYAS GR, 1987, BIOCHIM BIOPHYS ACTA, V921, P599, DOI 10.1016/0005-2760(87)90089-0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Radin N S, 1981, Methods Enzymol, V72, P673; RADIN NS, 1993, ADV LIPID RES, V26, P183; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SARTI P, 1990, BIOCHEM J, V267, P413, DOI 10.1042/bj2670413; SASAKI K, 1994, J BIOL CHEM, V269, P15950; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; TETTAMANTI G, 1994, PROG BRAIN RES, V101, P77; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; ZENG GC, 1995, P NATL ACAD SCI USA, V92, P8670, DOI 10.1073/pnas.92.19.8670	30	327	337	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1652	1655		10.1126/science.277.5332.1652	http://dx.doi.org/10.1126/science.277.5332.1652			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287216	Green Published			2022-12-24	WOS:A1997XV68400047
J	Sanchez, Y; Wong, C; Thoma, RS; Richman, R; Wu, RQ; PiwnicaWorms, H; Elledge, SJ				Sanchez, Y; Wong, C; Thoma, RS; Richman, R; Wu, RQ; PiwnicaWorms, H; Elledge, SJ			Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25	SCIENCE			English	Article							CELL-CYCLE CONTROL; FISSION YEAST; KINASE; PHOSPHORYLATION; IDENTIFICATION; ARREST; MUTATION; MITOSIS; CANCER; P21	In response to DNA damage, mammalian cells prevent cell cycle progression through the control of critical cell cycle regulators. A human gene was identified that encodes the protein Chk1, a homolog of the Schizosaccharomyces pombe Chk1 protein kinase, which is required for the DNA damage checkpoint. Human Chk1 protein was modified in response to DNA damage. In vitro Chk1 bound to and phosphorylated the dual-specificity protein phosphatases Cdc25A, Cdc25B, and Cdc25C, which control cell cycle transitions by dephosphorylating cyclin-dependent kinases. Chk1 phosphorylates Cdc25C on serine-216. As shown in an accompanying paper by Peng et al. in this issue, serine-216 phosphorylation creates a binding site for 14-3-3 protein and inhibits function of the phosphatase. These results suggest a model whereby in response to DNA damage, Chk1 phosphorylates and inhibits Cdc25C, thus preventing activation of the Cdc2-cyclin B complex and mitotic entry.	BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT MOL & HUMAN GENET,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Washington University (WUSTL); Baylor College of Medicine; Howard Hughes Medical Institute			Wu, R.Q./AAD-1067-2021; Piwnica-Worms, Helen/C-5214-2012	Wu, R.Q./0000-0002-6156-7874; 	NIGMS NIH HHS [GM17763, GM44664] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044664, R01GM044664, F32GM017763] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; DENG C, 1995, CELL, V82, P67; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; Fogarty P, 1997, CURR BIOL, V7, P418, DOI 10.1016/S0960-9822(06)00189-8; Gabra H, 1996, CANCER RES, V56, P950; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Laake K, 1997, GENE CHROMOSOME CANC, V18, P175, DOI 10.1002/(SICI)1098-2264(199703)18:3<175::AID-GCC4>3.0.CO;2-Z; Lakin ND, 1996, ONCOGENE, V13, P2707; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; SANCHEZ Y, UNPUB; Sibon OCM, 1997, NATURE, V388, P93, DOI 10.1038/40439; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Vorechovsky I, 1996, CANCER RES, V56, P2726; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353	26	1122	1180	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1497	1501		10.1126/science.277.5331.1497	http://dx.doi.org/10.1126/science.277.5331.1497			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278511				2022-12-24	WOS:A1997XV42900038
J	Wan, Q; Xiong, ZG; Man, YH; Ackerley, CA; Braunton, J; Lu, WY; Becker, LE; MacDonald, JF; Wang, YT				Wan, Q; Xiong, ZG; Man, YH; Ackerley, CA; Braunton, J; Lu, WY; Becker, LE; MacDonald, JF; Wang, YT			Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin	NATURE			English	Article							LONG-TERM POTENTIATION; CULTURED HIPPOCAMPAL-NEURONS; INHIBITION; SYNAPSES; RAT; CELLS; EXPRESSION; CHANNELS; RELEASE; LTP	Modification of synaptic strength in the mammalian central nervous system (CNS) occurs at both pre- and postsynaptic sites(1,2). However, because postsynaptic receptors are likely to be saturated by released transmitter, an increase in the number of active postsynaptic receptors may be a more efficient way of strengthening synaptic efficacy(3-7). But there has been no evidence for a rapid recruitment of neurotransmitter receptors to the postsynaptic membrane in the CNS, Here we report that insulin causes the type A gamma-aminobutyric acid (GABA(A)) receptor, the principal receptor that mediates synaptic inhibition in the CNS8, to translocate rapidly from the intracellular compartment to the plasma membrane in transfected HEK 293 cells, and that this relocation requires the beta 2 subunit of the GABA(A) receptor. In CNS neurons, insulin increases the expression of GABA(A) receptors on the postsynaptic and dendritic membranes. We found that insulin increases the number of functional postsynaptic GABA(A) receptors, thereby increasing the amplitude of the GABA(A)-receptor-mediated miniature inhibitory postsynaptic currents (mIPSCs) without altering their time course. These results provide evidence for a rapid recruitment of functional receptors to the postsynaptic plasmamembrane, suggesting a fundamental mechanism for the generation of synaptic plasticity.	UNIV TORONTO,HOSP SICK CHILDREN,DIV PATHOL,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,DIV NEUROSCI,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto			Lu, Wei-Yang/K-4404-2013; Wang, Yu Tian/A-4729-2008; Wang, Yu Tian/J-8255-2015					BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; Benson DL, 1996, J NEUROSCI, V16, P6424; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BUSCH C, 1990, COLD SH Q B, V55, P69; COHEN GA, 1992, NEURON, V9, P325, DOI 10.1016/0896-6273(92)90171-9; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1995, PHYSIOL REV, V75, P759, DOI 10.1152/physrev.1995.75.4.759; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; GARRY DJ, 1986, DIABETES, V35, P1090, DOI 10.2337/diabetes.35.10.1090; HAMILTON BJ, 1993, NEUROSCI LETT, V153, P206, DOI 10.1016/0304-3940(93)90323-D; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JESSELL TM, 1993, NEURON S, V10, P1; KAMATCHI GL, 1984, LIFE SCI, V34, P2297; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.ne.17.030194.003033; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; NUSSER Z, 1995, J NEUROSCI, V15, P2948; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; THOMPSON SM, 1993, TRENDS NEUROSCI, V16, P222, DOI 10.1016/0166-2236(93)90160-N; TONG G, 1994, NEURON, V12, P51, DOI 10.1016/0896-6273(94)90151-1; Ueno S, 1996, MOL PHARMACOL, V50, P931; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WANG YT, 1991, NEUROSCIENCE, V40, P759, DOI 10.1016/0306-4522(91)90010-L; WOZNIAK M, 1995, NEUROCHEM INT, V22, P1	30	438	453	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					686	690		10.1038/41792	http://dx.doi.org/10.1038/41792			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262404	Bronze			2022-12-24	WOS:A1997XQ86300052
J	Fraser, J; Mok, Q; Tasker, R				Fraser, J; Mok, Q; Tasker, R			Survey of occupancy of paediatric intensive care units by children who are dependent on ventilators	BRITISH MEDICAL JOURNAL			English	Article											Fraser, J (corresponding author), HOSP SICK CHILDREN,PAEDIAT INTENS CARE UNIT,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND.		Mok, Quen/AAA-2648-2019; Tasker, Robert C/R-5837-2019	Mok, Quen/0000-0003-4807-9275; Tasker, Robert/0000-0003-3647-8113				British Paediatric Association, 1993, REP MULT WORK PART P; DEWITT PK, 1993, CHEST, V103, P1560, DOI 10.1378/chest.103.5.1560; James I, 1996, BRIT MED J, V312, P1476, DOI 10.1136/bmj.312.7044.1476b	3	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					347	348						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270456				2022-12-24	WOS:A1997XQ86400021
J	Castillo, PE; Janz, R; Sudhof, TC; Tzounopoulos, T; Malenka, RC; Nicoll, RA				Castillo, PE; Janz, R; Sudhof, TC; Tzounopoulos, T; Malenka, RC; Nicoll, RA			Rab3A is essential for mossy fibre long-term potentiation in the hippocampus	NATURE			English	Article							FIBER LTP; 2 FORMS; PROTEIN; RABPHILIN-3A; FACILITATION; SYNAPSINS; NEURONS	Repetitive activation of excitatory synapses in the central nervous system results in a long-lasting increase in synaptic transmission called long-term potentiation (LTP). It is generally believed that this synaptic plasticity may underlie certain forms of learning and memory. LTP at most synapses involves the activation of the NMDA (N-methyl-D-aspartate) subtype of glutamate receptor, but LTP at hippocampal messy fibre synapses is independent of NMDA receptors and has a component that is induced and expressed presynaptically(1). It appears to be triggered by a rise in presynaptic Ca2+ (refs 2, 3), and requires the activation of protein kinase A(4-6), which leads to an increased release of glutamate(3,7-10). A great deal is known about the biochemical steps involved in the vesicular release of transmitter(11-13), but none of these steps has been directly implicated in long-term synaptic plasticity. Here we show that, although a variety of short-term plasticities are normal, LTP at messy fibre synapses is abolished in mice lacking the synaptic vesicle protein Rab3A.	UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Janz, Roger/0000-0002-9872-0596; Castillo, Pablo/0000-0002-9834-1801				BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DIXON D, 1989, J NEUROSCI, V9, P4246; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FYKSE EM, 1995, J NEUROSCI, V15, P2385, DOI 10.1523/JNEUROSCI.15-03-02385.1995; FYKSE EM, 1993, J NEUROSCI, V13, P4997; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; Kamiya H, 1996, J PHYSIOL-LONDON, V493, P447, DOI 10.1113/jphysiol.1996.sp021395; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LopezGarcia JC, 1996, P NATL ACAD SCI USA, V93, P4712, DOI 10.1073/pnas.93.10.4712; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; REGEHR WG, 1994, J NEUROSCI, V14, P523; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Salin PA, 1996, P NATL ACAD SCI USA, V93, P13304, DOI 10.1073/pnas.93.23.13304; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SPILLANE DM, 1995, NEUROPHARMACOLOGY, V34, P1573, DOI 10.1016/0028-3908(95)00107-H; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tong G, 1996, NEURON, V16, P1147, DOI 10.1016/S0896-6273(00)80141-5; WANG Y, 1997, NATURE, V387; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; XIANG ZX, 1994, J NEUROPHYSIOL, V71, P2552, DOI 10.1152/jn.1994.71.6.2552; Yokoi M, 1996, SCIENCE, V273, P645, DOI 10.1126/science.273.5275.645; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	30	281	288	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					590	593		10.1038/41574	http://dx.doi.org/10.1038/41574			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252190	Bronze			2022-12-24	WOS:A1997XP72200051
J	Sosa, H; Dias, DP; Hoenger, A; Whittaker, M; WilsonKubalek, E; Sablin, E; Fletterick, RJ; Vale, RD; Milligan, RA				Sosa, H; Dias, DP; Hoenger, A; Whittaker, M; WilsonKubalek, E; Sablin, E; Fletterick, RJ; Vale, RD; Milligan, RA			A model for the microtubule-Ncd motor protein complex obtained by cryo-electron microscopy and image analysis	CELL			English	Article							KINESIN HEAVY-CHAIN; 3-DIMENSIONAL STRUCTURE; DROSOPHILA; RECONSTRUCTION; MICROGRAPHS; MOTILITY; MOVEMENT; TUBULIN; DOMAINS; INVITRO	Kinesin motors convert chemical energy from ATP hydrolysis into unidirectional movement. To understand how kinesin motors bind to and move along microtubules, we fit the atomic structure of the motor domain of Ncd (a kinesin motor involved in meiosis and mitosis) into three-dimensional density maps of Ncd-microtubule complexes calculated by cryo-electron microscopy and image analysis. The model reveals that Ncd shares an extensive interaction surface with the microtubule, and that a portion of the binding site involves loops that contain conserved residues. In the Ncd dimer, the microtubule-bound motor domain makes intimate contact with its partner head, which is dissociated from the microtubule. This head-head interaction may be important in positioning the dissociated head to take a step to the next binding site on the microtubule protofilament.	SCRIPPS RES INST, DEPT CELL BIOL MB25, LA JOLLA, CA 92037 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT CELLULAR & MOL PHARMACOL, SAN FRANCISCO, CA 94143 USA	Scripps Research Institute; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Hoenger, Andreas/0000-0001-9176-6658	NIAMS NIH HHS [AR42895] Funding Source: Medline; NIGMS NIH HHS [GM52468] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052468, R37GM052468] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; AMOS LA, 1974, J CELL SCI, V14, P523; Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Carragher B, 1996, J STRUCT BIOL, V116, P107, DOI 10.1006/jsbi.1996.0018; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Fan J, 1996, J MOL BIOL, V259, P325, DOI 10.1006/jmbi.1996.0322; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; Hoenger A, 1996, J MOL BIOL, V263, P114, DOI 10.1006/jmbi.1996.0561; Hoenger A, 1997, J MOL BIOL, V265, P553, DOI 10.1006/jmbi.1996.0757; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; MANDELKOW EM, 1985, J MOL BIOL, V181, P123, DOI 10.1016/0022-2836(85)90330-4; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MORGAN D, 1993, BIOPHYS J, V64, pA243; RAY S, 1995, CELL MOTIL CYTOSKEL, V30, P146, DOI 10.1002/cm.970300206; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Rayment I, 1996, ANNU REV PHYSIOL, V58, P671; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P13259, DOI 10.1021/bi00040a042; Sosa H, 1996, J MOL BIOL, V260, P743, DOI 10.1006/jmbi.1996.0434; Sosa H, 1997, J STRUCT BIOL, V118, P149, DOI 10.1006/jsbi.1997.3851; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Tucker C, 1997, J BIOL CHEM, V272, P9481; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; Wade RH, 1995, PROTEINS, V23, P502, DOI 10.1002/prot.340230405; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WALKER RA, 1995, P NATL ACAD SCI USA, V92, P5960, DOI 10.1073/pnas.92.13.5960; WHITTAKER M, 1995, ULTRAMICROSCOPY, V58, P245, DOI 10.1016/0304-3991(95)00057-8; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	42	142	143	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					217	224		10.1016/S0092-8674(00)80330-X	http://dx.doi.org/10.1016/S0092-8674(00)80330-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244296	Bronze			2022-12-24	WOS:A1997XN24900006
J	Liu, LL; Clemens, CJ; Shay, DK; Davis, RL; Novack, AH				Liu, LL; Clemens, CJ; Shay, DK; Davis, RL; Novack, AH			The safety of newborn early discharge - The Washington State experience	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL DISCHARGE; MOTHERS; POPULATION; INFANTS	Context.-While early discharge of newborns following routine vaginal delivery has become common practice, its safety has not been firmly established. Objective.-To assess the risk for rehospitalization following newborn early discharge. Design.-Population-based, case-control study. Setting.-Washington State linked birth certificate and hospital discharge abstracts covering 310 578 live births from 1991 through 1994. Patients.-Case patients were 2029 newborns rehospitalized in the first month of life. Control subjects were 8657 randomly selected newborns not rehospitalized and frequency matched to case patients on year of birth. Cesarean deliveries, multiple births, and births at less than 36 weeks' gestation were not included. Main Outcome Measure.-Stratified analyses and logistic regression were performed to assess the risk for rehospitalization within a month of birth after early discharge (<30 hours after birth) compared with later discharge (30-78 hours after birth). Results.-Seventeen percent of newborns were discharged early. Newborns discharged early were more likely to be rehospitalized within 7 days (odds ratio [OR], 1.28; 95% confidence interval [CI], 1.11-1.47), 14 days (OR, 1.16; 95% CI, 1.03-1.32), and 28 days (OR, 1.12; 95% CI, 1.00-1.25) of discharge than newborns sent home later. Subgroups at increased risk for rehospitalization following early discharge included newborns born to primigravidas (OR,1.25; 95% CI, 1.07-1.45), mothers younger than 18 years (OR, 1.22; 95% CI, 0.79-1.91), and mothers with premature rupture of membranes (OR, 1.41;95% CI, 0.85-2.36). Early discharge was also associated with an increased risk of readmission for jaundice, dehydration, and sepsis. Conclusion.-Newborns discharged home early (<30 hours after birth) are at increased risk for rehospitalization during the first month of life.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,SEATTLE,WA 98101; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative; University of North Carolina; University of North Carolina Chapel Hill			Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Shay, David/0000-0001-9619-4820	BHP HRSA HHS [5-T32-PE10002] Funding Source: Medline	BHP HRSA HHS		ANNAS GJ, 1995, NEW ENGL J MED, V333, P1647, DOI 10.1056/NEJM199512143332420; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; BRESLOW NE, 1980, STATISTICAL METHODS, P1; BRITTON JR, 1994, PEDIATRICS, V94, P291; CARTY EM, 1990, BIRTH-ISS PERINAT C, V17, P199, DOI 10.1111/j.1523-536X.1990.tb00021.x; CLARK G, 1996, AAP NEWS, V12, P1; CONRAD PD, 1989, AM J DIS CHILD, V143, P98, DOI 10.1001/archpedi.1989.02150130108026; FROST F, 1984, AM J PUBLIC HEALTH, V74, P505, DOI 10.2105/AJPH.74.5.505; Gauda EB, 1996, JAMA-J AM MED ASSOC, V275, P1823, DOI 10.1001/jama.275.23.1823; HELLMAN LM, 1962, LANCET, V1, P227; JANSSON P, 1985, AM J NURS, V85, P547, DOI 10.2307/3425241; KEMPER KJ, 1990, AM J DIS CHILD, V144, P238, DOI 10.1001/archpedi.1990.02150260118043; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1414, DOI 10.2105/AJPH.84.9.1414; LEE KS, 1995, J PEDIATR-US, V127, P758, DOI 10.1016/S0022-3476(95)70170-2; MAISELS MJ, 1995, PEDIATRICS, V96, P730; Norr K F, 1989, J Obstet Gynecol Neonatal Nurs, V18, P133, DOI 10.1111/j.1552-6909.1989.tb00476.x; PARISI VM, 1995, NEW ENGL J MED, V333, P1635, DOI 10.1056/NEJM199512143332412; PARRISH KM, 1993, AM J EPIDEMIOL, V138, P119, DOI 10.1093/oxfordjournals.aje.a116834; PITTARD WB, 1988, J PEDIATR-US, V112, P257, DOI 10.1016/S0022-3476(88)80066-0; RHODES MK, 1994, MIL MED, V159, P227, DOI 10.1093/milmed/159.3.227; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCUPHOLME A, 1981, J NURSE-MIDWIFERY, V26, P19, DOI 10.1016/0091-2182(81)90171-3; SOLA A, 1996, SOC PED RES ANN M, V39, pA113; WALDENSTROM U, 1987, UPSALA J MED SCI, V92, P301, DOI 10.3109/03009738709178701; *WASH STAT DEP HLT, 1996, BIRA18M1 WASH STAT D; WELT SI, 1993, AM J PERINAT, V10, P384, DOI 10.1055/s-2007-994768; YANOVER MJ, 1976, NEW ENGL J MED, V294, P702, DOI 10.1056/NEJM197603252941306; 1995, NY TIMES        1011, pC18; 1995, VITAL HLTH STAT, V13	29	129	134	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					293	298		10.1001/jama.278.4.293	http://dx.doi.org/10.1001/jama.278.4.293			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XL059	9228434				2022-12-24	WOS:A1997XL05900029
J	Kenyon, TA; Ridzon, R; LuskinHawk, R; Schultz, C; Paul, WS; Valway, SE; Onorato, IM; Castro, K				Kenyon, TA; Ridzon, R; LuskinHawk, R; Schultz, C; Paul, WS; Valway, SE; Onorato, IM; Castro, K			A nosocomial outbreak of multidrug-resistant tuberculosis	ANNALS OF INTERNAL MEDICINE			English	Article							HIV-INFECTED PATIENTS; LENGTH-POLYMORPHISM ANALYSIS; HEALTH-CARE WORKERS; MYCOBACTERIUM-TUBERCULOSIS; TRANSMISSION; UNIT	Background: An outbreak of seven cases (in six patients and one health care worker, all of whom had AIDS) of multidrug-resistant tuberculosis occurred in a hospital in Chicago. The hospital had a respirator-fit testing program but no acid-fast bacilli isolation rooms. Objective: To identify risk factors for transmission of Mycobacterium tuberculosis. Design: Retrospective cohort study. Setting: Private hospital. Participants: Patients and health care workers exposed to M. tuberculosis. Measurements: Analysis of M. tuberculosis isolates, tuberculin skin testing, assessment of exposure, and assessment of participant characteristics. Results: All seven M. tuberculosis isolates had matching DNA fingerprints. Of patients exposed to M. tuberculosis, those who developed tuberculosis had lower CD4(+) T-lymphocyte counts (P = 0.02) and were more likely to be ambulatory (P = 0.03) than those who did not. Of 74 exposed health care workers, the 11 (15%)who had conversion on tuberculin skin testing were no more likely than those who did not have conversion to report that they always wore a respirator with a high-efficiency particulate air filter. Conclusions: Transmission of M. tuberculosis occurred in a hospital that did not have recommended isolation rooms. A respirator-fit testing program did not protect health care workers in this setting.	CTR DIS CONTROL & PREVENT, DIV TB ELIMINAT, ATLANTA, GA 30333 USA; ST JOSEPH HOSP, CHICAGO, IL USA; CHICAGO DEPT PUBL HLTH, CHICAGO, IL USA	Centers for Disease Control & Prevention - USA; Chicago Department of Public Health			Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003; CAIAFFA WT, 1995, ARCH INTERN MED, V155, P2111, DOI 10.1001/archinte.155.19.2111; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; Dean A.G., 1994, EPI INFO VERSION 6 W; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P129; IKEDA RM, 1995, INFECT CONT HOSP EP, V16, P152; JEREB JA, 1993, J INFECT DIS, V168, P1219, DOI 10.1093/infdis/168.5.1219; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; STROUD LA, 1995, INFECT CONT HOSP EP, V16, P141; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7	18	63	65	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					32	36		10.7326/0003-4819-127-1-199707010-00006	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214250				2022-12-24	WOS:A1997XG91400005
J	Endo, TA; Masuhara, M; Yokouchi, M; Suzuki, R; Sakamoto, H; Mitsui, K; Matsumoto, A; Tanimura, S; Ohtsubo, M; Misawa, H; Miyazaki, T; Leonor, N; Taniguchi, T; Fujita, T; Kanakura, Y; Komiya, S; Yoshimura, A				Endo, TA; Masuhara, M; Yokouchi, M; Suzuki, R; Sakamoto, H; Mitsui, K; Matsumoto, A; Tanimura, S; Ohtsubo, M; Misawa, H; Miyazaki, T; Leonor, N; Taniguchi, T; Fujita, T; Kanakura, Y; Komiya, S; Yoshimura, A			A new protein containing an SH2 domain that inhibits JAK kinases	NATURE			English	Article							RECEPTORS	The proliferation and differentiation of cells of many Lineages are regulated by secreted proteins known as cytokines. Cytokines exert their biological effect through binding to cell-surface receptors that are associated with one or more members of the JAK family of cytoplasmic tyrosine kinases. Cytokine-induced receptor dimerization leads to the activation of JAKs, rapid tyrosine-phosphorylation of the cytoplasmic domains, and subsequent recruitment of various signalling proteins, including members of the STAT family of transcription factors, to the receptor complex(1-5). Using the yeast two-hybrid system, we have now isolated a new SH2-domain-containing protein, TAB, which is a JAK-binding protein that interacts with the Jak2 tyrosine-kinase JH1 domain(6). JAB is structurally related to CIS, a cytokine-inducible SH2 protein(7,8). Interaction of JAB with Jak1, Jak2 or Jak3 markedly reduces their tyrosine-kinase activity and suppresses the tyrosine-phosphorylation and activation of STATs. TAB and CIS appear to function as negative regulators in the JAK signalling pathway.	KURUME UNIV,INST LIFE SCI,KURUME 839,JAPAN; KURUME UNIV,DEPT ORTHOPED SURG,KURUME 839,JAPAN; UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT TUMOR CELL BIOL,BUNKYO KU,TOKYO 113,JAPAN; OSAKA UNIV,SCH MED,DEPT HEMATOL & ONCOL,SUITA,OSAKA 565,JAPAN	Kurume University; Kurume University; University of Tokyo; Tokyo Metropolitan Institute of Medical Science; Osaka University			Nogueira, Leonor/L-2034-2014; Miyazaki, Tadaaki/D-9368-2012; Yoshimura, Akihiko/K-5515-2013; Endo, Takaho/B-5763-2017; Mitsui, Kaoru/E-1464-2011	Endo, Takaho/0000-0002-2801-2463; Mitsui, Kaoru/0000-0003-0534-9845; ohtsubo, motoaki/0000-0002-2479-3178				Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; HARPER JW, 1993, CELL, V75, P805; HARPUR AG, 1992, ONCOGENE, V7, P1347; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KAWAHARA A, 1995, P NATL ACAD SCI  US, V92, P8721; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schluter G, 1996, MOL REPROD DEV, V43, P1, DOI 10.1002/(SICI)1098-2795(199601)43:1&lt;1::AID-MRD1&gt;3.0.CO;2-W; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	19	1186	1255	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					921	924		10.1038/43213	http://dx.doi.org/10.1038/43213			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202126	Bronze			2022-12-24	WOS:A1997XG41600056
J	Frank, SH; Stange, KC; Langa, D; Workings, M				Frank, SH; Stange, KC; Langa, D; Workings, M			Direct observation of community-based ambulatory encounters involving medical students	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY CARE; PRODUCTIVITY; ATTITUDES; COSTS	Context.-The current shift of predoctoral medical education from inpatient tertiary settings to community-based, ambulatory practice has raised questions about the effect of the medical student on the process of patient care. Objective.-To determine how the presence of a medical student during the ambulatory medical encounter affects the use of clinical time and patient satisfaction. Design.-Cross-sectional, multimethod study using direct observation of ambulatory care by research-trained nurses. Setting.-A total of 16 community-based family practice offices accepting family practice clerkship students. Patients.-A total of 452 outpatient visits with and without student involvement. Main Outcome Measures.-Clinical time use as measured by the Davis Observation Code; patient satisfaction was assessed with the Medical Outcomes Study 9-item visit rating scale. Results.-When students were involved, physicians spent more time discussing visit expectations (P=.03) and less time in history taking (P=.007), providing assessment (P=.01), and answering questions (P=.04), Despite these differences, patients were equally satisfied with explanations received, and there was no change in the rank order of the 5 most commonly observed physician behaviors. There was no difference in time spent in treatment planning, physical examination, health education, or social chatting. The physician spent equal time with the patient with (10.3 minutes) and without (9.9 minutes, P=.6) student involvement, There was no decrease in patient satisfaction when students were involved. Physicians were more likely to discuss another family member's problems when a student was present (P=.001). Students were directed to care for minority patients at a disproportionate rate (P=.001), controlling for confounding variables. Conclusions.-Medical student involvement alters the content but not the duration of the ambulatory medical encounter. Application of validated measures indicate that students did not impair patient satisfaction or hinder the physicians' ability to ensure that patient expectations for the visit were met.	CASE WESTERN RESERVE UNIV, DEPT SOCIOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT EPIDEMIOL & BIOSTAT, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, CTR CANC RES, CLEVELAND, OH 44106 USA; HENRY FORD HLTH SYST, DEPT FAMILY MED, DETROIT, MI USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Henry Ford Health System; Henry Ford Hospital	Frank, SH (corresponding author), CASE WESTERN RESERVE UNIV, DEPT FAMILY MED, 10900 EUCLID AVE, CLEVELAND, OH 44106 USA.		Frank, Scott/R-5727-2019	Frank, Scott/0000-0002-2303-5922	NCI NIH HHS [1R01 CA60862] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060862] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM AC FAM PHYS, 1994, FACTS FAM PRACT; [Anonymous], 1993, ACAD MED, V68, P1; Bertakis K D, 1992, Fam Med, V24, P307; Bertakis K D, 1993, Fam Med, V25, P530; Callahan E J, 1993, Fam Pract Res J, V13, P171; Callahan E J, 1996, Fam Med, V28, P346; Callahan E J, 1991, Fam Med, V23, P19; Crandall L A, 1986, J Rural Health, V2, P7, DOI 10.1111/j.1748-0361.1986.tb00142.x; Delbanco T L, 1988, J Gen Intern Med, V3, pS34, DOI 10.1007/BF02600250; Doyle G A, 1997, Fam Med, V29, P12; FIELDS SA, 1994, ACAD MED, V69, pS87, DOI 10.1097/00001888-199410000-00052; FLOCKE SA, IN PRESS J FAM PRACT; GARG ML, 1991, ACAD MED, V66, P348, DOI 10.1097/00001888-199106000-00009; KEARL GW, 1993, ACAD MED, V68, P166, DOI 10.1097/00001888-199302000-00017; KIRZ HL, 1986, JAMA-J AM MED ASSOC, V256, P734, DOI 10.1001/jama.256.6.734; PAWLSON LG, 1980, J FAM PRACTICE, V10, P847; PERKOFF GT, 1986, NEW ENGL J MED, V314, P27, DOI 10.1056/NEJM198601023140105; PETERSDORF RG, 1989, JAMA-J AM MED ASSOC, V262, P826, DOI 10.1001/jama.262.6.826; Robbins J A, 1993, Fam Med, V25, P17; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; SCHAPPERT SM, 1996, ADV DATA, V273, P1; SIMONS RJ, 1995, J GEN INTERN MED, V10, P251, DOI 10.1007/BF02599880; SOSTOK MA, 1995, ACAD MED, V70, P949, DOI 10.1097/00001888-199511000-00003; STIMMEL B, 1992, JAMA-J AM MED ASSOC, V268, P2060, DOI 10.1001/jama.268.15.2060; VINSON DC, 1994, ACAD MED, V69, P237, DOI 10.1097/00001888-199403000-00020; Vinson DC, 1996, J FAM PRACTICE, V42, P243; WARE JE, 1992, MEASURING FUNCTIONIN, P291; YORK NL, 1995, AM J SURG, V169, P421, DOI 10.1016/S0002-9610(99)80189-5	28	51	51	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	1997	278	9					712	716		10.1001/jama.278.9.712	http://dx.doi.org/10.1001/jama.278.9.712			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT709	9286829				2022-12-24	WOS:A1997XT70900022
J	Wada, T; Tachibana, T; Shimura, Y; Okada, K				Wada, T; Tachibana, T; Shimura, Y; Okada, K			Epidermal cell differentiation in Arabidopsis determined by a Myb homolog, CPC	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; REGULATORY GENE; ROOT; THALIANA; PROTEIN; DOMAIN; PLANT; ORGANIZATION; ENCODES	The roots of plants normally carry small hairs arranged in a regular pattern. Transfer DNA-tagged lines of Arabidopsis thaliana included a mutant with few, randomly distributed root hairs. The mutated gene CAPRICE (CPC) encoded a protein with a Myb-like DNA binding domain typical of transcription factors involved in animal and plant development. Analysis in combination with other root hair mutations showed that CPC may work together with the TTG gene and upstream of the GL2 gene, Transgenic plants overexpressing CPC had more root hairs and fewer trichomes than normal. Thus, the CPC gene determines the fate of epidermal cell differentiation in Arabidopsis.	KYOTO UNIV,GRAD SCH SCI,DEPT BOT,KYOTO 60601,JAPAN; NATL INST BASIC BIOL,DIV GENE EXPRESS & REGULAT 1,OKAZAKI,AICHI 444,JAPAN; KYOTO UNIV,GRAD SCH SCI,DEPT BIOPHYS,KYOTO 60601,JAPAN	Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kyoto University				Tachibana, Tatsuhiko/0000-0001-8339-3986				ANZAI H, 1990, NUCLEIC ACIDS RES, V18, P1890, DOI 10.1093/nar/18.7.1890; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENFEY PN, 1994, TRENDS GENET, V10, P84, DOI 10.1016/0168-9525(94)90230-5; CHANG SS, 1994, PLANT J, V5, P551, DOI 10.1046/j.1365-313X.1994.5040551.x; CONE KC, 1993, PLANT CELL, V5, P1795, DOI 10.1105/tpc.5.12.1795; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DOLAN L, 1994, DEVELOPMENT, V120, P2465; DOLAN L, 1993, DEVELOPMENT, V119, P71; GALWAY ME, 1994, DEV BIOL, V166, P710; GROTEWOLD E, 1991, P NATL ACAD SCI USA, V88, P4687; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; LLOYD AM, 1992, SCIENCE, V258, P1773, DOI 10.1126/science.1465611; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Massucci JD, 1996, DEVELOPMENT, V122, P1253; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; NODA K, 1994, NATURE, V369, P661, DOI 10.1038/369661a0; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OKADA K, 1990, SCIENCE, V250, P274, DOI 10.1126/science.250.4978.274; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAZARES J, 1987, EMBO J, V6, P3353; RERIE WG, 1994, GENE DEV, V8, P1388, DOI 10.1101/gad.8.12.1388; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; WADA T, UNPUB	24	440	480	7	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1113	1116		10.1126/science.277.5329.1113	http://dx.doi.org/10.1126/science.277.5329.1113			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262483				2022-12-24	WOS:A1997XT03300040
J	Portenoy, RK; Dole, V; Joseph, H; Lowinson, J; Rice, C; Segal, S; Richman, BL				Portenoy, RK; Dole, V; Joseph, H; Lowinson, J; Rice, C; Segal, S; Richman, BL			Pain management and chemical dependency - Evolving perspectives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ADDICTION; CANCER		MEM SLOAN KETTERING CANC CTR,DEPT NEUROL,PAIN & PALLIAT CARE SERV,NEW YORK,NY 10021; ROCKEFELLER UNIV,NEW YORK,NY 10021; NEW YORK STATE OFF ALCOHOLISM & SUBST ABUSE SERV,NEW YORK,NY	Memorial Sloan Kettering Cancer Center; Rockefeller University	Portenoy, RK (corresponding author), BETH ISRAEL MED CTR,DEPT PAIN MED & PALLIAT CARE,1ST AVE & 16TH ST,NEW YORK,NY 10003, USA.							*AD HOC COMM CANC, 1992, J CLIN ONCOL, V10, P1976; ANGAROLA RT, 1989, ADV PAIN RES THER, V11, P213; [Anonymous], [No title captured]; BESSON JM, 1987, PHYSIOL REV, V67, P67, DOI 10.1152/physrev.1987.67.1.67; BREITBART W, 1996, PAIN, V65, P239; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COOPER JR, 1992, JAMA-J AM MED ASSOC, V268, P1306, DOI 10.1001/jama.268.10.1306; ELLIOTT KJ, IN PRESS ANESTHESIA; Jacox A, 1994, AHCPR PUBLICATION; JORANSON DE, 1992, FED B, V4, P415; NESTLER EJ, 1994, NEUROPSYCHOPHARMACOL, V11, P77, DOI 10.1038/npp.1994.37; Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V11, P203, DOI 10.1016/0885-3924(95)00187-5; PORTENOY RK, 1997, SUBSTANCE ABUSE COMP, P563; SEES KL, 1993, J PAIN SYMPTOM MANAG, V8, P257, DOI 10.1016/0885-3924(93)90154-N; WARD SE, 1993, PAIN, V52, P319, DOI 10.1016/0304-3959(93)90165-L; World Health Organization, 1996, CANC PAIN REL GUID O	16	53	55	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					592	593		10.1001/jama.278.7.592	http://dx.doi.org/10.1001/jama.278.7.592			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ986	9268282				2022-12-24	WOS:A1997XQ98600035
J	Marafioti, T; Hummel, M; Anagnostopoulos, I; Foss, HD; Falini, B; Delsol, G; Isaacson, PG; Pileri, S; Stein, H				Marafioti, T; Hummel, M; Anagnostopoulos, I; Foss, HD; Falini, B; Delsol, G; Isaacson, PG; Pileri, S; Stein, H			Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REED-STERNBERG CELLS; GENE REARRANGEMENTS; SOMATIC MUTATIONS; CHAIN; NEOPLASMS; LYMPHOMAS; SUBTYPE; LINEAGE; MARKER; PCR	Background The atypical cells of nodular lymphocyte-predominant Hodgkin's disease, designated lymphocytic and histiocytic (L&H) cells, have a B-cell phenotype. To clarify the clonality of these cells, we studied rearranged immunoglobulin genes for the variable region of the heavy chain (V-H genes) in individual L&H cells from 11 patients with nodular lymphocyte-predominant Hodgkin's disease. We also studied the expression of immunoglobulin light chains by those cells in six of the same patients. Methods Single CD20+ L&H cells were isolated from frozen sections by a technique of micromanipulation. The rearranged V-H genes of these cells were amplified by the polymerase chain reaction (PCR), sequenced, and compared with germ-line V-H genes. Immunoglobulin light-chain messenger RNA (mRNA) was detected by in situ hybridization. Results Of 615 L&H cells isolated from all the frozen sections, 160 yielded PCR products. In each of the 11 patients, the L&H cells that could be evaluated had identically rearranged V-H genes, whether they were isolated from the same nodule, different nodules, or different blocks of tissue. All the V-H sequences derived from the L&H cells were highly mutated (7.5 to 27.2 percent). in two cases the coding capacity of the V-H genes was completely or partially disrupted by mutations. Intraclonal diversity was found in six cases, and monotypic immunoglobulin light-chain mRNA was found in six. Conclusions The L&H cells of nodular lymphocyte-predominant Hodgkin's disease represent a monoclonal expansion of B cells. The high load of V-H gene mutations and signs of intraclonal diversity suggest a relation between L&H cells and germinal-center B cells at the centroblastic stage of differentiation. (C) 1997, Massachusetts Medical Society.	FREE UNIV BERLIN, KLINIKUM BENJAMIN FRANKLIN, INST PATHOL, D-12200 BERLIN, GERMANY; CONSULTAT & REFERENCE CTR LYMPH NODE PATHOL & HAE, BERLIN, GERMANY; UNIV PERUGIA, INST HEMATOL, I-06100 PERUGIA, ITALY; CHU PURPAN, HOP TOULOUSE, LAB CENT ANAT PATHOL, TOULOUSE, FRANCE; UCL, SCH MED, DEPT HISTOPATHOL, LONDON, ENGLAND; UNIV BOLOGNA, SEZ EMOLINFOPATOL, SERV ANAT PATOL 2, BOLOGNA, ITALY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Perugia; CHU de Toulouse; University of London; University College London; UCL Medical School; University of Bologna			Pileri, Stefano/AAP-6337-2020; Marafioti, Teresa/B-4493-2009; Marafioti, Teresa/AAA-4652-2019	Marafioti, Teresa/0000-0003-1223-6275; Marafioti, Teresa/0000-0003-1223-6275; FALINI, Brunangelo/0000-0002-7198-5965				ANGEL CA, 1993, J CLIN PATHOL, V46, P337, DOI 10.1136/jcp.46.4.337; ANGEL CA, 1993, J CLIN PATHOL, V46, P940, DOI 10.1136/jcp.46.10.940; COLBY TV, 1982, CANCER, V49, P1848, DOI 10.1002/1097-0142(19820501)49:9<1848::AID-CNCR2820490918>3.0.CO;2-Y; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; DELABIE J, 1994, BLOOD, V84, P3291; Falini B, 1996, BLOOD, V87, P465, DOI 10.1182/blood.V87.2.465.bloodjournal872465; FOSS HD, 1993, BRIT J HAEMATOL, V84, P627, DOI 10.1111/j.1365-2141.1993.tb03138.x; Greiner TC, 1996, BLOOD, V88, P657, DOI 10.1182/blood.V88.2.657.bloodjournal882657; HANSMANN ML, 1990, AM J CLIN PATHOL, V93, P219, DOI 10.1093/ajcp/93.2.219; HARRIS NL, 1994, BLOOD, V84, P1361; Hell K, 1995, HISTOPATHOLOGY, V27, P491, DOI 10.1111/j.1365-2559.1995.tb00319.x; HUMMEL M, 1995, NEW ENGL J MED, V333, P901, DOI 10.1056/NEJM199510053331403; HUMMEL M, 1994, BLOOD, V84, P403; Jackson H, 1944, NEW ENGL J MED, V230, P1, DOI 10.1056/NEJM194401062300101; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; KORKOLOPOULOU P, 1994, HISTOPATHOLOGY, V24, P511; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; LUKES RJ, 1966, CANCER RES, V26, P1063; MARKS JD, 1991, EUR J IMMUNOL, V21, P985, DOI 10.1002/eji.1830210419; Pan LX, 1996, BLOOD, V87, P2428, DOI 10.1182/blood.V87.6.2428.bloodjournal8762428; PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329; PINKUS GS, 1988, AM J PATHOL, V133, P211; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RAMASAMY I, 1992, J CLIN PATHOL, V45, P770, DOI 10.1136/jcp.45.9.770; REE HJ, 1989, CANCER, V63, P2030, DOI 10.1002/1097-0142(19890515)63:10<2030::AID-CNCR2820631027>3.0.CO;2-P; REGULA DP, 1988, NEW ENGL J MED, V318, P214, DOI 10.1056/NEJM198801283180404; ROTH J, 1994, INT J CANCER, V57, P799, DOI 10.1002/ijc.2910570607; SCHMID C, 1991, AM J PATHOL, V139, P1281; STEIN H, 1986, AM J CLIN PATHOL, V86, P292, DOI 10.1093/ajcp/86.3.292; STOLER MH, 1995, AM J PATHOL, V146, P812; SUNDEEN JT, 1988, AM J SURG PATHOL, V12, P599; TAMARU J, 1994, BLOOD, V84, P708; WICKERT RS, 1995, BLOOD, V86, P2312, DOI 10.1182/blood.V86.6.2312.bloodjournal8662312	34	240	246	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	1997	337	7					453	458		10.1056/NEJM199708143370703	http://dx.doi.org/10.1056/NEJM199708143370703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ499	9250847				2022-12-24	WOS:A1997XQ49900003
J	Price, CSC				Price, CSC			Conspecific sperm precedence in Drosophila	NATURE			English	Article							MELANOGASTER; DISPLACEMENT; HOMOGAMY; FEMALES; PROTEIN	Traits that influence the interactions between males and females can evolve very rapidly through sexual selection(1) or sexually antagonistic coevolution(2). Rapid change in the fertilization systems of independent populations can give rise to reproductive incompatibilities between populations(3,4), and may contribute to speciation(5). Here I provide evidence for cryptic reproductive divergence among three sibling species of Drosophila that leads to a form of postmating isolation. When a female mates with both a conspecific and a heterospecific male, the conspecific sperm fertilize the vast majority of the eggs, regardless of the order of the matings. Heterospecific sperm fertilize fewer eggs after these double matings than after single matings. Experiments using spermless males show that the seminal fluid of the conspecific male is largely responsible for this conspecific sperm precedence. Moreover, when two males of the same species mate sequentially with a female from a different species, a highly variable pattern of sperm precedence replaces the second-male sperm precedence that is consistently found within species. These results indicate that females mediate sperm competition, and that second-male sperm precedence is not an automatic consequence of the mechanics of sperm storage.			Price, CSC (corresponding author), UNIV CHICAGO,DEPT ECOL & EVOLUT,1101 E 57TH ST,CHICAGO,IL 60637, USA.							[Anonymous], [No title captured]; BELLA JL, 1992, HEREDITY, V68, P345, DOI 10.1038/hdy.1992.49; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; CLARK AG, 1995, GENETICS, V139, P189; COYNE JA, 1993, EVOLUTION, V47, P778, DOI 10.1111/j.1558-5646.1993.tb01233.x; DAVID J, 1974, ANN GENET-PARIS, V17, P235; Eberhard W. G., 1996, FEMALE CONTROL SEXUA; Fisher R. A., 1930, GENETICAL THEORY NAT, DOI 10.5962/bhl.title.27468; GREGORY PG, 1997, EVOLUTION, V48, P705; GROMKO MH, 1964, SPERM COMPETITION EV, P371; HARSHMAN LG, 1994, EVOLUTION, V48, P758, DOI [10.2307/2410484, 10.1111/j.1558-5646.1994.tb01359.x]; HERNDON LA, 1995, P NATL ACAD SCI USA, V92, P10114, DOI 10.1073/pnas.92.22.10114; HEWITT GM, 1989, HEREDITY, V62, P343, DOI 10.1038/hdy.1989.49; Hughes KA, 1997, GENETICS, V145, P139; INGMANBAKER J, 1980, BIOCHEM GENET, V18, P809, DOI 10.1007/BF00484595; LEE Y, 1992, BIOL BULL, V182, P97, DOI 10.2307/1542183; PALUMBI SR, 1991, MOL BIOL EVOL, V8, P227; PARKER GA, 1970, BIOL REV, V45, P525, DOI 10.1111/j.1469-185X.1970.tb01176.x; PYLE DW, 1978, EXPERIENTIA, V34, P449, DOI 10.1007/BF01935920; RICE WR, 1993, EVOLUTION, V47, P1637, DOI 10.1111/j.1558-5646.1993.tb01257.x; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; WADE MJ, 1994, HEREDITY, V72, P163, DOI 10.1038/hdy.1994.23	22	161	163	0	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					663	666		10.1038/41753	http://dx.doi.org/10.1038/41753			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262398	Bronze			2022-12-24	WOS:A1997XQ86300046
J	Shadmehr, R; Holcomb, HH				Shadmehr, R; Holcomb, HH			Neural correlates of motor memory consolidation	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; INITIATED HAND MOVEMENTS; PREMOTOR CORTEX; FUNCTIONAL-ANATOMY; NEURONAL-ACTIVITY; ELBOW MOVEMENTS; BLOOD-FLOW; CEREBELLUM; MONKEY; MODEL	Computational studies suggest that acquisition of a motor skill involves learning an internal model of the dynamics of the task, which enables the brain to predict and compensate for mechanical behavior. During the hours that follow completion of practice, representation of the internal model gradually changes, becoming less fragile with respect to behavioral interference. Here, functional imaging of the brain demonstrates that within 6 hours after completion of practice, while performance remains unchanged, the brain engages new regions to perform the task; there is a shift from prefrontal regions of the cortex to the premotor, posterior parietal, and cerebellar cortex structures. This shift is specific to recall of an established motor skill and suggests that with the passage of time, there is a change in the neural representation of the internal model and that this change may underlie its increased functional stability.	UNIV MARYLAND,MARYLAND PSYCHIAT RES CTR,BALTIMORE,MD 21228; JOHNS HOPKINS UNIV,DEPT RADIOL,BALTIMORE,MD	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University	Shadmehr, R (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOMED ENGN,720 RUTLAND AVE,419 TRAYLOR,BALTIMORE,MD 21205, USA.							AIZAWA H, 1991, EXP BRAIN RES, V84, P668; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; ALVAREZ P, 1994, P NATL ACAD SCI USA, V91, P7041, DOI 10.1073/pnas.91.15.7041; [Anonymous], 1993, BRAIN ACTIVATION; Bastian AJ, 1996, J NEUROPHYSIOL, V76, P492, DOI 10.1152/jn.1996.76.1.492; BOUSSAOUD D, 1993, EXP BRAIN RES, V95, P28; BrashersKrug T, 1996, NATURE, V382, P252, DOI 10.1038/382252a0; Brindley, 1964, INT BRAIN RES ORG B, V3, P80; Carelli RM, 1997, J NEUROSCI, V17, P1804; CHEN YC, 1995, EXP BRAIN RES, V102, P461; Clower DM, 1996, NATURE, V383, P618, DOI 10.1038/383618a0; CONRAD B, 1974, BRAIN RES, V71, P507, DOI 10.1016/0006-8993(74)90994-9; DETTMERS C, 1995, J NEUROPHYSIOL, V74, P802, DOI 10.1152/jn.1995.74.2.802; Flanagan JR, 1997, J NEUROSCI, V17, P1519; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; FRISTON KJ, 1993, P ROY SOC B-BIOL SCI, V254, P47, DOI 10.1098/rspb.1993.0125; FRISTON KJ, 1992, P ROY SOC B-BIOL SCI, V248, P223, DOI 10.1098/rspb.1992.0065; Fuster JM, 1995, MEMORY CEREBRAL CORT; GERMAIN L, 1993, BRAIN RES, V611, P175, DOI 10.1016/0006-8993(93)91792-Q; GHEZ C, 1995, CAN J PHYSIOL PHARM, V73, P273, DOI 10.1139/y95-038; GoldmanRakic PS, 1996, P NATL ACAD SCI USA, V93, P13473, DOI 10.1073/pnas.93.24.13473; Goodkin H. P., 1993, Canadian Journal of Neurological Sciences, V20, pS93; GORDON AM, 1993, J NEUROPHYSIOL, V69, P1789, DOI 10.1152/jn.1993.69.6.1789; GOTTLIEB GL, 1994, EXP BRAIN RES, V97, P545; Grafton S T, 1994, Hum Brain Mapp, V1, P221, DOI 10.1002/hbm.460010307; GRAFTON ST, 1992, J NEUROSCI, V12, P2542; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; HALSBAND U, 1990, BRAIN, V113, P207, DOI 10.1093/brain/113.1.207; HOUK JC, 1995, CEREB CORTEX, V5, P95, DOI 10.1093/cercor/5.2.95; HRELJAC A, 1993, BIOL CYBERN, V68, P375, DOI 10.1007/BF00201862; ITO M, 1972, BRAIN RES, V40, P80; JENKINS IH, 1994, J NEUROSCI, V14, P3775; Johnson PB, 1996, CEREB CORTEX, V6, P102, DOI 10.1093/cercor/6.2.102; Jueptner M, 1997, J NEUROPHYSIOL, V77, P1313, DOI 10.1152/jn.1997.77.3.1313; KADEKARO M, 1985, P NATL ACAD SCI USA, V82, P6010, DOI 10.1073/pnas.82.17.6010; KARNI A, 1995, NATURE, V377, P155; KAWASHIMA R, 1995, CEREB CORTEX, V5, P111, DOI 10.1093/cercor/5.2.111; KAWATO M, 1992, BIOL CYBERN, V68, P95, DOI 10.1007/BF00201431; KAWATO M, 1988, BIOL CYBERN, V59, P161, DOI 10.1007/BF00318008; KIM JJ, 1995, BEHAV NEUROSCI, V109, P195, DOI 10.1037/0735-7044.109.2.195; Kleim JA, 1997, J NEUROSCI, V17, P717; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; LACKNER JR, 1994, J NEUROPHYSIOL, V72, P299, DOI 10.1152/jn.1994.72.1.299; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MATA M, 1980, J NEUROCHEM, V34, P213, DOI 10.1111/j.1471-4159.1980.tb04643.x; MILNER TE, 1993, EXP BRAIN RES, V94, P522; MITZ AR, 1991, J NEUROSCI, V11, P1855; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; OJAKANGAS CL, 1992, J NEUROPHYSIOL, V68, P2222, DOI 10.1152/jn.1992.68.6.2222; PASCUALLEONE A, 1994, SCIENCE, V263, P1287, DOI 10.1126/science.8122113; PascualLeone A, 1996, EXP BRAIN RES, V107, P479; PASSINGHAM RE, 1988, EXP BRAIN RES, V70, P590; PASSINGHAM RE, 1989, BRAIN BEHAV EVOLUT, V33, P189, DOI 10.1159/000115927; PAVLIDES C, 1993, J NEUROPHYSIOL, V70, P733, DOI 10.1152/jn.1993.70.2.733; POIZNER H, 1995, BRAIN, V118, P227, DOI 10.1093/brain/118.1.227; QUINTANA J, 1992, NEUROREPORT, V3, P721, DOI 10.1097/00001756-199208000-00018; RAICHLE ME, 1983, J NUCL MED, V24, P790; Raymond JL, 1996, SCIENCE, V272, P1126, DOI 10.1126/science.272.5265.1126; SASAKI K, 1982, EXP BRAIN RES, V48, P429; SASAKI K, 1986, BRAIN RES, V374, P278, DOI 10.1016/0006-8993(86)90422-1; SCHLAUG G, 1994, EXP BRAIN RES, V98, P523; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; Seitz R J, 1990, Neuroreport, V1, P57, DOI 10.1097/00001756-199009000-00016; SEITZ RJ, 1994, NEUROREPORT, V5, P2541, DOI 10.1097/00001756-199412000-00034; SEITZ RJ, 1992, EUR J NEUROSCI, V4, P154, DOI 10.1111/j.1460-9568.1992.tb00862.x; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; Shadmehr R, 1997, J NEUROSCI, V17, P409, DOI 10.1523/JNEUROSCI.17-01-00409.1997; SHADMEHR R, IN PRESS NEUROMECHAN; SHIDARA M, 1993, NATURE, V365, P50, DOI 10.1038/365050a0; SHINDY WW, 1994, CEREB CORTEX, V4, P443, DOI 10.1093/cercor/4.4.443; Sirigu A, 1996, SCIENCE, V273, P1564, DOI 10.1126/science.273.5281.1564; Tanne J, 1995, NEUROREPORT, V7, P267, DOI 10.1097/00001756-199512000-00064; Thach W. T., 1996, Behavioral and Brain Sciences, V19, P411; VILIS T, 1980, J NEUROPHYSIOL, V43, P279, DOI 10.1152/jn.1980.43.2.279; Wise SP, 1996, ACQUISITION OF MOTOR BEHAVIOR IN VERTEBRATES, P261; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931; WOODS RP, 1992, J COMPUT ASSIST TOMO, V115, P665; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	78	730	738	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					821	825		10.1126/science.277.5327.821	http://dx.doi.org/10.1126/science.277.5327.821			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242612				2022-12-24	WOS:A1997XQ24700045
J	Shen, CP; Jan, LY; Jan, YN				Shen, CP; Jan, LY; Jan, YN			Miranda is required for the asymmetric localization of Prospero during mitosis in Drosophila	CELL			English	Article							C-ELEGANS EMBRYOS; PREDICTING COILED COILS; CAENORHABDITIS-ELEGANS; 2-HYBRID SYSTEM; CELL-DIVISION; GENE; PROTEIN; NUMB; SEGREGATION; FATES	Asymmetric division of Drosophila neuroblasts, sensory organ precursor cells, and cells in the procephalic neurogenic region involves the segregation of Numb and Prospero proteins into one of the two daughter cells. We have isolated a novel gene, miranda, based on the ability of its gene product to interact with the Prospero asymmetric localization domain. miranda expression coincides spatially and temporally with asymmetric cell divisions and asymmetric localization of Prospero. Miranda protein is localized asymmetrically, along with Prospero, to the basal cell membrane during mitosis. Loss of miranda gene function abolishes asymmetric Prospero localization during mitosis. The asymmetric localization of Miranda protein requires inscuteable. Our results suggest that miranda functions downstream of inscuteable and works as an adapter that connects Prospero to the basal cell membrane during asymmetric cell division.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Shen, CP (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BARTEL PL, 1993, USING 2 HYBRID SYSTE; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; LEVITAN DJ, 1994, P NATL ACAD SCI USA, V91, P6108, DOI 10.1073/pnas.91.13.6108; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)90126-7; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; RHYU MS, 1995, CELL, V82, P523, DOI 10.1016/0092-8674(95)90022-5; Shapiro L, 1997, SCIENCE, V276, P712, DOI 10.1126/science.276.5313.712; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STAUGER C, 1993, CURR OPIN CELL BIOL, V5, P226; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P942; Yamano H, 1996, EMBO J, V15, P5268, DOI 10.1002/j.1460-2075.1996.tb00912.x; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	40	230	235	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					449	458		10.1016/S0092-8674(00)80505-X	http://dx.doi.org/10.1016/S0092-8674(00)80505-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267025	Bronze			2022-12-24	WOS:A1997XQ06300009
J	Tomb, JF; White, O; Kerlavage, AR; Clayton, RA; Sutton, GG; Fleischmann, RD; Ketchum, KA; Klenk, HP; Gill, S; Dougherty, BA; Nelson, K; Quackenbush, J; Zhou, LX; Kirkness, EF; Peterson, S; Loftus, B; Richardson, D; Dodson, R; Khalak, HG; Glodek, A; McKenney, K; Fitzegerald, LM; Lee, N; Adams, MD; Hickey, EK; Berg, DE; Gocayne, JD; Utterback, TR; Peterson, JD; Kelley, JM; Cotton, MD; Weldman, JM; Fujii, C; Bowman, C; Watthey, L; Wallin, E; Hayes, WS; Weidman, JM; Fujii, C; Borodovsky, M; Karp, PD; Smith, HO; Fraser, CM; Venter, JC				Tomb, JF; White, O; Kerlavage, AR; Clayton, RA; Sutton, GG; Fleischmann, RD; Ketchum, KA; Klenk, HP; Gill, S; Dougherty, BA; Nelson, K; Quackenbush, J; Zhou, LX; Kirkness, EF; Peterson, S; Loftus, B; Richardson, D; Dodson, R; Khalak, HG; Glodek, A; McKenney, K; Fitzegerald, LM; Lee, N; Adams, MD; Hickey, EK; Berg, DE; Gocayne, JD; Utterback, TR; Peterson, JD; Kelley, JM; Cotton, MD; Weldman, JM; Fujii, C; Bowman, C; Watthey, L; Wallin, E; Hayes, WS; Weidman, JM; Fujii, C; Borodovsky, M; Karp, PD; Smith, HO; Fraser, CM; Venter, JC			The complete genome sequence of the gastric pathogen Helicobacter pylori	NATURE			English	Article							MYCOPLASMA-GENITALIUM; GENE; PROTEIN; IDENTIFICATION; EPITHELIUM; INFECTION; MUTATION	Helicobacter pylori, strain 26695, has a circular genome of 1,667,867 base pairs and 1,590 predicted coding sequences, Sequence analysis indicates that H. pylori has well-developed systems for motility, for scavenging iron, and for DNA restriction and modification, Many putative adhesins, lipoproteins and other outer membrane proteins were identified, underscoring the potential complexity of host-pathogen interaction, Based on the large number of sequence-related genes encoding outer membrane proteins and the presence of homopolymeric tracts and dinucleotide repeats in coding sequences, H. pylori, like several other mucosal pathogens, probably uses recombination and slipped-strand mispairing within repeats as mechanisms for antigenic variation and adaptive evolution, Consistent with its restricted niche, H. pylori has a few regulatory networks, and a limited metabolic repertoire and biosynthetic capacity, Its survival in acid conditions depends, in part, on its ability to establish a positive inside-membrane potential in low pH.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL,ST LOUIS,MO 63110; UNIV STOCKHOLM,ARRHENIUS LAB,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN; GEORGIA TECH RES INST,SCH BIOL,ATLANTA,GA 30332; SRI INT,CTR ARTIFICIAL INTELLIGENCE,MENLO PK,CA 94025; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205	Washington University (WUSTL); Stockholm University; University System of Georgia; Georgia Institute of Technology; SRI International; Johns Hopkins University	Tomb, JF (corresponding author), INST GENOM RES,9712 MED CTR DR,ROCKVILLE,MD 20850, USA.		; Karp, Peter/C-3514-2012	loftus, brendan/0000-0001-8871-8356; Fraser, Claire/0000-0003-1462-2428; Kerlavage, Anthony/0000-0002-3954-9653; Quackenbush, John/0000-0002-2702-5879; Karp, Peter/0000-0002-5876-6418				Akopyants Natalia S., 1996, Gut, V39, pA67; AKOPYANTS NS, 1995, INFECT IMMUN, V63, P116, DOI 10.1128/IAI.63.1.116-121.1995; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; BAKER PJ, 1994, INFECT IMMUN, V62, P2257, DOI 10.1128/IAI.62.6.2257-2269.1994; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; BORODOVSKY M, 1994, NUCLEIC ACIDS RES, V22, P4756, DOI 10.1093/nar/22.22.4756; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CLEMENS J, 1995, J INFECT DIS, V171, P1653, DOI 10.1093/infdis/171.6.1653; Cover TL, 1996, ADV INTERNAL MED, V41, P85; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; DOIG P, 1995, J BACTERIOL, V177, P5447, DOI 10.1128/jb.177.19.5447-5452.1995; EARHART CF, 1996, CELLULAR MOL BIOL, P1075; EVANS DJ, 1995, GENE, V153, P123, DOI 10.1016/0378-1119(94)00774-M; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FRAZIER BA, 1993, J BACTERIOL, V175, P966, DOI 10.1128/JB.175.4.966-972.1993; FUCHS R, 1991, COMPUT APPL BIOSCI, V7, P105; GO MF, 1994, J GASTROENTROL HEP S, V9, P8; HUGHES NJ, 1995, J BACTERIOL, V177, P3953, DOI 10.1128/jb.177.14.3953-3959.1995; Ilver D., 1996, Gut, V39, pA55; Jones A. C., 1996, Gut, V39, pA62; JONSSON AB, 1991, EMBO J, V10, P477, DOI 10.1002/j.1460-2075.1991.tb07970.x; Karp PD, 1997, NUCLEIC ACIDS RES, V25, P43, DOI 10.1093/nar/25.1.43; KORNBERG A, 1992, REPLICATION MECH OPE, P471; Labigne A, 1996, INFECT AGENT DIS, V5, P191; LINN S, 1996, CELLULAR MOL BIOL, P764; MACNAB RM, 1996, CELLULAR MOL BIOL, P123; MARCZYNSKI GT, 1993, CURR OPIN GENET DEV, V3, P775, DOI 10.1016/S0959-437X(05)80098-X; Matin A, 1996, INFECT IMMUN, V64, P1434, DOI 10.1128/IAI.64.4.1434-1436.1996; McGowan CC, 1996, GASTROENTEROLOGY, V110, P926, DOI 10.1053/gast.1996.v110.pm8608904; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; Melchers K., 1996, Gut, V39, pA67; MENDZ GL, 1995, INT J BIOCHEM CELL B, V27, P1085, DOI 10.1016/1357-2725(95)00069-2; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; Moran AP, 1996, ALIMENT PHARM THER, V10, P39, DOI 10.1046/j.1365-2036.1996.22164004.x; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Odenbreit S, 1996, MOL MICROBIOL, V20, P361, DOI 10.1111/j.1365-2958.1996.tb02623.x; Peek R. M., 1996, Gut, V39, pA71; PETERSON SN, 1995, P NATL ACAD SCI USA, V92, P11829, DOI 10.1073/pnas.92.25.11829; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SONNHAMMER ELL, IN PRESS PROTEINS; STROM MS, 1994, METHOD ENZYMOL, V235, P527; SUERBAUM S, 1995, TRENDS MICROBIOL, V3, P168, DOI 10.1016/S0966-842X(00)88913-1; Tummuru MKR, 1995, MOL MICROBIOL, V18, P867, DOI 10.1111/j.1365-2958.1995.18050867.x; WARREN JR, 1983, LANCET, V1, P1273; Winans SC, 1996, TRENDS MICROBIOL, V4, P64, DOI 10.1016/0966-842X(96)81513-7	50	2874	3665	6	195	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					539	547		10.1038/41483	http://dx.doi.org/10.1038/41483			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252185	Bronze			2022-12-24	WOS:A1997XP72200038
J	Torok, TJ; Tauxe, RV; Wise, RP; Livengood, JR; Sokolow, R; Mauvais, S; Birkness, KA; Skeels, MR; Horan, JM; Foster, LR				Torok, TJ; Tauxe, RV; Wise, RP; Livengood, JR; Sokolow, R; Mauvais, S; Birkness, KA; Skeels, MR; Horan, JM; Foster, LR			A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-This large outbreak of foodborne disease highlights the challenge of investigating outbreaks caused by intentional contamination and demonstrates the vulnerability of self-service foods to intentional contamination. Objective.-To investigate a large community outbreak of Salmonella Typhimurium infections. Design.-Epidemiologic investigation of patients with Salmonella gastroenteritis and possible exposures in The Dalles, Oregon. Cohort and case-control investigations were conducted among groups of restaurant patrons and employees to identify exposures associated with illness. Setting.-A community in Oregon. Outbreak period was September and October 1984. Patients.-A total of 751 persons with Salmonella gastroenteritis associated with eating or working at area restaurants. Most patients were identified through passive surveillance; active surveillance was conducted for selected groups. A case was defined either by clinical criteria or by a stool culture yielding S Typhimurium. Results.-The outbreak occurred in 2 waves, September 9 through 18 and September 19 through October 10. Most cases were associated with 10 restaurants, and epidemiologic studies of customers at 4 restaurants and of employees at all 10 restaurants implicated eating from salad bars as the major risk factor for infection. Eight (80%) of 10 affected restaurants compared with only 3 (11%) of the 28 other restaurants in The Dalles operated salad bars (relative risk, 7.5; 95% confidence interval, 2.4-22.7; P<.001). The implicated food items on the salad bars differed from one restaurant to another. The investigation did not identify any water supply, food item, supplier, or distributor common to all affected restaurants, nor were employees exposed to any single common source. In some instances, infected employees may have contributed to the spread of illness by inadvertently contaminating foods. However, no evidence was found linking ill employees to initiation of the outbreak. Errors in food rotation and inadequate refrigeration on ice-chilled salad bars may have facilitated growth of the S Typhimurium but could not have caused the outbreak. A subsequent criminal investigation revealed that members of a religious commune had deliberately contaminated the salad bars. An S Typhimurium strain found in a laboratory at the commune was indistinguishable from the outbreak strain. Conclusions.-This outbreak of salmonellosis was caused by intentional contamination of restaurant salad bars by members of a religious commune.	CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333; OREGON HLTH DIV,PORTLAND,OR	Centers for Disease Control & Prevention - USA; Oregon Health & Science University	Torok, TJ (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,MAILSTOP G-17,1600 CLIFTON RD NE,ATLANTA,GA 30333, USA.							BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLASER MJ, 1981, AM J EPIDEMIOL, V114, P663, DOI 10.1093/oxfordjournals.aje.a113237; BUCHWALD DS, 1984, REV INFECT DIS, V6, P345; CALLISTER S, 1985, OREGONIAN       1230, pB1; CALLISTER S, 1985, OREGONIAN          S, P36; DEAN A, 1995, EPI INFO VERSION 6 W; FITZGERALD F, 1986, CITIES HILL; JOSEPH PR, 1965, NEW ENGL J MED, V273, P188, DOI 10.1056/NEJM196507222730403; Kaplan David E., 1996, CULT END WORLD; LAATZ J, 1986, OREGONIAN       0320, pE6; LAATZ J, 1986, OREGONIAN       0320, pA1; LAATZ J, 1986, OREGONIAN       0723, pB2; MACDONALD KL, 1987, JAMA-J AM MED ASSOC, V258, P1496, DOI 10.1001/jama.258.11.1496; MANIATIS T, 1982, MOL CLONING LABORATO, P150; MARTIN WJ, 1980, MANUAL CLIN MICROBIO, P207; PETHER JVS, 1982, J INFECTION, V5, P81, DOI 10.1016/S0163-4453(82)93365-5; PHILLS JA, 1972, NEW ENGL J MED, V286, P965, DOI 10.1056/NEJM197205042861802; RILEY LW, 1984, J INFECT DIS, V149, P878, DOI 10.1093/infdis/149.6.878; ROBERTS D, 1982, J HYG-CAMBRIDGE, V89, P491, DOI 10.1017/S0022172400071059; RUBENSTEIN AD, 1953, NEW ENGL J MED, V248, P527, DOI 10.1056/NEJM195303262481301	20	369	384	2	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					389	395		10.1001/jama.278.5.389	http://dx.doi.org/10.1001/jama.278.5.389			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244330				2022-12-24	WOS:A1997XN51800030
J	Vogel, P; Fritz, DL; Kuehl, K; Davis, KJ; Geisbert, T				Vogel, P; Fritz, DL; Kuehl, K; Davis, KJ; Geisbert, T			The agents of biological warfare	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Vogel, P (corresponding author), USA,MIL RES INST INFECT DIS,DIV PATHOL,1425 PORTER ST,FT DETRICK,MD 21702, USA.		Vogel, Peter/N-2490-2018	Vogel, Peter/0000-0002-7535-0545					0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					438	439		10.1001/jama.278.5.438	http://dx.doi.org/10.1001/jama.278.5.438			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244340				2022-12-24	WOS:A1997XN51800040
J	DeLaet, CEDH; vanHout, LB; Burger, H; Hofman, A; Pols, HAP				DeLaet, CEDH; vanHout, LB; Burger, H; Hofman, A; Pols, HAP			Bone density and risk of hip fracture in men and women: Cross sectional analysis	BRITISH MEDICAL JOURNAL			English	Article							MINERAL DENSITY; ELDERLY MEN; OSTEOPOROSIS; EPIDEMIOLOGY; PREDICTION; MASS; AGE	Objective: To determine the relative contribution of decline in bone density to the increase in risk of hip fracture with age in men and women. Design: Incidence data of hip fracture from the general population were combined with the bone density distribution in a sample from the same population and with a risk estimate of low bone density known fi om literature. Setting: The Netherlands. Subjects: All people with a hospital admission for a hip fracture in 1993, and bone density measured in a sample of 5814 men and women aged 55 years and over in a district of Rotterdam. Main outcome measure: One year cumulative risk of hip fracture by age, sex, and bone density measured at the femoral neck. Results: A quarter of all hip fractures occurred in men. Men reached the same incidence as women at five years older. Controlled for age, the risk of hip fracture by bone density was similar in men and women. The risk of hip fracture increased 13-fold from age 60 to 80; decrease in bone density associated with age contributed 1.9 (95% confidence interval 1.5 to 2.4) in women and 1.6 (1.3 to 1.8) in men. Conclusions: The risk of hip fracture by age and bone density is similar in men and women. The decrease in bone density associated with age makes a limited contribution to the exponential increase of the risk of hip fracture with age.	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT INTERNAL MED 3,NL-3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,NL-3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,INST MED TECHNOL ASSESSMENT,NL-3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam				De Laet, Chris/0000-0002-1951-2079				BLACK DM, 1992, J BONE MINER RES, V7, P639; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BOEREBOOM FTJ, 1992, OSTEOPOROSIS INT, V2, P279, DOI 10.1007/BF01623183; *CENTR BUR STAT, 1994, STAT JB 1994; *CONS DEV C, 1993, AM J MED, V94, P646; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; HANNAN MT, 1992, J BONE MINER RES, V7, P547; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; JONES G, 1994, OSTEOPOROSIS INT, V4, P277, DOI 10.1007/BF01623352; Kanis JA, 1996, OSTEOPOROSIS INT, V6, P256, DOI 10.1007/BF01622743; KANIS JA, 1996, BONE S3, V18, P127; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; MELTON LJ, 1993, BONE, V14, pS1; NEVITT MC, 1994, OSTEOPOROSIS INT, V4, P325, DOI 10.1007/BF01622192; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; Nguyen TV, 1996, AM J EPIDEMIOL, V144, P255, DOI 10.1093/oxfordjournals.aje.a008920; PEARSON J, 1995, OSTEOPOROSIS INT, V5, P174, DOI 10.1007/BF02106097; *SPSS, 1995, STAT PACK SOC SCI RE; STEIGER P, 1992, J BONE MINER RES, V7, P625; TOSS G, 1992, J INTERN MED, V231, P181, DOI 10.1111/j.1365-2796.1992.tb00521.x; VANBURGER H, 1994, BONE MINER, V25, P1	24	255	257	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 26	1997	315	7102					221	225		10.1136/bmj.315.7102.221	http://dx.doi.org/10.1136/bmj.315.7102.221			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN517	9253270	Green Published			2022-12-24	WOS:A1997XN51700024
J	Mesecar, AD; Stoddard, BL; Koshland, DE				Mesecar, AD; Stoddard, BL; Koshland, DE			Orbital steering in the catalytic power of enzymes: Small structural changes with large catalytic consequences	SCIENCE			English	Article							DEPENDENT ISOCITRATE DEHYDROGENASE; NICOTINAMIDE ADENINE-DINUCLEOTIDE; LIVER DIHYDROFOLATE-REDUCTASE; HYDRIDE-DONATION REACTION; TRANSITION-STATE; PIG-HEART; CRYSTAL-STRUCTURES; SUBSTRATE BINDING; GLUTATHIONE-REDUCTASE; STO-3G CALCULATIONS	Small structural perturbations in the enzyme isocitrate dehydrogenase (IDH) were made in order to evaluate the contribution of precise substrate alignment to the catalytic power of an enzyme. The reaction trajectory of IDH was modified (i) after the adenine moiety of nicotinamide adenine dinucleotide phosphate was changed to hypoxanthine (the 6-amino was changed to 6-hydroxyl), and (ii) by replacing Mg2+, which has six coordinating ligands, with Ca2+, which has eight coordinating ligands. Both changes make large (10(-3) to 10(-5)) changes in the reaction velocity but only small changes in the orientation of the substrates (both distance and angle) as revealed by cryocrystallographic trapping of active IDH complexes. The results provide evidence that orbital overlap produced by optimal orientation of reacting orbitals plays a major quantitative role in the catalytic power of enzymes.	LAWRENCE BERKELEY NATL LAB,CTR ADV MAT,BERKELEY,CA; FRED HUTCHINSON CANC RES CTR,PROGRAM STRUCT BIOL,DIV BASIC SCI,SEATTLE,WA 98104	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Fred Hutchinson Cancer Center	Mesecar, AD (corresponding author), UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.			Mesecar, Andrew/0000-0002-1241-2577	NIGMS NIH HHS [GM49857] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049857] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMARSSON O, 1993, J AM CHEM SOC, V115, P2125, DOI 10.1021/ja00059a005; BAJORATH J, 1989, NATURE, V337, P481, DOI 10.1038/337481a0; BARTUNIK HD, 1992, PHILOS T ROY SOC A, V340, P209, DOI 10.1098/rsta.1992.0061; Bodor N., 1990, THEOCHEM, V65, P315, DOI 10.1016/0166-1280(90)85146-E; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; BROWN KA, 1992, FARADAY DISCUSS, V93, P217, DOI 10.1039/fd9929300217; BRUICE TC, 1960, J AM CHEM SOC, V82, P5858, DOI 10.1021/ja01507a023; BRUICE TC, 1976, ANNU REV BIOCHEM, V45, P331, DOI 10.1146/annurev.bi.45.070176.001555; BRUNGER AT, 1992, X PLOR VERSION 3 1; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; CHRISTIANSON DW, 1986, P NATL ACAD SCI USA, V83, P7568, DOI 10.1073/pnas.83.20.7568; COLMAN RF, 1972, J BIOL CHEM, V247, P215; CUMMINS PL, 1990, J COMPUT CHEM, V11, P791, DOI 10.1002/jcc.540110703; DAFFORN A, 1971, P NATL ACAD SCI USA, V68, P2463, DOI 10.1073/pnas.68.10.2463; DEAN AM, 1993, BIOCHEMISTRY-US, V32, P9302, DOI 10.1021/bi00087a007; DING XC, 1994, BIOCHEMISTRY-US, V33, P9285, DOI 10.1021/bi00197a032; DONKERSLOOT MCA, 1981, J AM CHEM SOC, V103, P6549, DOI 10.1021/ja00412a002; DONKERSLOOT MCA, 1981, J AM CHEM SOC, V103, P6554, DOI 10.1021/ja00412a003; EHRLICH RS, 1989, BIOCHEMISTRY-US, V28, P2058, DOI 10.1021/bi00431a014; EHRLICH RS, 1995, BBA-PROTEIN STRUCT M, V1246, P135, DOI 10.1016/0167-4838(94)00192-J; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; GROS P, 1992, PROTEINS, V12, P63, DOI 10.1002/prot.340120108; Hackney D. D., 1990, ENZYMES, P1; HALL MD, 1993, J MOL BIOL, V232, P213, DOI 10.1006/jmbi.1993.1377; HARRISON DH, 1994, BIOCHEMISTRY-US, V33, P2011, DOI 10.1021/bi00174a006; HUHTA DW, 1992, ACTA CHEM SCAND, P778; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KATI WM, 1992, BIOCHEMISTRY-US, V31, P7356, DOI 10.1021/bi00147a021; KOSHLAND DE, 1968, ANNU REV BIOCHEM, V37, P359, DOI 10.1146/annurev.bi.37.070168.002043; KOSHLAND DE, 1962, J THEOR BIOL, V2, P75, DOI 10.1016/0022-5193(62)90037-1; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MCTIGUE MA, 1992, BIOCHEMISTRY-US, V31, P7264, DOI 10.1021/bi00147a009; MCTIGUE MA, 1993, BIOCHEMISTRY-US, V32, P6855, DOI 10.1021/bi00078a008; MENGER FM, 1985, ACCOUNTS CHEM RES, V18, P128, DOI 10.1021/ar00113a001; MENGER FM, 1993, ACCOUNTS CHEM RES, V26, P206, DOI 10.1021/ar00028a011; NAVEZA J, 1994, ACTA CRYSTALLOGR A, V50, P157; NORTHROP DB, 1974, J BIOL CHEM, V249, P2928; OTWINOWSKI Z, P CCP4 STUD WEEK DAT; PAGE MI, 1972, J AM CHEM SOC, V94, P8828, DOI 10.1021/ja00780a031; Perutz M. F., 1990, MECH COOPERATIVITY; RAMASWAMY S, 1994, BIOCHEMISTRY-US, V33, P5230, DOI 10.1021/bi00183a028; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SCHREINER S, 1976, J AM CHEM SOC, V98, P4770; SHERROD MJ, 1989, J AM CHEM SOC, V111, P2611, DOI 10.1021/ja00189a040; SHERROD MJ, 1990, TETRAHEDRON LETT, V31, P459, DOI 10.1016/0040-4039(90)87007-M; Stoddard BL, 1996, NAT STRUCT BIOL, V3, P590, DOI 10.1038/nsb0796-590; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9317, DOI 10.1021/bi00087a009; STORM DR, 1970, P NATL ACAD SCI USA, V66, P445, DOI 10.1073/pnas.66.2.445; Stryer L., 1988, BIOCHEMISTRY-US, P375; SUSTMANN R, 1989, ANGEW CHEM INT EDIT, V28, P1023, DOI 10.1002/anie.198910231; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; Warshel A, 1991, COMPUTER MODELING CH; WILLIAMS IH, 1990, J AM CHEM SOC, V112, P530, DOI 10.1021/ja00158a009; WU YD, 1991, J AM CHEM SOC, V113, P2353, DOI 10.1021/ja00007a002; WU YD, 1987, J AM CHEM SOC, V109, P2226, DOI 10.1021/ja00241a074	61	198	205	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					202	206		10.1126/science.277.5323.202	http://dx.doi.org/10.1126/science.277.5323.202			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211842				2022-12-24	WOS:A1997XK41800034
J	Kim, KHS; Relkin, NR; Lee, KM; Hirsch, J				Kim, KHS; Relkin, NR; Lee, KM; Hirsch, J			Distinct cortical areas associated with native and second languages	NATURE			English	Article							BRAIN; SPEECH; REPRESENTATION; ORGANIZATION	The ability to acquire and use several languages selectively is a unique and essential human capacity. Here we investigate the fundamental question of how multiple languages are represented in a human brain. We applied functional magnetic resonance imaging (fMRI) to determine the spatial relationship between native and second languages in the human cortex, and show that within the frontal-lobe language-sensitive regions (Broca's area)(1-3), second languages acquired in adulthood ('late' bilingual subjects) are spatially separated from native languages. However, when acquired during the early language acquisition stage of development ('early' bilingual subjects), native and second languages tend to be represented in common frontal cortical areas. In both late and early bilingual subjects, the temporal-lobe language-sensitive regions (Wernicke's area)(1-3) also show effectively little or no separation of activity based on the age of language acquisition. This discovery of language-specific regions in Broca's area advances our understanding of the cortical representation that underlies multiple language functions.	MEM SLOAN KETTERING CANC CTR,DEPT NEUROL,NEW YORK,NY 10021; CORNELL UNIV MED COLL,DEPT NEUROL & NEUROSCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University			Lee, Kyoung Min/J-2775-2012	Hirsch, Joy/0000-0002-1418-6489				BLACK PM, 1987, NEUROSURGERY, V20, P914, DOI 10.1227/00006123-198706000-00016; Damasio H, 1989, LESION ANAL NEUROPSY; DAMASIO H, 1995, HUMAN BRAIN ANATOMY; Demonet J. F., 1993, Human Brain Mapping, V1, P39, DOI 10.1002/hbm.460010105; GESCHWIND N, 1970, SCIENCE, V170, P640; GOMEZTORTOSA E, 1995, BRAIN LANG, V48, P320, DOI 10.1006/brln.1995.1014; HINKE RM, 1993, NEUROREPORT, V4, P675, DOI 10.1097/00001756-199306000-00018; HIRSCH J, 1995, P NATL ACAD SCI USA, V92, P6469, DOI 10.1073/pnas.92.14.6469; HIRSCH J, 1994, P SOC MAG RES, V2, P637; KLEIN D, 1995, P NATL ACAD SCI USA, V92, P2899, DOI 10.1073/pnas.92.7.2899; KRETSCHMANN HJ, 1992, CRANIAL NEUROIMAGING; KUHL PK, 1994, CURR OPIN NEUROBIOL, V4, P812, DOI 10.1016/0959-4388(94)90128-7; Meyer KL, 1996, MAGNET RESON MED, V36, P606, DOI 10.1002/mrm.1910360416; OGAWA S, 1990, MAGNET RESON MED, V14, P68, DOI 10.1002/mrm.1910140108; OJEMANN GA, 1983, BEHAV BRAIN SCI, V6, P189, DOI 10.1017/S0140525X00015491; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PETSCHE H, 1993, ELECTROEN CLIN NEURO, V86, P385, DOI 10.1016/0013-4694(93)90134-H; SCHWARTZ MS, 1994, J NEUROL NEUROSUR PS, V57, P121, DOI 10.1136/jnnp.57.1.121; STEINMETZ H, 1991, NEUROPSYCHOLOGIA, V29, P1149, DOI 10.1016/0028-3932(91)90030-C; Talairach J., 1988, COPLANAR STEREOTAXIC; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; ZATORRE RJ, 1989, BRAIN LANG, V36, P127, DOI 10.1016/0093-934X(89)90056-4; Zatorre RJ, 1996, CEREB CORTEX, V6, P21, DOI 10.1093/cercor/6.1.21	24	642	667	5	158	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					171	174		10.1038/40623	http://dx.doi.org/10.1038/40623			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217156	Bronze			2022-12-24	WOS:A1997XK10900049
J	Lazazzera, BA; Solomon, JM; Grossman, AD				Lazazzera, BA; Solomon, JM; Grossman, AD			An exported peptide functions intracellularly to contribute to cell density signaling in B-subtilis	CELL			English	Article							CONTROL GENE-EXPRESSION; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; TRANSPORT-SYSTEM; STREPTOCOCCUS-PNEUMONIAE; TRANSCRIPTION FACTOR; TRANSDUCTION SYSTEM; SPORULATION; COMPETENCE; COMA	Competence development and sporulation in B. subtilis are partly controlled by peptides that accumulate in culture medium as cells grow to high density. We constructed two genes that encode mature forms of two different signaling molecules, the PhrA peptide that stimulates sporulation, and CSF, the competence- and sporulation-stimulating factor. Both pentapeptides are normally produced by secretion and processing of precursor molecules. The mature pentapeptides were functional when expressed inside the cell, indicating that they normally need to be imported to function. Furthermore, at physiological concentrations (10 nM), CSF was transported into the cell by the oligopeptide permease encoded by spoOK (opp). CSF was shown to have at least three different targets corresponding to its three activities: stimulating competence gene expression at low concentrations, and inhibiting competence gene expression and stimulating sporulation at high concentrations.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050895] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50895] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alloing G, 1996, MOL MICROBIOL, V21, P471; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BERGER EA, 1974, J BIOL CHEM, V249, P7747; CANGELOSI GA, 1990, P NATL ACAD SCI USA, V87, P6708, DOI 10.1073/pnas.87.17.6708; CARTER HL, 1991, GENE, V96, P101; COX GB, 1988, J BACTERIOL, V170, P2283, DOI 10.1128/jb.170.5.2283-2286.1988; DONOVAN W, 1987, J MOL BIOL, V196, P1, DOI 10.1016/0022-2836(87)90506-7; FERRARI FA, 1983, J BACTERIOL, V154, P1513, DOI 10.1128/JB.154.3.1513-1515.1983; Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727; Grossman AD, 1995, ANNU REV GENET, V29, P477, DOI 10.1146/annurev.ge.29.120195.002401; GROSSMAN AD, 1988, GENETICS BIOTECHNOLO, V2, P175; HAGEN DC, 1978, DEV BIOL, V64, P284, DOI 10.1016/0012-1606(78)90079-9; HAHN J, 1994, J BACTERIOL, V176, P5753, DOI 10.1128/JB.176.18.5753-5761.1994; Harwood C. R., 1990, MOL BIOL METHODS BAC; Havarstein LS, 1996, MOL MICROBIOL, V21, P863, DOI 10.1046/j.1365-2958.1996.521416.x; HAVARSTEIN LS, 1995, P NATL ACAD SCI USA, V92, P11140, DOI 10.1073/pnas.92.24.11140; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; Hoch JA, 1995, 2 COMPONENT SIGNAL T; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; JAACKS KJ, 1989, J BACTERIOL, V171, P4121, DOI 10.1128/JB.171.8.4121-4129.1989; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; KOIDE A, 1994, MOL MICROBIOL, V13, P417, DOI 10.1111/j.1365-2958.1994.tb00436.x; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; Leonard BAB, 1996, P NATL ACAD SCI USA, V93, P260, DOI 10.1073/pnas.93.1.260; MAGNUSON R, 1994, CELL, V77, P207, DOI 10.1016/0092-8674(94)90313-1; MANSON MD, 1986, NATURE, V321, P253, DOI 10.1038/321253a0; MATHIOPOULOS C, 1991, MOL MICROBIOL, V5, P1903, DOI 10.1111/j.1365-2958.1991.tb00814.x; Miller J.H., 1972, EXPT MOL GENETICS; MITANI T, 1977, BIOCHEM BIOPH RES CO, V77, P1118, DOI 10.1016/S0006-291X(77)80094-6; MOYE HA, 1979, ANAL LETT, V12, P25; MUELLER JP, 1992, J BACTERIOL, V174, P4361, DOI 10.1128/JB.174.13.4361-4373.1992; MUELLER JP, 1992, J BACTERIOL, V174, P4374, DOI 10.1128/JB.174.13.4374-4383.1992; NAKANO MM, 1989, J BACTERIOL, V171, P5347, DOI 10.1128/jb.171.10.5347-5353.1989; NAKANO MM, 1991, J BACTERIOL, V173, P5487, DOI 10.1128/jb.173.17.5487-5493.1991; NAKANO MM, 1991, J BACTERIOL, V173, P7269, DOI 10.1128/jb.173.22.7269-7274.1991; Nodwell JR, 1996, MOL MICROBIOL, V22, P881, DOI 10.1046/j.1365-2958.1996.01540.x; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PARMES JR, 1973, J BIOL CHEM, V248, P4429; PEARCE BJ, 1994, MOL MICROBIOL, V12, P881, DOI 10.1111/j.1365-2958.1994.tb01076.x; Perego M, 1996, P NATL ACAD SCI USA, V93, P1549, DOI 10.1073/pnas.93.4.1549; Perego M, 1996, MOL MICROBIOL, V19, P1151, DOI 10.1111/j.1365-2958.1996.tb02460.x; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Pestova EV, 1996, MOL MICROBIOL, V21, P853, DOI 10.1046/j.1365-2958.1996.501417.x; ROGGIANI M, 1993, J BACTERIOL, V175, P3182, DOI 10.1128/JB.175.10.3182-3187.1993; RUDNER DZ, 1991, J BACTERIOL, V173, P1388, DOI 10.1128/jb.173.4.1388-1398.1991; SANDMAN K, 1987, GENETICS, V117, P603; SOLOMON JM, 1995, GENE DEV, V9, P547, DOI 10.1101/gad.9.5.547; Solomon JM, 1996, GENE DEV, V10, P2014, DOI 10.1101/gad.10.16.2014; Solomon JM, 1996, TRENDS GENET, V12, P150, DOI 10.1016/0168-9525(96)10014-7; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WANNER BL, 1993, J CELL BIOCHEM, V51, P47, DOI 10.1002/jcb.240510110; WEINRAUCH Y, 1989, J BACTERIOL, V171, P5362, DOI 10.1128/jb.171.10.5362-5375.1989; WEINRAUCH Y, 1990, GENE DEV, V4, P860, DOI 10.1101/gad.4.5.860; YANSURA DG, 1984, P NATL ACAD SCI-BIOL, V81, P439, DOI 10.1073/pnas.81.2.439	59	192	198	1	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					917	925		10.1016/S0092-8674(00)80277-9	http://dx.doi.org/10.1016/S0092-8674(00)80277-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200610	Green Published, Bronze			2022-12-24	WOS:A1997XE35700012
J	Vinos, J; Jalink, K; Hardy, RW; Britt, SG; Zuker, CS				Vinos, J; Jalink, K; Hardy, RW; Britt, SG; Zuker, CS			A G protein-coupled receptor phosphatase required for rhodopsin function	SCIENCE			English	Article							ROD OUTER SEGMENTS; RETINAL-DEGENERATION; IN-VIVO; 48-KDA PROTEIN; PHOSPHODIESTERASE ACTIVATION; DROSOPHILA-MELANOGASTER; PHOTOEXCITED RHODOPSIN; ADRENERGIC-RECEPTOR; VISUAL TRANSDUCTION; PHOTORECEPTOR CELL	Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors are phosphorylated by kinases that mediate agonist-dependent receptor deactivation. Although many receptor kinases have been isolated, the corresponding phosphatases, necessary for restoring the ground state of the receptor, have not been identified. Drosophila RDGC (retinal degeneration C) is a phosphatase required for rhodopsin dephosphorylation in vivo. Loss of RDGC caused severe defects in the termination of the light response as well as extensive light-dependent retinal degeneration. These phenotypes resulted from the hyperphosphorylation of rhodopsin because expression of a truncated rhodopsin lacking the phosphorylation sites restored normal photoreceptor function. These results suggest the existence of a family of receptor phosphatases involved in the regulation of G protein-coupled signaling cascades.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Britt, Steven/GVT-1340-2022	Britt, Steven/0000-0001-7656-7984; Jalink, Kees/0000-0001-7019-3440				BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Fong TM, 1996, CELL SIGNAL, V8, P217; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HARRIS WA, 1977, J GEN PHYSIOL, V69, P261, DOI 10.1085/jgp.69.3.261; HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2; Hurley James B., 1994, Current Opinion in Neurobiology, V4, P481, DOI 10.1016/0959-4388(94)90047-7; KEEN TJ, 1991, GENOMICS, V11, P199, DOI 10.1016/0888-7543(91)90119-Y; KING AJ, 1994, EUR J BIOCHEM, V225, P383, DOI 10.1111/j.1432-1033.1994.00383.x; KUNH H, 1972, FEBS LETT, V20, P1; KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5; Kutuzov MA, 1996, EUR J BIOCHEM, V238, P613, DOI 10.1111/j.1432-1033.1996.0613w.x; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; Langlois G, 1996, P NATL ACAD SCI USA, V93, P4677, DOI 10.1073/pnas.93.10.4677; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEFKOWITZ RJ, 1993, ADV SEC MESS PHOSPH, V28, P1; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; MINKE B, 1986, MOL MECHANISM PHOTOR, P241; Montini E, 1997, HUM MOL GENET, V6, P1137, DOI 10.1093/hmg/6.7.1137; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Pak W.L., 1979, P67; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P415, DOI 10.1021/bi00428a001; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RANGANATHAN RS, UNPUB; RIM J, 1995, BIOCHEMISTRY-US, V34, P11938, DOI 10.1021/bi00037a035; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; SELINGER Z, 1993, BIOCHIM BIOPHYS ACTA, V1179, P283, DOI 10.1016/0167-4889(93)90084-3; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P2106; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; SMITH WC, 1994, J BIOL CHEM, V269, P15407; STEELE F, 1990, NEURON, V4, P883, DOI 10.1016/0896-6273(90)90141-2; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; VINOS J, UNPUB; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; YANG SD, 1988, J BIOL CHEM, V263, P8856; YANG SD, 1991, BIOCHEM BIOPH RES CO, V178, P1306, DOI 10.1016/0006-291X(91)91036-C; ZHAO XY, 1995, BIOPHYS CHEM, V56, P183, DOI 10.1016/0301-4622(95)00031-R; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	54	99	101	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					687	690		10.1126/science.277.5326.687	http://dx.doi.org/10.1126/science.277.5326.687			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235891				2022-12-24	WOS:A1997XN90700041
J	Morgan, D; Maude, GH; Malamba, SS; Okongo, MJ; Wagner, HU; Mulder, DW; Whitworth, JA				Morgan, D; Maude, GH; Malamba, SS; Okongo, MJ; Wagner, HU; Mulder, DW; Whitworth, JA			HIV-1 disease progression and AIDS-defining disorders in rural Uganda	LANCET			English	Article							SUB-SAHARAN AFRICA; STAGING SYSTEM; NATURAL-HISTORY; HOMOSEXUAL MEN; SLIM DISEASE; DRUG-USERS; INFECTION; COHORT; MORTALITY; WOMEN	Background The majority of people infected with HIV-1 live in Africa, yet little is known about the natural history of the disease in that continent. We studied survival times, disease progression, and AIDS-defining disorders, according to the proposed WHO staging system, in a population-based, rural cohort in Uganda. Methods In 1990 we recruited a random sample of people already infected with HIV-1 (as prevalent cases) detected during the initial survey round of a general-population study to form a natural-history cohort. Individuals from the general-population cohort who seroconverted between 1990 and 1995 (incident cases) were also invited to enrol. Participants were seen routinely every 3 months and when they were ill. Findings By the end of 1995, 93 prevalent cases and 86 incident cases had been enrolled. Four patients in the prevalent group were in stage 4 (AIDS) at the initial visit. During the next 5 years, 37 prevalent cases progressed to AIDS. Seven incident cases progressed to AIDS and the cumulative progression to AIDS at 1, 3, and 5 years after seroconversion was 2%, 6%, and 22%, respectively. The cumulative probability of AIDS at 4 years from entering stages 1, 2, and 3 was 11%, 33%, and 58%, respectively. There were 47 deaths among prevalent cases and seven among incident cases during follow-up. The cumulative mortality 4 years after patients entered stages 1, 2, 3, and 4 was 9%, 33%, 56%, and 86%, respectively. The median survival after the onset of AIDS was 9.3 months. Interpretation Our results are important for the setting of priorities and rationalisation of treatment availability in countries with poor resources. We found that progression rates to AIDS are similar to those in developed countries for homosexual cohorts and greater than for cohorts infected by other modes of transmission. However, we have found that the rates of all-cause mortality are much higher and the progression times to death are shorter than in developed countries.	UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	Morgan, D (corresponding author), UGANDA VIRUS RES INST,MED RES COUNCIL PROGRAMME AIDS,POB 49,ENTEBBE,UGANDA.							ANZALA OA, 1995, J INFECT DIS, V171, P686, DOI 10.1093/infdis/171.3.686; AYLWARD RB, 1994, AIDS, V8, P1129, DOI 10.1097/00002030-199408000-00015; BRETTLE RP, 1995, QJM-INT J MED, V88, P479; Brettle RP, 1996, AIDS, V10, P419, DOI 10.1097/00002030-199604000-00011; CARRE N, 1994, AIDS, V8, P797, DOI 10.1097/00002030-199406000-00012; CHEQUER P, 1992, AIDS, V6, P483, DOI 10.1097/00002030-199205000-00007; COLEBUNDERS RL, 1991, AIDS, V5, pS103; Darby SC, 1996, LANCET, V347, P1573, DOI 10.1016/S0140-6736(96)91073-9; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DelAmo J, 1996, INT J STD AIDS, V7, P44, DOI 10.1258/0956462961917041; FLEGG PJ, 1994, J INFECTION, V29, P311, DOI 10.1016/S0163-4453(94)91266-1; Hendriks JCM, 1996, AIDS, V10, P649, DOI 10.1097/00002030-199606000-00011; *HIV AIDS SURV REP, 1996, STD AIDS CONTR PROGR; HU DJ, 1995, J ACQ IMMUN DEF SYND, V10, P374; KAPLAN JE, 1988, JAMA-J AM MED ASSOC, V269, P2694; Kitayaporn D, 1996, J ACQ IMMUN DEF SYND, V11, P77, DOI 10.1097/00042560-199601010-00010; Kumarasamy N, 1995, INT J STD AIDS, V6, P447, DOI 10.1177/095646249500600615; LANGE JMA, 1993, AIDS, V7, P1675, DOI 10.1097/00002030-199312000-00021; LEPRI AC, 1994, BRIT MED J, V309, P1537, DOI 10.1136/bmj.309.6968.1537; LEROY V, 1995, J ACQ IMMUN DEF SYND, V9, P415; LIFSON AR, 1995, ANN INTERN MED, V122, P262, DOI 10.7326/0003-4819-122-4-199502150-00004; Low N, 1996, GENITOURIN MED, V72, P12; LUCAS S, 1989, AIDS, V3, P47, DOI 10.1097/00002030-198903010-00012; LUCAS SB, 1994, BRIT MED J, V308, P1531, DOI 10.1136/bmj.308.6943.1531; MALIN AS, 1995, LANCET, V346, P1258, DOI 10.1016/S0140-6736(95)91862-0; MONTANER JSG, 1992, AIDS, V6, P719, DOI 10.1097/00002030-199207000-00016; Morgan D, 1997, AIDS, V11, P633, DOI 10.1097/00002030-199705000-00011; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; NUNN AJ, 1993, AIDS, V7, P1057, DOI 10.1097/00002030-199308000-00005; OFARRELL N, 1995, GENITOURIN MED, V71, P358; SEELEY J, 1991, AIDS Care, V3, P207, DOI 10.1080/09540129108253064; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; TEMBO G, 1994, AIDS, V8, P1169, DOI 10.1097/00002030-199408000-00021; VEUGELERS PJ, 1994, AM J EPIDEMIOL, V140, P747, DOI 10.1093/oxfordjournals.aje.a117322; WHITMOREOVERTON SE, 1993, AIDS, V7, P415, DOI 10.1097/00002030-199303000-00017; *WHO, 1990, WKLY EPIDEMIOL REC, V65, P221; *WHO, 1994, WHOGPATCOSEP944; 1996, AIDS CARE, V8, P249	38	105	106	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					245	250		10.1016/S0140-6736(97)01474-8	http://dx.doi.org/10.1016/S0140-6736(97)01474-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242801				2022-12-24	WOS:A1997XM86600011
J	Rothman, N; Cantor, KP; Blair, A; Bush, D; Brook, JW; Helzlsouer, K; Zahm, SH; Needham, LL; Pearson, GR; Hoover, RN; Comstock, GW; Strickland, PT				Rothman, N; Cantor, KP; Blair, A; Bush, D; Brook, JW; Helzlsouer, K; Zahm, SH; Needham, LL; Pearson, GR; Hoover, RN; Comstock, GW; Strickland, PT			A nested case-control study of non-Hodgkin lymphoma and serum organochlorine residues	LANCET			English	Article							POLYCHLORINATED-BIPHENYLS; CANCER MORTALITY; DIETARY FACTORS; WORKERS; CONSUMPTION; EXPOSURE	Background The steady worldwide increase in the incidence of non-Hodgkin lymphoma during the past few decades remains mostly unexplained. Several studies suggest that there may be an association between the agricultural use of the organochlorine 1,1,1-trichloro-2,2'bis(p-chlorophenyl)ethane (DDT) and increased. risk of non-Hodgkin lymphoma. We have investigated the association between risk of non-Hodgkin lymphoma and body burden of selected organochlorines in the general population in a nested case-control study. Methods We measured prediagnostic serum concentrations of DDT, its metabolites, and other organochlorines, including polychlorinated biphenyls (PCBs), in 74 cases of non-Hodgkin lymphoma and 147 matched controls identified from a prospective cohort of 25 802 adults, established in 1974 in Washington County, Maryland, USA. We report results for total lipid-corrected serum concentrations of DDT and total PCBs. Findings There was a strong dose-response relation between quartiles of total lipid-corrected serum PCB concentrations and risk of non-Hodgkin lymphoma overall (odds ratios by quartile: 1.0; 1.3 [95% CI 0.5-3.3]; 2-8 [1.1-7.6]); and 4.5 [1.7-12.0]; p for trend=0.0008) and separately in men and in women. There was also evidence suggesting that seropositivity for the Epstein-Barr virus early antigen potentiated the effects of serum PCBs. By contrast, total lipid-corrected serum concentrations of DDT were not associated with risk of non-Hodgkin lymphoma. Interpretation These results should be regarded as hypothesis-generating. Before causal inferences can be made about exposure to PCBs and increased risk of non-Hodgkin lymphoma, our findings require replication and the biological plausibility of the association needs further investigation.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT ENVIRONM HLTH SCI,BALTIMORE,MD; CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,ATLANTA,GA; GEORGETOWN UNIV,SCH MED,WASHINGTON,DC	Johns Hopkins University; Johns Hopkins University; Centers for Disease Control & Prevention - USA; Georgetown University	Rothman, N (corresponding author), NCI,DIV CANC EPIDEMIOL & GENET,BETHESDA,MD 20892, USA.		Zahm, Shelia H/B-5025-2015; Needham, Larry/E-4930-2011		NCI NIH HHS [CA60754] Funding Source: Medline; NHLBI NIH HHS [HL21670] Funding Source: Medline; NIEHS NIH HHS [ES03819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERTAZZI PA, 1987, AM J IND MED, V11, P165, DOI 10.1002/ajim.4700110206; Brock JW, 1996, J ANAL TOXICOL, V20, P528, DOI 10.1093/jat/20.7.528; BROWN DP, 1987, ARCH ENVIRON HEALTH, V42, P333, DOI 10.1080/00039896.1987.9934355; BUSH DM, 1995, THESIS J HOPKINS U S; CANTOR KP, 1992, CANCER RES, V52, P2447; CARTWRIGHT RA, 1992, CANCER RES, V52, pS5441; Chiu BCH, 1996, JAMA-J AM MED ASSOC, V275, P1315, DOI 10.1001/jama.275.17.1315; CUNNINGHAM AS, 1976, LANCET, V2, P1184; DEVESA SS, 1992, CANCER RES, V52, pS5432; Dewailly E, 1996, AM J PUBLIC HEALTH, V86, P1241, DOI 10.2105/AJPH.86.9.1241; DUGGAN RE, 1983, PESTICIDE RESIDUE LE; FRANCESCHI S, 1989, NUTR CANCER, V12, P333, DOI 10.1080/01635588909514034; Hardell L, 1996, INT J ONCOL, V9, P603; HARTGE P, 1992, CANCER RES, V52, pS5566; HOOVER RN, 1992, CANCER RES, V52, pS5477; International Agency for Research on Cancer, 1987, IARC MON EV CARC R S, V7; KREISS K, 1985, ENVIRON HEALTH PERSP, V60, P193, DOI 10.2307/3429961; LUKA J, 1984, J IMMUNOL METHODS, V67, P145, DOI 10.1016/0022-1759(84)90093-0; MUELLER NE, 1992, CANCER RES, V52, pS5479; Nanni O, 1996, OCCUP ENVIRON MED, V53, P652, DOI 10.1136/oem.53.10.652; PHILLIPS DL, 1989, ARCH ENVIRON CON TOX, V18, P495, DOI 10.1007/BF01055015; SILBERHORN EM, 1990, CRIT REV TOXICOL, V20, P439, DOI 10.3109/10408449009029331; SINKS T, 1992, AM J EPIDEMIOL, V136, P389, DOI 10.1093/oxfordjournals.aje.a116511; SVENSSON BG, 1994, INT ARCH OCC ENV HEA, V65, P351, DOI 10.1007/BF00383243; SVENSSON BG, 1995, SCAND J WORK ENV HEA, V21, P106, DOI 10.5271/sjweh.17; TRYPHONAS H, 1994, EXP CLIN IMMUNOGENET, V11, P149; WARD MH, 1994, CANCER CAUSE CONTROL, V5, P422, DOI 10.1007/BF01694756; WEISGLASKUPERUS N, 1995, PEDIATR RES, V38, P404, DOI 10.1203/00006450-199509000-00022; WOODS JS, 1987, J NATL CANCER I, V78, P899; YASSI A, 1994, AM J IND MED, V25, P425, DOI 10.1002/ajim.4700250310; ZAHM SH, 1993, ARCH ENVIRON HEALTH, V48, P353, DOI 10.1080/00039896.1993.9936725; [No title captured]	32	145	151	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					240	244		10.1016/S0140-6736(97)02088-6	http://dx.doi.org/10.1016/S0140-6736(97)02088-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242800	hybrid			2022-12-24	WOS:A1997XM86600010
J	Ono, M; Okada, H; Bolland, S; Yanagi, S; Kurosaki, T; Ravetch, JV				Ono, M; Okada, H; Bolland, S; Yanagi, S; Kurosaki, T; Ravetch, JV			Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling	CELL			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; B-CELL ACTIVATION; CLASS-I MOLECULES; FC-GAMMA-RIIB; LYMPHOCYTES-B; IMMUNOGLOBULIN-SUPERFAMILY; CYTOPLASMIC DOMAIN; NEGATIVE SELECTION; SELF-TOLERANCE; CROSS-LINKING	Two signaling molecules have been implicated in the modulation of immune receptor activation by inhibitory coreceptors: an inositol polyphosphate 5'-phosphatase, SHIP, and a tyrosine phosphatase, SHP-1. To address the necessity, interaction, or redundancy of these signaling molecules, we have generated SHP-1-or SHIP-deficient B cell lines and determined their ability to mediate inhibitory signaling. Two distinct classes of inhibitory responses are defined, mediated by the selective recruitment of SHP-1 or SHIP. The Fc gamma RIIB class of inhibitory signaling is dependent on SHIP and not SHP-1; conversely, the KIR class requires SHP-1 and not SHIP. The consequence of this selective recruitment by inhibitory receptor engagement is seen in BCR-triggered apoptosis. SHP-1-mediated inhibitory signaling blocks apoptosis, while SHIP recruitment attenuates a proapoptotic signal initiated by Fc gamma RIIB.	KANSAI MED UNIV,INST LIVER RES,DEPT MOL GENET,MORIGUCHI,OSAKA 570,JAPAN; KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE,HYOGO 650,JAPAN	Kansai Medical University; Kobe University	Ono, M (corresponding author), ROCKEFELLER UNIV,LAB MOL GENET & IMMUNOL,1230 YORK AVE,NEW YORK,NY 10021, USA.		okada, hidetaka/C-6990-2011; Kurosaki, Tomohiro/D-1306-2009; Ravetch, Jeffrey/Z-1596-2019; Okada, Hidetaka/AAP-7775-2020	Kurosaki, Tomohiro/0000-0002-6352-304X; Ravetch, Jeffrey/0000-0003-2024-9041; 				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; Ashman RF, 1996, J IMMUNOL, V157, P5; Bikah G, 1996, SCIENCE, V274, P1906, DOI 10.1126/science.274.5294.1906; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Blery M, 1997, J BIOL CHEM, V272, P8989; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; CASTELLS MC, 1994, J BIOL CHEM, V269, P8393; CHEN CLH, 1982, J IMMUNOL, V129, P2580; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAndrea A, 1996, J EXP MED, V184, P789, DOI 10.1084/jem.184.2.789; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MINGARI MC, 1995, INT IMMUNOL, V7, P697, DOI 10.1093/intimm/7.4.697; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Olcese L, 1996, J IMMUNOL, V156, P4531; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; PHILLIPS JH, 1995, SCIENCE, V268, P1173; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; PHILLIPS NE, 1983, J IMMUNOL, V130, P602; Ravetch JV, 1997, CURR OPIN IMMUNOL, V9, P121, DOI 10.1016/S0952-7915(97)80168-9; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; VITALE M, 1995, P NATL ACAD SCI USA, V92, P3536, DOI 10.1073/pnas.92.8.3536; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; Yamashita Y, 1996, J EXP MED, V184, P113, DOI 10.1084/jem.184.1.113; YI TL, 1992, GENOMICS, V14, P793, DOI 10.1016/S0888-7543(05)80189-2	59	422	440	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					293	301		10.1016/S0092-8674(00)80337-2	http://dx.doi.org/10.1016/S0092-8674(00)80337-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244303	Bronze			2022-12-24	WOS:A1997XN24900013
J	Nygard, O; Nordrehaug, JE; Refsum, H; Ueland, PM; Farstad, M; Vollset, SE				Nygard, O; Nordrehaug, JE; Refsum, H; Ueland, PM; Farstad, M; Vollset, SE			Plasma homocysteine levels and mortality in patients with coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SERUM TOTAL HOMOCYSTEINE; MYOCARDIAL-INFARCTION; PYRIDOXAL-PHOSPHATE; RISK FACTOR; HOMOCYST(E)INE; ATHEROSCLEROSIS; MECHANISMS; STROKE; FOLATE	Background Elevated plasma homocysteine levels are a risk factor for coronary heart disease, but the prognostic value of homocysteine levels in patients with established coronary artery disease has not been defined. Methods We prospectively investigated the relation between plasma total homocysteine levels and mortality among 587 patients with angiographically confirmed coronary artery disease. At the time of angiography in 1991 or 1992, risk factors for coronary disease, including homocysteine levels, were evaluated. The majority of the patients subsequently underwent coronary-artery bypass grafting (318 patients) or percutaneous transluminal coronary angioplasty (120 patients); the remaining 149 were treated medically. Results After a median follow-up of 4.6 years, 64 patients (10.9 percent) had died. We found a strong, graded relation between plasma homocysteine levels and overall mortality. After four years, 3.8 percent of patients with homocysteine levels below 9 mu mol per liter had died, as compared with 24.7 percent of those with homocysteine levels of 15 mu mol per liter or higher. Homocysteine levels were only weakly related to the extent of coronary artery disease but were strongly related to the history with respect to myocardial infarction, the left ventricular ejection fraction, and the serum creatinine level. The relation of homocysteine levels to mortality remained strong after adjustment for these and other potential confounders. In an analysis in which the patients with homocysteine levels below 9 mu mol per liter were used as the reference group, the mortality ratios were 1.9 for patients with homocysteine levels of 9.0 to 14.9 mu mol per liter, 2.8 for those with levels of 15.0 to 19.9 mu mol per liter, and 4.5 for those with levels of 20.0 mu mol per liter or higher (P for trend = 0.02). When death due to cardiovascular disease (which occurred in 50 patients) was used as the end point in the analysis, the relation between homocysteine levels and mortality was slightly strengthened. Conclusions Plasma total homocysteine levels are a strong predictor of mortality in patients with angiographically confirmed coronary artery disease. (C)1997, Massachusetts Medical Society.	UNIV BERGEN, DEPT PUBL HLTH & PRIMARY HLTH CARE, DIV MED STAT, BERGEN, NORWAY; UNIV BERGEN, DEPT PHARMACOL, BERGEN, NORWAY; UNIV BERGEN, DEPT BIOL CLIN, DIV BIOCHEM, BERGEN, NORWAY	University of Bergen; University of Bergen; University of Bergen	Nygard, O (corresponding author), HAUKELAND UNIV HOSP, DEPT HEART DIS, N-5021 BERGEN, NORWAY.		Refsum, Helga/A-4073-2010; Ueland, Per M/C-7340-2013	Ueland, Per Magne/0000-0002-1903-0571				ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ALTMAN DG, 1995, BRIT J CANCER, V72, P511, DOI 10.1038/bjc.1995.364; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BOSTOM AG, IN PRESS KIDNEY INT; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1996, J NUTR, V126, pS1276, DOI 10.1093/jn/126.suppl_4.1276S; CARSON NAJ, 1962, ARCH DIS CHILD, V37, P505, DOI 10.1136/adc.37.195.505; DALERY K, 1995, AM J CARDIOL, V75, P1107, DOI 10.1016/S0002-9149(99)80739-5; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203; DIXON WJ, 1992, BMDP STATISTICAL SOF; FISKERSTRAND T, 1993, CLIN CHEM, V39, P263; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; FUSTER V, 1995, CIRCULATION, V91, P256; GERRITSEN T, 1962, BIOCHEM BIOPH RES CO, V9, P493, DOI 10.1016/0006-291X(62)90114-6; GLUECK CJ, 1995, AM J CARDIOL, V75, P132, DOI 10.1016/S0002-9149(00)80061-2; Hastie T. J., 1990, GEN ADDITIVE MODELS, V43; Malinow MR, 1996, J NUTR, V126, pS1238, DOI 10.1093/jn/126.suppl_4.1238S; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MALINOW MR, 1994, J INTERN MED, V236, P603, DOI 10.1111/j.1365-2796.1994.tb00854.x; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MEADE TW, 1988, AM J OBSTET GYNECOL, V158, P1646, DOI 10.1016/0002-9378(88)90203-7; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; MUDD SH, 1985, AM J HUM GENET, V37, P1; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; PEDERSEN TR, 1994, LANCET, V344, P1383; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Petri M, 1996, LANCET, V348, P1120, DOI 10.1016/S0140-6736(96)03032-2; REFSUM H, 1989, CLIN CHEM, V35, P1921; ROBINSON K, 1995, CIRCULATION, V92, P2825, DOI 10.1161/01.CIR.92.10.2825; SCHIMKE RN, 1965, J AMER MED ASSOC, V193, P711, DOI 10.1001/jama.1965.03090090017003; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Stamler JS, 1996, NUTR REV, V54, P1; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; *STAT SCI, 1995, S PLUS US MAN VERS 3; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828; VERHOEF P, 1995, NUTR REV, V53, P283, DOI 10.1111/j.1753-4887.1995.tb01478.x; 1995, CIRCULATION, V92, P3172	41	1426	1510	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 24	1997	337	4					230	236		10.1056/NEJM199707243370403	http://dx.doi.org/10.1056/NEJM199707243370403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL994	9227928				2022-12-24	WOS:A1997XL99400003
J	Parazzini, F; LaVecchia, C; Negri, E; Franceschi, S; Moroni, S; Chatenoud, L; Bolis, G				Parazzini, F; LaVecchia, C; Negri, E; Franceschi, S; Moroni, S; Chatenoud, L; Bolis, G			Case-control study of oestrogen replacement therapy and risk of cervical cancer	BRITISH MEDICAL JOURNAL			English	Article							HUMAN PAPILLOMAVIRUSES; ORAL-CONTRACEPTIVES; ONCOGENIC TRANSFORMATION; GENITAL-TRACT; PROGESTERONE; NEOPLASIA; ESTROGEN; TYPE-16; WOMEN	Objective : To examine the relation between use of oestrogen replacement therapy and risk of cervical cancer. Design : Case-control study. Setting : Northern Italy. Subjects : 645 women aged 40-75 years with cervical cancer admitted between 1981 and 1993 to university and general hospitals. The control group consisted of 749 women aged 40-75 years admitted to the same hospitals with acute conditions judged to be unrelated to any of the known or suspected risk factors for cervical cancer. Main outcome measures : Use of oestrogen replacement therapy and risk of cervical cancer. Results : 40 cases versus 86 controls had ever used oestrogens, and the corresponding multivariate odds ratio was 0.5 (95% confidence interval 0.3 to 0.8). The odds ratios of cervical cancer decreased with duration of use, being 0.6 (0.4 to 1.1) for less than 12 months' use and 0.5 (0.2 to 1.0) for use for 12 months or more compared with never users. The protection tended to be somewhat stronger for women reporting first oestrogen use before age 50. The odds ratio was 0.9 (0.5 to 1.7) for women who had taken oestrogens within the past 10 years and 0.4 (0.2 to 0.7) for those who had taken them 10 or more years ago. Conclusion :These findings suggest that exogenous oestrogens do not increase the risk of cervical cancer and may decrease the risk.	MARIO NEGRI INST PHARMACOL RES,UNIT EPIDEMIOL METHODOL,I-20157 MILAN,ITALY; UNIV MILAN,IST STAT MED & BIOMETRIA,I-20133 MILAN,ITALY; CTR RIFERIMENTO ONCOL,DIV EPIDEMIOL,I-33081 AVIANO,PN,ITALY; UNIV MILAN,IST CLIN OSTETR GINECOL,I-20129 MILAN,ITALY; IST NAZL TUMORI,DIV GYNECOL ONCOL,I-20133 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan; IRCCS Aviano (CRO); University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Parazzini, F (corresponding author), MARIO NEGRI INST PHARMACOL RES,ANALYT EPIDEMIOL UNIT,VIA ERITREA 62,I-20157 MILAN,ITALY.		Chatenoud, Liliane/AAA-6377-2020; franceschi, silvia/M-2452-2014; Negri, Eva/B-7244-2013; Negri, Eva Vanna Lorenza/AAC-5698-2019	Chatenoud, Liliane/0000-0001-9599-8229; franceschi, silvia/0000-0003-4181-8071; Negri, Eva/0000-0001-9712-8526; Negri, Eva Vanna Lorenza/0000-0001-9712-8526; parazzini, fabio/0000-0001-5624-4854; Bolis, Giorgio/0000-0001-8216-0080; La Vecchia, Carlo/0000-0003-1441-897X				ADAMI HO, 1989, INT J CANCER, V44, P833, DOI 10.1002/ijc.2910440515; BAKER RJ, 1978, GLIM SYSTEM; BERRY G, 1993, INT J CANCER, V55, P228; BRINTON LA, 1987, J NATL CANCER I, V79, P23; BRINTON LA, 1992, EPIDEMIOLOGY CERVICA, P3; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; HILDESHEIM A, 1990, INT J CANCER, V45, P860, DOI 10.1002/ijc.2910450513; LAVECCHIA C, 1986, BRIT J CANCER, V54, P311, DOI 10.1038/bjc.1986.178; MANTEL N, 1959, J NATL CANCER I, V22, P719; MONSONEGO J, 1991, INT J CANCER, V48, P533, DOI 10.1002/ijc.2910480410; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PARAZZINI F, 1993, REV EPIDEMIOL SANTE, V41, P53; PARAZZINI F, 1991, GYNECOL ONCOL, V41, P1, DOI 10.1016/0090-8258(91)90246-2; PARAZZINI F, 1989, BRIT J CANCER, V59, P805, DOI 10.1038/bjc.1989.168; PARAZZINI F, 1992, CANCER-AM CANCER SOC, V69, P2276, DOI 10.1002/1097-0142(19920501)69:9<2276::AID-CNCR2820690912>3.0.CO;2-Q; PATER A, 1990, AM J OBSTET GYNECOL, V162, P1099, DOI 10.1016/0002-9378(90)91323-5; PATER MM, 1988, NATURE, V335, P832, DOI 10.1038/335832a0; SCHNEIDER A, 1987, INT J CANCER, V40, P198, DOI 10.1002/ijc.2910400212; SERRA GB, 1992, TERAPIA ORMONALE NEL	19	42	51	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					85	88		10.1136/bmj.315.7100.85	http://dx.doi.org/10.1136/bmj.315.7100.85			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240046	Green Published			2022-12-24	WOS:A1997XL25200019
J	Chui, D; OhEda, M; Liao, YF; Panneerselvam, K; Lal, A; Marek, KW; Freeze, HH; Moremen, KW; Fukuda, MN; Marth, JD				Chui, D; OhEda, M; Liao, YF; Panneerselvam, K; Lal, A; Marek, KW; Freeze, HH; Moremen, KW; Fukuda, MN; Marth, JD			Alpha-mannosidase-II deficiency results in dyserythropoiesis and unveils an alternate pathway in oligosaccharide biosynthesis	CELL			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; ANEMIA TYPE-II; N-ACETYLGLUCOSAMINYLTRANSFERASE-II; BROAD-SPECIFICITY ALPHA-1->2; RAT-LIVER; ERYTHROCYTE-MEMBRANE; STRUCTURAL DETERMINANTS; CONCANAVALIN-A; SWAINSONINE; HEMPAS	Alpha-mannosidase-II (alpha M-II) catalyzes the first committed step in the biosynthesis of complex asparagine-linked (N-linked) oligosaccharides (N-glycans). Genetic deficiency of alpha M-II should abolish complex N-glycan production as reportedly does inhibition of alpha M-II by swainsonine. We find that mice lacking a functional alpha M-II gene develop a dyserythropoietic anemia concurrent with loss of erythrocyte complex N-glycans. Unexpectedly, nonerythroid cell types continued to produce complex N-glycans by an alternate pathway comprising a distinct alpha-mannosidase. These studies reveal cell-type-specific variations in N-linked oligosaccharide biosynthesis and an essential role for alpha M-II in the formation of erythroid complex N-glycans. alpha M-II deficiency elicits a phenotype in mice that correlates with human congenital dyserythropoietic anemia type II.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOL MED, LA JOLLA, CA 92093 USA; BURNHAM INST, LA JOLLA, CA 92037 USA; UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute; University System of Georgia; University of Georgia			Moremen, Kelley/AAD-4661-2019; Liao, Yung-Feng/A-9761-2011	Freeze, Hudson/0000-0001-6316-0501	NCI NIH HHS [CA71932] Funding Source: Medline; NIDDK NIH HHS [DK48247] Funding Source: Medline; NIGMS NIH HHS [GM32485] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032485] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL AS, 1991, ARCH BIOCHEM BIOPHYS, V291, P76, DOI 10.1016/0003-9861(91)90107-T; BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BAINES AJ, 1982, BRIT J HAEMATOL, V50, P563, DOI 10.1111/j.1365-2141.1982.tb01956.x; BEUTLER E, 1995, WILLIAMS HEMATOLOGY, P467; BONAY P, 1991, EUR J BIOCHEM, V197, P229, DOI 10.1111/j.1432-1033.1991.tb15903.x; BONAY P, 1992, EUR J BIOCHEM, V205, P399, DOI 10.1111/j.1432-1033.1992.tb16793.x; CAMPBELL RM, 1995, GLYCOBIOLOGY, V5, P535, DOI 10.1093/glycob/5.5.535; CHARUK JHM, 1995, EUR J BIOCHEM, V230, P797; COLEGATE SM, 1979, AUST J CHEM, V32, P2257, DOI 10.1071/CH9792257; CROOKSTON JH, 1969, BRIT J HAEMATOL, V17, P11, DOI 10.1111/j.1365-2141.1969.tb05660.x; DORLING PR, 1978, NEUROPATH APPL NEURO, V4, P285, DOI 10.1111/j.1365-2990.1978.tb00547.x; DORLING PR, 1980, BIOCHEM J, V191, P649, DOI 10.1042/bj1910649; ELBEIN AD, 1981, P NATL ACAD SCI-BIOL, V78, P7393, DOI 10.1073/pnas.78.12.7393; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FEIZI T, 1979, J EXP MED, V149, P975, DOI 10.1084/jem.149.4.975; FUKUDA MN, 1992, BRIT J HAEMATOL, V82, P745, DOI 10.1111/j.1365-2141.1992.tb06953.x; FUKUDA MN, 1984, BRIT J HAEMATOL, V56, P55, DOI 10.1111/j.1365-2141.1984.tb01271.x; FUKUDA MN, 1990, P NATL ACAD SCI USA, V87, P7443, DOI 10.1073/pnas.87.19.7443; FUKUDA MN, 1993, BAILLIERE CLIN HAEM, V6, P493, DOI 10.1016/S0950-3536(05)80156-8; FUKUDA MN, 1987, J BIOL CHEM, V262, P7195; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; FUKUDA MN, 1989, BLOOD, V73, P1331; HAKOMORI S, 1981, SEMIN HEMATOL, V82, P745; HARPAZ N, 1980, J BIOL CHEM, V255, P4894; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; HUGHES RC, 1986, EUR J BIOCHEM, V158, P227, DOI 10.1111/j.1432-1033.1986.tb09742.x; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; JAEKEN J, 1994, ARCH DIS CHILD, V71, P123, DOI 10.1136/adc.71.2.123; KOBATA A, 1992, J CHROMATOGR, V597, P111, DOI 10.1016/0021-9673(92)80101-Y; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Liao YF, 1996, J BIOL CHEM, V271, P28348, DOI 10.1074/jbc.271.45.28348; Marth JD, 1996, J CLIN INVEST, V97, P1999, DOI 10.1172/JCI118634; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; MERKLE RK, 1997, IN PRESS BIOCH BIOPH; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; MISAGO M, 1995, P NATL ACAD SCI USA, V92, P11766, DOI 10.1073/pnas.92.25.11766; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; MOREMEN KW, 1986, J BIOL CHEM, V261, P945; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; NARASIMHAN S, 1979, CAN J BIOCHEM CELL B, V57, P83, DOI 10.1139/o79-011; PALEK J, 1995, WILLIAMS HEMATOLOGY, P406; Panneerselvam K, 1996, J CLIN INVEST, V97, P1478, DOI 10.1172/JCI118570; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; Priatel JJ, 1997, GLYCOBIOLOGY, V7, P45, DOI 10.1093/glycob/7.1.45; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SCARTEZZINI P, 1982, BRIT J HAEMATOL, V51, P569, DOI 10.1111/j.1365-2141.1982.tb02820.x; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; STOLL J, 1982, P NATL ACAD SCI-BIOL, V79, P2296, DOI 10.1073/pnas.79.7.2296; Tan J, 1996, AM J HUM GENET, V59, P810; TULSIANI DRP, 1988, ARCH BIOCHEM BIOPHYS, V264, P607, DOI 10.1016/0003-9861(88)90327-X; TULSIANI DRP, 1987, J BIOL CHEM, V262, P6506; TULSIANI DRP, 1984, ARCH BIOCHEM BIOPHYS, V232, P76, DOI 10.1016/0003-9861(84)90522-8; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753	56	156	167	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 11	1997	90	1					157	167		10.1016/S0092-8674(00)80322-0	http://dx.doi.org/10.1016/S0092-8674(00)80322-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230311	Bronze			2022-12-24	WOS:A1997XL36200017
J	Hurme, R; Berndt, KD; Normark, SJ; Rhen, M				Hurme, R; Berndt, KD; Normark, SJ; Rhen, M			A proteinaceous gene regulatory thermometer in Salmonella	CELL			English	Article							HELICAL COILED-COILS; SHOCK TRANSCRIPTION FACTOR-1; SMOOTH-MUSCLE TROPOMYOSIN; HEAT-SHOCK; ESCHERICHIA-COLI; DNA-BINDING; ENVIRONMENTAL-REGULATION; TEMPERATURE REGULATION; PATHOGENIC BACTERIA; SHIGELLA-FLEXNERI	Novel utilization of the coiled-coil motif is presented that enables TlpA, an autoregulatory repressor protein in Salmonella, to sense temperature shifts directly and thereby to modulate the extent of transcription repression. Salmonella cells shifted to higher temperatures, such as those encountered at host entry, showed derepressed tlpA activity. tlpA::lacZ fusions indicated that the promoter itself is insensitive to thermal shifts and that transcription control was exerted by the autorepressor TlpA only. In vitro studies with highly purified TlpA showed concentration and temperature dependence for both fully folded conformation and function, indicating that the thermosensing in TlpA is based on monomer-to-coiled-coil equilibrium.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,MED NOBEL INST BIOCHEM,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet			Berndt, Kurt/J-8574-2015	Berndt, Kurt/0000-0002-3049-967X				Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAIRD GD, 1985, J GEN MICROBIOL, V131, P1815; BENSON NR, 1992, J BACTERIOL, V174, P1673, DOI 10.1128/jb.174.5.1673-1681.1992; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CORNELIS GR, 1991, MOL MICROBIOL, V5, P1023, DOI 10.1111/j.1365-2958.1991.tb01875.x; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DORMAN CJ, 1991, INFECT IMMUN, V59, P745, DOI 10.1128/IAI.59.3.745-749.1991; DORMAN CJ, 1990, NATURE, V344, P789, DOI 10.1038/344789a0; FOSTER JW, 1995, ANNU REV MICROBIOL, V49, P145, DOI 10.1146/annurev.micro.49.1.145; Galan JE, 1996, ANNU REV CELL DEV BI, V12, P221, DOI 10.1146/annurev.cellbio.12.1.221; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; GOODSON ML, 1995, J BIOL CHEM, V270, P2447, DOI 10.1074/jbc.270.6.2447; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; Greenfield NJ, 1995, BIOCHEMISTRY-US, V34, P16797, DOI 10.1021/bi00051a030; Groisman EA, 1996, TRENDS MICROBIOL, V4, P127, DOI 10.1016/0966-842X(96)30013-9; GULIG PA, 1993, MOL MICROBIOL, V7, P825, DOI 10.1111/j.1365-2958.1993.tb01172.x; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HIGGINS CF, 1990, MOL MICROBIOL, V4, P2007, DOI 10.1111/j.1365-2958.1990.tb00559.x; HODGES RS, 1981, J BIOL CHEM, V256, P1214; HOE NP, 1993, J BACTERIOL, V175, P7901, DOI 10.1128/JB.175.24.7901-7909.1993; HOLTZER ME, 1992, BIOPOLYMERS, V32, P1675, DOI 10.1002/bip.360321209; HROMOCKYJ AE, 1992, MOL MICROBIOL, V6, P2113, DOI 10.1111/j.1365-2958.1992.tb01385.x; HULTON CSJ, 1990, CELL, V63, P631, DOI 10.1016/0092-8674(90)90458-Q; HURME R, 1994, J BIOL CHEM, V269, P10675; Hurme R, 1996, J BIOL CHEM, V271, P12626, DOI 10.1074/jbc.271.21.12626; JAGURA-BURDZY G, 1992, J MOL BIOL, V225, P651, DOI 10.1016/0022-2836(92)90392-W; JANCSO A, 1991, J BIOL CHEM, V266, P5891; Jones BD, 1996, ANNU REV IMMUNOL, V14, P533, DOI 10.1146/annurev.immunol.14.1.533; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; LEHRER SS, 1991, BIOCHEMISTRY-US, V30, P5682, DOI 10.1021/bi00237a007; LEHRER SS, 1990, J BIOL CHEM, V265, P1134; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)90126-7; MAURELLI AT, 1989, MICROB PATHOGENESIS, V7, P1, DOI 10.1016/0882-4010(89)90106-X; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MIKULSKIS AV, 1994, MOL MICROBIOL, V11, P77, DOI 10.1111/j.1365-2958.1994.tb00291.x; Miller J.H., 1972, EXPT MOL GENETICS; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; MORA R, 1988, ANAL BIOCHEM, V172, P368, DOI 10.1016/0003-2697(88)90457-5; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; OAS TG, 1994, TRENDS BIOCHEM SCI, V19, P51, DOI 10.1016/0968-0004(94)90030-2; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; OSHEA EK, 1989, SCIENCE, V243, P536; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PAULING L, 1953, NATURE, V171, P59, DOI 10.1038/171059a0; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; QI SY, 1995, MOL MICROBIOL, V17, P523, DOI 10.1111/j.1365-2958.1995.mmi_17030523.x; RHEN M, 1993, MOL MICROBIOL, V10, P45, DOI 10.1111/j.1365-2958.1993.tb00902.x; RICHARDSON SMH, 1984, EMBO J, V3, P1745, DOI 10.1002/j.1460-2075.1984.tb02041.x; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHMIEGER H, 1972, MOL GEN GENET, V119, P75, DOI 10.1007/BF00270447; TOBE T, 1993, J BACTERIOL, V175, P6142, DOI 10.1128/JB.175.19.6142-6149.1993; VANBOGELEN RA, 1987, J BACTERIOL, V169, P26, DOI 10.1128/jb.169.1.26-32.1987; VONGABAIN A, 1983, P NATL ACAD SCI-BIOL, V80, P653; Wang X, 1996, DNA CELL BIOL, V15, P209, DOI 10.1089/dna.1996.15.209; WENDT H, 1995, BIOCHEMISTRY-US, V34, P4097, DOI 10.1021/bi00012a028; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cb.11.110195.002301; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	63	104	122	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					55	64		10.1016/S0092-8674(00)80313-X	http://dx.doi.org/10.1016/S0092-8674(00)80313-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230302	Bronze			2022-12-24	WOS:A1997XL36200008
J	KaneiIshii, C; Tanikawa, J; Nakai, A; Morimoto, RI; Ishii, S				KaneiIshii, C; Tanikawa, J; Nakai, A; Morimoto, RI; Ishii, S			Activation of heat shock transcription factor 3 by c-Myb in the absence of cellular stress	SCIENCE			English	Article							HSP70 GENE-TRANSCRIPTION; DNA-BINDING ABILITY; COILED-COIL; MOLECULAR-CLONING; LEUCINE-ZIPPER; OLIGOMERIZATION; EXPRESSION; HSF1; TRANSACTIVATION; TRIMERIZATION	In vertebrates, the presence of multiple heat shock transcription factors (HSFs) indicates that these factors may be regulated by distinct stress signals. HSF3 was specifically activated in unstressed proliferating cells by direct binding to the c-myb proto-oncogene product (c-Myb). These factors formed a complex through their DNA binding domains that stimulated the nuclear entry and formation of the transcriptionally active trimer of HSF3. Because c-Myb participates in cellular proliferation, this regulatory pathway may provide a link between cellular proliferation and the stress response.	RIKEN, TSUKUBA LIFE SCI CTR, MOL GENET LAB, TSUKUBA, IBARAKI 305, JAPAN; KYOTO UNIV, DEPT CELL BIOL, CHEST DIS RES INST, KYOTO 606, JAPAN; NORTHWESTERN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, RICE INST BIOMED RES, EVANSTON, IL 60208 USA; OSAKA UNIV, MICROBIAL DIS RES INST, SUITA, OSAKA 565, JAPAN	RIKEN; Kyoto University; Northwestern University; Osaka University			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; KANEIISHII C, 1994, J BIOL CHEM, V269, P15768; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KARISEDER J, 1996, BICOH BIOPHYS RES CO, V220, P153; KIMURA Y, IN PRESS GENES DEV; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MOROMOTO RI, 1994, BIOL HEAT SHOCK PROT, P417; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NAIR SC, IN PRESS CELL STRESS; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; OESTERREICH S, 1993, CANCER RES, V53, P4443; Ogata K, 1996, NAT STRUCT BIOL, V3, P178, DOI 10.1038/nsb0296-178; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wu C., 1994, BIOL HEAT SHOCK PROT, P395; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	34	58	58	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					246	248		10.1126/science.277.5323.246	http://dx.doi.org/10.1126/science.277.5323.246			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211854				2022-12-24	WOS:A1997XK41800047
J	Lindahl, P; Johansson, BR; Leveen, P; Betsholtz, C				Lindahl, P; Johansson, BR; Leveen, P; Betsholtz, C			Pericyte loss and microaneurysm formation in PDGF-B-deficient mice	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; ENDOTHELIAL-CELLS; BETA-RECEPTOR; EXPRESSION; INHIBITION; EMBRYO; TEK	Platelet-derived growth factor (pDGF)-B-deficient mouse embryos were found to lack microvascular pericytes, which normally form part of the capillary wall, and they developed numerous capillary microaneurysms that ruptured at late gestation. Endothelial cells of the sprouting capillaries in the mutant mice appeared to be unable to attract pDGF-R beta-positive pericyte progenitor cells. Pericytes may contribute to the mechanical stability of the capillary wall, Comparisons made between PDGF null mouse phenotypes suggest a general role for PDGFs in the development of myofibroblasts.	GOTHENBURG UNIV,DEPT MED BIOCHEM,S-41390 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT ANAT & CELL BIOL,S-41390 GOTHENBURG,SWEDEN	University of Gothenburg; University of Gothenburg								BERNSTEIN LR, 1982, J CELL SCI, V56, P71; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; BUZNEY SM, 1977, INVEST OPHTH VIS SCI, V16, P392; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; CROCKER DJ, 1970, EXP MOL PATHOL, V13, P51, DOI 10.1016/0014-4800(70)90084-5; DAMORE PA, 1993, GROWTH FACTORS, V8, P61, DOI 10.3109/08977199309029135; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Fujimoto K, 1995, ANAT RECORD, V242, P562, DOI 10.1002/ar.1092420412; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Hogan B, 1994, MANIPULATING MOUSE E; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; KUWABARA T, 1963, ARCH OPHTHALMOL-CHIC, V69, P492, DOI 10.1001/archopht.1963.00960040498013; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LINDAHL P, UNPUB; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; OSTERBY R, 1974, ACTA MED SCAND, V574, P1; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Raines E.W., 1990, PEPTIDE GROWTH FACTO, DOI [10.1007/978-3-642-49295-2_5, DOI 10.1007/978-3-642-49295-2_5]; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SHINBROT E, 1994, DEV DYNAM, V199, P169, DOI 10.1002/aja.1001990302; SIMS DE, 1986, TISSUE CELL, V18, P153, DOI 10.1016/0040-8166(86)90026-1; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; WESTERMARK B, 1993, BIOL PLATELET DERIVE	33	1587	1644	3	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					242	245		10.1126/science.277.5323.242	http://dx.doi.org/10.1126/science.277.5323.242			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211853				2022-12-24	WOS:A1997XK41800046
J	Zwilling, S; Dieckmann, A; Pfisterer, P; Angel, P; Wirth, T				Zwilling, S; Dieckmann, A; Pfisterer, P; Angel, P; Wirth, T			Inducible expression and phosphorylation of coactivator BOB.1/OBF.1 in T cells	SCIENCE			English	Article							BINDING TRANSCRIPTION FACTORS; FUNCTIONAL-CHARACTERIZATION; IMMUNOGLOBULIN PROMOTERS; OCT2 TRANSACTIVATION; ACTIVATION; SITES	BOB.1/OBF.1 is a transcriptional coactivator that is constitutively expressed in B cells and interacts with the Oct1 and Oct2 transcription factors. Upon activation of Jurkat T cells and primary murine thymocytes with phorbol esters and ionomycin, BOB.1/OBF.1 expression and transactivation function were induced. BOB.1/OBF.1 was phosphorylated at Ser(184) both in vivo and in vitro, and this modification was required for inducible activation. Mutation of Ser(184) also diminished transactivation function in B cells, suggesting that the activating phosphorylation that is inducible in T cells is constitutively present in B cells. Thus, BOB.1/OBF.1 is a transcriptional coactivator that is critically regulated by posttranslational modifications to mediate cell type-specific gene expression.	UNIV WURZBURG, INST MED STRAHLENKUNDE & ZELLFORSCH, D-97078 WURZBURG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, ABT SIGNALTRANSDUKT & WACHSTUMSKONTROLLE, D-69120 HEIDELBERG, GERMANY	University of Wurzburg; Helmholtz Association; German Cancer Research Center (DKFZ)			Wirth, Thomas/X-7172-2019					ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRUARTGOUILLEUX V, 1995, EUR J IMMUNOL, V25, P1431, DOI 10.1002/eji.1830250544; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; KONIG H, 1995, GENE DEV, V9, P1598, DOI 10.1101/gad.9.13.1598; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; PFISTERER P, 1995, J BIOL CHEM, V270, P29870, DOI 10.1074/jbc.270.50.29870; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; WIRTH T, 1995, IMMUNOBIOLOGY, V193, P161, DOI 10.1016/S0171-2985(11)80540-1	23	76	77	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					221	225		10.1126/science.277.5323.221	http://dx.doi.org/10.1126/science.277.5323.221			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211847				2022-12-24	WOS:A1997XK41800040
J	Castillo, PE; Malenka, RC; Nicoll, RA				Castillo, PE; Malenka, RC; Nicoll, RA			Kainate receptors mediate a slow postsynaptic current in hippocampal CA3 neurons	NATURE			English	Article							GLUTAMATE-RECEPTOR; AMPA RECEPTORS; BINDING-SITES; SUBUNITS; LOCALIZATION; RESPONSES; DESENSITIZATION; DEPOLARIZATIONS; ANTAGONIST; CLONING	Glutamate, the neurotransmitter at most excitatory synapses in the brain, activates a variety of receptor subtypes that can broadly be divided into ionotropic (ligand-gated ion channels) and metabotropic (G-protein-coupled) receptors. Ionotropic receptors mediate fast excitatory synaptic transmission, and based on pharmacological and molecular biological studies are divided into NMDA and non-NMDA subtypes. The non-NMDA receptor group is further divided into AMPA and kainate subtypes(1). Virtually all fast excitatory postsynaptic currents studied so far in the central nervous system are mediated by the AMPA and NMDA subtypes of receptors. Surprisingly, despite extensive analysis of their structural biophysical properties and anatomical distribution, a synaptic role for kainate receptors in the brain has not been found(2). Here we report that repetitive activation of the hippocampal messy fibre pathway, which is associated with high-affinity kainate binding(3) and many of the kainate receptor subtypes(4-8), generates a slow excitatory synaptic current with all of the properties expected of a kainate receptor. This activity-dependent synaptic current greatly augments the excitatory drive of CA3 pyramidal cells.	UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL & PSYCHIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco				Castillo, Pablo/0000-0002-9834-1801				BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; Burnashev N, 1996, J PHYSIOL-LONDON, V496, P165, DOI 10.1113/jphysiol.1996.sp021674; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; DONEVAN SD, 1993, NEURON, V10, P51, DOI 10.1016/0896-6273(93)90241-I; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FOSTER AC, 1981, NATURE, V289, P73, DOI 10.1038/289073a0; Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HUNTLEY GW, 1993, J NEUROSCI, V13, P2965; Kamiya H, 1996, J PHYSIOL-LONDON, V493, P447, DOI 10.1113/jphysiol.1996.sp021395; LERMA J, 1993, P NATL ACAD SCI USA, V90, P11688, DOI 10.1073/pnas.90.24.11688; Lerma J, 1997, TRENDS NEUROSCI, V20, P9, DOI 10.1016/S0166-2236(96)20055-4; MALVA JO, 1995, NEUROSCI LETT, V185, P83, DOI 10.1016/0304-3940(94)11230-G; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; PETRALIA RS, 1994, J COMP NEUROL, V349, P85, DOI 10.1002/cne.903490107; REPRESA A, 1987, NEUROSCIENCE, V20, P739, DOI 10.1016/0306-4522(87)90237-5; ROBINSON JH, 1981, BRAIN RES, V221, P117, DOI 10.1016/0006-8993(81)91067-2; Salin PA, 1996, P NATL ACAD SCI USA, V93, P13304, DOI 10.1073/pnas.93.23.13304; SAWADA S, 1988, EXP BRAIN RES, V72, P135, DOI 10.1007/BF00248508; SAWADA S, 1985, EXP BRAIN RES, V60, P323; SCANZIANI JH, 1997, NATURE, V385, P630; SIEGEL SJ, 1995, J NEUROSCI, V15, P2707; Swanson GT, 1996, J PHYSIOL-LONDON, V492, P129, DOI 10.1113/jphysiol.1996.sp021295; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; VERDOORN TA, 1994, EUR J PHARM-MOLEC PH, V269, P43, DOI 10.1016/0922-4106(94)90024-8; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WILDING TJ, 1995, MOL PHARMACOL, V47, P582; ZORUMSKI CF, 1993, NEURON, V10, P61, DOI 10.1016/0896-6273(93)90242-J	31	416	422	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					182	186		10.1038/40645	http://dx.doi.org/10.1038/40645			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217159	Bronze			2022-12-24	WOS:A1997XK10900052
J	Reppas, JB; Niyogi, S; Dale, AM; Sereno, MI; Tootell, RBH				Reppas, JB; Niyogi, S; Dale, AM; Sereno, MI; Tootell, RBH			Representation of motion boundaries in retinotopic human visual cortical areas	NATURE			English	Article							SENSORY STIMULATION; MACAQUE MONKEY; HUMAN BRAIN; MT; NEURONS; CORTEX; SEGREGATION; PERCEPTION; LESIONS; FMRI	Edges are important in the interpretation of the retinal image. Although luminance edges have been studied extensively, much less is known about how or where the primate visual system detects boundaries defined by differences in surface properties such as texture, motion or binocular disparity. Here we use functional magnetic resonance imaging (fMRI) to localize human visual cortical activity related to the processing of one such higher-order edge type: motion boundaries. We describe a robust fMRI signal that is selective for motion segmentation. This boundary-specific signal is present, and retinotopically organized, within early visual areas, beginning in the primary visual cortex (area V1). Surprisingly, it is largely absent from the motion-selective area MT/V5 and far extrastriate visual areas. Changes in the surface velocity defining the motion boundaries affect the strength of the fMRI signal. In parallel psychophysical experiments, the perceptual salience of the boundaries shows a similar dependence on surface velocity. These results demonstrate that information for segmenting scenes by relative motion is represented as early as V1.	MASSACHUSETTS GEN HOSP,NUCL MAGNET RESONANCE CTR,CHARLESTOWN,MA 02129; MIT,DEPT BRAIN & COGNIT SCI,PERCEPTUAL SCI GRP,CAMBRIDGE,MA 02139; UNIV CALIF SAN DIEGO,DEPT COGNIT SCI,LA JOLLA,CA 92093	Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego	Reppas, JB (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,220 LONGWOOD AVE,BOSTON,MA 02115, USA.		Dale, Anders M/A-5180-2010; Sereno, Martin I/F-7657-2012	Sereno, Martin I/0000-0002-7598-7829				BANTON T, 1993, PERCEPTION, V22, P1195, DOI 10.1068/p221195; BORN RT, 1992, NATURE, V357, P497, DOI 10.1038/357497a0; BRADDICK O, 1974, VISION RES, V14, P519, DOI 10.1016/0042-6989(74)90041-8; BRADDICK O, 1993, TRENDS NEUROSCI, V16, P263, DOI 10.1016/0166-2236(93)90179-P; BRITTEN KH, 1993, VISUAL NEUROSCI, V10, P1157, DOI 10.1017/S0952523800010269; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382; DEYOE EA, 1994, J NEUROSCI METH, V54, P171, DOI 10.1016/0165-0270(94)90191-0; DICK M, 1987, SCIENCE, V237, P400, DOI 10.1126/science.3603025; ENGEL SA, 1994, NATURE, V369, P525, DOI 10.1038/369525a0; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LAGAE L, 1989, BRAIN RES, V496, P361, DOI 10.1016/0006-8993(89)91089-5; LAMME VAF, 1993, NATURE, V363, P541, DOI 10.1038/363541a0; MARCAR VL, 1995, J NEUROPHYSIOL, V74, P1258, DOI 10.1152/jn.1995.74.3.1258; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MAUNSELL JHR, 1983, J NEUROSCI, V3, P2436; MURAKAMI I, 1995, VISION RES, V35, P1835, DOI 10.1016/0042-6989(94)00269-R; NAKAYAMA K, 1974, PERCEPTION, V3, P63, DOI 10.1068/p030063; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; ORBAN GA, 1995, P NATL ACAD SCI USA, V92, P993, DOI 10.1073/pnas.92.4.993; PATZWAHL DR, 1994, VISUAL NEUROSCI, V11, P1135, DOI 10.1017/S0952523800006945; REGAN D, 1992, J NEUROSCI, V12, P2198; REPPAS JB, 1996, RECHERCHE, V289, P52; SACHTLER WL, 1995, VISION RES, V35, P807, DOI 10.1016/0042-6989(94)00160-N; SCHILLER PH, 1993, VISUAL NEUROSCI, V10, P717, DOI 10.1017/S0952523800005423; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; VAINA LM, 1994, NEUROREPORT, V5, P2289, DOI 10.1097/00001756-199411000-00021; VANDOORN AJ, 1982, EXP BRAIN RES, V45, P189, DOI 10.1007/BF00235778	30	97	97	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					175	179		10.1038/40633	http://dx.doi.org/10.1038/40633			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217157	Bronze			2022-12-24	WOS:A1997XK10900050
J	Mason, D; Birmingham, L; Grubin, D				Mason, D; Birmingham, L; Grubin, D			Substance use in remand prisoners: A consecutive case study	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To determine the prevalence of drug and alcohol use among newly remanded prisoners, assess the effectiveness of prison reception screening, and examine the clinical management of substance misusers among remand prisoners. Design: A consecutive case study of remand prisoners screened at reception for substance misuse and treatment needs and comparison of findings with those of prison reception screening and treatment provision. Setting: A large adult male remand prison (Durham). Subjects: 548 men aged 21 and over awaiting trial. Main outcome measures: Prevalence of substance misuse; treatment needs of substance misusers; effectiveness of prison reception screening for substance misuse; provision of detoxification programmes. Results: Before remand 312 (57%) men were using illicit drugs and 181 (33%) met DSM-IV drug misuse or dependence criteria: 177 (32%) men met misuse or dependence criteria for alcohol. 391 (71%) men were judged to require help directed at their drug or alcohol use and 197 (36%) were judged to require a detoxification programme. The prison reception screen identified recent illicit drug use in 131 (24%) of 536 men and problem drinking in 103 (19%). Drug use was more likely to be identified by prison screening if an inmate was using multiple substances. using opiates, or had a diagnosis of abuse or dependence. 47 (9%) of 536 inmates were prescribed treatment to ease the symptoms of substance withdrawal. Conclusions: The prevalence of substance misuse in newly remanded prisoners is high. Prison reception health screening consistently underestimates drug and alcohol use. In many cases in which substance use is identified the quantities and numbers of different substances being used are underestimated. Initial management of inmates identified by prison screening as having problems with dependence producing substances is poor. Few receive a detoxification programme, so that many are left with the option of continuing to use drugs in prison or facing untreated withdrawal.	UNIV NEWCASTLE UPON TYNE,ST NICHOLAS HOSP,DEPT FORENS PSYCHIAT,NEWCASTLE TYNE NE3 3XT,TYNE & WEAR,ENGLAND	Newcastle University - UK								Birmingham L, 1996, BRIT MED J, V313, P1521, DOI 10.1136/bmj.313.7071.1521; BLUGLASS R, 1990, BRIT MED J, V301, P249, DOI 10.1136/bmj.301.6746.249; Brooke D, 1996, BRIT MED J, V313, P1524, DOI 10.1136/bmj.313.7071.1524; Gore SM, 1996, LANCET, V348, P1124, DOI 10.1016/S0140-6736(96)06318-0; Joyce L, 1996, PRISON SER J, V107, P16; MAXWELL AE, 1977, BRIT J PSYCHIAT, V130, P79, DOI 10.1192/bjp.130.1.79; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P121; PHILLIPS GT, 1987, BRIT J ADDICT, V82, P691; ROSS M, 1994, BRIT MED J, V308, P1092, DOI 10.1136/bmj.308.6936.1092; SMITH R, 1992, BRIT MED J, V304, P134, DOI 10.1136/bmj.304.6820.134	10	51	51	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					18	21		10.1136/bmj.315.7099.18	http://dx.doi.org/10.1136/bmj.315.7099.18			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XJ947	9233320	Green Published			2022-12-24	WOS:A1997XJ94700021
J	Campbell, RWF				Campbell, RWF			Whither digitalis?	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; SURVIVAL; DIGOXIN				Campbell, RWF (corresponding author), FREEMAN RD HOSP,ACAD DEPT CARDIOL,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND.							Banerjee AK, 1996, INT J CARDIOL, V55, P9, DOI 10.1016/0167-5273(96)02580-6; BIGGER JT, 1985, AM J CARDIOL, V55, P623, DOI 10.1016/0002-9149(85)90125-0; *DIG INV GROUP, 1997, NEW ENGL J MED, V336, P525; LEOR J, 1995, CARDIOVASC DRUG THER, V9, P723, DOI 10.1007/BF00878556; PUGH SE, 1989, BRIT HEART J, V61, P529; RYAN TJ, 1983, CIRCULATION, V67, P735, DOI 10.1161/01.CIR.67.4.735; Saunders KB, 1997, LANCET, V349, P833, DOI 10.1016/S0140-6736(96)09057-5	7	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1854	1855		10.1016/S0140-6736(05)63871-8	http://dx.doi.org/10.1016/S0140-6736(05)63871-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217753				2022-12-24	WOS:A1997XG41700004
J	Shale, DJ				Shale, DJ			Could diuretics in hypoxic states be bad for the pulmonary circulation?	LANCET			English	Editorial Material							DISEASE				Shale, DJ (corresponding author), LLANDOUGH HOSP,ACAD CTR,DEPT MED,CARDIFF CF64 2XX,S GLAM,WALES.							FARBER MO, 1982, ARCH INTERN MED, V142, P1326, DOI 10.1001/archinte.142.7.1326; FISHMAN AP, 1976, CIRC RES, V38, P221, DOI 10.1161/01.RES.38.4.221; KEILY DG, 1997, BR J CLIN PHARM, V43, P309; KLINGER JR, 1991, CHEST, V99, P715, DOI 10.1378/chest.99.3.715; LIPWORTH BJ, 1994, CHEST, V105, P1360, DOI 10.1378/chest.105.5.1360	5	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1856	1856		10.1016/S0140-6736(05)63873-1	http://dx.doi.org/10.1016/S0140-6736(05)63873-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217755				2022-12-24	WOS:A1997XG41700006
J	Adler, MW				Adler, MW			Sexual health - A Health of the Nation failure	BRITISH MEDICAL JOURNAL			English	Article											Adler, MW (corresponding author), UCL, SCH MED, DEPT SEXUALLY TRANSMITTED DIS, MORTIMER ST, LONDON WC1E 6AU, ENGLAND.							BABB P, 1993, POPULATION TRENDS, V74, P12; Catchpole MA, 1996, BRIT MED J, V312, P539, DOI 10.1136/bmj.312.7030.539; *COMM DIS SURV CTR, 1996, CDR, V6, P418; *COMM DIS SURV CTR, 1997, CDR, V4, P29; CONNOR N, IN PRESS CDR; COWAN FM, 1994, BRIT MED J, V309, P1325, DOI 10.1136/bmj.309.6965.1325; *DEP HLTH, 1996, UNL AN HIV PREV MON; Haines A, 1997, BRIT MED J, V314, P529, DOI 10.1136/bmj.314.7080.529; Johnson AM, 1996, GENITOURIN MED, V72, P197; Lacey CJN, 1997, BRIT MED J, V314, P1715, DOI 10.1136/bmj.314.7096.1715; Low N, 1997, BRIT MED J, V314, P1719, DOI 10.1136/bmj.314.7096.1719; MILLER E, 1995, BRIT MED J, V311, P545, DOI 10.1136/bmj.311.7004.545; *NHS CTR REV DIS U, 1997, EFFECTIVE HLTH CARE, V3; Secretary of State for Health, 1992, HLTH NAT STRAT HLTH; 1996, CDR, P6	15	40	40	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1743	1747		10.1136/bmj.314.7096.1743	http://dx.doi.org/10.1136/bmj.314.7096.1743			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9202507	Green Published			2022-12-24	WOS:A1997XE90900030
J	Paech, K; Webb, P; Kuiper, GGJM; Nilsson, S; Gustafsson, JA; Kushner, PJ; Scanlan, TS				Paech, K; Webb, P; Kuiper, GGJM; Nilsson, S; Gustafsson, JA; Kushner, PJ; Scanlan, TS			Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites	SCIENCE			English	Article							OVARIECTOMIZED RATS; RALOXIFENE; TAMOXIFEN; GENE; IDENTIFICATION; TRANSCRIPTION; ANTIESTROGENS; BONE	The transactivation properties of the two estrogen receptors, ER alpha and ER beta, were examined with different ligands in the context of an estrogen response element and an AP1 element. ER alpha and ER beta were shown to signal in opposite ways when complexed with the natural hormone estradiol from an AP1 site: with ER alpha, 17 beta-estradiol activated transcription, whereas with ER beta, 17 beta-estradiol inhibited transcription, Moreover, the antiestrogens tamoxifen, raloxifene, and imperial Chemical industries 164384 were potent transcriptional activators with ER beta at an AP1 site. Thus, the two ERs signal in different ways depending on ligand and response element, This suggests that ER alpha and ER beta may play different roles in gene regulation.	UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,NOVUM,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN; KARO BIO AB,NOVUM,S-14157 HUDDINGE,SWEDEN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet					NIGMS NIH HHS [GM 50672] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Grainger DJ, 1996, NAT MED, V2, P381, DOI 10.1038/nm0496-381; GRANDIEN K, UNPUB; JONES CD, 1984, J MED CHEM, V27, P1057, DOI 10.1021/jm00374a021; Katzenellenbogen JA, 1996, CHEM BIOL, V3, P529, DOI 10.1016/S1074-5521(96)90143-X; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KULPER GGJ, 1996, P NATL ACAD SCI USA, V93, P5925; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; PAECH K, UNPUB; RYLANDER T, UNPUB; Sato M, 1996, FASEB J, V10, P905, DOI 10.1096/fasebj.10.8.8666168; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	22	1926	2012	1	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1508	1510		10.1126/science.277.5331.1508	http://dx.doi.org/10.1126/science.277.5331.1508			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278514				2022-12-24	WOS:A1997XV42900041
J	Li, SH; Li, Y; Carthew, RW; Lai, ZC				Li, SH; Li, Y; Carthew, RW; Lai, ZC			Photoreceptor cell differentiation requires regulated proteolysis of the transcriptional repressor Tramtrack	CELL			English	Article							DROSOPHILA EYE DEVELOPMENT; ZINC-FINGER PROTEINS; ETS DOMAIN PROTEIN; FATE DETERMINATION; GENE; PATHWAY; ACTIVATION; BINDING; KINASE; SINA	The transcription repressor Tramtrack (TTK) is found in cone cells but not photoreceptor cells of the Drosophila eye. We show that down-regulation of TTK expression occurs in photoreceptor cells and is required for their fate determination. Down-regulation requires the presence of Phyllopod (PHYL), which is induced by the RAS pathway, and Seven In Absentia (SINA). Loss of either gene causes accumulation of TTK in photoreceptor cells, and TTK does not accumulate in cone cells if both PHYL and SINA are present. We report that SINA and PHYL promote ubiquitination and rapid degradation of TTK by the proteasome pathway in cell culture, and both SINA and PHYL bind to the N-terminal domain of TTK. These results argue that photoreceptor differentiation is regulated by the RAS pathway through targeted proteolysis of the TTK repressor.	UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260; PENN STATE UNIV,DEPT BIOL,UNIVERSITY PK,PA 16802; PENN STATE UNIV,DEPT BIOCHEM & MOL BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Li, Songhui/AAI-2919-2021		NEI NIH HHS [EY10111] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010111] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Boddy MN, 1996, ONCOGENE, V13, P971; BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CARTHEW RW, 1994, P NATL ACAD SCI USA, V91, P11689, DOI 10.1073/pnas.91.24.11689; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DELLA NG, 1993, DEVELOPMENT, V117, P1333; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; DICKSON BJ, 1995, CELL, V80, P543; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang YZ, 1996, DEVELOPMENT, V122, P3207; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Kauffmann RC, 1996, GENE DEV, V10, P2167, DOI 10.1101/gad.10.17.2167; Lai ZC, 1996, P NATL ACAD SCI USA, V93, P5025, DOI 10.1073/pnas.93.10.5025; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; Maufroid JP, 1996, INT J DEV BIOL, V40, P609; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Seyfert VL, 1996, ONCOGENE, V12, P2331; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; Yamamoto D, 1996, ROUX ARCH DEV BIOL, V205, P215, DOI 10.1007/BF00365799; Zhu AH, 1996, DEVELOPMENT, V122, P1577; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	37	184	187	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					469	478		10.1016/S0092-8674(00)80507-3	http://dx.doi.org/10.1016/S0092-8674(00)80507-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267027	Bronze			2022-12-24	WOS:A1997XQ06300011
J	Scully, R; Chen, JJ; Ochs, RL; Keegan, K; Hoekstra, M; Feunteun, J; Livingston, DM				Scully, R; Chen, JJ; Ochs, RL; Keegan, K; Hoekstra, M; Feunteun, J; Livingston, DM			Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage	CELL			English	Article							ATAXIA-TELANGIECTASIA GENE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; FAMILIAL BREAST; CELL-CYCLE; RECOMBINATION; CHECKPOINTS; CANCER; YEAST; DIFFERENTIATION	BRCA1 localizes to discrete nuclear foci (dots) during S phase. Hydroxyurea-mediated DNA synthesis arrest of S phase MCF7 cells led to a loss of BRCA1 from these structures. Ultraviolet light, mitomycin C, or gamma irradiation produced a similar effect but with no concurrent arrest of DNA synthesis. BARD1 and Rad51, two proteins associated with the BRCA1 dots, behaved similarly. Loss of the BRCA1 foci was accompanied by a specific, dose-dependent change(s) in the state of BRCA1 phosphorylation. Three distinct DNA damaging agents preferentially induced this change in S phase. The S phase BRCA1 phosphorylation response to DNA damage occurred in cells lacking, respectively, two DNA damage-sensing protein kinases, DNA-PK and Atm, implying that neither plays a prime role in this process. Finally, after BRCA1 dot dispersal, BRCA1, BARD1, and Rad51 accumulated, focally, on PCNA(+) replication structures, implying an interaction of BRCA1/BARD1/Rad51 containing complexes with damaged, replicating DNA. Taken together, the data imply that the BRCA1 S phase foci are dynamic physiological elements, responsive to DNA damage, and that BRCA1-containing multiprotein complexes participate in a replication checkpoint response.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA; ICOS CORP, BOTHELL, WA 98021 USA; INST GUSTAVE ROUSSY, CNRS, F-94805 VILLEJUIF, FRANCE	Scripps Research Institute; Icos Corporation; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Scully, R (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.		Scully, Ralph/F-5008-2013; Feunteun, Jean/AAZ-1267-2020	Feunteun, Jean/0000-0003-1212-9189				ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ASHLEY T, 1995, CHROMOSOMA, V104, P19, DOI 10.1007/BF00352222; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Bhatia PK, 1996, CURR OPIN GENET DEV, V6, P146, DOI 10.1016/S0959-437X(96)80043-8; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CARR AM, 1995, SEMIN CELL BIOL, V6, P65, DOI 10.1016/1043-4682(95)90002-0; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Feunteun J, 1996, BBA-REV CANCER, V1242, P177, DOI 10.1016/0304-419X(95)00016-9; FORNACE AJ, 1983, NATURE, V304, P552, DOI 10.1038/304552a0; FRIEDBERG EC, 1995, DNA REPAIR; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	55	787	810	2	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					425	435		10.1016/S0092-8674(00)80503-6	http://dx.doi.org/10.1016/S0092-8674(00)80503-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267023	Bronze			2022-12-24	WOS:A1997XQ06300007
J	Sheridan, JP; Marsters, SA; Pitti, RM; Gurney, A; Skubatch, M; Baldwin, D; Ramakrishnan, L; Gray, CL; Baker, K; Wood, WI; Goddard, AD; Godowski, P; Ashkenazi, A				Sheridan, JP; Marsters, SA; Pitti, RM; Gurney, A; Skubatch, M; Baldwin, D; Ramakrishnan, L; Gray, CL; Baker, K; Wood, WI; Goddard, AD; Godowski, P; Ashkenazi, A			Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors	SCIENCE			English	Article							TNF RECEPTOR; DEATH	TRAIL (also called Apo2L) belongs to the tumor necrosis factor family, activates rapid apoptosis in tumor cells, and binds to the death-signaling receptor DR4. Two additional TRAIL receptors were identified. The receptor designated death receptor 5 (DR5) contained a cytoplasmic death domain and induced apoptosis much like DR4. The receptor designated decoy receptor 1 (DcR1) displayed properties of a glycophospholipid-anchored cell surface protein. DcR1 acted as a decoy receptor that inhibited TRAIL signaling. Thus, a cell surface mechanism exists for the regulation of cellular responsiveness to pro-apoptotic stimuli.	GENENTECH INC,DEPT MOL ONCOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech			Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				[Anonymous], UNPUB; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; Ashkenazi Avi, 1995, Methods (Orlando), V8, P104, DOI 10.1006/meth.1995.9996; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Koke J A, 1991, Protein Expr Purif, V2, P51, DOI 10.1016/1046-5928(91)90009-8; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; MARSTERS SA, UNPUB; MORAN P, 1991, J BIOL CHEM, V266, P1250; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PITTI RM, 1996, J BIOL CHEM, V271, P12697; PITTI RM, UNPUB; SHERIDAN JB, UNPUB; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	29	1503	1662	2	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					818	821		10.1126/science.277.5327.818	http://dx.doi.org/10.1126/science.277.5327.818			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242611				2022-12-24	WOS:A1997XQ24700044
J	Tronchere, H; Wang, JW; Fu, XD				Tronchere, H; Wang, JW; Fu, XD			A protein related to splicing factor U2AF(35) that interacts with U2AF(65) and SR proteins in splicing of pre-mRNA	NATURE			English	Article							RIBONUCLEOPROTEIN AUXILIARY FACTOR; BIOCHEMICAL-CHARACTERIZATION; INTRACELLULAR-LOCALIZATION; SERINE-RICH; SNRNP; PURIFICATION; RECOGNITION; CLONING; GENE	Recognition of a functional 3' splice site in pre-mRNA splicing requires a heterodimer of the proteins U2AF(65)/U2AF(35). U2AF(65) binds to RNA at the polypyrimidine tract(1,2), whereas U2AF(35) is thought to interact through its arginine/serine-rich (RS) domain with other RS-domain-containing factors;bound at the 5' splice site, assembled in splicing enhancer complexes, or associated with the U4/U6 . U5 small nuclear ribonucleoprotein complex(3-7). It is unclear, however, how such network interactions can all be established through the small RS domain in U2AF(35). Here we describe the function of a U2AF(35)-related protein (Urp), which is the human homologue of a mouse imprinted gene. Nuclear extracts depleted of Urp are defective in splicing, but activity can be restored by addition of recombinant Urp. U2AF(35) could not replace Urp in complementation, indicating that their functions do not overlap. Co-immunodepletion showed that Urp is associated with the U2AF(65)/U2AF(35) heterodimer, Binding studies revealed that Urp specifically interacts with U2AF(65) through a U2AF(35)-homologous region and with SR proteins (a large family of RS-domain-containing proteins) through its RS domain. Therefore, Urp and U2AF(35) may independently position RS-domain-containing factors within spliceosomes.	UNIV CALIF SAN DIEGO, DEPT MED, DIV CELLULAR & MOL MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			TRONCHERE, Helene/M-5631-2014					Colwill K, 1996, J BIOL CHEM, V271, P24569, DOI 10.1074/jbc.271.40.24569; Fetzer S, 1997, RNA, V3, P344; FU XD, 1995, RNA, V1, P663; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harlow E, 1988, ANTIBODIES LAB MANUA; HAYASHIZAKI Y, 1994, NAT GENET, V6, P33, DOI 10.1038/ng0194-33; KITAGAWA K, 1995, GENOMICS, V30, P257, DOI 10.1006/geno.1995.9879; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Nabetani A, 1997, MOL CELL BIOL, V17, P789, DOI 10.1128/MCB.17.2.789; ROSCIGNO RF, 1995, RNA, V1, P692; Rudner DZ, 1996, P NATL ACAD SCI USA, V93, P10333, DOI 10.1073/pnas.93.19.10333; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; YAMAOKA T, 1995, GENOMICS, V27, P337, DOI 10.1006/geno.1995.1051; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	23	85	93	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 24	1997	388	6640					397	400		10.1038/41137	http://dx.doi.org/10.1038/41137			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237760	Bronze			2022-12-24	WOS:A1997XM52800056
J	Polyansky, OL; Zobov, NF; Viti, S; Tennyson, J; Bernath, PF; Wallace, L				Polyansky, OL; Zobov, NF; Viti, S; Tennyson, J; Bernath, PF; Wallace, L			Water on the sun: Line assignments based on variational calculations	SCIENCE			English	Article							HYDROGEN FLAME SPECTRA; RO-VIBRATIONAL LEVELS; GROUND-STATE; (H2O)-O-16; CM-1; SPECTROSCOPY; MOLECULES; STRENGTHS; H2O-16; BANDS	The infrared spectrum of hot water observed in a sunspot has been assigned. The high temperature of the sunspot, (3200 K) gave rise to a highly congested pure rotational spectrum in the 10-micrometer region that involved energy levels at least halfway to dissociation, Traditional spectroscopy, based on perturbation theory, is inadequate for this problem. Instead, accurate variational solutions of the vibration-rotation Schrodinger equation were used to make assignments, revealing unexpected features, including rotational difference bands and fewer degeneracies than anticipated. These results indicate that a shift away from perturbation theory to first. principles calculations is necessary in order to assign spectra of hot polyatomic molecules such as water.	UCL, DEPT PHYS & ASTRON, LONDON WC1E 6BT, ENGLAND; UNIV WATERLOO, DEPT CHEM, WATERLOO, ON N2L 3G1, CANADA; UNIV ARIZONA, DEPT CHEM, TUCSON, AZ 85721 USA; NATL OPT OBSERV, TUCSON, AZ 85732 USA; RUSSIAN ACAD SCI, INST APPL PHYS, NIZHNII NOVGOROD 603600, RUSSIA	University of London; University College London; University of Waterloo; University of Arizona; National Optical Astronomy Observatory; Russian Academy of Sciences; Institute of Applied Physics of the Russian Academy of Sciences			Tennyson, Jonathan/I-2222-2012; Nikolay, Zobov/U-1709-2019; Bernath, Peter F/B-6567-2012	Tennyson, Jonathan/0000-0002-4994-5238; Bernath, Peter F/0000-0002-1255-396X				ALLARD F, 1994, ASTROPHYS J, V426, pL39, DOI 10.1086/187334; BACIC Z, 1989, ANNU REV PHYS CHEM, V40, P469, DOI 10.1146/annurev.pc.40.100189.002345; CAMYPEYRET C, 1980, J PHYS LETT-PARIS, V41, pL23, DOI 10.1051/jphyslet:0198000410202300; CAMYPEYRET C, 1977, MOL PHYS, V33, P1641, DOI 10.1080/00268977700101361; FLAUD JM, 1976, MOL PHYS, V32, P499, DOI 10.1080/00268977600103251; FLAUD JM, 1974, J MOL SPECTROSC, V51, P142, DOI 10.1016/0022-2852(74)90177-5; FLAUD JM, 1977, J MOL SPECTROSC, V65, P219, DOI 10.1016/0022-2852(77)90189-8; FLAUD JM, 1981, WATER VAPOUR LINE PA; GABRIEL W, 1993, J CHEM PHYS, V99, P897, DOI 10.1063/1.465354; Herzberg G., 1945, INFRARED RAMAN SPECT, V2; HINKLE KH, 1979, ASTROPHYS J, V227, P923, DOI 10.1086/156801; JENSEN P, 1997, ADV SERIES PHYSICAL, V9; OPPENHEIMER BR, 1995, SCIENCE, V270, P1478, DOI 10.1126/science.270.5241.1478; Partridge H, 1997, J CHEM PHYS, V106, P4618, DOI 10.1063/1.473987; Polyansky OL, 1996, J CHEM PHYS, V105, P6490, DOI 10.1063/1.472501; Polyansky OL, 1996, J MOL SPECTROSC, V176, P305, DOI 10.1006/jmsp.1996.0091; Polyansky OL, 1997, J MOL SPECTROSC, V184, P35, DOI 10.1006/jmsp.1997.7307; POLYANSKY OL, 1994, J CHEM PHYS, V101, P7651, DOI 10.1063/1.468258; POLYANSKY OL, 1985, J MOL SPECTROSC, V112, P79, DOI 10.1016/0022-2852(85)90193-6; Polyansky OL, 1997, J MOL SPECTROSC, V186, P213, DOI 10.1006/jmsp.1997.7443; *PROP EN PAN WORK, 1993, 287 NATO AGARD PROP; ROTHMAN LS, 1992, J QUANT SPECTROSC RA, V48, P469, DOI 10.1016/0022-4073(92)90115-K; SAYKALLY RJ, 1993, SCIENCE, V259, P1570, DOI 10.1126/science.259.5101.1570; Schwenke D. W., COMMUNICATION; TENNYSON J, 1995, REP PROG PHYS, V58, P421, DOI 10.1088/0034-4885/58/4/002; TENNYSON J, 1995, COMPUT PHYS COMMUN, V86, P175, DOI 10.1016/0010-4655(94)00139-S; TENNYSON J, 1994, PHYS REV A, V50, P314, DOI 10.1103/PhysRevA.50.314; TOTH RA, 1994, APPL OPTICS, V33, P4851, DOI 10.1364/AO.33.004851; TOTH RA, 1993, J OPT SOC AM B, V10, P1526, DOI 10.1364/JOSAB.10.001526; TSUJI T, 1995, ELEMENTARY PROCESSES, P193; ULENIKOV ON, 1986, J MOL SPECTROSC, V117, P195, DOI 10.1016/0022-2852(86)90149-9; WALLACE L, 1995, SCIENCE, V268, P1155, DOI 10.1126/science.7761830; WALLACE L, 1994, 199401 NATL SOL OBS; Worden H, 1997, J GEOPHYS RES-ATMOS, V102, P1287, DOI 10.1029/96JD02982; Zobov NF, 1996, CHEM PHYS LETT, V260, P381, DOI 10.1016/0009-2614(96)00872-X	35	123	124	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					346	348		10.1126/science.277.5324.346	http://dx.doi.org/10.1126/science.277.5324.346			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219686				2022-12-24	WOS:A1997XL35800038
J	VarghaKhadem, F; Gadian, DG; Watkins, KE; Connelly, A; VanPaesschen, W; Mishkin, M				VarghaKhadem, F; Gadian, DG; Watkins, KE; Connelly, A; VanPaesschen, W; Mishkin, M			Differential effects of early hippocampal pathology on episodic and semantic memory	SCIENCE			English	Article							RHESUS-MONKEYS; ASSOCIATION; IMPAIRMENT; EPILEPSY; AMNESIA; CORTEX	Global anterograde amnesia is described in three patients with brain injuries that occurred in one case at birth, in another by age 4, and in the third at age 9. Magnetic resonance techniques revealed bilateral hippocampal pathology in ail three cases. Remarkably, despite their pronounced amnesia For the episodes of everyday life, all three patients attended mainstream schools and attained levels of speech and language competence, literacy, and factual knowledge that are within the low average to average range. The findings provide support for the view that the episodic and semantic components of cognitive memory are partly dissociable, with only the episodic component being fully dependent an the hippocampus.	UCL, SCH MED, INST CHILD HLTH, RADIOL & PHYS UNIT, LONDON WC1N 1EH, ENGLAND; INST NEUROL, LONDON WC1N 3BG, ENGLAND; NIMH, NEUROPSYCHOL LAB, BETHESDA, MD 20892 USA	University of London; University College London; UCL Medical School; University of London; University College London; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	VarghaKhadem, F (corresponding author), UCL, SCH MED,WOLFSON CTR,INST CHILD HLTH, COGNIT NEUROSCI UNIT, MECKLENBURGH SQ, LONDON WC1N 2AP, ENGLAND.		Gadian, David G/C-4961-2008; Vargha-Khadem, Faraneh/C-2558-2008; Van Paesschen, Wim/A-4540-2010; Fahimifar, Sepideh/M-5303-2019; Watkins, Kate E/A-6559-2012; Connelly, Alan/A-9065-2013	Van Paesschen, Wim/0000-0002-8535-1699; Watkins, Kate E/0000-0002-2621-482X; Connelly, Alan/0000-0001-7159-8079; vargha-khadem, faraneh/0000-0003-4890-8379	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CONNELLY A, 1994, NEUROLOGY, V44, P1411, DOI 10.1212/WNL.44.8.1411; Cross JH, 1996, ANN NEUROL, V39, P107, DOI 10.1002/ana.410390116; Gadian DG, 1996, NEUROLOGY, V46, P974, DOI 10.1212/WNL.46.4.974; Goulet S., 1995, Society for Neuroscience Abstracts, V21, P1446; ISAACS EB, 1989, BRIT J DEV PSYCHOL, V7, P377, DOI 10.1111/j.2044-835X.1989.tb00814.x; JACK CR, 1990, RADIOLOGY, V175, P423, DOI 10.1148/radiology.175.2.2183282; JACKSON GD, 1993, NEUROLOGY, V43, P1793, DOI 10.1212/WNL.43.9.1793; LANG C, 1981, J NEUROL NEUROSUR PS, V44, P626, DOI 10.1136/jnnp.44.7.626; MEUNIER M, 1993, J NEUROSCI, V13, P5418, DOI 10.1523/JNEUROSCI.13-12-05418.1993; MUGLER JP, 1990, MAGNET RESON MED, V15, P152, DOI 10.1002/mrm.1910150117; Murray E. A., 1996, Society for Neuroscience Abstracts, V22, P281; Murray E. A., 1993, Society for Neuroscience Abstracts, V19, P438; MURRAY EA, 1993, J NEUROSCI, V13, P4549; MURRAY EA, 1985, SCIENCE, V228, P604, DOI 10.1126/science.3983648; NATHAN PW, 1950, J NEUROL NEUROSUR PS, V13, P191, DOI 10.1136/jnnp.13.3.191; OSTERGAARD AL, 1987, NEUROPSYCHOLOGIA, V25, P341, DOI 10.1016/0028-3932(87)90023-6; Osterrieth P, 1944, ARCH PSYCHOL, V30, P306; PARKINSON JK, 1988, J NEUROSCI, V8, P4159; PRESS GA, 1989, NATURE, V341, P54, DOI 10.1038/341054a0; Rempel-Clower N. L., 1994, Society for Neuroscience Abstracts, V20, P1075; Rust J, 1993, WECHSLER OBJECTIVE R; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SPIEGLER BJ, 1981, BEHAV BRAIN RES, V3, P303, DOI 10.1016/0166-4328(81)90002-4; SPIEGLER BJ, 1979, SOC NEUR ABSTR, V5, P323; Squire Larry R., 1995, P825; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; Suzuki WA, 1996, SEMIN NEUROSCI, V8, P3, DOI 10.1006/smns.1996.0002; Talley JL, 1993, CAVLT 2 CHILDRENS AU; Tulving Endel, 1995, P839; VanPaesschen W, 1997, ANN NEUROL, V41, P41, DOI 10.1002/ana.410410109; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Wilson B, 1985, RIVERMEAD BEHAVIOURA; Wood F., 1982, HUMAN MEMORY AMNESIA, P167; WOOD FB, 1989, BRAIN COGNITION, V10, P76, DOI 10.1016/0278-2626(89)90076-6; ZOLAMORGAN S, 1994, HIPPOCAMPUS, V4, P483, DOI 10.1002/hipo.450040410; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	36	1179	1197	4	139	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					376	380		10.1126/science.277.5324.376	http://dx.doi.org/10.1126/science.277.5324.376			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219696				2022-12-24	WOS:A1997XL35800048
J	Brown, NJ; Snowden, M; Griffin, MR				Brown, NJ; Snowden, M; Griffin, MR			Recurrent angiotensin-converting enzyme inhibitor-associated angioedema	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Angiotensin-converting enzyme (ACE) inhibitors are associated with an increased risk of angioedema, but the risk of recurrent angioedema if treatment is continued is not known. Objective.-To test the hypothesis that the association between ACE inhibitor use and angioedema may not be recognized and to determine characteristics of angioedema associated with continued use of ACE inhibitors. Design.-Retrospective cohort study. Setting.-Tennessee Medicaid program. Patients.-Medicaid enrollees aged 15 years or older who used an ACE inhibitor and had a first documented episode of angioedema between 1986 and 1992 were followed up for recurrent episodes through June 1993. Measurements and Main Results.-We previously identified 82 patients with a first confirmed diagnosis of angioedema during 51 752 person-years of ACE inhibitor use in this population (1.6 per 1000 person-years). Among these 82 patients, there were 16 outpatient recurrences of angioedema among 13 patients during 189 patient-years of follow-up (8.5 per 100 patient-years). The rate of angioedema was much higher in users of ACE inhibitors with continued exposure (18.7 per 100 patient-years) than in those whose use of the drug was discontinued (1.8 per 100 patient-years) (P=.001). Review of the medical records for patients taking ACE inhibitors who had recurrent angioedema revealed that physicians attributed angioedema to a number of causes not related to ACE inhibitor use, even after multiple recurrences. Conclusion.-Continuing use of ACE inhibitors in spite of angioedema results in a markedly increased rate of angioedema recurrence with serious morbidity.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT PREVENT MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University	Brown, NJ (corresponding author), VANDERBILT UNIV,DEPT MED,560 MED RES BLDG 1,NASHVILLE,TN 37232, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER; NCRR NIH HHS [MOI-RR00095-533] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Brown NJ, 1996, CLIN PHARMACOL THER, V60, P8, DOI 10.1016/S0009-9236(96)90161-7; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; *PHS US DEP HLTH H, 1988, INT CLASS DIS 9 REV; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P153	4	117	121	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	1997	278	3					232	233		10.1001/jama.278.3.232	http://dx.doi.org/10.1001/jama.278.3.232			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK108	9218671				2022-12-24	WOS:A1997XK10800030
J	Altuvia, S; WeinsteinFischer, D; Zhang, AX; Postow, L; Storz, G				Altuvia, S; WeinsteinFischer, D; Zhang, AX; Postow, L; Storz, G			A small, stable RNA induced by oxidative stress: Role as a pleiotropic regulator and antimutator	CELL			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; TRANSCRIPTIONAL ACTIVATOR; FORMATE HYDROGENLYASE; GENETIC-REGULATION; POSITIVE CONTROL; OPERON FUSIONS; ANTISENSE RNA; OMPF PROTEIN	Exposure of E. coli to hydrogen peroxide induces the transcription of a small RNA denoted oxyS. The oxyS RNA is stable, abundant, and does not encode a protein. oxyS activates and represses the expression of numerous genes in E. coli, and eight targets, including genes encoding the transcriptional regulators FhlA and sigma(s), were identified. oxyS expression also leads to a reduction in spontaneous and chemically-induced mutagenesis. Our results suggest that the oxyS RNA acts as a regulator that integrates adaptation to hydrogen peroxide with other cellular stress responses and helps to protect cells against oxidative damage.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOL GENET & BIOTECHNOL,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	Altuvia, S (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,NIH,BETHESDA,MD 20892, USA.			Storz, Gisela/0000-0001-6698-1241				ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; ALTUVIA S, 1991, J MOL BIOL, V218, P723, DOI 10.1016/0022-2836(91)90261-4; ANDERSEN J, 1989, J BIOL CHEM, V264, P17961; BECKERHAPAK M, 1995, FEMS MICROBIOL LETT, V134, P39, DOI 10.1111/j.1574-6968.1995.tb07911.x; BERLYN MKB, 1996, ESCHERICHIA COLI SAL, P1715; BREMER E, 1985, J BACTERIOL, V162, P1092, DOI 10.1128/JB.162.3.1092-1099.1985; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BROWNLEE GG, 1971, NATURE-NEW BIOL, V229, P147, DOI 10.1038/newbio229147a0; CHOU JH, 1993, J BACTERIOL, V175, P1026, DOI 10.1128/JB.175.4.1026-1031.1993; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; DELIHAS N, 1995, MOL MICROBIOL, V15, P411, DOI 10.1111/j.1365-2958.1995.tb02254.x; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; ELASCO JG, 1993, CONTROL MESSENGER RN, P3; GILMAN MZ, 1983, CELL, V35, P285, DOI 10.1016/0092-8674(83)90231-3; GONZALEZFLECHA B, 1995, J BIOL CHEM, V270, P13681, DOI 10.1074/jbc.270.23.13681; GUSTAFSSON C, 1992, J BACTERIOL, V174, P7878, DOI 10.1128/JB.174.23.7878-7879.1992; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; ISLAND MD, 1992, J BACTERIOL, V174, P2754, DOI 10.1128/JB.174.9.2754-2762.1992; IVANOVA A, 1994, MOL MICROBIOL, V12, P571, DOI 10.1111/j.1365-2958.1994.tb01043.x; Jamieson D. J., 1997, OXIDATIVE STRESS MOL, P91; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Korsa I, 1997, J BACTERIOL, V179, P41, DOI 10.1128/jb.179.1.41-45.1997; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8; MAUPIN JA, 1990, J BACTERIOL, V172, P4798, DOI 10.1128/jb.172.9.4798-4806.1990; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; McKenney K, 1981, Gene Amplif Anal, V2, P383; Miller J.H., 1972, EXPT MOL GENETICS; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; SALSER W, 1967, NATURE, V215, P588, DOI 10.1038/215588a0; SCHLENSOG V, 1990, MOL MICROBIOL, V4, P1319, DOI 10.1111/j.1365-2958.1990.tb00711.x; Silhavy T.J., 1984, EXPT GENE FUSIONS; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SLEDJESKI D, 1995, P NATL ACAD SCI USA, V92, P2003, DOI 10.1073/pnas.92.6.2003; Sledjeski DD, 1996, EMBO J, V15, P3993, DOI 10.1002/j.1460-2075.1996.tb00773.x; SMITH DK, 1992, J BACTERIOL, V174, P5820, DOI 10.1128/jb.174.18.5820-5826.1992; Springer AL, 1996, J BACTERIOL, V178, P2154, DOI 10.1128/jb.178.7.2154-2157.1996; STORZ G, 1994, METHOD ENZYMOL, V234, P217; TADMOR Y, 1992, J BACTERIOL, V174, P2517, DOI 10.1128/jb.174.8.2517-2524.1992; Turlin E, 1996, BIOCHIMIE, V78, P822, DOI 10.1016/S0300-9084(97)84334-9; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4	51	367	374	1	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					43	53		10.1016/S0092-8674(00)80312-8	http://dx.doi.org/10.1016/S0092-8674(00)80312-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230301	hybrid			2022-12-24	WOS:A1997XL36200007
J	Bershitsky, SY; Tsaturyan, AK; Bershitskaya, ON; Mashanov, GI; Brown, P; Burns, R; Ferenczi, MA				Bershitsky, SY; Tsaturyan, AK; Bershitskaya, ON; Mashanov, GI; Brown, P; Burns, R; Ferenczi, MA			Muscle force is generated by myosin heads stereospecifically attached to actin	NATURE			English	Article							X-RAY-DIFFRACTION; SKELETAL-MUSCLE; CROSS-BRIDGES; CONTRACTING MUSCLE; STRUCTURAL-CHANGES; STRIATED-MUSCLE; FIBERS; REFLECTIONS; MOVEMENTS; STATES	Muscle force is generated by myosin crossbridges interacting with actin. As estimated from stiffness(1,2) and equatorial X-ray diffraction(3) of muscle and muscle fibres, most myosin cross-bridges are attached to actin during isometric contraction, but a much smaller fraction is bound stereospecifically(4-7). To determine the fraction of crossbridges contributing to tension and the structural changes that attached crossbridges undergo when generating force, we monitored the X-ray diffraction pattern during temperature-induced tension rise in fully activated permeabilized frog muscle fibres. Temperature jumps(8) from 5-6 degrees C to 16-19 degrees C initiated a 1.7-fold increase in tension without significantly changing fibre stiffness or the intensities of the (1,1) equatorial and (14.5 nm)(-1) meridional X-ray reflections. However, tension rise was accompanied by a 20% decrease in the intensity of the (1,0) equatorial reflection and an increase in the intensity of the first actin layer line by similar to 13% of that in rigor. Our results show that muscle force is associated with a transition of the crossbridges from a state in which they are nonspecifically attached to actin to one in which stereospecifically bound myosin crossbridges label the actin helix.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; RUSSIAN ACAD SCI,INST PHYSIOL,URALS BRANCH,EKATERINBURG 620219,RUSSIA; MOSCOW MV LOMONOSOV STATE UNIV,INST MECH,MOSCOW 119899,RUSSIA	MRC National Institute for Medical Research; Russian Academy of Sciences; Lomonosov Moscow State University			Tsaturyan, Andrey K/B-1037-2014; Bershitsky, Sergey/S-4829-2016; Bershitsky, Sergey/AAE-6814-2019; Tsaturyan, Andrey/GXF-8722-2022; Ferenczi, Michael/F-9510-2015	Tsaturyan, Andrey K/0000-0002-0447-7725; Bershitsky, Sergey/0000-0001-5342-1739; Ferenczi, Michael/0000-0002-0349-331X				AMEMIYA Y, 1987, SCIENCE, V237, P164, DOI 10.1126/science.3496662; Bershitsky S, 1996, BIOPHYS J, V71, P1462, DOI 10.1016/S0006-3495(96)79347-5; BERSHITSKY SY, 1995, BIOPHYS J, V69, P1011, DOI 10.1016/S0006-3495(95)79976-3; BORDOGNA G, 1991, INFORM PROCESS MANAG, V27, P15, DOI 10.1016/0306-4573(91)90028-K; BRENNER B, 1993, P NATL ACAD SCI USA, V90, P5252, DOI 10.1073/pnas.90.11.5252; COOKE R, 1984, CONTRACTILE MECHANIS, P413; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; GOLDMAN YE, 1977, J PHYSIOL-LONDON, V269, pP55; HARFORD JJ, 1992, BIOPHYS J, V63, P387, DOI 10.1016/S0006-3495(92)81613-2; HASELGROVE JC, 1973, J MOL BIOL, V77, P549, DOI 10.1016/0022-2836(73)90222-2; HIGUCHI H, 1995, BIOPHYS J, V69, P1000, DOI 10.1016/S0006-3495(95)79975-1; HIROSE K, 1993, BIOPHYS J, V65, P397, DOI 10.1016/S0006-3495(93)81061-0; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; HUXLEY HE, 1982, J MOL BIOL, V158, P637, DOI 10.1016/0022-2836(82)90253-4; HUXLEY HE, 1967, J MOL BIOL, V30, P383, DOI 10.1016/S0022-2836(67)80046-9; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; KRESS M, 1986, J MOL BIOL, V188, P325, DOI 10.1016/0022-2836(86)90158-0; Ling N, 1996, BIOPHYS J, V70, P1836, DOI 10.1016/S0006-3495(96)79749-7; LOMBARDI V, 1995, NATURE, V374, P553, DOI 10.1038/374553a0; MARTINFERNANDEZ ML, 1994, J MUSCLE RES CELL M, V15, P319; OSTAP EM, 1995, BIOPHYS J, V69, P177, DOI 10.1016/S0006-3495(95)79888-5; PIAZZESI G, 1995, BIOPHYS J, V68, pS92; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765; VAINSHTEIN BK, 1963, DIFFRACTION XRAYS CH; Yagi N, 1991, Adv Biophys, V27, P35, DOI 10.1016/0065-227X(91)90006-Y	29	82	84	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					186	190		10.1038/40651	http://dx.doi.org/10.1038/40651			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217160	Bronze			2022-12-24	WOS:A1997XK10900053
J	Brunn, GJ; Hudson, CC; Sekulic, A; Williams, JM; Hosoi, H; Houghton, PJ; Lawrence, JC; Abraham, RT				Brunn, GJ; Hudson, CC; Sekulic, A; Williams, JM; Hosoi, H; Houghton, PJ; Lawrence, JC; Abraham, RT			Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; MALIGNANT TRANSFORMATION; MAP KINASE; INITIATION; INSULIN; IDENTIFICATION; ADIPOCYTES; REGULATOR; COMPLEX; BINDS	The immunosuppressant rapamycin interferes with G(1)-phase progression in lymphoid and other cell types by inhibiting the function; of the mammalian target of rapamycin (mTOR), mTOR was determined to be a terminal kinase in a signaling pathway that couples mitogenic stimulation to the phosphorylation of the eukaryotic initiation factor (eIF)-4E-binding protein, PHAS-I. The rapamycin-sensitive protein kinase activity of mTOR was required for phosphorylation of PHAS-I in insulin-stimulated human embryonic kidney cells. mTOR phosphorylated PHAS-I on serine and threonine residues in vitro, and these modifications inhibited the binding of PHAS-I to eIF-4E. These studies define a role for mTOR in translational control and offer further insights into the mechanism whereby rapamycin inhibits G(1)-phase progression in mammalian cells.	MAYO CLIN, DIV ONCOL RES, ROCHESTER, MN 55905 USA; UNIV VIRGINIA, SCH MED, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT MED, CHARLOTTESVILLE, VA 22908 USA; ST JUDE CHILDRENS RES HOSP, DEPT MOL PHARMACOL, MEMPHIS, TN 38105 USA	Mayo Clinic; University of Virginia; University of Virginia; St Jude Children's Research Hospital					NIAMS NIH HHS [AR41189] Funding Source: Medline; NIDDK NIH HHS [DK50628, DK28312] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, CURR OPIN IMMUNOL, V8, P412, DOI 10.1016/S0952-7915(96)80132-4; Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BRUNN GJ, UNPUB; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DOWNWARD J, 1994, NATURE, V371, P378, DOI 10.1038/371378a0; Fadden P, 1997, J BIOL CHEM, V272, P10240; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Hall MN, 1996, BIOCHEM SOC T, V24, P234, DOI 10.1042/bst0240234; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KAMITZ LM, 1995, MOL CELL BIOL, V15, P3049; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; LAWRENCE J, IN PRESS ADV ENZYME; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Rousseau D, 1996, ONCOGENE, V13, P2415; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SMITH M R, 1990, New Biologist, V2, P648; Sonenberg Nahum, 1993, Gene Expression, V3, P317; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076	35	775	795	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	1997	277	5322					99	101		10.1126/science.277.5322.99	http://dx.doi.org/10.1126/science.277.5322.99			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204908				2022-12-24	WOS:A1997XJ41800048
J	Eghbali, M; Curmi, JP; Birnir, B; Gage, PW				Eghbali, M; Curmi, JP; Birnir, B; Gage, PW			Hippocampal GABA(A) channel conductance increased ky diazepam	NATURE			English	Article							OPEN-STATE SUBSTRUCTURE; PIG HEART-CELLS; CHLORIDE CHANNELS; POTASSIUM CHANNELS; RECEPTOR CHANNELS; AMINO-ACIDS; NEURONS; CULTURE; BENZODIAZEPINE; CLAMP	Benzodiazepines, which are widely used clinically for relief of anxiety and for sedation(1), are thought to enhance synaptic inhibition in the central nervous system by increasing the open probability of chloride channels activated by the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)(2,3). Here we show that the benzodiazepine diazepam tan also increase the conductance of GABA(A) channels activated by low concentrations of GABA (0.5 or 5 mu M) in rat cultured hippocampal neurons. Before exposure to diazepam, chloride channels activated by GABA had conductances of 8 to 53 pS. Diazepam caused a concentration-dependent and reversible increase in the conductance of these channels towards a maximum conductance of 70-80 pS and the effect was as great as 7-fold in channels of lowest initial conductance. Increasing the conductance of GABA(A) channels tonically activated by low ambient concentrations of GABA in the extracellular environment(4) maybe an important way in which these drugs depress excitation in the central nervous system. That any drug has such a large effect on single channel conductance has not been reported previously and has implications for models of channel structure and conductance.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,CANBERRA,ACT 2601,AUSTRALIA	Australian National University; John Curtin School of Medical Research				Birnir, Bryndis/0000-0002-1763-0266				BIRNIR B, 1994, J MEMBRANE BIOL, V142, P93; CURMI JP, 1993, J MEMBRANE BIOL, V136, P2673; FATIMASHAD K, 1992, P ROY SOC B-BIOL SCI, V250, P99, DOI 10.1098/rspb.1992.0136; GAGE PW, 1994, P ROY SOC B-BIOL SCI, V255, P167, DOI 10.1098/rspb.1994.0024; GRAY R, 1985, J NEUROPHYSIOL, V54, P134, DOI 10.1152/jn.1985.54.1.134; LERMA J, 1986, BRAIN RES, V384, P145, DOI 10.1016/0006-8993(86)91230-8; LUDEWIG W, 1996, NATURE, V383, P340; MATHERS DA, 1991, CAN J PHYSIOL PHARM, V69, P1057, DOI 10.1139/y91-157; MATSUDA H, 1989, J PHYSIOL-LONDON, V413, P139, DOI 10.1113/jphysiol.1989.sp017646; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; Otis TS, 1992, P NATL ACAD SCI USA, V78, P7180; PREMKUMAR LS, 1990, P ROY SOC B-BIOL SCI, V241, P153, DOI 10.1098/rspb.1990.0079; ROGERS CJ, 1994, J PHYSIOL-LONDON, V475, P69, DOI 10.1113/jphysiol.1994.sp020050; SEGAL M, 1984, J NEUROPHYSIOL, V52, P469, DOI 10.1152/jn.1984.52.3.469; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; STUDY RE, 1981, P NATL ACAD SCI-BIOL, V78, P7180, DOI 10.1073/pnas.78.11.7180; TANELIAN DL, 1993, ANESTHESIOLOGY, V78, P757, DOI 10.1097/00000542-199304000-00020; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V127, P533, DOI 10.1111/j.1748-1716.1986.tb07938.x; TWYMAN RE, 1989, ANN NEUROL, V25, P213, DOI 10.1002/ana.410250302; VICINI S, 1987, J PHARMACOL EXP THER, V243, P1195	23	132	135	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					71	75		10.1038/40404	http://dx.doi.org/10.1038/40404			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214504	Bronze			2022-12-24	WOS:A1997XJ14300052
J	Kallipolitis, BH; NorregaardMadsen, M; ValentinHansen, P				Kallipolitis, BH; NorregaardMadsen, M; ValentinHansen, P			Protein-protein communication: Structural model of the repression complex formed by CytR and the global regulator CRP	CELL			English	Article							CAMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; CLONING VECTORS; ACTIVATOR COMPLEX; CRYSTAL-STRUCTURE; DEOP2 PROMOTER; DNA; BINDING; PROGRAM; GENE	The cAMP receptor protein (CRP) and the Lad-related CytR antiactivator bind cooperatively to adjacent DNA sites at or near promoters, an interaction that involves direct protein contacts. Here, we identify a collection of amino acid substitutions in CytR that reestablish protein-protein communication to mutant CRP proteins specifically defective in cooperative binding with wild-type CytR. To assess the location and spatial arrangement of these substitutions, we built a three-dimensional model of CytR based on the recent X-ray structure of the highly homologous PurR repressor bound to DNA. This approach enables us to specify the patch on CytR's surface that contacts CRP. Furthermore, our results permit the construction of a three-dimensional structure of the higher order nucleoprotein complex formed by CytR and CRP.			Kallipolitis, BH (corresponding author), ODENSE UNIV, DEPT MOL BIOL, CAMPUSVEJ 55, DK-5230 ODENSE M, DENMARK.			Kallipolitis, Birgitte H./0000-0003-1233-9776				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLARK DJ, 1967, J MOL BIOL, V23, P99, DOI 10.1016/S0022-2836(67)80070-6; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; GERLACH P, 1991, J BACTERIOL, V173, P5419, DOI 10.1128/jb.173.17.5419-5430.1991; GHOSAINI LR, 1988, BIOCHEMISTRY-US, V27, P5257, DOI 10.1021/bi00414a046; GREER J, 1991, METHOD ENZYMOL, V202, P239; HOLST B, 1992, EMBO J, V11, P3635, DOI 10.1002/j.1460-2075.1992.tb05448.x; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LARSEN JEL, 1984, GENE, V28, P45, DOI 10.1016/0378-1119(84)90086-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leung DW, 1989, TECHNIQUE, V1, P11; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Maniatis T, 1989, MOL CLONING; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOLLEGAARD NE, 1993, J BIOL CHEM, V268, P17471; NAGADOI A, 1995, STRUCTURE, V3, P1217, DOI 10.1016/S0969-2126(01)00257-X; PEDERSEN H, 1992, J MOL BIOL, V227, P396, DOI 10.1016/0022-2836(92)90896-R; PEDERSEN H, 1991, J BIOL CHEM, V266, P17804; PEDERSEN H, 1995, MOL MICROBIOL, V17, P843, DOI 10.1111/j.1365-2958.1995.mmi_17050843.x; Pedersen H, 1997, EMBO J, V16, P2108, DOI 10.1093/emboj/16.8.2108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SOGAARDANDERSEN L, 1993, CELL, V75, P557, DOI 10.1016/0092-8674(93)90389-8; SOGAARDANDERSEN L, 1991, P NATL ACAD SCI USA, V88, P4921, DOI 10.1073/pnas.88.11.4921; Spronk CAEM, 1996, NAT STRUCT BIOL, V3, P916, DOI 10.1038/nsb1196-916; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; ValentinHansen P, 1996, MOL MICROBIOL, V20, P461, DOI 10.1046/j.1365-2958.1996.5341056.x; VALENTINHANSEN P, 1986, NUCLEIC ACIDS RES, V14, P2215, DOI 10.1093/nar/14.5.2215; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	43	35	35	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	1997	89	7					1101	1109		10.1016/S0092-8674(00)80297-4	http://dx.doi.org/10.1016/S0092-8674(00)80297-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215632	Bronze			2022-12-24	WOS:A1997XG83000014
J	Subramanian, K; Meyer, T				Subramanian, K; Meyer, T			Calcium-induced restructuring of nuclear envelope and endoplasmic reticulum calcium stores	CELL			English	Article							GREEN-FLUORESCENT PROTEIN; MEIOTIC MATURATION; CA2+ STORES; SEA-URCHIN; RELEASE; REORGANIZATION; FERTILIZATION; CELLS; EGG; GRADIENTS	The spatial organization of endoplasmic reticulum (ER) and nuclear envelope (NE) calcium stores is important for the regulation of localized calcium signals and sustained calcium gradients. Here, we have used a lumenal GFP fusion protein and shown that, in resting cells, large molecules can rapidly diffuse across the cell within the lumenal storage space defined by the ER and NE membranes. Increases in cytosolic calcium concentration reversibly fragmented ER tubules and prevented lumenal diffusion. However, the integrity of the NE was maintained, and a significant fraction of NE lumenal protein accumulated in an NE-associated vesicle. These dynamic properties of ER-NE calcium stores provide insights into the spatiotemporal control of calcium signaling.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University				Meyer, Tobias/0000-0003-4339-3804	NIGMS NIH HHS [GM-51457, GM-48113] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM048113, R01GM048113] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458, DOI 10.1073/pnas.91.26.12458; ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; Button D, 1996, MOL BIOL CELL, V7, P419, DOI 10.1091/mbc.7.3.419; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHANG DC, 1995, J CELL BIOL, V131, P1539, DOI 10.1083/jcb.131.6.1539; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DOWD DR, 1995, ADV SEC MESS PHOSPH, V30, P255; ELLIOTT AC, 1992, PFLUG ARCH EUR J PHY, V422, P245, DOI 10.1007/BF00376209; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; HASHIMOTO S, 1988, J CELL BIOL, V107, P2523, DOI 10.1083/jcb.107.6.2523; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HENSON JH, 1989, J CELL BIOL, V109, P149, DOI 10.1083/jcb.109.1.149; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HIROSE K, 1994, NATURE, V372, P791; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; JAFFE LA, 1994, DEV BIOL, V164, P579, DOI 10.1006/dbio.1994.1225; KOCH GLE, 1988, J CELL SCI, V91, P511; MEHLMANN LM, 1995, DEV BIOL, V170, P607, DOI 10.1006/dbio.1995.1240; MELDOLESI J, 1992, J PHYSIOLOGY-PARIS, V86, P23, DOI 10.1016/S0928-4257(05)80004-X; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MEYER T, 1995, CIBA F SYMP, V188, P252; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; MOHR FC, 1990, AM J PHYSIOL, V258, pC217, DOI 10.1152/ajpcell.1990.258.2.C217; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NICOTERA P, 1994, CELL CALCIUM, V16, P279, DOI 10.1016/0143-4160(94)90091-4; Parys JB, 1996, PFLUG ARCH EUR J PHY, V432, P359, DOI 10.1007/s004240050145; PETERSEN OH, 1995, CIBA F SYMP, V188, P85; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SPEKSNIJDER JE, 1993, J CELL BIOL, V120, P1337, DOI 10.1083/jcb.120.6.1337; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Terasaki M, 1996, DEV BIOL, V179, P320, DOI 10.1006/dbio.1996.0263; TERASAKI M, 1991, J CELL BIOL, V114, P929, DOI 10.1083/jcb.114.5.929; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TRUMP BF, 1981, CELL DEATH BIOL PATH, P209; Vertel B M, 1992, Semin Cell Biol, V3, P325, DOI 10.1016/1043-4682(92)90019-R; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252	46	190	194	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					963	971		10.1016/S0092-8674(00)80281-0	http://dx.doi.org/10.1016/S0092-8674(00)80281-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200614	Bronze			2022-12-24	WOS:A1997XE35700016
J	Adami, J; Nyren, O; Bergstrom, R; Ekbom, A; McLaughlin, JK; Hogman, C; Fraumeni, JF; Glimelius, B				Adami, J; Nyren, O; Bergstrom, R; Ekbom, A; McLaughlin, JK; Hogman, C; Fraumeni, JF; Glimelius, B			Blood transfusion and non-Hodgkin lymphoma: Lack of association	ANNALS OF INTERNAL MEDICINE			English	Article						blood transfusion; lymphoma, non-Hodgkin's; case-control studies; leukemia, lymphocytic, chronic; immunosuppression	C VIRUS-INFECTION; POSTOPERATIVE INFECTIONS; CANCER RISK; SELECTION; INCREASE; SURGERY; SWEDEN; WOMEN	Background: Non-Hodgkin lymphoma is the seventh most commonly diagnosed malignant condition worldwide, and its incidence has increased markedly in recent decades. Blood transfusions have been implicated as a possible risk factor for non-Hodgkin lymphoma. Objective: To determine whether blood transfusions are associated with an elevated risk for non-Hodgkin lymphoma. Design: Population-based, nested case-control study. Setting: Nationwide cohort in Sweden. Patients: 361 patients with non-Hodgkin lymphoma and 705 matched controls, nested within a population-based cohort of 96 795 patients at risk for blood transfusion between 1970 and 1983. Prospectively collected information on exposure was retrieved from computerized transfusion registries. Measurements: Odds ratios obtained from conditional logistic regression models were used as measures of relative risks. Results: No association was found between blood transfusions and the risk for non-Hodgkin lymphoma when patients who had received transfusions were compared with patients who had not received transfusions (odds ratio, 0.93 [95% Cf, 0.71 to 1.23]). A reduction in risk was seen among persons who received transfusion of blood without leukocyte depletion (odds ratio, 0.72 [CI, 0.53 to 0.97]). Risk was not related to number of transfusions, and no interaction was seen with latency after transfusion. Conclusion: The findings in this study do not support previous observations of an association between blood transfusions and the risk for non-Hodgkin lymphoma.	INT EPIDEMIOL INST LTD, ROCKVILLE, MD 20850 USA; UPPSALA UNIV, UPPSALA, SWEDEN; NCI, BETHESDA, MD 20892 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Uppsala University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health	Adami, J (corresponding author), KAROLINSKA INST, DEPT MED EPIDEMIOL, BOX 281, S-17177 STOCKHOLM, SWEDEN.		Adami, Johanna/AAA-3312-2021					Biggar Robert J., 1992, Current Opinion in Oncology, V4, P883, DOI 10.1097/00001622-199210000-00011; BLOMBERG J, 1993, EUR J CANCER, V29A, P2101, DOI 10.1016/0959-8049(93)90042-E; BLUMBERG N, 1994, SCI BASIS TRANSFUSIO, P580; Brandt L, 1996, BRIT J CANCER, V73, P1148, DOI 10.1038/bjc.1996.220; BRUNSON ME, 1990, TRANSFUSION, V30, P651, DOI 10.1046/j.1537-2995.1990.30790385527.x; CARLI PM, 1994, BRIT J CANCER, V70, P713, DOI 10.1038/bjc.1994.380; CARTWRIGHT RA, 1992, CANCER RES, V52, pS5441; CERHAN JR, 1993, ANN INTERN MED, V119, P8, DOI 10.7326/0003-4819-119-1-199307010-00002; DAVIS W, 1980, STAT METHODS CANC RE, V1; DEVESA SS, 1992, CANCER RES, V52, pS5432; FERRI C, 1994, BRIT J HAEMATOL, V88, P392, DOI 10.1111/j.1365-2141.1994.tb05036.x; FILIPOVICH AH, 1990, NONHODGKINS LYMPHOMA, P135; Hakulinen T, 1986, Acta Pathol Microbiol Immunol Scand Suppl, V288, P1; Hansson LE, 1996, NEW ENGL J MED, V335, P242, DOI 10.1056/NEJM199607253350404; HARRIS NL, 1994, BLOOD, V84, P1361; Hjalgrim H, 1996, BRIT J CANCER, V73, P951, DOI 10.1038/bjc.1996.170; HOGMAN CF, 1970, TRANSFUSION, V10, P121; Izumi T, 1996, BLOOD, V87, P5380, DOI 10.1182/blood.V87.12.5380.bloodjournal87125380; KINLEN L, 1982, CANCER SURV, V1, P565; MARTINSSON U, 1992, ACTA ONCOL, V31, P275, DOI 10.3109/02841869209108173; MEMON A, 1994, INT J CANCER, V58, P366, DOI 10.1002/ijc.2910580310; MEZROW CK, 1992, TRANSFUSION, V32, P27, DOI 10.1046/j.1537-2995.1992.32192116427.x; MUELLER BU, 1995, J PEDIATR-US, V126, P1, DOI 10.1016/S0022-3476(95)70491-4; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; Nilsson A C, 1994, Lakartidningen, V91, P603; Nilsson AC, 1994, LAKARTIDNINGEN, V91, P603; NYREN O, 1995, JNCI-J NATL CANCER I, V87, P28, DOI 10.1093/jnci/87.1.28; OPELZ G, 1993, LANCET, V342, P1514, DOI 10.1016/S0140-6736(05)80084-4; PENN I, 1988, CANCER DETECT PREV, V12, P39; Pioltelli P, 1996, LANCET, V347, P624, DOI 10.1016/S0140-6736(96)91328-8; RABKIN CS, 1991, INT J CANCER, V47, P692, DOI 10.1002/ijc.2910470511; *SWED CANC REG, 1996, CANC INC SWED; TARTTER PI, 1988, BRIT J SURG, V75, P789, DOI 10.1002/bjs.1800750822; TARTTER PI, 1989, TRANSFUSION, V29, P456, DOI 10.1046/j.1537-2995.1989.29589284149.x; TARTTER PI, 1993, BEITR INFUS, V31, P52; TRIULZI DJ, 1992, TRANSFUSION, V32, P517, DOI 10.1046/j.1537-2995.1992.32692367194.x; TRIULZI DJ, 1990, TRANSFUSION MEDICINE IN THE 1990S, P1; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1042, DOI 10.1093/oxfordjournals.aje.a116398; ZHENG TZ, 1992, CANCER, V70, P840, DOI 10.1002/1097-0142(19920815)70:4&lt;840::AID-CNCR2820700420&gt;3.0.CO;2-I	41	31	32	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1997	127	5					365	+		10.7326/0003-4819-127-5-199709010-00004	http://dx.doi.org/10.7326/0003-4819-127-5-199709010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU100	9273827				2022-12-24	WOS:A1997XU10000004
J	Laor, A; Stevenson, DK; Shemer, J; Gale, R; Seidman, DS				Laor, A; Stevenson, DK; Shemer, J; Gale, R; Seidman, DS			Size at birth, maternal nutritional status in pregnancy, and blood pressure at age 17: population based analysis	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; FETAL INFLUENCES; WEIGHT; HYPERTENSION; CHILDHOOD; GROWTH; ADOLESCENCE; CHILDREN; INFANTS; WOMEN	Objective: To assess the effect of size at birth, maternal nutrition, and body mass index on blood pressure in late adolescence. Design: Population based analysis of birth weight corrected for gestational age, mother's weight before pregnancy and weight gain in pregnancy, obtained from the Jerusalem perinatal study, and blood pressure and body mass index at age 17, available from military draft records. Setting: Jerusalem, Israel. Subjects: 10 883 subjects (6684 men and 4199 women) born in Jerusalem during 1974-6 and subsequently drafted to the army. Main outcome measures: Systolic and diastolic blood pressures measured at age 17 and their correlation with birth weight, size at birth, mother's body mass index and weight gain during pregnancy, and height and weight at age 17. Results: Systolic and diastolic blood pressures were significantly and positively correlated with body weight, height, body mass index at age 17, and with mother's body weight and body mass index before pregnancy, but not with birth weight or mother's weight gain in pregnancy. Conclusion: Variables reflecting poor intrauterine nutrition, including low maternal body mass index before pregnancy, poor maternal weight gain in pregnancy, and being born small for gestational age, were not associated with a higher blood pressure in late adolescence.	CHAIM SHEBA MED CTR,DEPT OBSTET & GYNECOL,IL-52621 TEL HASHOMER,ISRAEL; CARMEL HOSP,DEPT INTERNAL MED,HAIFA,ISRAEL; STANFORD UNIV,SCH MED,DEPT PEDIAT,STANFORD,CA 94305; TEL AVIV UNIV,SACKLER SCH MED,CHAIM SHEBA MED CTR,DEPT INTERNAL MED,TEL HASHOMER,ISRAEL; BIKUR CHOLIM HOSP,DEPT NEONATOL,JERUSALEM,ISRAEL	Chaim Sheba Medical Center; Clalit Health Services; Carmel Medical Center; Stanford University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine								BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; CAMBELL DM, 1996, BRIT J OBSTET GYNAEC, V103, P273; DANN PM, 1985, ACTA PAEDIATR SC   S, V319, P7; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; Forrester TE, 1996, BRIT MED J, V312, P156; GODFREY KM, 1994, BRIT J OBSTET GYNAEC, V101, P398, DOI 10.1111/j.1471-0528.1994.tb11911.x; HARLAP S, 1979, NEW ENGL J MED, V300, P1445, DOI 10.1056/NEJM197906283002601; HARLAP S, 1977, ISRAEL J MED SCI, V13, P1073; HARLAP S, 1978, PILLS BIRTHS JERUSAL; JONES DW, 1994, J HYPERTENS, V12, P1433, DOI 10.1097/00004872-199412000-00018; KARK JD, 1986, ISRAEL J MED SCI, V12, P318; LAUNER LJ, 1993, BMJ-BRIT MED J, V307, P1451, DOI 10.1136/bmj.307.6917.1451; LAW C, 1995, J HUM HYPERTENS, V9, P649; LAW CM, 1994, J HYPERTENS, V12, P1329; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Lindsay CA, 1997, OBSTET GYNECOL, V89, P377, DOI 10.1016/S0029-7844(96)00517-0; LUCAS A, 1994, BRIT MED J, V309, P302; MACINTYRE S, 1991, J EPIDEMIOL COMMUN H, V45, P143, DOI 10.1136/jech.45.2.143; MATTHES JWA, 1994, BMJ-BRIT MED J, V308, P1074, DOI 10.1136/bmj.308.6936.1074; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; SEIDMAN DS, 1989, OBSTET GYNECOL, V74, P240; WHINCUP P, 1995, BRIT MED J, V311, P773, DOI 10.1136/bmj.311.7008.773; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L	26	88	94	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					449	453		10.1136/bmj.315.7106.449	http://dx.doi.org/10.1136/bmj.315.7106.449			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284660	Green Published			2022-12-24	WOS:A1997XT71400014
J	Pearlman, M; Faix, R				Pearlman, M; Faix, R			No rush to obliterate genital tract colonisation in pregnant women	LANCET			English	Editorial Material							INFECTIONS; BIRTH		UNIV MICHIGAN,CTR MED,DEPT PAEDIAT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Pearlman, M (corresponding author), UNIV MICHIGAN,CTR MED,DEPT OBSTET & GYNAECOL,ANN ARBOR,MI 48109, USA.							BARTLETT JG, 1977, J INFECT DIS, V136, P271, DOI 10.1093/infdis/136.2.271; ESCHENBACH DA, 1991, AM J OBSTET GYNECOL, V164, P734, DOI 10.1016/0002-9378(91)90506-M; HALL RT, 1976, AM J OBSTET GYNECOL, V124, P630, DOI 10.1016/0002-9378(76)90065-X; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; Krohn MA, 1997, J INFECT DIS, V175, P606, DOI 10.1093/infdis/175.3.606; MCGREGOR JA, 1995, AM J OBSTET GYNECOL, V173, P157, DOI 10.1016/0002-9378(95)90184-1; MEIS PJ, 1995, AM J OBSTET GYNECOL, V173, P1231, DOI 10.1016/0002-9378(95)91360-2; MORALES WJ, 1994, AM J OBSTET GYNECOL, V171, P345, DOI 10.1016/S0002-9378(94)70033-8	8	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					531	532		10.1016/S0140-6736(05)63133-9	http://dx.doi.org/10.1016/S0140-6736(05)63133-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284770				2022-12-24	WOS:A1997XT22100003
J	Sorensen, HT; Sabroe, S; Olsen, J; Rothman, KJ; Gillman, MW; Fischer, P				Sorensen, HT; Sabroe, S; Olsen, J; Rothman, KJ; Gillman, MW; Fischer, P			Birth weight and cognitive function in young adult life: historical cohort study	BRITISH MEDICAL JOURNAL			English	Article							INFANTS	Objective: To examine the relation between birth weight and cognitive function in young adult life. Design: Retrospective cohort study based on birth registry data and cognitive function measured during evaluation for military service. Subjects: 4300 Danish conscripts born between 1973 and 1975. Main outcome measures: Mean score in the Boerge Prien test of cognitive function; score is the number of correct answers to 78 questions and correlates with full scale intelligence quotient (IQ). Results: Mean score in the Boerge Prien test increased from 39.9 at a birth weight of less than or equal to 2500 g to 44.6 at a birth weight of 4200 g even after adjustment for gestational age and length at birth, maternal age and parity and other variables. Above a birth weight of 4200 g the test score decreased slightly. Conclusion: Birth weight is associated with cognitive performance in young adult life, Interference with fetal growth may influence adult cognitive performance.	AARHUS UNIV HOSP,DEPT INTERNAL MED 5,DK-8000 AARHUS C,DENMARK; BOSTON UNIV,SCH MED,DEPT EPIDEMIOL & PREVENT MED,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02215; HARVARD PILGRIM HLTH CARE,BOSTON,MA 02215; CONSCRIPT ADM,COUNTY N JUTLAND,DK-9000 AALBORG,DENMARK	Aarhus University; Boston University; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care			Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Rothman, Kenneth/0000-0003-2398-1705				Barker D. J. P., 1994, MOTHERS BABIES DIS L; ELARDO R, 1975, CHILD DEV, V46, P71; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; LANTING CI, 1994, LANCET, V344, P1319, DOI 10.1016/S0140-6736(94)90692-0; Martyn CN, 1996, BRIT MED J, V312, P1393; MORGANE PJ, 1993, NEUROSCI BIOBEHAV R, V17, P91, DOI 10.1016/S0149-7634(05)80234-9; Mortensen EL, 1989, SCAND J PSYCHOL, V30, P3115; OLSEN J, 1994, SCAND J SOC MED, V22, P213, DOI 10.1177/140349489402200310; Osofsky H J, 1975, Obstet Gynecol Surv, V30, P227, DOI 10.1097/00006254-197504000-00001; TEMBOURY MC, 1994, J PEDIATR GASTR NUTR, V18, P32, DOI 10.1097/00005176-199401000-00005	10	164	168	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					401	403		10.1136/bmj.315.7105.401	http://dx.doi.org/10.1136/bmj.315.7105.401			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XR549	9277604	Green Published			2022-12-24	WOS:A1997XR54900020
J	Nakamura, TM; Morin, GB; Chapman, KB; Weinrich, SL; Andrews, WH; Lingner, J; Harley, CB; Cech, TR				Nakamura, TM; Morin, GB; Chapman, KB; Weinrich, SL; Andrews, WH; Lingner, J; Harley, CB; Cech, TR			Telomerase catalytic subunit homologs from fission yeast and human	SCIENCE			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; TETRAHYMENA TELOMERASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; IMMORTAL CELLS; DNA; RNA; SEQUENCES; CANCER; GENES	Catalytic protein subunits of telomerase from the ciliate Euplotes aediculatus and the yeast Saccharomyces cerevisiae contain reverse transcriptase motifs. Here the homologous genes from the fission yeast Schizosaccharomyces pombe and human are identified. Disruption of the S. pombe gene resulted in telomere shortening and senescence, and expression of mRNA from the human gene correlated with telomerase activity in cell lines. Sequence comparisons placed the telomerase proteins in the reverse transcriptase family but revealed hallmarks that distinguish them from retroviral and retrotransposon relatives. Thus, the proposed telomerase catalytic subunits are phylogenetically conserved and represent a deep branch in the evolution of reverse transcriptases.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; GERON CORP,MENLO PK,CA 94025	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Geron Corporation			Nakamura, Toru M/B-2055-2008; Morin, Gregg B/E-9123-2012	Nakamura, Toru M/0000-0001-5752-0814; Morin, Gregg B/0000-0001-8949-4374; Lingner, Joachim/0000-0002-2853-5803	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028039, R01GM028039] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28039] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfa C., 1993, EXPT FISSION YEAST; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, IN PRESS P NATL ACAD; Eickbush Thomas H., 1994, P121; Felsenstein J, 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P4673; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1996, DNA REPLICATION EUKA, P619; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Javerzat JP, 1996, NUCLEIC ACIDS RES, V24, P4676, DOI 10.1093/nar/24.23.4676; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lendvay TS, 1996, GENETICS, V144, P1399; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LEVIS RW, 1993, CELL, V75, P1; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Pardue ML, 1996, TRENDS GENET, V12, P48, DOI 10.1016/0168-9525(96)81399-0; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; Powell MD, 1997, J BIOL CHEM, V272, P13262, DOI 10.1074/jbc.272.20.13262; Ricchetti M, 1996, BIOCHEMISTRY-US, V35, P14970, DOI 10.1021/bi961274v; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZHANG MQ, 1994, NUCLEIC ACIDS RES, V22, P1750, DOI 10.1093/nar/22.9.1750	41	2006	2185	3	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					955	959		10.1126/science.277.5328.955	http://dx.doi.org/10.1126/science.277.5328.955			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252327				2022-12-24	WOS:A1997XQ98500042
J	Hedtke, B; Borner, T; Weihe, A				Hedtke, B; Borner, T; Weihe, A			Mitochondrial and chloroplast phage-type RNA polymerases in Arabidopsis	SCIENCE			English	Article							PROTEIN-TRANSPORT; BACTERIOPHAGE-T7; SUBUNIT	In addition to the RNA polymerases (RNAPs) transcribing the nuclear genes, eukaryotic cells also require RNAPs to transcribe the genes of the mitochondrial genome and, in plants, of the chloroplast genome, The plant Arabidopsis thaliana was found to contain two nuclear genes similar to genes encoding the mitochondrial RNAP from yeast and RNAPs of bacteriophages T7, T3, and SP6. The putative transit peptides of the two polymerases were capable of targeting fusion proteins to mitochondria and chloroplasts, respectively, in vitro. The results indicate that the mitochondrial RNAP in plants is a bacteriophage-type enzyme. A gene duplication event may have generated the second RNAP, which along with the plastid-encoded eubacteria-like RNAP could transcribe the chloroplast genome.	HUMBOLDT UNIV BERLIN,INST BIOL,D-10115 BERLIN,GERMANY	Humboldt University of Berlin				Borner, Thomas/0000-0001-9548-3348				Allison LA, 1996, EMBO J, V15, P2802, DOI 10.1002/j.1460-2075.1996.tb00640.x; BOGORAD L, 1990, MOL BIOL PLASTIDS, P93; Bruce B.D., 1994, PLANT MOL BIOL MANUA, VJ1, P1; Cermakian N, 1996, NUCLEIC ACIDS RES, V24, P648, DOI 10.1093/nar/24.4.648; CHAUMONT F, 1994, PLANT MOL BIOL, V24, P631, DOI 10.1007/BF00023559; CHAUMONT F, 1990, J BIOL CHEM, V265, P16856; Chen B, 1996, J BIOL CHEM, V271, P6537, DOI 10.1074/jbc.271.11.6537; Ems SC, 1995, PLANT MOL BIOL, V29, P721, DOI 10.1007/BF00041163; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; HESS WR, 1993, EMBO J, V12, P563, DOI 10.1002/j.1460-2075.1993.tb05688.x; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KELLY JL, 1986, J BIOL CHEM, V261, P348; KLOSGEN RB, 1989, MOL GEN GENET, V217, P155, DOI 10.1007/BF00330955; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; LERBSMACHE S, 1993, P NATL ACAD SCI USA, V90, P5509, DOI 10.1073/pnas.90.12.5509; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; PATRA D, 1992, J MOL BIOL, V224, P307, DOI 10.1016/0022-2836(92)90996-W; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Weihe A, 1997, NUCLEIC ACIDS RES, V25, P2319, DOI 10.1093/nar/25.12.2319	21	302	320	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					809	811		10.1126/science.277.5327.809	http://dx.doi.org/10.1126/science.277.5327.809			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242608				2022-12-24	WOS:A1997XQ24700041
J	DiDonato, JA; Hayakawa, M; Rothwarf, DM; Zandi, E; Karin, M				DiDonato, JA; Hayakawa, M; Rothwarf, DM; Zandi, E; Karin, M			A cytokine-responsive I kappa B kinase that activates the transcription factor NF-kappa B	NATURE			English	Article							ALPHA PROTEOLYSIS; PHOSPHORYLATION; FAMILY; DISSOCIATION; DEGRADATION; SUFFICIENT; PROTEINS; RECEPTOR; DOMAIN	Nuclear transcription factors of the NF-kappa B/Rel family are inhibited by I kappa B proteins, which inactivate NF-kappa B by trapping it in the cell cytoplasm. Phosphorylation of I kappa Bs marks them out for destruction, thereby relieving their inhibitory effect on NF-kappa B. A cytokine-activated protein kinase complex, IKK (for I kappa B kinase), has now been purified that phosphorylates I kappa Bs on the sites that trigger their degradation. A component of IKK was molecularly cloned and identified as a serine kinase. IKK turns out to be the long-sought-after protein kinase that mediates the critical regulatory step In NF-kappa B activation.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LAB GENE REGULAT & SIGNAL TRANSDUCT,LA JOLLA,CA 92093	University of California System; University of California San Diego			Hazen, Stanley L/ABD-5845-2021					ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CAO Z, 1996, SCIENCE, V383, P443; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	31	1845	1946	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					548	554		10.1038/41493	http://dx.doi.org/10.1038/41493			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252186	Bronze			2022-12-24	WOS:A1997XP72200039
J	Kolavic, SA; Kimura, A; Simons, SL; Slutsker, L; Barth, S				Kolavic, SA; Kimura, A; Simons, SL; Slutsker, L; Barth, S			An outbreak of Shigella dysenteriae type 2 among laboratory workers due to intentional food contamination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIELD GEL-ELECTROPHORESIS; SONNEI	Context.-Shigella dysenteriae type 2 is rare in the United States, and outbreaks associated with this pathogen are uncommon. Objective.-To determine the magnitude and source of an outbreak of S dysenteriae type 2. Design.-Retrospective cohort. Setting.-Laboratory of a large medical center. Patients.-Case patients were identified as laboratory workers who had diarrhea on or after October 28 and a positive stool culture or temperature greater than 37.8 degrees C. Laboratory workers with diarrhea only were probable case patients. Main Outcome Measures.-We interviewed laboratory staff and performed identification, serotyping, and pulsed-field gel electrophoresis on isolates from case patients, implicated food, and laboratory stock culture. Results.-From October 29 through November 1, a total of 12 (27%) of 45 laboratory staff developed severe, acute diarrheal illness; 8 had S dysenteriae isolated from stool and 4 were hospitalized. All case patients reported having eaten muffins or doughnuts placed in the staff break room on October 29. Pulsed-field gel electrophoresis showed stool isolates from 9 case patients were indistinguishable from S dysenteriae type 2 recovered from an uneaten muffin and from the laboratory's stock strain, a portion of which was missing. Conclusions.-The source of the outbreak was most likely the laboratory's stock culture, which was used to contaminate the pastries. Results of this investigation underscore the need for adequate precautions to prevent inadvertent or intentional contamination from highly pathogenic laboratory specimens.	CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,FOODBORNE & DIARRHEAL DIS BRANCH,ATLANTA,GA 30333; TEXAS DEPT HLTH,BUR LABS,AUSTIN,TX 78756; TEXAS DEPT HLTH,BUR CHRON DIS PREVENT & CONTROL,AUSTIN,TX 78756; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,STATE BRANCH,ATLANTA,GA 30333; DALLAS CTY HLTH & HUMAN SERV,DALLAS,TX	Centers for Disease Control & Prevention - USA; Texas Department of State Health Services; Texas Department of State Health Services; Centers for Disease Control & Prevention - USA								[Anonymous], 1995, CONTROL COMMUNICABLE; *ASS OFF AN CHEM, 1992, BACT AN MAN; BLASER MJ, 1983, J INFECT DIS, V147, P771, DOI 10.1093/infdis/147.4.771; BRIAN MJ, 1993, J CLIN MICROBIOL, V31, P2152, DOI 10.1128/JCM.31.8.2152-2156.1993; *CDC, 1983, MMWR-MORBID MORTAL W, V32, P250; Dean A.G., 1994, EPI INFO VERSION 6 W; Evans AC, 1938, LANCET, V2, P187; LIU PYF, 1995, J CLIN MICROBIOL, V33, P1779, DOI 10.1128/JCM.33.7.1779-1783.1995; NASTASI A, 1991, MICROBIOLOGICA, V14, P219; *OR HLTH DIV, 1984, COMM DIS SUMM, V33, P1; PARKER MT, 1983, TOPLEY WILSONS PRINC, V3, P434; PHILLS JA, 1972, NEW ENGL J MED, V286, P965, DOI 10.1056/NEJM197205042861802; ROWE B, 1983, TOPLEY WILSONS PRINC, V2, P320; SCHMITZ K. E. F., 1917, Zeitschrift fur Hygiene und Infektionskrankheiten, V84, P449, DOI 10.1007/BF02284440; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Torok TJ, 1997, JAMA-J AM MED ASSOC, V278, P389, DOI 10.1001/jama.278.5.389; 1966, SCIENCE J, V2, P11; 1988, UPI             1214	18	110	115	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					396	398		10.1001/jama.278.5.396	http://dx.doi.org/10.1001/jama.278.5.396			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244331				2022-12-24	WOS:A1997XN51800031
J	Rybenkov, VV; Ullsperger, C; Vologodskii, AV; Cozzarelli, NR				Rybenkov, VV; Ullsperger, C; Vologodskii, AV; Cozzarelli, NR			Simplification of DNA topology below equilibrium values by type II topoisomerases	SCIENCE			English	Article							ESCHERICHIA-COLI; PURIFICATION; MECHANISM; TRANSPORT; ENZYME; HELIX; IV	Type II DNA topoisomerases catalyze the interconversion of DNA topoisomers by transporting one DNA segment through another. The steady-state fraction of knotted or catenated DNA molecules produced by prokaryotic and eukaryotic type II topoisomerases was found to be as much as 80 times lower than at thermodynamic equilibrium. These enzymes also yielded a tighter distribution of linking number topoisomers than at equilibrium. Thus, topoisomerases do not merely catalyze passage of randomly juxtaposed DNA segments but control a global property of DNA, its topology. The results imply that type II topoisomerases use the energy of adenosine triphosphate hydrolysis to preferentially remove the topological links that provide barriers to DNA segregation.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; NYU,DEPT CHEM,NEW YORK,NY 10003	University of California System; University of California Berkeley; New York University			Vologodskii, Alexander V/I-6201-2013; Vologodskii, Alexander V/A-6994-2009		NIGMS NIH HHS [GM31657, GM54215] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054215, R37GM031657, R01GM031657] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATES AD, 1993, DNA TOPOLOGY; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; Eckstein F., 1995, NUCLEIC ACIDS MOL BI, P115; KATO J, 1992, J BIOL CHEM, V267, P25676; KELLENBERGER E, 1987, TRENDS BIOCHEM SCI, V12, P105, DOI 10.1016/0968-0004(87)90049-1; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PENG H, 1993, J BIOL CHEM, V268, P24481; POHL WF, 1978, J MATH BIOL, V6, P383, DOI 10.1007/BF02463003; PULLEYBLANK DE, 1975, P NATL ACAD SCI USA, V72, P4280, DOI 10.1073/pnas.72.11.4280; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; Roca J, 1996, GENES CELLS, V1, P17, DOI 10.1046/j.1365-2443.1996.01001.x; RYBENKOV VV, 1993, P NATL ACAD SCI USA, V90, P5307, DOI 10.1073/pnas.90.11.5307; Rybenkov VV, 1997, J MOL BIOL, V267, P312, DOI 10.1006/jmbi.1996.0877; SHAW SY, 1993, SCIENCE, V260, P533, DOI 10.1126/science.8475384; SHORE D, 1983, J MOL BIOL, V170, P983, DOI 10.1016/S0022-2836(83)80199-5; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; VASSETZKY YS, 1994, MOL CELL BIOL, V14, P6962, DOI 10.1128/MCB.14.10.6962; Vologodskii A, 1996, BIOPHYS J, V70, P2548, DOI 10.1016/S0006-3495(96)79826-0; WANG JC, 1966, J MOL BIOL, V15, P111, DOI 10.1016/S0022-2836(66)80213-9; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	25	230	231	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					690	693		10.1126/science.277.5326.690	http://dx.doi.org/10.1126/science.277.5326.690			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235892				2022-12-24	WOS:A1997XN90700042
J	Gillum, RF; Mussolino, ME; Madans, JH				Gillum, RF; Mussolino, ME; Madans, JH			Coronary heart disease incidence and survival in African-American women and men - The NHANES I epidemiologic follow-up study	ANNALS OF INTERNAL MEDICINE			English	Article						coronary disease; blacks; follow-up studies; myocardial infarction; sex factors	RISK-FACTORS; UNITED-STATES; MYOCARDIAL-INFARCTION; BLACK POPULATIONS; CIGARETTE-SMOKING; EVANS COUNTY; WHITE MEN; MORTALITY; INFORMATION; CHOLESTEROL	Background: Relatively few data are available on risk for or survival with cor Objective: To determine whether incidence of coronary heart disease, rate of survival with the disease. and rate of coronary surgery differ between ethnic groups. Design: Prospective cohort study. Setting: United States. Participants: Persons who responded to the National Health and Nutrition Examination Survey (NHANES) I Epidemiologic Follow-up Study. Included in this analysis were 11 406 white persons and African-American persons aged 25 to 74 years who had no history of coronary heart disease. Average follow-up for survivors was 19 years (maximum, 22 years). Measurements: Incident coronary heart disease. Results: Compared with that in white persons, the age-adjusted risk for coronary heart disease was higher in African-American women aged 25 to 54 years (relative risk. 1.76 [95% CI, 1.36 to 2.29]) but was lower in African-American men within each age subgroup. The age-adjusted risk was lower in African-American men for all ages combined (25 to 74 years) (relative risk, 0.78 [CI, 0.65 to 0.93] for coronary heart disease and 0.62 [CI, 0.42 to 0.92] for acute myocardial infarction). The higher rate in African-American women aged 25 to 54 years could be explained statistically by the higher risk factor levels iri these women. Ethnic groups did not significantly differ in survival after the first hospitalization for coronary heart disease. However, the incidence of coronary procedures after hospitalization for coronary heart disease was markedly lower in African-American persons than in white persons (age- and sex-adjusted relative risk, 0.40 [CI, 0.16 to 0.991). Conclusions: Total incidence of coronary heart disease is higher in African-American women aged 25 to 54 years than in white women of the same ages and is lower in African-American men aged 25 to 74 years than in white men of the same ages.	CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, OFF CTR DIRECTOR, HYATTSVILLE, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Gillum, RF (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, OFF ANAL EPIDEMIOL & HLTH PROMOT, 6525 BELCREST RD, HYATTSVILLE, MD 20782 USA.							Cohen B B, 1987, Vital Health Stat 1, P1; COOPER R, 1991, CARDIOVASCULAR DISEA, P205; Cooper R S, 1992, Ann Epidemiol, V2, P637; Cox C S, 1992, Vital Health Stat 1, P1; Engel A, 1978, Vital Health Stat 1, P1; Finucane F F, 1990, Vital Health Stat 1, P1; GILLUM RF, 1987, AM HEART J, V113, P1255, DOI 10.1016/0002-8703(87)90952-5; Gillum RF, 1996, NEW ENGL J MED, V335, P1597, DOI 10.1056/NEJM199611213352110; GILLUM RF, 1982, AM HEART J, V104, P839, DOI 10.1016/0002-8703(82)90021-7; GILLUM RF, 1982, AM HEART J, V104, P852, DOI 10.1016/0002-8703(82)90022-9; GILLUM RF, 1987, AM HEART J, V113, P804, DOI 10.1016/0002-8703(87)90723-X; GILLUM RF, 1989, CIRCULATION, V79, P756, DOI 10.1161/01.CIR.79.4.756; GILLUM RF, 1984, AM HEART J, V108, P727, DOI 10.1016/0002-8703(84)90664-1; GILLUM RF, 1991, CARDIOVASCULAR DIS B, P3; INGRAM DD, 1989, STAT MED, V8, P525, DOI 10.1002/sim.4780080502; INGRAM DD, 1994, SERIES VITAL HLTH ST, V2, P1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KEIL JE, 1995, ARCH INTERN MED, V155, P1521, DOI 10.1001/archinte.155.14.1521; KEIL JE, 1984, AM HEART J, V108, P779, DOI 10.1016/0002-8703(84)90671-9; KLAG MJ, 1989, CIRCULATION S1, V80, P300; Kumanyika S, 1996, NEW ENGL J MED, V335, P738, DOI 10.1056/NEJM199609053351011; LEAVERTON PE, 1990, HLTH STATUS WELL BEI, P53; Lee Marshall H., 1990, Annals of Epidemiology, V1, P1; LIAO YL, 1992, JAMA-J AM MED ASSOC, V268, P1867, DOI 10.1001/jama.268.14.1867; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MADANS JH, 1986, PUBLIC HEALTH REP, V101, P474; MADANS JH, 1986, PUBLIC HEALTH REP, V101, P465; MADANS JH, 1995, STAT MED, V14, P643, DOI 10.1002/sim.4780140521; MAYNARD C, 1987, AM J CARDIOL, V60, P513, DOI 10.1016/0002-9149(87)90296-7; MCLAUGHLIN JK, 1987, AM J EPIDEMIOL, V126, P144, DOI 10.1093/oxfordjournals.aje.a114647; MILLER HERBERT S., 1978, PLAN OPERATION HLTH, P1; *NAT CTR HLTH STAT, 1979, HANES 1 HEM CLIN CHE; National Heart Lung and Blood Institute, 1994, REP WORK GROUP RES C, P1; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; Popkin BM, 1996, NEW ENGL J MED, V335, P716, DOI 10.1056/NEJM199609053351006; *RES TRIANGL I, 1992, SOFTW SURV DES AN SU; *SAS I INC, 1991, P217 SAS I INC, P1; *SAS I INC, 1985, SAS US GUID STAT, P529; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; Traven ND, 1996, ANN EPIDEMIOL, V6, P130, DOI 10.1016/1047-2797(95)00131-X; TYROLER HA, 1984, AM HEART J, V108, P738, DOI 10.1016/0002-8703(84)90667-7; WATKINS LO, 1986, AM J CARDIOL, V57, P538, DOI 10.1016/0002-9149(86)90831-3; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0	45	124	124	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					111	+		10.7326/0003-4819-127-2-199707150-00003	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9229999				2022-12-24	WOS:A1997XK15800005
J	Bird, AG; Gore, SM; Hutchinson, SJ; Lewis, SC; Cameron, S; Burns, S				Bird, AG; Gore, SM; Hutchinson, SJ; Lewis, SC; Cameron, S; Burns, S			Harm reduction measures and injecting inside prison versus mandatory drugs testing: Results of a cross sectional anonymous questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							HIV SURVEILLANCE	Objectives: (a) To determine both the frequency of injecting inside prison and use of sterilising tablets to clean needles in the previous four weeks; (b) to assess the efficiency of random mandatory drugs testing at detecting prisoners who inject heroin inside prison; (c) to determine the percentage of prisoners who had been offered vaccination against hepatitis B. Design: Cross sectional willing anonymous salivary HIV surveillance linked to a self completion risk factor questionnaire. Setting: Lowmoss prison, Glasgow, and Aberdeen prison on 11 and 30 October 1996. Subjects: 293 (94%) of all 312 inmates at Lowmoss and 146 (93%) of all 157 at Aberdeen, resulting in 286 and 143 valid questionnaires. Main outcome measures: Frequency of injecting inside prison in the precious four weeks by injector inmates who had been in prison for at least four weeks. Results: 116 (41%) Lowmoss and 53 (37%) Aberdeen prisoners had a history of injecting drug use but only 4% of inmates (17/395; 95% confidence interval 2% to 6%) had ever been offered vaccination against hepatitis B. 42 Lowmoss prisoners (estimated 207 injections and 258 uses of sterilising tablets) and 31 Aberdeen prisoners (229 injections, 221 uses) had injected inside prison in the previous four weeks. The prisons together held 112 injector inmates who had been in prison for more than four weeks, of whom 57 (51%; 42% to 60%) had injected in prison in the past four weeks; their estimated mean number of injections was 6.0 (SD 5.7). Prisoners injecting heroin six times in four weeks will test positive in random mandatory drugs testing on at most 18 days out of 28. Conclusions: Sterilising tablets and hepatitis B vaccination should be offered to all prisoners. Random mandatory drugs testing seriously underestimates injector inmates' harm reduction needs.	REG VIRUS LAB,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND; CHURCHILL HOSP,OXFORD OX3 7LJ,ENGLAND; MRC BIAS,EDINBURGH EH9 3JN,MIDLOTHIAN,SCOTLAND; REG VIRUS LAB,GLASGOW G20 9NB,LANARK,SCOTLAND	MRC Biostatistics Unit; University of Oxford								Acheson D, 1997, BRIT MED J, V314, P302; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BIRD AG, 1995, AIDS, V9, P801, DOI 10.1097/00002030-199507000-00019; BIRD AG, 1994, AIDS, V8, P1345, DOI 10.1097/00002030-199409000-00021; BIRD AG, 1996, HERALD          0122, P12; CROFTS N, 1995, BRIT MED J, V310, P285, DOI 10.1136/bmj.310.6975.285; FREEMAN J, 1996, HERALD          1012, P4; GORE SM, 1995, BRIT MED J, V310, P293, DOI 10.1136/bmj.310.6975.293; GORE SM, 1995, BRIT MED J, V310, P595, DOI 10.1136/bmj.310.6979.595; GORE SM, IN PRESS INT J STD A; GORE SM, 1995, ANSWER, V39, P1; Her Majesty's Inspectorate of Prisons, 1996, PAT PRIS NEW STRAT H; *HM PRIS SERV, 1995, DRUG MIS PRIS POL ST, P7; JURGENS R, 1996, HIV AIDS PRISONS; MANGTANI P, 1995, BRIT MED J, V311, P1500, DOI 10.1136/bmj.311.7018.1500; Nelles J., 1995, DRUG HIV PREVENTION; PAYNEJAMES JJ, 1994, J ROY SOC MED, V87, P13; *TASK FORC REV SER, 1996, IND REV DRUG TREATM; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289; *WHO, 1993, GLOB PROGR AIDS WHO; WOODS J, 1997, SCOTSMAN        0114, P13	21	55	55	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					21	24		10.1136/bmj.315.7099.21	http://dx.doi.org/10.1136/bmj.315.7099.21			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ947	9233321	Green Published			2022-12-24	WOS:A1997XJ94700022
J	Bullitt, E; Rout, MP; Kilmartin, JV; Akey, CW				Bullitt, E; Rout, MP; Kilmartin, JV; Akey, CW			The yeast spindle pole body is assembled around a central crystal of Spc42p	CELL			English	Article							CRYO-ELECTRON MICROSCOPY; SACCHAROMYCES-CEREVISIAE; TILT SERIES; HALF-BRIDGE; CELL-CYCLE; PROTEIN; RECONSTRUCTION; PLAQUES; DUPLICATION; CENTROSOMES	The spindle pole body (SPB) is the microtubule organizing center (MTOC) in the yeast Saccharomyces that plays a pivotal role in such diverse processes as mitosis, budding, and mating. We have used cryoelectron microscopy and image processing to study the structure of isolated diploid SPBs. We show that SPBs are present in two lateral-size classes, sharing a similar vertical architecture comprised of six major layers. Tomographic reconstructions of heparin-stripped SPBs reveal a central hexagonally packed layer. Overexpression of Spc42p results in the growth of a similar layer, forming a crystal that encircles the SPB. Hence, the SPB is an MTOC that utilizes crystallographic packing of subunits in its construction.	ROCKEFELLER UNIV,CELL BIOL LAB,NEW YORK,NY 10021; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Rockefeller University; MRC Laboratory Molecular Biology	Bullitt, E (corresponding author), BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02118, USA.		Rout, Michael/Y-7090-2018	Rout, Michael/0000-0003-2010-706X; Akey, Christopher/0000-0002-3059-3121				AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; AKEY CW, 1992, NUCLEAR TRAFFICKING, P31; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; BYERS B, 1978, J CELL SCI, V30, P331; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; BYERS B, 1974, COLD SPRING HARB SYM, V38, P123; Byers B, 1981, MOL BIOL YEAST SACCH, P59; DENGLER J, 1989, ULTRAMICROSCOPY, V30, P337, DOI 10.1016/0304-3991(89)90063-6; Donaldson AD, 1996, J CELL BIOL, V132, P887, DOI 10.1083/jcb.132.5.887; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; ERRABOLU R, 1994, J CELL SCI, V107, P9; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Geissler S, 1996, EMBO J, V15, P3899, DOI 10.1002/j.1460-2075.1996.tb00764.x; GUCKENBERGER R, 1982, ULTRAMICROSCOPY, V9, P167, DOI 10.1016/0304-3991(82)90239-X; Hardt S, 1996, J STRUCT BIOL, V116, P68, DOI 10.1006/jsbi.1996.0012; Kilmartin JV, 1996, EMBO J, V15, P4592, DOI 10.1002/j.1460-2075.1996.tb00837.x; KILMARTIN JV, 1993, J CELL BIOL, V123, P1175, DOI 10.1083/jcb.123.5.1175; KING SM, 1982, J CELL BIOL, V94, P341, DOI 10.1083/jcb.94.2.341; Knop M, 1997, EMBO J, V16, P1550, DOI 10.1093/emboj/16.7.1550; LEE VD, 1993, P NATL ACAD SCI USA, V90, P11039, DOI 10.1073/pnas.90.23.11039; LIU Y, 1995, ULTRAMICROSCOPY, V58, P393, DOI 10.1016/0304-3991(95)00006-M; Marschall LG, 1996, J CELL BIOL, V134, P443, DOI 10.1083/jcb.134.2.443; MOENS PB, 1971, J CELL BIOL, V50, P344, DOI 10.1083/jcb.50.2.344; MORITZ M, 1995, J CELL BIOL, V130, P1149, DOI 10.1083/jcb.130.5.1149; Owen CH, 1996, ULTRAMICROSCOPY, V63, P27, DOI 10.1016/0304-3991(95)00154-9; PETERSON JB, 1972, J CELL BIOL, V53, P837, DOI 10.1083/jcb.53.3.837; PETERSON JB, 1976, J CELL SCI, V22, P219; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; ROBINOW CF, 1966, J CELL BIOL, V29, P129, DOI 10.1083/jcb.29.1.129; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROUT MP, 1991, COLD SH Q B, V56, P687; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; SCHMID MF, 1993, ULTRAMICROSCOPY, V48, P251, DOI 10.1016/0304-3991(93)90099-J; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; SPANG A, 1993, J CELL BIOL, V123, P405, DOI 10.1083/jcb.123.2.405; Spang A, 1996, J CELL BIOL, V134, P429, DOI 10.1083/jcb.134.2.429; SPANG A, 1995, J CELL BIOL, V128, P863, DOI 10.1083/jcb.128.5.863; STALLMEYER MJB, 1989, J MOL BIOL, V205, P519, DOI 10.1016/0022-2836(89)90223-4; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; TOYOSHIMA C, 1989, ULTRAMICROSCOPY, V30, P439, DOI 10.1016/0304-3991(89)90076-4; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745	43	154	154	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1077	1086		10.1016/S0092-8674(00)80295-0	http://dx.doi.org/10.1016/S0092-8674(00)80295-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215630	hybrid			2022-12-24	WOS:A1997XG83000012
J	Parekh, AB; Fleig, A; Penner, R				Parekh, AB; Fleig, A; Penner, R			The store-operated calcium current I-CRAC: Nonlinear activation by InsP(3) and dissociation from calcium release	CELL			English	Article							HUMAN UMBILICAL VEIN; RBL-2H3 CELLS; INOSITOL TRISPHOSPHATE; ENDOTHELIAL-CELLS; ACINAR-CELLS; CA2+ ENTRY; MAST-CELLS; DEPLETION; RECEPTOR; SIGNALS	Patch-clamp experiments aimed at determining the relationship between intracellular Ca2+ release and activation of store-operated calcium current I-CRAC reveal that both agonist and InsP(3)-mediated activation of I-CRAC are highly nonlinear, occurring over a narrow concentration range. Ca2+ release and Ca2+ influx can be dissociated, as they possess differential sensitivities to InsP(3): low concentrations induce substantial Ca2+ release without any activation of I-CRAC, whereas micromolar concentrations of InsP(3) are required to activate Ca2+ influx. This suggests functionally distinct stores controlling Ca2+ release and influx and enables cells to switch between sources of Ca2+ to fit best their current needs.	MAX PLANCK INST BIOPHYS CHEM, D-37077 GOTTINGEN, GERMANY	Max Planck Society				Penner, Reinhold/0000-0002-5366-1537; Fleig, Andrea/0000-0001-8396-7249				ALI H, 1990, J BIOL CHEM, V265, P745; ALI H, 1994, BIOCHEM J, V304, P431, DOI 10.1042/bj3040431; Berridge Michael J., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P211; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CHIAVAROLI C, 1994, J BIOL CHEM, V269, P25570; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CHOI OH, 1993, J IMMUNOL, V151, P5586; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; GIOVANNARDI S, 1992, EXP CELL RES, V202, P398, DOI 10.1016/0014-4827(92)90092-M; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1994, AM J PHYSIOL, V266, pC1736, DOI 10.1152/ajpcell.1994.266.6.C1736; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; NILIUS B, 1993, PFLUG ARCH EUR J PHY, V424, P285, DOI 10.1007/BF00384354; Parekh AB, 1995, J PHYSIOL-LONDON, V489, P377, DOI 10.1113/jphysiol.1995.sp021058; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Schrenzel J, 1995, BIOPHYS J, V69, P2378, DOI 10.1016/S0006-3495(95)80107-4; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209	29	199	202	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					973	980		10.1016/S0092-8674(00)80282-2	http://dx.doi.org/10.1016/S0092-8674(00)80282-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200615	Bronze			2022-12-24	WOS:A1997XE35700017
J	Miyawaki, A; Llopis, J; Heim, R; McCaffery, JM; Adams, JA; Ikura, M; Tsien, RY				Miyawaki, A; Llopis, J; Heim, R; McCaffery, JM; Adams, JA; Ikura, M; Tsien, RY			Fluorescent indicators for Ca2+ based on green fluorescent proteins and calmodulin	NATURE			English	Article							ENDOPLASMIC-RETICULUM; POINT MUTATIONS; INTACT-CELLS; 2 SERIES; BINDING; AEQUORIN; SITES	Important Ca2+ signals in the cytosol and organelles are often extremely localized and hard to measure. To overcome this problem we have constructed new fluorescent indicators for Ca2+ that are genetically encoded without cofactors and are targetable to specific intracellular locations. We have dubbed these fluorescent indicators 'cameleons', They consist of tandem fusions of a blue-or cyan-emitting mutant of the green fluorescent protein (GFP)(1,2), calmodulin(3-5), the calmodulin-binding peptide M13 (ref, 6), and an enhanced green-or yellow-emitting GFP(7-9). Binding of Ca2+ makes calmodulin wrap around the M13 domain, increasing the fluorescence resonance energy transfer (FRET) between the flanking GFPs(2), Calmodulin mutations can tune the Ca2+ affinities to measure free Ca2+ concentrations in the range 10(-8) to 10(-2) M, We have visualized free Ca2+ dynamics in the cytosol, nucleus and endoplasmic reticulum of single HeLa cells transfected with complementary DNAs encoding chimaeras bearing appropriate localization signals, Ca2+ concentration in the endoplasmic reticulum of individual cells ranged from 60 to 400 mu M at rest, and 1 to 50 mu M after Ca2+ mobilization, FRET is also an indicator of the reversible intermolecular association of cyan-GFP-labelled calmodulin with yellow-GFP-labelled M13, Thus FRET between GFP mutants can monitor localized Ca2+ signals and protein heterodimerization in individual live cells.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOL MED, LA JOLLA, CA 92093 USA; SAN DIEGO STATE UNIV, DEPT CHEM, SAN DIEGO, CA 92182 USA; UNIV TORONTO, ONTARIO CANC INST, DIV MOL & STRUCT BIOL, TORONTO, ON M5G 2M9, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON M5G 2M9, CANADA; UNIV TSUKUBA, CTR TSUKUBA ADV RES ALLIANCE, TSUKUBA, IBARAKI 305, JAPAN	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; California State University System; San Diego State University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Tsukuba			Wood, David W/B-2992-2012; Miyawaki, Atsushi/K-3569-2014; Llopis, Juan/I-2622-2012	Miyawaki, Atsushi/0000-0002-2329-3235; Llopis, Juan/0000-0002-9460-0642; Ikura, Mitsuhiko/0000-0002-9524-1303				Adams S.R., 1993, FLUORESCENT PROBES B, P133; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BOOTMAN MD, 1994, J BIOL CHEM, V269, P24783; BRINI M, 1994, CELL CALCIUM, V16, P259, DOI 10.1016/0143-4160(94)90089-2; Button D, 1996, MOL BIOL CELL, V7, P419, DOI 10.1091/mbc.7.3.419; Bygrave FL, 1996, CELL CALCIUM, V19, P547, DOI 10.1016/S0143-4160(96)90064-0; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; GAO ZH, 1993, J BIOL CHEM, V268, P20096; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hofer AM, 1996, CELL CALCIUM, V20, P235, DOI 10.1016/S0143-4160(96)90029-9; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V189, P1008, DOI 10.1016/0006-291X(92)92304-G; Kendall JM, 1996, BIOCHEM J, V318, P383, DOI 10.1042/bj3180383; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Martin SR, 1996, BIOCHEMISTRY-US, V35, P3508, DOI 10.1021/bi952522a; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PORUMB T, 1994, PROTEIN ENG, V7, P109, DOI 10.1093/protein/7.1.109; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; SMIT MJ, 1993, EUR J PHARM-MOLEC PH, V247, P223, DOI 10.1016/0922-4106(93)90082-K; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	30	2409	2595	19	787	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	1997	388	6645					882	887		10.1038/42264	http://dx.doi.org/10.1038/42264			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278050	Bronze			2022-12-24	WOS:A1997XT75400051
J	Walker, SS; Shen, WC; Reese, JC; Apone, LM; Green, MR				Walker, SS; Shen, WC; Reese, JC; Apone, LM; Green, MR			Yeast TAF(II)145 required for transcription of G1/S cyclin genes and regulated by the cellular growth state	CELL			English	Article							TATA-BINDING PROTEIN; RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; ACTIVATION; COMPLEX; KINASE; CELLS; TRANSITION; MITOSIS; TARGETS	TFIID comprises the TATA box-binding protein and a set of highly conserved associated factors (TAF(II)s). yTAF(II)145, the core subunit of the yeast TAF(II) complex, is dispensable for transcription of most yeast genes but specifically required for progression through G1/S. Here we show that transcription of G1 and certain B-type cyclin genes is dependent upon yTAF(II)145. At high cell density or following nutrient deprivation, yeast cells cease division, enter a G(0)-like state, and terminate transcription of most genes. In this stationary phase, we find that the levels of yTAF(II)145, several other yTAF(II)s, and TBP are drastically reduced. Collectively, our results indicate that yTAF(II)145 and other TFIID components have a specialized role in transcriptional regulation of cell cycle progression and growth control.	UNIV MASSACHUSETTS, MED CTR, PROGRAM MOL MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Breeden L, 1996, CURR TOP MICROBIOL, V208, P95; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIA LL, 1979, MOL GEN GENET, V170, P137, DOI 10.1007/BF00337788; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Guthrie C, 1991, GUIDE YEAST GENETICS; Harlow E, 1988, ANTIBODIES LAB MANUA; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; Hung DT, 1996, CHEM BIOL, V3, P623, DOI 10.1016/S1074-5521(96)90129-5; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLENK HP, 1994, CURR BIOL, V4, P920, DOI 10.1016/S0960-9822(00)00206-2; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; LIU HT, 1985, J BIOL CHEM, V260, P3269; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; Moore DD, 1995, GLOB MOB SURV; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; POON D, 1993, J BIOL CHEM, V268, P15325; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sauer F, 1996, CELL, V87, P1271, DOI 10.1016/S0092-8674(00)81822-X; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; SIKORSKI RS, 1989, GENETICS, V122, P19; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	46	125	125	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					607	614		10.1016/S0092-8674(00)80522-X	http://dx.doi.org/10.1016/S0092-8674(00)80522-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288741	Bronze			2022-12-24	WOS:A1997XT06600005
J	Wilson, PWF; Hoeg, JM; DAgostino, RB; Silbershatz, H; Belanger, AM; Poehlmann, H; OLeary, D; Wolf, PA				Wilson, PWF; Hoeg, JM; DAgostino, RB; Silbershatz, H; Belanger, AM; Poehlmann, H; OLeary, D; Wolf, PA			Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; ARTERY WALL THICKNESS; ELEVATED SERUM-CHOLESTEROL; RISK FACTOR; FAMILIAL HYPERCHOLESTEROLEMIA; CARDIOVASCULAR HEALTH; ATHEROSCLEROSIS RISK; OLDER PERSONS; FRAMINGHAM; LIPOPROTEIN	Background Single measurements of cardiovascular risk factors may not accurately reflect a person's past exposure to those risk factors. We therefore studied the long-term associations of cardiovascular risk factors such as high serum cholesterol levels, high blood pressure, and cigarette smoking with the prevalence of carotid stenosis. Methods We studied cross-sectional and longitudinal information from a sample of 429 men and 661 women in the Framingham Heart Study who underwent B-mode ultrasound measurements of the carotid artery. Their mean age was 75 years, and each had attended most of the biennial clinic examinations over the 34 years before the carotid ultrasound study. We used time-integrated measurements to assess the associations between various cardiovascular risk factors and the degree of carotid stenosis. Results Moderate carotid stenosis (greater than or equal to 25 percent) was present in 189 men and 226 women. We assessed the odds ratios for this degree of stenosis as compared with minimal stenosis (<25 percent) according to increases in risk factors. In the men, the odds ratio for moderate carotid stenosis associated with an increase of 20 mm Hg in systolic blood pressure was 2.11 (95 percent confidence interval, 1.51 to 2.97). The odds ratio for an increase of 10 mg per deciliter (0.26 mmol per liter) in the cholesterol level was 1.10 (95 percent confidence interval, 1.03 to 1.16), and for an increase of five pack-years of smoking it was 1.03 (95 percent confidence interval, 1.03 to 1.13). The results were similar in the women. Time-integrated measurements of diastolic blood pressure showed significant associations with carotid stenosis in men and insignificant associations in women. Conclusions Over the long term, high systolic blood pressure, high cholesterol levels, and smoking were associated with an increased risk of carotid stenosis in this elderly population. (C) 1997, Massachusetts Medical Society.	NHLBI, BETHESDA, MD 20892 USA; BOSTON UNIV, DEPT MATH, BOSTON, MA 02215 USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; TUFTS UNIV, MED CTR, DEPT RADIOL, MEDFORD, MA 02155 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Tufts University	Wilson, PWF (corresponding author), NHLBI, FRAMINGHAM HEART STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA.		Wilson, Peter W.F./J-2455-2016	Wolf, Philip/0000-0002-3628-301X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [5R01-NS17950] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELL LL, 1952, J BIOL CHEM, V195, P357; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1995, Lancet, V345, P209; BENFANTE R, 1994, STROKE, V25, P814, DOI 10.1161/01.STR.25.4.814; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BROWN SA, 1993, ARTERIOSCLER THROMB, V13, P1558, DOI 10.1161/01.ATV.13.11.1558; COOPER GR, 1992, JAMA-J AM MED ASSOC, V267, P1652, DOI 10.1001/jama.267.12.1652; COOPER GR, 1994, CLIN CHEM, V40, P227; CORTI MC, 1995, JAMA-J AM MED ASSOC, V274, P539, DOI 10.1001/jama.274.7.539; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; CROUSE JR, 1995, AM J CARDIOL, V75, P862; FABRIS F, 1994, STROKE, V25, P1133, DOI 10.1161/01.STR.25.6.1133; FOLSOM AR, 1994, STROKE, V25, P66, DOI 10.1161/01.STR.25.1.66; GORDON T, 1977, JAMA-J AM MED ASSOC, V238, P497, DOI 10.1001/jama.238.6.497; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; HOEG JM, 1994, ARTERIOSCLER THROMB, V14, P1066, DOI 10.1161/01.ATV.14.7.1066; HOEG JM, 1994, JAMA-J AM MED ASSOC, V271, P543, DOI 10.1001/jama.271.7.543; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; KANNEL WB, 1981, JAMA-J AM MED ASSOC, V245, P1225, DOI 10.1001/jama.245.12.1225; KANNEL WB, 1979, LANCET, V2, P950; KLEINBAUM DG, 1988, APPLIED REGRESSION A, P124; KRITCHEVSKY SB, 1995, CIRCULATION, V92, P2142, DOI 10.1161/01.CIR.92.8.2142; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; *NAT CHOL ED PROGR, 1988, CLIN CHEM, V34, P193; O'Leary D H, 1992, Ann Epidemiol, V2, P147, DOI 10.1016/1047-2797(92)90049-V; OLeary DH, 1996, STROKE, V27, P224, DOI 10.1161/01.STR.27.2.224; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; PERSSON J, 1994, ARTERIOSCLER THROMB, V14, P261, DOI 10.1161/01.ATV.14.2.261; SALOMAA V, 1995, CIRCULATION, V91, P284, DOI 10.1161/01.CIR.91.2.284; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; Schmidt HHJ, 1996, AM J CARDIOL, V77, P575, DOI 10.1016/S0002-9149(97)89309-5; SHARRETT AR, 1994, ARTERIOSCLER THROMB, V14, P1098, DOI 10.1161/01.ATV.14.7.1098; Sidhu P S, 1996, J Cardiovasc Risk, V3, P61, DOI 10.1097/00043798-199602000-00009; Stamler J, 1989, Hypertension, V13, pI2; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TELL GS, 1994, CIRCULATION, V90, P2905, DOI 10.1161/01.CIR.90.6.2905; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WILSON PWF, 1994, J GERONTOL, V49, pM252, DOI 10.1093/geronj/49.6.M252; WILSON PWF, 1995, ARCH INTERN MED, V155, P2146; WILSON PWF, 1993, AM J GERIATR CARDIOL, V2, P52	46	201	209	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					516	522		10.1056/NEJM199708213370802	http://dx.doi.org/10.1056/NEJM199708213370802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262494				2022-12-24	WOS:A1997XR54800002
J	Ray, P; Black, S; Shinefield, H; Dillon, A; Schwalbe, J; Holmes, S; Hadler, S; Chen, R; Cochi, S; Wassilak, S				Ray, P; Black, S; Shinefield, H; Dillon, A; Schwalbe, J; Holmes, S; Hadler, S; Chen, R; Cochi, S; Wassilak, S			Risk of chronic arthropathy among women after rubella vaccination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RHEUMATOID-ARTHRITIS; PROLONGED ARTHRITIS; JOINT REACTIONS; PREGNANCY; IMMUNIZATION; ASSOCIATION; VIREMIA	Context.-A review by the institute of Medicine found a possible relationship between rubella vaccination and chronic arthritis among women. Objective.-To evaluate the risk of persistent joint and neurologic symptoms in rubella seronegative women subsequently vaccinated with RA 27/3 rubella vaccine. Design.-Retrospective cohort study based on computerized laboratory data and medical record review. Records were reviewed for symptoms occurring within 2 years before and after the date of serological testing and to identify vaccinees. Possible cases were evaluated by a rheumatologist blinded to serological findings and vaccination status. Setting.-Large health maintenance organization in northern California. Patients.-Women aged 15 to 59 years serotested for rubella during 1990 with continuous health plan membership for 2 years before and after the date of their serological test. Seronegative women immunized within 1 year of serotesting (n=971) were defined as exposed. Primary comparison groups included all unvaccinated, seronegative women (n=924) and randomly selected, seropositive, unvaccinated women (n=2421) matched to exposed subjects on serological test date and age (+/-3 years). Main Outcome Measures.-Prevalence and incidence of chronic joint and neurologic symptoms during 1-year follow-up period stratified by age and serological findings, immunization, and postpartum status. Results.-No significantly increased risk was associated with receipt of rubella vaccine for any outcome except for prevalence of carpal tunnel syndrome in vaccinated women at least 30 years old compared with seropositive, unvaccinated women (2.9% vs 1.4%; P=.03), A total of 34 women had onset of conditions within the 1-year follow-up period; 9 of these were in the group of seronegative, immunized women, of whom 6 had onset of symptoms within 6 weeks of vaccination. Among these 6 women, symptoms included transient arthritis or arthralgias (6 weeks duration) in 4 women, arthralgia of indeterminate chronicity in 1 woman, and carpal tunnel syndrome in 1 woman. Postpartum women across all groups were less likely to be seen for nontraumatic arthropathies than nonpostpartum women (4.5% vs 7.2%, P=.08 in vaccinated women; 4.8% vs 8.1%, P=.09 in seronegative controls; and 4.8% vs 10.0%, P=.01 in seropositive controls). Conclusions.-In this large retrospective cohort analysis there was no evidence of any increased risk of new onset chronic arthropathies or neurologic conditions in women receiving the RA 27/3 rubella vaccine. These data support the continued vaccination of rubella-susceptible women to reduce the risk of congenital rubella syndrome.	NO CALIF KAISER PERMANENTE VACCINE STUDY CTR, OAKLAND, CA USA; EASTERN VIRGINIA MED SCH, CTR PEDIAT RES, NORFOLK, VA 23501 USA; CTR DIS CONTROL & PREVENT, NATL IMMUNIZAT PROGRAM, ATLANTA, GA 30333 USA	Kaiser Permanente; Eastern Virginia Medical School; Centers for Disease Control & Prevention - USA								*CDC, 1990, MMWR-MORBID MORTAL W, V39, P10; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P329; Chen RT, 1997, PEDIATRICS, V99, P765, DOI 10.1542/peds.99.6.765; DASILVA JAP, 1992, CLIN RHEUMATOL, V11, P189, DOI 10.1007/BF02207955; DUGOWSON CE, 1991, ARTHRITIS RHEUM-US, V34, P1502; FREY T, 1994, J INFECT DIS, V170, P507; HOWSON CP, 1992, CLIN INFECT DIS, V15, P307, DOI 10.1093/clinids/15.2.307; *I MED, 1991, ADV EFF PERT RUB VAC; KAPLAN KM, 1990, AM J DIS CHILD, V144, P118, DOI 10.1001/archpedi.1990.02150250130050; LANSINK M, 1993, CLIN EXP RHEUMATOL, V11, P171; LERMAN SJ, 1971, ANN INTERN MED, V74, P67, DOI 10.7326/0003-4819-74-1-67; LINOS A, 1980, AM J EPIDEMIOL, V111, P87, DOI 10.1093/oxfordjournals.aje.a112878; MITCHELL LA, 1993, ARCH INTERN MED, V153, P2268, DOI 10.1001/archinte.153.19.2268; MORTONKUTE L, 1985, ANN INTERN MED, V102, P563, DOI 10.7326/0003-4819-102-4-563_3; NEELY NT, 1977, TEX MED, V73, P59; OSTENSEN M, 1983, SCAND J RHEUMATOL, V12, P69, DOI 10.3109/03009748309102886; OSTENSEN M, 1983, ARTHRITIS RHEUM, V26, P1155, DOI 10.1002/art.1780260915; PELTOLA H, 1986, LANCET, V1, P939; Persellin R H, 1976, Bull Rheum Dis, V27, P922; POLK BF, 1982, AM J EPIDEMIOL, V115, P19, DOI 10.1093/oxfordjournals.aje.a113276; SCHUMACHER HR, 1993, PRIMER RHEUMATIC DIS, P328; SILMAN AJ, 1986, ANN RHEUM DIS, V45, P1031, DOI 10.1136/ard.45.12.1031; SLATER PE, 1995, VACCINE, V13, P1529, DOI 10.1016/0264-410X(95)00096-J; SPRUANCE SL, 1977, ARTHRITIS RHEUM, V20, P741, DOI 10.1002/art.1780200216; THOMPSON GR, 1971, ARTHRITIS RHEUM, V14, P19, DOI 10.1002/art.1780140104; THOMPSON GR, 1973, AM J DIS CHILD, V125, P526, DOI 10.1001/archpedi.1973.04160040040008; TINGLE AJ, 1983, INFECT IMMUN, V40, P22, DOI 10.1128/IAI.40.1.22-28.1983; TINGLE AJ, 1985, J INFECT DIS, V152, P606, DOI 10.1093/infdis/152.3.606; TINGLE AJ, 1986, ANN RHEUM DIS, V45, P110, DOI 10.1136/ard.45.2.110; TINGLE AJ, 1984, LANCET, V1, P1475; VALENSIN PE, 1987, VACCINE, V5, P289, DOI 10.1016/0264-410X(87)90154-X	31	57	60	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					551	556		10.1001/jama.278.7.551	http://dx.doi.org/10.1001/jama.278.7.551			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ986	9268275				2022-12-24	WOS:A1997XQ98600028
J	Bottaci, L; Drew, PJ; Hartley, JE; Hadfield, MB; Farouk, R; Lee, PWR; Macintyre, IMC; Duthie, GS; Monson, JRT				Bottaci, L; Drew, PJ; Hartley, JE; Hadfield, MB; Farouk, R; Lee, PWR; Macintyre, IMC; Duthie, GS; Monson, JRT			Artificial neural networks applied to outcome prediction for colorectal cancer patients in separate institutions	LANCET			English	Article							MYOCARDIAL-INFARCTION; SURVIVAL ANALYSIS; CENSORED-DATA; CLASSIFICATION; BREAST	Background Artificial neural networks are computer programs that can be used to discover complex relations within data sets. They permit the recognition of patterns in complex biological data sets that cannot be detected with conventional linear statistical analysis. One such complex problem is the prediction of outcome for individual patients treated for colorectal cancer. Predictions of outcome in such patients have traditionally been based on population statistics. However, these predictions have little meaning for the individual patient. We report the training of neural networks to predict outcome for individual patients from one institution and their predictive performance on data from a different institution in another region. Methods 5-year follow-up data from 334 patients treated for colorectal cancer were used to train and validate six neural networks designed for the prediction of death within 9, 12, 15, 18, 21, and 24 months. The previously trained 12-month neural network was then applied to 2-year followup data from patients from a second institution; outcome was concealed. No further training of the neural network was undertaken. The network's predictions were compared with those of two consultant colorectal surgeons supplied with the same data. Findings All six neural networks were able to achieve overall accuracy greater than 80% for the prediction of death for individual patients al institution I within 9, 12, 15, 18, 21, and 24 months. The mean sensitivity and specificity were 60% and 88%. When the neural network trained to predict death within 12 months was applied to data from the second institution, overall accuracy of 90% (95% CI 84-96) was achieved, compared with the overall accuracy of the colorectal surgeons of 79% (71-87) and 75% (66-84). Interpretation The neural networks were able to predict outcome for individual patients with colorectal cancer much more accurately than the currently available clinicopathological methods. Once trained on data from one institution, the neural networks were able to predict outcome for patients from an unrelated institution.	UNIV HULL, ACAD SURG UNIT, CASTLE HILL HOSP, KINGSTON UPON HULL HU16 5JQ, N HUMBERSIDE, ENGLAND; UNIV HULL, KINGSTON UPON HULL HU6 7RX, N HUMBERSIDE, ENGLAND; WESTERN GEN HOSP, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	University of Hull; University of Hull; University of Edinburgh			Farouk, Ridzuan/T-5968-2017	Macintyre, Iain/0000-0003-2716-8500; Farouk, Ridzuan/0000-0002-7644-4682				ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102; BAXT WG, 1995, LANCET, V346, P1135, DOI 10.1016/S0140-6736(95)91804-3; BAXT WG, 1994, MED DECIS MAKING, V14, P217, DOI 10.1177/0272989X9401400303; BAXT WG, 1991, ANN INTERN MED, V115, P843, DOI 10.7326/0003-4819-115-11-843; Bishop C.M., 1995, NEURAL NETWORKS PATT; CARPENTER GA, 1993, P WORLD C NEURAL NET, V1, P501; CLARK GM, 1994, BREAST CANCER RES TR, V32, P105, DOI 10.1007/BF00666211; CROFT DJ, 1974, ANN BIOMED ENG, V2, P69, DOI 10.1007/BF02368087; CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; DELAURENTIIS M, 1994, BREAST CANCER RES TR, V32, P113, DOI 10.1007/BF00666212; DELAURENTIIS M, 1994, CANCER LETT, V77, P127, DOI 10.1016/0304-3835(94)90095-7; Downs J, 1996, ARTIF INTELL MED, V8, P403, DOI 10.1016/0933-3657(95)00044-5; DOYE HR, 1994, ANN SURG, V219, P408; Engle Ralph L., 1963, ARCH INTERN MED, V112, P108; ENGLE RL, 1963, ARCH INTERN MED, V112, P512, DOI 10.1001/archinte.1963.03860040108009; FISHER ER, 1989, CANCER, V64, P2354, DOI 10.1002/1097-0142(19891201)64:11<2354::AID-CNCR2820641127>3.0.CO;2-#; Hartman EJ, 1990, NEURAL COMPUT, V2, P210, DOI 10.1162/neco.1990.2.2.210; HORROCKS JC, 1972, BMJ-BRIT MED J, V2, P5, DOI 10.1136/bmj.2.5804.5; JASS JR, 1987, LANCET, V1, P1303; KAPLAN D, 1995, UNDERSTANDING NONLIN; MA Z, 1996, EXPLANATION GEN RULE; Mackay D., 1994, MODELS NEURAL NETWOR; MCGUIRE WL, 1992, J NATL CANCER I MONO, V11, P173; NEWLAND RC, 1994, CANCER, V73, P2076, DOI 10.1002/1097-0142(19940415)73:8<2076::AID-CNCR2820730811>3.0.CO;2-6; RAVDIN PM, 1992, BREAST CANCER RES TR, V22, P285, DOI 10.1007/BF01840841; RAYDIN PM, 1992, BREAST CANCER RES TR, V21, P47, DOI 10.1007/BF01811963; Rumelhart D., 1986, PARALLEL DISTRIBUTED; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; Shortliffe, 1984, READINGS MED ARTIFIC; *U STUTTG, STUTTG NEUR NETW SIM	30	138	142	1	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	1997	350	9076					469	472		10.1016/S0140-6736(96)11196-X	http://dx.doi.org/10.1016/S0140-6736(96)11196-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274582				2022-12-24	WOS:A1997XR13500008
J	Brown, JP; Wei, WY; Sedivy, JM				Brown, JP; Wei, WY; Sedivy, JM			Bypass of senescence after disruption of p21(CIP1/WAF1) gene in normal diploid human fibroblasts	SCIENCE			English	Article							REPLICATIVE SENESCENCE; TELOMERASE ACTIVITY; IMMORTAL CELLS; P53; EXPRESSION; MECHANISMS; P16(INK4); DIVISION; CULTURE; CANCER	Most somatic cells die after a finite number of cell divisions, a phenomenon described as senescence. The p21(CIP1/WAF1) gene encodes an inhibitor of cyclin-dependent kinases. Inactivation: of p21 by two sequential rounds of targeted homologous recombination was sufficient to bypass senescence in normal diploid human fibroblasts. At the checkpoint between the prereplicative phase of growth and the phase of chromosome replication, cells lacking p21 failed to arrest the cell cycle in response to DNA damage, but their apoptotic response and genomic stability were unaltered. These results establish the feasibility of using gene targeting for genetic studies of normal human cells.			Brown, JP (corresponding author), BROWN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, PROVIDENCE, RI 02912 USA.				NIGMS NIH HHS [GM41690] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bond J, 1996, ONCOGENE, V13, P2097; BROWN JP, UNPUYB; Campisi Judith, 1996, P121; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GREENE AE, 1973, TISSUE CULTURE METHO, P69; HANSON KD, 1995, MOL CELL BIOL, V15, P45, DOI 10.1128/MCB.15.1.45; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TAHARA H, 1995, ONCOGENE, V10, P835; TROTT DA, 1995, CARCINOGENESIS, V16, P193, DOI 10.1093/carcin/16.2.193; VARIZI H, 1996, EXP GERONTOL, V31, P295; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WEI W, UNPUB; WHITAKER NJ, 1995, ONCOGENE, V11, P971; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9	36	660	686	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 8	1997	277	5327					831	834		10.1126/science.277.5327.831	http://dx.doi.org/10.1126/science.277.5327.831			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242615				2022-12-24	WOS:A1997XQ24700048
J	Li, P; Yang, XH; Wasser, M; Cai, Y; Chia, W				Li, P; Yang, XH; Wasser, M; Cai, Y; Chia, W			Inscuteable and staufen mediate asymmetric localization and segregation of prospero RNA during Drosophila neuroblast cell divisions	CELL			English	Article							OSKAR MESSENGER-RNA; POSTERIOR DETERMINANT; PROTEIN; GENE; OOCYTE; EMBRYO; NANOS; NUMB; SPECIFICATION; ORIENTATION	When neuroblasts divide, inscuteable acts to coordinate protein localization and mitotic spindle orientation, ensuring that asymmetrically localized determinants like Prospero partition into one progeny. staufen encodes a dsRNA-binding protein implicated in mRNA transport in oocytes. We demonstrate that prospero RNA is also asymmetrically localized and partitioned during neuroblast cell divisions, a process requiring both inscuteable and staufen. Inscuteable and Staufen interact and colocalize with prospero RNA on the apical cortex of interphase neuroblasts. Staufen binds prospero RNA in its 3'UTR. Our findings suggest that Inscuteable nucleates an apical complex and is required for protein localization, spindle orientation, and RNA localization. Stau, as one component of this complex, is required only for RNA localization. Hence staufen also acts zygotically, downstream of inscuteable, to effect aspects of neuroblast asymmetry.	NATL UNIV SINGAPORE,INST MOL & CELL BIOL,DEV NEUROBIOL LAB,SINGAPORE 119260,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Cai, Yu/R-7737-2019	Cai, Yu/0000-0003-2044-3290; Wasser, Martin/0000-0002-8753-2346				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bossing T, 1996, DEV BIOL, V179, P41, DOI 10.1006/dbio.1996.0240; CamposOrtega JA, 1996, NEURON, V17, P1, DOI 10.1016/S0896-6273(00)80274-3; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; DAVIS I, 1993, COLD SPRING HARB SYM, V58, P793, DOI 10.1101/SQB.1993.058.01.086; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DOE CQ, 1995, NEURON, V15, P991, DOI 10.1016/0896-6273(95)90088-8; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; FERRANDON D, 1994, CELL, V79, P1121; FINLEY RL, 1994, GENE PROBES PRACTICA; FrancisLang H, 1996, EMBO J, V15, P640, DOI 10.1002/j.1460-2075.1996.tb00396.x; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; JAN YN, 1995, NEURON, V14, P1; KarlinMcginness M, 1996, DEV GENET, V19, P238, DOI 10.1002/(SICI)1520-6408(1996)19:3<238::AID-DVG7>3.0.CO;2-A; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LUNDELL MJ, 1994, BIOTECHNIQUES, V16, P434; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; RHYU MS, 1995, CELL, V82, P523, DOI 10.1016/0092-8674(95)90022-5; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; STERNBERG PW, 1984, ANNU REV GENET, V18, P489, DOI 10.1146/annurev.ge.18.120184.002421; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; TAUTZ D, 1989, DROSOPHILA LAB MANUA, P194; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; UEMERA T, 1989, CELL, V5, P349; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K	44	194	199	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					437	447		10.1016/S0092-8674(00)80504-8	http://dx.doi.org/10.1016/S0092-8674(00)80504-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267024	Bronze			2022-12-24	WOS:A1997XQ06300008
J	Annas, GJ				Annas, GJ			'Reefer Madness' - The Federal response to California's medical-marijuana law	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				Annas George J, 1989, Villanova Law Rev, V34, P771; ANNAS GJ, 1991, NEW ENGL J MED, V325, P362, DOI 10.1056/NEJM199108013250519; DOBLIN RE, 1991, J CLIN ONCOL, V9, P1314, DOI 10.1200/JCO.1991.9.7.1314; GOLDEN T, 1997, NY TIMES        0417, pA14; Golden Tim, 1997, N Y Times Web, P7; GOODMAN E, 1997, BOSTON GLOBE    0202, pC7; GOULD SJ, 1993, TIMES           0504; Grinspoon L, 1995, MARIHUANA FORBIDDEN; Kassirer JP, 1997, NEW ENGL J MED, V336, P366, DOI 10.1056/NEJM199701303360509; LEARY WE, 1997, NY TIMES        0221, pA27; Sidney S, 1997, AM J PUBLIC HEALTH, V87, P585, DOI 10.2105/AJPH.87.4.585; STAPLETON S, 1997, AM MED NEWS     0317, P1; STAPLETON S, 1997, AM MED NEWS     0317, P33; WREN C, 1997, NY TIMES        0420, pE4	14	37	37	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 7	1997	337	6					435	439		10.1056/NEJM199708073370621	http://dx.doi.org/10.1056/NEJM199708073370621			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP407	9241134	Green Published			2022-12-24	WOS:A1997XP40700029
J	Bender, JB; Hedberg, CW; Besser, JM; Boxrud, DJ; MacDonald, KL; Osterholm, MT				Bender, JB; Hedberg, CW; Besser, JM; Boxrud, DJ; MacDonald, KL; Osterholm, MT			Surveillance for Escherichia coli O157:H7 infections in Minnesota by molecular subtyping	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FIELD GEL-ELECTROPHORESIS; HEMOLYTIC UREMIC SYNDROME; OUTBREAK; EPIDEMIOLOGY	Background Escherichia coli O157:H7 is a leading cause of diarrhea and the hemolytic-uremic syndrome. Current public health surveillance for E. coli O157:H7 requires considerable resources; traditional methods lack the sensitivity and specificity to detect outbreaks effectively. Methods During 1994 and 1995, the Minnesota Department of Health requested that all clinical isolates of E. coli O157:H7 be submitted to our laboratory. Isolates were subtyped by pulsed-field gel electrophoresis (PFGE), and patients were interviewed about potential sources of infection. Results In 1994 and 1995, 344 cases of E. coli O157:H7 infection were reported to the Minnesota Department of Health; 317 (92 percent) were subtyped by PFGE, and 143 distinct PFGE patterns were identified. Ten outbreaks of E. coli O157:H7 were identified; these accounted for 56 (18 percent) of the 317 subtyped cases, Four outbreaks were detected solely as a result of subtype-specific surveillance. In 11 two-week periods, the number of reported cases of E. coli O157:H7 doubled from the previous two weeks. In eight of these instances, the patterns identified were dissimilar and there were no outbreaks. Two of the remaining three increases resulted from multiple simultaneous outbreaks. Conclusions Subtype-specific surveillance for E. coli O157:H7 can identify outbreaks that are not detected by traditional methods and can ascertain whether sudden increases in reported cases are due to sporadic isolated cases or to one or more outbreaks. (C) 1997, Massachusetts Medical Society.	MINNESOTA DEPT HLTH,DIV PUBL HLTH LABS,MINNEAPOLIS,MN 55440	Minnesota Department of Health (MHD)	Bender, JB (corresponding author), MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,717 DELAWARE ST SE,MINNEAPOLIS,MN 55440, USA.			Bender, Jeffrey/0000-0003-4645-9936	PHS HHS [U50/CCU511190] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Banatvala N, 1996, J INFECT DIS, V173, P480, DOI 10.1093/infdis/173.2.480; BARRETT TJ, 1994, J CLIN MICROBIOL, V32, P3013, DOI 10.1128/JCM.32.12.3013-3017.1994; BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; HEDBERG CW, 1994, CLIN INFECT DIS, V18, P671, DOI 10.1093/clinids/18.5.671; Krause U, 1996, J CLIN MICROBIOL, V34, P959, DOI 10.1128/JCM.34.4.959-961.1996; *MN DEP HLTH, 1996, MINN HLTH STAT 1994; OSTROFF SM, 1990, AM J EPIDEMIOL, V132, P239, DOI 10.1093/oxfordjournals.aje.a115653; RODRIGUE DC, 1995, J INFECT DIS, V172, P1122, DOI 10.1093/infdis/172.4.1122; Shefer AM, 1996, WESTERN J MED, V165, P15; SWAMINATHAN B, 1995, DIAGNOSTIC MOL MICRO, P26; TARR PI, 1995, CLIN INFECT DIS, V20, P1, DOI 10.1093/clinids/20.1.1; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; 1996, MMWR-MORBID MORTAL W, V45, P437; 1995, MMWR-MORBID MORTAL W, V44, P417; 1995, MMWR-MORBID MORTAL W, V44, P157	17	118	126	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 7	1997	337	6					388	394		10.1056/NEJM199708073370604	http://dx.doi.org/10.1056/NEJM199708073370604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP407	9241128				2022-12-24	WOS:A1997XP40700004
J	Mannings, V; Koerner, DW; Sargent, AI				Mannings, V; Koerner, DW; Sargent, AI			A rotating disk of gas and dust around a young counterpart to beta Pictoris	NATURE			English	Article							T-TAURI STARS; CIRCUMSTELLAR DISKS; GRAINS; ABSORPTION	beta Pictoris is the best known example of a main-sequence star encircled by a tenuous disk(1), Optical(2,3) and infrared(4) images of beta Pic suggest that the disk is composed of dust grains which have been interpreted(1) as the debris generated by the disruption of the asteroid-sized remnants of planet-formation processes(5), The star itself is relatively old, with an age in excess of 100 Myr, Here we present high-resolution millimetre-wave images of continuum and molecular-line emission from dust and gas surrounding a much younger star, MWC480: the stellar properties of MWC480 are similar to those of beta Pic, but its age is just 6 Myr, The morphology of the circumstellar material and a comparison with the predictions of kinematic modelling indicate the presence of a rotating disk, gravitationally bound to the star, Moreover, the mass of the disk is greater than the minimum required to form a planetary system like our own(5), We therefore suggest that the disk around the young star MWC480 could be a progenitor of debris disks of the type associated with older stars such as beta Pic, and so holds much promise for the study of both the origin of debris disks and the early stages of the formation of planetary systems.	CALTECH,JET PROP LAB,PASADENA,CA 91109	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Mannings, V (corresponding author), CALTECH,DIV PHYS MATH & ASTRON,MS 105-24,PASADENA,CA 91125, USA.							AUMANN HH, 1984, ASTROPHYS J, V278, pL23, DOI 10.1086/184214; Backman D. E., 1993, PROTOSTARS PLANETS, P1253; Beckwith SVW, 1996, NATURE, V383, P139, DOI 10.1038/383139a0; BECKWITH SVW, 1990, ASTRON J, V99, P924, DOI 10.1086/115385; BECKWITH SVW, 1991, ASTROPHYS J, V381, P250, DOI 10.1086/170646; BEUST H, 1994, ASTRON ASTROPHYS, V282, P804; DANTONA F, 1994, ASTROPHYS J SUPPL S, V90, P467, DOI 10.1086/191867; DENT WRF, 1995, MON NOT R ASTRON SOC, V277, pL25; DRAINE BT, 1984, ASTROPHYS J, V285, P89, DOI 10.1086/162480; DUTREY A, 1994, ASTRON ASTROPHYS, V286, P149; GOLIMOWSKI DA, 1993, ASTROPHYS J, V411, pL41, DOI 10.1086/186907; Herbig G. H., 1960, AP J SUPPL, V4, P337, DOI DOI 10.1086/190050; HILDEBRAND RH, 1983, Q J ROY ASTRON SOC, V24, P267; KOERNER DW, 1993, ICARUS, V106, P2, DOI 10.1006/icar.1993.1154; KOERNER DW, 1997, 25 YEARS MILLIMETER, V170, P162; LAGAGE PO, 1994, NATURE, V369, P628, DOI 10.1038/369628a0; LISSAUER JJ, 1993, ANNU REV ASTRON ASTR, V31, P129, DOI 10.1146/annurev.aa.31.090193.001021; MANNINGS V, 1994, MON NOT R ASTRON SOC, V267, P361, DOI 10.1093/mnras/267.2.361; MANNINGS V, IN PRESS ASTROPHYS J; MIYAKE K, 1993, ICARUS, V106, P20, DOI 10.1006/icar.1993.1156; POLLACK JB, 1994, ASTROPHYS J, V421, P615, DOI 10.1086/173677; SARGENT AI, 1996, DISKS OUTFLOWS YOUNG, P1; SCOVILLE NZ, 1986, ASTROPHYS J, V303, P416, DOI 10.1086/164086; SMITH BA, 1984, SCIENCE, V226, P1421, DOI 10.1126/science.226.4681.1421; Sylvester RJ, 1996, MON NOT R ASTRON SOC, V279, P915, DOI 10.1093/mnras/279.3.915; WEIDENSCHILLING S, IN PRESS ICARUS; WRIGHT EL, 1987, ASTROPHYS J, V320, P818, DOI 10.1086/165597	27	90	90	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					555	557		10.1038/41505	http://dx.doi.org/10.1038/41505			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252187				2022-12-24	WOS:A1997XP72200040
J	Preti, HA; Cabanillas, F; Talpaz, M; Tucker, SL; Seymour, JF; Kurzrock, R				Preti, HA; Cabanillas, F; Talpaz, M; Tucker, SL; Seymour, JF; Kurzrock, R			Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma	ANNALS OF INTERNAL MEDICINE			English	Article						interleukin-6; lymphoma, large-cell, diffuse; outcome assessment (health care); disease-free survival; survival rate	NON-HODGKINS-LYMPHOMA; MULTIPLE-MYELOMA; MONOCLONAL-ANTIBODY; LEVELS CORRELATE; B CELLS; DISEASE; EXPRESSION; CANCER; PARAMETERS; SURVIVAL	Background: Interleukin-6 has important lymphoid bioregulatory effects, and serum levels of interleukin-6 are often elevated in patients with lymphoma. Objective: To determine the relation between serum levels of interleukin-6 before treatment and outcome in patients with diffuse large-cell lymphoma. Design: Retrospective cohort analysis with multivariate analysis. Setting: Tertiary referral center. Participants: 118 untreated patients with diffuse large-cell lymphoma who were enrolled in frontline chemotherapy protocols and 45 healthy controls. Measurements: Serum levels of interleukin-6 were measured by using a sensitive enzyme-linked immunosorbent assay. Levels below the upper limit of the range for controls were considered normal. Outcomes were complete response, failure-free survival, and overall survival. Results: Serum levels of interleukin-6 were higher in patients with lymphoma (median, 4.6 pg/mL [range, undetectable to 224 pg/mL]) than in controls (median, undetectable [range, undetectable to 4.3 pg/mL]) (P = 0.009). The complete response rate was 95% for persons with normal interleukin-6 levels and 66% for persons with high interleukin-6 levels (P = 0.001). Patients with high interleukin-6 levels had inferior failure-free and overall survival rates (P < 0.001 for both comparisons). The actuarial 4-year failure-free and overall survival rates were 72% and 85%, respectively, for persons with normal interleukin-6 levels and 37% and 46%, respectively, for persons with high interleukin-6 levels. In multivariate analysis, interleukin-6 was selected as the most significant predictor of complete response and failure-free survival. Failure-free and overall survival of patients stratified according to International Prognostic Index score could be further stratified by interleukin-6 level (P less than or equal to 0.03 for all comparisons). Conclusion: In patients with diffuse large-cell lymphoma, serum interleukin-6 levels are an independent prognostic factor for complete response and failure-free survival.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOIMMUNOTHERAPY, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT HEMATOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOMATH, HOUSTON, TX 77030 USA; ROYAL MELBOURNE HOSP, DEPT CLIN HAEMATOL & MED ONCOL, PARKVILLE, VIC 3050, AUSTRALIA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Royal Melbourne Hospital			Kurzrock, Razelle/AAU-9782-2020; Seymour, John/K-7326-2019	Seymour, John/0000-0003-2188-6835; Cabanillas, Fernando/0000-0001-9234-7893; Talpaz, Moshe/0000-0003-3361-3981				Altman D., 1991, PRACTICAL STAT MED R; BEREK JS, 1991, AM J OBSTET GYNECOL, V164, P1038, DOI 10.1016/0002-9378(91)90582-C; BLAY JY, 1992, CANCER RES, V52, P3317; CABANILLAS F, 1990, SEMIN ONCOL, V17, P28; COX DR, 1972, J R STAT SOC B, V34, P187; EMILIE D, 1994, BLOOD, V84, P2472; Fisher RA, 1922, J R STAT SOC, V85, P87, DOI 10.2307/2340521; FREEMAN GJ, 1989, J CLIN INVEST, V83, P1512, DOI 10.1172/JCI114046; GAUSE A, 1991, HEMATOL ONCOL, V9, P307; GROGAN TM, 1988, BLOOD, V71, P1157; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HONG C, 1992, LEUKEMIA LYMPHOMA, V8, P97, DOI 10.3109/10428199209049823; HORST E, 1990, LEUKEMIA, V4, P595; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KURZROCK R, 1993, CANCER RES, V53, P2118; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; LU ZY, 1995, BLOOD, V86, P3123; LUDWIG H, 1991, BLOOD, V77, P2794; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; NACHBAUR DM, 1991, ANN HEMATOL, V62, P54, DOI 10.1007/BF01714900; PLUDA JM, 1993, J CLIN ONCOL, V11, P1099, DOI 10.1200/JCO.1993.11.6.1099; ROSENBERG SA, 1982, CANCER, V49, P2112; SCALA G, 1990, J EXP MED, V172, P61, DOI 10.1084/jem.172.1.61; Seymour JF, 1997, AM J MED, V102, P21; SEYMOUR JF, 1995, J CLIN ONCOL, V13, P575, DOI 10.1200/JCO.1995.13.3.575; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SHIPP MA, 1994, BLOOD, V83, P1165; SWAN F, 1989, J CLIN ONCOL, V7, P1518, DOI 10.1200/JCO.1989.7.10.1518; TOSATO G, 1993, J CLIN INVEST, V91, P2806, DOI 10.1172/JCI116523; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; UCHIYAMA H, 1993, BLOOD, V82, P3712; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VELASQUEZ WS, 1989, BLOOD, V74, P551; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; YEE C, 1989, BLOOD, V74, P798; YOSHIZAKI K, 1989, BLOOD, V74, P1360	40	93	94	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					186	+		10.7326/0003-4819-127-3-199708010-00002	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245223				2022-12-24	WOS:A1997XN12900002
J	Levine, RL; Wayne, MA; Miller, CC				Levine, RL; Wayne, MA; Miller, CC			End-tidal carbon dioxide and outcome of out-of-hospital cardiac arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVE COMPRESSION-DECOMPRESSION; CARDIOPULMONARY-RESUSCITATION; PROGNOSTIC INDICATOR; SURVIVAL; PRESSURE; EPINEPHRINE; PREDICTION; EMERGENCY; INDEX; PCO2	Background Survival after cardiac arrest occurring outside the hospital averages less than 3 percent, Unfortunately, the outcome of prolonged resuscitative attempts cannot be predicted. End-tidal carbon dioxide levels reflect cardiac output during cardiopulmonary resuscitation. We prospectively determined whether death could be predicted by monitoring end-tidal carbon dioxide during resuscitation after cardiac arrest. Methods We performed a prospective observational study in 150 consecutive victims of cardiac arrest outside the hospital who had electrical activity but no pulse. The patients were intubated and evaluated by mainstream end-tidal carbon dioxide monitoring. Our hypothesis was that an end-tidal carbon dioxide level of 10 mm Hg or less after 20 minutes of standard advanced cardiac life support would predict death. Results There was no difference in the mean age or initial end-tidal carbon dioxide level between patients who survived to hospital admission (survivors) and those who did not (nonsurvivors). After 20 minutes of advanced cardiac life support, end-tidal carbon dioxide (+/-SD) averaged 4.4+/-2.9 mm Hg in nonsurvivors and 32.8+/-7.4 mm Hg in survivors (P<0.001). A 20-minute end-tidal carbon dioxide value of 10 mm Hg or less successfully discriminated between the 35 patients who survived to hospital admission and the 115 nonsurvivors. When a 20-minute end-tidal carbon dioxide value of 10 mm Hg or less was used as a screening test to predict death, the sensitivity, specificity, positive predictive value, and negative predictive value were all 100 percent. Conclusions An end-tidal carbon dioxide level of 10 mm Hg or less measured 20 minutes after the initiation of advanced cardiac life support accurately predicts death in patients with cardiac arrest associated with electrical activity but no pulse. Cardiopulmonary resuscitation may reasonably be terminated in such patients. (C) 1997, Massachusetts Medical Society.	CITY BELLINGHAM EMERGENCY MED SERV,BELLINGHAM,WA 98225; BAYLOR COLL MED,DEPT MED,DIV PULM CRIT CARE,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,DIV EMERGENCY MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT SURG,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine								ASPLIN BR, 1995, ANN EMERG MED, V25, P756, DOI 10.1016/S0196-0644(95)70203-2; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; Bhende MS, 1995, PEDIATR EMERG CARE, V11, P365, DOI 10.1097/00006565-199512000-00008; CALLAHAM M, 1992, CRIT CARE MED, V20, P337, DOI 10.1097/00003246-199203000-00008; CALLAHAM M, 1990, CRIT CARE MED, V18, P358, DOI 10.1097/00003246-199004000-00002; Cantineau JP, 1996, CRIT CARE MED, V24, P791, DOI 10.1097/00003246-199605000-00011; CANTINEAU JP, 1994, AM J EMERG MED, V12, P267, DOI 10.1016/0735-6757(94)90136-8; COHEN TJ, 1992, JAMA-J AM MED ASSOC, V267, P2916, DOI 10.1001/jama.267.21.2916; CUMMINS RO, 1994, TXB ADV CARDIAC LIFE; DOHI S, 1987, CRIT CARE MED, V15, P944, DOI 10.1097/00003246-198710000-00010; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; FALK JL, 1988, NEW ENGL J MED, V318, P607, DOI 10.1056/NEJM198803103181005; GARNETT AR, 1987, JAMA-J AM MED ASSOC, V257, P512, DOI 10.1001/jama.257.4.512; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GRAY WA, 1993, JAMA-J AM MED ASSOC, V270, P1471, DOI 10.1001/jama.270.12.1471; GULY UM, 1995, BRIT HEART J, V73, P372; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P333; IDRIS AH, 1994, ANN EMERG MED, V23, P568, DOI 10.1016/S0196-0644(94)70080-X; ISSERLES SA, 1991, ANESTH ANALG, V73, P808; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1433, DOI 10.1001/jama.270.12.1433; KERN KB, 1992, ARCH INTERN MED, V152, P145, DOI 10.1001/archinte.152.1.145; KERN KB, 1989, J AM COLL CARDIOL, V13, P1184, DOI 10.1016/0735-1097(89)90282-9; LAMBERT Y, 1992, ANESTHESIOLOGY S, V77, pA1081; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; MARWICK TH, 1991, RESUSCITATION, V22, P129, DOI 10.1016/0300-9572(91)90003-H; ORNATO JP, 1988, CRIT CARE MED, V16, P241, DOI 10.1097/00003246-198803000-00007; PANTRIDG.JF, 1967, LANCET, V2, P271; PEPE PE, 1993, CRIT CARE MED, V21, P1838, DOI 10.1097/00003246-199312000-00009; SANDERS AB, 1989, JAMA-J AM MED ASSOC, V262, P1347, DOI 10.1001/jama.262.10.1347; SANDERS AB, 1985, AM J EMERG MED, V3, P147, DOI 10.1016/0735-6757(85)90039-7; SANDERS AB, 1985, ANN EMERG MED, V14, P948, DOI 10.1016/S0196-0644(85)80235-3; SAS Institute, 1988, SAS STAT US GUID VER; SCHWAB TM, 1995, JAMA-J AM MED ASSOC, V273, P1261, DOI 10.1001/jama.273.16.1261; SHIBUTANI K, 1994, ANESTH ANALG, V79, P829; VARON AJ, 1991, J CLIN MONITOR, V7, P289, DOI 10.1007/BF01619347; WAYNE MA, 1995, ANN EMERG MED, V25, P762, DOI 10.1016/S0196-0644(95)70204-0; WEIL MH, 1985, CRIT CARE MED, V13, P907, DOI 10.1097/00003246-198511000-00011; WEST JB, 1977, AM REV RESPIR DIS, V116, P919; WRIGHT D, 1990, BRIT MED J, V301, P600, DOI 10.1136/bmj.301.6752.600	39	276	282	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 31	1997	337	5					301	306		10.1056/NEJM199707313370503	http://dx.doi.org/10.1056/NEJM199707313370503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN119	9233867				2022-12-24	WOS:A1997XN11900003
J	Dale, JK; Vesque, C; Lints, TJ; Sampath, TK; Furley, A; Dodd, J; Placzek, M				Dale, JK; Vesque, C; Lints, TJ; Sampath, TK; Furley, A; Dodd, J; Placzek, M			Cooperation of BMP7 and SHH in the induction of forebrain ventral midline cells by prechordal mesoderm	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-7; FLOOR PLATE DIFFERENTIATION; MOTOR-NEURON INDUCTION; CENTRAL-NERVOUS-SYSTEM; SONIC-HEDGEHOG; SPINAL-CORD; EXPRESSION; SIGNALS; BRAIN; EYE	Ventral midline cells at different rostrocaudal levels of the central nervous system exhibit distinct properties but share the ability to pattern the dorsoventral axis of the neural tube. We show here that ventral midline cells acquire distinct identities in response to the different signaling activities of underlying mesoderm. Signals from prechordal mesoderm control the differentiation of rostral diencephalic ventral midline cells, whereas notochord induces floor plate cells caudally. Sonic hedgehog (SHH) is expressed throughout axial mesoderm and is required for the induction of both rostral diencephalic ventral midline cells and floor plate. However, prechordal mesoderm also expresses BMP7 whose function is required coordinately with SHH to induce rostral diencephalic ventral midline eels. BMP7 acts directly on neural cells, modifying their response to SHH so that they differentiate into rostral diencephalic Ventral midline cells rather than floor prate cells. Our results suggest a model whereby axial mesoderm both induces the differentiation of overlying neural cells and controls the rostrocaudal character of the ventral midline of the neural tube.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; COLUMBIA UNIV,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; CREAT BIOMOL,HOPKINTON,MA 01748	MRC National Institute for Medical Research; Columbia University; Columbia University			Furley, Andrew JW/B-7316-2012; Furley, Andrew J. W./D-4798-2013; Lints, Thierry/K-4408-2012; Dale, Kim J/A-4480-2016; Vesque, Christine/Q-8461-2019; Vesque, Christine/L-9839-2017; Placzek, Marysia/E-6172-2010	Furley, Andrew JW/0000-0001-5549-8668; Dale, Kim J/0000-0002-9294-947X; Vesque, Christine/0000-0001-7983-4953; Placzek, Marysia/0000-0002-4106-9229	NINDS NIH HHS [NS 30532] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030532] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACAMPORA D, 1995, DEVELOPMENT, V121, P3279; Adelmann H. B., 1922, American Journal of Anatomy, V31, P55, DOI 10.1002/aja.1000310104; Adelmann HB, 1932, J MORPHOL, V54, P1, DOI 10.1002/jmor.1050540102; Adelmann HB, 1930, J EXP ZOOL, V57, P223, DOI 10.1002/jez.1400570204; ANG SL, 1994, DEVELOPMENT, V120, P2979; BARTH KA, 1995, DEVELOPMENT, V121, P1755; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COLAMARINO SA, 1995, ANNU REV NEUROSCI, V18, P497, DOI 10.1146/annurev.ne.18.030195.002433; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; HARLAND RM, 1997, IN PRESS NEURONAL DE; HATTA K, 1994, P NATL ACAD SCI USA, V91, P2061, DOI 10.1073/pnas.91.6.2061; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HEATH MJS, 1995, J PHYSIOL-LONDON, V486, P139, DOI 10.1113/jphysiol.1995.sp020798; Itasaki N, 1996, NEURON, V16, P487, DOI 10.1016/S0896-6273(00)80069-0; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MARTI E, 1995, DEVELOPMENT, V121, P2537; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NIEUWKOOP PD, 1952, J EXP ZOOL, V120, P1, DOI 10.1002/jez.1401200102; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1990, COLD SPRING HARB SYM, V55, P279; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; SEIFERT R, 1993, J ANAT, V183, P75; Solursh M, 1996, BIOCHEM BIOPH RES CO, V218, P438, DOI 10.1006/bbrc.1996.0078; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Varlet I, 1997, DEVELOPMENT, V124, P1033; VUKICEVIC S, 1994, BIOCHEM BIOPH RES CO, V198, P693, DOI 10.1006/bbrc.1994.1100; ZECCA M, 1995, DEVELOPMENT, V121, P2265	49	245	251	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					257	269		10.1016/S0092-8674(00)80334-7	http://dx.doi.org/10.1016/S0092-8674(00)80334-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244300	hybrid			2022-12-24	WOS:A1997XN24900010
J	Hua, W; Young, EC; Fleming, ML; Gelles, J				Hua, W; Young, EC; Fleming, ML; Gelles, J			Coupling of kinesin steps to ATP hydrolysis	NATURE			English	Article							MICROTUBULE MOVEMENT; HEAVY-CHAIN; DERIVATIVES; MOLECULES	A key goal in the study of the function of ATP-driven motor enzymes is to quantify the movement produced from consumption of one ATP molecule(1-3). Discrete displacements of the processive motor kinesin along a microtubule have been reported as 5 and/or 8 mn (refs 4, 5). However, analysis of nanometre-scale movements is hindered by superimposed brownian motion, Moreover, because kinesin is processive and turns over stochastically, some observed displacements must arise from summation of smaller movements that are too closely spaced in time to be resolved, To address both of these problems, we used light microscopy instrumentation(6) with low positional drift (<39 pm s(-1)) to observe single molecules of a kinesin derivative moving slowly (similar to 2.5 nm s(-1)) at very low (150 nM) ATP concentration, so that ATP-induced displacements were widely spaced in time, This allowed increased time-averaging to suppress brownian noise (without application of external force(4,5)), permitting objective measurement of the distribution of all observed displacement sizes, The distribution was analysed with a statistics-based method which explicitly takes into account the occurrence of unresolved movements, and determines both the underlying step size and the coupling of steps to ATP hydrolytic events, Our data support a fundamental enzymatic cycle for kinesin in which hydrolysis of a single ATP molecule is coupled to a step distance of the microtubule protofilament lattice spacing of 8.12 nm (ref. 7). Step distances other than 8 nm are excluded, as is the coupling of each step to two or more consecutive ATP hydrolysis reactions with similar rates, or the coupling of two 8-nm steps to a single hydrolysis. The measured ratio of ATP consumption rate to stepping rate is invariant over a wide range of ATP concentration, suggesting that the 1 ATP to 8 nm coupling inferred from behaviour at low ATP can be generalized to high ATP.	BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOCHEM,BIOPHYS & STRUCT BIOL GRAD PROGRAM,WALTHAM,MA 02254	Brandeis University; Brandeis University				Young, Edgar C./0000-0002-8453-088X				Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BERLINER E, 1994, J BIOL CHEM, V269, P8610; BERLINER E, 1995, THESIS BRANDEIS U WA; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Coppin CM, 1996, P NATL ACAD SCI USA, V93, P1913, DOI 10.1073/pnas.93.5.1913; GALLAGHER NC, 1981, IEEE T ACOUST SPEECH, V29, P1136, DOI 10.1109/TASSP.1981.1163708; GELLES J, 1995, BIOPHYS J, V68, pS276; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1989, J BIOL CHEM, V264, P15943; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; Segel I.H., 1975, ENZYME KINETICS; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TAYLOR EW, 1993, NATURE, V361, P115, DOI 10.1038/361115a0; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; YOUNG EC, 1995, J BIOL CHEM, V270, P3926, DOI 10.1074/jbc.270.8.3926	29	270	274	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					390	393		10.1038/41118	http://dx.doi.org/10.1038/41118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237758				2022-12-24	WOS:A1997XM52800054
J	Paushkin, SV; Kushnirov, VV; Smirnov, VN; TerAvanesyan, MD				Paushkin, SV; Kushnirov, VV; Smirnov, VN; TerAvanesyan, MD			In vitro propagation of the prion-like state of yeast Sup35 protein	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; BIOLOGY; GENE; DISEASES; URE3	The yeast cytoplasmically inherited genetic determinant [PSI+] is presumed to be a manifestation of the prion-like properties of the Sup35 protein (Sup35p). Here, cell-free conversion of Sup35p from [psi(-)] cells (Sup35(psi-)) to the prion-like [PSI+]-specific form (Sup35p(PSI+)) was observed. The conversion reaction could be repeated for several consecutive cycles, thus modeling in vitro continuous [PSI+] propagation. Size fractionation of lysates of [PSI+] cells demonstrated that the converting activity was associated solely with Sup35p(PSI+) aggregates, which agrees with the nucleation model for [PSI+] propagation. Sup35p(PSI+) was purified and showed high conversion activity, thus confirming the prion hypothesis for Sup35p.	CARDIOL RES CTR,INST EXPT CARDIOL,MOSCOW 121552,RUSSIA	National Medical Research Center of Cardiology			Vitaly, Kushnirov/AAU-6003-2021	Kushnirov, Vitaly/0000-0003-0316-0766				AIGLE M, 1975, MOL GEN GENET, V136, P327, DOI 10.1007/BF00341717; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Frolova L, 1996, RNA, V2, P334; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KUSHNIROV VV, 1988, GENE, V66, P45, DOI 10.1016/0378-1119(88)90223-5; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, MOL CELL BIOL, V17, P2798, DOI 10.1128/MCB.17.5.2798; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; PAUSHKIN SV, UNPUB; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; TUITE MF, 1987, FEBS LETT, V225, P205, DOI 10.1016/0014-5793(87)81158-4; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	22	196	201	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					381	383		10.1126/science.277.5324.381	http://dx.doi.org/10.1126/science.277.5324.381			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219697				2022-12-24	WOS:A1997XL35800049
J	Bellis, MA; Weild, AR; Beeching, NJ; Mutton, KJ; Syed, Q				Bellis, MA; Weild, AR; Beeching, NJ; Mutton, KJ; Syed, Q			Prevalence of HIV and injecting drug use in men entering Liverpool prison	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIVERPOOL LIVERPOOL SCH TROP MED,LIVERPOOL L3 5QA,MERSEYSIDE,ENGLAND; LIVERPOOL PUBL HLTH LAB,COMMUNICABLE DIS SURVEILLANCE CTR NW,LIVERPOOL L9 7AL,MERSEYSIDE,ENGLAND	Liverpool School of Tropical Medicine	Bellis, MA (corresponding author), UNIV LIVERPOOL,DEPT PUBL HLTH,SEXUAL HLTH & ENVIRONM EPIDEMIOL UNIT,LIVERPOOL L69 3GB,MERSEYSIDE,ENGLAND.		Bellis, Mark A./HGA-2019-2022; Beeching, Nicholas J/L-5363-2017	Beeching, Nicholas/0000-0002-7019-8791				Curtis SP, 1995, INT J STD AIDS, V6, P387, DOI 10.1177/095646249500600602; FORD BT, 1992, AIDS, V6, P623; JOHNSON AM, 1988, AIDS, V2, P369, DOI 10.1097/00002030-198810000-00006; MORRISON CL, 1995, POSTGRAD MED J, V71, P593, DOI 10.1136/pgmj.71.840.593; Yirrell DI, 1997, BRIT MED J, V314, P1446, DOI 10.1136/bmj.314.7092.1446	5	37	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					30	31		10.1136/bmj.315.7099.30	http://dx.doi.org/10.1136/bmj.315.7099.30			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ947	9233323	Green Published			2022-12-24	WOS:A1997XJ94700024
J	West, JB; Elliott, AR; Guy, HJB; Prisk, GK				West, JB; Elliott, AR; Guy, HJB; Prisk, GK			Pulmonary function in space	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUSTAINED MICROGRAVITY; LUNG-VOLUMES; BLOOD-FLOW; BREATH WASHOUTS; SHORT PERIODS; GAS-EXCHANGE; SLS-1; INHOMOGENEITY; VENTILATION; INEQUALITY	The lung is exquisitely sensitive to gravity, and so it is of interest to know how its function is altered in the weightlessness of space. Studies on National Aeronautics and Space Administration (NASA) Spacelabs during the last 4 years have provided the first comprehensive data on the extensive changes in pulmonary function that occur in sustained microgravity. Measurements of pulmonary function were made on astronauts during space shuttle flights lasting 9 and 14 days and were compared with extensive ground-based measurements before and after the flights. Compared with preflight measurements, cardiac output increased by 18% during space flight, and stroke volume increased by 46%. Paradoxically, the increase in stroke volume occurred in the face of reductions in central venous pressure and circulating blood volume. Diffusing capacity increased by 28%, and the increase in the diffusing capacity of the alveolar membrane was unexpectedly large based on findings in normal gravity. The change in the alveolar membrane may reflect the effects of uniform filling of the pulmonary capillary bed. Distributions of blood flow and ventilation throughout the lung were more uniform in space, but some unevenness remained, indicating the importance of nongravitational factors. A surprising finding was that airway closing volume was approximately the same in microgravity and in normal gravity, emphasizing the importance of mechanical properties of the airways in determining whether they close. Residual volume was unexpectedly reduced by 18% in microgravity, possibly because of uniform alveolar expansion. The findings indicate that pulmonary function is greatly altered in microgravity, but none of the changes observed so far will apparently limit long-term space flight. In addition, the data help to clarify how gravity affects pulmonary function in the normal gravity environment on Earth.			West, JB (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,0623A,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							AGOSTONI E, 1964, HDB PHYSL RESP, P00387; BECK KC, 1986, J APPL PHYSIOL, V61, P530, DOI 10.1152/jappl.1986.61.2.530; Buckey JC, 1996, J APPL PHYSIOL, V81, P19, DOI 10.1152/jappl.1996.81.1.19; BUONO MJ, 1983, J APPL PHYSIOL, V54, P1094, DOI 10.1152/jappl.1983.54.4.1094; CRAWFORD ABH, 1985, J APPL PHYSIOL, V59, P838, DOI 10.1152/jappl.1985.59.3.838; EDYVEAN J, 1991, J APPL PHYSIOL, V71, P1956, DOI 10.1152/jappl.1991.71.5.1956; ELLIOTT AR, 1994, J APPL PHYSIOL, V77, P2005, DOI 10.1152/jappl.1994.77.4.2005; Elliott AR, 1996, J APPL PHYSIOL, V81, P33, DOI 10.1152/jappl.1996.81.1.33; ESTENNE M, 1992, J APPL PHYSIOL, V73, P946, DOI 10.1152/jappl.1992.73.3.946; GLAISTER DH, 1973, RESP PHYSIOL, V17, P365, DOI 10.1016/0034-5687(73)90010-8; GLENNY RW, 1990, J APPL PHYSIOL, V69, P532, DOI 10.1152/jappl.1990.69.2.532; GUY HJB, 1994, J APPL PHYSIOL, V76, P1719, DOI 10.1152/jappl.1994.76.4.1719; GUY HJB, 1991, J APPL PHYSIOL, V70, P2587, DOI 10.1152/jappl.1991.70.6.2587; HAKIM TS, 1987, J APPL PHYSIOL, V63, P1114, DOI 10.1152/jappl.1987.63.3.1114; MICHELS DB, 1978, J APPL PHYSIOL, V45, P987, DOI 10.1152/jappl.1978.45.6.987; MICHELS MD, 1979, J APPL PHYSIOL, V47, P851; MILICEMI.J, 1966, J APPL PHYSIOL, V21, P749, DOI 10.1152/jappl.1966.21.3.749; PAIVA M, 1989, J APPL PHYSIOL, V67, P1542, DOI 10.1152/jappl.1989.67.4.1542; PAIVA M, 1981, RESP PHYSIOL, V44, P325, DOI 10.1016/0034-5687(81)90027-X; PERMUTT SOLBERT, 1967, NAT ACAD SCI NAT RES COUNC PUBL, V1485 B, P38; PRISK GK, 1995, J APPL PHYSIOL, V79, P1290, DOI 10.1152/jappl.1995.79.4.1290; PRISK GK, 1994, J APPL PHYSIOL, V76, P1730, DOI 10.1152/jappl.1994.76.4.1730; PRISK GK, 1995, J APPL PHYSIOL, V78, P597, DOI 10.1152/jappl.1995.78.2.597; PRISK GK, 1993, J APPL PHYSIOL, V75, P15, DOI 10.1152/jappl.1993.75.1.15; UDDEN MM, 1995, J LAB CLIN MED, V125, P442; WAGNER P, 1967, J APPL PHYSIOL, V22, P1115, DOI 10.1152/jappl.1967.22.6.1115; WARRELL DA, 1972, J APPL PHYSIOL, V32, P346, DOI 10.1152/jappl.1972.32.3.346; WEST JB, 1972, J APPL PHYSIOL, V32, P357, DOI 10.1152/jappl.1972.32.3.357; WEST JB, 1960, J APPL PHYSIOL, V15, P405, DOI 10.1152/jappl.1960.15.3.405; WEST JB, 1977, REGIONAL DIFFERENCES	30	28	33	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1957	1961		10.1001/jama.277.24.1957	http://dx.doi.org/10.1001/jama.277.24.1957			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF087	9200637				2022-12-24	WOS:A1997XF08700041
J	Irie, M; Hata, Y; Takeuchi, M; Ichtchenko, K; Toyoda, A; Hirao, K; Takai, Y; Rosahl, TW; Sudhof, TC				Irie, M; Hata, Y; Takeuchi, M; Ichtchenko, K; Toyoda, A; Hirao, K; Takai, Y; Rosahl, TW; Sudhof, TC			Binding of neuroligins to PSD-95	SCIENCE			English	Article							TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR SUBUNITS; POSTSYNAPTIC DENSITY; SEPTATE JUNCTIONS; GUANYLATE KINASES; MEMBRANE PROTEIN; NEUREXINS; INTERACTS; HOMOLOG; FAMILY	PSD-95 is a component of postsynaptic densities in central synapses, It contains three PDZ domains that localize N-methyl-D-aspartate receptor subunit 2 (NMDA2 receptor) and K+ channels to synapses. In mouse forebrain, PSD-95 bound to the cytoplasmic COOH-termini of neuroligins, which are neuronal cell adhesion molecules that interact with beta-neurexins and form intercellular junctions. Neuroligins bind to the third PDZ domain of PSD-95, whereas NMDA2 receptors and K+ channels interact with the first and second PDZ domains. Thus different PDZ domains of PSD-95 are specialized for distinct functions. PSD-95 may recruit ion channels and neurotransmitter receptors to intercellular junctions formed between neurons by neuroligins and beta-neurexins.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; JAPAN SCI & TECHNOL CORP,ERATO,TAKAI BIOTIMER PROJECT,NISHI KU,KOBE,HYOGO 65122,JAPAN; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Japan Science & Technology Agency (JST); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Osaka University			Toyoda, Atsushi/AAA-5885-2020	Toyoda, Atsushi/0000-0002-0245-3244	NIMH NIH HHS [R01-MH52804] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; Hata Y, 1996, J NEUROSCI, V16, P2488; Hunt CA, 1996, J NEUROSCI, V16, P1380; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JOEHNSSON U, 1991, EIOTECHNIQUES, V11, P520; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NGUYEN T, IN PRESS J BIOL CHEM; Niethammer M, 1996, J NEUROSCI, V16, P2157; Rose MD., 1990, METHODS YEAST GENETI; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; Russell AB, 1997, J NEUROSCI, V17, P4734; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Woods D F, 1993, J Cell Sci Suppl, V17, P171; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	30	569	590	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1511	1515		10.1126/science.277.5331.1511	http://dx.doi.org/10.1126/science.277.5331.1511			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278515				2022-12-24	WOS:A1997XV42900042
J	Barger, SW; Harmon, AD				Barger, SW; Harmon, AD			Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E	NATURE			English	Article							CEREBROSPINAL-FLUID; SENILE PLAQUES; HEAD-INJURY; DISEASE; IMMUNOREACTIVITY; EXPRESSION; DOMAIN; CELLS; ONSET; BRAIN	A role for beta-amyloid precursor protein (beta-APP) in the development of Alzheimer's disease has been indicated by genetics', and many conditions in which beta-APP is raised have been associated with an increased risk of Alzheimer's disease or an Alzheimer's-like pathology(2-4). Inflammatory events may also contribute to Alzheimer's disease(5), Here we investigate whether a secreted derivative of beta-APP (sAPP-alpha) can induce inflammatory reactions in microglia, which are brain cells of monocytic lineage. We found that treatment with sAPP-alpha increased markers of activation in microglia and enhanced their production of neurotoxins. The ability of sAPP-alpha to activate microglia was blocked by prior incubation of the protein with apolipoprotein E3 but not apolipoprotein E4, a variant associated with an increased risk for Alzheimer's(6). A product of amyloidogenic beta-APP processing (sAPP-beta) also activated microglia. Because sAPP-beta is deficient in the neuroprotective activity shown by sAPP-alpha, our results indicate that increased amyloidogenic processing could adversely affect the balance of sAPP activities that determine neuronal viability.	UNIV ARKANSAS MED SCI,DEPT ANAT CELL BIOL & NEUROBIOL,LITTLE ROCK,AR 72205; JOHN L MCCLELLAN MEM VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences; Geriatric Research Education & Clinical Center	Barger, SW (corresponding author), UNIV ARKANSAS MED SCI,DONALD W REYNOLDS DEPT GERIATR,LITTLE ROCK,AR 72205, USA.			Barger, Steven/0000-0001-6049-6480				Barger SW, 1997, J NEUROCHEM, V69, P60; Barger SW, 1996, MOL BRAIN RES, V40, P116; BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K; CLAY MA, 1995, BIOCHEMISTRY-US, V34, P11142, DOI 10.1021/bi00035a020; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORRADIN SB, 1993, GLIA, V7, P255, DOI 10.1002/glia.440070309; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; GRIFFIN WST, 1995, J NEUROPATH EXP NEUR, V54, P276; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Hardy J, 1996, ANN MED, V28, P255, DOI 10.3109/07853899609033127; LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24; MARTIN LJ, 1994, AM J PATHOL, V145, P1358; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MORAN PM, 1995, P NATL ACAD SCI USA, V92, P5341, DOI 10.1073/pnas.92.12.5341; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; PALMERT MR, 1990, NEUROLOGY, V40, P1028, DOI 10.1212/WNL.40.7.1028; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; Rossi F, 1996, BIOCHEM BIOPH RES CO, V225, P474, DOI 10.1006/bbrc.1996.1197; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SHENG JG, 1994, J NEUROCHEM, V63, P1872; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2551, DOI 10.1073/pnas.89.7.2551; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	29	514	548	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					878	881		10.1038/42257	http://dx.doi.org/10.1038/42257			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278049				2022-12-24	WOS:A1997XT75400050
J	Tsukamoto, Y; Kato, J; Ikeda, H				Tsukamoto, Y; Kato, J; Ikeda, H			Silencing factors participate in DNA repair and recombination in Saccharomyces cerevisiae	NATURE			English	Article							2-HYBRID SYSTEM; YEAST; PROTEINS; TELOMERES; RAP1	DNA double-strand breaks are repaired by homologous recombination or DNA end-joining, but the latter process often causes illegitimate recombination and chromosome rearrangements. One of the factors involved in the end-joining process is Hdf1, a yeast homologue of Ku protein(1-4). We used the yeast two-hybrid assay to show that Hdf1 interacts with Sir4, which is involved in transcriptional silencing at telomeres and HM loci(5,6). Analyses of sir4 mutants showed that Sir4 is required for deletion by illegitimate recombination and DNA end-joining in the pathway involving Hdf1. Sir2 and Sir3, but not Sir1, were also found to participate in these processes. Furthermore, mutations of the SIR2, SIR3 and SIR4 genes conferred increased sensitivity to gamma-radiation in a genetic background with a mutation of the RAD52 gene, which is essential for double-strand break repair mediated by homologous recombination. These results indicate that Sir proteins are involved in double-strand break repair mediated by end-joining. We propose that Sir proteins act with Hdf1 to alter broken DNA ends to create an inactivated chromatin structure that is essential for the rejoining of DNA ends.	UNIV TOKYO,INST MED SCI,DEPT MOL BIOL,TOKYO 108,JAPAN	University of Tokyo								APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; Lea D, 1948, J GENET, V49, P264; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; Luria SE, 1943, GENETICS, V28, P491; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; PILUS L, 1989, CELL, V59, P637; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SHORE D, 1995, TELOMERES, P139; Siede W, 1996, GENETICS, V142, P91; SIKORSKI RS, 1989, GENETICS, V122, P19; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TSKAMOTO Y, IN PRESS MOL GEN GEN; Tsukamoto Y, 1996, GENETICS, V142, P383; Tsukamoto Y, 1996, NUCLEIC ACIDS RES, V24, P2067, DOI 10.1093/nar/24.11.2067; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0	30	293	304	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					900	903		10.1038/42288	http://dx.doi.org/10.1038/42288			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278054	Bronze			2022-12-24	WOS:A1997XT75400055
J	Hurwitz, A; Brady, DA; Schaal, E; Samloff, IM; Dedon, J; Ruhl, CE				Hurwitz, A; Brady, DA; Schaal, E; Samloff, IM; Dedon, J; Ruhl, CE			Gastric acidity in older adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DUODENAL-ULCER PATIENTS; SERUM PEPSINOGEN-I; BACTERIAL OVERGROWTH; INTRAGASTRIC ACIDITY; ATROPHIC GASTRITIS; SMALL-INTESTINE; HEALTHY-MEN; SECRETION; AGE; PH	Context.-Early studies suggested that gastric acidity declines as people age. However, sequelae of achlorhydria are uncommon in older people, making this conventional wisdom unlikely. Objective.-To ascertain the prevalence of basal gastric acidity and atrophic gastritis (indicated by serum pepsinogen ratio) in older adults. Design.-Cross-sectional study in a volunteer sample. Setting.-Retirement communities in suburbs of Kansas City, Mo. Subjects.-A total of 248 white male and female volunteers aged 65 years or older living independently. Main Outcome Measures.-Presence of basal unstimulated gastric acid was evaluated noninvasively by having subjects swallow quininium resin. Gastric acid with a pH lower than 3.5 releases quinine, which is then absorbed and excreted into urine, Atrophic gastritis was defined as a ratio of serum pepsinogen I/pepsinogen II of less than 2.9. Results.-Basal unstimulated gastric content was acidic (pH <3.5) in 208 (84%) of 248 elderly subjects. On retesting 66 subjects (35 normals and 31 hyposecretors), 28 (80%) of 35 had pH less than 3.5 both times, and 22 (71%) of 31 had pH of 3.5 or higher twice; in the remaining 16 subjects, low vs high gastric pH changed between tests, Weighted population prevalence estimates in this sample were 67% for consistent acid secretion, 22% for intermittent secretion, and 11% for consistent gastric pH higher than 3.5. Whereas 14 (67%) of 21 consistent hyposecretors had serum pepsinogen ratios of less than 2.9, indicating atrophic gastritis, only 2 (5%) of 44 consistent or intermittent secretors of acid had ratios in this range (P<.001). Conclusions.-In contrast to what is commonly stated, nearly 90% of elderly people in this study were able to acidity gastric contents, even in the basal, unstimulated state. Of those who were consistent hyposecretors of acid, most had serum markers of atrophic gastritis.	UNIV KANSAS,MED CTR,CTR AGING,KANSAS CITY,KS 66160; VET AFFAIRS MED CTR,SEPULVEDA,CA; TRUMAN MED CTR,DEPT COMMUNITY MED & FAMILY PRACTICE,KANSAS CITY,MO	University of Kansas; University of Kansas Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Hurwitz, A (corresponding author), UNIV KANSAS,MED CTR,DEPT MED,3901 RAINBOW BLVD,KANSAS CITY,KS 66160, USA.				NIA NIH HHS [R01AG02780] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREWS GR, 1967, AUSTRALAS ANN MED, V16, P230; BARON JH, 1963, GUT, V4, P136, DOI 10.1136/gut.4.2.136; BIEMOND I, 1994, SCAND J GASTROENTERO, V29, P238, DOI 10.3109/00365529409090470; BLAIR AJ, 1987, J CLIN INVEST, V79, P582, DOI 10.1172/JCI112850; BORCH K, 1989, SCAND J GASTROENTERO, V24, P870, DOI 10.3109/00365528909089228; COLLEN MJ, 1994, AM J GASTROENTEROL, V89, P712; CONNELL AM, 1973, CLIN TESTS GASTRIC F, P20; CORAZZA GR, 1990, GASTROENTEROLOGY, V98, P302, DOI 10.1016/0016-5085(90)90818-L; CRAMER G, 1963, SCAND J CLIN LAB INV, V15, P553, DOI 10.3109/00365516309079786; DRESSMAN JB, 1990, PHARMACEUT RES, V7, P756, DOI 10.1023/A:1015827908309; FELDMAN M, 1991, DIGEST DIS SCI, V36, P866, DOI 10.1007/BF01297133; Feldman M, 1996, GASTROENTEROLOGY, V110, P1043, DOI 10.1053/gast.1996.v110.pm8612992; GOLDSCHMIEDT M, 1991, GASTROENTEROLOGY, V101, P977, DOI 10.1016/0016-5085(91)90724-Y; GOLDSCHMIEDT M, 1993, CHRONIC GASTRITIS HY, P13; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; GREENBLATT DJ, 1982, NEW ENGL J MED, V306, P1081; HIRSCHOWITZ BI, 1992, GASTROENTEROLOGY, V103, pA83; HOLT PR, 1989, DIGEST DIS SCI, V34, P933, DOI 10.1007/BF01540281; Holt PR, 1993, CHRONIC GASTRITIS HY; HOWDEN CW, 1987, GUT, V28, P96, DOI 10.1136/gut.28.1.96; HUSEBYE E, 1992, GUT, V33, P1331, DOI 10.1136/gut.33.10.1331; JOHNSEN R, 1991, BRIT MED J, V302, P749, DOI 10.1136/bmj.302.6779.749; KEKKI M, 1991, SCAND J GASTROENTERO, V26, P109, DOI 10.3109/00365529109103997; KERLIN P, 1988, GASTROENTEROLOGY, V95, P982, DOI 10.1016/0016-5085(88)90173-4; KING CE, 1986, GASTROENTEROLOGY, V91, P1447, DOI 10.1016/0016-5085(86)90199-X; KIRSNER JB, 1956, GASTROENTEROLOGY, V30, P779; KRASINSKI SD, 1986, J AM GERIATR SOC, V34, P800, DOI 10.1111/j.1532-5415.1986.tb03985.x; KUNA S., 1964, ARCH INT PHARMACODYN THERAP, V151, P79; MERKI HS, 1988, GASTROENTEROLOGY, V94, P887, DOI 10.1016/0016-5085(88)90543-4; MODLIN IM, 1994, AM J GASTROENTEROL, V89, P308; OCHS HR, 1978, AM J CARDIOL, V42, P481, DOI 10.1016/0002-9149(78)90944-X; POUNDER RE, 1993, BAILLIERE CLIN GASTR, V7, P55, DOI 10.1016/0950-3528(93)90031-M; RUSSELL TL, 1993, PHARMACEUT RES, V10, P187, DOI 10.1023/A:1018970323716; SALTZMAN JR, 1994, GASTROENTEROLOGY, V106, P615, DOI 10.1016/0016-5085(94)90693-9; SAMLOFF IM, 1982, GASTROENTEROLOGY, V83, P204; SAMLOFF IM, 1982, GASTROENTEROLOGY, V82, P26; SAVARINO V, 1988, DIGEST DIS SCI, V33, P1077, DOI 10.1007/BF01535781; SEGAL HL, 1953, ANN NY ACAD SCI, V57, P308, DOI 10.1111/j.1749-6632.1953.tb36405.x; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; ZAR JH, 1984, BIOSTAT ANAL, P380	40	113	122	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	1997	278	8					659	662		10.1001/jama.278.8.659	http://dx.doi.org/10.1001/jama.278.8.659			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR547	9272898				2022-12-24	WOS:A1997XR54700039
J	Foster, GR; Goldin, RD; Main, J; MurrayLyon, I; Hargreaves, S; Thomas, HC				Foster, GR; Goldin, RD; Main, J; MurrayLyon, I; Hargreaves, S; Thomas, HC			Management of chronic hepatitis C: clinical audit of biopsy based management algorithm	BRITISH MEDICAL JOURNAL			English	Article							RECOMBINANT INTERFERON-ALFA; CONTROLLED TRIAL; VIRUS-INFECTION; ALPHA	Objective: To assess the attendance, outcome, compliance with treatment, and response to interferon alfa in patients with chronic hepatitis C who attended during 1995 and were treated according to a biopsy based algorithm. Design: Retrospective audit of all patients with chronic hepatitis C attending outpatient clinics over one year. Setting: The liver unit at a London teaching hospital. Subjects: 255 patients with chronic hepatitis C. Main outcome measures: Patient survival, attendance, and compliance with diagnostic and therapeutic regimens. Response to interferon alfa treatment, based on loss of viraemia three months after cessation of treatment. Results: A large proportion of patients (39%) with newly diagnosed chronic hepatitis C infection do not want to undergo further investigation. Of those patients who do attend for further treatment, a large proportion with severe hepatic fibrosis (42%) do not want to undergo currently available treatment. The response rate to interferon (21%) in treated patients was similar to that previously reported in a trial setting. There was no significant difference in response rates in patients with or without severe fibrosis not amounting to cirrhosis. In patients with cirrhosis there was a high incidence of hepatocellular carcinoma (18%) over a follow up period of 20 months. Conclusion: Current strategies aimed at investigating and treating patients with chronic hepatitis C are not acceptable to a large proportion of patients. Many patients with cirrhosis related to hepatitis C infection develop hepatic neoplasms, and management strategies to deal with this problem are urgently required.	ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT HISTOPATHOL,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT MED,LONDON W2 1PG,ENGLAND; CHELSEA & WESTMINSTER HOSP,LONDON SW10 9NH,ENGLAND; KENSINGTON & CHELSEA & WESTMINSTER HLTH AUTHOR,LONDON W2 6LX,ENGLAND	Imperial College London; Imperial College London; Imperial College London	Foster, GR (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,LIVER UNIT,PRAED ST,LONDON W2 1PG,ENGLAND.		Thomas, Howard C/A-3152-2009	Hargreaves, Sally/0000-0003-2974-4348; Foster, Graham/0000-0002-3704-386X; Goldin, Robert/0000-0001-5184-4519				BOOTH JCL, 1995, GUT, V36, P427, DOI 10.1136/gut.36.3.427; BOOTH JCL, 1995, GUT, V37, P449, DOI 10.1136/gut.37.4.449; CHEMELLO L, 1995, J VIRAL HEPATITIS, V2, P91, DOI 10.1111/j.1365-2893.1995.tb00012.x; Davis G L, 1994, J Viral Hepat, V1, P55, DOI 10.1111/j.1365-2893.1994.tb00062.x; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; Dusheiko GM, 1996, BMJ-BRIT MED J, V312, P357, DOI 10.1136/bmj.312.7027.357; Fattovich G, 1996, J HEPATOL, V24, P38, DOI 10.1016/S0168-8278(96)80184-X; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; MALAGUARNERA M, 1995, CLIN DRUG INVEST, V9, P141, DOI 10.2165/00044011-199509030-00002; MUTIMER DJ, 1995, J VIRAL HEPATITIS, V2, P47, DOI 10.1111/j.1365-2893.1995.tb00071.x; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; SCHALM SW, 1996, DIGEST DIS SCI, V41, P1315; TIBBS CJ, 1995, J VIRAL HEPATITIS, V2, P113, DOI 10.1111/j.1365-2893.1995.tb00016.x; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607	16	72	75	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					453	458		10.1136/bmj.315.7106.453	http://dx.doi.org/10.1136/bmj.315.7106.453			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284661	Green Published			2022-12-24	WOS:A1997XT71400015
J	Cella, M; Engering, A; Pinet, V; Pieters, J; Lanzavecchia, A				Cella, M; Engering, A; Pinet, V; Pieters, J; Lanzavecchia, A			Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells	NATURE			English	Article							ANTIGEN PROCESSING CAPACITY; EPIDERMAL LANGERHANS CELLS; TUMOR-NECROSIS-FACTOR; INVARIANT CHAIN; MOLECULES; COMPARTMENT; LYMPHOCYTES; EXPRESSION; PEPTIDES; CULTURE	Dendritic cells have the remarkable property of presenting any incoming antigen(1). To do so they must not only capture antigens with high efficiency and broad specificity, but must also maximize their capacity to load class II molecules of the major histocompatibility complex (MHC) with antigenic peptides in order to present a large array of epitopes from different proteins, each at a sufficient copy number. Here we show that formation of peptide-MHC class II complexes is boosted by inflammatory stimuli that induce maturation of dendritic cells. In immature dendritic cells, class II molecules are rapidly internalized and recycled, turning over with a half-life of about 10 hours. Inflammatory stimuli induce a rapid and transient boost of class II synthesis, while the half-life of dass II molecules increases to over 100 hours. These coordinated changes result in the rapid accumulation of a large number of long-lived peptide-loaded MHC dass II molecules capable of stimulating T cells even after several days, The capacity of dendritic cells to load many antigenic peptides over a short period of initial exposure to inflammatory stimuli could favour presentation of infectious antigens.	HOP ST ELOI,IMMUNOL LAB,INSERM,U291,F-34295 MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Cella, M (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.		PINET, Valérie/G-6085-2012; Cella, Marina/ABA-8564-2020; Cella, Marina/G-8850-2011	PINET, Valérie/0000-0002-4044-6440; Pieters, Jean/0000-0002-5284-9757; Cella, Marina/0000-0003-1230-1313				AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; ENK AH, 1992, P NATL ACAD SCI USA, V89, P1398, DOI 10.1073/pnas.89.4.1398; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; KAMPGEN E, 1991, P NATL ACAD SCI USA, V88, P3014, DOI 10.1073/pnas.88.8.3014; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; PINET V, 1995, NATURE, V375, P603, DOI 10.1038/375603a0; PINET V, 1994, J IMMUNOL, V152, P4852; PURE E, 1990, J EXP MED, V172, P1459, DOI 10.1084/jem.172.5.1459; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; ROOSNEK E, 1988, J IMMUNOL, V140, P4079; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; STOSSEL H, 1990, J EXP MED, V172, P1471, DOI 10.1084/jem.172.5.1471; Zhong GM, 1997, J EXP MED, V185, P429, DOI 10.1084/jem.185.3.429	19	907	932	2	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					782	787		10.1038/42030	http://dx.doi.org/10.1038/42030			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285591	Bronze			2022-12-24	WOS:A1997XR66700053
J	Barquet, N; Domingo, P; Cayla, JA; Gonzalez, J; Rodrigo, C; FernandezViladrich, P; MoragaLlop, FA; Marco, F; Vazquez, J; SaezNieto, JA; Casal, J; Canela, J; Foz, M				Barquet, N; Domingo, P; Cayla, JA; Gonzalez, J; Rodrigo, C; FernandezViladrich, P; MoragaLlop, FA; Marco, F; Vazquez, J; SaezNieto, JA; Casal, J; Canela, J; Foz, M			Prognostic factors in meningococcal disease - Development of a bedside predictive model and scoring system	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEPTICEMIA; INFECTIONS; PENICILLIN; THERAPY; SCALE; COMA	Context.-Meningococcal disease is associated with significant morbidity and mortality. Development of a prognostic model based on clinical findings may be useful for identification and management of patients with meningococcal infection. Objectives.-To construct and validate a bedside model and scoring system for prognosis in meningococcal disease. Design.-Prospective, population-based study. Setting.-Twenty-four hospitals in the metropolitan area of Barcelona, Spain. Patients.-A total of 907 patients with microbiologically proven meningococcal disease. Patients diagnosed with meningococcal disease from 1987 through 1990 were used to develop the prognostic model, and those diagnosed in 1991. and 1992 were used to validate it. Outcome Measures.-Clinical independent prognostic factors for mortality in meningococcal disease. The association between outcome and independent prognostic factors was determined by logistic regression analysis. A scoring system was constructed and tested using receiver operating characteristic curves. Results.-Among 624 patients in the derivation set, 287 (46%) were male, the mean age was 12.4 years, and 34 patients (5.4%) died. Among 283 patients in the validation set, 124 (43.8%) were male, the mean age was 12.7 years, and 17 patients (6.0%) died. In multivariate analysis, independent predictors of death were hemorrhagic diathesis (odds ratio [OR], 101; 95% confidence interval [CI], 30-333), focal neurologic signs (OR, 25; 95% CI, 7-83), and age 60 years or older (OR, 10; 95% CI, 3-34), whereas receipt of adequate antibiotic therapy prior to admission was associated with reduced likelihood of death (OR, 0.09; 95% CI, 0.02-0.4). Hemorrhagic diathesis was scored with 2 points, presence of focal neurologic signs with 1 point, age of 60 years or older with 1 point, and preadmission antibiotic therapy was scored as -1. The clinical scores of -1, 0, 1, 2, and 3 or more points were associated with a probability of death of 0%, 2.3%, 27.3%, 73.3%, and 100%, respectively. Conclusions.-Hemorrhagic diathesis, focal neurologic signs, and age of 60 years or older were independent predictors of death in meningococcal disease, whereas receipt of adequate antibiotic therapy was associated with a more favorable prognosis. The scoring system presented is simple, is based on findings readily ;available at the bedside, and may be useful to help guide aggressive therapy.	INST CATALA SALUT, CAP GRACIA, BARCELONA, SPAIN; HOSP SANTA CRUZ & SAN PABLO, E-08025 BARCELONA, SPAIN; INST MUNICIPAL SALUT, BARCELONA, SPAIN; HOSP CLIN BARCELONA, BARCELONA, SPAIN; HOSP INFANTIL VALL HEBRON, BARCELONA, SPAIN; DEPT SALUT PUBL & LEGISLACIO SANITARIA, BARCELONA, SPAIN; HOSP GERMANS TRIAS & PUJOL, BADALONA, SPAIN; BELLVITGE HOSP, LHOSPITALET DE LLOBREGAT, SPAIN; CTR NACL MICROBIOL VIROL & INMUNOL SANITARIAS, LAB REFERENCIA MENINGOCOCOS, MADRID, SPAIN	University of Barcelona; Hospital Clinic de Barcelona; Hospital Universitari Vall d'Hebron; Hospital Germans Trias i Pujol; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital			Domingo, Pere/AAP-7571-2021; Domingo, Pere/CAF-3577-2022; Rodrigo, Carlos/F-7602-2017; Marco, Francesc D/K-2900-2017; Moraga Llop, Fernando/E-2316-2016	Domingo, Pere/0000-0003-1138-5770; Rodrigo, Carlos/0000-0003-1140-2585; Marco, Francesc D/0000-0002-1863-6379; Moraga Llop, Fernando/0000-0001-7449-2632; Vazquez, Julio A/0000-0003-3326-8831; Cayla, Joan A./0000-0003-3891-111X				BJORVATN B, 1984, BRIT MED J, V288, P439, DOI 10.1136/bmj.288.6415.439; BOHR V, 1983, J INFECTION, V7, P193, DOI 10.1016/S0163-4453(83)96980-3; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; BRANDTZEAG P, 1987, LANCET, V2, P862; BUSUND R, 1993, CRIT CARE MED, V21, P1699, DOI 10.1097/00003246-199311000-00019; CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; DOMINGO P, 1995, LANCET, V345, P460, DOI 10.1016/S0140-6736(95)90446-8; DRAPER WH, 1864, AM MED TIMES, V9, P114; DRAPER WH, 1864, AM MED TIMES, V9, P99; DRAPER WH, 1864, AM MED TIMES, V9, P101; EMPARANZA JI, 1988, CRIT CARE MED, V16, P168, DOI 10.1097/00003246-198802000-00015; Flexner S, 1913, J EXP MED, V17, P553, DOI 10.1084/jem.17.5.553; GARDLUND B, 1986, INTENS CARE MED, V12, P302, DOI 10.1007/BF00261740; GEDDEDAHL TW, 1990, REV INFECT DIS, V12, P973; GIRAUD T, 1991, ARCH INTERN MED, V151, P310, DOI 10.1001/archinte.151.2.310; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer DW, 1989, APPL LOGISTIC REGRES, P140; KAHN A, 1978, CLIN PEDIATR, V17, P680, DOI 10.1177/000992287801700902; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LEWIS LS, 1979, ARCH DIS CHILD, V54, P44, DOI 10.1136/adc.54.1.44; MORELLO JA, 1991, MANUAL CLIN MICROBIO, P258; NIKLASSON P-M, 1971, Scandinavian Journal of Infectious Diseases, V3, P17, DOI 10.3109/inf.1971.3.issue-1.03; Norusis M. J., 1986, SPSS PC IBM PC XT AT; SAUKKONEN K, 1988, J INFECT DIS, V158, P209, DOI 10.1093/infdis/158.1.209; SIMPSON D, 1982, LANCET, V2, P450; SINCLAIR JF, 1987, LANCET, V2, P38; *STAT EP RES CORP, 1990, EP GRAPH EST TEST PA; STIEHM ER, 1966, J PEDIATR-US, V68, P457, DOI 10.1016/S0022-3476(66)80250-0; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; STRONG N, 1811, MED PHILOS REG, V1, P12; STRONG N, 1811, MED PHILOS REG, V1, P57; STRONG N, 1811, MED PHILOS REG, V1, P96; TEASDALE G, 1974, LANCET, V2, P81; TESORO LJ, 1991, AM J DIS CHILD, V145, P218, DOI 10.1001/archpedi.1991.02160020112029; THOMSON APJ, 1991, CRIT CARE MED, V19, P26, DOI 10.1097/00003246-199101000-00010; THOMSON APJ, 1991, PEDIATRIC REV COMMUN, V5, P199; TUYSUZ B, 1993, ACTA PAEDIATR, V82, P1053, DOI 10.1111/j.1651-2227.1993.tb12809.x; Vieusseux G, 1806, J MED CHIR PHARMACOL, V11, P163; VIKMO H, 1978, SCAND J INFECT DIS, V10, P187, DOI 10.3109/inf.1978.10.issue-3.06; WONG VK, 1989, PEDIATR INFECT DIS J, V8, P224	42	62	63	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	1997	278	6					491	496		10.1001/jama.278.6.491	http://dx.doi.org/10.1001/jama.278.6.491			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP243	9256224				2022-12-24	WOS:A1997XP24300031
J	Bannerman, E; Reilly, JJ; MacLennan, WJ; Kirk, T; Pender, F				Bannerman, E; Reilly, JJ; MacLennan, WJ; Kirk, T; Pender, F			Evaluation of validity of British anthropometric reference data for assessing nutritional state of elderly people in Edinburgh: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							SKELETAL SIZE; MALNUTRITION; INDEXES; VALUES	Objectives: To evaluate the appropriateness of two sets of commonly used anthropometric reference data for nutritional assessment of elderly people. Design: Cross sectional study. Setting: Two general practices in Edinburgh. Subjects: 200 independently living men and women aged 75 or over randomly recruited from the age and sex register of the practices. Main outcome measures: Weight (kg), knee height (cm), demispan (cm), mid-upper arm circumference (cm), triceps skinfold thickness (mm), arm muscle circumference (cm) body mass index (kg/m(2)), and demiquet (kg/m(2)) in men and minder (kg/m) in women. Results: Men and women in Edinburgh were significantly shorter than those in measured for the Nottingham reference data (demispan 0.79 v 0.80 (P < 0.05) for men and 0.72 v 0.73 (P < 0.01) for women). Comparison with data from South Wales showed that men and women from Edinburgh had significantly greater mid-upper arm circumference, triceps skinfold thickness, and arm muscle circumference. No one fell below the 10th centile of the South Wales data (the commonly used cut off point for determining malnutrition) for these measures. Conclusions: Both sets of reference data commonly used in Britain may be inappropriate for nutritional screening of elderly people in Edinburgh. Contemporary reference data appropriate for the whole of Britain need to be developed, and in the longer term biologically or clinically defined criteria for undernutrition should be established.	QUEEN MARGARET COLL,DEPT NUTR & DIETET,EDINBURGH EH12 8TS,MIDLOTHIAN,SCOTLAND; YORKHILL HOSP,DEPT HUMAN NUTR,GLASGOW G3 8SJ,LANARK,SCOTLAND; UNIV EDINBURGH,ROYAL INFIRM EDINBURGH,GERIATR MED UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Queen Margaret University; Royal Infirmary of Edinburgh; University of Edinburgh								[Anonymous], 1991, ANTHROPOMETRIC STAND; Bannerman E, 1997, P NUTR SOC, V55, p249A; BASSEY EJ, 1986, ANN HUM BIOL, V13, P499, DOI 10.1080/03014468600008661; BURR ML, 1984, BRIT J NUTR, V51, P165, DOI 10.1079/BJN19840020; CHUMLEA WC, 1985, J AM GERIATR SOC, V33, P116, DOI 10.1111/j.1532-5415.1985.tb02276.x; CHUMLEA WC, 1989, AM J CLIN NUTR, V50, P1158, DOI 10.1093/ajcn/50.5.1158; COCKRAM DB, 1990, AM J CLIN NUTR, V52, P397, DOI 10.1093/ajcn/52.2.397; DELARUE J, 1994, BRIT J NUTR, V71, P295, DOI 10.1079/BJN19940135; Department of Health, 1992, 43 DEP HLTH; FRIEDMAN PJ, 1985, AGE AGEING, V14, P149, DOI 10.1093/ageing/14.3.149; Gibson RS, 1990, Q REV BIOL; Gregory J., 1990, DIETARY NUTR SURVEY; LEHMANN AB, 1991, CLIN NUTR, V10, P18, DOI 10.1016/0261-5614(91)90076-O; Lennard-Jones J E, 1992, POSITIVE APPROACH NU; LOHMAN TG, 1993, ADV BODY COMPOSITION, V3; MCWHIRTER JP, 1994, BRIT MED J, V308, P945, DOI 10.1136/bmj.308.6934.945; MORGAN DB, 1986, AGE AGEING, V15, P65, DOI 10.1093/ageing/15.2.65; POTTER J, 1995, AGE AGEING, V24, P131, DOI 10.1093/ageing/24.2.131; SAVAGE SA, 1997, P NUTR SOC, V55, pA81; Thuluvath PJ, 1995, NUTRITION, V11, P731; Wright CM, 1996, BMJ-BRIT MED J, V313, P513, DOI 10.1136/bmj.313.7056.513	21	31	31	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					338	341						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270454	Green Published			2022-12-24	WOS:A1997XQ86400019
J	Carlezon, WA; Boundy, VA; Haile, CN; Lane, SB; Kalb, RG; Neve, RL; Nestler, EJ				Carlezon, WA; Boundy, VA; Haile, CN; Lane, SB; Kalb, RG; Neve, RL; Nestler, EJ			Sensitization to morphine induced by viral-mediated gene transfer	SCIENCE			English	Article							GLUTAMATE-RECEPTOR CHANNELS; VENTRAL TEGMENTAL AREA; TYROSINE-HYDROXYLASE; BEHAVIORAL SENSITIZATION; INDIVIDUAL-DIFFERENCES; AMPHETAMINE; COCAINE; NEURONS; RATS; EXPRESSION	Repeated administration of morphine sensitizes animals to the stimulant and rewarding properties of the drug. It also selectively increases expression of GluR1 (an AMPA glutamate receptor subunit) in the ventral tegmental area, a midbrain region implicated in morphine action, By viral-mediated gene transfer, a causal relation is shown between these behavioral and biochemical adaptations: Morphine's stimulant and rewarding properties are intensified after microinjections of a viral vector expressing GluR1 into the ventral tegmental area, These results confirm the importance of AMPA receptors in morphine action and demonstrate specific locomotor and motivational adaptations resulting from altered expression of a single localized gene product.	YALE UNIV, SCH MED, CONNECTICUT MENTAL HLTH CTR, DEPT PSYCHIAT, NEW HAVEN, CT 06508 USA; YALE UNIV, SCH MED, DEPT NEUROL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06520 USA; HARVARD UNIV, MCLEAN HOSP, SCH MED, DEPT GENET, BELMONT, MA 02178 USA	Yale University; Yale University; Yale University; Harvard University; McLean Hospital				/0000-0002-4162-3947; Haile, Colin/0000-0001-8293-7291				Berhow MT, 1996, J NEUROSCI, V16, P4707; Berhow MT, 1996, J NEUROSCI, V16, P8019; BOZARTH MA, 1981, LIFE SCI, V28, P551, DOI 10.1016/0024-3205(81)90148-X; CARLEZON WA, UNPUB; DEROCHE V, 1993, BRAIN RES, V623, P341, DOI 10.1016/0006-8993(93)91451-W; DURING MJ, 1994, SCIENCE, V266, P1399, DOI 10.1126/science.266.5189.1399; Fink DJ, 1996, ANNU REV NEUROSCI, V19, P265; Fitzgerald LW, 1996, J NEUROSCI, V16, P274; GALEY D, 1977, BRAIN RES, V124, P83, DOI 10.1016/0006-8993(77)90865-4; HENRY DJ, 1995, J NEUROSCI, V15, P6287; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; ISACSON O, 1995, SCIENCE, V269, P856, DOI 10.1126/science.7638605; JAKOWEC MW, 1995, NEUROSCIENCE, V67, P909, DOI 10.1016/0306-4522(95)00094-Y; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; KARIER R, 1991, BRAIN RES, V552, P295; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LETT BT, 1989, PSYCHOPHARMACOLOGY, V98, P357, DOI 10.1007/BF00451687; LI Y, IN PRESS PSYCHOPHARM; Lim F, 1996, BIOTECHNIQUES, V20, P460; MIN N, 1994, MOL BRAIN RES, V27, P281, DOI 10.1016/0169-328X(94)90011-6; MISERENDINO MJD, 1993, MOL CELL NEUROSCI, V4, P440, DOI 10.1006/mcne.1993.1055; Neve RL, 1997, NEUROSCIENCE, V79, P435, DOI 10.1016/S0306-4522(96)00645-8; Neve RL, 1996, CLIN NEUROSCI, V3, P262; ORTIZ J, 1995, SYNAPSE, V21, P289, DOI 10.1002/syn.890210403; PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295; PRUSS RM, 1991, NEURON, V7, P509, DOI 10.1016/0896-6273(91)90302-G; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SEGAL DS, 1992, BRAIN RES, V577, P351, DOI 10.1016/0006-8993(92)90297-M; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.neuro.18.1.463; SklairTavron L, 1996, P NATL ACAD SCI USA, V93, P11202, DOI 10.1073/pnas.93.20.11202; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; VEZINA P, 1989, BRAIN RES, V499, P108, DOI 10.1016/0006-8993(89)91140-2; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; WISE RA, 1989, NEUROPHARMACOLOGICAL; Zhang XF, 1997, J PHARMACOL EXP THER, V281, P699	36	233	239	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 8	1997	277	5327					812	814		10.1126/science.277.5327.812	http://dx.doi.org/10.1126/science.277.5327.812			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242609				2022-12-24	WOS:A1997XQ24700042
J	Lewis, FD; Wu, TF; Zhang, YF; Letsinger, RL; Greenfield, SR; Wasielewski, MR				Lewis, FD; Wu, TF; Zhang, YF; Letsinger, RL; Greenfield, SR; Wasielewski, MR			Distance-dependent electron transfer in DNA hairpins	SCIENCE			English	Article							OLIGONUCLEOTIDES; FLUORESCENCE; DYNAMICS	The distance dependence of photoinduced electron transfer in duplex DNA was determined for a family of synthetic DNA hairpins in which a stilbene dicarboxamide forms a bridge connecting two oligonucleotide arms. Investigation of the fluorescence and transient absorption spectra of these hairpins established that no photoinduced electron transfer occurs for a hairpin that has six deoxyadenosine-deoxythymidine base pairs. However, the introduction of a single deoxyguanosine-deoxycytidine base pair resulted in distance-dependent fluorescence quenching and the formation of the stilbene anion radical. Kinetic analysis suggests that duplex DNA is somewhat more effective than proteins as a medium for electron transfer but that it does not function as a molecular wire.	ARGONNE NATL LAB,DIV CHEM,ARGONNE,IL 60439	United States Department of Energy (DOE); Argonne National Laboratory	Lewis, FD (corresponding author), NORTHWESTERN UNIV,DEPT CHEM,2145 SHERIDAN RD,EVANSTON,IL 60208, USA.		Greenfield, Scott/GOE-6006-2022					[Anonymous], 1988, ELECT ABSORPTION SPE; Arkin MR, 1996, SCIENCE, V273, P475, DOI 10.1126/science.273.5274.475; Beratan DN, 1997, CHEM BIOL, V4, P3, DOI 10.1016/S1074-5521(97)90230-1; BIRKS JB, 1970, PHOTOPHYSICS AROMATI, P128; BRUN AM, 1992, J AM CHEM SOC, V114, P3656, DOI 10.1021/ja00036a013; CANDEIAS LP, 1989, J AM CHEM SOC, V111, P1094, DOI 10.1021/ja00185a046; Dandliker PJ, 1997, SCIENCE, V275, P1465, DOI 10.1126/science.275.5305.1465; GREENFIELD SR, 1995, OPT LETT, V20, P1394, DOI 10.1364/OL.20.001394; Greenfield SR, 1996, J AM CHEM SOC, V118, P6767, DOI 10.1021/ja9600789; Guckian KM, 1996, J AM CHEM SOC, V118, P8182, DOI 10.1021/ja961733f; Hall DB, 1996, NATURE, V382, P731, DOI 10.1038/382731a0; LETSINGER RL, 1995, J AM CHEM SOC, V117, P7323, DOI 10.1021/ja00133a005; LEWIS FD, 1995, J AM CHEM SOC, V117, P8785, DOI 10.1021/ja00139a011; Lincoln P, 1997, J AM CHEM SOC, V119, P1454, DOI 10.1021/ja9631965; MATAGA N, 1990, J PHYS CHEM-US, V94, P1443, DOI 10.1021/j100367a045; MURPHY CJ, 1993, SCIENCE, V262, P1025, DOI 10.1126/science.7802858; Olson EJC, 1997, J PHYS CHEM B, V101, P299, DOI 10.1021/jp963109v; Priyadarshy S, 1996, J PHYS CHEM-US, V100, P17678, DOI 10.1021/jp961731h; REHM D, 1970, ISRAEL J CHEM, V8, P259; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Taubes G, 1997, SCIENCE, V275, P1420, DOI 10.1126/science.275.5305.1420; WALDECK DH, 1991, CHEM REV, V91, P415, DOI 10.1021/cr00003a007; WILSON EK, 1997, CHEM ENG NEWS, P33	23	553	566	4	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					673	676		10.1126/science.277.5326.673	http://dx.doi.org/10.1126/science.277.5326.673			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235887				2022-12-24	WOS:A1997XN90700037
J	Moll, S; Ortel, TL				Moll, S; Ortel, TL			Monitoring warfarin therapy in patients with lupus anticoagulants	ANNALS OF INTERNAL MEDICINE			English	Article						warfarin; lupus coagulation inhibitor; anticoagulants; prothrombin time; thromboembolism	DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; PROTHROMBIN TIME; ANTIBODIES; THROMBOPLASTIN; ERYTHEMATOSUS; POPULATION; INHIBITION; DIAGNOSIS; PLASMA	Background: Recommended therapeutic international normalized ratios (INRs) for oral anticoagulation in patients with lupus anticoagulants who sustain a thromboembolic event are controversial. Patients with lupus anticoagulants often have a prolonged prothrombin time, which may complicate management of anticoagulant therapy. Objectives: To determine the validity of the INR as a monitor for warfarin therapy in patients with lupus anticoagulants and to investigate alternate approaches to monitoring warfarin therapy in these patients. Design: Prospective case series. Setting: Tertiary care hospital. Patients: 34 patients with lupus anticoagulants. Measurements: Prothrombin times were determined by using several thromboplastins, and INRs were calculated for the patients receiving warfarin. Factor II levels, chromogenic factor X levels, and prothrombin-proconvertin times were determined for patients receiving warfarin. Results: For patients with lupus anticoagulants who were not receiving warfarin, prothrombin times were often elevated and varied significantly with different thromboplastins. individual thromboplastins differed in sensitivity to the presence of a lupus anticoagulant. For patients receiving warfarin, INRs obtained by using different thromboplastins greatly varied and often overestimated the extent of anticoagulation. Chromogenic factor X levels and prothrombin-proconvertin times correlated well with each other and with established therapeutic ranges. Conclusions: Lupus anticoagulants can influence prothrombin times and lead to INRs that do not accurately reflect the true level of anticoagulation. Use of the INR to standardize prothrombin times is invalid for some patients with lupus anticoagulants. To prevent supratherapeutic or subtherapeutic anticoagulation, these patients must be individually monitored with a test that is insensitive to lupus anticoagulants.	DUKE UNIV, DEPT MED, DIV HEMATOL, MED CTR, DURHAM, NC 27710 USA; FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, FRANZ VOLHARD KLIN, D-13122 BERLIN, GERMANY	Duke University; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin					NCRR NIH HHS [MO1-RR-30] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; BAJAJ SP, 1983, BLOOD, V61, P684; BICK RL, 1994, MED CLIN N AM, V78, P667, DOI 10.1016/S0025-7125(16)30152-3; BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185; BRANDT JT, 1991, THROMB HAEMOSTASIS, V66, P453; CIAVARELLA N, 1980, THROMB RES, V19, P493, DOI 10.1016/0049-3848(80)90022-5; COON WW, 1973, CIRCULATION, V48, P839, DOI 10.1161/01.CIR.48.4.839; EGBERG N, 1982, THROMB RES, V25, P437, DOI 10.1016/0049-3848(82)90134-7; FLECK RA, 1988, BLOOD, V72, P512; GALLI M, 1989, BRIT J HAEMATOL, V72, P549, DOI 10.1111/j.1365-2141.1989.tb04322.x; GINSBERG JS, 1995, BLOOD, V86, P3685, DOI 10.1182/blood.V86.10.3685.bloodjournal86103685; GINSBERG JS, 1993, BLOOD, V81, P2958; HIRSH J, 1995, CHEST, V108, pS258, DOI 10.1378/chest.108.4_Supplement.258S; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; HORELLOU MH, 1987, J MED, V18, P199; Khamashta MA, 1996, LUPUS, V5, P463, DOI 10.1177/096120339600500527; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; KHAMASHTA MA, 1995, NEW ENGL J MED, V333, P666; KOVACS MJ, 1994, THROMB HAEMOSTASIS, V71, P727; LE DT, 1994, ANN INTERN MED, V120, P552, DOI 10.7326/0003-4819-120-7-199404010-00004; Lind SE, 1997, BLOOD COAGUL FIBRIN, V8, P48, DOI 10.1097/00001721-199701000-00008; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; MANNUCCI PM, 1979, SCAND J HAEMATOL, V22, P423; NASR SZ, 1995, NEW ENGL J MED, V333, P666; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; OUT HJ, 1989, ANN RHEUM DIS, V48, P1023, DOI 10.1136/ard.48.12.1023; OWREN PA, 1951, SCAND J CLIN LAB INV, V3, P201, DOI 10.3109/00365515109060600; RAPAPORT SI, 1995, NEW ENGL J MED, V333, P665; RAPAPORT SI, 1960, BLOOD, V15, P212, DOI 10.1182/blood.V15.2.212.212; ROSOVE MH, 1992, ANN INTERN MED, V117, P303, DOI 10.7326/0003-4819-117-4-303; ROUBEY RAS, 1994, BLOOD, V84, P2854; Shapiro SS, 1996, ANNU REV MED, V47, P533; Simioni P, 1996, THROMB HAEMOSTASIS, V76, P187; SKOGEN WF, 1983, BIOCHEM BIOPH RES CO, V111, P14, DOI 10.1016/S0006-291X(83)80110-7; SLIVKA A, 1995, NEW ENGL J MED, V333, P665; The Committee of Stratigraphy of China, 1996, CPMPBWP21496, P1; TRIPLETT DA, 1983, AM J CLIN PATHOL, V79, P678, DOI 10.1093/ajcp/79.6.678; VANDENBESSELAAR AMHP, 1993, THROMB HAEMOSTASIS, V69, P85	38	156	171	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					177	+		10.7326/0003-4819-127-3-199708010-00001	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245222				2022-12-24	WOS:A1997XN12900001
J	Stokoe, D; Stephens, LR; Copeland, T; Gaffney, PRJ; Reese, CB; Painter, GF; Holmes, AB; McCormick, F; Hawkins, PT				Stokoe, D; Stephens, LR; Copeland, T; Gaffney, PRJ; Reese, CB; Painter, GF; Holmes, AB; McCormick, F; Hawkins, PT			Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B	SCIENCE			English	Article							C-AKT; V-AKT	Protein kinase B (PKB) is a proto-oncogene that is activated in signaling pathways initiated by phosphoinositide 3-kinase. Chromatographic separation of brain cytosol revealed a kinase activity that phosphorylated and activated PKB only in the presence of phosphatidylinositol-3,4,5-trisphosphate [PtdIns(3,4,5)P-3]. Phosphorylation occurred exclusively on threonine-308, a residue implicated in activation of PKB in vivo. PtdIns(3,4,5)P-3 was determined to have a dual role: its binding to the pleckstrin homology domain of PKB was required to allow phosphorylation by the upstream kinase and it directly activated the upstream kinase.	ONYX PHARMACEUT,RICHMOND,CA 94806; BABRAHAM INST,CAMBRIDGE CB2 4AT,ENGLAND; NCI,ABL BASIC RES PROGRAM,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; UNIV LONDON KINGS COLL,DEPT CHEM,LONDON WC2R 2LS,ENGLAND; UNIV CAMBRIDGE,DEPT CHEM,CAMBRIDGE CB2 3RA,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of London; King's College London; University of Cambridge				Hawkins, Phillip/0000-0002-6979-0464; stephens, len/0000-0002-2771-3487				AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BELLACOSA A, 1993, ONCOGENE, V8, P745; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOKOE D, UNPUB	23	1031	1078	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					567	570		10.1126/science.277.5325.567	http://dx.doi.org/10.1126/science.277.5325.567			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228007				2022-12-24	WOS:A1997XM86700052
J	Impicciatore, P; Pandolfini, C; Casella, N; Bonati, M				Impicciatore, P; Pandolfini, C; Casella, N; Bonati, M			Reliability of health information for the public on the world wide web: Systematic survey of advice on managing fever in children at home	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RECTAL TEMPERATURE; PARENTS; INFANTS	Objective: To assess the reliability of healthcare information on the world wide web and therefore how it may help lay people cope with common health problems. Methods: Systematic search by means of two search engines, Yahoo and Excite, of parent oriented web pages relating to home management of feverish children. Reliability of information on the web sites was checked by comparison with published guidelines. Main outcome measures: Minimum temperature of child that should be considered as fever, optimal sites for measuring temperature, pharmacological and physical treatment of fever, conditions that may warrant a doctor's visit. Results: 41 web pages were retrieved and considered. 28 web pages gave a temperature above which a child is feverish; 26 pages indicated the optimal site for taking temperature, most recommending rectal measurement; 31 of the 34 pages that mentioned drug treatment recommended paracetamol as an antipyretic; 38 pages recommended non-drug measures, most commonly tepid sponging, dressing lightly, and increasing fluid intake; and 36 pages gave some indication of when a doctor should be called. Only four web pages adhered closely to the main recommendations in the guidelines. The largest deviations were in sponging procedures and how to take a child's temperature, whereas there was a general agreement in the use of paracetamol. Conclusions: Only a few web sites provided complete and accurate information for this common and widely discussed condition. This suggests an urgent need to check public oriented healthcare information on the internet for accuracy, completeness, and consistency.	MARIO NEGRI INST PHARMACOL RES, LAB MOTHER & CHILD HLTH, I-20157 MILAN, ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS			Bonati, Maurizio/K-8980-2016; Pandolfini, Chiara/K-5693-2016	Bonati, Maurizio/0000-0003-3997-3726; Pandolfini, Chiara/0000-0001-9809-2991				ADAM D, 1994, EUR J PEDIATR, V153, P394; CASEY R, 1984, PEDIATRICS, V73, P600; Coeira E., 1996, BRIT MED J, V312, P3; DEAN AG, 1994, EPI INFO VERSION 6; ELRADHI AS, 1994, FEVER PAEDIAT PRACTI, P229; Fagan E, 1996, BRIT MED J, V313, P1417, DOI 10.1136/bmj.313.7070.1417; GRIBETZ B, 1987, PEDIATRICS, V80, P630; Impicciatore P, 1997, BRIT MED J, V314, P373, DOI 10.1136/bmj.314.7077.373a; KAI J, 1993, BRIT MED J, V307, P660, DOI 10.1136/bmj.307.6905.660; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; KEELEY D, 1992, BRIT MED J, V304, P931, DOI 10.1136/bmj.304.6832.931; KINMONTH AL, 1992, BRIT MED J, V305, P1134, DOI 10.1136/bmj.305.6862.1134; KLUGER MJ, 1992, PEDIATRICS, V90, P846; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V272, P1025, DOI 10.1001/jama.272.13.1025; KRAMER MS, 1991, LANCET, V337, P591, DOI 10.1016/0140-6736(91)91648-E; KRAMER MS, 1985, PEDIATRICS, V75, P1110; KRESCH MJ, 1984, J PEDIATR-US, V104, P596, DOI 10.1016/S0022-3476(84)80558-2; LAPORTE RE, 1994, BRIT MED J, V308, P1651, DOI 10.1136/bmj.308.6945.1651; LaPorte RE, 1996, ANN EPIDEMIOL, V6, P162, DOI 10.1016/1047-2797(95)00133-6; LESKO SM, 1995, JAMA-J AM MED ASSOC, V273, P929, DOI 10.1001/jama.273.12.929; McIntyre J, 1996, ARCH DIS CHILD, V74, P164, DOI 10.1136/adc.74.2.164; MORLEY CJ, 1992, ARCH DIS CHILD, V67, P122, DOI 10.1136/adc.67.1.122; MOSS MH, 1970, PEDIATRICS, V46, P445; PALLEN M, 1995, BRIT MED J, V311, P1552, DOI 10.1136/bmj.311.7019.1552; PENNA A, 1991, BRIT J CLIN PHARMACO, V32, P143, DOI 10.1111/j.1365-2125.1991.tb03873.x; ROBINSON JS, 1989, AM J DIS CHILD, V143, P698, DOI 10.1001/archpedi.1989.02150180076024; SAPER CB, 1994, NEW ENGL J MED, V330, P1880; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.1997.03540390074039; Spooner SA, 1996, PEDIATRICS, V98, P1185; TARLOW M, 1986, BRIT MED J, V292, P1543, DOI 10.1136/bmj.292.6535.1543; The International Agranulocytosis and Aplastic Anemia Study, 1986, JAMA-J AM MED ASSOC, V256, P1749; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209; 1991, LANCET, V338, P1049	33	414	421	1	45	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 28	1997	314	7098					1875	1879		10.1136/bmj.314.7098.1875	http://dx.doi.org/10.1136/bmj.314.7098.1875			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224132	Green Published			2022-12-24	WOS:A1997XH73800028
J	Veronesi, U; Paganelli, G; Galimberti, V; Viale, G; Zurrida, S; Bedoni, M; Costa, A; deCicco, C; Geraghty, JG; Luini, A; Sacchini, V; Veronesi, P				Veronesi, U; Paganelli, G; Galimberti, V; Viale, G; Zurrida, S; Bedoni, M; Costa, A; deCicco, C; Geraghty, JG; Luini, A; Sacchini, V; Veronesi, P			Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes	LANCET			English	Article							GAMMA-PROBE; LYMPHADENECTOMY; MELANOMA	Background Axillary lymph-node dissection is an important staging procedure in the surgical treatment of breast cancer. However, early diagnosis has led to increasing numbers of dissections in which axillary nodes are free of disease. This raises questions about the need for the procedure. We carried out a study to assess, first, whether a single axillary lymph node (sentinel node) initially receives malignant cells from a breast carcinoma and, second, whether a clear sentinel node reliably forecasts a disease-free axilla. Methods In a consecutive series of 163 women with operable breast carcinoma, we injected microcolloidal human serum albumin labelled with technetium-99m. This tracer was injected subdermally, close to the tumour site, on the day before surgery, and scintigraphic images of the axilla and breast were taken 10 min, 30 min, and 3 h later. A mark was placed on the skin over the site of the radioactive node (sentinel node). During breast surgery, a hand-held gamma-ray detector probe was used to locate the sentinel node, and make possible its separate removal via a small axillary incision. Complete axillary lymphadenectomy was then done. The sentinel node was tagged separately from other nodes. Permanent sections of all removed nodes were prepared for pathological examination. Findings From the sentinel node, we could accurately predict axillary lymph-node status in 156 (97.5%) of the 160 patients in whom a sentinel node was identified, and in all cases (45 patients) with tumours less than 1.5 cm in diameter. In 32 (38%) of the 85 cases with metastatic axillary nodes, the only positive node was the sentinel node. Interpretation in the large majority of patients with breast cancer, lymphoscintigraphy and gamma-probe-guided surgery can be used to locate the sentinel node in the axilla, and thereby provide important information about the status of axillary nodes. Patients without clinical involvement of the axilla should undergo sentinel-node biopsy routinely, and may be spared complete axillary dissection when the sentinel node is disease-free.	EUROPEAN INST ONCOL,DIV NUCL MED,I-20141 MILAN,ITALY; EUROPEAN INST ONCOL,DEPT PATHOL,I-20141 MILAN,ITALY; EUROPEAN INST ONCOL,DEPT ANAESTHESIOL,I-20141 MILAN,ITALY	IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO)	Veronesi, U (corresponding author), EUROPEAN INST ONCOL,DIV SURG,VIA RIPAMONTI 435,I-20141 MILAN,ITALY.		Luini, Alberto/AAS-4322-2020; VERONESI, PAOLO/AAS-4132-2020; GALIMBERTI, Viviana Enrica/AAS-3963-2020; Viale, Giuseppe/AAE-8921-2019; paganelli, giovanni/AAC-5267-2022	VERONESI, PAOLO/0000-0001-8926-4106; GALIMBERTI, Viviana Enrica/0000-0002-5036-7439; Paganelli, Giovanni/0000-0002-2631-4652				Albertini JJ, 1996, JAMA-J AM MED ASSOC, V276, P1818, DOI 10.1001/jama.276.22.1818; [Anonymous], 1992, SURG ONCOLOGY CLIN; CHILOSI M, 1994, BIOTECH HISTOCHEM, V69, P235, DOI 10.3109/10520299409106292; *CONS C, 1985, JAMA-J AM MED ASSOC, V254, P461; Doglioni C, 1996, AM J SURG PATHOL, V20, P1037, DOI 10.1097/00000478-199609000-00001; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FISHER B, 1981, SURG GYNECOL OBSTET, V152, P765; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; Giuliano AE, 1996, J SURG ONCOL, V62, P75, DOI 10.1002/(SICI)1096-9098(199606)62:2<75::AID-JSO1>3.0.CO;2-N; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; Greco M, 1996, ANTICANCER RES, V16, P3913; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KRAG DN, 1993, SURG ONCOL, V2, P335, DOI 10.1016/0960-7404(93)90064-6; MOFFAT FL, 1992, J SURG ONCOL, V51, P8, DOI 10.1002/jso.2930510105; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; Rosen PP, 1993, TUMORS MAMMARY GLAND; VANDERVEEN H, 1994, BRIT J SURG, V81, P1769, DOI 10.1002/bjs.1800811220; VERONESI U, 1990, EUR J SURG ONCOL, V16, P127; VERONESI U, 1987, CANCER, V59, P682, DOI 10.1002/1097-0142(19870215)59:4<682::AID-CNCR2820590403>3.0.CO;2-Z; *WHO, 1981, 2 WHO INT HIST CLASS	20	1541	1595	1	85	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1864	1867		10.1016/S0140-6736(97)01004-0	http://dx.doi.org/10.1016/S0140-6736(97)01004-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217757				2022-12-24	WOS:A1997XG41700008
J	Roberts, RL; Mosch, HU; Fink, GR				Roberts, RL; Mosch, HU; Fink, GR			14-3-3 proteins are essential for RAS/MAPK cascade signaling during pseudohyphal development in S-cerevisiae	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; FILAMENTOUS GROWTH; YEAST; KINASE; 14-3-3-PROTEINS; ACTIVATION; RAS; PATHWAY; RAF-1; IDENTIFICATION	14-3-3 proteins are highly conserved ubiquitous proteins whose explicit functions have remained elusive. Here, we show that the S. cerevisiae 14-3-3 homologs BMH1 and BMH2 are not essential for viability or mating MAPK cascade signaling, but they are essential for pseudohyphal-development MAPK cascade signaling and other processes. Activated alleles of RAS2 and CDC42 induce pseudohyphal development and FG(TyA)-lacZ signaling in Bmh(+) strains but not in ste20 (p65(PAK)) Or bmh1 bmh2 mutant strains. Moreover, Bmh1p and Bmh2p associate with Ste20p in vivo. Three alleles of BMH1 encode proteins defective for FG(TyA)-lacZ signaling and association with Ste20p, yet these alleles complement other 14-3-3 functions. Therefore, the 14-3-3 proteins are specifically required for RAS/MAPK cascade signaling during pseudohyphal development in S. cerevisiae.	UNIV GOTTINGEN, INST MICROBIOL, D-37077 GOTTINGEN, GERMANY	University of Gottingen	Roberts, RL (corresponding author), MIT, WHITEHEAD INST BIOMED RES, DEPT BIOL, CAMBRIDGE, MA 02142 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040266] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07348] Funding Source: Medline; NIGMS NIH HHS [GM40266] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACS P, 1995, BIOCHEM BIOPH RES CO, V216, P103, DOI 10.1006/bbrc.1995.2597; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; Cherry J, 1997, SACCHAROMYCES GENOME; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Gavrias V, 1996, MOL MICROBIOL, V19, P1255, DOI 10.1111/j.1365-2958.1996.tb02470.x; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; LALOUX I, 1994, NUCLEIC ACIDS RES, V22, P999, DOI 10.1093/nar/22.6.999; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mosch HU, 1997, GENETICS, V145, P671; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; Sherman F., 1986, METHODS YEAST GENETI; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; SUEN KL, 1995, ONCOGENE, V11, P825; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; vanHeusden GPH, 1996, FEBS LETT, V391, P252, DOI 10.1016/0014-5793(96)00746-6; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	43	186	187	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	1997	89	7					1055	1065		10.1016/S0092-8674(00)80293-7	http://dx.doi.org/10.1016/S0092-8674(00)80293-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215628	Bronze			2022-12-24	WOS:A1997XG83000010
J	Kirkpatrick, DT; Petes, TD				Kirkpatrick, DT; Petes, TD			Repair of DNA loops involves DNA-mismatch and nucleotide-excision repair proteins	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; YEAST; MUTANTS	A number of enzymes recognize and repair DNA lesions(1). The DNA-mismatch repair system corrects base-base mismatches and small loops, whereas the nucleotide-excision repair systems removes pyrimidine dimers and other helix-distorting lesions. DNA molecules with mismatches or loops can arise as a consequence of heteroduplex formation during meiotic recombination(2). In the yeast Saccharomyces cerevisiae, repair of mismatches results in gene conversion or restoration, and failure to repair the mismatch results in post-meiotic segregation (PMS) (Fig. 1). The ratio of gene-conversion to PMS events reflects the efficiency of DNA repair(3,4). By examining the PMS patterns in yeast strains heterozygous for a mutant allele with a 26-base-pair insertion, we find that the repair of 26-base loops involves Msh2 (a DNA-mismatch repair protein) and Rad1 (a protein required for nucleotide-excision repair).	UNIV N CAROLINA,DEPT BIOL,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill								ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; ALANI E, 1994, GENETICS, V137, P19; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CARPENTER ATC, 1982, P NATL ACAD SCI-BIOL, V79, P5961, DOI 10.1073/pnas.79.19.5961; DETLOFF P, 1991, MOL CELL BIOL, V11, P737, DOI 10.1128/MCB.11.2.737; DICAPRIO L, 1976, MUTAT RES, V37, P137, DOI 10.1016/0027-5107(76)90061-0; DOWLING EL, 1985, GENETICS, V109, P283; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; FOGEL S, 1981, MOL BIOL YEAST SACCH, P289; Friedberg E. C., 1995, DNA REPAIR MUTAGENES, P1; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NAG DK, 1989, NATURE, V340, P318, DOI 10.1038/340318a0; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; REENAN RAG, 1992, GENETICS, V132, P975; RESNICK MA, 1983, GENETICS, V104, P603; Saparbaev M, 1996, GENETICS, V142, P727; SEKELSKY JJ, 1995, GENETICS, V141, P619; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; STAPLETON A, 1991, GENETICS, V127, P39; Tran HT, 1996, GENETICS, V143, P1579	24	128	130	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					929	931		10.1038/43225	http://dx.doi.org/10.1038/43225			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202128				2022-12-24	WOS:A1997XG41600058
J	Panin, VM; Papayannopoulos, V; Wilson, R; Irvine, KD				Panin, VM; Papayannopoulos, V; Wilson, R; Irvine, KD			Fringe modulates notch ligand interactions	NATURE			English	Article							DROSOPHILA; GENE; EXPRESSION; PROTEIN; DELTA; BOUNDARY; RECEPTOR; SERRATE; ENCODES; MEMBER	Notch family of transmembrane receptor proteins mediate developmental cell-fate decisions(1), and mutations in mammalian Notch genes have been implicated in leukaemia, breast cancer, stroke and dementia(2-4). During wing development in Drosophila, the Notch receptor is activated along the border between dorsal and ventral cells(5-7), leading to the specification of specialized cells that express Wingless (Wg) and organize wing growth and patterning(6,8,9). Three genes, fringe (fng), Serrate (Ser) and Delta (Dl), are involved in the cellular interactions leading to Notch activation(7,9-15). Ser and Dl encode transmembrane ligands for Notch(16,17), whereas fng encodes a pioneer protein(10). We have investigated the relationship between these genes by a combination of expression and coexpression studies in the Drosophila wing, We found that Ser and Dl maintain each other's expression by a positive feedback loop, fng is expressed specifically by dorsal cells and functions to position and restrict this feedback loop to the developing dorsal-ventral boundary, This is achieved by fng through a cell-autonomous mechanism that inhibits a cell's ability to respond to Serrate protein and potentiates its ability to respond to Delta protein.	RUTGERS STATE UNIV,WAKSMAN INST,PISCATAWAY,NJ 08855; RUTGERS STATE UNIV,DEPT MOL BIOL & BIOCHEM,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick			Panin, Vlad/G-1583-2016	Panin, Vlad/0000-0001-9126-1481; Papayannopoulos, Venizelos/0000-0002-3741-8190				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BRAND AH, 1993, DEVELOPMENT, V118, P401; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; deCelis JF, 1996, DEVELOPMENT, V122, P359; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, IN PRESS DEVELOPMENT; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Johnston SH, 1997, DEVELOPMENT, V124, P2245; JONSSON E, 1996, DEV GENES EVOL, V206, P91; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOPCZYNSKI CC, 1989, DEVELOPMENT, V107, P623; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; SPELCHER SA, 1994, DEVELOPMENT, V120, P535; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; THOMAS U, 1991, DEVELOPMENT, V111, P749; Wu JY, 1996, SCIENCE, V273, P355, DOI 10.1126/science.273.5273.355; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	31	496	501	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					908	912		10.1038/43191	http://dx.doi.org/10.1038/43191			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202123				2022-12-24	WOS:A1997XG41600053
J	Harris, TB; Launer, LJ; Madans, J; Feldman, JJ				Harris, TB; Launer, LJ; Madans, J; Feldman, JJ			Cohort study of effect of being overweight and change in weight on risk of coronary heart disease in old age	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NUTRITION EXAMINATION SURVEY; BODY-WEIGHT; FOLLOW-UP; NATIONAL-HEALTH; BLOOD-PRESSURE; OBESITY; MORTALITY; HAZARDS; CHOLESTEROL; PROGRAM	Objective: To evaluate risk of late life coronary heart disease associated with being overweight in late middle or old age and to assess whether weight change modifies this risk. Design: Longitudinal study of subjects in the epidemiological follow up study of the national health and nutrition examination survey I. Setting: United States. Subjects: 621 men and 960 women free of coronary heart disease in 1982-84 (mean age 77 years). Main outcome measure: Incidence of coronary heart disease. Results: Body mass index of 27 or more in late middle age nas associated with increased risk of coronary heart disease in late life (relative risk = 1.7 (95% confidence interval 1.3 to 2.1)) while body mass index of 27 or more in old age was not (1.1 (0.8 to 1.5)). This difference in risk was due largely to weight loss between middle and old age. Exclusion of those with weight loss of 10% or more increased risk associated with heavier weight in old age (1.4 (1.0 to 1.9)). Thinner older people who lost weight and heavier people who had gained weight showed increased risk of coronary heart disease compared with thinner people with stable weight. Conclusions: Heavier weight in late middle age was a risk factor for coronary heart disease in late life. Heavier weight in old age was associated with an increased risk once those with substantial weight loss were excluded. The contribution of weight to risk of coronary heart disease in older people may be underestimated if weight history is neglected.	NATL INST PUBL HLTH & ENVIRONM PROTECT, DEPT CHRON DIS & ENVIRONM EPIDEMIOL, BILTHOVEN, NETHERLANDS; NATL CTR HLTH STAT, HYATTSVILLE, MD 20782 USA	Netherlands National Institute for Public Health & the Environment; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Harris, TB (corresponding author), NIA, EPIDEMIOL DEMOG & BIOMETRY PROGRAM, BETHESDA, MD 20892 USA.							ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; BLAIR SN, 1993, ANN INTERN MED, V119, P749, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00024; BURACK RC, 1985, J CHRON DIS, V38, P865, DOI 10.1016/0021-9681(85)90111-0; CORNONIHUNTLEY JC, 1991, J CLIN EPIDEMIOL, V44, P743, DOI 10.1016/0895-4356(91)90126-T; COX DR, 1972, J R STAT SOC B, V34, P187; GURWITZ JH, 1994, J AM GERIATR SOC, V42, P1235, DOI 10.1111/j.1532-5415.1994.tb06503.x; HARRIS T, 1988, J AM GERIATR SOC, V36, P1023, DOI 10.1111/j.1532-5415.1988.tb04370.x; HARRIS TB, 1993, AM J EPIDEMIOL, V137, P1318, DOI 10.1093/oxfordjournals.aje.a116641; HIGGINS M, 1993, ANN INTERN MED, V119, P758, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00025; INGRAM DD, 1994, VITAL HLTH STAT, V1, P121; KORN EL, 1991, AM J PUBLIC HEALTH, V81, P1166, DOI 10.2105/AJPH.81.9.1166; LEAN MEJ, 1990, DIABETIC MED, V44, P133; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MUST A, 1993, AM J EPIDEMIOL, V138, P56, DOI 10.1093/oxfordjournals.aje.a116777; *NAT CTR HLTH STAT, 1983, VIT HLTH STAT, V11, P230; PAMUK ER, 1993, ANN INTERN MED, V119, P744, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00023; PEKKANEN J, 1994, AM J EPIDEMIOL, V139, P155, DOI 10.1093/oxfordjournals.aje.a116977; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; SHINTON R, 1995, J EPIDEMIOL COMMUN H, V49, P259, DOI 10.1136/jech.49.3.259; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; STEVENS J, 1990, AM J EPIDEMIOL, V132, P1156, DOI 10.1093/oxfordjournals.aje.a115758; WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; YANO K, 1989, ARCH INTERN MED, V149, P1528, DOI 10.1001/archinte.149.7.1528; 1987, VITAL HLTH STAT, V1, P22; 1979, VITAL HLTH STAT, V1, pA10	28	87	88	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 21	1997	314	7097					1791	1794		10.1136/bmj.314.7097.1791	http://dx.doi.org/10.1136/bmj.314.7097.1791			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG166	9224080	Green Published			2022-12-24	WOS:A1997XG16600021
J	Gallagher, RB				Gallagher, RB			Nota bene: Immunology - Population biology of lymphocytes	SCIENCE			English	Editorial Material														Gallagher, Richard/0000-0001-5639-2187				McLean AR, 1997, P NATL ACAD SCI USA, V94, P5792, DOI 10.1073/pnas.94.11.5792; WESTMAN BS, 1982, J NUTR, V112, P562	2	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1817	1817		10.1126/science.276.5320.1817	http://dx.doi.org/10.1126/science.276.5320.1817			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9206842				2022-12-24	WOS:A1997XF10300034
J	Mata, J; Nurse, P				Mata, J; Nurse, P			tea1 and the microtubular cytoskeleton are important for generating global spatial order within the fission yeast cell	CELL			English	Article							SCHIZOSACCHAROMYCES-POMBE; GENETIC-ANALYSIS; S-POMBE; PROTEIN; ENCODES; GROWTH; MORPHOGENESIS; ORGANIZATION; CYTOKINESIS; SCRUIN	Fission yeast cells identify and maintain growing regions exactly opposed at the ends of a cylindrical cell. tea1 mutants disrupt this organization, producing bent and T-shaped cells. We have cloned teal and shown that teal is located at the cell poles. Microtubules are continuously required to transfer teal to the cell ends, and teal is located at the ends of microtubules growing toward the cell poles. We suggest that teal acts as an end marker, directing the growth machinery to the cell poles. tea1 is down-regulated in cells treated with pheromone that grow toward a mating partner and no longer maintain their ends exactly opposed. teal may also influence microtubular organization, affecting the maintenance of a single central axis.			Mata, J (corresponding author), IMPERIAL CANC RES FUND, CELL CYCLE LAB, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.			Mata, Juan/0000-0002-5514-3653				ALFA CE, 1983, METHOD CELL BIOL, V37, P201; BALASUBRAMANIAN MK, 1992, NATURE, V360, P84, DOI 10.1038/360084a0; BALASUBRAMANIAN MK, 1994, J CELL BIOL, V125, P1289, DOI 10.1083/jcb.125.6.1289; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; Chang F, 1996, J CELL SCI, V109, P131; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; Eichinger L, 1996, EMBO J, V15, P5547, DOI 10.1002/j.1460-2075.1996.tb00939.x; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; FUKUI Y, 1986, EMBO J, V5, P1991, DOI 10.1002/j.1460-2075.1986.tb04454.x; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; HAGAN IM, 1988, J CELL SCI, V89, P343; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; IMAI Y, 1992, MOL CELL BIOL, V12, P1827, DOI 10.1128/MCB.12.4.1827; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LEHMANN R, 1995, CELL, V83, P353, DOI 10.1016/0092-8674(95)90111-6; LEUPOLD U, 1987, CURR GENET, V12, P543, DOI 10.1007/BF00419564; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAEDA T, 1990, P NATL ACAD SCI USA, V87, P7814, DOI 10.1073/pnas.87.20.7814; MARKS J, 1986, J CELL SCI, P229; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MITCHISON JM, 1985, J CELL SCI, V75, P357; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Morgan BA, 1996, P NATL ACAD SCI USA, V93, P2801, DOI 10.1073/pnas.93.7.2801; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Roemer T, 1996, TRENDS CELL BIOL, V6, P434, DOI 10.1016/S0962-8924(96)10039-8; SCHMIDT H, 1993, CURR GENET, V24, P271, DOI 10.1007/BF00351803; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; SNELL V, 1993, J CELL SCI DEV S, P289; Stern B, 1997, EMBO J, V16, P534, DOI 10.1093/emboj/16.3.534; TODA T, 1984, CELL, V37, P233, DOI 10.1016/0092-8674(84)90319-2; UMESONO K, 1983, J MOL BIOL, V168, P271, DOI 10.1016/S0022-2836(83)80018-7; VARKEY JP, 1995, GENE DEV, V9, P1074, DOI 10.1101/gad.9.9.1074; VERDE F, 1995, J CELL BIOL, V131, P1529, DOI 10.1083/jcb.131.6.1529; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; WOODS A, 1989, J CELL SCI, V93, P491; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Yaffe MP, 1996, P NATL ACAD SCI USA, V93, P11664, DOI 10.1073/pnas.93.21.11664	40	297	304	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					939	949		10.1016/S0092-8674(00)80279-2	http://dx.doi.org/10.1016/S0092-8674(00)80279-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200612	Bronze			2022-12-24	WOS:A1997XE35700014
J	Ortmann, B; Copeman, J; Lehner, PJ; Sadasivan, B; Herberg, JA; Grandea, AG; Riddell, SR; Tampe, R; Spies, T; Trowsdale, J; Cresswell, P				Ortmann, B; Copeman, J; Lehner, PJ; Sadasivan, B; Herberg, JA; Grandea, AG; Riddell, SR; Tampe, R; Spies, T; Trowsdale, J; Cresswell, P			A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes	SCIENCE			English	Article							HLA CLASS-I; PEPTIDE-BINDING; ANTIGEN PRESENTATION; CELL LINE; MOLECULES; TRANSPORTERS; EXPRESSION; RETENTION; PATHWAY; CHARGE	Newly assembled major histocompatibility complex (MHC) class I molecules, together with the endoplasmic reticulum chaperone calreticulin, interact with the transporter associated with antigen processing (TAP) through a molecule called tapasin, The molecular cloning of tapasin revealed it to be a transmembrane glycoprotein encoded by an MHC-linked gene. It is a member of the immunoglobulin superfamily with a probable cytoplasmic endoplasmic reticulum retention signal. Up to four MHC class I-tapasin complexes were found to bind to each TAP molecule. Expression of tapasin in a negative mutant human cell line (220) restored class I-TAP association and normal class I cell surface expression. Tapasin expression also corrected the defective recognition of virus-infected 220 cells by class I-restricted cytotoxic T cells, establishing a critical functional role for tapasin in MHC class I-restricted antigen processing.	YALE UNIV, SCH MED, HOWARD HUGHES MED INST, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA; IMPERIAL CANC RES FUND, HUMAN IMMUNOGENET LAB, LONDON WC2A 3PX, ENGLAND; FRED HUTCHINSON CANC RES CTR, DIV CLIN RES, SEATTLE, WA 98104 USA; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Howard Hughes Medical Institute; Yale University; Cancer Research UK; Fred Hutchinson Cancer Center; Max Planck Society			Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160; Herberg, Jethro/0000-0001-6941-6491; Lehner, Paul Joseph/0000-0001-9383-1054	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030581, R01AI030581] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30581] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BUSCH R, 1996, EMBO J, V15, P412; COLLINS JF, 1990, METHOD ENZYMOL, V183, P474; COLLINS JF, 1987, NUCLEIC ACID PROTEIN, P323; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; GRANDEA AG, IN PRESS IMMUNOGENET; GREEN NM, 1991, NATURE, V351, P349, DOI 10.1038/351349a0; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOWARD JC, 1995, CURR OPIN IMMUNOL, V7, P69, DOI 10.1016/0952-7915(95)80031-X; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JONES T, 1997, GENOMICS, V40, P189; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; LUTZ PM, 1987, IMMUNOGENETICS, V25, P228, DOI 10.1007/BF00404692; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Neisig A, 1996, J IMMUNOL, V156, P3196; Nelson K, 1989, IMMUNOBIOLOGY HLA, P292; Noessner Elfriede, 1995, Journal of Experimental Medicine, V181, P327; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; ORTMANN B, UNPUB; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SENGER G, 1993, CYTOGENET CELL GENET, V64, P49, DOI 10.1159/000133559; Solheim JC, 1997, J IMMUNOL, V158, P2236; Suh WK, 1996, J EXP MED, V184, P337, DOI 10.1084/jem.184.2.337; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLISON K, 1987, EMBO J, V6, P1967, DOI 10.1002/j.1460-2075.1987.tb02459.x	38	428	435	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	1997	277	5330					1306	1309		10.1126/science.277.5330.1306	http://dx.doi.org/10.1126/science.277.5330.1306			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT827	9271576				2022-12-24	WOS:A1997XT82700055
J	Goodrich, LV; Milenkovic, L; Higgins, KM; Scott, MP				Goodrich, LV; Milenkovic, L; Higgins, KM; Scott, MP			Altered neural cell fates and medulloblastoma in mouse patched mutants	SCIENCE			English	Article							SONIC-HEDGEHOG; FLOOR PLATE; INDUCTION; GENE; EXPRESSION; ECTODERM; MICE; CNS	The PATCHED (PTC) gene encodes a Sonic hedgehog (Shh) receptor and a tumor suppressor protein that is defective in basal cell nevus syndrome (BCNS). Functions of PTC were investigated by inactivating the mouse gene. Mice homozygous for the ptc mutation died during embryogenesis and were found to have open and overgrown neural tubes. Two Shh target genes, ptc itself and Gli, were derepressed in the ectoderm and mesoderm but not in the endoderm. Shh targets that are, under normal conditions, transcribed ventrally were aberrantly expressed in dorsal and lateral neural tube cells. Thus Ptc appears to be essential for repression of genes that are locally activated by Shh. Mice heterozygous for the ptc mutation were larger than normal, and a subset of them developed hindlimb defects or cerebellar medulloblastomas, abnormalities also seen in BCNS patients.	STANFORD UNIV, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University								AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BONNEROT C, 1993, GUIDE TECHNIQUES MOU, P463; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Concordet JP, 1996, DEVELOPMENT, V122, P2835; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; GREEN MARGARET C., 1952, OHIO JOUR SCI, V52, P31; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hepker J, 1997, DEVELOPMENT, V124, P549; HOGAN B, 1994, MANIPULATING MOUSE E, P196; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JOYNER AL, 1993, GENE TARGETING PRACT, P33; KADIN ME, 1970, J NEUROPATH EXP NEUR, V29, P583, DOI 10.1097/00005072-197010000-00005; LACOMBE D, 1990, Genetic Counseling, V1, P273; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marigo V, 1996, DEVELOPMENT, V122, P1225; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NOVAKOVIC B, 1994, MED PEDIATR ONCOL, V23, P480, DOI 10.1002/mpo.2950230606; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Provias JP, 1996, J NEURO-ONCOL, V29, P35, DOI 10.1007/BF00165516; Raffel C, 1997, CANCER RES, V57, P842; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RORKE LB, 1994, AM J PATHOL, V144, P444; Shimamura K, 1995, DEVELOPMENT, V121, P3923; Stevenson L, 1934, ARCH NEURO PSYCHIATR, V31, P93, DOI 10.1001/archneurpsyc.1934.02250010105005; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Xie JW, 1997, CANCER RES, V57, P2369	45	1360	1407	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	1997	277	5329					1109	1113		10.1126/science.277.5329.1109	http://dx.doi.org/10.1126/science.277.5329.1109			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262482				2022-12-24	WOS:A1997XT03300039
J	Stella, N; Schweitzer, P; Piomelli, D				Stella, N; Schweitzer, P; Piomelli, D			A second endogenous cannabinoid that modulates long-term potentiation	NATURE			English	Article							ARACHIDONIC-ACID; BRAIN; ANANDAMIDE; RECEPTOR; NEURONS; IDENTIFICATION; INHIBITION; SLICES; BINDS	Cannabinoid receptors are molecular targets for marijuana and hashish, the widespread drugs of abuse. These receptors are expressed in areas of the central nervous system that contribute in important ways to the control of memory, cognition, movement and pain perception(1). Indeed, such functions can be strongly influenced by cannabinoid drugs, with consequences that include euphoria, analgesia, sedation and memory impairment(2). Although the pharmacology of cannabinoid drugs is now beginning to be understood, we still lack essential information on the endogenous signalling system(s) by which cannabinoid receptors are normally engaged. An endogenous ligand for cannabinoid receptors, anandamide, has been described(3). Here we report that sn-2 arachidonylglycerol (2-AG), a cannabinoid ligand isolated from intestinal tissue(4), is present in brain in amounts 170 times greater than anandamide. 2-AG is produced in hippocampal slices by stimulation of the Schaffer collaterals, an excitatory fibre tract that projects from CA3 to CA1 neurons. Formation of 2-AG is calcium dependent and is mediated by the enzymes phospholipase C and diacylglycerol lipase. 2-AG activates neuronal cannabinoid receptors as a full agonist, and prevents the induction of long-term potentiation at CA3-CA1 synapses. Our results indicate that 2-AG is a second endogenous cannabinoid ligand in the central nervous system.	INST NEUROSCI, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BELTRAMO M, IN PRESS SCIENCE; BRINDLEY DN, 1985, BIOCH LIPIDS MEMBRAN, P213; Cadas H, 1996, J NEUROSCI, V16, P3934; Cadas H, 1997, J NEUROSCI, V17, P1226; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; EVANS DM, 1994, J PHARMACOL EXP THER, V268, P1271; FAROOQUI AA, 1986, INT J BIOCHEM, V18, P991, DOI 10.1016/0020-711X(86)90244-2; Felder CC, 1996, FEBS LETT, V393, P231, DOI 10.1016/0014-5793(96)00891-5; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HEYSER CJ, 1993, J PHARMACOL EXP THER, V264, P294; HOWLETT AC, 1995, ANNU REV PHARMACOL, V35, P607, DOI 10.1146/annurev.pharmtox.35.1.607; Jung M, 1997, J NEUROCHEM, V68, P402; Mallet PE, 1996, BEHAV PHARMACOL, V7, P276; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; NOWICKY AV, 1987, BRAIN RES BULL, V19, P663, DOI 10.1016/0361-9230(87)90052-9; PRESCOTT SM, 1983, J BIOL CHEM, V258, P764; Schmid HHO, 1996, CHEM PHYS LIPIDS, V80, P133, DOI 10.1016/0009-3084(96)02554-6; Schmid PC, 1996, FEBS LETT, V385, P125; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; STELLA N, 1995, J NEUROSCI, V15, P3307; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; TERRANOVA JP, 1995, N-S ARCH PHARMACOL, V352, P576, DOI 10.1007/BF00169393; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823; WEISS S, 1986, P NATL ACAD SCI USA, V83, P2238, DOI 10.1073/pnas.83.7.2238	30	1161	1191	0	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					773	778		10.1038/42015	http://dx.doi.org/10.1038/42015			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285589	Green Submitted, Bronze			2022-12-24	WOS:A1997XR66700051
J	Weinstein, LB; Jones, BCNM; Cosstick, R; Cech, TR				Weinstein, LB; Jones, BCNM; Cosstick, R; Cech, TR			A second catalytic metal ion in a group I ribozyme	NATURE			English	Article							TETRAHYMENA RIBOZYME; ENDORIBONUCLEASE ACTIVITY; GUANOSINE BINDING; RNA; SUBSTRATE; SITE; MECHANISM; COMPLEXES; CLEAVAGE; STEP	Although only a subset of protein enzymes depend on the presence of a metal ion for their catalytic function, all naturally occurring RNA enzymes require metal ions to stabilize their structure and for catalytic competence(1). In the self-splicing group I intron from Tetrahymena thermophila(2), several divalent metals can serve structural roles, but only Mg2+ and Mn2+ promote splice-site cleavage and exon ligation(3,4). A study of a ribozyme reaction analogous to 5'-splice-site cleavage by guanosine uncovered the first metal ion with a definitive role in catalysis. Substitution of the 3'-oxygen of the leaving group with sulphur resulted in a metal-specificity switch, indicating an interaction between the leaving group and the metal ion(5). Here we use 3'-(thioinosylyl)-(3' --> 5')-uridine(6), IspU, as a substrate in a reaction that emulates exon ligation. Activity requires the addition of a thiophilic metal ion (Cd2+ or Mn2+), providing evidence for stabilization of the leaving group by a metal ion in that step of splicing. Based on the principle of microscopic reversibility, this metal ion activates the nucleophilic 3'-hydroxyl of guanosine in the first step of splicing, supporting the model of a two-metal-ion active site(7).	UNIV COLORADO,DEPT CHEM & BIOCHEM,HOWARD HUGHES MED INST,BOULDER,CO 80309; UNIV LIVERPOOL,DEPT CHEM,ROBERT ROBINSON LABS,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Liverpool								BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P648, DOI 10.1021/bi951962z; BHAT V, 1992, SYNTHETIC COMMUN, V22, P1481, DOI 10.1080/00397919208021616; Cech T.R., 1993, RA WELCH FDN C CHEM, VXXXVII, P91; CECH TR, 1996, NUCL ACIDS MOL BIOL, P1; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; HERSCHLAG D, 1994, BIOCHEMISTRY-US, V33, P5291, DOI 10.1021/bi00183a036; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; KAY PS, 1987, NATURE, V327, P343, DOI 10.1038/327343a0; Kuimelis RG, 1995, NUCLEIC ACIDS RES, V23, P4753, DOI 10.1093/nar/23.23.4753; MCCONNELL TS, 1995, BIOCHEMISTRY-US, V34, P4056, DOI 10.1021/bi00012a024; McConnell TS, 1997, BIOCHEMISTRY-US, V36, P8293, DOI 10.1021/bi9700678; MCCONNELL TS, 1994, THESIS U COLORADO; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; Pyle AM, 1996, MET IONS BIOL SYST, V32, P479; Sjogren AS, 1997, NUCLEIC ACIDS RES, V25, P648, DOI 10.1093/nar/25.3.648; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Thomson JB, 1996, J ORG CHEM, V61, P6273, DOI 10.1021/jo960795l; Weinstein LB, 1996, J AM CHEM SOC, V118, P10341, DOI 10.1021/ja9616903; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	26	153	157	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					805	808		10.1038/42076	http://dx.doi.org/10.1038/42076			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285596	Bronze			2022-12-24	WOS:A1997XR66700058
J	Lo, YMD; Corbetta, N; Chamberlain, PF; Rai, V; Sargent, IL; Redman, CWG; Wainscoat, JS				Lo, YMD; Corbetta, N; Chamberlain, PF; Rai, V; Sargent, IL; Redman, CWG; Wainscoat, JS			Presence of fetal DNA in maternal plasma and serum	LANCET			English	Article							PRENATAL-DIAGNOSIS; PERIPHERAL-BLOOD; AMPLIFICATION; DISEASE; CELLS	Background The potential use of plasma and serum for molecular diagnosis has generated interest. Tumour DNA has been found in the plasma and serum of cancer patients, and molecular analysis has been done on this material. We investigated the equivalent condition in pregnancy-that is, whether fetal DNA is present in maternal plasma and serum. Methods We used a rapid-boiling method to extract DNA from plasma and serum. DNA from plasma, serum, and nucleated blood cells from 43 pregnant women underwent a sensitive Y-PCR assay to detect circulating male fetal DNA from women bearing male fetuses. Findings Fetus-derived Y sequences were detected in 24 (80%) of the 30 maternal plasma samples, and in 21 (70%) of the 30 maternal serum samples, from women bearing male fetuses. These results were obtained with only 10 mu L of the samples. When DNA from nucleated blood cells extracted from a similar volume of blood was used, only five (17%) of the 30 samples gave a positive Y signal. None of the 13 women bearing female fetuses, and none of the ten non-pregnant control women, had positive results for plasma, serum or nucleated blood cells. Interpretation Our finding of circulating fetal DNA in maternal plasma may have implications for non-invasive prenatal diagnosis, and for improving our understanding of the fetomaternal relationship.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN BIOCHEM,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,DEPT HAEMATOL,OXFORD OX3 9DU,ENGLAND; OSPED MAGGIORE,IRCCS,IST MED INTERNA & FISIOPATOL MED,MILAN,ITALY	University of Oxford; University of Oxford; University of Oxford; IRCCS Ca Granda Ospedale Maggiore Policlinico			Lo, Yuk Ming Dennis/D-4468-2011	Lo, Yuk Ming Dennis/0000-0001-8746-0293	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIANCHI DW, 1996, PEDIATR RES, V39, P142; CAMASCHELLA C, 1990, BLOOD, V75, P2102; Chen XQ, 1996, NAT MED, V2, P1033; Cheung MC, 1996, NAT GENET, V14, P264, DOI 10.1038/ng1196-264; EMANUEL SL, 1993, GENET ANAL-BIOMOL E, V10, P144, DOI 10.1016/1050-3862(93)90009-8; Lo YMD, 1996, BLOOD, V88, P4390; LO YMD, 1993, LANCET, V341, P1147, DOI 10.1016/0140-6736(93)93161-S; LO YMD, 1990, LANCET, V335, P1463, DOI 10.1016/0140-6736(90)91491-R; LO YMD, 1989, LANCET, V2, P1363; Mulcahy HE, 1996, LANCET, V348, P628, DOI 10.1016/S0140-6736(05)65067-2; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; REBELLO MT, 1991, PRENATAL DIAG, V11, P41, DOI 10.1002/pd.1970110108; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SIMPSON JL, 1993, JAMA-J AM MED ASSOC, V270, P2357, DOI 10.1001/jama.270.19.2357; STROUN M, 1989, ONCOLOGY, V46, P318	15	1991	2415	11	191	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					485	487		10.1016/S0140-6736(97)02174-0	http://dx.doi.org/10.1016/S0140-6736(97)02174-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274585				2022-12-24	WOS:A1997XR13500011
J	Shapiro, RL; Hatheway, C; Becher, J; Swerdlow, DL				Shapiro, RL; Hatheway, C; Becher, J; Swerdlow, DL			Botulism surveillance and emergency response - A public health strategy for a global challenge	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Shapiro, RL (corresponding author), CTR DIS CONTROL & PREVENT,FOODBORNE & DIARRHEAL DIS BRANCH,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333, USA.							Aureli P, 1996, LANCET, V348, P1594, DOI 10.1016/S0140-6736(05)66220-4; CARDELLA MA, 1964, PHS PUBLICATION; COLE LA, 1996, SCI AM           DEC, P60; DANZIG R, 1996, STRATEGIC FORUM  JAN; FRANZ DR, 1997, JAMA-J AM MED ASSOC, V278, P3990; MCNALLY RE, 1994, EFFECTIVENESS MED DE; Siegel LS, 1993, CLOSTRIDIUM BOTULINU, P323; Smith L. D. S., 1988, BOTULISM ORGANISM IT; TACKET CO, 1984, AM J MED, V76, P794, DOI 10.1016/0002-9343(84)90988-4; WANNEMACHER RW, 9120 US ARM BIOM RES; WEBER JT, 1993, J INFECT DIS, V167, P451, DOI 10.1093/infdis/167.2.451	11	65	72	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					433	435		10.1001/jama.278.5.433	http://dx.doi.org/10.1001/jama.278.5.433			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244338				2022-12-24	WOS:A1997XN51800038
J	Conrad, B; Weissmahr, RN; Boni, J; Arcari, R; Schupbach, J; Mach, B				Conrad, B; Weissmahr, RN; Boni, J; Arcari, R; Schupbach, J; Mach, B			A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes	CELL			English	Article							MAMMARY-TUMOR VIRUS; LONG TERMINAL REPEAT; MYELIN BASIC-PROTEIN; T-CELLS; RHEUMATOID-ARTHRITIS; NUCLEOTIDE-SEQUENCE; CLONAL DELETION; B RETROVIRUS; STIMULATION; TRANSCRIPTION	Microbial superantigens (SAGs) have been implicated in the pathogenesis of human autoimmune diseases. Preferential expansion of the V beta 7 T cell receptor positive T cell subset in patients suffering from acute-onset type I diabetes has indicated the presence of a surface membrane-bound SAG. Here, we have isolated a novel mouse mammary tumor virus-related human endogenous retrovirus. We further show that the N-terminal moiety of the envelope gene encodes an MHC class II-dependent SAG. We propose that expression of this SAG, induced in extrapancreatic and professional antigen-presenting cells, leads to beta-cell destruction via the systemic activation of autoreactive T cells. The SAG encoded by this novel retrovirus thus constitutes a candidate autoimmune gene in type I diabetes.	UNIV ZURICH,SWISS NATL CTR RETROVIRUSES,CH-8028 ZURICH,SWITZERLAND; UNIV TURIN,SCH MED,DEPT INTERNAL MED,I-10126 TURIN,ITALY	University of Zurich; University of Turin	Conrad, B (corresponding author), UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,CH-1211 GENEVA 4,SWITZERLAND.		Boeni, Juerg/B-8386-2015; Schüpbach, Jörg/G-4209-2016	Schüpbach, Jörg/0000-0002-8074-5891				ACHAORBEA H, 1995, ANNU REV IMMUNOL, V13, P459, DOI 10.1146/annurev.iy.13.040195.002331; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; Badenhoop K, 1996, HUM IMMUNOL, V50, P103, DOI 10.1016/0198-8859(96)00146-2; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; BRUNO G, 1993, DIABETES CARE, V16, P133, DOI 10.2337/diacare.16.1.133; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; COLE BC, 1993, ARTHRITIS RHEUM-US, V36, P994, DOI 10.1002/art.1780360717; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; DOBRESCU D, 1995, CELL, V82, P753, DOI 10.1016/0092-8674(95)90472-7; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; HOWELL MD, 1991, P NATL ACAD SCI USA, V88, P10921, DOI 10.1073/pnas.88.23.10921; *INT UN BIOCH NOM, 1985, EUR J BIOCHEM, V150, P1; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; LO D, 1993, EUR J IMMUNOL, V23, P1693, DOI 10.1002/eji.1830230744; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; MCCLURE MA, 1988, P NATL ACAD SCI USA, V85, P2469, DOI 10.1073/pnas.85.8.2469; MEDSTRAND P, 1993, J VIROL, V67, P6778, DOI 10.1128/JVI.67.11.6778-6787.1993; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; ONO M, 1987, J VIROL, V61, P2059, DOI 10.1128/JVI.61.6.2059-2062.1987; ONO M, 1986, J VIROL, V58, P937, DOI 10.1128/JVI.58.3.937-944.1986; ONO M, 1986, J VIROL, V60, P589, DOI 10.1128/JVI.60.2.589-598.1986; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; PETTE M, 1990, P NATL ACAD SCI USA, V87, P7968, DOI 10.1073/pnas.87.20.7968; Preston BD, 1996, TRENDS MICROBIOL, V4, P16, DOI 10.1016/0966-842X(96)81500-9; PYRA H, 1994, P NATL ACAD SCI USA, V91, P1544, DOI 10.1073/pnas.91.4.1544; Roizman B, 1996, FIELDS VIROLOGY, P2221; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Stegall MD, 1996, TRANSPLANTATION, V61, P1272, DOI 10.1097/00007890-199604270-00027; STEINMAN L, 1995, CELL, V80, P7, DOI 10.1016/0092-8674(95)90443-3; Sutkowski N, 1996, J EXP MED, V184, P971, DOI 10.1084/jem.184.3.971; TASSABEHJI M, 1994, NUCLEIC ACIDS RES, V22, P5211, DOI 10.1093/nar/22.24.5211; TEMIN HM, 1981, CELL, V27, P1, DOI 10.1016/0092-8674(81)90353-6; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; Tonjes RR, 1996, J ACQ IMMUN DEF SYND, V1, P261; Tyden G, 1996, NEW ENGL J MED, V335, P860, DOI 10.1056/NEJM199609193351205; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WainHobson S, 1996, TRENDS MICROBIOL, V4, P135, DOI 10.1016/0966-842X(96)10023-8; Weissmahr RN, 1997, J VIROL, V71, P3005, DOI 10.1128/JVI.71.4.3005-3012.1997; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WILKINSON DA, 1994, RETROVIRIDAE, V3, P465; WINSLOW GM, 1992, CELL, V71, P719, DOI 10.1016/0092-8674(92)90549-R; WUCHERPFENNIG KW, 1995, J EXP MED, V181, P1597, DOI 10.1084/jem.181.5.1597; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; YORK DF, 1992, J VIROL, V66, P4930, DOI 10.1128/JVI.66.8.4930-4939.1992	52	346	356	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					303	313		10.1016/S0092-8674(00)80338-4	http://dx.doi.org/10.1016/S0092-8674(00)80338-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244304	Bronze, Green Accepted			2022-12-24	WOS:A1997XN24900014
J	McDonald, TV; Yu, ZH; Ming, Z; Palma, E; Meyers, MB; Wang, KW; Goldstein, SAN; Fishman, GI				McDonald, TV; Yu, ZH; Ming, Z; Palma, E; Meyers, MB; Wang, KW; Goldstein, SAN; Fishman, GI			A minK-HERG complex regulates the cardiac potassium current I-Kr	NATURE			English	Article							RECTIFIER K+ CURRENT; XENOPUS-OOCYTES; CHANNEL; EXPRESSION; PROTEIN; CELLS; LOCALIZATION; ARRHYTHMIA; MUTATIONS; MEMBRANE	MinK is a widely expressed protein of relative molecular mass similar to 15K that forms potassium channels by aggregation with other membrane proteins(1-3) MinK: governs :ion channel activiation(4) regulation by second messengers(5,6), and the function and structure of the ion conduction pathway(7,8). Association of minK with a channel protein known as KvLQT1 produces a voltage-gated outward K+ current (I-sK) resembling the slow cardiac repolarization current (I-Ks)(9,10). HERG, a human homologue of the ether-a-go-go gene of the fruitfly Drosophila melanogaster, encodes a protein that produces the rapidly activating cardiac delayed rectifier (I-Kr)(11,12). These two potassium currents, I-Kc, and I-Kr, provide the principal repolarizing currents in cardiac myocytes for the termination of action potentials(13,14). Although heterologously expressed HERG channels are largely indistinguishable from native cardiac I-Kr, a role for minK in this current is suggested by the diminished I-Kr in an atrial tumour line subjected to minK antisense suppression(15). Here we show that HERG and minK form a stable complex, and that this heteromultimerization regulates I-Kr activity. MinK, through the formation of heteromeric channel complexes, is thus central to the control of the heart rate and rhythm.	YALE UNIV,SCH MED,BOYER CTR MOL MED,DEPT PEDIAT,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,BOYER CTR MOL MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06536	Yale University; Yale University	McDonald, TV (corresponding author), ALBERT EINSTEIN COLL MED,SECT MOL CARDIOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		; Goldstein, Steven A./E-9817-2015	Fishman, Glenn/0000-0002-2366-8527; Goldstein, Steven A./0000-0001-5207-5061				ATTALI B, 1992, J BIOL CHEM, V267, P8650; BARHANIN J, 1996, NATURE, V384, P80; BLUMENTHAL EM, 1992, J NEUROSCI, V12, P290; BLUMENTHAL EM, 1994, J NEUROSCI, V14, P3097; Brahmajothi MV, 1996, CIRC RES, V78, P1083, DOI 10.1161/01.RES.78.6.1083; BUSCH AE, 1992, J PHYSIOL-LONDON, V450, P491, DOI 10.1113/jphysiol.1992.sp019138; CHOY AMJ, 1996, CIRCULATION, V94, P164; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; FREEMAN LC, 1993, CIRC RES, V73, P968, DOI 10.1161/01.RES.73.5.968; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; MARGIOTTA JF, 1987, P NATL ACAD SCI USA, V84, P8155, DOI 10.1073/pnas.84.22.8155; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; POND AL, UNPUB CIRC RES; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; SAKAGAMI M, 1991, HEARING RES, V56, P168, DOI 10.1016/0378-5955(91)90166-7; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1991, AM J PHYSIOL, V260, pH393, DOI 10.1152/ajpheart.1991.260.2.H393; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; SUGIMOTO T, 1990, J MEMBRANE BIOL, V113, P39, DOI 10.1007/BF01869604; Tai KK, 1997, J BIOL CHEM, V272, P1654, DOI 10.1074/jbc.272.3.1654; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WANG W, 1996, NEURON, V16, P571; YANG T, 1995, CIRC RES, V77, P1246, DOI 10.1161/01.RES.77.6.1246	30	296	306	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					289	292		10.1038/40882	http://dx.doi.org/10.1038/40882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230439	Green Submitted			2022-12-24	WOS:A1997XL12100054
J	Rizzolatti, G; Fadiga, L; Fogassi, L; Gallese, V				Rizzolatti, G; Fadiga, L; Fogassi, L; Gallese, V			The space around us	SCIENCE			English	Editorial Material							INFERIOR AREA-6; MACAQUE MONKEY; FUNCTIONAL-ORGANIZATION; VISUAL RESPONSES; PROJECTIONS; NEURONS; MOVEMENTS; AFFERENT; CORTEX				Rizzolatti, G (corresponding author), UNIV PARMA, IST FISIOL UMANA, VIA GRAMSCI 14, I-43100 PARMA, ITALY.		Gallese, Vittorio/ABD-5097-2021; Fadiga, Luciano/AAC-7404-2022; Galantucci, Bruno/E-5770-2010; FOGASSI, Leonardo/K-3541-2018	Gallese, Vittorio/0000-0003-4815-3607; fadiga, luciano/0000-0001-5691-5080; FOGASSI, Leonardo/0000-0003-3348-039X				Arbib M. A., 2011, HDB PHYSL NERVOUS SY, P1449, DOI [DOI 10.1016/J.JPHYSPARIS.2008.03.001, 10.1002/cphy.cp010233]; Colby CL, 1996, COGNITIVE BRAIN RES, V5, P105, DOI 10.1016/S0926-6410(96)00046-8; COLBY CL, 1993, J NEUROPHYSIOL, V69, P902, DOI 10.1152/jn.1993.69.3.902; Fogassi L, 1996, J NEUROPHYSIOL, V76, P141, DOI 10.1152/jn.1996.76.1.141; Fogassi L, 1996, NATO ADV SCI I D-BEH, V85, P99; GENTILUCCI M, 1983, EXP BRAIN RES, V50, P464; GENTILUCCI M, 1988, EXP BRAIN RES, V71, P475, DOI 10.1007/BF00248741; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; Graziano MSA, 1997, SCIENCE, V277, P239, DOI 10.1126/science.277.5323.239; Graziano MSA, 1997, J NEUROPHYSIOL, V77, P2268, DOI 10.1152/jn.1997.77.5.2268; GRAZIANO MSA, 1994, COGNITIVE NEUROSCIEN, P1021; Gross C.G., 1995, NEUROSCIENTIST, V1, P43, DOI [10.1177/107385849500100107, DOI 10.1177/107385849500100107]; HE SQ, 1993, J NEUROSCI, V13, P952; JEANNEROD M, 1995, TRENDS NEUROSCI, V18, P314, DOI 10.1016/0166-2236(95)93921-J; LEINONEN L, 1979, EXP BRAIN RES, V34, P299; MATELLI M, 1986, J COMP NEUROL, V251, P281, DOI 10.1002/cne.902510302; Matelli M, 1994, SOC NEUR ABSTR, V20; Merleau-Ponty M., 1962, PHENOMENOLOGY PERCEP; MURATA A, IN PRESS J NEUROPHYS; PETRIDES M, 1984, J COMP NEUROL, V228, P105, DOI 10.1002/cne.902280110; RIZZOLATTI G, 1988, EXP BRAIN RES, V71, P491, DOI 10.1007/BF00248742; RIZZOLATTI G, 1994, ATTENTION PERFORM, V15, P231; RIZZOLATTI G, 1981, BEHAV BRAIN RES, V2, P147, DOI 10.1016/0166-4328(81)90053-X	23	472	472	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					190	191		10.1126/science.277.5323.190	http://dx.doi.org/10.1126/science.277.5323.190			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9235632				2022-12-24	WOS:A1997XK41800028
J	Cumming, RG; Mitchell, P; Leeder, SR				Cumming, RG; Mitchell, P; Leeder, SR			Use of inhaled corticosteroids and the risk of cataracts	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BEAVER DAM EYE; STEROID-THERAPY; LENS OPACITIES; ASTHMA; BECLOMETHASONE; ASSOCIATION; PREVALENCE; CHILDREN; AEROSOL	Background The use of systemic corticosteroids is a risk factor for the development of posterior subcapsular cataracts, but the association between inhaled corticosteroids and cataracts is uncertain. Methods We conducted a population-based, cross-sectional study of vision and common eye diseases in an urban area of the Blue Mountains, near Sydney, Australia. We recruited 3654 people 49 to 97 years of age; the participation rare was 82 percent. We collected information by questionnaire on potential risk factors for cataracts, including the current or prior use of inhaled corticosteroids (beclomethasone or budesonide). Photographs of the subjects' lenses were graded, without information on the subjects, to determine the presence and severity of cortical, nuclear, and posterior subcapsular cataracts. Results Three hundred seventy subjects reported using inhaled corticosteroids, 164 currently and 206 previously. Among these subjects, after adjustment for age and sex, there was a higher prevalence of nuclear cataracts (relative prevalence, 1.5; 95 percent confidence interval, 1.2 to 1.9) and posterior subcapsular cataracts (relative prevalence, 1.9; 95 percent confidence interval, 1.3 to 2.8) than among the subjects with no inhaled-corticosteroid use, but the prevalence of cortical cataracts was nor significantly higher (relative prevalence, 1.1; 95 percent confidence interval, 0.9 to 1.3). Higher cumulative lifetime doses of beclomethasone were associated with higher risks of posterior subcapsular cataracts (P for trend <0.001); the highest prevalence (27 percent) was found in subjects whose lifetime dose was over 2000 mg (relative prevalence, 5.5). Adjusting for the use of systemic corticosteroids and other potential confounders had little effect on the magnitude of the associations. The associations with posterior subcapsular cataracts, but not those with nuclear cataracts, were less marked when the analyses were restricted to subjects who had never used systemic corticosteroids. Conclusions The use of inhaled corticosteroids is associated with the development of posterior subcapsular and nuclear cataracts. (C) 1997, Massachusetts Medical Society.	UNIV SYDNEY, DEPT OPHTHALMOL, SYDNEY, NSW 2006, AUSTRALIA; WESTMEAD HOSP, SYDNEY, NSW, AUSTRALIA	University of Sydney; University of Sydney	Cumming, RG (corresponding author), UNIV SYDNEY, DEPT PUBL HLTH & COMMUNITY MED, BLDG A27, SYDNEY, NSW 2006, AUSTRALIA.		Cumming, Robert G/R-1548-2016	Cumming, Robert G/0000-0002-0261-6103				ABUEKTEISH F, 1995, THORAX, V50, P674, DOI 10.1136/thx.50.6.674; ADAMSONS I, 1991, ARCH OPHTHALMOL-CHIC, V109, P993, DOI 10.1001/archopht.1991.01080070105046; ALLEN MB, 1989, BRIT MED J, V299, P432, DOI 10.1136/bmj.299.6696.432; ARMSTRONG BG, 1989, AM J EPIDEMIOL, V129, P191, DOI 10.1093/oxfordjournals.aje.a115109; Attebo K, 1996, OPHTHALMOLOGY, V103, P357; BLACK RL, 1960, JAMA-J AM MED ASSOC, V174, P166, DOI 10.1001/jama.1960.63030020005014; Hodge WG, 1995, EPIDEMIOL REV, V17, P336, DOI 10.1093/oxfordjournals.epirev.a036197; IP M, 1994, CHEST, V105, P1722, DOI 10.1378/chest.105.6.1722; KARIM AKA, 1989, EXP EYE RES, V48, P215, DOI 10.1016/S0014-4835(89)80071-5; KEWLEY GD, 1980, AUST PAEDIATR J, V16, P117; KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428; KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546; Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; PANCHAPAKESAN J, IN PRESS OPHTHALMIC; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P17; SIMONS FER, 1993, LANCET, V342, P776, DOI 10.1016/0140-6736(93)91541-S; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; TOOGOOD JH, 1993, J ALLERGY CLIN IMMUN, V91, P571, DOI 10.1016/0091-6749(93)90263-F; TOOGOOD JH, 1993, BRONCHIAL ASTHMA MEC, P818; URBAN RC, 1986, SURV OPHTHALMOL, V31, P102, DOI 10.1016/0039-6257(86)90077-9	21	374	382	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	1997	337	1					8	14		10.1056/NEJM199707033370102	http://dx.doi.org/10.1056/NEJM199707033370102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH186	9203425				2022-12-24	WOS:A1997XH18600002
J	Daley, J; Delbanco, TL; Hartman, EE				Daley, J; Delbanco, TL; Hartman, EE			A 17-year-old mother seeking contraception, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Grimes DA, 1996, JAMA-J AM MED ASSOC, V276, P1163, DOI 10.1001/jama.276.14.1163	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1976	1976						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF087	9200640				2022-12-24	WOS:A1997XF08700044
J	Honour, JW				Honour, JW			Misuse of natural hormones in sport	LANCET			English	Editorial Material											Honour, JW (corresponding author), UCL, DEPT MOL PATHOL, MORTIMER ST, LONDON W1N 8AA, ENGLAND.							BILTON RF, 1995, LANCET, V345, P1186, DOI 10.1016/S0140-6736(95)91022-0; DONIKE M, 1996, RECENT ADV DOPING AN, V3, P95; DONIKE M, 1993, SPORT LEISTUNG GESUN, P293; Honour JW, 1996, LANCET, V348, P41, DOI 10.1016/S0140-6736(96)05336-6; KICMAN AT, 1992, BRIT MED BULL, V48, P496, DOI 10.1093/oxfordjournals.bmb.a072559; SCHANZER W, 1997, RECENT ADV DOPING AN, V4	6	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1786	1786		10.1016/S0140-6736(05)61689-3	http://dx.doi.org/10.1016/S0140-6736(05)61689-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269210				2022-12-24	WOS:A1997XF73500006
J	DeCock, KM; Low, N				DeCock, KM; Low, N			HIV and AIDS, other sexually transmitted diseases, and tuberculosis in ethnic minorities in United Kingdom: Is surveillance serving its purpose?	BRITISH MEDICAL JOURNAL			English	Article							STATES; INFECTION	Experience of disease differs across ethnic groups, and ethnicity is a relevant personal characteristic for descriptive epidemiology, Information about ethnicity and country of birth is omitted from the routine notification of many diseases, HIV infection and AIDS, other sexually transmitted diseases, and tuberculosis have different incidence rates in different ethnic groups in the United Kingdom. Omission of ethnic data from surveillance activities allows such differences in incidence to go undetected and unaddressed. Surveillance data that included ethnic details could guide interventions to reduce inequalities in health between different subpopulations.	UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT GENITOURINARY MED,LONDON,ENGLAND	University of London; King's College London	DeCock, KM (corresponding author), LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.		Low, Nicola/H-4718-2019	Low, Nicola/0000-0003-4817-8986				ADES AE, 1993, BRIT MED J, V306, P1296, DOI 10.1136/bmj.306.6888.1296; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; Catchpole M A, 1992, Commun Dis Rep CDR Rev, V2, pR1; *CDC, 1989, MMWR-MORBID MORTAL W, V38, P236; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P121; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DelAmo J, 1996, AIDS, V10, P1563, DOI 10.1097/00002030-199611000-00016; *DEP HLTH, 1996, UNL AN HIV PREV MON; *DEP HLTH, 1992, HLTH NAT; DOHERTY MJ, 1995, TUBERCLE LUNG DIS, V76, P196, DOI 10.1016/S0962-8479(05)80004-8; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; HAHN RA, 1992, JAMA-J AM MED ASSOC, V267, P268, DOI 10.1001/jama.267.2.268; Herrera J. L., 1993, Morbidity and Mortality Weekly Report, V42, P1; HOLMES KK, 1990, SEXUALLY TRANSMITTED; JOHNSON AM, 1994, SEXUAL ATTITUDES LIF; LACEY CJN, 1995, 11 M INT SOC STD RES; LAGA M, 1994, AIDS S1, V8, pS119; LANGMUIR AD, 1963, NEW ENGL J MED, V268, P182, DOI 10.1056/NEJM196301242680405; LOW N, 1996, GENITORURIN MED, V72, P305; MacDonagh SE, 1996, BRIT MED J, V313, P532; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; Mortimer J Y, 1995, Commun Dis Rep CDR Rev, V5, pR183; NAVARRO V, 1990, LANCET, V336, P1238, DOI 10.1016/0140-6736(90)92846-A; Noone A, 1991, CDR (Lond Engl Rev), V1, pR39; *OFF POP CENS SURV, 1993, 1991 CENS; *OFF POP CENS SURV, 1993, 1991 CENS US GUID 58; Ormerod P, 1996, BRIT J HOSP MED, V56, P209; *PHLS AIDS CTR, 1991, CDR REV, V1, pR51; *PUBL HLTH AB SERV, 1995, CDR WKLY, V5, P62; *PUBL HLTH LAB SER, 1996, COMMUN DIS REP CDR R, V6, P251; Rieder HL, 1996, EUR RESPIR J, V9, P1097, DOI 10.1183/09031936.96.09051097; SENIOR PA, 1994, BRIT MED J, V309, P327, DOI 10.1136/bmj.309.6950.327; THACKER SB, 1994, AM J EPIDEMIOL, V140, P383, DOI 10.1093/oxfordjournals.aje.a117261; WATSON JM, 1993, BRIT MED J, V306, P221, DOI 10.1136/bmj.306.6872.221	34	32	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1747	1751		10.1136/bmj.314.7096.1747	http://dx.doi.org/10.1136/bmj.314.7096.1747			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9202508	Green Published			2022-12-24	WOS:A1997XE90900031
J	Kawata, T; Shevchenko, A; Fukuzawa, M; Jermyn, KA; Totty, NF; Zhukovskaya, NV; Sterling, AE; Mann, M; Williams, JG				Kawata, T; Shevchenko, A; Fukuzawa, M; Jermyn, KA; Totty, NF; Zhukovskaya, NV; Sterling, AE; Mann, M; Williams, JG			SH2 signaling in a lower eukaryote: A STAT protein that regulates stalk cell differentiation in Dictyostelium	CELL			English	Article							GENE-EXPRESSION; PRESTALK CELLS; DISCOIDEUM; KINASE; PRESPORE; CAMP; SPORE; MATURATION; MORPHOGEN; DNA	The TTGA-binding factor is a transcriptional regulator activated by DIF, the chlorinated hexaphenone that induces prestalk cell differentiation in Dictyostelium. The same activity also functions as a repressor, controlling stalk cell differentiation. We show that the TTGA-binding factor is a STAT protein. Like the metazoan STATs, it functions via the reciprocal interaction of a phosphotyrosine residue on one molecule with an SH2 domain on a dimerizing partner. Furthermore, it will bind specifically to a mammalian interferon-stimulated response element. In Saccharomyces cerevisiae, where the entire genomic sequence is known, SH2 domains have not been identified. It would seem, therefore, that SH2 signaling pathways arose very early in the evolution of multicellular organisms, perhaps to facilitate intercellular communication.	UCL, DEPT BIOL, LONDON WC1E 6BT, ENGLAND; EUROPEAN MOL BIOL LAB, PROT & PEPTIDE GRP, D-69117 HEIDELBERG, GERMANY; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	University of London; University College London; European Molecular Biology Laboratory (EMBL); Ludwig Institute for Cancer Research	Kawata, T (corresponding author), UCL, MRC, MOL CELL BIOL LAB, GOWER ST, LONDON WC1E 6BT, ENGLAND.		Mann, Matthias/A-3454-2013; Fukuzawa, Masashi/G-1726-2014	Mann, Matthias/0000-0003-1292-4799; Kawata, Takefumi/0000-0002-3685-4492	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adler K, 1996, FEBS LETT, V395, P286, DOI 10.1016/0014-5793(96)01053-8; Briscoe J, 1996, PHILOS T ROY SOC B, V351, P167, DOI 10.1098/rstb.1996.0013; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; Clarke M, 1995, EXPERIENTIA, V51, P1124, DOI 10.1007/BF01944730; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EARLY A, 1995, CELL, V83, P91, DOI 10.1016/0092-8674(95)90237-6; FUKUZAWA M, 1997, IN PRESS DEVELOPMENT, V124; Gamper M, 1996, MOL CELL BIOL, V16, P2431; HARWOOD AJ, 1993, DEVELOPMENT, V118, P1041; HARWOOD AJ, 1992, CELL, V69, P615, DOI 10.1016/0092-8674(92)90225-2; HOPPER NA, 1993, EMBO J, V12, P2459, DOI 10.1002/j.1460-2075.1993.tb05900.x; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; HOWARD PK, 1994, MOL CELL BIOL, V14, P5154, DOI 10.1128/MCB.14.8.5154; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; INOUYE K, 1993, DEVELOPMENT, V118, P523; INSALL R, 1990, EMBO J, V9, P3323, DOI 10.1002/j.1460-2075.1990.tb07532.x; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; JERMYN KA, 1987, DEVELOPMENT, V100, P745; Kawata T, 1996, EMBO J, V15, P3085, DOI 10.1002/j.1460-2075.1996.tb00671.x; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KAY RR, 1989, DEVELOPMENT, V105, P753; KIMMEL AR, 1985, MOL CELL BIOL, V5, P2123, DOI 10.1128/MCB.5.8.2123; KUBOHARA Y, 1993, EXP CELL RES, V207, P107, DOI 10.1006/excr.1993.1168; MAEDA M, 1988, DEV GROWTH DIFFER, V30, P573; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MANN SKO, 1993, DEVELOPMENT, V119, P135; MANN SKO, 1994, P NATL ACAD SCI USA, V91, P10561, DOI 10.1073/pnas.91.22.10561; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; Nuckolls GH, 1996, DEVELOPMENT, V122, P3295; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; RICHARDSON DL, 1994, DEVELOPMENT, V120, P2891; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SIMON MN, 1992, NATURE, V356, P171, DOI 10.1038/356171a0; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8	47	187	189	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 13	1997	89	6					909	916		10.1016/S0092-8674(00)80276-7	http://dx.doi.org/10.1016/S0092-8674(00)80276-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200609	Bronze			2022-12-24	WOS:A1997XE35700011
J	Katan, MB; Grundy, SM; Willett, WC				Katan, MB; Grundy, SM; Willett, WC			Beyond low-fat diets	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RANDOMIZED TRIAL; LIPOPROTEINS; ACIDS; WOMEN; CHOLESTEROL		UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard T.H. Chan School of Public Health	Katan, MB (corresponding author), AGR UNIV WAGENINGEN, DIV HUMAN NUTR & EPIDEMIOL, BOMENWEG 2, NL-6703 HD WAGENINGEN, NETHERLANDS.							BLACK HS, 1994, NEW ENGL J MED, V330, P1272, DOI 10.1056/NEJM199405053301804; ERNST N, 1980, CIRCULATION, V62, P41; GRUNDY SM, 1986, NEW ENGL J MED, V314, P745, DOI 10.1056/NEJM198603203141204; HYEWON LH, 1988, AM J CLIN NUTR, V48, P575, DOI 10.1093/ajcn/48.3.575; JEFFERY RW, 1995, INT J OBESITY, V19, P132; KASIM SE, 1993, AM J CLIN NUTR, V57, P146, DOI 10.1093/ajcn/57.2.146; KEYS A, 1957, LANCET, V2, P959; MENSINK RP, 1987, LANCET, V1, P122, DOI 10.1016/S0140-6736(87)91965-9; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; *NAT DIET HEART ST, 1968, CIRCULATION S1, V37, P170; SACKS RM, 1994, J CARDIOVASC RISK, V1, P3; SHEPPARD L, 1991, AM J CLIN NUTR, V54, P821, DOI 10.1093/ajcn/54.5.821; Vega GL, 1996, CURR OPIN LIPIDOL, V7, P209, DOI 10.1097/00041433-199608000-00007; Willett Walter C., 1997, P559; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011; WILLETT WC, IN PRESS AM J CLIN N	16	206	209	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					563	566						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262504				2022-12-24	WOS:A1997XR54800012
J	Rye, HS; Burston, SG; Fenton, WA; Beechem, JM; Xu, ZH; Sigler, PB; Horwich, AL				Rye, HS; Burston, SG; Fenton, WA; Beechem, JM; Xu, ZH; Sigler, PB; Horwich, AL			Distinct actions of cis and trans ATP within the double ring of the chaperonin GroEL	NATURE			English	Article							PROTEIN; CYCLE; CARBOXYLASE; MECHANISM; INTENSITY; RELEASE; BINDING; DOMAIN	The chaperonin GroEL is a double-ring structure with a central cavity in each ring that provides an environment for the efficient folding of proteins(1-3) when capped by the co-chaperone GroES in the presence of adenine nucleotides(4-8). Productive folding of the substrate rhodanese has been observed in cis ternary complexes, where GroES and polypeptide are bound to the same ring, formed with either ATP, ADP or non-hydrolysable ATP analogues(2,9), suggesting that the specific requirement for ATP is confined to an action in the trans ring that evicts GroES and polypeptide from the cis side(9). We show here, however, that for the folding of malate dehydrogenase and Rubisco there is also an absolute requirement for ATP in the cis ring, as ADP and AMP-PNP are unable to promote folding. We investigated the specific roles of binding and hydrolysis of ATP in the cis and trans rings using mutant forms of GroEL that bind ATP but are defective in its hydrolysis. Binding of ATP and GroES in cis initiated productive folding inside a highly stable GroEL-ATP-GroES complex. To discharge GroES and polypeptide, ATP hydrolysis in the cis ring was required to form a GroEL-ADP-GroES complex with decreased stability, priming the cis complex for release by ATP binding (without hydrolysis) in the trans ring. These observations offer an explanation of why GroEL functions as a double-ring complex.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; VANDERBILT UNIV,DEPT MOL PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Vanderbilt University				Rye, Hays/0000-0002-9420-3137; Burston, Steven/0000-0003-1848-1853				BEECHEM JM, 1995, BIOCHEMISTRY-US, V34, P13943, DOI 10.1021/bi00042a028; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ETFINK MR, 1994, BIOPHYS J, V66, P482; Fenton WA, 1997, PROTEIN SCI, V6, P743; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; PIERCE J, 1986, ARCH BIOCHEM BIOPHYS, V245, P483, DOI 10.1016/0003-9861(86)90241-9; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	24	348	350	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					792	798		10.1038/42047	http://dx.doi.org/10.1038/42047			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285593	Bronze			2022-12-24	WOS:A1997XR66700055
J	Beller, M; Ellis, A; Lee, SH; Drebot, MA; Jenkerson, SA; Funk, E; Sobsey, MD; Simmons, OD; Monroe, SS; Ando, T; Noel, J; Petric, M; Middaugh, JP; Spika, JS				Beller, M; Ellis, A; Lee, SH; Drebot, MA; Jenkerson, SA; Funk, E; Sobsey, MD; Simmons, OD; Monroe, SS; Ando, T; Noel, J; Petric, M; Middaugh, JP; Spika, JS			Outbreak of viral gastroenteritis due to a contaminated well - International consequences	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ROUND STRUCTURED VIRUS; REVERSE TRANSCRIPTION-PCR; NORWALK-LIKE VIRUSES; HOSPITAL OUTBREAK; AIRBORNE TRANSMISSION; SRSV GASTROENTERITIS; WATER-SYSTEM; CRUISE SHIP; ABOARD; EPIDEMIOLOGY	Context.-Small round-structured viruses (SRSVs) are known to cause viral gastroenteritis, but until now have not been confirmed in the implicated Vehicle in outbreaks. Objective.-Investigation of a gastroenteritis outbreak. Design.-After applying epidemiologic methods to locate the outbreak source, we conducted environmental and laboratory investigations to elucidate the cause. Setting.-Tourists traveling by bus through Alaska and the Yukon Territory of Canada. Participants.-Staff of a restaurant at a business complex implicated as the outbreak source, convenience sample of persons on buses that had stopped there, and bus employees. Main Outcome Measures.-Odds ratios (ORs) for illness associated with exposures. Water samples from the restaurant and stool specimens from tourists and restaurant staff were examined by nucleic acid amplification using reverse transcription polymerase chain reaction and sequencing of viral amplification products. Results.-The itineraries of groups of tourists manifesting vomiting or diarrhea were traced back to a restaurant where buses had stopped 33 to 36 hours previously, Water consumption was associated with illness (OR, 5.3; 95% confidence interval [CI], 2.3-12.6). Eighteen of 26 employees of the business complex were ill; although not the index case, an employee ill shortly before the outbreak lived in a building connected to a septic pit, which was found to contaminate the well supplying the restaurant's water, Genotype 2/P2B SRSV was identified in stool specimens of 2 tourists and 1 restaurant employee. Stools and water samples yielded identical amplification product sequences. Conclusions.-The investigation documented SRSVs in a vehicle epidemiologically linked to a gastroenteritis outbreak. The findings demonstrate the power of molecular detection and identification and underscore the importance of fundamental public health practices such as restaurant inspection, assurance of a safe water supply, and disease surveillance.	LAB CTR DIS CONTROL,BUR DIS SURVEILLANCE & FIELD EPIDEMIOL,OTTAWA,ON K1A 0L2,CANADA; NATL CTR ENTEROVIRUSES,HALIFAX,NS,CANADA; CTR DIS CONTROL & PREVENT,DIV VIRAL & RICKETTSIAL DIS,NATL CTR INFECT DIS,ATLANTA,GA; UNIV N CAROLINA,SCH PUBL HLTH,DEPT ENVIRONM SCI & ENGN,CHAPEL HILL,NC 27599; HOSP SICK CHILDREN,DEPT MICROBIOL,VIROL LAB,TORONTO,ON M5G 1X8,CANADA; LAB CTR DIS CONTROL,BUR INFECT DIS,OTTAWA,ON K1A 0L2,CANADA	Centers for Disease Control & Prevention - USA; University of North Carolina; University of North Carolina Chapel Hill; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Beller, M (corresponding author), ALASKA DEPT HLTH & SOCIAL SERV,DIV PUBL HLTH,POB 240249,ANCHORAGE,AK 99524, USA.			Monroe, Stephan/0000-0002-5424-716X				ANDO T, 1995, J MED VIROL, V47, P145, DOI 10.1002/jmv.1890470207; ANDO T, 1995, J CLIN MICROBIOL, V33, P64, DOI 10.1128/JCM.33.1.64-71.1995; CANNON RO, 1991, J INFECT DIS, V164, P860, DOI 10.1093/infdis/164.5.860; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P446; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P37; CHADWICK PR, 1994, LANCET, V343, P171, DOI 10.1016/S0140-6736(94)90959-8; CHADWICK PR, 1994, J HOSP INFECT, V26, P251, DOI 10.1016/0195-6701(94)90015-9; CHALMERS JWT, 1995, EPIDEMIOL INFECT, V115, P163, DOI 10.1017/S0950268800058222; DINGLE KE, 1995, J GEN VIROL, V76, P2349, DOI 10.1099/0022-1317-76-9-2349; DREBOT MA, 1994, J MED VIROL, V44, P340, DOI 10.1002/jmv.1890440406; DREBOT MA, IN PRESS BIOTECHNIQU; FLEISSNER ML, 1989, AM J EPIDEMIOL, V129, P165, DOI 10.1093/oxfordjournals.aje.a115105; GELLERT GA, 1990, INFECT CONT HOSP EP, V11, P459; GOODMAN RA, 1982, ARCH ENVIRON HEALTH, V37, P358, DOI 10.1080/00039896.1982.10667591; HO MS, 1989, LANCET, V2, P961; KAPIKIAN AZ, 1996, FIELDS VIROLOGY, P783; KAPLAN JE, 1982, J INFECT DIS, V146, P190, DOI 10.1093/infdis/146.2.190; KHAN AS, 1994, J CLIN MICROBIOL, V32, P318, DOI 10.1128/JCM.32.2.318-322.1994; KOBAYASHI S, 1991, EPIDEMIOL INFECT, V107, P81, DOI 10.1017/S0950268800048706; KOHN MA, 1995, JAMA-J AM MED ASSOC, V273, P466, DOI 10.1001/jama.273.6.466; LAWSON HW, 1991, LANCET, V337, P1200, DOI 10.1016/0140-6736(91)92868-3; Levett PN, 1996, J CLIN MICROBIOL, V34, P1497, DOI 10.1128/JCM.34.6.1497-1501.1996; LO SV, 1994, EPIDEMIOL INFECT, V113, P513, DOI 10.1017/S0950268800068527; MCANULTY JM, 1993, AUST J PUBLIC HEALTH, V17, P86; Morgan D, 1994, Commun Dis Rep CDR Rev, V4, pR91; NELSON M, 1992, J ENVIRON HEALTH, V54, P50; PATTERSON T, 1993, EPIDEMIOL INFECT, V111, P157, DOI 10.1017/S0950268800056776; Perrett K, 1995, Commun Dis Rep CDR Rev, V5, pR153; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER LA, 1988, AM J EPIDEMIOL, V127, P1261, DOI 10.1093/oxfordjournals.aje.a114918; SCHWAB KJ, 1995, APPL ENVIRON MICROB, V61, P531, DOI 10.1128/AEM.61.2.531-537.1995; SHARP TW, 1995, J MED VIROL, V45, P61, DOI 10.1002/jmv.1890450112; SOBSEY MD, 1979, APPL ENVIRON MICROB, V37, P588, DOI 10.1128/AEM.37.3.588-595.1979; SOBSEY MD, 1994, RAPID METHODS AND AUTOMATION IN MICROBIOLOGY AND IMMUNOLOGY, P387; STEVENSON P, 1994, J HOSP INFECT, V26, P261, DOI 10.1016/0195-6701(94)90016-7; TREANOR J, 1995, PRINCIPLES PRACTICE, P1666; WARNER RD, 1991, ARCH INTERN MED, V151, P2419, DOI 10.1001/archinte.151.12.2419; WILSON R, 1982, AM J PUBLIC HEALTH, V72, P72, DOI 10.2105/AJPH.72.1.72; 1994, COMMUN DIS REP CDR W, V4, P43	39	140	145	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					563	568		10.1001/jama.278.7.563	http://dx.doi.org/10.1001/jama.278.7.563			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ986	9268277				2022-12-24	WOS:A1997XQ98600030
J	Mouzin, E; Mascola, L; Tormey, MP; Dassey, DE				Mouzin, E; Mascola, L; Tormey, MP; Dassey, DE			Prevention of Vibrio vulnificus infections - Assessment of regulatory educational strategies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Vibrio vulnificus-related disease caused by eating contaminated raw oysters prompted California to implement regulatory educational initiatives in 1991. Objective.-To assess California guidelines and education efforts with regard to the prevention of V vulnificus infections in Los Angeles County and to evaluate compliance with state regulations mandating posting of warning signs concerning risks of eating raw oysters. Design.-Review of epidemiologic investigations of V vulnificus infections in Los Angeles County between 1993 and 1995; telephone interviews of patients or surrogates; and a survey of restaurants serving raw oysters in Los Angeles County. Setting-General community. Main Outcome Measures.-Prior warning of patients and posting of warning signs in restaurants. Results.-Recent cases of V vulnificus infections in Los Angeles County suggest that a unique, vulnerable group (uninsured Hispanic men with viral or alcoholic liver disease) has not been reached through education efforts. Of a total of 11 cases, information regarding being warned about the hazard of eating raw shellfish was available for 8; of these, only 1 case was reported as having been warned, but he had misunderstood the preventive message. Warning signs were not posted adequately in more than 50% of restaurants surveyed and one third of these establishments had signs in English only. Warnings were never located on dining tables and rarely included in menus. Conclusion.-A more effective strategy is required to prevent V vulnificus infections in Los Angeles County.			Mouzin, E (corresponding author), LOS ANGELES CTY DEPT HLTH SERV,ACUTE COMMUNICABLE DIS CONTROL UNIT,313 N FIGUEROA ST,ROOM 212,LOS ANGELES,CA 90012, USA.							BLAKE PA, 1979, NEW ENGL J MED, V300, P1, DOI 10.1056/NEJM197901043000101; *CA STAT DEP HLTH, 1993, CALIFORNIA MORBIDITY, V31; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P405; Center for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P621; DAYAL HH, 1993, AM J PREV MED, V9, P191, DOI 10.1016/S0749-3797(18)30737-2; FELIX CW, 1995, FOOD PROTECTION REP, V11, P1; JOHNSTON JM, 1985, JAMA-J AM MED ASSOC, V253, P2850, DOI 10.1001/jama.253.19.2850; KELLY MT, 1982, APPL ENVIRON MICROB, V44, P820, DOI 10.1128/AEM.44.4.820-824.1982; OLIVER JD, 1982, MAR TECHNOL SOC J, V25, P49; TACKET CO, 1984, J INFECT DIS, V149, P558, DOI 10.1093/infdis/149.4.558; TAMPLIN M, 1982, APPL ENVIRON MICROB, V44, P1466, DOI 10.1128/AEM.44.6.1466-1470.1982; TUTTLE J, 1994, J TRANSPLANT COORDIN, V4, P60	12	34	34	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					576	578		10.1001/jama.278.7.576	http://dx.doi.org/10.1001/jama.278.7.576			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ986	9268279				2022-12-24	WOS:A1997XQ98600032
J	Hendry, BM; James, AF				Hendry, BM; James, AF			Endothelin antagonists in renal disease	LANCET			English	Editorial Material											Hendry, BM (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,LONDON SE5 9PJ,ENGLAND.							Benigni A, 1996, AM J KIDNEY DIS, V27, P416, DOI 10.1016/S0272-6386(96)90366-2; FIRTH JD, 1995, AM J PHYSIOL-RENAL, V269, pF522, DOI 10.1152/ajprenal.1995.269.4.F522; GELLAI M, 1995, J PHARMACOL EXP THER, V275, P200; Kaddoura S, 1996, LANCET, V348, P418, DOI 10.1016/S0140-6736(05)64531-X; Kohan DE, 1997, AM J KIDNEY DIS, V29, P2, DOI 10.1016/S0272-6386(97)90004-4; Nabokov A, 1996, NEPHROL DIAL TRANSPL, V11, P514; ONG ACM, 1995, KIDNEY INT, V48, P390, DOI 10.1038/ki.1995.307; Parkinson NA, 1996, NEPHROL DIAL TRANSPL, V11, P1532; Weber C, 1996, CLIN PHARMACOL THER, V60, P124, DOI 10.1016/S0009-9236(96)90127-7	9	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					381	382		10.1016/S0140-6736(05)64131-1	http://dx.doi.org/10.1016/S0140-6736(05)64131-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259650				2022-12-24	WOS:A1997XQ24800006
J	Lovestone, S; Graham, N; Howard, R				Lovestone, S; Graham, N; Howard, R			Guidelines on drug treatments for Alzheimer's disease	LANCET			English	Editorial Material									ROYAL FREE HOSP,DEPT OLD AGE PSYCHIAT,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Lovestone, S (corresponding author), INST PSYCHIAT,OLD AGE PSYCHIAT SECT,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND.		Lovestone, Simon/E-8725-2010	Lovestone, Simon/0000-0003-0473-4565; Howard, Robert/0000-0002-3071-2338; Livingston, Gill/0000-0001-6741-5516				FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Kelly CA, 1997, BRIT MED J, V314, P693, DOI 10.1136/bmj.314.7082.693; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939	3	59	59	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					232	233		10.1016/S0140-6736(05)62221-0	http://dx.doi.org/10.1016/S0140-6736(05)62221-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242796				2022-12-24	WOS:A1997XM86600005
J	Regnier, CH; Song, HY; Gao, X; Goeddel, DV; Cao, ZD; Rothe, M				Regnier, CH; Song, HY; Gao, X; Goeddel, DV; Cao, ZD; Rothe, M			Identification and characterization of an I kappa B kinase	CELL			English	Article							TUMOR-NECROSIS-FACTOR; DEATH DOMAIN; CYTOPLASMIC DOMAIN; FACTOR RECEPTOR; FACTOR-ALPHA; ACTIVATION; PROTEIN; INTERACTS; FAMILY; CD40	Activation of the transcription factor NF-kappa B by tumor necrosis factor (TNF) and interleukin-1 (IL-1) requires the NF-kappa B-inducing kinase (NIK). In a yeast two-hybrid screen for NIK-interacting proteins, we have identified a protein kinase previously known as CHUK. Overexpression of CHUK activates a NF-kappa B-dependent reporter gene. A catalytically inactive mutant of CHUK is a dominant-negative inhibitor of TNF-, IL-1-, TRAF-, and NIK-induced NF-kappa B activation. CHUK associates with the NF-kappa B inhibitory protein, I kappa B-alpha, in mammalian cells. CHUK specifically phosphorylates I kappa B-alpha on both serine 32 and serine 36, modifications that are required for targeted degradation of I kappa B-alpha via the ubiquitin-proteasome pathway. This phosphorylation of I kappa B-alpha is greatly enhanced by NIK costimulation. Thus, CHUK is a NIK-activated I kappa B-alpha kinase that links TNF- and IL-1-induced kinase cascades to NF-kappa B activation.	TULARIK INC, San Francisco, CA 94080 USA					Regnier, Catherine/0000-0002-4386-1324				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHOI KY, 1994, CELL, V78, P499; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MOCK BA, 1995, GENOMICS, V27, P348, DOI 10.1006/geno.1995.1054; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Orth R, 1997, J BIOL CHEM, V272, P8841; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1997, IN PRESS P NATL ACAD; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784	56	1071	1123	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					373	383		10.1016/S0092-8674(00)80344-X	http://dx.doi.org/10.1016/S0092-8674(00)80344-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244310	Bronze			2022-12-24	WOS:A1997XN24900020
J	Medzhitov, R; PrestonHurlburt, P; Janeway, CA				Medzhitov, R; PrestonHurlburt, P; Janeway, CA			A human homologue of the Drosophila Toll protein signals activation of adaptive immunity	NATURE			English	Article							IL-1 RECEPTOR; LEUCINE; DORSAL; EMBRYO; IMMUNOLOGY	Induction of the adaptive immune response depends on the expression of co-stimulatory molecules and cytokines by antigen-presenting cells. The mechanisms that control the initial induction of these signals upon infection are poorly understood. It has been proposed that their expression is controlled by the non-clonal, or innate, component of immunity that preceded in evolution the development of an adaptive immune system in vertebrates(1). We report here the cloning and characterization of a human homologue of the Drosophila toll protein (Toll) which has been shown to induce the innate immune response in adult Drosophila(2-4). Like Drosophila Toll, human Toll is a type I transmembrane protein with an extracellular domain consisting of a leucine-rich repeat (LRR) domain, and a cytoplasmic domain homologous to the cytoplasmic domain of the human interleukin (IL)-1 receptor. Both Drosophila Toll and the IL-1 receptor are known to signal through the NF-kappa B pathway(5-7). We show that a constitutively active mutant of human Toll transfected into human cell lines can induce the activation of NF-kappa B and the expression of NF-kappa B-controlled genes for the inflammatory cytokines IL-1, IL-6 and IL-8, as well as the expression of the co-stimulatory molecule B7.1, which is required for the activation of naive T cells.	HOWARD HUGHES MED INST,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06520	Howard Hughes Medical Institute; Yale University								ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; HULTMARK D, 1994, NATURE, V367, P116, DOI 10.1038/367116a0; INNIS MA, 1992, PCR PROTOCOLS GUIDE; IP YT, 1994, CURR OPIN GENET DEV, V4, P672, DOI 10.1016/0959-437X(94)90133-N; JANEWAY CA, 1989, COLD SH Q B, V54, P1; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Medzhitov R, 1996, RES IMMUNOL, V147, P208, DOI 10.1016/0923-2494(96)87222-1; MIYAKE K, 1995, J IMMUNOL, V154, P3333; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; ROSETTO M, 1995, BIOCHEM BIOPH RES CO, V209, P111, DOI 10.1006/bbrc.1995.1477; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; WINANS KA, 1995, MOL BIOL CELL, V6, P587, DOI 10.1091/mbc.6.5.587; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	21	3911	4385	11	345	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					394	397		10.1038/41131	http://dx.doi.org/10.1038/41131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237759	Bronze			2022-12-24	WOS:A1997XM52800055
J	Pettitt, DJ; Forman, MR; Hanson, RL; Knowler, WC; Bennett, PH				Pettitt, DJ; Forman, MR; Hanson, RL; Knowler, WC; Bennett, PH			Breastfeeding and incidence of non-insulin-dependent diabetes mellitus in Pima Indians	LANCET			English	Article							FORMULA-FED INFANTS; 1ST YEAR; BREAST; MILK; LIFE	Background Early exposure to cow's milk has been implicated in the occurrence of insulin-dependent diabetes mellitus but there is little information about infant-feeding practices and subsequent non-insulin-dependent diabetes mellitus (NIDDM). We examined the association between breastfeeding and NIDDM in a population with a high prevalence of this disorder, the Pima Indians. Methods Glucose-tolerance status was obtained from a 75 g oral glucose-tolerance test. A standard questionnaire given to mothers was used to classify infant-feeding practices for the first 2 months of life into three groups; exclusively breastfed, some breastfeeding, or exclusively bottlefed. The association between the three infant-feeding groups and NIDDM was analysed by multiple logistic regression. Findings Data were available for 720 Pima Indians aged between 10 and 39 years. 325 people who were Background Early exposure to cow's milk has been implicated in the occurrence of insulin-dependent diabetes mellitus but there is little information about infant-feeding practices and subsequent non-insulin-dependent diabetes mellitus (NIDDM). We examined the association between breastfeeding and NIDDM in a population with a high prevalence of this disorder, the Pima Indians. Methods Glucose-tolerance exclusively bottlefed had significantly higher age-adjusted and sex-adjusted mean relative weights (146%) than 144 people who were exclusively breastfed (140%) or 251 people who had some breastfeeding (139%) (p=0.019), People who were exclusively breastfed had significantly lower rates of NIDDM than those who were exclusively bottlefed in ail age-groups (age 10-19, 0 of 56 vs 6 [3.6%] of 165; age 20-29, 5 [8.6%] of 58 vs 17 [14.7%] of 116]; age 30-39, 6 [20.0%] of 30 vs 13 [29.6%] of 44). The odds ratio for NIDDM in exclusively breastfed people, compared with those exclusively bottlefed, was 0.41 (95% CI 0.18-0.93) adjusted for age, sex, birthdate, parental diabetes, and birthweight. Interpretation Exclusive breastfeeding for the first 2 months of life is associated with a significantly lower rate of NIDDM in Pima Indians. The increase in prevalence of diabetes in some populations may be due to the concomitant decrease in breastfeeding.	NIDDK,PHOENIX EPIDEMIOL & CLIN RES BRANCH,PHOENIX,AZ 85014; NATL CANC INST,CANC PREVENT STUDIES BRANCH,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pettitt, DJ (corresponding author), NIDDK,DIABET & ARTHRIT EPIDEMIOL SECT,PHOENIX,AZ 85014, USA.		Bennett, Peter/AAH-9605-2021; Hanson, Robert L/O-3238-2015	Hanson, Robert L/0000-0002-4252-7068				AYNSLEYGREEN A, 1989, BAILLIERE CLIN ENDOC, V3, P837, DOI 10.1016/S0950-351X(89)80056-4; BENNETT PH, 1971, LANCET, V2, P125; BORCHJOHNSEN K, 1984, LANCET, V2, P1083; BROOK CGD, 1972, LANCET, V2, P624; Cavallo MG, 1996, LANCET, V348, P926, DOI 10.1016/S0140-6736(95)12065-3; DEWEY KG, 1992, PEDIATRICS, V89, P1035; DEWEY KG, 1995, J PEDIATR-US, V126, P696, DOI 10.1016/S0022-3476(95)70395-0; EVANS HE, 1979, PEDIATR ANN, V8, P110; FORMAN MR, 1984, AM J EPIDEMIOL, V119, P335, DOI 10.1093/oxfordjournals.aje.a113752; FORMAN MR, 1984, INT J EPIDEMIOL, V13, P447, DOI 10.1093/ije/13.4.447; FORMAN MR, 1982, AM J CLIN NUTR, V35, P1477, DOI 10.1093/ajcn/35.6.1477; Frederick I B, 1984, Obstet Gynecol Annu, V13, P131; GERSTEIN HC, 1994, DIABETES CARE, V17, P13, DOI 10.2337/diacare.17.1.13; GrummerStrawn LM, 1996, INT J EPIDEMIOL, V25, P94, DOI 10.1093/ije/25.1.94; HALL B, 1975, LANCET, V1, P779; HAMOSH M, 1988, J PEDIATR GASTR NUTR, V7, P10, DOI 10.1097/00005176-198801000-00004; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; JELLIFFE DB, 1966, ASSESSMENT NUTRITION; KARGES W, 1995, MOL MECH MOL ASPECTS, P79; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; KNOWLER WC, 1978, AM J EPIDEMIOL, V108, P497, DOI 10.1093/oxfordjournals.aje.a112648; KNOWLER WC, 1979, DIABETOLOGIA, V17, P161, DOI 10.1007/BF01219743; KOVAR MG, 1984, PEDIATRICS, V74, P615; KRAMER MS, 1981, J PEDIATR-US, V98, P883, DOI 10.1016/S0022-3476(81)80579-3; LUCAS A, 1980, LANCET, V1, P1267; LUCAS A, 1979, LANCET, V2, P57; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; *NAT RES COUNC, 1964, NAT AC SCI PUBL, V1146, P4; PETTITT DJ, 1988, DIABETES, V37, P622, DOI 10.2337/diabetes.37.5.622; SALMENPERA L, 1988, J PEDIATR GASTR NUTR, V7, P651, DOI 10.1097/00005176-198809000-00005; SILVERMAN BL, 1991, DIABETES, V40, P121, DOI 10.2337/diab.40.2.S121; Thorogood M, 1979, J R Coll Gen Pract, V29, P427; *WHO STUD GROUP PR, 1994, WHO TECHN REP SER, V844; Wright P, 1981, Health Bull (Edinb), V39, P197	34	191	195	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					166	168		10.1016/S0140-6736(96)12103-6	http://dx.doi.org/10.1016/S0140-6736(96)12103-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250183				2022-12-24	WOS:A1997XL72200010
J	Tichonova, L; Borisenko, K; Ward, H; Meheus, A; Gromyko, A; Renton, A				Tichonova, L; Borisenko, K; Ward, H; Meheus, A; Gromyko, A; Renton, A			Epidemics of syphilis in the Russian Federation: Trends, origins, and priorities for control	LANCET			English	Article							SEXUALLY-TRANSMITTED DISEASES; INFECTION	After continuous decline throughout the 1980s, surveillance-defined estimates of the incidence of syphilis in Russia have shown a rapid and substantial increase during the 1990s. The reasons for this epidemic are unclear, but must be sought among changes both in sexual behaviour and in the patterns of provision, use, and effectiveness of diagnostic, treatment, and contact tracing services. High incidence of sexually transmitted disease causes correspondingly high levels of morbidity and suffering as well as significant health-care and other economic costs. Our current understanding suggests that the transmissibility of HIV is increased by infection with sexually transmitted disease. The syphilis epidemic together with changes in sexual behaviour, increased travel and migration, and rapid increases in injecting drug use may create the conditions for an epidemic of sexually acquired HIV infection in Russia that substantially outstrips those encountered in most Western European countries.	MINIST HLTH RUSSIAN FEDERAT,MOSCOW,RUSSIA; RUSSIAN ASSOC AGAINST STD,SANAM,MOSCOW,RUSSIA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT EPIDEMIOL & COMMUNITY HLTH,LONDON,ENGLAND; UNIV INSTELLING ANTWERP,DEPT EPIDEMIOL & COMMUNITY HLTH,ANTWERP,BELGIUM; WHO,REG OFF EUROPE,DK-2100 COPENHAGEN,DENMARK	Ministry of Health of the Russian Federation; Imperial College London; University of Antwerp; World Health Organization			Ward, Helen/A-1836-2009	Ward, Helen/0000-0001-8238-5036				AKOVBIAN BA, 1995, SEX TRANSM DIS, V4, P15; *EC INT UN, 1995, COUNTR REP; GARNETT GP, 1993, PHILOS T R SOC B, V342, P137, DOI 10.1098/rstb.1993.0143; GASPARD M, 1993, NATO EC C EC DEV COO; GIMPELSON V, 1993, NATO EC C EC DEV COO; GROMYKO A, 1996, WHO M EP SEX TRANSM; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Hardy IRB, 1996, LANCET, V347, P1739, DOI 10.1016/S0140-6736(96)90811-9; Hethcote H., 1984, LECT NOTES BIOMATH, V56, P18; INGRAM M, 1995, BRIT MED J, V311, P528, DOI 10.1136/bmj.311.7004.528b; KREISS J, 1988, GENITOURIN MED, V64, P1; LINGLOF T, 1995, SEX TRANSM DIS, V22, P160, DOI 10.1097/00007435-199505000-00005; *MIN HLTH RUSS FED, 1993, 286 MIN HLTH RUSS FE; *MIN HLTH RUSS FED, 1993, TREATM PREV SYPH REC; *MIN HLTH USSR, 1986, 1570 MIN HLTH USSR; *MIN HLTH USSR, 1985, 1161 MIN HLTH USSR; *NAT AIDS PREV CON, 1994, RUSS FED ASS NAT PRO; PLUMMER FA, 1991, AIDS, V5, pS169; RENTON AM, 1994, SOC SCI MED, V38, P1153, DOI 10.1016/0277-9536(94)90230-5; TICHONOVA L, 1995, ANN M ALL RUSS ASS V; TICHONOVA LI, 1995, SEX TRANSM DIS, V4, P15	21	147	153	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					210	213		10.1016/S0140-6736(97)01382-2	http://dx.doi.org/10.1016/S0140-6736(97)01382-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250199				2022-12-24	WOS:A1997XL72200046
J	Antonsson, B; Conti, F; Ciavatta, A; Montessuit, S; Lewis, S; Martinou, I; Bernasconi, L; Bernard, A; Mermod, JJ; Mazzei, G; Maundrell, K; Gambale, F; Sadoul, R; Martinou, JC				Antonsson, B; Conti, F; Ciavatta, A; Montessuit, S; Lewis, S; Martinou, I; Bernasconi, L; Bernard, A; Mermod, JJ; Mazzei, G; Maundrell, K; Gambale, F; Sadoul, R; Martinou, JC			Inhibition of Bax channel-forming activity by Bcl-2	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; SYMPATHETIC NEURONS; PROTEIN	Proteins of the Bcl-2 family are intracellular membrane-associated proteins that regulate programmed cell death (apoptosis) either positively or negatively by as yet unknown mechanisms. Bax, a pro-apoptotic member of the Bcl-2 family, was shown to form channels in lipid membranes. Bax triggered the release of liposome-encapsulated carboxyfluorescein at both neutral and acidic pH. AS physiological pH, release could be blocked by Bcl-2, Bcl-2, in contrast, triggered carboxyfluorescein release at acidic pH only. In planar lipid bilayers, Bax formed pH- and voltage-dependent ion-conducting channels. Thus, the pro-apoptotic effects of Bax may be elicited through an intrinsic pore-forming activity that can be antagonized by Bcl-2.	IST CIBERNET & BIOFIS, I-16149 GENOA, ITALY		Antonsson, B (corresponding author), GLAXO WELLCOME RES & DEV SA, GENEVA BIOMED RES INST, CH-1288 GENEVA, SWITZERLAND.			martinou, Jean-claude/0000-0002-9847-2051; SADOUL, Remy/0000-0002-4763-0320				BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Conti F., UNPUB; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; HALDAR S, 1994, ARCH BIOCHEM BIOPHYS, V315, P483, DOI 10.1006/abbi.1994.1529; HENNET T, 1993, CANCER RES, V53, P1456; KENNY B, 1994, MOL MICROBIOL, V11, P99, DOI 10.1111/j.1365-2958.1994.tb00293.x; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Montal M, 1974, Methods Enzymol, V32, P545; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113	16	901	927	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					370	372		10.1126/science.277.5324.370	http://dx.doi.org/10.1126/science.277.5324.370			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219694				2022-12-24	WOS:A1997XL35800046
J	Kliore, AJ; Hinson, DP; Flasar, FM; Nagy, AF; Cravens, TE				Kliore, AJ; Hinson, DP; Flasar, FM; Nagy, AF; Cravens, TE			The ionosphere of Europa from Galileo radio occultations	SCIENCE			English	Article							ATMOSPHERE; JUPITER	The Galileo spacecraft performed six radio occultation observations of Jupiter's Galilean satellite Europa during its tour of the jovian system, In five of the six instances, these occultations revealed the presence of a tenuous ionosphere on Europa, with an average maximum electron density of nearly 10(4) per cubic centimeter near the surface and a plasma scale height of about 240 +/- 40 kilometers from the surface to 300 kilometers and of 440 +/- 60 kilometers above 300 kilometers. Such an ionosphere could be produced by solar photoionization and jovian magnetospheric particle impact in an atmosphere having a surface density of about 10(8) electrons per cubic centimeter. If this atmosphere is composed primarily of O-2, then the principal ion is O-2(+) and the neutral atmosphere temperature implied by the 240-kilometer scale height is about 600 kelvin. If it is composed of H2O, the principal ion is H3O+ and the neutral temperature is about 340 kelvin. In either case, these temperatures are much higher than those observed on Europa's surface, and an external heating source from the jovian magnetosphere is required.	STANFORD UNIV,CTR RADAR ASTRON,STANFORD,CA 94305; NASA,GODDARD SPACE FLIGHT CTR,EXTRATERR PHYS LAB,GREENBELT,MD 20771; UNIV MICHIGAN,SPACE PHYS RES LAB,ANN ARBOR,MI 48109; UNIV KANSAS,DEPT PHYS & ASTRON,LAWRENCE,KS 66045	Stanford University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Michigan System; University of Michigan; University of Kansas	Kliore, AJ (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.		Flasar, F Michael/C-8509-2012	Hinson, David/0000-0002-1620-4011				BARTH CA, COMMUNICATION; BARTH CA, IN PRESS GEOPHYS RES; BROADFOOT AL, 1979, SCIENCE, V204, P979, DOI 10.1126/science.204.4396.979; CALVIN WM, 1995, J GEOPHYS RES-PLANET, V100, P19041, DOI 10.1029/94JE03349; FJELDBO G, 1971, ASTRON J, V76, P123, DOI 10.1086/111096; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; HOWARD HT, 1992, SPACE SCI REV, V60, P565, DOI 10.1007/BF00216868; Ip WH, 1996, ICARUS, V120, P317, DOI 10.1006/icar.1996.0052; Johnson R.E., 1990, ENERGETIC CHARGED PA, DOI [10.1007/978-3-642-48375-2, DOI 10.1007/978-3-642-48375-2]; KLIORE A, 1974, SCIENCE, V183, P323, DOI 10.1126/science.183.4122.323; KLIORE AJ, 1972, X62150 NASA TM AM RE; LINDAL GF, 1992, ASTRON J, V103, P967, DOI 10.1086/116119; SCHREIER R, 1993, J GEOPHYS RES-SPACE, V98, P21231, DOI 10.1029/93JA02585; TORR MR, 1985, J GEOPHYS RES-SPACE, V90, P6675, DOI 10.1029/JA090iA07p06675; WU FM, 1978, ASTROPHYS J, V325, P325; [No title captured]	16	95	95	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					355	358		10.1126/science.277.5324.355	http://dx.doi.org/10.1126/science.277.5324.355			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219689				2022-12-24	WOS:A1997XL35800041
J	Scheffzek, K; Ahmadian, MR; Kabsch, W; Wiesmuller, L; Lautwein, A; Schmitz, F; Wittinghofer, A				Scheffzek, K; Ahmadian, MR; Kabsch, W; Wiesmuller, L; Lautwein, A; Schmitz, F; Wittinghofer, A			The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic Ras mutants	SCIENCE			English	Article							C-TERMINAL DOMAIN; TYPE-1 NF1 GENE; NEUROFIBROMATOSIS TYPE-1; TRIPHOSPHATE CONFORMATION; 3-DIMENSIONAL STRUCTURES; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; BINDING DOMAIN; PROTEIN GAP; MECHANISM	The three-dimensional structure of the complex between human H-Ras bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human GTPase-activating protein p120(GAP) (GAP-334) in the presence of aluminum fluoride was solved at a resolution of 2.5 angstroms, The structure shows the partly hydrophilic and partly hydrophobic nature of the communication between the two molecules, which explains the sensitivity of the interaction toward both sails and lipids, An arginine side chain (arginine-789) of GAP-334 is supplied into the active site of Pas to neutralize developing charges in the transition state, The switch II region of Pas is stabilized by GAP-334, thus allowing glutamine-61 of Pas, mutation of which activates the oncogenic potential, to participate in catalysis, The structural arrangement in the active site is consistent with a mostly associative mechanism of phosphoryl transfer and provides an explanation for the activation of Pas by glycine-12 and glutamine-61 mutations, Glycine-12 in the transition state mimic is within van der Waals distance of both arginine-789 of GAP-334 and glutamine-61 of Pas, and even its mutation to alanine would disturb the arrangements of residues in the transition state.	MAX PLANCK INST MOL PHYSIOL, ABT STRUKT BIOL, D-44139 DORTMUND, GERMANY; MAX PLANCK INST MED RES, D-69120 HEIDELBERG, GERMANY	Max Planck Society; Max Planck Society								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Ahmadian MR, 1996, J BIOL CHEM, V271, P16409, DOI 10.1074/jbc.271.27.16409; Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; AHMADIAN MR, IN PRESS NATURE STRU; AHMADIAN MR, UNPUB; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; BRUNGER AT, 1996, X PLOR VERSION 3 8; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARSHALL MS, 1993, ONCOGENE, V8, P425; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; Morcos P, 1996, MOL CELL BIOL, V16, P2496; MORI S, 1995, J BIOL CHEM, V270, P28834, DOI 10.1074/jbc.270.48.28834; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Parrini MC, 1996, EMBO J, V15, P1107, DOI 10.1002/j.1460-2075.1996.tb00448.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; POULLET P, 1994, MOL CELL BIOL, V14, P815, DOI 10.1128/MCB.14.1.815; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; SCHEFFZEK K, UNPUB; SCHLICTING I, IN PRESS BIOCHEMISTR; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Sermon BA, 1996, J BIOL CHEM, V271, P1566, DOI 10.1074/jbc.271.3.1566; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; VANDOP C, 1984, J BIOL CHEM, V259, P696; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; 1997, PROTEIN-STRUCT FUNCT, V27, P315	77	1161	1206	3	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 18	1997	277	5324					333	338		10.1126/science.277.5324.333	http://dx.doi.org/10.1126/science.277.5324.333			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219684				2022-12-24	WOS:A1997XL35800036
J	Webb, JK; Carswell, RF; Lanzetta, KM; Ferlet, R; Lemoine, M; VidalMadjar, A; Bowen, DV				Webb, JK; Carswell, RF; Lanzetta, KM; Ferlet, R; Lemoine, M; VidalMadjar, A; Bowen, DV			A high deuterium abundance at redshift z=0.7	NATURE			English	Article							NUCLEOSYNTHESIS	Of the light elements, the primordial abundance of deuterium relative to hydrogen, (D/H)(p), provides the most sensitive diagnostic(1) for the cosmological mass density parameter, Omega(B). Recent high-redshift D/H measurements are highly discrepant(2-6), although this may reflect observational uncertainties(7,8). The larger primordial D/H values imply a low Omega(B) (requiring the Universe to be. dominated by non-baryonic matter), and cause problems for galactic chemical evolution models, which have difficulty in reproducing the steep decline in D/H to the present-day values, Conversely, the lower D/H values measured at high redshift imply an Omega(B) greater than that derived from Li-7 and He-4 abundance measurements, and may require a deuterium-abundance evolution that is too low to easily explain. Here we report the first measurement of D/H at intermediate redshift (z = 0.7010), in a gas cloud selected to minimize observational uncertainties, Our analysis yields a value of D/H ((2.0 +/- 0.5) x 10(-4)) which is at the upper end of the range of values measured at high redshifts. This finding, together with other independent observations, suggests that there may be inhomogeneity in (D/H)(p) of at least a factor of ten.	SUNY STONY BROOK,DEPT PHYS & ASTRON,STONY BROOK,NY 11794; UNIV SUSSEX,CTR ASTRON,BRIGHTON BN1 9QH,E SUSSEX,ENGLAND; INST ASTRON,CAMBRIDGE CB3 0HA,ENGLAND; INST ASTROPHYS,F-75014 PARIS,FRANCE; UNIV CHICAGO,ENRICO FERMI INST,DEPT ASTRON & ASTROPHYS,CHICAGO,IL 60637; ROYAL OBSERV,EDINBURGH EH9 3HJ,MIDLOTHIAN,SCOTLAND; UNIV NEW S WALES,SCH PHYS,SYDNEY,NSW 2052,AUSTRALIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Sussex; University of Cambridge; UDICE-French Research Universities; Sorbonne Universite; University of Chicago; University of Edinburgh; University of New South Wales Sydney			Lemoine, Martin/AAE-6416-2019; Webb, John/J-9122-2018	Lemoine, Martin/0000-0002-2395-7812; Webb, John/0000-0002-0004-9360				BURLES S, UNPUB SCIENCE; CARSWELL RF, 1994, MON NOT R ASTRON SOC, V268, pL1, DOI 10.1093/mnras/268.1.L1; Copi C.J., ASTROPH9606156; COPI CJ, 1995, SCIENCE, V267, P192, DOI 10.1126/science.7809624; EPSTEIN RI, 1976, NATURE, V263, P198, DOI 10.1038/263198a0; Hata N, 1997, PHYS REV D, V55, P540, DOI 10.1103/PhysRevD.55.540; HOGAN CJ, ASTROPH9609138; JEDAMZIK K, 1995, ASTROPHYS J, V452, P33, DOI 10.1086/176278; JEDAMZIK K, ASTROPH9609103; LANZETTA KM, 1993, ASTROPHYS J SUPPL S, V84, P109, DOI 10.1086/191749; Pagel B.E.J., 1997, NUCLEOSYNTHESIS CHEM; Rugers M, 1996, ASTRON J, V111, P2135, DOI 10.1086/117949; Rugers M, 1996, ASTROPHYS J, V459, pL1, DOI 10.1086/309931; Schramm DN, 1996, NATURE, V381, P193, DOI 10.1038/381193a0; Songaila A, 1997, NATURE, V385, P137, DOI 10.1038/385137a0; Tytler D, 1996, NATURE, V381, P207, DOI 10.1038/381207a0; TYTLER D, ASTROPH9612121; VANGIONIFLAM E, 1995, ASTROPHYS J, V441, P471, DOI 10.1086/175373; VIDALMADJAR A, ASTROPH9612020; Wampler EJ, 1996, NATURE, V383, P308, DOI 10.1038/383308a0; WEBB JK, 1991, MON NOT R ASTRON SOC, V250, P657, DOI 10.1093/mnras/250.4.657; WEBB JK, 1987, THESIS CAMBRIDGE U; White M, 1996, MON NOT R ASTRON SOC, V283, P107, DOI 10.1093/mnras/283.1.107; WHITE SDM, 1993, NATURE, V366, P429, DOI 10.1038/366429a0	24	141	141	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					250	252		10.1038/40814	http://dx.doi.org/10.1038/40814			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230433				2022-12-24	WOS:A1997XL12100042
J	Saketkhou, BB; Conte, FJ; Noris, M; Tilkemeier, P; Miller, G; Forman, DE; Cannistra, L; Leavitt, J; Sharma, SC; Garber, C; Parisi, AF				Saketkhou, BB; Conte, FJ; Noris, M; Tilkemeier, P; Miller, G; Forman, DE; Cannistra, L; Leavitt, J; Sharma, SC; Garber, C; Parisi, AF			Emergency department use of aspirin in patients with possible acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article							UNSTABLE ANGINA; TRIAL	Background: Efforts have been made to improve the suboptimal use of aspirin af Objective: To assess the frequency and timing of aspirin administration in emergency department patients with possible myocardial infarction. Design: Retrospective record review. Setting: Emergency departments of four hospitals affiliated with the same university. Patients: All patients who were admitted to the four hospitals in 1994 for evaluation and treatment of suspected acute myocardial infarction. Measurements: The frequency and timing of aspirin administration and the definitive diagnosis established before discharge from the hospital. Results: Aspirin was not given to 253 of 463 emergency department patients (55%) who had a definitive diagnosis of acute myocardial infarction. Seventy-eight pet-cent of patients who did receive aspirin received it more than 30 minutes after arrival in the emergency department. Conclusion: Aspirin therapy is underutilized as the first intervention in patients who are admitted with suspected myocardial infarction.	MIRIAM HOSP, DEPT MED, DIV CARDIOL, PROVIDENCE, RI 02906 USA; MEM HOSP, DEPT MED, DIV CARDIOL, PAWTUCKET, RI 02860 USA; VET AFFAIRS MED CTR, DEPT MED, DIV CARDIOL, PROVIDENCE, RI 02908 USA; ROGER WILLIAMS CANC MED CTR, PROVIDENCE, RI USA; BROWN UNIV, PROVIDENCE, RI 02912 USA	Lifespan Health Rhode Island; Miriam Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center; Roger Williams Medical Center; Brown University			Tilkemeier, Peter/AAW-4936-2020; Garber, Carol/ABD-4375-2021	Garber, Carol/0000-0002-1268-576X				[Anonymous], 1988, LANCET, V2, P349; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Gunnar R M, 1990, Circulation, V82, P664; JULIAN DG, 1989, BMJ-BRIT MED J, V299, P555; KRUMHOLZ HM, 1995, CIRCULATION, V92, P2841, DOI 10.1161/01.CIR.92.10.2841; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; MOHER M, 1994, BMJ-BRIT MED J, V308, P760, DOI 10.1136/bmj.308.6931.760; Ryan TJ, 1996, CIRCULATION, V94, P2341, DOI 10.1161/01.CIR.94.9.2341; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WYLLIE HR, 1994, BMJ-BRIT MED J, V308, P760, DOI 10.1136/bmj.308.6931.760a	13	23	23	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					126	129		10.7326/0003-4819-127-2-199707150-00005	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9230001				2022-12-24	WOS:A1997XK15800007
J	James, JA; Laing, GJ; Logan, S; Rossdale, M				James, JA; Laing, GJ; Logan, S; Rossdale, M			Feasibility of screening toddlers for iron deficiency anaemia in general practice	BRITISH MEDICAL JOURNAL			English	Article									DEPT CHILD HLTH,LONDON N1 5LZ,ENGLAND; INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,LONDON WC1N 1EH,ENGLAND	University of London; University College London	James, JA (corresponding author), MONTPELIER HLTH CTR,BRISTOL BS6 5PT,AVON,ENGLAND.			Logan, Stuart/0000-0002-9279-261X				AUKETT MA, 1986, ARCH DIS CHILD, V61, P849, DOI 10.1136/adc.61.9.849; HALL D, 1996, HLTH CHILDREN; IDJRADINATA P, 1993, LANCET, V341, P1, DOI 10.1016/0140-6736(93)92477-B; JAMES J, 1989, BRIT MED J, V299, P838, DOI 10.1136/bmj.299.6703.838; JAMES JA, 1995, BRIT MED J, V311, P230, DOI 10.1136/bmj.311.6999.230	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					102	103		10.1136/bmj.315.7100.102	http://dx.doi.org/10.1136/bmj.315.7100.102			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240051	Green Published			2022-12-24	WOS:A1997XL25200026
J	Liao, SR; Lin, JL; Do, H; Johnson, AE				Liao, SR; Lin, JL; Do, H; Johnson, AE			Both lumenal and cytosolic gating of the aqueous ER translocon pore are regulated from inside the ribosome during membrane protein integration	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; CONDUCTING CHANNEL; MESSENGER-RNA; TRANSLATION; GLYCOPROTEIN; ENVIRONMENT; BIOGENESIS; SEQUENCES; SEGMENTS; SIGNAL	Portions of the nascent chain are exposed to the lumen, the cytosol, or neither at different stages during the cotranslational integration of a protein into the ER membrane, as shown by compartment-specific collisional quenching of fluorophores incorporated into the polypeptide. The opening or closing of each end of the aqueous translocon pore is tightly controlled and occurs in a sequence that does not compromise the membrane's permeability barrier. Surprisingly, these structural changes at the membrane are effected by the transmembrane segment in the nascent protein from inside the ribosome. Thus, the ribosome, not the translocon, first recognizes the transmembrane segment and triggers long-range structural changes at the translocon that may be involved in shifting its function from translocation to integration.	TEXAS A&M UNIV,HLTH SCI CTR,DEPT CHEM,COLLEGE STN,TX 77843; TEXAS A&M UNIV,HLTH SCI CTR,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Liao, SR (corresponding author), TEXAS A&M UNIV,HLTH SCI CTR,DEPT MED BIOCHEM & GENET,COLLEGE STN,TX 77843, USA.		Johnson, Arthur E/G-3457-2012		NIGMS NIH HHS [F32 GM017828-02, F32 GM017828-01, F32 GM17828] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017828] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; CRANNEY M, 1983, BIOCHIM BIOPHYS ACTA, V735, P418, DOI 10.1016/0005-2736(83)90156-6; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HEDGE RS, 1996, CELL, V85, P217; Johnson AE, 1995, COLD SPRING HARB SYM, V60, P71, DOI 10.1101/SQB.1995.060.01.010; KEHRY M, 1980, CELL, V21, P393, DOI 10.1016/0092-8674(80)90476-6; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; LIN JL, 1995, J BIOL CHEM, V270, P6942, DOI 10.1074/jbc.270.12.6942; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MCCUNE JM, 1980, J EXP MED, V152, P463, DOI 10.1084/jem.152.2.463; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SPIESS M, 1989, J BIOL CHEM, V264, P19117; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; TWETEN RK, 1988, INFECT IMMUN, V56, P3228, DOI 10.1128/IAI.56.12.3228-3234.1988; WALTEWR P, 1994, ANN REV CELL BIOL, V140, P87; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519	30	211	212	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					31	41		10.1016/S0092-8674(00)80311-6	http://dx.doi.org/10.1016/S0092-8674(00)80311-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230300	Bronze			2022-12-24	WOS:A1997XL36200006
J	Quake, SR; Babcock, H; Chu, S				Quake, SR; Babcock, H; Chu, S			The dynamics of partially extended single molecules of DNA	NATURE			English	Article							STRETCHED POLYMER-CHAINS; TRANSIENT ELECTRIC BIREFRINGENCE; DIELECTRIC-RELAXATION; SCATTERING; FRAGMENTS; MODES	The behaviour of an isolated polymer floating in a solvent forms the basis of our understanding of polymer dynamics(1,2). Classical theories describe the motion of a polymer with linear equations of motion, which yield a set of 'normal modes', analogous to the fundamental frequency and the harmonics of a vibrating violin string. But hydrodynamic interactions make polymer dynamics inherently nonlinear, and the linearizing approximations required for the normal-mode picture have therefore been questioned(1). Here we test the normal-mode theory by measuring the fluctuations of single molecules of DNA held in a partially extended state with optical tweezers. We find that the motion of the DNA can be described by linearly independent normal modes, and we have experimentally determined the eigenstates of the system. Furthermore, we show that the spectrum of relaxation times obeys a power law.	STANFORD UNIV,DEPT PHYS,STANFORD,CA 94305	Stanford University				Babcock, Hazen/0000-0003-4835-3692				ADAM M, 1977, MACROMOLECULES, V10, P1229, DOI 10.1021/ma60060a014; AMELAR S, 1991, MACROMOLECULES, V24, P3505, DOI 10.1021/ma00012a007; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; de Gennes P. G., 1979, SCALING CONCEPTS POL, P128; DEGENNES PG, 1974, J CHEM PHYS, V60, P5030, DOI 10.1063/1.1681018; Doi M., 1986, THEORY POLYM DYNAMIC; HONG MK, 1992, PHYS REV LETT, V68, P1430, DOI 10.1103/PhysRevLett.68.1430; Johnson R.M., 1970, POLYM JPN, V1, P742, DOI [10.1295/polymj.1.742, DOI 10.1295/POLYMJ.1.742]; KIRKWOOD JG, 1948, J CHEM PHYS, V16, P565, DOI 10.1063/1.1746947; LEWIS RJ, 1986, MACROMOLECULES, V19, P134, DOI 10.1021/ma00155a021; MARCIANO Y, 1995, MACROMOLECULES, V28, P985, DOI 10.1021/ma00108a028; PECORA R, 1991, SCIENCE, V251, P893, DOI 10.1126/science.2000490; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; PINCUS P, 1977, MACROMOLECULES, V10, P210, DOI 10.1021/ma60055a042; PINCUS P, 1976, MACROMOLECULES, V9, P386, DOI 10.1021/ma60051a002; Press W.H., 1994, NUMERICAL RECIPES; SAHOUANI H, 1992, MACROMOLECULES, V25, P5632, DOI 10.1021/ma00047a012; SAMMLER RL, 1990, MACROMOLECULES, V23, P2388, DOI 10.1021/ma00210a042; Smith DE, 1996, MACROMOLECULES, V29, P1372, DOI 10.1021/ma951455p; SORLIE SS, 1990, MACROMOLECULES, V23, P487, DOI 10.1021/ma00204a022; WATANABE H, 1995, MACROMOLECULES, V28, P6443, DOI 10.1021/ma00123a009; Watanabe H, 1996, MACROMOLECULES, V29, P97, DOI 10.1021/ma9510348; WATANABE H, 1993, MACROMOLECULES, V26, P5073, DOI 10.1021/ma00071a015; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462; ZIMM BH, 1956, J CHEM PHYS, V24, P279, DOI 10.1063/1.1742463	25	233	241	2	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					151	154		10.1038/40588	http://dx.doi.org/10.1038/40588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217154				2022-12-24	WOS:A1997XK10900043
J	Braun, BR; Johnson, AD				Braun, BR; Johnson, AD			Control of filament formation in Candida albicans by the transcriptional repressor TUP1	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; GROWTH; TRANSFORMATION; MORPHOGENESIS; ALPHA-2	The pathogenic yeast Candida albicans regulates its cellular morphology in response to environmental conditions. Ellipsoidal, single cells (blastospores) predominate in rich media, whereas filaments composed of elongated cells that are attached end-to-end form in response to starvation, serum, and other conditions. The TUP1 gene, which encodes a general transcriptional repressor in Saccharomyces cerevisiae, was isolated from C. albicans and disrupted. The resulting tup1 mutant strain of C. albicans grew exclusively as filaments under all conditions tested. TUP1 was epistatic to the transcriptional activator CPH1, previously found to promote filamentous growth. The results suggest a model where TUP1 represses genes responsible for initiating filamentous growth and this repression is lifted under inducing environmental conditions.			Braun, BR (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, 513 PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA.				NIGMS NIH HHS [GM37049] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037049] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DUDLEY MN, 1990, PHARMACOTHERAPY, V10, P133; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; FIDEL PL, UNPUB; FONZI WA, 1993, GENETICS, V134, P717; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GIMENO GJ, 1992, CELL, V68, P14077; GOW NAR, 1984, SABOURAUDIA, V22, P137; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KRON SJ, 1995, CURR OPIN CELL BIOL, V7, P845, DOI 10.1016/0955-0674(95)80069-7; LEBERER E, 1996, P NATL ACAD SCI US, V93; LEMONTT JF, 1980, GENETICS, V94, P899; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; McGinnis M.R., 1980, LAB HDB MED MYCOLOGY; MERSONDAVIES LA, 1989, J GEN MICROBIOL, V135, P3143; Odds F. C., 1994, ASM News (Washington), V60, P313; ODDS FC, 1985, CRC CR REV MICROBIOL, V12, P45, DOI 10.3109/10408418509104425; Odds FC., 1988, CANDIDA CANDIDOSIS; OHAMA T, 1993, NUCLEIC ACIDS RES, V21, P4039, DOI 10.1093/nar/21.17.4039; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Rubin R. H., 1993, European Journal of Clinical Microbiology and Infectious Diseases, V12, pS42; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; WAHI M, 1995, GENETICS, V140, P79; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WRIGHT RM, 1993, CURR GENET, V23, P388, DOI 10.1007/BF00312623	30	444	454	4	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	1997	277	5322					105	109		10.1126/science.277.5322.105	http://dx.doi.org/10.1126/science.277.5322.105			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204892				2022-12-24	WOS:A1997XJ41800050
J	Xia, D; Yu, CA; Kim, H; Xian, JZ; Kachurin, AM; Zhang, L; Yu, L; Deisenhofer, J				Xia, D; Yu, CA; Kim, H; Xian, JZ; Kachurin, AM; Zhang, L; Yu, L; Deisenhofer, J			Crystal structure of the cytochrome bc(1) complex from bovine heart mitochondria	SCIENCE			English	Article							AMINO-ACID SEQUENCE; C REDUCTASE COMPLEX; UBIQUINONE-BINDING-PROTEIN; ELECTRON-TRANSPORT CHAIN; RAT-LIVER MITOCHONDRIA; PROTONMOTIVE Q-CYCLE; IRON SULFUR PROTEIN; BEEF-HEART; BC1 COMPLEX; RHODOBACTER-SPHAEROIDES	On the basis of x-ray diffraction data to a resolution of 2.9 angstroms, atomic models of most protein components of the bovine cytochrome bc(1) complex were built, including core 1, core 2, cytochrome b, subunit 6 subunit 7, a carboxyl-terminal fragment of cytochrome c(1), and an amino-terminal fragment of the iron-sulfur protein. The positions of the four iron centers within the be, complex and the binding sites of the two specific respiratory inhibitors antimycin A and myxothiazol were identified. The membrane-spanning region of each bc(1) complex monomer consists of 13 transmembrane helices, eight of which belong to cytochrome b. Closely interacting monomers are arranged as symmetric dimers and form cavities through which the inhibitor binding pockets can be accessed. The proteins core 1 and core 2 are structurally similar to each other and consist of two domains of roughly equal size and identical folding topology.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; OKLAHOMA STATE UNIV, DEPT BIOCHEM & MOL BIOL, STILLWATER, OK 74078 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Oklahoma State University System; Oklahoma State University - Stillwater					NIGMS NIH HHS [GM 30721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiba T, 1996, NAT STRUCT BIOL, V3, P553, DOI 10.1038/nsb0696-553; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BERRY EA, 1992, J MOL BIOL, V224, P1161, DOI 10.1016/0022-2836(92)90476-Z; BERRY EA, 1995, ACTA CRYSTALLOGR D, V51, P235, DOI 10.1107/S0907444994010486; BORCHART U, 1986, FEBS LETT, V200, P81, DOI 10.1016/0014-5793(86)80515-4; BORCHART U, 1985, FEBS LETT, V191, P125, DOI 10.1016/0014-5793(85)81007-3; BRAND MD, 1976, J BIOL CHEM, V251, P5670; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; COCCO T, 1991, EUR J BIOCHEM, V195, P731, DOI 10.1111/j.1432-1033.1991.tb15760.x; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; *DAR LAB, 1979, CCP4 SERC UK COLL CO; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DENG K, UNPUB; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; ERECINSKA M, 1972, P NATL ACAD SCI USA, V69, P50, DOI 10.1073/pnas.69.1.50; Ernster, 1987, CYTOCHROME SYSTEMS M, P617; GENCIC S, 1991, EUR J BIOCHEM, V199, P123, DOI 10.1111/j.1432-1033.1991.tb16099.x; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; Glaser E, 1996, BBA-BIOENERGETICS, V1275, P33, DOI 10.1016/0005-2728(96)00046-1; GLASER E, 1994, FEBS LETT, V346, P83, DOI 10.1016/0014-5793(94)00312-2; GLASER EG, 1984, BIOCHIM BIOPHYS ACTA, V766, P322, DOI 10.1016/0005-2728(84)90248-2; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; GREEN DW, 1954, PROC R SOC LON SER-A, V225, P287, DOI 10.1098/rspa.1954.0203; HATEFI Y, 1962, J BIOL CHEM, V237, P1681; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWAMOTO M, 1994, J MOL BIOL, V244, P238, DOI 10.1006/jmbi.1994.1722; KUBOTA T, 1991, J MOL BIOL, V221, P379, DOI 10.1016/0022-2836(91)80059-4; LEE JW, 1995, J MOL BIOL, V252, P15, DOI 10.1006/jmbi.1994.0470; LEONARD K, 1981, J MOL BIOL, V149, P259, DOI 10.1016/0022-2836(81)90301-6; MIKI T, 1994, J BIOL CHEM, V269, P1827; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MITCHELL R, 1986, BIOCHIM BIOPHYS ACTA, V849, P229, DOI 10.1016/0005-2728(86)90029-0; MUSATOV A, 1994, BIOCHEMISTRY-US, V33, P13005, DOI 10.1021/bi00248a009; NALECZ MJ, 1985, ARCH BIOCHEM BIOPHYS, V236, P619; OHNISHI T, 1989, J BIOL CHEM, V264, P735; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROBERTSON DE, 1988, BIOCHIM BIOPHYS ACTA, V935, P273, DOI 10.1016/0005-2728(88)90223-X; SALERNO JC, 1990, BIOCHEMISTRY-US, V29, P6987, DOI 10.1021/bi00482a006; SCHAGGER H, 1987, FEBS LETT, V219, P161, DOI 10.1016/0014-5793(87)81210-3; SCHAGGER H, 1985, FEBS LETT, V190, P89, DOI 10.1016/0014-5793(85)80434-8; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; Tolkatchev D, 1996, J BIOL CHEM, V271, P12356, DOI 10.1074/jbc.271.21.12356; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSAI AL, 1983, J BIOL CHEM, V258, P2122; USUI S, 1990, BIOCHEM BIOPH RES CO, V167, P575, DOI 10.1016/0006-291X(90)92063-6; VONJAGOW G, 1986, J BIOENERG BIOMEMBR, V18, P157, DOI 10.1007/BF00743462; WAKABAYASHI S, 1985, J BIOL CHEM, V260, P337; WAKABAYASHI S, 1982, J BIOCHEM, V91, P2077, DOI 10.1093/oxfordjournals.jbchem.a133901; WEST IC, 1986, BIOCHIM BIOPHYS ACTA, V849, P236, DOI 10.1016/0005-2728(86)90030-7; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; WIKSTROM MK, 1972, BIOCHIM BIOPHYS ACTA, V283, P403, DOI 10.1016/0005-2728(72)90258-7; YU CA, 1994, J MOL BIOL, V243, P802, DOI 10.1016/0022-2836(94)90051-5; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YU CA, 1978, BIOCHEM BIOPH RES CO, V82, P1070, DOI 10.1016/0006-291X(78)90296-6; YU L, 1995, J BIOL CHEM, V270, P25634, DOI 10.1074/jbc.270.43.25634; YUE WH, 1991, BIOCHEMISTRY-US, V30, P2303, DOI 10.1021/bi00223a002; YUN CH, 1991, BIOCHEMISTRY-US, V30, P6747, DOI 10.1021/bi00241a017	69	868	901	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	1997	277	5322					60	66		10.1126/science.277.5322.60	http://dx.doi.org/10.1126/science.277.5322.60			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204897				2022-12-24	WOS:A1997XJ41800037
J	Linet, MS; Hatch, EE; Kleinerman, RA; Robison, LL; Kaune, WT; Friedman, DR; Severson, RK; Haines, CM; Hartsock, CT; Niwa, S; Wacholder, S; Tarone, RE				Linet, MS; Hatch, EE; Kleinerman, RA; Robison, LL; Kaune, WT; Friedman, DR; Severson, RK; Haines, CM; Hartsock, CT; Niwa, S; Wacholder, S; Tarone, RE			Residential exposure to magnetic fields and acute lymphoblastic leukemia in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ELECTRICAL WIRING CONFIGURATIONS; CHILDHOOD-CANCER; SELECTION BIAS; POWER-LINES; WIRE CODES; RISK	Background Previous studies found associations between childhood leukemia and surrogate indicators of exposure to magnetic fields (the power-line classification scheme known as ''wire coding''), but not between childhood leukemia and measurements of 60-Hz residential magnetic fields. Methods We enrolled 638 children with acute lymphoblastic leukemia (ALL) who were under 15 years of age and were registered with the Children's Cancer Group and 620 controls in a study of residential exposure to magnetic fields generated by nearby power lines. In the subjects' current and former homes, data collectors blinded to the subjects' health status measured magnetic fields for 24 hours in each child's bedroom and for 30 seconds in three or four other rooms and outside the front door. A computer algorithm assigned wire-code categories, based on the distance and configuration of nearby power lines, to the subjects' main residences (for 416 case patients and 416 controls) and to those where the family had lived during the mother's pregnancy with the subject (for 230 case patients and 230 controls). Results The risk of childhood ALL was not linked to summary time-weighted average residential magnetic-field levels, categorized according to a priori criteria. The odds ratio for ALL was 1.24 (95 percent confidence interval, 0.86 to 1.79) at exposures of 0.200 mu T or greater as compared with less than 0.065 mu T. The risk of ALL was not increased among children whose main residences were in the highest wire-code category (odds ratio as compared with the lowest category, 0.88; 95 percent confidence interval, 0.48 to 1.63). Furthermore, the risk was not significantly associated with either residential magnetic-field levels or the wire codes of the homes mothers resided in when pregnant with the subjects. Conclusions Our results provide little evidence that living in homes characterized by high measured time-weighted average magnetic-field levels or by the highest wire-code category increases the risk of ALL in children. (C) 1997, Massachusetts Medical Society.	CHILDRENS CANC GRP,ARCADIA,CA; UNIV MINNESOTA,SCH MED,DIV PEDIAT EPIDEMIOL & CLIN RES,MINNEAPOLIS,MN 55455; EM FACTORS,RICHLAND,WA; WESTAT CORP,ROCKVILLE,MD; INFORMAT MANAGEMENT SERV INC,ROCKVILLE,MD	University of Minnesota System; University of Minnesota Twin Cities; Westat; Information Management Services, Inc.	Linet, MS (corresponding author), NCI,DIV CANC EPIDEMIOL & GENET,EXECUT PLAZA N,SUITE 408,BETHESDA,MD 20892, USA.		Robison, Leslie/N-8122-2018	Hatch, Elizabeth/0000-0001-7901-3928; Kleinerman, Ruth/0000-0001-7415-2478	NCI NIH HHS [R01 CA48051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNES F, 1989, BIOELECTROMAGNETICS, V10, P13, DOI 10.1002/bem.2250100103; Breslow NE., 1980, IARC SCI PUBL, V32, P122; *COMM POSS EFF EL, 1996, POSS HLTH EFF EXP RE, P113; DOVAN T, 1993, BIOELECTROMAGNETICS, V14, P145, DOI 10.1002/bem.2250140207; FEYCHTING M, 1993, AM J EPIDEMIOL, V138, P467, DOI 10.1093/oxfordjournals.aje.a116881; Friedman DR, 1996, EPIDEMIOLOGY, V7, P151, DOI 10.1097/00001648-199603000-00008; FULTON JP, 1980, AM J EPIDEMIOL, V111, P292, DOI 10.1093/oxfordjournals.aje.a112899; GURNEY JG, 1995, EPIDEMIOLOGY, V6, P31, DOI 10.1097/00001648-199501000-00007; *HIGH VOLT TRANSM, 1993, SURV RES MAGN FIELD, V1; JONES TL, 1993, J CLIN EPIDEMIOL, V46, P545, DOI 10.1016/0895-4356(93)90127-M; KAUNE WT, 1994, BIOELECTROMAGNETICS, V15, P33, DOI 10.1002/bem.2250150108; KAUNE WT, 1987, BIOELECTROMAGNETICS, V8, P315, DOI 10.1002/bem.2250080402; KAUNE WT, 1994, BIOELECTROMAGNETICS, V15, P275, DOI 10.1002/bem.2250150402; KLEINERMAN RA, IN PRESS EPIDEMIOLOG; LONDON S, 1993, AM J EPIDEMIOL, V137, P381; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; *NAT RAD PROT BOAR, 1992, DOC NRPB, V3, P54; *OAK RIDG ASS U PA, 1992, PUBL OAK RID ASS U P, pR1; OLSEN JH, 1993, BRIT MED J, V307, P891, DOI 10.1136/bmj.307.6909.891; POOLE C, 1991, CANCER CAUSE CONTROL, V2, P267, DOI 10.1007/BF00052144; Robison L L, 1987, Prog Clin Biol Res, V246, P19; ROBISON LL, 1984, AM J EPIDEMIOL, V120, P164, DOI 10.1093/oxfordjournals.aje.a113866; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SAVITZ DA, 1989, EPIDEMIOL REV, V11, P59, DOI 10.1093/oxfordjournals.epirev.a036045; Tenforde T. S., 1996, P185; TOMENIUS L, 1986, BIOELECTROMAGNETICS, V7, P191, DOI 10.1002/bem.2250070209; Tynes T, 1997, AM J EPIDEMIOL, V145, P219, DOI 10.1093/oxfordjournals.aje.a009094; VERKASALO PK, 1993, BRIT MED J, V307, P895, DOI 10.1136/bmj.307.6909.895; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; WERTHEIMER N, 1982, INT J EPIDEMIOL, V11, P345, DOI 10.1093/ije/11.4.345	31	309	319	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	1997	337	1					1	7		10.1056/NEJM199707033370101	http://dx.doi.org/10.1056/NEJM199707033370101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH186	9203424	Bronze			2022-12-24	WOS:A1997XH18600001
J	Yang, XL; KhosraviFar, R; Chang, HY; Baltimore, D				Yang, XL; KhosraviFar, R; Chang, HY; Baltimore, D			Daxx, a novel Fas-binding protein that activates JNK and apoptosis	CELL			English	Article							C-JUN; TNF RECEPTOR; DEATH DOMAIN; CELL-DEATH; ANTIGEN; INTERACTS; KINASE	The Fas cell surface receptor induces apoptosis upon receptor oligomerization. We have identified a novel signaling protein, termed Daxx, that binds specifically to the Fas death domain. Overexpression of Daxx enhances Fas-mediated apoptosis and activates the Jun N-terminal kinase (JMK) pathway. A C-terminal portion of Daxx interacts with the Fas death domain, while a different region activates both JNK and apoptosis. The Fas-binding domain of Daxx is a dominant-negative inhibitor of both Fas-induced apoptosis and JMK activation, while the FADD death domain partially inhibits death but not JNK activation. The Daxx apoptotic pathway is sensitive to both Bcl-2 and dominant-negative JNK pathway components and acts cooperatively with the FADD pathway. Thus, Daxx and FADD define two distinct apoptotic pathways downstream of Fas.			Yang, XL (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.		Khosravi-Far, Roya/C-3789-2008		NATIONAL CANCER INSTITUTE [R01CA051462] Funding Source: NIH RePORTER; NCI NIH HHS [CA51462, R01 CA051462-17] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROWN PH, 1994, ONCOGENE, V9, P791; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HSU H, 1996, CELL, V84, P290; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; JOHNSON NL, 1996, J BIOL CHEM, V271, P3299; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x	44	804	857	2	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1067	1076		10.1016/S0092-8674(00)80294-9	http://dx.doi.org/10.1016/S0092-8674(00)80294-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215629	Green Accepted, Bronze			2022-12-24	WOS:A1997XG83000011
J	Wilson, DS				Wilson, DS			Evolution - Human groups as units of selection	SCIENCE			English	Editorial Material											Wilson, DS (corresponding author), SUNY BINGHAMTON,DEPT BIOL SCI,BINGHAMTON,NY 13902, USA.							Boehm C, 1997, AM NAT, V150, pS100, DOI 10.1086/286052; WILSON DS, 1997, AM NAT S, V150	2	26	26	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1816	1817		10.1126/science.276.5320.1816	http://dx.doi.org/10.1126/science.276.5320.1816			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9206841				2022-12-24	WOS:A1997XF10300033
J	Yeh, KC; Wu, SH; Murphy, JT; Lagarias, JC				Yeh, KC; Wu, SH; Murphy, JT; Lagarias, JC			A cyanobacterial phytochrome two-component light sensory system	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; AVENA PHYTOCHROME; GENE; PROTEINS; SIMILARITY; MECHANISM; ETR1	The biliprotein phytochrome regulates plant growth and developmental responses to the ambient light environment through an unknown mechanism. Biochemical analyses demonstrate that phytochrome is an ancient molecule that evolved from a more compact light sensor in cyanobacteria. The cyanobacterial phytochrome Cph1 is a light-regulated histidine kinase that mediates red, far-red reversible phosphorylation of a small response regulator, Rcp1 (response regulator for cyanobacterial phytochrome), encoded by the adjacent gene, thus implicating protein phosphorylation-dephosphorylation in the initial step of light signal transduction by phytochrome.	UNIV CALIF DAVIS, SECT MOL & CELLULAR BIOL, DAVIS, CA 95616 USA	University of California System; University of California Davis			Wu, Shu-Hsing/B-4317-2009; Lagarias, John Clark/L-3139-2013; Yeh, Kuo-Chen/AAG-4485-2021	Wu, Shu-Hsing/0000-0002-7179-3138; Lagarias, John Clark/0000-0002-2093-0403; Yeh, Kuo-Chen/0000-0002-3791-3423	NCRR NIH HHS [1 P41 RR06009] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006009] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Allen JF, 1997, TRENDS PLANT SCI, V2, P41, DOI 10.1016/S1360-1385(97)82554-X; BORTHWICK HA, 1960, SCIENCE, V132, P1223, DOI 10.1126/science.132.3435.1223; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Chory J, 1996, P NATL ACAD SCI USA, V93, P12066, DOI 10.1073/pnas.93.22.12066; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Jones Alan M., 1994, Seminars in Cell Biology, V5, P295, DOI 10.1006/scel.1994.1036; Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982; Kaneko T, 1996, DNA Res, V3, P109; Kehoe DM, 1997, J BACTERIOL, V179, P3914, DOI 10.1128/jb.179.12.3914-3921.1997; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Lagarias DM, 1995, PLANT MOL BIOL, V29, P1127, DOI 10.1007/BF00020457; LI LM, 1992, J BIOL CHEM, V267, P19204; LINO M, 1997, PHOTOCHEM PHOTOBIOL, V65, P1032; LITTS JC, 1983, J BIOL CHEM, V258, P1025; Murphy JT, 1997, PHOTOCHEM PHOTOBIOL, V65, P750, DOI 10.1111/j.1751-1097.1997.tb01920.x; MUTCH N, 1986, J BACTERIOL, V165, P161; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; PRATT LH, 1995, PHOTOCHEM PHOTOBIOL, V61, P10, DOI 10.1111/j.1751-1097.1995.tb09238.x; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; SCHMIDT TGM, 1994, J CHROMATOGR A, V676, P337, DOI 10.1016/0021-9673(94)80434-6; SCHNEIDERPOETSCH HAW, 1991, FEBS LETT, V281, P245, DOI 10.1016/0014-5793(91)80403-P; SMITH H, 1995, ANNU REV PLANT PHYS, V46, P289, DOI 10.1146/annurev.pp.46.060195.001445; VIERSTRA RD, 1993, PLANT PHYSIOL, V103, P679, DOI 10.1104/pp.103.3.679; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807; WONG YS, 1989, PLANT PHYSIOL, V91, P709, DOI 10.1104/pp.91.2.709; WONG YS, 1986, J BIOL CHEM, V261, P2089	33	437	463	4	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	1997	277	5331					1505	1508		10.1126/science.277.5331.1505	http://dx.doi.org/10.1126/science.277.5331.1505			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278513				2022-12-24	WOS:A1997XV42900040
J	Uesugi, M; Nyanguile, O; Lu, H; Levine, AJ; Verdine, GL				Uesugi, M; Nyanguile, O; Lu, H; Levine, AJ; Verdine, GL			Induced alpha helix in the VP16 activation domain upon binding to a human TAF	SCIENCE			English	Article							TRANSCRIPTION FACTOR-TFIIB; TRANSACTIVATION DOMAIN; NMR-SPECTROSCOPY; PROTEINS; GAL4; C-13; H-1; EXPRESSION; TAF(II)40; SPECTRA	Activation domains are functional modules that enable sequence-specific DNA binding proteins to stimulate transcription. The structural basis for the function of activation domains is poorly understood. A combination of nuclear magnetic resonance (NMR) and biochemical experiments revealed that the minimal acidic activation domain of the herpes simplex virus VP16 protein undergoes an induced transition from random coil to or helix upon binding to its target protein, hTAF(parallel to)31 (a human TFIID TATA box-binding protein-associated factor). Identification of the two hydrophobic residues that make nonpolar contacts suggests a general recognition motif of acidic activation domains for hTAF(parallel to)31.	HARVARD UNIV,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138; PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Harvard University; Princeton University			Uesugi, Motonari/AAM-9777-2020					BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CAMPBELL AP, 1993, ANNU REV BIOPH BIOM, V22, P99, DOI 10.1146/annurev.bb.22.060193.000531; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; HAMPSEY M, 1997, CURR BIOL, V7, P44; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MACFERRIN KD, 1993, METHOD ENZYMOL, V217, P79; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; MORIUCHI H, 1995, P NATL ACAD SCI USA, V92, P9333, DOI 10.1073/pnas.92.20.9333; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; Sauer F, 1996, CELL, V87, P1271, DOI 10.1016/S0092-8674(00)81822-X; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Shen F, 1996, J BIOL CHEM, V271, P4827; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P1163, DOI 10.1021/bi00171a016	38	272	278	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 29	1997	277	5330					1310	1313		10.1126/science.277.5330.1310	http://dx.doi.org/10.1126/science.277.5330.1310			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT827	9271577				2022-12-24	WOS:A1997XT82700056
J	Elghanian, R; Storhoff, JJ; Mucic, RC; Letsinger, RL; Mirkin, CA				Elghanian, R; Storhoff, JJ; Mucic, RC; Letsinger, RL; Mirkin, CA			Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles	SCIENCE			English	Article							PARTICLES; PROBES	A highly selective, colorimetric polynucleotide detection method based on mercaptoal-kyloligonucleotide-modified gold nanoparticle probes is reported. Introduction of a single-stranded target oligonucleotide (30 bases) into a solution containing the appropriate probes resulted in the formation of a polymeric network of nanoparticles with a concomitant red-to-pinkish/purple color change. Hybridization was facilitated by freezing and thawing of the solutions, and the denaturation of these hybrid materials showed transition temperatures over a narrow range that allowed differentiation of a variety of imperfect targets. Transfer of the hybridization mixture to a reverse-phase silica plate resulted in a blue color upon drying that could be detected visually. The unoptimized system can detect about 10 femtomoles of an oligonucleotide.	NORTHWESTERN UNIV,DEPT CHEM,EVANSTON,IL 60208	Northwestern University			Mirkin, Chad A/E-3911-2010	Mirkin, Chad/0000-0002-6634-7627	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM010265, R01GM010265] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 10265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; BRUST M, 1995, ADV MATER, V7, P795, DOI 10.1002/adma.19950070907; DUSEMUND B, 1991, Z PHYS D ATOM MOL CL, V20, P305, DOI 10.1007/BF01543997; FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0; Grabar KC, 1996, J AM CHEM SOC, V118, P1148, DOI 10.1021/ja952233+; GRABAR KC, 1995, ANAL CHEM, V67, P735, DOI 10.1021/ac00100a008; GRYAZNOV SM, 1993, J AM CHEM SOC, V115, P3808, DOI 10.1021/ja00062a070; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; HAMES BD, 1995, GENES PROBES, V1; KREIBIG U, 1985, SURF SCI, V156, P678, DOI 10.1016/0039-6028(85)90239-0; Kricka L. J., 1992, NONISOTOPIC DNA PROB; MANSFIELD ES, 1995, MOL CELL PROBE, V9, P145, DOI 10.1006/mcpr.1995.0023; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; RAZIN S, 1994, MOL CELL PROBE, V8, P497, DOI 10.1006/mcpr.1994.1071; Storhoff J. J., 1997, J CLUST SCI, V8, P179; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; URDEA MS, 1988, NUCLEIC ACIDS RES, V16, P4937, DOI 10.1093/nar/16.11.4937; Wang J, 1996, J AM CHEM SOC, V118, P7667, DOI 10.1021/ja9608050; Weisbecker CS, 1996, LANGMUIR, V12, P3763, DOI 10.1021/la950776r; YANG WH, 1995, J CHEM PHYS, V103, P869, DOI 10.1063/1.469787	20	3833	4154	25	1704	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1078	1081		10.1126/science.277.5329.1078	http://dx.doi.org/10.1126/science.277.5329.1078			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262471				2022-12-24	WOS:A1997XT03300028
J	Gabay, L; Seger, R; Shilo, BZ				Gabay, L; Seger, R; Shilo, BZ			In situ activation pattern of Drosophila EGF receptor pathway during development	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; SIGNALING PATHWAY; RHOMBOID GENE; CELL FATE; ECTODERM; HOMOLOG; ENCODES; KINASE; ESTABLISHMENT; MELANOGASTER	Signaling cascades triggered by receptor tyrosine kinases (RTKs) participate in diverse developmental processes. The active state of these signaling pathways was monitored by examination of the in situ distribution of the active, dual phosphorylated form of mitogen-activated protein kinase (ERK) with a specific monoclonal antibody. Detection of the active state of the Drosophila epidermal growth factor receptor (DER) pathway allowed the visualization of gradients and boundaries of receptor activation, assessment of the distribution of activating ligands, and analysis of interplay with the inhibitory ligand Argos. This in situ approach can be used to monitor other receptor-triggered pathways in a wide range of organisms.	WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science				Shilo, Ben Zion/0000-0003-4903-8889				BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; DIAZBENJUMEA FJ, 1990, P ROY SOC B-BIOL SCI, V242, P36, DOI 10.1098/rspb.1990.0100; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Gabay L, 1997, DEVELOPMENT, V124, P3535; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; Golembo M, 1996, DEVELOPMENT, V122, P3363; Golembo M, 1996, DEVELOPMENT, V122, P223; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KOLODKIN AL, 1994, DEVELOPMENT, V120, P1731; NOLL R, 1994, DEVELOPMENT, V120, P2329; Okabe M, 1997, DEVELOPMENT, V124, P1045; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; RAZ E, 1992, DEVELOPMENT, V114, P113; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; Schnepp B, 1996, GENE DEV, V10, P2302, DOI 10.1101/gad.10.18.2302; Scholz H, 1997, MECH DEVELOP, V62, P79, DOI 10.1016/S0925-4773(96)00652-1; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Simcox AA, 1996, DEV BIOL, V177, P475, DOI 10.1006/dbio.1996.0179; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; Tio M, 1997, DEVELOPMENT, V124, P343; Xiao H, 1996, MECH DEVELOP, V58, P65, DOI 10.1016/S0925-4773(96)00559-X; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; zurLage P, 1997, CURR BIOL, V7, P166, DOI 10.1016/S0960-9822(97)70087-3	34	326	326	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1103	1106		10.1126/science.277.5329.1103	http://dx.doi.org/10.1126/science.277.5329.1103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262480				2022-12-24	WOS:A1997XT03300037
J	Jacobsen, SE; Meyerowitz, EM				Jacobsen, SE; Meyerowitz, EM			Hypermethylated SUPERMAN epigenetic alleles in Arabidopsis	SCIENCE			English	Article							HOMEOTIC GENES; THALIANA	Mutations in the SUPERMAN gene affect flower development in Arabidopsis. Seven heritable but unstable sup epi-alleles (the clark kent alleles) are associated with nearly identical patterns of excess cytosine methylation within the SUP gene and a decreased level of SUP RNA. Revertants of these alleles are largely demethylated at the SUP locus and have restored levels of SUP RNA. A transgenic Arabidopsis line carrying an antisense methyltransferase gene, which shows an overall decrease in genomic cytosine methylation, also contains a hypermethylated sup allele. Thus, disruption of methylation systems may yield more complex outcomes than expected and can result in methylation defects at known genes. The clark kent alleles differ from the antisense line because they do not show a general decrease in genomic methylation.	CALTECH,DIV BIOL 156 29,PASADENA,CA 91125	California Institute of Technology			Meyerowitz, Elliot M/A-7118-2009					BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; FEIL R, 1994, NUCLEIC ACIDS RES, V22, P695, DOI 10.1093/nar/22.4.695; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; GAISER JC, 1995, PLANT CELL, V7, P333, DOI 10.1105/tpc.7.3.333; Huang H, 1997, PLANT CELL, V9, P115; Kakutani T, 1996, P NATL ACAD SCI USA, V93, P12406, DOI 10.1073/pnas.93.22.12406; KOORNNEEF M, 1982, MUTAT RES, V93, P109, DOI 10.1016/0027-5107(82)90129-4; MARTIENSSEN RA, 1995, CURR OPIN GENET DEV, V5, P234, DOI 10.1016/0959-437X(95)80014-X; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; SAKAI H, 1995, NATURE, V378, P199, DOI 10.1038/378199a0; SAKAI H, COMMUNICATION; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832	17	348	370	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1100	1103		10.1126/science.277.5329.1100	http://dx.doi.org/10.1126/science.277.5329.1100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262479				2022-12-24	WOS:A1997XT03300036
J	RichEdwards, JW; Stampfer, MJ; Manson, JE; Rosner, B; Hankinson, SE; Colditz, GA; Willett, WC; Hennekens, CH				RichEdwards, JW; Stampfer, MJ; Manson, JE; Rosner, B; Hankinson, SE; Colditz, GA; Willett, WC; Hennekens, CH			Birth weight and risk of cardiovascular disease in a cohort of women followed up since 1976	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; ADULT LIFE; BLOOD-PRESSURE; INFANT GROWTH; FETAL; DEATH; HYPERTENSION; CHILDHOOD; INUTERO	Objective: To examine the association between birth weight and non-fatal adult cardiovascular disease while controlling for potential confounders such as socioeconomic group and adult lifestyle. Design: Retrospective self report of birth weight in an ongoing longitudinal cohort of nurses followed up by postal questionnaire every two years. Setting: Nurses' health study, a cohort of 121 700 women followed up since 1976. Main outcome measures: Non-fatal cardiovascular disease, including myocardial infarction, coronary revascularisation, and stroke. Results: Among the 70 297 women free of cardiovascular disease at baseline who reported birth weight in the 1992 questionnaire there were 1309 first cases of non-fatal cardiovascular disease. Increasing birth weight was associated with decreasing risk of non-fatal cardiovascular disease. There were 1216 first cases of non-fatal cardiovascular disease among women who were singletons and had been born full term; their relative risks adjusted for several cardiovascular risk factors were 1.49 (95% confidence interval 1.05 to 2.10) for birth weight < 2268 g (< 5 lb 0 oz); 1.25 (0.98 to 1.61) for birth weight 2268-2495 g (5 lb 0 oz to 5 lb 8 oz); 1.12 (0.98 to 1.27) for birth weight > 2495-3175 g (> 5 lb 8 oz to 7 lb 0 oz); 1.00 (referent) for birth weight >3175-3856 g(>7 lb 0 oz to 8 lb 8 oz); 0.96 (0.80 to 1.15) for birth weight > 3856-4536 g (> 8 lb 8 oz to 10 lb 0 oz); and 0.68 (0.46 to 1.00) for birth weight > 4536 g (> 10 lb 0 oz) (P value for trend = 0.0004). The inverse trend was apparent for both coronary heart disease and stroke. Conclusions: These data Provide strong evidence of an association between birth weight and adult coronary heart disease and stroke.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV PREVENT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,CHANNING LAB,BOSTON,MA 02215; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL-07575, HL 34594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; COX DR, 1972, J R STAT SOC B, V34, P187; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; FALL CHD, 1995, BRIT MED J, V310, P17, DOI 10.1136/bmj.310.6971.17; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; GABH Rose, 1982, WHO MONOGRAPH SERIES; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HENNEKENS CH, 1979, LANCET, V1, P1301; HOLLAND FJ, 1993, J EPIDEMIOL COMMUN H, V47, P432, DOI 10.1136/jech.47.6.432; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P336; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Rich-Edwards J. W., 1996, American Journal of Epidemiology, V143, pS39; Troy LM, 1996, INT J EPIDEMIOL, V25, P122, DOI 10.1093/ije/25.1.122; US Census Bureau, 1994, STAT ABSTR US; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157; Walker AE, 1981, STROKE S1, V12, P13	23	575	591	0	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					396	400		10.1136/bmj.315.7105.396	http://dx.doi.org/10.1136/bmj.315.7105.396			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277603	Green Published			2022-12-24	WOS:A1997XR54900019
J	King, RW; Lustig, KD; Stukenberg, PT; McGarry, TJ; Kirschner, MW				King, RW; Lustig, KD; Stukenberg, PT; McGarry, TJ; Kirschner, MW			Expression cloning in the test tube	SCIENCE			English	Article									TULARIK INC,DEPT BIOL,S SAN FRANCISCO,CA 94080		King, RW (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.			Stukenberg, Todd/0000-0002-6788-2111				CRYNS V, COMMUNICATION; KING RW, 1997, Patent No. 5654150; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; MCGARRY T, UNPUB; MEAD P, COMMUNICATION; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; XUE D, COMMUNICATION	7	41	45	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					973	974		10.1126/science.277.5328.973	http://dx.doi.org/10.1126/science.277.5328.973			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9281074				2022-12-24	WOS:A1997XQ98500046
J	Steyer, JA; Horstmann, H; Almers, W				Steyer, JA; Horstmann, H; Almers, W			Transport, docking and exocytosis of single secretory granules in live chromaffin cells	NATURE			English	Article							NEUROTRANSMITTER RELEASE; VESICLE; ACTIN; SYNAPTOBREVIN; MICROSCOPY; CULTURE; QUANTA; POOL	Neurons maintain a limited pool of synaptic vesicles which are docked at active zones and are awaiting exocytosis(1-4). By contrast, endocrine cells releasing large, dense-core secretory granules have no active zones, and there is disagreement about the size(5) and even the existence(6) of the docked pool. It is not known how, and how rapidly, secretory vesicles are replaced at exocytic sites in either neurons or endocrine cells. By using electron microscopy, we have now been able to identify a pool of docked granules in chromaffin cells that is selectively depleted when cells secrete. With evanescent-wave fluorescence microscopy(7), we observed single granules undergoing exocytosis and leaving behind patches of bare plasmalemma. Fresh granules travelled to the plasmalemma at a top speed of 114 nm s(-1), taking an average of 6 min to arrive. On arrival, their motility diminished 4-food, probably as a result of docking. Some granules detached and returned to the cytosol. We conclude that a large pool of docked granules turns over slowly, that granules move actively to their docking sites, that docking is reversible, and that the 'rapidly releasable pool' measured electrophysiologically represents a small subset of docked granules.	MAX PLANCK INST MED RES,D-69120 HEIDELBERG,GERMANY	Max Planck Society								BETZ WJ, 1995, CURR BIOL, V5, P1098, DOI 10.1016/S0960-9822(95)00220-X; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; CECCARELLI B, 1980, PHYSIOL REV, V60, P396, DOI 10.1152/physrev.1980.60.2.396; CHEEK TR, 1986, FEBS LETT, V207, P110, DOI 10.1016/0014-5793(86)80022-9; Chow Robert H., 1995, P245; EVANS LL, 1995, P NATL ACAD SCI USA, V92, P10954, DOI 10.1073/pnas.92.24.10954; GHOSH RN, 1994, BIOPHYS J, V66, P1301, DOI 10.1016/S0006-3495(94)80939-7; GILLIS KD, IN PRESS SEM CELL DE; GINGELL D, 1979, BIOPHYS J, V26, P507, DOI 10.1016/S0006-3495(79)85268-6; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; LEE RWH, 1981, NEUROSCIENCE, V6, P2087, DOI 10.1016/0306-4522(81)90048-8; Moser T, 1997, J NEUROSCI, V17, P2314; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; SCHROEDER TJ, 1994, J BIOL CHEM, V269, P17215; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; STOUT AL, 1989, APPL OPTICS, V28, P5237, DOI 10.1364/AO.28.005237; TERAKAWA S, 1991, NEUROSCI LETT, V123, P82, DOI 10.1016/0304-3940(91)90163-N; TRIFARO JM, 1993, TRENDS NEUROSCI, V16, P466, DOI 10.1016/0166-2236(93)90079-2; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; vonGersdorff H, 1997, J NEUROSCI, V17, P1919; WEIBEL ER, 1966, J CELL BIOL, V30, P23, DOI 10.1083/jcb.30.1.23; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754	24	349	354	2	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					474	478		10.1038/41329	http://dx.doi.org/10.1038/41329			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242406	Green Submitted, Bronze			2022-12-24	WOS:A1997XN55300049
J	Stager, CL; Werker, JF				Stager, CL; Werker, JF			Infants listen for more phonetic detail in speech perception than in word-learning tasks	NATURE			English	Article								Infants aged 4-6 months discriminate the fine phonetic differences that distinguish syllables in both their native and unfamiliar languages(1-3), but by 10-12 months their perceptual sensitivities are reorganized so that they discriminate only the phonetic variations that are used to distinguish meaning in their native language(12). It would seem, then, that infants apply their well honed phonetic sensitivities as they advance and begin to associate words with objects, but the question of how speech perception sensitivities are used in early word learning has not yet been answered. Here we use a recently developed technique to show that when they are required to pair words with objects, infants of 14 months fail to use the fine phonetic detail they detect in syllable discrimination tasks. In contrast, infants of 8 months-who are not yet readily learning words-successfully discriminate phonetic detail in the same task in which infants aged 14 months fail. Taken together, these results suggest a second reorganization in infants's use of phonetic detail as they move from listening to syllables to learning words.			Stager, CL (corresponding author), UNIV BRITISH COLUMBIA,DEPT PSYCHOL,2136 W MALL,VANCOUVER,BC V6T 1Z4,CANADA.			Werker, Janet F./0000-0002-1168-9013				Barton D., 1978, DEV COMMUNICATION, P255; BENEDICT H, 1979, J CHILD LANG, V6, P183, DOI 10.1017/S0305000900002245; CharlesLuce J, 1995, J CHILD LANG, V22, P727, DOI 10.1017/S0305000900010023; JUSCZYK PW, 1995, HDB PERCEPTION COGNI, V11, P263; NEWPORT EL, 1990, COGNITIVE SCI, V14, P11, DOI 10.1207/s15516709cog1401_2; OVIATT SL, 1980, CHILD DEV, V51, P97, DOI 10.1111/j.1467-8624.1980.tb02514.x; SPELKE ES, 1994, COGNITIVE NEUROSCIEN, P165; TURKEWITZ G, 1982, DEV PSYCHOBIOL, V15, P357, DOI 10.1002/dev.420150408; WERKER JF, 1984, INFANT BEHAV DEV, V7, P49, DOI 10.1016/S0163-6383(84)80022-3; WERKER JF, 1995, INVITATION COGNITIVE, P87; WOODWARD A, 1993, 24 ANN CHILD LANGUAG, P35; [No title captured]	12	479	483	4	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					381	382		10.1038/41102	http://dx.doi.org/10.1038/41102			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XM528	9237755	Bronze			2022-12-24	WOS:A1997XM52800051
J	Barnes, CA; Suster, MS; Shen, JM; McNaughton, BL				Barnes, CA; Suster, MS; Shen, JM; McNaughton, BL			Multistability of cognitive maps in the hippocampus of old rats	NATURE			English	Article							MEMORY DYSFUNCTION; PLACE CELLS; WATER MAZE; PERFORMANCE; STABILITY	Hippocampal neurons provide a population code for location(1). In young rats, environments are reliably 'mapped' by groups of neurons that have firing locations ('place fields'(2)) that can be stable for several months(3). Old animals exhibit deficits in spatial memory, raising the question of whether the quality or stability of their hippocampal 'cognitive maps'(4) is altered. By recording from large groups of neurons, we observed the hippocampal spatial code to be multistable. In young rats, the place field maps were reliable both within and between episodes in a familiar environment. In old rats, place field maps were accurate and stable during an episode, but frequently exhibited complete rearrangements between episodes. In a spatial memory task, both young and old rats exhibited bimodal performance, consistent with map multistability early in training. However, the performance of young rats became almost unimodal with further training, whereas that of old rats remained markedly bimodal. The multistability of the hippocampal map provides an insight into the dynamics of neural coding in high-level cortical structures and their changes during ageing, and may provide an explanation for the frequent failure of place recognition in elderly humans.	UNIV ARIZONA,DEPT NEUROL,TUCSON,AZ 85724; UNIV ARIZONA,DEPT PHYSIOL,TUCSON,AZ 85724; UNIV ARIZONA,DIV NEURAL SYST MEMORY & AGING,ARIZONA RES LABS,TUCSON,AZ 85724	University of Arizona; University of Arizona; University of Arizona	Barnes, CA (corresponding author), UNIV ARIZONA,DEPT PSYCHOL,LIFE SCI N BLDG,ROOM 384,TUCSON,AZ 85724, USA.							BARNES CA, 1983, NEUROBIOL AGING, V4, P113, DOI 10.1016/0197-4580(83)90034-9; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BARNES CA, 1994, TRENDS NEUROSCI, V17, P13, DOI 10.1016/0166-2236(94)90029-9; DETOLEDOMORRELL L, 1988, NEUROBIOL AGING, V9, P581, DOI 10.1016/S0197-4580(88)80117-9; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; GEINISMAN Y, 1995, PROG NEUROBIOL, V45, P223, DOI 10.1016/0301-0082(94)00047-L; GOTHARD M, 1996, J NEUROSCI, V16, P8027; KNIERIM JJ, 1995, J NEUROSCI, V15, P1648, DOI 10.1523/JNEUROSCI.15-03-01648.1995; Kubie J. L., 1983, NEUROBIOLOGY HIPPOCA, P433; LANDFIELD PW, 1988, NEUROBIOL AGING, V9, P571, DOI 10.1016/S0197-4580(88)80116-7; MARKUS EJ, 1994, HIPPOCAMPUS, V4, P410, DOI 10.1002/hipo.450040404; McNaughton BL, 1996, J EXP BIOL, V199, P173; MCNAUGHTON BL, 1989, PSYCHOBIOLOGY, V17, P230; Mizumori SJY, 1996, BEHAV NEUROSCI, V110, P1006; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Muller R U, 1991, Hippocampus, V1, P243, DOI 10.1002/hipo.450010306; Nadel L., 1985, CONTEXT LEARNING, P385; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; QUIRK GJ, 1990, J NEUROSCI, V10, P2008; Rapp P. R., 1995, Society for Neuroscience Abstracts, V21, P1710; Samsonovich A. V., 1997, THESIS U ARIZONA; SHAPIRO ML, 1993, BEHAV NEUROSCI, V107, P34, DOI 10.1037/0735-7044.107.1.34; SHEN J, 1996, THESIS U ARIZONA; Skaggs W., 1993, ADV NEURAL INFORM PR, V5, P1030; SPENCER RL, 1995, BEHAV BRAIN RES, V68, P139, DOI 10.1016/0166-4328(94)00167-E; THOMPSON LT, 1990, BRAIN RES, V509, P299, DOI 10.1016/0006-8993(90)90555-P; Tsodyks M, 1995, INT J NEURAL SYS S, V6, P81; UTTL B, 1993, PSYCHOL AGING, V8, P257, DOI 10.1037/0882-7974.8.2.257; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	30	266	272	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					272	275		10.1038/40859	http://dx.doi.org/10.1038/40859			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230435				2022-12-24	WOS:A1997XL12100050
J	Tsunoda, S; Sierralta, J; Sun, YM; Bodner, R; Suzuki, E; Becker, A; Socolich, M; Zuker, CS				Tsunoda, S; Sierralta, J; Sun, YM; Bodner, R; Suzuki, E; Becker, A; Socolich, M; Zuker, CS			A multivalent PDZ-domain protein assembles signalling complexes in a g-protein-coupled cascade	NATURE			English	Article							SIGNALING PROTEINS; PTB DOMAIN; DROSOPHILA; TRANSDUCTION; JUNCTIONS; HOMOLOG; SEPTATE; KINASES; MODULE; GENE	How are signalling molecules organized into different pathways within the same cell? In Drosophila, the inaD gene encodes a protein consisting of five PDZ domains which serves as a scaffold to assemble different components of the phototransduction cascade, including the principal fight-activated ion channels, the effector phospholipase C-beta and protein kinase C, Null inaD mutants have a dramatically reorganized subcellular distribution of signalling molecules, and a total loss of transduction complexes. Also, mutants defective in a single PDZ domain produce signalling complexes that lack the target protein and display corresponding defects in their physiology. A picture emerges of a highly organized unit of signalling, a 'transducisome', with PDZ domains functioning as key elements in the organization of transduction complexes in vivo.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; UNIV TOKYO,INST MED SCI,TOKYO,JAPAN	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Tokyo			Sierralta, Jimena Alejandra/AAG-8877-2021; Sierralta, Jimena/A-7591-2008	Sierralta, Jimena/0000-0002-0257-146X; Socolich, Michael/0000-0002-0702-1061; Suzuki, Emiko/0000-0002-4005-0542				BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Budnik V, 1996, NEURON, V17, P627, DOI 10.1016/S0896-6273(00)80196-8; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOI KY, 1994, CELL, V78, P499; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HUALING D, 1997, NATURE, V386, P279; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; JOHNSON EC, 1986, J GEN PHYSIOL, V88, P651, DOI 10.1085/jgp.88.5.651; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MINKE B, 1994, COMMENTS THEOR BIOL, V3, P229; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Niethammer M, 1996, J NEUROSCI, V16, P2157; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; PAK WL, 1975, MUTANTS AFFECTING VI; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PRINTEN JA, 1994, GENETICS, V138, P309; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Sheng M, 1996, CURR OPIN NEUROBIOL, V6, P602, DOI 10.1016/S0959-4388(96)80091-2; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SUZUKI E, 1993, J ELECTRON MICROSC, V42, P178; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; YEANDLE S, 1957, THESIS J HOPKINS U	50	538	549	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					243	249		10.1038/40805	http://dx.doi.org/10.1038/40805			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230432	Bronze			2022-12-24	WOS:A1997XL12100041
J	Ralph, J; MacKay, JJ; Hatfield, RD; OMalley, DM; Whetten, RW; Sederoff, RR				Ralph, J; MacKay, JJ; Hatfield, RD; OMalley, DM; Whetten, RW; Sederoff, RR			Abnormal lignin in a loblolly pine mutant	SCIENCE			English	Article							CINNAMYL-ALCOHOL-DEHYDROGENASE; BROWN-MIDRIB MUTANT; COMPRESSION WOOD; BM3 MUTATION; CROSS-LINKS; MAIZE; CONIFERYL; GRASSES; GENE; NMR	Novel lignin is formed in a mutant loblolly pine (Pinus taeda L.) severely depleted in cinnamyl alcohol dehydrogenase (E.C. 1.1.1.195), which converts coniferaldehyde to coniferyl alcohol, the primary lignin precursor in pines. Dihydrocbniferyl alcohol, a monomer not normally associated with the lignin biosynthetic pathway, is the major component of the mutant's lignin, accounting for similar to 30 percent (versus similar to 3 percent in normal pine) of the units. The level of aldehydes, including new 2-methoxybenzaldehydes, is also increased. The mutant pines grew normally indicating that, even within a species, extensive variations in lignin composition need not disrupt the essential functions of lignin.	UNIV WISCONSIN, DEPT FORESTRY, MADISON, WI 53706 USA; N CAROLINA STATE UNIV, DEPT GENET, RALEIGH, NC 27695 USA; N CAROLINA STATE UNIV, DEPT FORESTRY, RALEIGH, NC 27695 USA	University of Wisconsin System; University of Wisconsin Madison; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University	Ralph, J (corresponding author), USDA ARS, US DAIRY FORAGE RES CTR, 1925 LINDEN DR W, MADISON, WI 53706 USA.		MacKay, John/M-6978-2014; Whetten, Ross W/A-9734-2013; Ralph, John/C-3161-2009	MacKay, John/0000-0002-4883-195X; Ralph, John/0000-0002-6093-4521	NIGMS NIH HHS [GM45344-07] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER E, 1948, ACTA CHEM SCAND, V2, P839, DOI 10.3891/acta.chem.scand.02-0839; ADLER E, 1948, ACTA CHEM SCAND, V2, P93, DOI 10.3891/acta.chem.scand.02-0093; Baucher M, 1996, PLANT PHYSIOL, V112, P1479, DOI 10.1104/pp.112.4.1479; BJORKMAN A, 1954, NATURE, V174, P1057, DOI 10.1038/1741057a0; BUCHOLTZ DL, 1980, J AGR FOOD CHEM, V28, P1239, DOI 10.1021/jf60232a045; Campbell MM, 1996, PLANT PHYSIOL, V110, P3, DOI 10.1104/pp.110.1.3; CHABBERT B, 1994, J SCI FOOD AGR, V64, P349, DOI 10.1002/jsfa.2740640317; CHAPPLE CCS, 1992, PLANT CELL, V4, P1413, DOI 10.1105/tpc.4.11.1413; CHERNEY JH, 1991, ADV AGRON, V46, P157; Davin LB, 1997, SCIENCE, V275, P362, DOI 10.1126/science.275.5298.362; FREUDENBERG K, 1959, NATURE, V183, P1152, DOI 10.1038/1831152a0; FUKUSHIMA K, 1991, WOOD SCI TECHNOL, V25, P371, DOI 10.1007/BF00226177; GRAND C, 1985, PHYSIOL VEG, V23, P905; HALPIN C, 1994, PLANT J, V6, P339, DOI 10.1046/j.1365-313X.1994.06030339.x; Harkin J.M., 1967, OXIDATIVE COUPLING P, P243; HARKIN JM, 1973, CHEMISTRY BIOCHEMIST, V1, P323; HATFIELD RD, 1994, J SCI FOOD AGR, V65, P51, DOI 10.1002/jsfa.2740650109; HIBINO T, 1995, BIOSCI BIOTECH BIOCH, V59, P929, DOI 10.1271/bbb.59.929; HIGUCHI T, 1994, J BIOTECHNOL, V37, P151, DOI 10.1016/0168-1656(94)90006-X; KAMISAKA S, 1983, PLANT CELL PHYSIOL, V24, P369; KARHUNEN P, 1995, TETRAHEDRON LETT, V36, P169, DOI 10.1016/0040-4039(94)02203-N; KUC J, 1964, ARCH BIOCHEM BIOPHYS, V105, P103, DOI 10.1016/0003-9861(64)90240-1; LAPIERRE C, 1988, CR ACAD SCI III-VIE, V307, P723; LAPIERRE C, 1993, FORAGE CELL WALL STRUCTURE AND DIGESTIBILITY, P133; LAPIERRE C, 1988, HOLZFORSCHUNG, V42, P409, DOI 10.1515/hfsg.1988.42.6.409; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; LU F, IN PRESS J AGR FOOD; Ludley FH, 1996, J AGR FOOD CHEM, V44, P2942, DOI 10.1021/jf9604908; MACKAY JJ, 1997, THESIS N CAROLINA ST; MACKAY JJ, IN PRESS P NATL ACAD; Meyer K, 1996, P NATL ACAD SCI USA, V93, P6869, DOI 10.1073/pnas.93.14.6869; MONTIES B, 1995, ANN P PHYTOCHEM SOC, V5, P161; NAKAMURA M, 1978, MOL CELL ENDOCRINOL, V12, P209; NAKAMURA Y, 1976, HOLZFORSCHUNG, V30, P187, DOI 10.1515/hfsg.1976.30.6.187; Nakamura Y, 1978, CELL CHEM TECHNOL, V12, P199; NIMZ HH, 1981, HOLZFORSCHUNG, V35, P16, DOI 10.1515/hfsg.1981.35.1.16; OMALLEY DM, 1992, PLANT PHYSIOL, V98, P1364, DOI 10.1104/pp.98.4.1364; PILLONEL C, 1991, PLANTA, V185, P538, DOI 10.1007/BF00202964; QUIDEAU S, 1992, J AGR FOOD CHEM, V40, P1108, DOI 10.1021/jf00019a003; RALPH J, 1992, J CHEM SOC PERK T 1, P2961, DOI 10.1039/p19920002961; Ralph J, 1996, J NAT PROD, V59, P341, DOI 10.1021/np960143s; RALPH J, 1994, J AM CHEM SOC, V116, P9448, DOI 10.1021/ja00100a006; RALPH J, 1995, CARBOHYD RES, V275, P167, DOI 10.1016/0008-6215(95)00237-N; RALPH J, IN PRESS LIGNIN LIGN; Rolando C., 1992, METHODS LIGNIN CHEM, P334, DOI DOI 10.1007/978-3-642-74065-7_23; SARKANEN KV, 1967, TAPPI, V50, P587; SARKANEN KV, 1971, LIGNINS; SAVIDGE RA, 1987, PHYTOCHEMISTRY, V26, P93, DOI 10.1016/S0031-9422(00)81488-0; Timell T.E., 1986, COMPRESSION WOOD GYM; VIGNOLS F, 1995, PLANT CELL, V7, P407, DOI 10.1105/tpc.7.4.407	50	246	267	3	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					235	239		10.1126/science.277.5323.235	http://dx.doi.org/10.1126/science.277.5323.235			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211851				2022-12-24	WOS:A1997XK41800044
J	RochetteEgly, C; Adam, S; Rossignol, M; Egly, JM; Chambon, P				RochetteEgly, C; Adam, S; Rossignol, M; Egly, JM; Chambon, P			Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7	CELL			English	Article							RETINOIC ACID RECEPTOR; PROTEIN-KINASE; CELL-CYCLE; RESPONSE ELEMENT; IMMUNODETECTION	The activity of the N-terminal activation function AF-1 of RAR alpha 1 is abrogated upon mutation of a phosphorylatable serine residue (Ser-77). Recombinant RAR alpha was phosphorylated by a variety of proline-directed protein kinases in vitro. However, only the coexpression of cdk7 stimulated Ser-77 phosphorylation in vivo and enhanced transactivation by RAR alpha, but not by a S77A RAR mutant. Both free CAK (cdk7, cyclin H, MAT1) and the CAK-containing general transcription factor TFIIH phosphorylated Ser-77 in vitro. Furthermore RAR alpha bound free CAK and purified TFIIH in vitro, and RAR alpha-TFIIH complexes could be isolated from HeLa nuclear extracts. These findings represent the first example of activation of a transactivator through binding to and phosphorylation by a general transcription factor.			RochetteEgly, C (corresponding author), UNIV STRASBOURG 1,COLL FRANCE,INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,BP 163,F-67404 ILLKIRCH GRAFFENS,FRANCE.							Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DRAPKIN R, 1996, P NATL ACAD SCI UYS, V93, P6468; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GRONEMEYER H, 1995, TRANSCRIPTION FACTOR, V3; HOELJMAKERS JHJ, 1996, CURR OPIN GENE DEV, V6, P26; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; READON JT, 1996, P NATL ACAD SCI USA, V93, P6482; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Warbrick E, 1996, CURR BIOL, V6, P1057, DOI 10.1016/S0960-9822(02)70663-5; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638	44	255	267	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					97	107		10.1016/S0092-8674(00)80317-7	http://dx.doi.org/10.1016/S0092-8674(00)80317-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230306	Bronze			2022-12-24	WOS:A1997XL36200012
J	Tsang, AP; Visvader, JE; Turner, CA; Fujiwara, Y; Yu, CN; Weiss, MJ; Crossley, M; Orkin, SH				Tsang, AP; Visvader, JE; Turner, CA; Fujiwara, Y; Yu, CN; Weiss, MJ; Crossley, M; Orkin, SH			FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation	CELL			English	Article							DNA-BINDING PROTEIN; HEMATOPOIETIC-CELLS; MAMMALIAN-CELLS; EXPRESSION; GENE; ASSOCIATION; NF-E2; MICE; LINEAGES; CLONING	The hematopoietic transcription factor GATA-1 is essential for development of the erythroid and megakaryocytic lineages. Using the conserved zinc finger DNA-binding domain of GATA-1 in the yeast two-hybrid system, we have identified a novel, multitype zinc finger protein, friend of GATA-1 (FOG), which binds GATA-1 but not a functionally inactive mutant lacking the amino (N) finger. FOG is coexpressed with GATA-1 during embryonic development and in erythroid and megakaryocytic cells. Furthermore, FOG and GATA-1 synergistically activate transcription from a hematopoietic-specific regulatory region and cooperate during both erythroid and megakaryocytic cell differentiation. These findings indicate that FOG acts as a cofactor for GATA-1 and provide a paradigm for the regulation of cell type-specific gene expression by GATA transcription factors.	CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute			Weiss, Mitchell J/A-1245-2013; Crossley, Merlin/D-7888-2011; Weiss, Mitchell J/W-9814-2018	Crossley, Merlin/0000-0003-2057-3642; Weiss, Mitchell J/0000-0003-2460-3036; Yu, Channing/0000-0002-3231-2565	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM07753-18, T32 GM007753] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Basson M, 1996, GENE DEV, V10, P1953, DOI 10.1101/gad.10.15.1953; Bellefroid EJ, 1996, CELL, V87, P1191, DOI 10.1016/S0092-8674(00)81815-2; BLOBEL GA, 1995, MOL CELL BIOL, V15, P626; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUI DHK, 1995, BIOCHEM BIOPH RES CO, V209, P40, DOI 10.1006/bbrc.1995.1467; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SHIVDASANI RA, 1997, IN PRESS EMBO J; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; TING KCN, 1996, NATURE, V384, P474; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VISVADER J, 1991, ONCOGENE, V6, P187; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO	51	588	604	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					109	119		10.1016/S0092-8674(00)80318-9	http://dx.doi.org/10.1016/S0092-8674(00)80318-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230307	Bronze			2022-12-24	WOS:A1997XL36200013
J	deGennes, PG				deGennes, PG			Polymer physics - Molecular individualism	SCIENCE			English	Editorial Material											deGennes, PG (corresponding author), ECOLE SUPER PHYS & CHIM IND VILLE PARIS,10 RUE VAUQUELIN,F-75231 PARIS 05,FRANCE.							BrochardWyart F, 1997, MRS BULL, V22, P48, DOI 10.1557/S0883769400032346; Ferry J.D., 1980, VISCOELASTIC PROPERT; KELLER A, 1985, COLLOID POLYM SCI, V263, P181, DOI 10.1007/BF01415506; Perkins TT, 1997, SCIENCE, V276, P2016, DOI 10.1126/science.276.5321.2016; STOCKMAYER WH, 1976, MOL FLUIDS, P107; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462	6	97	98	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					1999	1999		10.1126/science.276.5321.1999	http://dx.doi.org/10.1126/science.276.5321.1999			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9221507				2022-12-24	WOS:A1997XG74800048
J	Elders, MJ; Scott, CR; Frindik, JP; Kemp, SF				Elders, MJ; Scott, CR; Frindik, JP; Kemp, SF			Clinical workup for precocious puberty	LANCET			English	Editorial Material							ADULT				Elders, MJ (corresponding author), UNIV ARKANSAS MED SCI,ARKANSAS CHILDRENS HOSP,LITTLE ROCK,AR 72202, USA.							*A GUTTM I, 1994, SEX AM TEEN; CUTLER GB, 1992, MED PRACTICING PHYSI, P577; Eckert KL, 1996, PEDIATRICS, V97, P517; HermanGiddens ME, 1997, PEDIATRICS, V99, P505, DOI 10.1542/peds.99.4.505; MALES MA, 1995, LANCET, V346, P64, DOI 10.1016/S0140-6736(95)92105-2; OERTER KE, 1991, J CLIN ENDOCR METAB, V73, P1235, DOI 10.1210/jcem-73-6-1235	6	13	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					457	458		10.1016/S0140-6736(05)63075-9	http://dx.doi.org/10.1016/S0140-6736(05)63075-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274578				2022-12-24	WOS:A1997XR13500004
J	Kimura, KD; Tissenbaum, HA; Liu, YX; Ruvkun, G				Kimura, KD; Tissenbaum, HA; Liu, YX; Ruvkun, G			daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans	SCIENCE			English	Article							DAUER LARVA DEVELOPMENT; INTERMEDIARY METABOLISM; HORMONE; ENCODES; KINASE; MUTATIONS; PEPTIDE; FAMILY; CYCLE	A C. elegans neurosecretory signaling system regulates whether animals enter the reproductive life cycle or arrest development at the long-lived dauer diapause stage. daf-2, a key gene in the genetic pathway that mediates this endocrine signaling, encodes an insulin receptor family member. Decreases in DAF-2 signaling induce metabolic and developmental changes, as in mammalian metabolic control by the insulin receptor, Decreased DAF-2 signaling also causes an increase in life-span. Life-span regulation by insulin-like metabolic control is analogous to mammalian longevity enhancement induced by caloric restriction, suggesting a general link between metabolism, diapause, and longevity.	MASSACHUSETTS GEN HOSP, DEPT MOL BIOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Kimura, Koutarou D./T-9645-2019	Kimura, Koutarou D./0000-0002-3359-1578	NATIONAL INSTITUTE ON AGING [R01AG014161] Funding Source: NIH RePORTER; NIA NIH HHS [R01AG14161] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARPAGAUS M, 1987, ROUX ARCH DEV BIOL, V196, P527, DOI 10.1007/BF00399877; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; COLEMAN DL, 1979, SCIENCE, V203, P663, DOI 10.1126/science.760211; DORMAN JB, 1995, GENETICS, V141, P1399; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; Finch CE, 1990, LONGEVITY SENESCENCE; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOTTLIEB S, 1994, GENETICS, V137, P107; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HETRU C, 1991, EUR J BIOCHEM, V201, P495, DOI 10.1111/j.1432-1033.1991.tb16308.x; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Jonas EA, 1997, NATURE, V385, P343, DOI 10.1038/385343a0; Kahn CR, 1996, ANNU REV MED, V47, P509; KAHN CR, 1994, JOSLINS DIABETES MEI; KAWAKAMI A, 1989, P NATL ACAD SCI USA, V86, P6843, DOI 10.1073/pnas.86.18.6843; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KENYON C, 1997, C ELEGANS, V2, P791; KIM H, 1992, DIABETOLOGIA, V35, P261, DOI 10.1007/BF00400927; Krause M, 1995, METHOD CELL BIOL, V48, P483; LARSEN PL, 1995, GENETICS, V139, P1567; MALONE EA, 1994, GENETICS, V136, P879; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; NAGASAWA H, 1984, SCIENCE, V226, P1344, DOI 10.1126/science.226.4680.1344; ORIORDAN VB, 1989, COMP BIOCHEM PHYS B, V92, P233, DOI 10.1016/0305-0491(89)90271-X; ORIORDAN VB, 1990, COMP BIOCHEM PHYS B, V95, P125, DOI 10.1016/0305-0491(90)90258-U; PATTERSON GI, UNPUB; POPHAM JD, 1979, CAN J ZOOL, V57, P794, DOI 10.1139/z79-098; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; Riddle DL, 1997, C ELEGANS, P739; ROOVERS E, 1995, GENE, V162, P181, DOI 10.1016/0378-1119(95)00323-X; Schackwitz WS, 1996, NEURON, V17, P719, DOI 10.1016/S0896-6273(00)80203-2; SHIER P, 1989, J BIOL CHEM, V264, P14605; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Tauber M.J., 1986, SEASONAL ADAPTATIONS; THOMAS JH, 1993, GENETICS, V134, P1105; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOWELS JJ, 1992, GENETICS, V130, P105; WADSWORTH WG, 1989, DEV BIOL, V132, P167, DOI 10.1016/0012-1606(89)90214-5; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	1637	1702	2	250	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	1997	277	5328					942	946		10.1126/science.277.5328.942	http://dx.doi.org/10.1126/science.277.5328.942			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252323				2022-12-24	WOS:A1997XQ98500038
J	Miles, P; Everett, J; Murphy, J; Kerr, D				Miles, P; Everett, J; Murphy, J; Kerr, D			Comparison of blood or urine testing by patients with newly diagnosed non-insulin dependent diabetes: patient survey after randomised crossover trial	BRITISH MEDICAL JOURNAL			English	Article									ROYAL BOURNEMOUTH HOSP,BOURNEMOUTH DIABET & ENDOCRINE CTR,BOURNEMOUTH BH7 7DW,DORSET,ENGLAND									BRADLEY C, 1995, HDB PSYCHOL DIABETES, P92; *DCGT RES GROUP, 1993, NEW ENGL J MED, V329, P977; TATTERSALL R, 1992, BRIT MED J, V305, P1171, DOI 10.1136/bmj.305.6863.1171; WATKINS PJ, 1993, J ROY COLL PHYS LOND, V27, P259; WING RR, 1986, AM J MED, V81, P830, DOI 10.1016/0002-9343(86)90354-2	5	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					348	349						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270457				2022-12-24	WOS:A1997XQ86400022
J	Wang, Y; Okamoto, M; Schmitz, F; Hofmann, K; Sudhof, TC				Wang, Y; Okamoto, M; Schmitz, F; Hofmann, K; Sudhof, TC			Rim is a putative Rab3 effector in regulating synaptic-vesicle fusion	NATURE			English	Article							PROTEIN; EXOCYTOSIS; RABPHILIN-3A; CELLS	Rab3 is a neuronal GTP-binding protein that regulates fusion of synaptic vesicles and is essential for long-term potentiation of hippocampal messy fibre synapses(1-5). More than thirty Rab GTP-binding proteins are known to function in diverse membrane transport pathways, although their mechanisms of action are unclear. We have now identified a putative Rab3-effector protein called Rim. Rim is composed of an amino-terminal zinc-finger motif and carboxy-terminal PDZ and C-2 domains. It binds only to GTP (but not to GDP)-complexed Rab3, and interacts with no other Rab protein tested. There is enrichment of Rab3 and Rim in neurons, where they have complementary distributions. Rab3 is found only on synaptic vesicles, whereas Rim is localized to presynaptic active zones in conventional synapses, and to presynaptic ribbons in ribbon synapses. Transfection of PC12 cells with the amino-terminal domains of Rim greatly enhances regulated exocytosis in a Rab3-dependent manner. We propose that Rim serves as a Rab3-dependent regulator of synaptic-vesicle fusion by forming a GTP-dependent complex between synaptic plasma membranes and docked synaptic vesicles.	UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; MAX PLANCK INST EXPT MED,ABT 9,D-37075 GOTTINGEN,GERMANY; SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Max Planck Society; Swiss Institute Experimental Cancer Research			Hofmann, Kay/D-6714-2011	Hofmann, Kay/0000-0002-2289-9083				Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; BURSTEIN ES, 1993, J BIOL CHEM, V268, P22247; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Dowling J. E., 1987, RETINA APPROACHABLE; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHMITZ F, 1996, J NEUROSCI, V15, P7109; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sudhof TC, 1997, NEURON, V18, P519, DOI 10.1016/S0896-6273(00)80292-5; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525	30	511	540	0	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					593	598		10.1038/41580	http://dx.doi.org/10.1038/41580			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252191	Bronze			2022-12-24	WOS:A1997XP72200052
J	Harris, WM; Combi, MR; Honeycutt, RK; Mueller, BEA; Scherb, F				Harris, WM; Combi, MR; Honeycutt, RK; Mueller, BEA; Scherb, F			Evidence for interacting gas flows and an extended volatile source distribution in the coma of comet C/1996 B2 (Hyakutake)	SCIENCE			English	Article							PHYSICO-CHEMICAL PHENOMENA; P/HALLEY; NUCLEUS; WEST	Images of comet C/1996 B2 (Hyakutake) taken during its close approach to Earth show differences in the distribution of gas and dust in the inner coma and reveal two are-shaped molecular resonant emission features. The morphology of these features, as well as the apparent decoupling gas from dust in the inner coma, suggest that an extended region of icy grains surrounds the nucleus of Hyakutake and contributes substantially to the production of volatiles. Model simulations suggest the same conclusion and indicate that the brighter are is explainable by the presence of a trailing condensation of ice-bearing granules with a rate of volatile production approximately 23 percent of that of the nucleus.	UNIV MICHIGAN,SPACE PHYS RES LAB,ANN ARBOR,MI 48109; INDIANA UNIV,DEPT ASTRON,BLOOMINGTON,IN 47405; NATL OPT ASTRON OBSERV,TUCSON,AZ 85719; UNIV WISCONSIN,DEPT PHYS,MADISON,WI 53706	University of Michigan System; University of Michigan; Indiana University System; Indiana University Bloomington; National Optical Astronomy Observatory; University of Wisconsin System; University of Wisconsin Madison	Harris, WM (corresponding author), UNIV WISCONSIN,SPACE ASTRON LAB,1150 UNIV AVE,MADISON,WI 53706, USA.		Combi, Michael/J-1697-2012	Combi, Michael/0000-0002-9805-0078				AHEARN MF, 1980, MOON PLANETS, V23, P41; AHEARN MF, 1977, ASTRON J, V82, P518, DOI 10.1086/112085; AHEARN MF, IN PRESS P 1996 AST; Combi MR, 1996, ICARUS, V123, P207, DOI 10.1006/icar.1996.0150; COMBI MR, 1980, ASTROPHYS J, V237, P1026; DELSEMME AH, 1970, PLANET SPACE SCI, V18, P709, DOI 10.1016/0032-0633(70)90052-8; DELSEMME AH, 1971, PLANET SPACE SCI, V19, P1259, DOI 10.1016/0032-0633(71)90181-4; FEHRENBACH C, 1973, CR ACAD SCI B PHYS, V277, P569; HAFFNER LM, COMMUNICATION; HANNER MS, 1981, ICARUS, V47, P342, DOI 10.1016/0019-1035(81)90182-2; Harmon J.K., 1996, BAAS, V28, P1195; HARRIS WM, 1996, B AM ASTRON SOC, V28, P1088; HUGGINS W, 1981, CR HEBD ACAD SCI, V10, P26; JEWITT DC, 1987, ASTROPHYS J, V317, P992, DOI 10.1086/165347; KELLER HU, 1987, ASTRON ASTROPHYS, V187, P807; KITAMURA Y, 1986, ICARUS, V66, P241, DOI 10.1016/0019-1035(86)90155-7; KOROSMEZEY A, 1990, ICARUS, V84, P118, DOI 10.1016/0019-1035(90)90162-3; LAFFONT C, 1996, B AM ASTRON SOC, V28, P926; LARSON S, 1987, ASTRON ASTROPHYS, V187, P639; MAZETS EP, 1987, ASTRON ASTROPHYS, V187, P699; Mukai T., 1985, Advances in Space Research, V5, P339, DOI 10.1016/0273-1177(85)90107-3; NEWBURN RL, 1981, ASTRON J, V86, P469, DOI 10.1086/112906; SAITO K, 1981, ICARUS, V41, P351; SCHLEICHER DG, 1996, B AM ASTRON SOC, V28, P1089; TOZZI GP, COMMUNICATION; TOZZI GP, 1996, B AM ASTRON SOC, V28, P1089	26	39	39	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					676	681		10.1126/science.277.5326.676	http://dx.doi.org/10.1126/science.277.5326.676			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235888				2022-12-24	WOS:A1997XN90700038
J	Cardone, MH; Salvesen, GS; Widmann, C; Johnson, G; Frisch, SM				Cardone, MH; Salvesen, GS; Widmann, C; Johnson, G; Frisch, SM			The regulation of anoikis: MEKK-1 activation requires cleavage by caspases	CELL			English	Article							EXTRACELLULAR-MATRIX; APOPTOSIS; SURVIVAL; KINASE; EXPRESSION; PROTEINASE; CELLS; RAF-1; ICE	Certain cell types undergo apoptosis when they lose integrin-mediated contacts with the extracellular matrix (''anoikis''). The Jun N-terminal kinase (JNK) pathway is activated in and promotes anoikis. This activation requires caspase activity. We presently report that a DEVD motif-specific caspase that cleaves MEKK-1 specifically is activated when cells lose matrix contact. This cleavage is required for the activation of the kinase activity. When overexpressed, the MEKK-1 cleavage product stimulates apoptosis; the wild-type, full-length MEKK-1 sensitizes cells to anoikis; and a cleavage-resistant mutant of MEKK-1 partially protects cells against anoikis. The cleavage-resistant or kinase-inactive mutants also prevent caspase-7 from being activated completely. Thus, caspases can induce apoptosis by activating MEKK-1, which in turn activates more caspase activity, comprising a positive feedback loop.	BURNHAM INST,LA JOLLA,CA 92037; UNIV COLORADO,SCH MED,DIV BASIC SCI,NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80206	Sanford Burnham Prebys Medical Discovery Institute; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051452] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51452] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cahill MA, 1996, ONCOGENE, V13, P2087; CHINNAIYAN A, 1997, SCIENCE, V275, P1081; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Gilmore TD, 1996, ONCOGENE, V13, P1367; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LASSIGNALJOHNSO.N, 1996, J BIOL CHEM, V271, P3229; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAGATA S, 1997, J BIOL CHEM, V274, P20977; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; Vachon PH, 1996, J CELL BIOL, V134, P1483, DOI 10.1083/jcb.134.6.1483; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WIDMANN C, 1997, UNPUB SCIENCE; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	34	459	468	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					315	323		10.1016/S0092-8674(00)80339-6	http://dx.doi.org/10.1016/S0092-8674(00)80339-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244305	Bronze			2022-12-24	WOS:A1997XN24900015
J	Hunt, JF; vanderVies, SM; Henry, L; Deisenhofer, J				Hunt, JF; vanderVies, SM; Henry, L; Deisenhofer, J			Structural adaptations in the specialized bacteriophage T4 co-chaperonin Gp31 expand the size of the Anfinsen cage	CELL			English	Article							BYPASS 31 MUTATIONS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; GENE-PRODUCTS; PROTEIN; GROEL; BACTERIAL; LAMBDA; HEAD; MORPHOGENESIS	The Gp31 protein from bacteriophage T4 functionally substitutes for the bacterial co-chaperonin GroES in assisted protein folding reactions both in vitro and in vivo. But Gp31 is required for the folding and/or assembly of the T4 major capsid protein Gp23, and this requirement cannot be satisfied by GroES. The 2.3 Angstrom crystal structure of Gp31 shows that its tertiary and quaternary structures are similar to those of GroES despite the existence of only 14% sequence identity between the two proteins. However, Gp31 shows a series of structural adaptations which will increase the size and the hydrophilicity of the ''Anfinsen cage,'' the enclosed cavity within the GroEL/GroES complex that is the location of the chaperonin-assisted protein folding reaction.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV GENEVA, DEPT BIOCHIM MED, CH-1211 GENEVA 4, SWITZERLAND	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Geneva	Hunt, JF (corresponding author), UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA.							Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CASTILLO CJ, 1978, J BIOL CHEM, V253, P2132; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Corrales FJ, 1996, P NATL ACAD SCI USA, V93, P4509, DOI 10.1073/pnas.93.9.4509; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DOERMANN AH, 1984, J VIROL, V51, P315, DOI 10.1128/JVI.51.2.315-320.1984; Drenth J, 1994, PRINCIPLES PROTEIN X; ELLIS RJ, 1994, CURR BIOL, V4, P633; ELLIS RJ, 1996, CHAPERONINS; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GEORGOPOULOS CP, 1972, NATURE-NEW BIOL, V239, P38, DOI 10.1038/newbio239038a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEPPEL F, 1990, GENE, V86, P19, DOI 10.1016/0378-1119(90)90109-5; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KOONIN EV, 1995, TRENDS BIOCHEM SCI, V20, P14, DOI 10.1016/S0968-0004(00)88941-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIVINSKAS R, 1988, GENE, V73, P251, DOI 10.1016/0378-1119(88)90332-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SIMON LD, 1984, J VIROL, V51, P321, DOI 10.1128/JVI.51.2.321-328.1984; STERNBERG N, 1973, J MOL BIOL, V76, P25, DOI 10.1016/0022-2836(73)90079-X; TAKANO T, 1972, NATURE-NEW BIOL, V239, P34, DOI 10.1038/newbio239034a0; THORN JM, 1995, J MOL BIOL, V249, P785, DOI 10.1006/jmbi.1995.0337; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; Walter S, 1996, P NATL ACAD SCI USA, V93, P9425, DOI 10.1073/pnas.93.18.9425; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; YIFRACH O, 1994, J MOL BIOL, V243, P397, DOI 10.1006/jmbi.1994.1667; Yifrach O, 1996, J MOL BIOL, V255, P356, DOI 10.1006/jmbi.1996.0028; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993; ZeilstraRyalls J, 1996, FASEB J, V10, P148, DOI 10.1096/fasebj.10.1.8566535; ZWEIG M, 1973, J MOL BIOL, V80, P505, DOI 10.1016/0022-2836(73)90418-X	71	87	90	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					361	371		10.1016/S0092-8674(00)80343-8	http://dx.doi.org/10.1016/S0092-8674(00)80343-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244309	Bronze			2022-12-24	WOS:A1997XN24900019
J	Festing, MFW				Festing, MFW			Fat rats and carcinogenesis screening	NATURE			English	Editorial Material							LABORATORY RODENTS; BODY-WEIGHT; PATHOLOGY; SURVIVAL; MICE				Festing, MFW (corresponding author), UNIV LEICESTER,MRC,TOXICOL UNIT,POB 138,LEICESTER LE1 9HN,LEICS,ENGLAND.							ABELSON PH, 1992, SCIENCE, V255, P141, DOI 10.1126/science.1553536; ARCOS JC, 1968, CHEM INDUCTION CANC; BRONSON RT, 1993, AGING-CLIN EXP RES, V5, P253, DOI 10.1007/BF03324169; FELTON RP, 1989, J TOXICOL ENV HEALTH, V26, P399, DOI 10.1080/15287398909531264; FESTING MFW, 1990, TOXICOL APPL PHARM, V102, P197, DOI 10.1016/0041-008X(90)90020-U; FESTING MFW, 1993, AGING-CLIN EXP RES, V5, P309, DOI 10.1007/BF03324180; FESTING MFW, 1995, ENVIRON HEALTH PERSP, V103, P44, DOI 10.2307/3432255; HASEMAN JK, 1979, J TOXICOL ENV HEALTH, V5, P89, DOI 10.1080/15287397909529728; HASEMAN JK, 1992, FUND APPL TOXICOL, V19, P207, DOI 10.1016/0272-0590(92)90153-9; MCAUSLANE JAN, 1991, HUM EXP TOXICOL, V10, P205, DOI 10.1177/096032719101000310; NOHYNEK GJ, 1993, HUM EXP TOXICOL, V12, P87, DOI 10.1177/096032719301200201; Nomura T., 1991, ILAR J, V33, P42; Popper Karl R., 1972, OBJECTIVE KNOWLEDGE; RAO GN, 1989, LAB ANIM SCI, V39, P389; ROE FJC, 1994, LAB ANIM, V28, P148, DOI 10.1258/002367794780745236; SHELLABARGER CJ, 1978, JNCI-J NATL CANCER I, V61, P1505; SPROTT RL, 1993, AGING-CLIN EXP RES, V5, P249, DOI 10.1007/BF03324168; Tennant RW, 1996, MUTAT RES-REV GENET, V365, P119, DOI 10.1016/S0165-1110(96)90016-0	18	9	9	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					321	322		10.1038/40964	http://dx.doi.org/10.1038/40964			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237745				2022-12-24	WOS:A1997XM52800020
J	Long, RM; Singer, RH; Meng, XH; Gonzalez, I; Nasmyth, K; Jansen, RP				Long, RM; Singer, RH; Meng, XH; Gonzalez, I; Nasmyth, K; Jansen, RP			Mating type switching in yeast controlled by asymmetric localization of ASH1 mRNA	SCIENCE			English	Article							CLASS-V MYOSIN; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; MUTATIONAL ANALYSIS; GENE; IDENTIFICATION; TROPOMYOSIN; REQUIREMENT; TRANSPORT; MYO2	Cell divisions that produce progeny differing in their patterns of gene expression are key to the development of multicellular organisms. In the budding yeast Saccharomyces cerevisiae, mother cells but not daughter cells can switch mating type because they selectively express the HO endonuclease gene. This asymmetry is due to the preferential accumulation of an unstable transcriptional repressor protein, Ash1p, in daughter cell nuclei. Here it is shown that ASH1 messenger RNA (mRNA) preferentially accumulates in daughter cells by a process that is dependent on actin and myosin. A cis-acting element in the 3'-untranslated region of ASH1 mRNA is sufficient to localize a chimeric RNA to daughter cells. These results suggest that localization of mRNA may have been an early property of the eukaryotic lineage.	RES INST MOL PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Long, RM (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Calatrava, Isidro González/S-4410-2018	Calatrava, Isidro González/0000-0003-4784-2582; Nasmyth, Kim/0000-0001-7030-4403	NICHD NIH HHS [7 F32 HD08088-02] Funding Source: Medline; NIGMS NIH HHS [GM54887] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD008088] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ayscough KR, 1996, ANNU REV CELL DEV BI, V12, P129, DOI 10.1146/annurev.cellbio.12.1.129; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BOGUCKAGLOTZER J, 1996, SEMIN CELL DEV BIOL, V7, P357; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; Govindan B, 1995, J EXP ZOOL, V273, P401, DOI 10.1002/jez.1402730505; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; HAARER BK, 1994, J CELL SCI, V107, P1055; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; Hill KL, 1996, J CELL BIOL, V135, P1535, DOI 10.1083/jcb.135.6.1535; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; Kislauskis Edward H., 1992, Current Opinion in Cell Biology, V4, P975, DOI 10.1016/0955-0674(92)90128-Y; LIU H, 1989, CELL, V57, P233, DOI 10.1016/0092-8674(89)90961-6; Long RM, 1995, RNA, V1, P1071; Long Roy M., 1996, Molecular Biology of the Cell, V7, p104A; Manseau L, 1996, DEVELOPMENT, V122, P2109; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; Politz JC, 1995, NUCLEIC ACIDS RES, V23, P4946, DOI 10.1093/nar/23.24.4946; Pringle JR, 1995, COLD SPRING HARB SYM, V60, P729, DOI 10.1101/SQB.1995.060.01.079; Roemer T, 1996, TRENDS CELL BIOL, V6, P434, DOI 10.1016/S0962-8924(96)10039-8; Sherman F, 1986, LAB COURSE MANUAL ME; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; SINGER RH, 1993, CURR BIOL, V3, P719, DOI 10.1016/0960-9822(93)90079-4; St. Johnston D., 1995, CELL, V81, P161, DOI DOI 10.1016/0092-8674(95)90324-0; STEWARD O, 1997, MRNA METABOLISM POST; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; SULLIVAN DS, 1992, J CELL BIOL, V119, P379, DOI 10.1083/jcb.119.2.379; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; Tetzlaff MT, 1996, EMBO J, V15, P1247, DOI 10.1002/j.1460-2075.1996.tb00466.x; WERTMAN KF, 1992, GENETICS, V132, P337	39	390	396	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					383	387		10.1126/science.277.5324.383	http://dx.doi.org/10.1126/science.277.5324.383			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219698				2022-12-24	WOS:A1997XL35800050
J	Lecuit, T; Cohen, SM				Lecuit, T; Cohen, SM			Proximal-distal axis formation in the Drosophila leg	NATURE			English	Article							PROTEIN-KINASE-A; LIMB DEVELOPMENT; IMAGINAL DISKS; SIGNAL-TRANSDUCTION; MORPHOGEN GRADIENT; WING DEVELOPMENT; VENTRAL CELLS; FEEDBACK LOOP; HEDGEHOG; GENE	Limb development requires the formation of a proximal-distal axis perpendicular to the main anterior-posterior and dorsal-ventral body axes. The secreted signalling proteins Decapentaplegic and Wingless act in a concentration-dependent manner to organize the proximal-distal axis. Discrete domains of proximal-distal gene expression are defined by different thresholds of Decapentaplegic and Wingless activities. Subsequent modulation of the relative sires of these domains by growth of the leg is required to form the mature pattern.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; BROOK WJ, 1996, SCIENCE, V273, P1371; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; GURDON JB, 1995, NATURE, V376, P520, DOI 10.1038/376520a0; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HELD LI, 1994, ROUX ARCH DEV BIOL, V203, P310, DOI 10.1007/BF00457802; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MARDON G, 1994, DEVELOPMENT, V120, P3473; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; Neumann CJ, 1997, DEVELOPMENT, V124, P871; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PANGANIBAN G, 1995, SCIENCE, V270, P1363, DOI 10.1126/science.270.5240.1363; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Penton A, 1996, NATURE, V382, P162, DOI 10.1038/382162a0; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; RUEL L, 1993, EMBO J, V12, P1657, DOI 10.1002/j.1460-2075.1993.tb05811.x; Singer MA, 1997, DEVELOPMENT, V124, P79; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; Theisen H, 1996, DEVELOPMENT, V122, P3939; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; ZECCA M, 1995, DEVELOPMENT, V121, P2265	46	308	311	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					139	145		10.1038/40563	http://dx.doi.org/10.1038/40563			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217152	Bronze			2022-12-24	WOS:A1997XK10900040
J	Kondo, H; Rabouille, C; Newman, R; Levine, TP; Pappin, D; Freemont, P; Warren, G				Kondo, H; Rabouille, C; Newman, R; Levine, TP; Pappin, D; Freemont, P; Warren, G			p47 is a cofactor for p97-mediated membrane fusion	NATURE			English	Article							MITOTIC GOLGI FRAGMENTS; VESICLE FUSION; CELL-CYCLE; YEAST; IDENTIFICATION; PROTEINS; HOMOLOGY; ATPASE; STACKS; FAMILY	At least two distinct ATPases, NSF and p97, are known to be involved in the heterotypic fusion of transport vesicles with their target membranes and the homotypic fusion of membrane compartments(1). The NSF-mediated fusion pathway is the best characterized, many of the components having been identified and their functions analysed(2-7). In contrast, none of the accessory proteins for the p97-mediated fusion pathway has been identified(8-10). Now we have identified the first such component, a protein of relative molecular mass 47,000 (p47), which forms a tight, stoichiometric complex with cytosolic p97 (one trimer of p47 per hexamer of p97). It is essential for the p97-mediated regrowth of Golgi cisternae from mitotic Golgi fragments, a process restricted to animal cells(11). As a homologue of p47 exists in budding yeast, this indicates that it might also be involved in other membrane fusion reactions catalysed by p97, such as karyogamy(10).	IMPERIAL CANC RES FUND,CELL BIOL LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,PROT STRUCT LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,PROT SEQUENCING LAB,LONDON WC2A 3PX,ENGLAND; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Cancer Research UK; Cancer Research UK; Cancer Research UK; MRC Laboratory Molecular Biology				Pappin, Darryl/0000-0002-8981-8401; Levine, Timothy/0000-0002-7231-0775				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; CONFALONIERI F, 1994, J MOL BIOL, V235, P396, DOI 10.1016/S0022-2836(05)80047-6; COULL JM, 1991, ANAL BIOCHEM, V194, P110, DOI 10.1016/0003-2697(91)90157-O; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Saxton WO, 1996, J STRUCT BIOL, V116, P230, DOI 10.1006/jsbi.1996.0035; SCHERENS B, 1993, YEAST, V9, P1355, DOI 10.1002/yea.320091210; Schiavo Giampietro, 1994, Seminars in Cell Biology, V5, P221, DOI 10.1006/scel.1994.1028; SUTTON A, 1991, COLD SPRING HARB SYM, V56, P75; SUTTON CW, 1995, ELECTROPHORESIS, V16, P308, DOI 10.1002/elps.1150160151; Tu JL, 1996, MOL CELL BIOL, V16, P4199; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; ZHANG SR, 1995, MOL CELL BIOL, V15, P2037	24	351	361	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					75	78		10.1038/40411	http://dx.doi.org/10.1038/40411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214505	Bronze			2022-12-24	WOS:A1997XJ14300053
J	Sibon, OCM; Stevenson, VA; Theurkauf, WE				Sibon, OCM; Stevenson, VA; Theurkauf, WE			DNA-replication checkpoint control at the Drosophila midblastula transition	NATURE			English	Article							CELL-CYCLE CONTROL; MITOTIC-CYCLES; EMBRYOS; XENOPUS; EMBRYOGENESIS; BLASTODERM; BEHAVIOR; NUCLEAR	Embryogenesis is typically initiated by a series of rapid mitotic divisions that are under maternal genetic control(1). The switch to zygotic control of embryogenesis at the midblastula transition is accompanied by significant increases in cell-cycle length and gene transcription, and changes in embryo morphology(2,3). Here we show that mutations in the grapes (grp) checkpoint 1 kinase homologue(4) in Drosophila block the morphological and biochemical changes that accompany the midblastula transition, lead to a continuation of the maternal cell-cycle programme, and disrupt DNA-replication checkpoint control of cell-cycle progression. The timing of the midblastula transition is controlled by the ratio of nuclei to cytoplasm (the nucleocytoplasmic ratio), suggesting that this developmental transition is triggered by titration of a maternal factor by the increasing mass of nuclear material that accumulates during the rapid embryonic mitoses(5-9). Our observations support a model for cell-cycle control at the midblastula transition in which titration of a maternal component of the DNA-replication machinery slows DNA synthesis and induces a checkpoint-dependent delay in cell-cycle progression(10). This delay may allow both completion of S phase and transcription of genes that initiate the switch to zygotic control of embryogenesis.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794; SUNY STONY BROOK,INST CELL & DEV BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Sibon, Ody/0000-0002-6836-6063; Theurkauf, William/0000-0001-7342-1912				BANGA SS, 1986, MUTAT RES, V163, P157, DOI 10.1016/0027-5107(86)90044-8; CAMPBELL SD, 1995, MOL BIOL CELL, V6, P1333, DOI 10.1091/mbc.6.10.1333; CLUTE P, 1995, DEV BIOL, V171, P273, DOI 10.1006/dbio.1995.1280; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Edgar BA, 1996, GENE DEV, V10, P1966, DOI 10.1101/gad.10.15.1966; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FOE VE, 1983, J CELL SCI, V61, P31; Foe Victoria E., 1993, P149; FOGARTY P, 1994, DEVELOPMENT, V120, P2131; FOGARTY P, IN PRESS CURR BIOL; Francesconi S, 1997, EMBO J, V16, P1332, DOI 10.1093/emboj/16.6.1332; GILBERT SF, 1991, DEV BIOL, P75; KANE DA, 1993, DEVELOPMENT, V119, P447; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; KLINGLER M, 1993, MECH DEVELOP, V43, P3, DOI 10.1016/0925-4773(93)90019-T; MATTHIES HJ, 1996, J CELL BIOL, V341, P455; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Pritchard DK, 1996, GENE DEV, V10, P1131, DOI 10.1101/gad.10.9.1131; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; RUDEN DM, 1995, DEVELOPMENT, V121, P63; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SULLIVAN W, 1993, DEVELOPMENT, V118, P1245; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Theurkauf William E., 1994, V44, P489; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; YASUDA GK, 1991, GENE DEV, V5, P1800, DOI 10.1101/gad.5.10.1800	29	225	226	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					93	97		10.1038/40439	http://dx.doi.org/10.1038/40439			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214509	Bronze			2022-12-24	WOS:A1997XJ14300057
J	Avantaggiati, ML; Ogryzko, V; Gardner, K; Giordano, A; Levine, AS; Kelly, K				Avantaggiati, ML; Ogryzko, V; Gardner, K; Giordano, A; Levine, AS; Kelly, K			Recruitment of p300/CBP in p53-dependent signal pathways	CELL			English	Article							CELL-PROLIFERATION; P53; TRANSFORMATION; ACTIVATION; MUTANT; BCL-2; CYCLE; GENE	The products of the p53 and CBP/p300 genes have been individually implicated in control of cell growth and regulation of transcription. p53 is known to act as a positive and negative regulator of gene expression. Here we show that p53, in both wild-type and mutant conformation, forms a specific protein complex with p300. However, in its wild-type but not mutant conformation, p53 inhibits a promoter containing the DNA-binding sequences for the transcription factor AP1, in a p300-dependent manner. p300 stimulates the transcriptional activity of p53 on p53-regulated promoters, and it enhances the responsiveness to a physiological upstream modulator of p53 function, ionizing radiation. A dominant negative form of p300 prevents transcriptional activation by p53, and it counteracts p53-mediated G1 arrest and apoptosis. The data implicate p300 as an important component of p53-signaling, thus providing new insight into the mechanisms of cellular proliferation.	NCI,PATHOL LAB,BETHESDA,MD 20892; NICHHD,LAB MOL GROWTH REGULAT,NIH,BETHESDA,MD 20892; NICHHD,SECT DNA REPLICAT REPAIR & MUTAGENESIS,NIH,BETHESDA,MD 20892; THOMAS JEFFERSON UNIV,SBARRO INST CANC RES & MOL MED,PHILADELPHIA,PA 19107	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Jefferson University			Giordano, Antonio/F-1927-2010; Ogryzko, Vasily/M-6665-2015	Giordano, Antonio/0000-0002-5959-016X; Ogryzko, Vasily/0000-0002-8548-1389				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; CHEN KV, 1992, SCIENCE, V255, P459; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FAN SJ, 1995, CANCER RES, V55, P1649; GIORDANO T, 1991, EXP CELL RES, V192, P193, DOI 10.1016/0014-4827(91)90175-T; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Muraoka M, 1996, ONCOGENE, V12, P1565; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PURI L, 1997, EMBO J, V16, P369; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	35	593	607	1	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1175	1184		10.1016/S0092-8674(00)80304-9	http://dx.doi.org/10.1016/S0092-8674(00)80304-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215639	Bronze			2022-12-24	WOS:A1997XG83000021
J	AzaBlanc, P; RamirezWeber, FA; Laget, MP; Schwartz, C; Kornberg, TB				AzaBlanc, P; RamirezWeber, FA; Laget, MP; Schwartz, C; Kornberg, TB			Proteolysis that is inhibited by Hedgehog targets Cubitus interruptus protein to the nucleus and converts it to a repressor	CELL			English	Article							DROSOPHILA IMAGINAL DISKS; SIGNAL-TRANSDUCTION; KINASE-A; GENE-EXPRESSION; FUSED GENE; POLARITY; COMPARTMENTS; MELANOGASTER; PATTERN; ENCODES	Cell-cell communication at anterior/posterior compartment borders in Drosophila involves Hedgehog (Hh), a protein secreted by posterior cells, and Cubitus interruptus (Ci), a protein in the Hh response pathway in anterior cells. Although Ci is thought to have roles as a transcription factor repressing hh expression and activating target genes, it localizes in the cytoplasm of anterior cells. We report here the identification of a domain that tethers Ci in the cytoplasm and show that in some anterior cells, Ci is cleaved to generate a form that lacks the tethering domain. This form translocates to the nucleus where it represses hh and other target genes. Hh inhibits proteolysis of Ci, and we suggest that this inhibition leads to the observed patterns of expression of key target genes at the compartment border.			AzaBlanc, P (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; CRICK FHC, 1975, SCIENCE, V189, P340, DOI 10.1126/science.806966; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FELSENFELD AL, 1995, DEVELOPMENT, V121, P1; Harlow E, 1988, ANTIBODIES LAB MANUA; HEBERLEIN U, 1995, CELL, V81, P987, DOI 10.1016/S0092-8674(05)80003-0; Hepker J, 1997, DEVELOPMENT, V124, P549; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KANG G, 1997, NAT GENET, V15, P266; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PHAM A, 1995, GENETICS, V140, P587; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; ROBBINS DJ, 1997, IN PRESS CELL; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; SanchezHerrero E, 1996, MECH DEVELOP, V55, P159, DOI 10.1016/0925-4773(96)00498-4; SANICOLA M, 1995, GENETICS, V139, P754; SCHWARTZ C, 1995, DEVELOPMENT, V121, P1626; SISSON JC, 1997, IN PRESS CELL; SLUSARSKI DC, 1995, GENETICS, V139, P229; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TABATA T, 1995, DEVELOPMENT, V121, P3359; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; THEROND P, 1993, MECH DEVELOP, V44, P65, DOI 10.1016/0925-4773(93)90017-R; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X; ZECCA M, 1995, DEVELOPMENT, V121, P2265	53	538	555	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1043	1053		10.1016/S0092-8674(00)80292-5	http://dx.doi.org/10.1016/S0092-8674(00)80292-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215627	Bronze			2022-12-24	WOS:A1997XG83000009
J	Rook, GAW; Zumla, A				Rook, GAW; Zumla, A			Gulf War syndrome: Is it due to a systemic shift in cytokine balance towards a Th2 profile?	LANCET			English	Article							MEASLES IMMUNIZATION; SUSCEPTIBLE MICE; IMMUNE-RESPONSE; T-CELLS; DEHYDROEPIANDROSTERONE; INTERLEUKIN-2; CORTICOTROPIN; INHIBITION; RESISTANT; CORTISOL	The symptoms of Gulf War syndrome are compatible with the hypothesis that the immune system of affected individuals is biased towards a Th2-cytokine pattern. Factors that could lead to a Th2 shift among Gulf War veterans include exposure to multiple Th2-inducing vaccinations under stressful circumstances and the way in which such vaccinations were administered, which would be expected to maximise Th2 immunogenicity. These factors may have led to a long-term systemic shift towards a Th2-cytokine balance and to mood changes related to the immunoendocrine state. Other vaccines that lead to similar long-term, non-specific shifts in cytokine balance are well-established. If our hypothesis is proven, treatment may be possible with regimens that induce a systemic Th1 bias.	UCL, SCH MED, DEPT MED, ACAD INFECT DIS UNIT, LONDON W1P 6DB, ENGLAND	University of London; University College London; UCL Medical School	Rook, GAW (corresponding author), UCL, SCH MED, DEPT BACTERIOL, LONDON W1P 6DB, ENGLAND.		ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735; Rook, Graham/0000-0002-8041-8110				AABY P, 1995, BRIT MED J, V311, P481, DOI 10.1136/bmj.311.7003.481; AABY P, 1995, SOC SCI MED, V41, P673, DOI 10.1016/0277-9536(95)00038-9; Bernton E, 1995, ANN NY ACAD SCI, V774, P217; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BRINKMANN V, 1995, J IMMUNOL, V155, P3322; BROWN DH, 1993, INFECT IMMUN, V61, P4793, DOI 10.1128/IAI.61.11.4793-4800.1993; CASALE GP, 1993, IMMUNOPHARM IMMUNOT, V15, P199, DOI 10.3109/08923979309025994; David A, 1997, BRIT MED J, V314, P239, DOI 10.1136/bmj.314.7076.239; DAYNES RA, 1990, J EXP MED, V171, P979, DOI 10.1084/jem.171.4.979; DAYNES RA, 1995, J INVEST DERMATOL, V105, pS14, DOI 10.1111/1523-1747.ep12315187; DAYNES RA, 1993, J IMMUNOL, V150, P5319; FISCHER A, 1991, IMMUNOLOGY, V74, P228; GARG M, 1993, INFECT IMMUN, V61, P2238, DOI 10.1128/IAI.61.5.2238-2241.1993; GLASER R, 1993, BEHAV NEUROSCI, V107, P525, DOI 10.1037/0735-7044.107.3.525; HERNANDEZPANDO R, 1994, IMMUNOLOGY, V82, P591; HOLSBOER F, 1984, NEW ENGL J MED, V311, P1127; MORALES AJ, 1994, J CLIN ENDOCR METAB, V78, P1360, DOI 10.1210/jc.78.6.1360; MU HH, 1993, INFECT IMMUN, V61, P2834, DOI 10.1128/IAI.61.7.2834-2840.1993; Nilsson L, 1996, JAMA-J AM MED ASSOC, V275, P760, DOI 10.1001/jama.275.10.760; ODENT MR, 1994, JAMA-J AM MED ASSOC, V272, P592, DOI 10.1001/jama.1994.03520080034035; Padgett DA, 1995, ANN NY ACAD SCI, V774, P323; Ramirez F, 1996, J IMMUNOL, V156, P2406; Ramiya VK, 1996, J AUTOIMMUN, V9, P349, DOI 10.1006/jaut.1996.0047; RAVEN PW, 1995, CLIN ENDOCRINOL, V43, P637, DOI 10.1111/j.1365-2265.1995.tb02930.x; RAVEN PW, 1996, PSYCHONEUROENDOCRINO, V20, P543; Rook GAW, 1996, QJM-INT J MED, V89, P333; Rook GAW, 1996, ANNU REV MICROBIOL, V50, P259, DOI 10.1146/annurev.micro.50.1.259; RUPPRECHT M, 1995, PSYCHONEUROENDOCRINO, V20, P543, DOI 10.1016/0306-4530(94)00082-L; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Smit JA, 1996, TRANSPLANT P, V28, P665; Strachan DP, 1996, ARCH DIS CHILD, V74, P422, DOI 10.1136/adc.74.5.422; STRAUS S, 1996, NIH PUBLICATION, P1; Suitters AJ, 1997, IMMUNOLOGY, V91, P314, DOI 10.1046/j.1365-2567.1997.00254.x; SUZUKI T, 1991, CLIN IMMUNOL IMMUNOP, V61, P202, DOI 10.1016/S0090-1229(05)80024-8; TOBACH E, 1956, AM J PHYSIOL, V187, P399, DOI 10.1152/ajplegacy.1956.187.2.399; WU CY, 1991, J CLIN INVEST, V87, P870, DOI 10.1172/JCI115092; YOUNG MRI, 1995, CHRONOBIOL INT, V12, P19, DOI 10.3109/07420529509064496; Zwilling B, 1992, ASM NEWS, V58, P23; 1997, ECONOMIST       0111, P87	40	129	131	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1831	1833		10.1016/S0140-6736(97)01164-1	http://dx.doi.org/10.1016/S0140-6736(97)01164-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269228				2022-12-24	WOS:A1997XF73500044
J	Gruer, L; Wilson, P; Scott, R; Elliott, L; Macleod, J; Harden, K; Forrester, E; Hinshelwood, S; McNulty, H; Silk, P				Gruer, L; Wilson, P; Scott, R; Elliott, L; Macleod, J; Harden, K; Forrester, E; Hinshelwood, S; McNulty, H; Silk, P			General practitioner centred scheme for treatment of opiate dependent drug injectors in Glasgow	BMJ-BRITISH MEDICAL JOURNAL			English	Article							METHADONE-MAINTENANCE; USERS		UNIV GLASGOW, DEPT GEN PRACTICE, WOODSIDE HLTH CTR, GLASGOW G20 7LR, LANARK, SCOTLAND; RUCHILL HOSP, PROBLEM SERV, GLASGOW G20 9NB, LANARK, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP, SCH NURSING & MIDWIFERY, DUNDEE DD1 9SY, SCOTLAND; LOCAL MED COMM, GLASGOW G4 9JT, LANARK, SCOTLAND; GLASGOW ROYAL INFIRM, PRESCRIBING ADVISERS DEPT, GLASGOW G4 0SF, LANARK, SCOTLAND; GREATER GLASGOW HLTH BOARD, GLASGOW G1 1ET, LANARK, SCOTLAND; GLASGOW CITY COUNCIL, DEPT SOCIAL WORK, COMMUNITY CARE SERV, GLASGOW G2 4PF, LANARK, SCOTLAND	University of Glasgow; University of Dundee; University of Glasgow	Gruer, L (corresponding author), RUCHILL HOSP, HIV & ADDICT RESOURCE CTR, GLASGOW G20 9NB, LANARK, SCOTLAND.		Wilson, Philip/V-6519-2019	Wilson, Philip/0000-0002-4123-8248; Gruer, Laurence/0000-0002-1089-2896				ABED RT, 1990, BRIT J ADDICT, V85, P131; *ADV COUNC MIS DRU, 1993, AIDS DRUG MIS UPD RE; Ball J.C., 2012, EFFECTIVENESS METHAD; Bell J, 1996, ADDICT RES, V3, P315, DOI 10.3109/16066359609005245; BURY J, 1995, INT J DRUG POLICY, V6, P267; Cairns A, 1996, BMJ-BRIT MED J, V313, P264, DOI 10.1136/bmj.313.7052.264; CLANZ A, 1986, BRIT MED J, V293, P543; COHEN J, 1992, BRIT MED J, V304, P1158, DOI 10.1136/bmj.304.6835.1158; DARKE S, 1992, BR J ADDICT, V87, P593; FARRELL M, 1994, BMJ-BRIT MED J, V309, P997, DOI 10.1136/bmj.309.6960.997; FRISCHER M, 1993, AM J EPIDEMIOL, V138, P170, DOI 10.1093/oxfordjournals.aje.a116843; FRISCHER M, 1993, J EPIDEMIOL COMMUN H, V47, P59, DOI 10.1136/jech.47.1.59; GREENWOOD J, 1992, BRIT J ADDICT, V87, P567; GREENWOOD J, 1990, BRIT MED J, V300, P587, DOI 10.1136/bmj.300.6724.587; GREENWOOD J, 1996, PSYCHIAT B, V20, P8; Gruer L, 1997, BRIT MED J, V314, P1691, DOI 10.1136/bmj.314.7095.1691; GRUER L, 1993, DRUG MISUSE HLTH GLA; *I STUD DRUG DEP, 1997, DRUG US BRIT 1996; MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953; *MIN DRUGS TASK FO, 1994, SCOTL M CHALL; PLATT JJ, 1995, HEROIN ADDICTION THE, V3; *SCOTT CTR INF ENV, 1995, HIV AIDS SURV SCOTL; SCOTT RA, 1994, BRIT MED J, V308, P1438, DOI 10.1136/bmj.308.6941.1438; SCOTT RTA, 1995, BMJ-BRIT MED J, V310, P464, DOI 10.1136/bmj.310.6977.464c; Strang J, 1996, BMJ-BRIT MED J, V313, P270, DOI 10.1136/bmj.313.7052.270; *TASK FORC REV SER, 1996, REP; WILSON P, 1994, BRIT MED J, V309, P641, DOI 10.1136/bmj.309.6955.641	27	61	62	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	1997	314	7096					1730	1735		10.1136/bmj.314.7096.1730	http://dx.doi.org/10.1136/bmj.314.7096.1730			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9202504	Green Published			2022-12-24	WOS:A1997XE90900026
J	Nightingale, SL				Nightingale, SL			Workshop on thalidomide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					379	379		10.1001/jama.278.5.379	http://dx.doi.org/10.1001/jama.278.5.379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244318				2022-12-24	WOS:A1997XN51800011
J	Nightingale, SL				Nightingale, SL			Health advisory on concomitant fenfluramine and phentermine use	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					379	379		10.1001/jama.278.5.379	http://dx.doi.org/10.1001/jama.278.5.379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244318				2022-12-24	WOS:A1997XN51800008
